<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="0" size="12" family="Times" color="#ffffff"/>
	<fontspec id="1" size="26" family="Times" color="#15539a"/>
	<fontspec id="2" size="15" family="Times" color="#000000"/>
	<fontspec id="3" size="15" family="Times" color="#327eb1"/>
	<fontspec id="4" size="9" family="Times" color="#000000"/>
	<fontspec id="5" size="9" family="Times" color="#327eb1"/>
	<fontspec id="6" size="8" family="Times" color="#ffffff"/>
<text top="112" left="75" width="151" height="13" font="0">PRACTICE GUIDELINE</text>
<text top="162" left="91" width="386" height="24" font="1">2013 ACCF/AHA Guideline for the</text>
<text top="198" left="91" width="336" height="24" font="1">Management of Heart Failure</text>
<text top="240" left="91" width="435" height="17" font="2">A Report of the American College of Cardiology Foundation/</text>
<text top="261" left="91" width="444" height="17" font="2">American Heart Association Task Force on Practice Guidelines</text>
<text top="290" left="91" width="681" height="15" font="2">Developed in Collaboration With the American College of Chest Physicians, Heart Rhythm Society</text>
<text top="309" left="214" width="435" height="15" font="2">and International Society for Heart and Lung Transplantation</text>
<text top="338" left="122" width="619" height="15" font="2">Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation</text>
<text top="366" left="292" width="270" height="15" font="2">WRITING COMMITTEE MEMBERS</text>
<text top="366" left="563" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="392" left="244" width="356" height="15" font="2">Clyde W. Yancy, MD, MSc, FACC, FAHA, <a href="e147.full.html#1">Chair</a></text>
<text top="387" left="600" width="15" height="22" font="3"><a href="e147.full.html#1">yz</a></text>
<text top="392" left="615" width="5" height="15" font="2">;</text>
<text top="411" left="93" width="334" height="15" font="2">Mariell Jessup, MD, FACC, FAHA, Vice Chair</text>
<text top="411" left="428" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="407" left="436" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="411" left="444" width="314" height="15" font="2"><a href="e147.full.html#1">; </a>Biykem Bozkurt, MD, PhD, FACC, <a href="e147.full.html#1">FAHA</a></text>
<text top="407" left="758" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="411" left="766" width="5" height="15" font="2"><a href="e147.full.html#1">;</a></text>
<text top="430" left="93" width="256" height="15" font="2">Javed Butler, MBBS, FACC, FAHA</text>
<text top="430" left="349" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="426" left="358" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="430" left="365" width="394" height="15" font="2"><a href="e147.full.html#1">; </a>Donald E. Casey, Jr, MD, MPH, MBA, FACP, FAHA</text>
<text top="426" left="759" width="8" height="22" font="3"><a href="e147.full.html#1">x</a></text>
<text top="430" left="766" width="5" height="15" font="2">;</text>
<text top="450" left="113" width="311" height="15" font="2">Mark H. Drazner, MD, MSc, FACC, FAHA</text>
<text top="450" left="424" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="445" left="433" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="450" left="440" width="290" height="15" font="2"><a href="e147.full.html#1">; </a>Gregg C. Fonarow, MD, FACC, FAHA</text>
<text top="450" left="730" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="445" left="738" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="450" left="746" width="5" height="15" font="2"><a href="e147.full.html#1">;</a></text>
<text top="469" left="147" width="329" height="15" font="2">Stephen A. Geraci, MD, FACC, FAHA, FCCP</text>
<text top="465" left="476" width="9" height="22" font="3"><a href="e147.full.html#1">jj</a></text>
<text top="469" left="485" width="220" height="15" font="2">; Tamara Horwich, MD, FACC</text>
<text top="465" left="705" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="469" left="712" width="5" height="15" font="2">;</text>
<text top="489" left="169" width="211" height="15" font="2">James L. Januzzi, MD, FACC</text>
<text top="489" left="380" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="484" left="388" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="489" left="396" width="284" height="15" font="2"><a href="e147.full.html#1">; </a>Maryl R. Johnson, MD, FACC, FAHA</text>
<text top="484" left="680" width="10" height="22" font="3"><a href="e147.full.html#1">{</a></text>
<text top="489" left="690" width="5" height="15" font="2">;</text>
<text top="508" left="172" width="278" height="15" font="2">Edward K. Kasper, MD, FACC, <a href="e147.full.html#1">FAHA</a></text>
<text top="504" left="450" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="508" left="458" width="213" height="15" font="2"><a href="e147.full.html#1">; </a>Wayne C. Levy, MD, FACC</text>
<text top="508" left="671" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="504" left="680" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="508" left="687" width="5" height="15" font="2">;</text>
<text top="528" left="92" width="358" height="15" font="2">Frederick A. Masoudi, MD, MSPH, FACC, FAHA</text>
<text top="523" left="450" width="16" height="22" font="3"><a href="e147.full.html#1">y#</a></text>
<text top="528" left="466" width="284" height="15" font="2">; Patrick E. McBride, MD, MPH, <a href="e147.full.html#1">FACC</a></text>
<text top="528" left="750" width="17" height="15" font="3"><a href="e147.full.html#1">**</a></text>
<text top="528" left="768" width="5" height="15" font="2"><a href="e147.full.html#1">;</a></text>
<text top="547" left="154" width="243" height="15" font="2">John J. V. McMurray, MD, FACC</text>
<text top="547" left="397" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="542" left="406" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="547" left="413" width="284" height="15" font="2">; Judith E. Mitchell, MD, FACC, FAHA</text>
<text top="542" left="698" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="547" left="705" width="5" height="15" font="2">;</text>
<text top="566" left="123" width="342" height="15" font="2">Pamela N. Peterson, MD, MSPH, FACC, FAHA</text>
<text top="562" left="465" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="566" left="472" width="256" height="15" font="2">; Barbara Riegel, DNSc, RN, FAHA</text>
<text top="562" left="729" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="566" left="736" width="5" height="15" font="2">;</text>
<text top="586" left="183" width="221" height="15" font="2">Flora Sam, MD, FACC, FAHA</text>
<text top="581" left="404" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="586" left="411" width="248" height="15" font="2">; Lynne W. Stevenson, MD, FACC</text>
<text top="586" left="660" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="581" left="668" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="586" left="676" width="5" height="15" font="2"><a href="e147.full.html#1">;</a></text>
<text top="605" left="204" width="231" height="15" font="2">W. H. Wilson Tang, MD, <a href="e147.full.html#1">FACC</a></text>
<text top="605" left="435" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="601" left="444" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="605" left="451" width="196" height="15" font="2">; Emily J. Tsai, MD, <a href="e147.full.html#1">FACC</a></text>
<text top="601" left="647" width="8" height="22" font="3"><a href="e147.full.html#1">y</a></text>
<text top="605" left="655" width="5" height="15" font="2"><a href="e147.full.html#1">;</a></text>
<text top="625" left="287" width="266" height="15" font="2">Bruce L. Wilkoff, MD, FACC, FHRS</text>
<text top="625" left="553" width="9" height="15" font="3"><a href="e147.full.html#1">*</a></text>
<text top="620" left="561" width="15" height="22" font="3"><a href="e147.full.html#1">yy</a></text>
<text top="869" left="64" width="511" height="11" font="4">*Writing committee members are required to recuse themselves from voting on sections to which their speci</text>
<text top="866" left="575" width="224" height="16" font="4">ﬁc relationships with industry and other entities</text>
<text top="883" left="64" width="74" height="11" font="4">may apply; see</text>
<text top="883" left="142" width="57" height="11" font="5"><a href="e147.full.html#86">Appendix 1</a></text>
<text top="883" left="204" width="114" height="11" font="4">for recusal information.</text>
<text top="879" left="322" width="477" height="16" font="4"><a href="e147.full.html#86">y</a>ACCF/AHA representative. <a href="e147.full.html#86">z</a>ACCF/AHA Task Force on Practice Guidelines liaison. <a href="e147.full.html#86">x</a>American</text>
<text top="896" left="64" width="178" height="11" font="4">College of Physicians representative.</text>
<text top="893" left="246" width="553" height="16" font="4"><a href="e147.full.html#86">jj</a>American College of Chest Physicians representative. <a href="e147.full.html#86">{</a>International Society for Heart and Lung Transplantation</text>
<text top="909" left="64" width="652" height="11" font="4">representative. #ACCF/AHA Task Force on Performance Measures liaison. **American Academy of Family Physicians representative.</text>
<text top="906" left="720" width="79" height="16" font="4"><a href="e147.full.html#86">yy</a>Heart Rhythm</text>
<text top="923" left="64" width="108" height="11" font="4">Society representative.</text>
<text top="920" left="176" width="273" height="16" font="4"><a href="e147.full.html#86">zz</a>Former Task Force member during this writing effort.</text>
<text top="936" left="76" width="723" height="11" font="4">This document was approved by the American College of Cardiology Foundation Board of Trustees and the American Heart Association Science</text>
<text top="950" left="64" width="258" height="11" font="4">Advisory and Coordinating Committee in May 2013.</text>
<text top="963" left="76" width="723" height="11" font="4">The American College of Cardiology Foundation requests that this document be cited as follows: Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE</text>
<text top="977" left="64" width="735" height="11" font="4">Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV,</text>
<text top="990" left="64" width="735" height="11" font="4">Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart</text>
<text top="1004" left="64" width="735" height="11" font="4">failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol</text>
<text top="1017" left="64" width="65" height="11" font="4">2013;62:e147</text>
<text top="1014" left="130" width="27" height="16" font="4">–239.</text>
<text top="1030" left="76" width="236" height="11" font="4">This article has been copublished in Circulation.</text>
<text top="1044" left="76" width="522" height="11" font="4">Copies: This document is available on the World Wide Web sites of the American College of Cardiology (</text>
<text top="1044" left="598" width="108" height="11" font="5"><a href="http://www.cardiosource.org">www.cardiosource.org</a></text>
<text top="1044" left="706" width="94" height="11" font="4"><a href="http://www.cardiosource.org">) </a>and the American</text>
<text top="1057" left="64" width="95" height="11" font="4">Heart Association (</text>
<text top="1057" left="160" width="103" height="11" font="5"><a href="http://my.americanheart.org">my.americanheart.org</a></text>
<text top="1057" left="263" width="536" height="11" font="4">). For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail</text>
<text top="1071" left="64" width="107" height="11" font="5"><a href="mailto:reprints@elsevier.com">reprints@elsevier.com</a></text>
<text top="1071" left="171" width="3" height="11" font="4"><a href="mailto:reprints@elsevier.com">.</a></text>
<text top="1084" left="76" width="176" height="11" font="4">Permissions: Multiple copies, modi</text>
<text top="1081" left="252" width="547" height="16" font="4">ﬁcation, alteration, enhancement, and/or distribution of this document are not permitted without the express</text>
<text top="1098" left="64" width="421" height="11" font="4">permission of the American College of Cardiology Foundation. Please contact Elsevier</text>
<text top="1095" left="486" width="134" height="16" font="4">’s permission department at</text>
<text top="1098" left="623" width="156" height="11" font="5"><a href="mailto:healthpermissions@elsevier.com">healthpermissions@elsevier.com</a></text>
<text top="1098" left="779" width="3" height="11" font="4"><a href="mailto:healthpermissions@elsevier.com">.</a></text>
<text top="51" left="64" width="199" height="10" font="6">Journal of the American College of Cardiology</text>
<text top="60" left="64" width="437" height="14" font="6">Ó 2013 by the American College of Cardiology Foundation and the American Heart Association, Inc.</text>
<text top="75" left="64" width="110" height="10" font="6">Published by Elsevier Inc.</text>
<text top="51" left="705" width="95" height="10" font="6">Vol. 62, No. 16, 2013</text>
<text top="63" left="694" width="105" height="10" font="6">ISSN 0735-1097/$36.00</text>
<text top="75" left="613" width="186" height="10" font="6"><a href="http://dx.doi.org/10.1016/j.jacc.2013.05.019">http://dx.doi.org/10.1016/j.jacc.2013.05.019</a></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="7" size="11" family="Times" color="#ffffff"/>
	<fontspec id="8" size="11" family="Times" color="#a70c2f"/>
	<fontspec id="9" size="11" family="Times" color="#000000"/>
	<fontspec id="10" size="10" family="Times" color="#005c58"/>
	<fontspec id="11" size="10" family="Times" color="#000000"/>
<text top="115" left="288" width="287" height="15" font="2">ACCF/AHA TASK FORCE MEMBERS</text>
<text top="141" left="261" width="341" height="15" font="2">Jeffrey L. Anderson, MD, FACC, FAHA, Chair;</text>
<text top="160" left="212" width="419" height="15" font="2">Alice K. Jacobs, MD, FACC, FAHA, Immediate Past Chair</text>
<text top="156" left="632" width="15" height="22" font="3"><a href="e147.full.html#1">zz</a></text>
<text top="160" left="647" width="5" height="15" font="2"><a href="e147.full.html#1">;</a></text>
<text top="180" left="238" width="388" height="15" font="2">Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect;</text>
<text top="199" left="109" width="646" height="15" font="2">Nancy M. Albert, PhD, CCNS, CCRN, FAHA; Biykem Bozkurt, MD, PhD, FACC, FAHA;</text>
<text top="218" left="151" width="542" height="15" font="2">Ralph G. Brindis, MD, MPH, MACC; Mark A. Creager, MD, FACC, FAHA</text>
<text top="214" left="693" width="15" height="22" font="3"><a href="e147.full.html#1">zz</a></text>
<text top="218" left="708" width="5" height="15" font="2">;</text>
<text top="238" left="162" width="541" height="15" font="2">Lesley H. Curtis, PhD; David DeMets, PhD; Robert A. Guyton, MD, FACC;</text>
<text top="257" left="145" width="573" height="15" font="2">Judith S. Hochman, MD, FACC, FAHA; Richard J. Kovacs, MD, FACC, FAHA;</text>
<text top="277" left="155" width="300" height="15" font="2">Frederick G. Kushner, MD, FACC, FAHA</text>
<text top="272" left="455" width="15" height="22" font="3"><a href="e147.full.html#1">zz</a></text>
<text top="277" left="470" width="239" height="15" font="2"><a href="e147.full.html#1">; </a>E. Magnus Ohman, MD, FACC;</text>
<text top="296" left="141" width="582" height="15" font="2">Susan J. Pressler, PhD, RN, FAAN, FAHA; Frank W. Sellke, MD, FACC, FAHA;</text>
<text top="316" left="131" width="582" height="15" font="2">Win-Kuang Shen, MD, FACC, FAHA; William G. Stevenson, MD, FACC, <a href="e147.full.html#1">FAHA</a></text>
<text top="311" left="713" width="15" height="22" font="3"><a href="e147.full.html#1">zz</a></text>
<text top="316" left="728" width="5" height="15" font="2">;</text>
<text top="335" left="270" width="308" height="15" font="2">Clyde W. Yancy, MD, MSc, FACC, FAHA</text>
<text top="330" left="579" width="15" height="22" font="3"><a href="e147.full.html#1">zz</a></text>
<text top="413" left="75" width="132" height="12" font="7">TABLE OF CONTENTS</text>
<text top="442" left="64" width="61" height="12" font="8">Preamble</text>
<text top="442" left="129" width="285" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e150</text>
<text top="476" left="64" width="98" height="12" font="8">1. Introduction</text>
<text top="475" left="166" width="248" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e152</text>
<text top="511" left="84" width="242" height="11" font="10">1.1. Methodology and Evidence Review</text>
<text top="510" left="334" width="80" height="13" font="9">. . . . . . . . . e152</text>
<text top="527" left="84" width="266" height="11" font="10">1.2. Organization of the Writing Committee</text>
<text top="526" left="358" width="56" height="13" font="9">. . . . . e152</text>
<text top="542" left="84" width="223" height="11" font="10">1.3. Document Review and Approval</text>
<text top="541" left="315" width="99" height="13" font="9">. . . . . . . . . . . . e152</text>
<text top="558" left="84" width="290" height="11" font="10">1.4. Scope of This Guideline With Reference to</text>
<text top="574" left="115" width="250" height="11" font="10">Other Relevant Guidelines or Statements</text>
<text top="573" left="371" width="43" height="13" font="9">. . . e153</text>
<text top="594" left="64" width="37" height="12" font="8">2. De</text>
<text top="591" left="101" width="83" height="17" font="8">ﬁnition of HF</text>
<text top="594" left="190" width="224" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e153</text>
<text top="630" left="84" width="177" height="11" font="10">2.1. HF With Reduced EF (HF</text>
<text top="626" left="262" width="24" height="17" font="10">rEF)</text>
<text top="628" left="291" width="123" height="13" font="9">. . . . . . . . . . . . . . . . e153</text>
<text top="645" left="84" width="186" height="11" font="10">2.2. HF With Preserved EF (HF</text>
<text top="642" left="271" width="26" height="17" font="10">pEF)</text>
<text top="644" left="303" width="111" height="13" font="9">. . . . . . . . . . . . . . e154</text>
<text top="666" left="64" width="79" height="12" font="8">3. HF Classi</text>
<text top="662" left="144" width="55" height="17" font="8">ﬁcations</text>
<text top="665" left="203" width="211" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e155</text>
<text top="706" left="64" width="105" height="12" font="8">4. Epidemiology</text>
<text top="705" left="178" width="236" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e156</text>
<text top="741" left="84" width="85" height="11" font="10">4.1. Mortality</text>
<text top="740" left="173" width="241" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e156</text>
<text top="756" left="84" width="128" height="11" font="10">4.2. Hospitalizations</text>
<text top="755" left="217" width="197" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . e156</text>
<text top="772" left="84" width="213" height="11" font="10">4.3. Asymptomatic LV Dysfunction</text>
<text top="771" left="303" width="111" height="13" font="9">. . . . . . . . . . . . . . e156</text>
<text top="788" left="84" width="237" height="11" font="10">4.4. Health-Related Quality of Life and</text>
<text top="804" left="115" width="107" height="11" font="10">Functional Status</text>
<text top="803" left="229" width="185" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . e156</text>
<text top="819" left="84" width="172" height="11" font="10">4.5. Economic Burden of HF</text>
<text top="818" left="260" width="154" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . e157</text>
<text top="835" left="84" width="303" height="11" font="10">4.6. Important Risk Factors for HF (Hypertension,</text>
<text top="851" left="115" width="268" height="11" font="10">Diabetes Mellitus, Metabolic Syndrome, and</text>
<text top="866" left="115" width="150" height="11" font="10">Atherosclerotic Disease)</text>
<text top="865" left="272" width="142" height="13" font="9">. . . . . . . . . . . . . . . . . . . e157</text>
<text top="887" left="64" width="297" height="12" font="8">5. Cardiac Structural Abnormalities and Other</text>
<text top="903" left="84" width="85" height="12" font="8">Causes of HF</text>
<text top="903" left="178" width="236" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e157</text>
<text top="938" left="84" width="187" height="11" font="10">5.1. Dilated Cardiomyopathies</text>
<text top="937" left="278" width="136" height="13" font="9">. . . . . . . . . . . . . . . . . . e157</text>
<text top="953" left="115" width="54" height="13" font="9">5.1.1. De</text>
<text top="950" left="169" width="194" height="17" font="9">ﬁnition and Classiﬁcation of Dilated</text>
<text top="969" left="153" width="95" height="13" font="9">Cardiomyopathies</text>
<text top="969" left="254" width="160" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . e157</text>
<text top="985" left="115" width="178" height="13" font="9">5.1.2. Epidemiology and Natural</text>
<text top="1000" left="153" width="92" height="13" font="9">History of DCM</text>
<text top="1000" left="247" width="167" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . e157</text>
<text top="1017" left="84" width="191" height="11" font="10">5.2. Familial Cardiomyopathies</text>
<text top="1016" left="278" width="136" height="13" font="9">. . . . . . . . . . . . . . . . . . e158</text>
<text top="1033" left="84" width="245" height="11" font="10">5.3. Endocrine and Metabolic Causes of</text>
<text top="1048" left="115" width="98" height="11" font="10">Cardiomyopathy</text>
<text top="1047" left="217" width="197" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . e158</text>
<text top="1063" left="115" width="78" height="13" font="9">5.3.1. Obesity</text>
<text top="1063" left="198" width="216" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e158</text>
<text top="1079" left="115" width="173" height="13" font="9">5.3.2. Diabetic Cardiomyopathy</text>
<text top="1079" left="297" width="117" height="13" font="9">. . . . . . . . . . . . . . . e158</text>
<text top="409" left="501" width="124" height="13" font="9">5.3.3. Thyroid Disease</text>
<text top="408" left="633" width="167" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . e158</text>
<text top="424" left="501" width="224" height="13" font="9">5.3.4. Acromegaly and Growth Hormone</text>
<text top="440" left="538" width="16" height="13" font="9">De</text>
<text top="437" left="554" width="245" height="17" font="9">ﬁciency . . . . . . . . . . . . . . . . . . . . . . . . . . . . e158</text>
<text top="456" left="470" width="164" height="11" font="10">5.4. Toxic Cardiomyopathy</text>
<text top="455" left="639" width="160" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . e159</text>
<text top="471" left="501" width="179" height="13" font="9">5.4.1. Alcoholic Cardiomyopathy</text>
<text top="471" left="688" width="111" height="13" font="9">. . . . . . . . . . . . . . e159</text>
<text top="487" left="501" width="172" height="13" font="9">5.4.2. Cocaine Cardiomyopathy</text>
<text top="487" left="676" width="123" height="13" font="9">. . . . . . . . . . . . . . . . e159</text>
<text top="503" left="501" width="258" height="13" font="9">5.4.3. Cardiotoxicity Related to Cancer Therapies</text>
<text top="503" left="763" width="37" height="13" font="9">. . e159</text>
<text top="519" left="501" width="259" height="13" font="9">5.4.4. Other Myocardial Toxins and Nutritional</text>
<text top="534" left="538" width="143" height="13" font="9">Causes of Cardiomyopathy</text>
<text top="534" left="688" width="111" height="13" font="9">. . . . . . . . . . . . . . e159</text>
<text top="551" left="470" width="255" height="11" font="10">5.5. Tachycardia-Induced Cardiomyopathy</text>
<text top="550" left="732" width="68" height="13" font="9">. . . . . . . e159</text>
<text top="566" left="470" width="285" height="11" font="10">5.6. Myocarditis and Cardiomyopathies Due to</text>
<text top="582" left="501" width="11" height="11" font="10">In</text>
<text top="579" left="512" width="67" height="17" font="10">ﬂammation</text>
<text top="581" left="584" width="216" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e159</text>
<text top="597" left="501" width="100" height="13" font="9">5.6.1. Myocarditis</text>
<text top="597" left="608" width="191" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . e159</text>
<text top="613" left="501" width="148" height="13" font="9">5.6.2. Acquired Immunode</text>
<text top="610" left="649" width="151" height="17" font="9">ﬁciency Syndrome . . . . e160</text>
<text top="628" left="501" width="120" height="13" font="9">5.6.3. Chagas Disease</text>
<text top="628" left="627" width="173" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . e160</text>
<text top="645" left="470" width="42" height="11" font="10">5.7. In</text>
<text top="641" left="512" width="224" height="17" font="10">ﬂammation-Induced Cardiomyopathy:</text>
<text top="660" left="501" width="133" height="11" font="10">Noninfectious Causes</text>
<text top="659" left="639" width="160" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . e160</text>
<text top="675" left="501" width="188" height="13" font="9">5.7.1. Hypersensitivity Myocarditis</text>
<text top="675" left="695" width="105" height="13" font="9">. . . . . . . . . . . . . e160</text>
<text top="691" left="501" width="227" height="13" font="9">5.7.2. Rheumatological/Connective Tissue</text>
<text top="707" left="538" width="51" height="13" font="9">Disorders</text>
<text top="707" left="596" width="204" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . e160</text>
<text top="723" left="470" width="200" height="11" font="10">5.8. Peripartum Cardiomyopathy</text>
<text top="722" left="676" width="123" height="13" font="9">. . . . . . . . . . . . . . . . e160</text>
<text top="739" left="470" width="282" height="11" font="10">5.9. Cardiomyopathy Caused By Iron Overload</text>
<text top="738" left="756" width="43" height="13" font="9">. . . e160</text>
<text top="755" left="470" width="111" height="11" font="10">5.10. Amyloidosis</text>
<text top="754" left="590" width="210" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e161</text>
<text top="770" left="470" width="158" height="11" font="10">5.11. Cardiac Sarcoidosis</text>
<text top="769" left="633" width="167" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . e161</text>
<text top="786" left="470" width="256" height="11" font="10">5.12. Stress (Takotsubo) Cardiomyopathy</text>
<text top="785" left="732" width="68" height="13" font="9">. . . . . . . e161</text>
<text top="806" left="450" width="306" height="12" font="8">6. Initial and Serial Evaluation of the HF Patient</text>
<text top="806" left="761" width="39" height="13" font="9">. . e161</text>
<text top="842" left="470" width="143" height="11" font="10">6.1. Clinical Evaluation</text>
<text top="841" left="621" width="179" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . e161</text>
<text top="857" left="501" width="222" height="13" font="9">6.1.1. History and Physical Examination:</text>
<text top="872" left="538" width="97" height="13" font="9">Recommendations</text>
<text top="872" left="639" width="160" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . e161</text>
<text top="888" left="501" width="205" height="13" font="9">6.1.2. Risk Scoring: Recommendation</text>
<text top="888" left="713" width="87" height="13" font="9">. . . . . . . . . . e161</text>
<text top="904" left="470" width="251" height="11" font="10">6.2. Diagnostic Tests: Recommendations</text>
<text top="903" left="725" width="74" height="13" font="9">. . . . . . . . e163</text>
<text top="920" left="470" width="219" height="11" font="10">6.3. Biomarkers: Recommendations</text>
<text top="919" left="695" width="105" height="13" font="9">. . . . . . . . . . . . . e163</text>
<text top="935" left="501" width="254" height="13" font="9">6.3.1. Natriuretic Peptides: BNP or NT-proBNP</text>
<text top="935" left="760" width="40" height="13" font="9">. . e164</text>
<text top="951" left="501" width="259" height="13" font="9">6.3.2. Biomarkers of Myocardial Injury: Cardiac</text>
<text top="966" left="538" width="88" height="13" font="9">Troponin T or I</text>
<text top="966" left="633" width="167" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . e164</text>
<text top="982" left="501" width="189" height="13" font="9">6.3.3. Other Emerging Biomarkers</text>
<text top="982" left="695" width="105" height="13" font="9">. . . . . . . . . . . . . e165</text>
<text top="999" left="470" width="209" height="11" font="10">6.4. Noninvasive Cardiac Imaging:</text>
<text top="1014" left="501" width="112" height="11" font="10">Recommendations</text>
<text top="1013" left="621" width="179" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . e165</text>
<text top="1030" left="470" width="268" height="11" font="10">6.5. Invasive Evaluation: Recommendations</text>
<text top="1029" left="744" width="56" height="13" font="9">. . . . . e167</text>
<text top="1045" left="501" width="188" height="13" font="9">6.5.1. Right-Heart Catheterization</text>
<text top="1045" left="695" width="105" height="13" font="9">. . . . . . . . . . . . . e167</text>
<text top="1061" left="501" width="180" height="13" font="9">6.5.2. Left-Heart Catheterization</text>
<text top="1060" left="688" width="111" height="13" font="9">. . . . . . . . . . . . . . e168</text>
<text top="1076" left="501" width="163" height="13" font="9">6.5.3. Endomyocardial Biopsy</text>
<text top="1076" left="670" width="130" height="13" font="9">. . . . . . . . . . . . . . . . . e168</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e148</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="12" size="7" family="Times" color="#000000"/>
<text top="103" left="64" width="197" height="12" font="8">7. Treatment of Stages A to D</text>
<text top="103" left="264" width="150" height="13" font="9">. . . . . . . . . . . . . . . . . . . . e168</text>
<text top="138" left="84" width="198" height="11" font="10">7.1. Stage A: Recommendations</text>
<text top="137" left="291" width="123" height="13" font="9">. . . . . . . . . . . . . . . . e168</text>
<text top="153" left="115" width="199" height="13" font="9">7.1.1. Recognition and Treatment of</text>
<text top="169" left="153" width="128" height="13" font="9">Elevated Blood Pressure</text>
<text top="169" left="284" width="130" height="13" font="9">. . . . . . . . . . . . . . . . . e168</text>
<text top="185" left="115" width="205" height="13" font="9">7.1.2. Treatment of Dyslipidemia and</text>
<text top="201" left="153" width="72" height="13" font="9">Vascular Risk</text>
<text top="200" left="229" width="185" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . e168</text>
<text top="216" left="115" width="199" height="13" font="9">7.1.3. Obesity and Diabetes Mellitus</text>
<text top="216" left="321" width="93" height="13" font="9">. . . . . . . . . . . e168</text>
<text top="232" left="115" width="221" height="13" font="9">7.1.4. Recognition and Control of Other</text>
<text top="248" left="153" width="185" height="13" font="9">Conditions That May Lead to HF</text>
<text top="247" left="346" width="68" height="13" font="9">. . . . . . . e169</text>
<text top="264" left="84" width="198" height="11" font="10">7.2. Stage B: Recommendations</text>
<text top="263" left="291" width="123" height="13" font="9">. . . . . . . . . . . . . . . . e169</text>
<text top="279" left="115" width="226" height="13" font="9">7.2.1. Management Strategies for Stage B</text>
<text top="279" left="346" width="68" height="13" font="9">. . . . . . . e170</text>
<text top="295" left="84" width="79" height="11" font="10">7.3. Stage C</text>
<text top="294" left="167" width="247" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e171</text>
<text top="310" left="115" width="219" height="13" font="9">7.3.1. Nonpharmacological Interventions</text>
<text top="310" left="340" width="74" height="13" font="9">. . . . . . . . e171</text>
<text top="327" left="153" width="31" height="8" font="12">7.3.1.1.</text>
<text top="327" left="192" width="130" height="8" font="12">EDUCATION: RECOMMENDATION</text>
<text top="324" left="328" width="86" height="13" font="9">. . . . . . . . . .e171</text>
<text top="340" left="153" width="31" height="8" font="12">7.3.1.2.</text>
<text top="340" left="192" width="70" height="8" font="12">SOCIAL SUPPORT</text>
<text top="337" left="267" width="147" height="13" font="9">. . . . . . . . . . . . . . . . . . . .e171</text>
<text top="354" left="153" width="31" height="8" font="12">7.3.1.3.</text>
<text top="354" left="192" width="172" height="8" font="12">SODIUM RESTRICTION: RECOMMENDATION</text>
<text top="351" left="371" width="43" height="13" font="9">. . .e171</text>
<text top="367" left="153" width="31" height="8" font="12">7.3.1.4.</text>
<text top="367" left="192" width="143" height="8" font="12">TREATMENT OF SLEEP DISORDERS:</text>
<text top="381" left="192" width="78" height="8" font="12">RECOMMENDATION</text>
<text top="377" left="279" width="135" height="13" font="9">. . . . . . . . . . . . . . . . . .e172</text>
<text top="394" left="153" width="31" height="8" font="12">7.3.1.5.</text>
<text top="394" left="192" width="56" height="8" font="12">WEIGHT LOSS</text>
<text top="391" left="254" width="160" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . .e172</text>
<text top="408" left="153" width="31" height="8" font="12">7.3.1.6.</text>
<text top="408" left="192" width="144" height="8" font="12">ACTIVITY, EXERCISE PRESCRIPTION,</text>
<text top="421" left="192" width="128" height="8" font="12">AND CARDIAC REHABILITATION:</text>
<text top="435" left="192" width="83" height="8" font="12">RECOMMENDATIONS</text>
<text top="431" left="279" width="135" height="13" font="9">. . . . . . . . . . . . . . . . . .e172</text>
<text top="447" left="115" width="249" height="13" font="9">7.3.2. Pharmacological Treatment for Stage C</text>
<text top="463" left="153" width="19" height="13" font="9">HF</text>
<text top="460" left="172" width="242" height="17" font="9">rEF: Recommendations . . . . . . . . . . . . . . e172</text>
<text top="480" left="153" width="31" height="8" font="12">7.3.2.1.</text>
<text top="480" left="192" width="126" height="8" font="12">DIURETICS: RECOMMENDATION</text>
<text top="476" left="322" width="92" height="13" font="9">. . . . . . . . . . .e173</text>
<text top="493" left="153" width="31" height="8" font="12">7.3.2.2.</text>
<text top="493" left="192" width="149" height="8" font="12">ACE INHIBITORS: RECOMMENDATION</text>
<text top="489" left="347" width="67" height="13" font="9">. . . . . . .e174</text>
<text top="506" left="153" width="31" height="8" font="12">7.3.2.3.</text>
<text top="506" left="192" width="111" height="8" font="12">ARBS: RECOMMENDATIONS</text>
<text top="503" left="310" width="104" height="13" font="9">. . . . . . . . . . . . .e175</text>
<text top="520" left="153" width="31" height="8" font="12">7.3.2.4.</text>
<text top="520" left="192" width="150" height="8" font="12">BETA BLOCKERS: RECOMMENDATION</text>
<text top="516" left="347" width="67" height="13" font="9">. . . . . . .e176</text>
<text top="533" left="153" width="31" height="8" font="12">7.3.2.5.</text>
<text top="533" left="192" width="168" height="8" font="12">ALDOSTERONE RECEPTOR ANTAGONISTS:</text>
<text top="547" left="192" width="83" height="8" font="12">RECOMMENDATIONS</text>
<text top="543" left="279" width="135" height="13" font="9">. . . . . . . . . . . . . . . . . .e177</text>
<text top="560" left="153" width="31" height="8" font="12">7.3.2.6.</text>
<text top="560" left="192" width="178" height="8" font="12">HYDRALAZINE AND ISOSORBIDE DINITRATE:</text>
<text top="574" left="192" width="83" height="8" font="12">RECOMMENDATIONS</text>
<text top="570" left="279" width="135" height="13" font="9">. . . . . . . . . . . . . . . . . .e179</text>
<text top="587" left="153" width="31" height="8" font="12">7.3.2.7.</text>
<text top="587" left="192" width="118" height="8" font="12">DIGOXIN: RECOMMENDATION</text>
<text top="584" left="316" width="98" height="13" font="9">. . . . . . . . . . . .e179</text>
<text top="601" left="153" width="31" height="8" font="12">7.3.2.8.</text>
<text top="601" left="192" width="105" height="8" font="12">OTHER DRUG TREATMENT</text>
<text top="597" left="303" width="111" height="13" font="9">. . . . . . . . . . . . . .e180</text>
<text top="611" left="192" width="128" height="12" font="12">7.3.2.8.1. ANTICOAGULATION:</text>
<text top="625" left="241" width="85" height="12" font="12">RECOMMENDATIONS</text>
<text top="624" left="330" width="84" height="13" font="9">. . . . . . . . . e180</text>
<text top="638" left="192" width="169" height="12" font="12">7.3.2.8.2. STATINS: RECOMMENDATION</text>
<text top="637" left="367" width="47" height="13" font="9">. . . e181</text>
<text top="652" left="192" width="145" height="12" font="12">7.3.2.8.3. OMEGA-3 FATTY ACIDS:</text>
<text top="665" left="241" width="80" height="12" font="12">RECOMMENDATION</text>
<text top="664" left="324" width="90" height="13" font="9">. . . . . . . . . . e181</text>
<text top="681" left="153" width="31" height="8" font="12">7.3.2.9.</text>
<text top="681" left="192" width="178" height="8" font="12">DRUGS OF UNPROVEN VALUE OR THAT MAY</text>
<text top="695" left="192" width="139" height="8" font="12">WORSEN HF: RECOMMENDATIONS</text>
<text top="691" left="334" width="80" height="13" font="9">. . . . . . . . .e182</text>
<text top="705" left="192" width="188" height="12" font="12">7.3.2.9.1. NUTRITIONAL SUPPLEMENTS AND</text>
<text top="719" left="241" width="96" height="12" font="12">HORMONAL THERAPIES</text>
<text top="718" left="342" width="72" height="13" font="9">. . . . . . . e182</text>
<text top="732" left="192" width="158" height="12" font="12">7.3.2.9.2. ANTIARRHYTHMIC AGENTS</text>
<text top="732" left="355" width="59" height="13" font="9">. . . . . e182</text>
<text top="746" left="192" width="179" height="12" font="12">7.3.2.9.3. CALCIUM CHANNEL BLOCKERS:</text>
<text top="759" left="241" width="80" height="12" font="12">RECOMMENDATION</text>
<text top="758" left="324" width="90" height="13" font="9">. . . . . . . . . . e182</text>
<text top="773" left="192" width="137" height="12" font="12">7.3.2.9.4. NONSTEROIDAL ANTI-</text>
<text top="786" left="241" width="97" height="12" font="12">INFLAMMATORY DRUGS</text>
<text top="785" left="342" width="72" height="13" font="9">. . . . . . . e182</text>
<text top="800" left="192" width="137" height="12" font="12">7.3.2.9.5. THIAZOLIDINEDIONES</text>
<text top="799" left="336" width="78" height="13" font="9">. . . . . . . . e182</text>
<text top="815" left="115" width="249" height="13" font="9">7.3.3. Pharmacological Treatment for Stage C</text>
<text top="830" left="153" width="19" height="13" font="9">HF</text>
<text top="827" left="172" width="242" height="17" font="9">pEF: Recommendations . . . . . . . . . . . . . . e183</text>
<text top="846" left="115" width="210" height="13" font="9">7.3.4. Device Therapy for Stage C HF</text>
<text top="843" left="325" width="25" height="17" font="9">rEF:</text>
<text top="862" left="153" width="97" height="13" font="9">Recommendations</text>
<text top="862" left="254" width="160" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . e183</text>
<text top="879" left="153" width="31" height="8" font="12">7.3.4.1.</text>
<text top="879" left="192" width="124" height="8" font="12">IMPLANTABLE CARDIOVERTER-</text>
<text top="892" left="192" width="63" height="8" font="12">DEFIBRILLATOR</text>
<text top="888" left="260" width="154" height="13" font="9">. . . . . . . . . . . . . . . . . . . . .e186</text>
<text top="905" left="153" width="31" height="8" font="12">7.3.4.2.</text>
<text top="905" left="192" width="127" height="8" font="12">CARDIAC RESYNCHRONIZATION</text>
<text top="919" left="192" width="37" height="8" font="12">THERAPY</text>
<text top="915" left="236" width="178" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . .e188</text>
<text top="932" left="84" width="79" height="11" font="10">7.4. Stage D</text>
<text top="931" left="167" width="247" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e189</text>
<text top="947" left="115" width="54" height="13" font="9">7.4.1. De</text>
<text top="944" left="169" width="245" height="17" font="9">ﬁnition of Advanced HF . . . . . . . . . . . . . e189</text>
<text top="963" left="115" width="260" height="13" font="9">7.4.2. Important Considerations in Determining</text>
<text top="978" left="153" width="143" height="13" font="9">If the Patient Is Refractory</text>
<text top="978" left="303" width="111" height="13" font="9">. . . . . . . . . . . . . . e189</text>
<text top="994" left="115" width="232" height="13" font="9">7.4.3. Water Restriction: Recommendation</text>
<text top="994" left="352" width="62" height="13" font="9">. . . . . . e190</text>
<text top="1010" left="115" width="237" height="13" font="9">7.4.4. Inotropic Support: Recommendations</text>
<text top="1009" left="358" width="56" height="13" font="9">. . . . . e190</text>
<text top="1025" left="115" width="210" height="13" font="9">7.4.5. Mechanical Circulatory Support:</text>
<text top="1041" left="153" width="97" height="13" font="9">Recommendations</text>
<text top="1041" left="254" width="160" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . e191</text>
<text top="1057" left="115" width="169" height="13" font="9">7.4.6. Cardiac Transplantation:</text>
<text top="1073" left="153" width="93" height="13" font="9">Recommendation</text>
<text top="1072" left="254" width="160" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . e192</text>
<text top="103" left="450" width="177" height="12" font="8">8. The Hospitalized Patient</text>
<text top="103" left="631" width="168" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . e193</text>
<text top="138" left="470" width="67" height="11" font="10">8.1. Classi</text>
<text top="135" left="537" width="101" height="17" font="10">ﬁcation of Acute</text>
<text top="154" left="501" width="117" height="11" font="10">Decompensated HF</text>
<text top="153" left="621" width="179" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . e193</text>
<text top="170" left="470" width="298" height="11" font="10">8.2. Precipitating Causes of Decompensated HF:</text>
<text top="186" left="501" width="112" height="11" font="10">Recommendations</text>
<text top="185" left="621" width="179" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . e194</text>
<text top="201" left="470" width="306" height="11" font="10">8.3. Maintenance of GDMT During Hospitalization:</text>
<text top="217" left="501" width="112" height="11" font="10">Recommendations</text>
<text top="216" left="621" width="179" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . e195</text>
<text top="233" left="470" width="238" height="11" font="10">8.4. Diuretics in Hospitalized Patients:</text>
<text top="248" left="501" width="112" height="11" font="10">Recommendations</text>
<text top="247" left="621" width="179" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . e195</text>
<text top="264" left="470" width="298" height="13" font="10">8.5. Renal Replacement TherapydUltraﬁltration:</text>
<text top="280" left="501" width="112" height="11" font="10">Recommendations</text>
<text top="279" left="621" width="179" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . e196</text>
<text top="295" left="470" width="263" height="11" font="10">8.6. Parenteral Therapy in Hospitalized HF:</text>
<text top="311" left="501" width="105" height="11" font="10">Recommendation</text>
<text top="310" left="614" width="185" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . e196</text>
<text top="327" left="470" width="265" height="11" font="10">8.7. Venous Thromboembolism Prophylaxis</text>
<text top="343" left="501" width="149" height="11" font="10">in Hospitalized Patients:</text>
<text top="358" left="501" width="105" height="11" font="10">Recommendation</text>
<text top="357" left="614" width="185" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . e197</text>
<text top="374" left="470" width="239" height="11" font="10">8.8. Arginine Vasopressin Antagonists:</text>
<text top="390" left="501" width="105" height="11" font="10">Recommendation</text>
<text top="389" left="614" width="185" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . e198</text>
<text top="405" left="470" width="234" height="11" font="10">8.9. Inpatient and Transitions of Care:</text>
<text top="421" left="501" width="112" height="11" font="10">Recommendations</text>
<text top="420" left="621" width="179" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . e198</text>
<text top="441" left="450" width="213" height="12" font="8">9. Important Comorbidities in HF</text>
<text top="441" left="668" width="131" height="13" font="9">. . . . . . . . . . . . . . . . . e200</text>
<text top="477" left="470" width="132" height="11" font="10">9.1. Atrial Fibrillation</text>
<text top="476" left="608" width="191" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . e200</text>
<text top="492" left="470" width="76" height="11" font="10">9.2. Anemia</text>
<text top="491" left="553" width="247" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e201</text>
<text top="508" left="470" width="98" height="11" font="10">9.3. Depression</text>
<text top="507" left="571" width="228" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e203</text>
<text top="524" left="470" width="206" height="11" font="10">9.4. Other Multiple Comorbidities</text>
<text top="523" left="682" width="117" height="13" font="9">. . . . . . . . . . . . . . . e203</text>
<text top="544" left="450" width="273" height="12" font="8">10. Surgical/Percutaneous/Transcatheter</text>
<text top="561" left="478" width="209" height="12" font="8">Interventional Treatments of HF:</text>
<text top="577" left="478" width="118" height="12" font="8">Recommendations</text>
<text top="577" left="601" width="199" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . e204</text>
<text top="617" left="450" width="258" height="12" font="8">11. Coordinating Care for Patients With</text>
<text top="633" left="478" width="69" height="12" font="8">Chronic HF</text>
<text top="633" left="551" width="248" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e205</text>
<text top="669" left="478" width="256" height="11" font="10">11.1. Coordinating Care for Patients With</text>
<text top="684" left="516" width="185" height="11" font="10">Chronic HF: Recommendations</text>
<text top="683" left="709" width="91" height="13" font="9">. . . . . . . . . . e205</text>
<text top="700" left="478" width="244" height="11" font="10">11.2. Systems of Care to Promote Care</text>
<text top="716" left="516" width="186" height="11" font="10">Coordination for Patients With</text>
<text top="731" left="516" width="65" height="11" font="10">Chronic HF</text>
<text top="730" left="585" width="214" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e207</text>
<text top="747" left="478" width="255" height="11" font="10">11.3. Palliative Care for Patients With HF</text>
<text top="746" left="740" width="60" height="13" font="9">. . . . . e207</text>
<text top="768" left="450" width="287" height="12" font="8">12. Quality Metrics/Performance Measures:</text>
<text top="784" left="478" width="118" height="12" font="8">Recommendations</text>
<text top="783" left="601" width="199" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . e207</text>
<text top="824" left="450" width="259" height="12" font="8">13. Evidence Gaps and Future Research</text>
<text top="840" left="478" width="65" height="12" font="8">Directions</text>
<text top="840" left="551" width="248" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e208</text>
<text top="879" left="450" width="73" height="12" font="8">References</text>
<text top="878" left="527" width="273" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e210</text>
<text top="916" left="450" width="251" height="12" font="8">Appendix 1. Author Relationships With</text>
<text top="933" left="533" width="173" height="12" font="8">Industry and Other Entities</text>
<text top="949" left="533" width="67" height="12" font="8">(Relevant)</text>
<text top="949" left="607" width="193" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . e232</text>
<text top="989" left="450" width="268" height="12" font="8">Appendix 2. Reviewer Relationships With</text>
<text top="1006" left="533" width="173" height="12" font="8">Industry and Other Entities</text>
<text top="1022" left="533" width="67" height="12" font="8">(Relevant)</text>
<text top="1022" left="607" width="193" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . . . . e235</text>
<text top="1062" left="450" width="171" height="12" font="8">Appendix 3. Abbreviations</text>
<text top="1062" left="625" width="174" height="13" font="9">. . . . . . . . . . . . . . . . . . . . . . . . e239</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e149</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="13" size="15" family="Times" color="#a70c2f"/>
	<fontspec id="14" size="12" family="Times" color="#000000"/>
	<fontspec id="15" size="12" family="Times" color="#327eb1"/>
<text top="103" left="64" width="77" height="15" font="13">Preamble</text>
<text top="146" left="65" width="349" height="13" font="14">The medical profession should play a central role in evalu-</text>
<text top="164" left="64" width="350" height="13" font="14">ating the evidence related to drugs, devices, and procedures</text>
<text top="182" left="64" width="350" height="13" font="14">for the detection, management, and prevention of disease.</text>
<text top="200" left="64" width="350" height="13" font="14">When properly applied, expert analysis of available data on</text>
<text top="218" left="64" width="49" height="13" font="14">the bene</text>
<text top="214" left="114" width="300" height="18" font="14">ﬁts and risks of these therapies and procedures can</text>
<text top="236" left="64" width="350" height="13" font="14">improve the quality of care, optimize patient outcomes, and</text>
<text top="254" left="64" width="350" height="13" font="14">favorably affect costs by focusing resources on the most</text>
<text top="272" left="64" width="350" height="13" font="14">effective strategies. An organized and directed approach to</text>
<text top="290" left="64" width="350" height="13" font="14">a thorough review of evidence has resulted in the production</text>
<text top="308" left="64" width="350" height="13" font="14">of clinical practice guidelines that assist clinicians in selecting</text>
<text top="326" left="64" width="350" height="13" font="14">the best management strategy for an individual patient.</text>
<text top="344" left="64" width="350" height="13" font="14">Moreover, clinical practice guidelines can provide a founda-</text>
<text top="362" left="64" width="350" height="13" font="14">tion for other applications, such as performance measures,</text>
<text top="380" left="64" width="350" height="13" font="14">appropriate use criteria, and both quality improvement and</text>
<text top="397" left="64" width="175" height="13" font="14">clinical decision support tools.</text>
<text top="415" left="79" width="335" height="13" font="14">The American College of Cardiology Foundation (ACCF)</text>
<text top="433" left="64" width="350" height="13" font="14">and the American Heart Association (AHA) have jointly</text>
<text top="451" left="64" width="350" height="13" font="14">produced guidelines in the area of cardiovascular disease</text>
<text top="469" left="64" width="350" height="13" font="14">since 1980. The ACCF/AHA Task Force on Practice Guide-</text>
<text top="487" left="64" width="350" height="13" font="14">lines (Task Force), charged with developing, updating, and</text>
<text top="505" left="64" width="350" height="13" font="14">revising practice guidelines for cardiovascular diseases and</text>
<text top="523" left="64" width="350" height="13" font="14">procedures, directs and oversees this effort. Writing commit-</text>
<text top="541" left="64" width="350" height="13" font="14">tees are charged with regularly reviewing and evaluating</text>
<text top="559" left="64" width="350" height="13" font="14">all available evidence to develop balanced, patient-centric</text>
<text top="577" left="64" width="217" height="13" font="14">recommendations for clinical practice.</text>
<text top="595" left="79" width="335" height="13" font="14">Experts in the subject under consideration are selected by</text>
<text top="613" left="64" width="278" height="13" font="14">the ACCF and AHA to examine subject-speci</text>
<text top="609" left="342" width="72" height="18" font="14">ﬁc data and</text>
<text top="631" left="64" width="350" height="13" font="14">write guidelines in partnership with representatives from</text>
<text top="649" left="64" width="350" height="13" font="14">other medical organizations and specialty groups. Writing</text>
<text top="666" left="64" width="350" height="13" font="14">committees are asked to perform a literature review; weigh the</text>
<text top="684" left="64" width="350" height="13" font="14">strength of evidence for or against particular tests, treatments,</text>
<text top="702" left="64" width="350" height="13" font="14">or procedures; and include estimates of expected outcomes</text>
<text top="720" left="64" width="209" height="13" font="14">where such data exist. Patient-speci</text>
<text top="717" left="273" width="141" height="18" font="14">ﬁc modiﬁers, comorbid-</text>
<text top="738" left="64" width="287" height="13" font="14">ities, and issues of patient preference that may in</text>
<text top="734" left="351" width="63" height="18" font="14">ﬂuence the</text>
<text top="756" left="64" width="350" height="13" font="14">choice of tests or therapies are considered. When available,</text>
<text top="774" left="64" width="350" height="13" font="14">information from studies on cost is considered, but data on</text>
<text top="792" left="64" width="11" height="13" font="14">ef</text>
<text top="788" left="75" width="339" height="18" font="14">ﬁcacy and outcomes constitute the primary basis for the</text>
<text top="810" left="64" width="203" height="13" font="14">recommendations contained herein.</text>
<text top="828" left="79" width="335" height="13" font="14">In analyzing the data and developing recommendations and</text>
<text top="846" left="64" width="350" height="13" font="14">supporting text, the writing committee uses evidence-based</text>
<text top="864" left="64" width="260" height="13" font="14">methodologies developed by the Task Force</text>
<text top="864" left="330" width="16" height="13" font="15"><a href="e147.full.html#64">(1)</a></text>
<text top="864" left="347" width="67" height="13" font="14"><a href="e147.full.html#64">. </a>The Class</text>
<text top="882" left="64" width="350" height="13" font="14">of Recommendation (COR) is an estimate of the size of the</text>
<text top="900" left="64" width="265" height="13" font="14">treatment effect considering risks versus bene</text>
<text top="896" left="329" width="85" height="18" font="14">ﬁts in addition</text>
<text top="918" left="64" width="350" height="13" font="14">to evidence and/or agreement that a given treatment or</text>
<text top="936" left="64" width="350" height="13" font="14">procedure is or is not useful/effective or in some situations</text>
<text top="953" left="64" width="350" height="13" font="14">may cause harm. The Level of Evidence (LOE) is an estimate</text>
<text top="971" left="64" width="350" height="13" font="14">of the certainty or precision of the treatment effect. The</text>
<text top="989" left="64" width="350" height="13" font="14">writing committee reviews and ranks evidence supporting</text>
<text top="1007" left="64" width="350" height="13" font="14">each recommendation with the weight of evidence ranked as</text>
<text top="1025" left="64" width="218" height="13" font="14">LOE A, B, or C according to speci</text>
<text top="1021" left="282" width="132" height="18" font="14">ﬁc deﬁnitions that are</text>
<text top="1043" left="64" width="65" height="13" font="14">included in</text>
<text top="1043" left="135" width="45" height="13" font="15"><a href="e147.full.html#5">Table 1</a></text>
<text top="1043" left="180" width="111" height="13" font="14"><a href="e147.full.html#5">. </a>Studies are identi</text>
<text top="1039" left="291" width="123" height="18" font="14">ﬁed as observational,</text>
<text top="1061" left="64" width="350" height="13" font="14">retrospective, prospective, or randomized where appropriate.</text>
<text top="1079" left="64" width="350" height="13" font="14">For certain conditions for which inadequate data are available,</text>
<text top="103" left="450" width="350" height="13" font="14">recommendations are based on expert consensus and clinical</text>
<text top="121" left="450" width="350" height="13" font="14">experience and are ranked as LOE C. When recommendations</text>
<text top="139" left="450" width="350" height="13" font="14">at LOE C are supported by historical clinical data, appropriate</text>
<text top="157" left="450" width="350" height="13" font="14">references (including clinical reviews) are cited if available.</text>
<text top="175" left="450" width="350" height="13" font="14">For issues for which sparse data are available, a survey of</text>
<text top="193" left="450" width="350" height="13" font="14">current practice among the clinicians on the writing committee</text>
<text top="211" left="450" width="350" height="13" font="14">is the basis for LOE C recommendations and no references are</text>
<text top="229" left="450" width="350" height="13" font="14">cited. The schema for COR and LOE are summarized in</text>
<text top="247" left="450" width="45" height="13" font="15"><a href="e147.full.html#5">Table 1</a></text>
<text top="247" left="495" width="305" height="13" font="14"><a href="e147.full.html#5">, </a>which also provides suggested phrases for writing</text>
<text top="265" left="450" width="350" height="13" font="14">recommendations within each COR. A new addition to this</text>
<text top="283" left="450" width="350" height="13" font="14">methodology is separation of the Class III recommendations to</text>
<text top="301" left="450" width="350" height="13" font="14">delineate whether the recommendation is determined to be of</text>
<text top="315" left="450" width="350" height="18" font="14">“no beneﬁt” or is associated with “harm” to the patient. In</text>
<text top="337" left="450" width="350" height="13" font="14">addition, in view of the increasing number of comparative</text>
<text top="354" left="450" width="350" height="13" font="14">effectiveness studies, comparator verbs and suggested phrases</text>
<text top="372" left="450" width="350" height="13" font="14">for writing recommendations for the comparative effectiveness</text>
<text top="390" left="450" width="350" height="13" font="14">of one treatment or strategy versus another have been added</text>
<text top="408" left="450" width="214" height="13" font="14">for COR I and IIa, LOE A or B only.</text>
<text top="426" left="465" width="335" height="13" font="14">In view of the advances in medical therapy across the</text>
<text top="444" left="450" width="350" height="13" font="14">spectrum of cardiovascular diseases, the Task Force has</text>
<text top="462" left="450" width="350" height="13" font="14">designated the term guideline-directed medical therapy</text>
<text top="480" left="450" width="302" height="13" font="14">(GDMT) to represent optimal medical therapy as de</text>
<text top="476" left="752" width="48" height="18" font="14">ﬁned by</text>
<text top="498" left="450" width="134" height="13" font="14">ACCF/AHA guideline</text>
<text top="494" left="584" width="215" height="18" font="14">–recommended therapies (primarily</text>
<text top="516" left="450" width="350" height="13" font="14">Class I). This new term, GDMT, will be used herein and</text>
<text top="534" left="450" width="185" height="13" font="14">throughout all future guidelines.</text>
<text top="552" left="465" width="335" height="13" font="14">Because the ACCF/AHA practice guidelines address</text>
<text top="570" left="450" width="350" height="13" font="14">patient populations (and clinicians) residing in North America,</text>
<text top="588" left="450" width="350" height="13" font="14">drugs that are not currently available in North America are</text>
<text top="606" left="450" width="223" height="13" font="14">discussed in the text without a speci</text>
<text top="602" left="673" width="126" height="18" font="14">ﬁc COR. For studies</text>
<text top="624" left="450" width="350" height="13" font="14">performed in large numbers of subjects outside North America,</text>
<text top="641" left="450" width="290" height="13" font="14">each writing committee reviews the potential in</text>
<text top="638" left="740" width="60" height="18" font="14">ﬂuence of</text>
<text top="659" left="450" width="350" height="13" font="14">different practice patterns and patient populations on the</text>
<text top="677" left="450" width="350" height="13" font="14">treatment effect and relevance to the ACCF/AHA target pop-</text>
<text top="695" left="450" width="203" height="13" font="14">ulation to determine whether the</text>
<text top="691" left="661" width="138" height="18" font="14">ﬁndings should inform</text>
<text top="713" left="450" width="39" height="13" font="14">a speci</text>
<text top="709" left="489" width="116" height="18" font="14">ﬁc recommendation.</text>
<text top="731" left="465" width="335" height="13" font="14">The ACCF/AHA practice guidelines are intended to assist</text>
<text top="749" left="450" width="350" height="13" font="14">clinicians in clinical decision making by describing a range of</text>
<text top="767" left="450" width="350" height="13" font="14">generally acceptable approaches to the diagnosis, manage-</text>
<text top="785" left="450" width="173" height="13" font="14">ment, and prevention of speci</text>
<text top="781" left="623" width="176" height="18" font="14">ﬁc diseases or conditions. The</text>
<text top="803" left="450" width="139" height="13" font="14">guidelines attempt to de</text>
<text top="799" left="589" width="210" height="18" font="14">ﬁne practices that meet the needs of</text>
<text top="821" left="450" width="350" height="13" font="14">most patients in most circumstances. The ultimate judgment</text>
<text top="839" left="450" width="350" height="13" font="14">regarding care of a particular patient must be made by the</text>
<text top="857" left="450" width="350" height="13" font="14">clinician and patient in light of all the circumstances presented</text>
<text top="874" left="450" width="350" height="13" font="14">by that patient. As a result, situations may arise for which</text>
<text top="892" left="450" width="350" height="13" font="14">deviations from these guidelines may be appropriate. Clinical</text>
<text top="910" left="450" width="350" height="13" font="14">decision making should involve consideration of the quality</text>
<text top="928" left="450" width="350" height="13" font="14">and availability of expertise in the area where care is</text>
<text top="946" left="450" width="350" height="13" font="14">provided. When these guidelines are used as the basis for</text>
<text top="964" left="450" width="350" height="13" font="14">regulatory or payer decisions, the goal should be improve-</text>
<text top="982" left="450" width="350" height="13" font="14">ment in quality of care. The Task Force recognizes that</text>
<text top="1000" left="450" width="350" height="13" font="14">situations arise in which additional data are needed to inform</text>
<text top="1018" left="450" width="329" height="13" font="14">patient care more effectively; these areas will be identi</text>
<text top="1014" left="778" width="21" height="18" font="14">ﬁed</text>
<text top="1036" left="450" width="292" height="13" font="14">within each respective guideline when appropriate.</text>
<text top="1054" left="465" width="335" height="13" font="14">Prescribed courses of treatment in accordance with these</text>
<text top="1072" left="450" width="350" height="13" font="14">recommendations are effective only if followed. Because lack</text>
<text top="1090" left="450" width="350" height="13" font="14">of patient understanding and adherence may adversely affect</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e150</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1160" width="864">
<text top="928" left="64" width="350" height="13" font="14">outcomes, clinicians should make every effort to engage the</text>
<text top="946" left="64" width="38" height="13" font="14">patient</text>
<text top="942" left="102" width="312" height="18" font="14">’s active participation in prescribed medical regimens</text>
<text top="964" left="64" width="350" height="13" font="14">and lifestyles. In addition, patients should be informed of the</text>
<text top="982" left="64" width="60" height="13" font="14">risks, bene</text>
<text top="978" left="124" width="290" height="18" font="14">ﬁts, and alternatives to a particular treatment and be</text>
<text top="1000" left="64" width="350" height="13" font="14">involved in shared decision making whenever feasible,</text>
<text top="1018" left="64" width="297" height="13" font="14">particularly for COR IIa and IIb, for which the bene</text>
<text top="1014" left="361" width="53" height="18" font="14">ﬁt-to-risk</text>
<text top="1036" left="64" width="113" height="13" font="14">ratio may be lower.</text>
<text top="1054" left="79" width="335" height="13" font="14">The Task Force makes every effort to avoid actual,</text>
<text top="1072" left="64" width="155" height="13" font="14">potential, or perceived con</text>
<text top="1068" left="219" width="195" height="18" font="14">ﬂicts of interest that may arise as</text>
<text top="1090" left="64" width="350" height="13" font="14">a result of industry relationships or personal interests among</text>
<text top="928" left="450" width="350" height="13" font="14">the members of the writing committee. All writing committee</text>
<text top="946" left="450" width="350" height="13" font="14">members and peer reviewers of the guideline are required to</text>
<text top="964" left="450" width="350" height="13" font="14">disclose all current healthcare-related relationships, including</text>
<text top="982" left="450" width="350" height="13" font="14">those existing 12 months before initiation of the writing effort.</text>
<text top="1000" left="450" width="350" height="13" font="14">In December 2009, the ACCF and AHA implemented a new</text>
<text top="1018" left="450" width="350" height="13" font="14">policy for relationship with industry and other entities (RWI)</text>
<text top="1036" left="450" width="350" height="13" font="14">that requires the writing committee chair plus a minimum of</text>
<text top="1054" left="450" width="350" height="13" font="14">50% of the writing committee to have no relevant RWI</text>
<text top="1072" left="450" width="5" height="13" font="14"><a href="e147.full.html#86">(</a></text>
<text top="1072" left="454" width="71" height="13" font="15"><a href="e147.full.html#86">Appendix 1</a></text>
<text top="1072" left="533" width="173" height="13" font="14">includes the ACCF/AHA de</text>
<text top="1068" left="706" width="94" height="18" font="14">ﬁnition of rele-</text>
<text top="1090" left="450" width="350" height="13" font="14">vance). These statements are reviewed by the Task Force and</text>
<text top="103" left="64" width="410" height="12" font="9">Table 1. Applying Classification of Recommendation and Level of Evidence</text>
<text top="798" left="76" width="723" height="11" font="4">A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do</text>
<text top="813" left="64" width="735" height="11" font="4">not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful</text>
<text top="828" left="64" width="53" height="11" font="4">or effective.</text>
<text top="843" left="76" width="723" height="11" font="4">*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior</text>
<text top="858" left="64" width="304" height="11" font="4">myocardial infarction, history of heart failure, and prior aspirin use.</text>
<text top="870" left="76" width="723" height="16" font="4"><a href="e147.full.html#86">y</a>For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve</text>
<text top="888" left="64" width="305" height="11" font="4">direct comparisons of the treatments or strategies being evaluated.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e151</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="16" size="13" family="Times" color="#005c58"/>
<text top="103" left="64" width="350" height="13" font="14">all members during each conference call and/or meeting of the</text>
<text top="121" left="64" width="350" height="13" font="14">writing committee and are updated as changes occur. All</text>
<text top="139" left="64" width="235" height="13" font="14">guideline recommendations require a con</text>
<text top="135" left="300" width="114" height="18" font="14">ﬁdential vote by the</text>
<text top="157" left="64" width="350" height="13" font="14">writing committee and must be approved by a consensus of</text>
<text top="175" left="64" width="350" height="13" font="14">the voting members. Members are not permitted to draft or</text>
<text top="193" left="64" width="350" height="13" font="14">vote on any text or recommendations pertaining to their RWI.</text>
<text top="211" left="64" width="350" height="13" font="14">Members who recused themselves from voting are indicated</text>
<text top="229" left="64" width="292" height="13" font="14">in the list of writing committee members, and speci</text>
<text top="225" left="356" width="58" height="18" font="14">ﬁc section</text>
<text top="247" left="64" width="136" height="13" font="14">recusals are noted in</text>
<text top="247" left="211" width="73" height="13" font="15"><a href="e147.full.html#86">Appendix 1</a></text>
<text top="247" left="284" width="59" height="13" font="14">. Authors</text>
<text top="243" left="344" width="70" height="18" font="14">’ and peer</text>
<text top="265" left="64" width="54" height="13" font="14">reviewers</text>
<text top="261" left="119" width="295" height="18" font="14">’ RWI pertinent to this guideline are disclosed in</text>
<text top="283" left="64" width="82" height="13" font="15"><a href="e147.full.html#86">Appendixes 1</a></text>
<text top="283" left="153" width="20" height="13" font="14">and</text>
<text top="283" left="181" width="7" height="13" font="15"><a href="e147.full.html#89">2</a></text>
<text top="283" left="188" width="226" height="13" font="14"><a href="e147.full.html#89">, </a>respectively. Additionally, to ensure</text>
<text top="301" left="64" width="308" height="13" font="14">complete transparency, writing committee members</text>
<text top="297" left="373" width="41" height="18" font="14">’ com-</text>
<text top="319" left="64" width="61" height="13" font="14">prehensive</text>
<text top="319" left="138" width="57" height="13" font="14">disclosure</text>
<text top="319" left="209" width="205" height="15" font="14">informationdincluding RWI not</text>
<text top="337" left="64" width="350" height="15" font="14">pertinent to this documentdis available as an online supple-</text>
<text top="354" left="64" width="350" height="13" font="14">ment. Comprehensive disclosure information for the Task</text>
<text top="372" left="64" width="180" height="13" font="14">Force is also available online at</text>
<text top="372" left="249" width="165" height="13" font="15"><a href="http://www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">http://www.cardiosource.org/</a></text>
<text top="390" left="64" width="349" height="13" font="15"><a href="http://www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-</a></text>
<text top="408" left="64" width="201" height="13" font="15"><a href="http://www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx">and-Documents-Task-Forces.aspx</a></text>
<text top="408" left="265" width="149" height="13" font="14">. The work of writing</text>
<text top="426" left="64" width="350" height="13" font="14">committees is supported exclusively by the ACCF and AHA</text>
<text top="444" left="64" width="350" height="13" font="14">without commercial support. Writing committee members</text>
<text top="462" left="64" width="222" height="13" font="14">volunteered their time for this activity.</text>
<text top="480" left="79" width="335" height="13" font="14">In an effort to maintain relevance at the point of care for</text>
<text top="498" left="64" width="350" height="13" font="14">practicing clinicians, the Task Force continues to oversee an</text>
<text top="516" left="64" width="350" height="13" font="14">ongoing process improvement initiative. As a result, in</text>
<text top="534" left="64" width="350" height="13" font="14">response to pilot projects, several changes to these guidelines</text>
<text top="552" left="64" width="350" height="13" font="14">will be apparent, including limited narrative text, a focus on</text>
<text top="570" left="64" width="350" height="13" font="14">summary and evidence tables (with references linked to</text>
<text top="588" left="64" width="350" height="13" font="14">abstracts in PubMed), and more liberal use of summary</text>
<text top="606" left="64" width="350" height="13" font="14">recommendation tables (with references that support LOE) to</text>
<text top="623" left="64" width="153" height="13" font="14">serve as a quick reference.</text>
<text top="641" left="79" width="335" height="13" font="14">In April 2011, the Institute of Medicine released 2 reports:</text>
<text top="659" left="64" width="350" height="13" font="14">Clinical Practice Guidelines We Can Trust and Finding What</text>
<text top="677" left="64" width="350" height="13" font="14">Works in Health Care: Standards for Systematic Reviews</text>
<text top="695" left="64" width="27" height="13" font="15"><a href="e147.full.html#64">(2,3)</a></text>
<text top="695" left="91" width="323" height="13" font="14">. It is noteworthy that the ACCF/AHA practice guide-</text>
<text top="713" left="64" width="350" height="13" font="14">lines are cited as being compliant with many of the proposed</text>
<text top="731" left="64" width="350" height="13" font="14">standards. A thorough review of these reports and of our</text>
<text top="749" left="64" width="350" height="13" font="14">current methodology is under way, with further enhancements</text>
<text top="767" left="64" width="65" height="13" font="14">anticipated.</text>
<text top="785" left="79" width="335" height="13" font="14">The recommendations in this guideline are considered</text>
<text top="803" left="64" width="350" height="13" font="14">current until they are superseded by a focused update or the</text>
<text top="821" left="64" width="266" height="13" font="14">full-text guideline is revised. Guidelines are of</text>
<text top="817" left="330" width="83" height="18" font="14">ﬁcial policy of</text>
<text top="839" left="64" width="152" height="13" font="14">both the ACCF and AHA.</text>
<text top="857" left="183" width="231" height="13" font="14">Jeffrey L. Anderson, MD, FACC, FAHA</text>
<text top="875" left="99" width="315" height="13" font="14">Chair, ACCF/AHA Task Force on Practice Guidelines</text>
<text top="921" left="64" width="123" height="15" font="13">1. Introduction</text>
<text top="963" left="64" width="296" height="14" font="16">1.1. Methodology and Evidence Review</text>
<text top="982" left="65" width="349" height="13" font="14">The recommendations listed in this document are, whenever</text>
<text top="1000" left="64" width="350" height="13" font="14">possible, evidence based. An extensive evidence review was</text>
<text top="1018" left="64" width="350" height="13" font="14">conducted through October 2011 and includes selected other</text>
<text top="1036" left="64" width="350" height="13" font="14">references through April 2013. Searches were extended to</text>
<text top="1054" left="64" width="350" height="13" font="14">studies, reviews, and other evidence conducted in human</text>
<text top="1072" left="64" width="350" height="13" font="14">subjects and that were published in English from PubMed,</text>
<text top="1090" left="64" width="350" height="13" font="14">EMBASE, Cochrane, Agency for Healthcare Research and</text>
<text top="103" left="450" width="350" height="13" font="14">Quality Reports, and other selected databases relevant to this</text>
<text top="121" left="450" width="350" height="13" font="14">guideline. Key search words included but were not limited to</text>
<text top="139" left="450" width="350" height="13" font="14">the following: heart failure, cardiomyopathy, quality of life,</text>
<text top="157" left="450" width="350" height="13" font="14">mortality, hospitalizations, prevention, biomarkers, hyper-</text>
<text top="175" left="450" width="350" height="13" font="14">tension, dyslipidemia, imaging, cardiac catheterization,</text>
<text top="193" left="450" width="92" height="13" font="14">endomyocardial</text>
<text top="193" left="557" width="40" height="13" font="14">biopsy,</text>
<text top="193" left="612" width="130" height="13" font="14">angiotensin-converting</text>
<text top="193" left="758" width="41" height="13" font="14">enzyme</text>
<text top="211" left="450" width="350" height="13" font="14">inhibitors, angiotensin-receptor antagonists/blockers, beta</text>
<text top="229" left="450" width="338" height="13" font="14">blockers, cardiac, cardiac resynchronization therapy, de</text>
<text top="225" left="788" width="12" height="18" font="14">ﬁ-</text>
<text top="247" left="450" width="350" height="13" font="14">brillator, device-based therapy, implantable cardioverter-</text>
<text top="265" left="450" width="13" height="13" font="14">de</text>
<text top="261" left="463" width="336" height="18" font="14">ﬁbrillator, device implantation, medical therapy, acute</text>
<text top="283" left="450" width="350" height="13" font="14">decompensated heart failure, preserved ejection fraction,</text>
<text top="301" left="450" width="350" height="13" font="14">terminal care and transplantation, quality measures, and</text>
<text top="319" left="450" width="350" height="13" font="14">performance measures. Additionally, the committee reviewed</text>
<text top="337" left="450" width="350" height="13" font="14">documents related to the subject matter previously published</text>
<text top="354" left="450" width="350" height="13" font="14">by the ACCF and AHA. References selected and published in</text>
<text top="372" left="450" width="311" height="13" font="14">this document are representative and not all-inclusive.</text>
<text top="390" left="465" width="335" height="13" font="14">To provide clinicians with a representative evidence base,</text>
<text top="408" left="450" width="350" height="13" font="14">whenever deemed appropriate or when published, the abso-</text>
<text top="426" left="450" width="350" height="13" font="14">lute risk difference and number needed to treat or harm are</text>
<text top="444" left="450" width="337" height="13" font="14">provided in the guideline (within tables), along with con</text>
<text top="440" left="787" width="12" height="18" font="14">ﬁ-</text>
<text top="462" left="450" width="350" height="13" font="14">dence intervals and data related to the relative treatment</text>
<text top="480" left="450" width="350" height="13" font="14">effects such as odds ratio, relative risk, hazard ratio, and</text>
<text top="498" left="450" width="113" height="13" font="14">incidence rate ratio.</text>
<text top="533" left="450" width="326" height="14" font="16">1.2. Organization of the Writing Committee</text>
<text top="552" left="451" width="349" height="13" font="14">The committee was composed of physicians and a nurse with</text>
<text top="570" left="450" width="350" height="13" font="14">broad expertise in the evaluation, care, and management of</text>
<text top="588" left="450" width="350" height="13" font="14">patients with heart failure (HF). The authors included general</text>
<text top="605" left="450" width="350" height="13" font="14">cardiologists, HF and transplant specialists, electrophysiolo-</text>
<text top="623" left="450" width="350" height="13" font="14">gists, general internists, and physicians with methodological</text>
<text top="641" left="450" width="350" height="13" font="14">expertise. The committee included representatives from the</text>
<text top="659" left="450" width="350" height="13" font="14">ACCF, AHA, American Academy of Family Physicians,</text>
<text top="677" left="450" width="350" height="13" font="14">American College of Chest Physicians, American College of</text>
<text top="695" left="450" width="350" height="13" font="14">Physicians, Heart Rhythm Society, and International Society</text>
<text top="713" left="450" width="208" height="13" font="14">for Heart and Lung Transplantation.</text>
<text top="748" left="450" width="273" height="14" font="16">1.3. Document Review and Approval</text>
<text top="767" left="451" width="227" height="13" font="14">This document was reviewed by 2 of</text>
<text top="763" left="678" width="122" height="18" font="14">ﬁcial reviewers each</text>
<text top="785" left="450" width="350" height="13" font="14">nominated by both the ACCF and the AHA, as well as 1 to 2</text>
<text top="803" left="450" width="350" height="13" font="14">reviewers each from the American Academy of Family</text>
<text top="821" left="450" width="350" height="13" font="14">Physicians, American College of Chest Physicians, Heart</text>
<text top="839" left="450" width="350" height="13" font="14">Rhythm Society, and International Society for Heart and Lung</text>
<text top="857" left="450" width="350" height="13" font="14">Transplantation, as well as 32 individual content reviewers</text>
<text top="874" left="450" width="350" height="13" font="14">(including members of the ACCF Adult Congenital and</text>
<text top="892" left="450" width="350" height="13" font="14">Pediatric Cardiology Council, ACCF Cardiovascular Team</text>
<text top="910" left="450" width="350" height="13" font="14">Council, ACCF Council on Cardiovascular Care for Older</text>
<text top="928" left="450" width="350" height="13" font="14">Adults, ACCF Electrophysiology Committee, ACCF Heart</text>
<text top="946" left="450" width="350" height="13" font="14">Failure and Transplant Council, ACCF Imaging Council,</text>
<text top="964" left="450" width="284" height="13" font="14">ACCF Prevention Committee, ACCF Surgeons</text>
<text top="960" left="734" width="65" height="18" font="14">’ Scientiﬁc</text>
<text top="982" left="450" width="350" height="13" font="14">Council, and ACCF Task Force on Appropriate Use Criteria).</text>
<text top="1000" left="450" width="173" height="13" font="14">All information on reviewers</text>
<text top="996" left="623" width="176" height="18" font="14">’ RWI was distributed to the</text>
<text top="1018" left="450" width="350" height="13" font="14">writing committee and is published in this document</text>
<text top="1036" left="450" width="5" height="13" font="14"><a href="e147.full.html#86">(</a></text>
<text top="1036" left="454" width="68" height="13" font="15"><a href="e147.full.html#86">Appendix 2</a></text>
<text top="1036" left="522" width="8" height="13" font="14"><a href="e147.full.html#86">).</a></text>
<text top="1054" left="465" width="335" height="13" font="14">This document was approved for publication by the gov-</text>
<text top="1072" left="450" width="350" height="13" font="14">erning bodies of the ACCF and AHA and endorsed by the</text>
<text top="1090" left="450" width="350" height="13" font="14">American Association of Cardiovascular and Pulmonary</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e152</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">Rehabilitation, American College of Chest Physicians, Heart</text>
<text top="121" left="64" width="350" height="13" font="14">Rhythm Society, and International Society for Heart and Lung</text>
<text top="139" left="64" width="92" height="13" font="14">Transplantation.</text>
<text top="190" left="64" width="332" height="14" font="16">1.4. Scope of This Guideline With Reference</text>
<text top="210" left="64" width="330" height="14" font="16">to Other Relevant Guidelines or Statements</text>
<text top="229" left="65" width="349" height="13" font="14">This guideline covers multiple management issues for the</text>
<text top="247" left="64" width="350" height="13" font="14">adult patient with HF. Although there is an abundance of</text>
<text top="265" left="64" width="350" height="13" font="14">evidence addressing HF, for many important clinical consid-</text>
<text top="283" left="64" width="337" height="13" font="14">erations, this writing committee was unable to identify suf</text>
<text top="279" left="402" width="12" height="18" font="14">ﬁ-</text>
<text top="301" left="64" width="350" height="13" font="14">cient data to properly inform a recommendation. The writing</text>
<text top="319" left="64" width="324" height="13" font="14">committee actively worked to reduce the number of LOE</text>
<text top="315" left="392" width="22" height="18" font="14">“C”</text>
<text top="337" left="64" width="259" height="13" font="14">recommendations, especially for Class I</text>
<text top="333" left="323" width="91" height="18" font="14">recommended</text>
<text top="354" left="64" width="350" height="13" font="14">therapies. Despite these limitations, it is apparent that much</text>
<text top="372" left="64" width="350" height="13" font="14">can be done for HF. Adherence to the clinical practice</text>
<text top="390" left="64" width="350" height="13" font="14">guidelines herein reproduced should lead to improved patient</text>
<text top="408" left="64" width="57" height="13" font="14">outcomes.</text>
<text top="426" left="79" width="335" height="13" font="14">Although of increasing importance, HF in children and</text>
<text top="444" left="64" width="315" height="13" font="14">congenital heart lesions in adults are not speci</text>
<text top="440" left="379" width="35" height="18" font="14">ﬁcally</text>
<text top="462" left="64" width="350" height="13" font="14">addressed in this guideline. The reader is referred to publically</text>
<text top="480" left="64" width="350" height="13" font="14">available resources to address questions in these areas.</text>
<text top="498" left="64" width="350" height="13" font="14">However, this guideline does address HF with preserved</text>
<text top="516" left="64" width="350" height="13" font="14">ejection fraction (EF) in more detail and similarly revisits</text>
<text top="534" left="64" width="350" height="13" font="14">hospitalized HF. Additional areas of renewed interest are in</text>
<text top="552" left="64" width="350" height="13" font="14">stage D HF, palliative care, transition of care, and quality of</text>
<text top="570" left="64" width="350" height="13" font="14">care for HF. Certain management strategies appropriate for</text>
<text top="588" left="64" width="350" height="13" font="14">the patient at risk for HF or already affected by HF are also</text>
<text top="606" left="64" width="350" height="13" font="14">reviewed in numerous relevant clinical practice guidelines and</text>
<text top="623" left="64" width="36" height="13" font="14">scienti</text>
<text top="620" left="101" width="313" height="18" font="14">ﬁc statements published by the ACCF/AHA Task Force</text>
<text top="641" left="64" width="350" height="13" font="14">on Practice Guidelines, AHA, ACCF Task Force on Appro-</text>
<text top="659" left="64" width="350" height="13" font="14">priate Use Criteria, European Society of Cardiology, Heart</text>
<text top="677" left="64" width="350" height="13" font="14">Failure Society of America, and the National Heart, Lung, and</text>
<text top="695" left="64" width="350" height="13" font="14">Blood Institute. The writing committee saw no need to reit-</text>
<text top="713" left="64" width="350" height="13" font="14">erate the recommendations contained in those guidelines and</text>
<text top="731" left="64" width="350" height="13" font="14">chose to harmonize recommendations when appropriate and</text>
<text top="749" left="64" width="350" height="13" font="14">eliminate discrepancies. This is especially the case for device-</text>
<text top="767" left="64" width="350" height="13" font="14">based therapeutics, where complete alignment between the</text>
<text top="785" left="64" width="350" height="13" font="14">HF guideline and the device-based therapy guideline was</text>
<text top="803" left="64" width="109" height="13" font="14">deemed imperative</text>
<text top="803" left="178" width="16" height="13" font="15"><a href="e147.full.html#64">(4)</a></text>
<text top="803" left="195" width="219" height="13" font="14"><a href="e147.full.html#64">. </a>Some recommendations from earlier</text>
<text top="821" left="64" width="350" height="13" font="14">guidelines have been updated as warranted by new evidence</text>
<text top="839" left="64" width="350" height="13" font="14">or a better understanding of earlier evidence, whereas others</text>
<text top="857" left="64" width="350" height="13" font="14">that were no longer accurate or relevant or which were</text>
<text top="875" left="64" width="134" height="13" font="14">overlapping were modi</text>
<text top="871" left="198" width="216" height="18" font="14">ﬁed; recommendations from previous</text>
<text top="892" left="64" width="350" height="13" font="14">guidelines that were similar or redundant were eliminated or</text>
<text top="910" left="64" width="161" height="13" font="14">consolidated when possible.</text>
<text top="928" left="79" width="335" height="13" font="14">The present document recommends a combination of life-</text>
<text top="946" left="64" width="62" height="13" font="14">style modi</text>
<text top="943" left="126" width="288" height="18" font="14">ﬁcations and medications that constitute GDMT.</text>
<text top="964" left="64" width="89" height="13" font="14">GDMT is speci</text>
<text top="960" left="153" width="261" height="18" font="14">ﬁcally referenced in the recommendations for</text>
<text top="982" left="64" width="131" height="13" font="14">the treatment of HF (</text>
<text top="982" left="196" width="77" height="13" font="15"><a href="e147.full.html#26">Section 7.3.2</a></text>
<text top="982" left="273" width="141" height="13" font="14"><a href="e147.full.html#26">). </a>Both for GDMT and</text>
<text top="1000" left="64" width="350" height="13" font="14">other recommended drug treatment regimens, the reader is</text>
<text top="1018" left="64" width="81" height="13" font="14">advised to con</text>
<text top="1014" left="146" width="268" height="18" font="14">ﬁrm dosages with product insert material and to</text>
<text top="1036" left="64" width="350" height="13" font="14">evaluate carefully for contraindications and drug-drug inter-</text>
<text top="1054" left="64" width="43" height="13" font="14">actions.</text>
<text top="1054" left="111" width="42" height="13" font="15"><a href="e147.full.html#8">Table 2</a></text>
<text top="1054" left="157" width="257" height="13" font="14">is a list of documents deemed pertinent to this</text>
<text top="1072" left="64" width="350" height="13" font="14">effort and is intended for use as a resource; it obviates the</text>
<text top="1090" left="64" width="350" height="13" font="14">need to repeat already extant guideline recommendations.</text>
<text top="103" left="450" width="350" height="13" font="14">Additional other HF guideline statements are highlighted as</text>
<text top="121" left="450" width="312" height="13" font="14">well for the purpose of comparison and completeness.</text>
<text top="161" left="450" width="46" height="15" font="13">2. De</text>
<text top="156" left="496" width="106" height="22" font="13">ﬁnition of HF</text>
<text top="204" left="451" width="349" height="13" font="14">HF is a complex clinical syndrome that results from any</text>
<text top="222" left="450" width="291" height="13" font="14">structural or functional impairment of ventricular</text>
<text top="218" left="748" width="52" height="18" font="14">ﬁlling or</text>
<text top="240" left="450" width="350" height="13" font="14">ejection of blood. The cardinal manifestations of HF are</text>
<text top="258" left="450" width="350" height="13" font="14">dyspnea and fatigue, which may limit exercise tolerance, and</text>
<text top="272" left="450" width="350" height="18" font="14">ﬂuid retention, which may lead to pulmonary and/or</text>
<text top="294" left="450" width="350" height="13" font="14">splanchnic congestion and/or peripheral edema. Some patients</text>
<text top="312" left="450" width="263" height="13" font="14">have exercise intolerance but little evidence of</text>
<text top="308" left="716" width="83" height="18" font="14">ﬂuid retention,</text>
<text top="329" left="450" width="350" height="13" font="14">whereas others complain primarily of edema, dyspnea, or</text>
<text top="347" left="450" width="350" height="13" font="14">fatigue. Because some patients present without signs or</text>
<text top="365" left="450" width="243" height="13" font="14">symptoms of volume overload, the term</text>
<text top="361" left="699" width="100" height="18" font="14">“heart failure” is</text>
<text top="383" left="450" width="82" height="13" font="14">preferred over</text>
<text top="379" left="537" width="263" height="18" font="14">“congestive heart failure.” There is no single</text>
<text top="401" left="450" width="350" height="13" font="14">diagnostic test for HF because it is largely a clinical diagnosis</text>
<text top="419" left="450" width="303" height="13" font="14">based on a careful history and physical examination.</text>
<text top="437" left="465" width="335" height="13" font="14">The clinical syndrome of HF may result from disorders of</text>
<text top="455" left="450" width="350" height="13" font="14">the pericardium, myocardium, endocardium, heart valves, or</text>
<text top="473" left="450" width="350" height="13" font="14">great vessels or from certain metabolic abnormalities, but</text>
<text top="491" left="450" width="350" height="13" font="14">most patients with HF have symptoms due to impaired left</text>
<text top="509" left="450" width="350" height="13" font="14">ventricular (LV) myocardial function. It should be empha-</text>
<text top="527" left="450" width="350" height="13" font="14">sized that HF is not synonymous with either cardiomyopathy</text>
<text top="545" left="450" width="350" height="13" font="14">or LV dysfunction; these latter terms describe possible</text>
<text top="563" left="450" width="350" height="13" font="14">structural or functional reasons for the development of HF.</text>
<text top="581" left="450" width="350" height="13" font="14">HF may be associated with a wide spectrum of LV functional</text>
<text top="598" left="450" width="350" height="13" font="14">abnormalities, which may range from patients with normal</text>
<text top="616" left="450" width="350" height="13" font="14">LV size and preserved EF to those with severe dilatation and/</text>
<text top="634" left="450" width="350" height="13" font="14">or markedly reduced EF. In most patients, abnormalities of</text>
<text top="652" left="450" width="350" height="13" font="14">systolic and diastolic dysfunction coexist, irrespective of EF.</text>
<text top="670" left="450" width="211" height="13" font="14">EF is considered important in classi</text>
<text top="666" left="661" width="139" height="18" font="14">ﬁcation of patients with</text>
<text top="688" left="450" width="350" height="13" font="14">HF because of differing patient demographics, comorbid</text>
<text top="706" left="450" width="290" height="13" font="14">conditions, prognosis, and response to therapies</text>
<text top="706" left="748" width="23" height="13" font="15"><a href="e147.full.html#65">(35)</a></text>
<text top="706" left="779" width="20" height="13" font="14">and</text>
<text top="724" left="450" width="350" height="13" font="14">because most clinical trials selected patients based on EF. EF</text>
<text top="742" left="450" width="350" height="13" font="14">values are dependent on the imaging technique used, method</text>
<text top="760" left="450" width="350" height="13" font="14">of analysis, and operator. Because other techniques may</text>
<text top="778" left="450" width="350" height="13" font="14">indicate abnormalities in systolic function among patients</text>
<text top="796" left="450" width="350" height="13" font="14">with a preserved EF, it is preferable to use the terms preserved</text>
<text top="814" left="450" width="350" height="13" font="14">or reduced EF over preserved or reduced systolic function.</text>
<text top="832" left="450" width="350" height="13" font="14">For the remainder of this guideline, we will consistently refer</text>
<text top="850" left="450" width="350" height="13" font="14">to HF with preserved EF and HF with reduced EF as HFpEF</text>
<text top="867" left="450" width="150" height="13" font="14">and HFrEF, respectively <a href="e147.full.html#9">(</a></text>
<text top="867" left="600" width="44" height="13" font="15"><a href="e147.full.html#9">Table 3</a></text>
<text top="867" left="644" width="8" height="13" font="14"><a href="e147.full.html#9">).</a></text>
<text top="909" left="450" width="217" height="14" font="16">2.1. HF With Reduced EF (HF</text>
<text top="905" left="666" width="30" height="20" font="16">rEF)</text>
<text top="928" left="451" width="349" height="13" font="14">In approximately half of patients with HFrEF, variable</text>
<text top="946" left="450" width="300" height="13" font="14">degrees of LV enlargement may accompany HFrEF</text>
<text top="946" left="755" width="41" height="13" font="15"><a href="e147.full.html#65">(36,37)</a></text>
<text top="946" left="796" width="4" height="13" font="14"><a href="e147.full.html#65">.</a></text>
<text top="964" left="450" width="44" height="13" font="14">The de</text>
<text top="960" left="494" width="306" height="18" font="14">ﬁnition of HFrEF has varied, with guidelines of</text>
<text top="982" left="450" width="250" height="13" font="14">left ventricular ejection fraction (LVEF)</text>
<text top="978" left="709" width="90" height="18" font="14">35%, &lt;40%,</text>
<text top="1000" left="450" width="20" height="13" font="14">and</text>
<text top="996" left="476" width="37" height="18" font="14">40%</text>
<text top="1000" left="518" width="59" height="13" font="15"><a href="e147.full.html#64">(18,19,38)</a></text>
<text top="1000" left="577" width="223" height="13" font="14"><a href="e147.full.html#64">. </a>Randomized controlled trials (RCTs)</text>
<text top="1018" left="450" width="350" height="13" font="14">in patients with HF have mainly enrolled patients with HFrEF</text>
<text top="1036" left="450" width="65" height="13" font="14">with an EF</text>
<text top="1032" left="520" width="280" height="18" font="14">35% or 40%, and it is only in these patients</text>
<text top="1054" left="450" width="39" height="13" font="14">that ef</text>
<text top="1050" left="489" width="311" height="18" font="14">ﬁcacious therapies have been demonstrated to date.</text>
<text top="1072" left="450" width="233" height="13" font="14">For the present guideline, HFrEF is de</text>
<text top="1068" left="683" width="117" height="18" font="14">ﬁned as the clinical</text>
<text top="1090" left="450" width="150" height="13" font="14">diagnosis of HF and EF</text>
<text top="1086" left="608" width="192" height="18" font="14">40%. Those with LV systolic</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e153</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1160" width="864">
<text top="1017" left="64" width="350" height="13" font="14">dysfunction commonly have elements of diastolic dysfunction</text>
<text top="1035" left="64" width="42" height="13" font="14">as well</text>
<text top="1035" left="112" width="23" height="13" font="15"><a href="e147.full.html#65">(39)</a></text>
<text top="1035" left="135" width="279" height="13" font="14">. Although coronary artery disease (CAD) with</text>
<text top="1053" left="64" width="350" height="13" font="14">antecedent myocardial infarction (MI) is a major cause of</text>
<text top="1071" left="64" width="187" height="13" font="14">HFrEF, many other risk factors (</text>
<text top="1071" left="252" width="64" height="13" font="15"><a href="e147.full.html#11">Section 4.6</a></text>
<text top="1071" left="316" width="98" height="13" font="14"><a href="e147.full.html#11">) </a>may lead to LV</text>
<text top="1089" left="64" width="143" height="13" font="14">enlargement and HFrEF.</text>
<text top="1017" left="450" width="227" height="14" font="16">2.2. HF With Preserved EF (HF</text>
<text top="1013" left="677" width="33" height="20" font="16">pEF)</text>
<text top="1036" left="451" width="349" height="13" font="14">In patients with clinical HF, studies estimate that the preva-</text>
<text top="1054" left="450" width="350" height="13" font="14">lence of HFpEF is approximately 50% (range 40% to 71%)</text>
<text top="1072" left="450" width="23" height="13" font="15"><a href="e147.full.html#65">(40)</a></text>
<text top="1072" left="473" width="326" height="13" font="14">. These estimates vary largely because of the differing</text>
<text top="1090" left="450" width="350" height="13" font="14">EF cut-off criteria and challenges in diagnostic criteria for</text>
<text top="103" left="64" width="258" height="12" font="9">Table 2. Associated Guidelines and Statements</text>
<text top="149" left="64" width="19" height="11" font="4">Title</text>
<text top="149" left="563" width="55" height="11" font="4">Organization</text>
<text top="134" left="728" width="72" height="11" font="4">Publication Year</text>
<text top="149" left="738" width="50" height="11" font="4">(Reference)</text>
<text top="169" left="64" width="46" height="11" font="4">Guidelines</text>
<text top="189" left="76" width="326" height="11" font="4">Guidelines for the Management of Adults With Congenital Heart Disease</text>
<text top="189" left="567" width="46" height="11" font="4">ACCF/AHA</text>
<text top="189" left="744" width="23" height="11" font="4">2008</text>
<text top="189" left="771" width="11" height="11" font="5"><a href="e147.full.html#64">(5)</a></text>
<text top="208" left="76" width="293" height="11" font="4">Guidelines for the Management of Patients With Atrial Fibrillation</text>
<text top="208" left="556" width="68" height="11" font="4">ACCF/AHA/HRS</text>
<text top="208" left="739" width="23" height="11" font="4">2011</text>
<text top="208" left="765" width="23" height="11" font="5"><a href="e147.full.html#64">(6–8)</a></text>
<text top="228" left="76" width="328" height="11" font="4">Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults</text>
<text top="228" left="567" width="46" height="11" font="4">ACCF/AHA</text>
<text top="228" left="744" width="23" height="11" font="4">2010</text>
<text top="228" left="771" width="11" height="11" font="5"><a href="e147.full.html#64">(9)</a></text>
<text top="247" left="76" width="229" height="11" font="4">Guideline for Coronary Artery Bypass Graft Surgery</text>
<text top="247" left="567" width="46" height="11" font="4">ACCF/AHA</text>
<text top="247" left="742" width="23" height="11" font="4">2011</text>
<text top="247" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(10)</a></text>
<text top="266" left="76" width="318" height="11" font="4">Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities</text>
<text top="266" left="556" width="68" height="11" font="4">ACCF/AHA/HRS</text>
<text top="266" left="744" width="23" height="11" font="4">2013</text>
<text top="266" left="771" width="11" height="11" font="5"><a href="e147.full.html#64">(4)</a></text>
<text top="286" left="76" width="338" height="11" font="4">Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy</text>
<text top="286" left="567" width="46" height="11" font="4">ACCF/AHA</text>
<text top="286" left="742" width="23" height="11" font="4">2011</text>
<text top="286" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(11)</a></text>
<text top="305" left="76" width="220" height="11" font="4">Guideline for Percutaneous Coronary Intervention</text>
<text top="305" left="555" width="69" height="11" font="4">ACCF/AHA/SCAI</text>
<text top="305" left="742" width="23" height="11" font="4">2011</text>
<text top="305" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(12)</a></text>
<text top="325" left="76" width="370" height="11" font="4">Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and</text>
<text top="340" left="88" width="239" height="11" font="4">Other Atherosclerotic Vascular Disease: 2011 Update</text>
<text top="325" left="567" width="45" height="11" font="4">AHA/ACCF</text>
<text top="325" left="742" width="23" height="11" font="4">2011</text>
<text top="325" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(13)</a></text>
<text top="359" left="76" width="354" height="11" font="4">Guideline for the Diagnosis and Management of Patients With Stable Ischemic</text>
<text top="374" left="88" width="62" height="11" font="4">Heart Disease</text>
<text top="359" left="507" width="166" height="11" font="4">ACCF/AHA/ACP/AATS/PCNA/SCAI/STS</text>
<text top="359" left="742" width="23" height="11" font="4">2012</text>
<text top="359" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(14)</a></text>
<text top="393" left="76" width="306" height="11" font="4">Guideline for the Management of ST-Elevation Myocardial Infarction</text>
<text top="393" left="567" width="46" height="11" font="4">ACCF/AHA</text>
<text top="393" left="742" width="23" height="11" font="4">2013</text>
<text top="393" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(15)</a></text>
<text top="413" left="76" width="375" height="11" font="4">Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation</text>
<text top="428" left="88" width="94" height="11" font="4">Myocardial Infarction</text>
<text top="413" left="567" width="46" height="11" font="4">ACCF/AHA</text>
<text top="413" left="742" width="23" height="11" font="4">2013</text>
<text top="413" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(16)</a></text>
<text top="447" left="76" width="322" height="11" font="4">Guidelines for the Management of Patients With Valvular Heart Disease</text>
<text top="447" left="567" width="46" height="11" font="4">ACCF/AHA</text>
<text top="447" left="742" width="23" height="11" font="4">2008</text>
<text top="447" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(17)</a></text>
<text top="467" left="76" width="214" height="11" font="4">Comprehensive Heart Failure Practice Guideline</text>
<text top="467" left="578" width="24" height="11" font="4">HFSA</text>
<text top="467" left="742" width="23" height="11" font="4">2010</text>
<text top="467" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(18)</a></text>
<text top="486" left="76" width="356" height="11" font="4">Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure</text>
<text top="486" left="581" width="18" height="11" font="4">ESC</text>
<text top="486" left="741" width="23" height="11" font="4">2012</text>
<text top="486" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(19)</a></text>
<text top="506" left="76" width="377" height="11" font="4">Chronic Heart Failure: Management of Chronic Heart Failure in Adults in Primary and</text>
<text top="521" left="88" width="71" height="11" font="4">Secondary Care</text>
<text top="506" left="580" width="21" height="11" font="4">NICE</text>
<text top="506" left="742" width="23" height="11" font="4">2010</text>
<text top="506" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(20)</a></text>
<text top="540" left="76" width="242" height="11" font="4">Antithrombotic Therapy and Prevention of Thrombosis</text>
<text top="540" left="578" width="24" height="11" font="4">ACCP</text>
<text top="540" left="741" width="23" height="11" font="4">2012</text>
<text top="540" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(21)</a></text>
<text top="559" left="76" width="244" height="11" font="4">Guidelines for the Care of Heart Transplant Recipients</text>
<text top="559" left="577" width="26" height="11" font="4">ISHLT</text>
<text top="559" left="741" width="23" height="11" font="4">2010</text>
<text top="559" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(22)</a></text>
<text top="579" left="64" width="50" height="11" font="4">Statements</text>
<text top="598" left="76" width="308" height="11" font="4">Contemporary Definitions and Classification of the Cardiomyopathies</text>
<text top="598" left="581" width="18" height="11" font="4">AHA</text>
<text top="598" left="741" width="23" height="11" font="4">2006</text>
<text top="598" left="768" width="17" height="11" font="5"><a href="e147.full.html#64">(23)</a></text>
<text top="618" left="76" width="166" height="11" font="4">Genetics and Cardiovascular Disease</text>
<text top="618" left="581" width="18" height="11" font="4">AHA</text>
<text top="618" left="742" width="23" height="11" font="4">2012</text>
<text top="618" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(24)</a></text>
<text top="637" left="76" width="292" height="11" font="4">Appropriate Utilization of Cardiovascular Imaging in Heart Failure</text>
<text top="637" left="578" width="24" height="11" font="4">ACCF</text>
<text top="637" left="741" width="23" height="11" font="4">2013</text>
<text top="637" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(25)</a></text>
<text top="657" left="76" width="323" height="11" font="4">Appropriate Use Criteria for Coronary Revascularization Focused Update</text>
<text top="657" left="578" width="24" height="11" font="4">ACCF</text>
<text top="657" left="741" width="23" height="11" font="4">2012</text>
<text top="657" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(26)</a></text>
<text top="676" left="76" width="377" height="11" font="4">Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,</text>
<text top="691" left="88" width="173" height="11" font="4">and Treatment of High Blood Pressure</text>
<text top="676" left="577" width="27" height="11" font="4">NHLBI</text>
<text top="676" left="742" width="23" height="11" font="4">2003</text>
<text top="676" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(27)</a></text>
<text top="710" left="76" width="377" height="11" font="4">Implications of Recent Clinical Trials for the National Cholesterol Education Program</text>
<text top="725" left="88" width="161" height="11" font="4">Adult Treatment Panel III Guidelines</text>
<text top="710" left="577" width="27" height="11" font="4">NHLBI</text>
<text top="710" left="742" width="23" height="11" font="4">2002</text>
<text top="710" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(28)</a></text>
<text top="745" left="76" width="365" height="11" font="4">Referral, Enrollment, and Delivery of Cardiac Rehabilitation/Secondary Prevention</text>
<text top="760" left="88" width="185" height="11" font="4">Programs at Clinical Centers and Beyond</text>
<text top="745" left="561" width="57" height="11" font="4">AHA/AACVPR</text>
<text top="745" left="742" width="23" height="11" font="4">2011</text>
<text top="745" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(29)</a></text>
<text top="779" left="76" width="195" height="11" font="4">Decision Making in Advanced Heart Failure</text>
<text top="779" left="581" width="18" height="11" font="4">AHA</text>
<text top="779" left="742" width="23" height="11" font="4">2012</text>
<text top="779" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(30)</a></text>
<text top="798" left="76" width="377" height="11" font="4">Recommendations for the Use of Mechanical Circulatory Support: Device Strategies</text>
<text top="813" left="88" width="95" height="11" font="4">and Patient Selection</text>
<text top="798" left="581" width="18" height="11" font="4">AHA</text>
<text top="798" left="742" width="23" height="11" font="4">2012</text>
<text top="798" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(31)</a></text>
<text top="833" left="76" width="142" height="11" font="4">Advanced Chronic Heart Failure</text>
<text top="833" left="581" width="18" height="11" font="4">ESC</text>
<text top="833" left="742" width="23" height="11" font="4">2007</text>
<text top="833" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(32)</a></text>
<text top="852" left="76" width="344" height="11" font="4">Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial</text>
<text top="867" left="88" width="46" height="11" font="4">Fibrillation</text>
<text top="852" left="570" width="40" height="11" font="4">AHA/ASA</text>
<text top="852" left="742" width="23" height="11" font="4">2012</text>
<text top="852" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(33)</a></text>
<text top="887" left="76" width="222" height="11" font="4">Third Universal Definition of Myocardial Infarction</text>
<text top="887" left="545" width="90" height="11" font="4">ESC/ACCF/AHA/WHF</text>
<text top="887" left="742" width="23" height="11" font="4">2012</text>
<text top="887" left="768" width="17" height="11" font="5"><a href="e147.full.html#65">(34)</a></text>
<text top="908" left="76" width="723" height="11" font="4">AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AATS, American Association for Thoracic Surgery; ACCF, American College</text>
<text top="923" left="64" width="735" height="11" font="4">of Cardiology Foundation; ACCP, American College of Chest Physicians; ACP, American College of Physicians; AHA, American Heart Association; ASA, American Stroke</text>
<text top="938" left="64" width="735" height="11" font="4">Association; ESC, European Society of Cardiology; HFSA, Heart Failure Society of America; HRS, Heart Rhythm Society; ISHLT, International Society for Heart and Lung</text>
<text top="953" left="64" width="735" height="11" font="4">Transplantation; NHLBI, National Heart, Lung, and Blood Institute; NICE, National Institute for Health and Clinical Excellence; PCNA, Preventive Cardiovascular Nurses</text>
<text top="968" left="64" width="664" height="11" font="4">Association; SCAI, Society for Cardiovascular Angiography and Interventions; STS, Society of Thoracic Surgeons; and WHF, World Heart Federation.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e154</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1160" width="864">
<text top="371" left="64" width="241" height="13" font="14">HFpEF. HFpEF has been variably classi</text>
<text top="367" left="305" width="109" height="18" font="14">ﬁed as EF &gt;40%,</text>
<text top="385" left="64" width="350" height="18" font="14">&gt;45%, &gt;50%, and 55%. Because some of these patients do</text>
<text top="407" left="64" width="350" height="13" font="14">not have entirely normal EF but also do not have major</text>
<text top="425" left="64" width="350" height="13" font="14">reduction in systolic function, the term preserved EF has</text>
<text top="443" left="64" width="350" height="13" font="14">been used. Patients with an EF in the range of 40% to 50%</text>
<text top="461" left="64" width="350" height="13" font="14">represent an intermediate group. These patients are often</text>
<text top="479" left="64" width="350" height="13" font="14">treated for underlying risk factors and comorbidities and with</text>
<text top="497" left="64" width="350" height="13" font="14">GDMT similar to that used in patients with HFrEF. Several</text>
<text top="515" left="64" width="185" height="13" font="14">criteria have been proposed to de</text>
<text top="511" left="250" width="164" height="18" font="14">ﬁne the syndrome of HFpEF.</text>
<text top="533" left="64" width="350" height="13" font="14">These include a) clinical signs or symptoms of HF; b)</text>
<text top="550" left="64" width="350" height="13" font="14">evidence of preserved or normal LVEF; and c) evidence of</text>
<text top="568" left="64" width="350" height="13" font="14">abnormal LV diastolic dysfunction that can be determined by</text>
<text top="586" left="64" width="314" height="13" font="14">Doppler echocardiography or cardiac catheterization</text>
<text top="586" left="387" width="23" height="13" font="15"><a href="e147.full.html#65">(41)</a></text>
<text top="586" left="410" width="4" height="13" font="14">.</text>
<text top="604" left="64" width="350" height="13" font="14">The diagnosis of HFpEF is more challenging than the diag-</text>
<text top="622" left="64" width="350" height="13" font="14">nosis of HFrEF because it is largely one of excluding other</text>
<text top="640" left="64" width="350" height="13" font="14">potential noncardiac causes of symptoms suggestive of HF.</text>
<text top="658" left="64" width="350" height="13" font="14">Studies have suggested that the incidence of HFpEF is</text>
<text top="676" left="64" width="350" height="13" font="14">increasing and that a greater portion of patients hospitalized</text>
<text top="694" left="64" width="123" height="13" font="14">with HF have HFpEF</text>
<text top="694" left="191" width="23" height="13" font="15"><a href="e147.full.html#65">(42)</a></text>
<text top="694" left="214" width="200" height="13" font="14"><a href="e147.full.html#65">. </a>In the general population, patients</text>
<text top="712" left="64" width="350" height="13" font="14">with HFpEF are usually older women with a history of</text>
<text top="730" left="64" width="311" height="13" font="14">hypertension. Obesity, CAD, diabetes mellitus, atrial</text>
<text top="726" left="382" width="32" height="18" font="14">ﬁbril-</text>
<text top="748" left="64" width="350" height="13" font="14">lation (AF), and hyperlipidemia are also highly prevalent in</text>
<text top="766" left="64" width="297" height="13" font="14">HFpEF in population-based studies and registries</text>
<text top="766" left="369" width="41" height="13" font="15"><a href="e147.full.html#65">(40,43)</a></text>
<text top="766" left="410" width="4" height="13" font="14">.</text>
<text top="784" left="64" width="350" height="13" font="14">Despite these associated cardiovascular risk factors, hyper-</text>
<text top="802" left="64" width="350" height="13" font="14">tension remains the most important cause of HFpEF, with</text>
<text top="371" left="450" width="350" height="13" font="14">a prevalence of 60% to 89% from large controlled trials,</text>
<text top="389" left="450" width="246" height="13" font="14">epidemiological studies, and HF registries</text>
<text top="389" left="701" width="23" height="13" font="15"><a href="e147.full.html#65">(44)</a></text>
<text top="389" left="725" width="75" height="13" font="14"><a href="e147.full.html#65">. </a>It has been</text>
<text top="407" left="450" width="350" height="13" font="14">recognized that a subset of patients with HFpEF previously</text>
<text top="425" left="450" width="71" height="13" font="14">had HFrEF</text>
<text top="425" left="531" width="23" height="13" font="15"><a href="e147.full.html#65">(45)</a></text>
<text top="425" left="555" width="245" height="13" font="14"><a href="e147.full.html#65">. </a>These patients with improvement or</text>
<text top="443" left="450" width="350" height="13" font="14">recovery in EF may be clinically distinct from those with</text>
<text top="461" left="450" width="350" height="13" font="14">persistently preserved or reduced EF. Further research is</text>
<text top="479" left="450" width="249" height="13" font="14">needed to better characterize these patients.</text>
<text top="497" left="465" width="20" height="13" font="14">See</text>
<text top="497" left="492" width="163" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 1</a></text>
<text top="497" left="663" width="137" height="13" font="14">for additional data on</text>
<text top="515" left="450" width="47" height="13" font="14">HFpEF.</text>
<text top="562" left="450" width="100" height="15" font="13">3. HF Classi</text>
<text top="557" left="550" width="71" height="22" font="13">ﬁcations</text>
<text top="605" left="451" width="206" height="13" font="14">Both the ACCF/AHA stages of HF</text>
<text top="605" left="662" width="23" height="13" font="15"><a href="e147.full.html#65">(38)</a></text>
<text top="605" left="691" width="109" height="13" font="14">and the New York</text>
<text top="623" left="450" width="260" height="13" font="14">Heart Association (NYHA) functional classi</text>
<text top="619" left="710" width="42" height="18" font="14">ﬁcation</text>
<text top="623" left="758" width="41" height="13" font="15"><a href="e147.full.html#65">(38,46)</a></text>
<text top="641" left="450" width="350" height="13" font="14">provide useful and complementary information about the</text>
<text top="659" left="450" width="350" height="13" font="14">presence and severity of HF. The ACCF/AHA stages of HF</text>
<text top="676" left="450" width="350" height="13" font="14">emphasize the development and progression of disease and</text>
<text top="694" left="450" width="350" height="13" font="14">can be used to describe individuals and populations, whereas</text>
<text top="712" left="450" width="350" height="13" font="14">the NYHA classes focus on exercise capacity and the symp-</text>
<text top="730" left="450" width="171" height="13" font="14">tomatic status of the disease <a href="e147.full.html#9">(</a></text>
<text top="730" left="621" width="44" height="13" font="15"><a href="e147.full.html#9">Table 4</a></text>
<text top="730" left="665" width="8" height="13" font="14"><a href="e147.full.html#9">).</a></text>
<text top="748" left="465" width="335" height="13" font="14">The ACCF/AHA stages of HF recognize that both risk</text>
<text top="766" left="450" width="350" height="13" font="14">factors and abnormalities of cardiac structure are associated</text>
<text top="784" left="450" width="350" height="13" font="14">with HF. The stages are progressive and inviolate; once</text>
<text top="802" left="450" width="350" height="13" font="14">a patient moves to a higher stage, regression to an earlier stage</text>
<text top="103" left="64" width="141" height="12" font="9">Table 3. Definitions of HF</text>
<text top="100" left="205" width="82" height="17" font="9">rEF and HFpEF</text>
<text top="135" left="64" width="58" height="11" font="4">Classification</text>
<text top="135" left="247" width="30" height="11" font="4">EF (%)</text>
<text top="135" left="536" width="50" height="11" font="4">Description</text>
<text top="154" left="64" width="127" height="11" font="4">I. Heart failure with reduced</text>
<text top="169" left="84" width="108" height="11" font="4">ejection fraction (HFrEF)</text>
<text top="151" left="251" width="21" height="16" font="4">40</text>
<text top="154" left="321" width="478" height="11" font="4">Also referred to as systolic HF. Randomized controlled trials have mainly enrolled patients with HFr EF, and it</text>
<text top="169" left="341" width="379" height="11" font="4">is only in these patients that efficacious therapies have been demonstrated to date.</text>
<text top="189" left="64" width="137" height="11" font="4">II. Heart failure with preserved</text>
<text top="204" left="84" width="110" height="11" font="4">ejection fraction (HFpEF)</text>
<text top="186" left="251" width="21" height="16" font="4">50</text>
<text top="189" left="321" width="465" height="11" font="4">Also referred to as diastolic HF. Several different criteria have been used to further define HFp EF. The</text>
<text top="204" left="341" width="448" height="11" font="4">diagnosis of HFp EF is challenging because it is largely one of excluding other potential noncardiac</text>
<text top="219" left="341" width="428" height="11" font="4">causes of symptoms suggestive of HF. To date, efficacious therapies have not been identified.</text>
<text top="238" left="76" width="91" height="11" font="4">a. HFpEF, borderline</text>
<text top="238" left="242" width="39" height="11" font="4">41 to 49</text>
<text top="238" left="321" width="473" height="11" font="4">These patients fall into a borderline or intermediate group. Their characteristics, treatment patterns, and</text>
<text top="253" left="341" width="262" height="11" font="4">outcomes appear similar to those of patients with HFp EF.</text>
<text top="272" left="76" width="88" height="11" font="4">b. HFpEF, improved</text>
<text top="270" left="251" width="21" height="16" font="4">&gt;40</text>
<text top="272" left="321" width="469" height="11" font="4">It has been recognized that a subset of patients with HFp EF previously had HFr EF. These patients with</text>
<text top="287" left="341" width="445" height="11" font="4">improvement or recovery in EF may be clinically distinct from those with persistently preserved or</text>
<text top="302" left="341" width="349" height="11" font="4">reduced EF. Further research is needed to better characterize these patients.</text>
<text top="324" left="76" width="711" height="11" font="4">EF indicates ejection fraction; HF, heart failure; HFp EF, heart failure with preserved ejection fraction; and HFr EF, heart failure with reduced ejection fraction.</text>
<text top="840" left="64" width="464" height="12" font="9">Table 4. Comparison of ACCF/AHA Stages of HF and NYHA Functional Classifications</text>
<text top="872" left="64" width="108" height="11" font="4">ACCF/AHA Stages of HF</text>
<text top="872" left="176" width="17" height="11" font="5"><a href="e147.full.html#65">(38)</a></text>
<text top="872" left="491" width="136" height="11" font="4">NYHA Functional Classification</text>
<text top="872" left="631" width="17" height="11" font="5"><a href="e147.full.html#65">(46)</a></text>
<text top="892" left="64" width="6" height="11" font="4">A</text>
<text top="892" left="89" width="211" height="11" font="4">At high risk for HF but without structural heart</text>
<text top="907" left="101" width="124" height="11" font="4">disease or symptoms of HF</text>
<text top="892" left="340" width="23" height="11" font="4">None</text>
<text top="926" left="64" width="6" height="11" font="4">B</text>
<text top="926" left="89" width="202" height="11" font="4">Structural heart disease but without signs or</text>
<text top="941" left="101" width="74" height="11" font="4">symptoms of HF</text>
<text top="926" left="350" width="2" height="11" font="4">I</text>
<text top="926" left="381" width="417" height="11" font="4">No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF.</text>
<text top="960" left="64" width="6" height="11" font="4">C</text>
<text top="960" left="89" width="202" height="11" font="4">Structural heart disease with prior or current</text>
<text top="975" left="99" width="74" height="11" font="4">symptoms of HF</text>
<text top="960" left="350" width="2" height="11" font="4">I</text>
<text top="960" left="381" width="417" height="11" font="4">No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF.</text>
<text top="980" left="349" width="5" height="11" font="4">II</text>
<text top="980" left="381" width="418" height="11" font="4">Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in</text>
<text top="995" left="393" width="77" height="11" font="4">symptoms of HF.</text>
<text top="1014" left="348" width="7" height="11" font="4">III</text>
<text top="1014" left="381" width="400" height="11" font="4">Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity</text>
<text top="1029" left="393" width="111" height="11" font="4">causes symptoms of HF.</text>
<text top="1049" left="348" width="8" height="11" font="4">IV</text>
<text top="1049" left="381" width="418" height="11" font="4">Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest.</text>
<text top="1068" left="64" width="7" height="11" font="4">D</text>
<text top="1068" left="89" width="218" height="11" font="4">Refractory HF requiring specialized interventions</text>
<text top="1068" left="348" width="8" height="11" font="4">IV</text>
<text top="1068" left="381" width="418" height="11" font="4">Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest.</text>
<text top="1089" left="76" width="687" height="11" font="4">ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; HF, heart failure; and NYHA, New York Heart Association.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e155</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">of HF is not observed. Progression in HF stages is associated</text>
<text top="121" left="64" width="350" height="13" font="14">with reduced 5-year survival and increased plasma natriuretic</text>
<text top="139" left="64" width="127" height="13" font="14">peptide concentrations</text>
<text top="139" left="195" width="23" height="13" font="15"><a href="e147.full.html#65">(47)</a></text>
<text top="139" left="218" width="196" height="13" font="14">. Therapeutic interventions in each</text>
<text top="157" left="64" width="350" height="13" font="14">stage aimed at modifying risk factors (stage A), treating</text>
<text top="175" left="64" width="350" height="13" font="14">structural heart disease (stage B), and reducing morbidity and</text>
<text top="193" left="64" width="267" height="13" font="14">mortality (stages C and D) (covered in detail in</text>
<text top="193" left="335" width="53" height="13" font="15"><a href="e147.full.html#22">Section 7</a></text>
<text top="193" left="389" width="25" height="13" font="14"><a href="e147.full.html#22">) </a>are</text>
<text top="211" left="64" width="337" height="13" font="14">reviewed in this document. The NYHA functional classi</text>
<text top="207" left="402" width="12" height="18" font="14">ﬁ-</text>
<text top="229" left="64" width="350" height="13" font="14">cation gauges the severity of symptoms in those with struc-</text>
<text top="247" left="64" width="350" height="13" font="14">tural heart disease, primarily stages C and D. It is a subjective</text>
<text top="265" left="64" width="350" height="13" font="14">assessment by a clinician and can change frequently over</text>
<text top="283" left="64" width="350" height="13" font="14">short periods of time. Although reproducibility and validity</text>
<text top="301" left="64" width="113" height="13" font="14">may be problematic</text>
<text top="301" left="182" width="23" height="13" font="15"><a href="e147.full.html#65">(48)</a></text>
<text top="301" left="205" width="167" height="13" font="14">, the NYHA functional classi</text>
<text top="297" left="372" width="42" height="18" font="14">ﬁcation</text>
<text top="319" left="64" width="223" height="13" font="14">is an independent predictor of mortality</text>
<text top="319" left="291" width="23" height="13" font="15"><a href="e147.full.html#65">(49)</a></text>
<text top="319" left="314" width="100" height="13" font="14">. It is widely used</text>
<text top="337" left="64" width="350" height="13" font="14">in clinical practice and research and for determining the</text>
<text top="354" left="64" width="298" height="13" font="14">eligibility of patients for certain healthcare services.</text>
<text top="372" left="79" width="20" height="13" font="14">See</text>
<text top="372" left="106" width="163" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 2</a></text>
<text top="372" left="277" width="137" height="13" font="14">for additional data on</text>
<text top="390" left="64" width="67" height="13" font="14">ACCF/AHA</text>
<text top="390" left="149" width="35" height="13" font="14">stages</text>
<text top="390" left="201" width="11" height="13" font="14">of</text>
<text top="390" left="229" width="19" height="13" font="14">HF</text>
<text top="390" left="265" width="21" height="13" font="14">and</text>
<text top="390" left="304" width="36" height="13" font="14">NYHA</text>
<text top="390" left="357" width="57" height="13" font="14">functional</text>
<text top="408" left="64" width="32" height="13" font="14">classi</text>
<text top="404" left="96" width="51" height="18" font="14">ﬁcations.</text>
<text top="448" left="64" width="133" height="15" font="13">4. Epidemiology</text>
<text top="491" left="65" width="320" height="13" font="14">The lifetime risk of developing HF is 20% for Americans</text>
<text top="487" left="389" width="25" height="18" font="14">40</text>
<text top="509" left="64" width="74" height="13" font="14">years of age</text>
<text top="509" left="145" width="23" height="13" font="15"><a href="e147.full.html#65">(50)</a></text>
<text top="509" left="169" width="245" height="13" font="14"><a href="e147.full.html#65">. </a>In the United States, HF incidence has</text>
<text top="527" left="64" width="350" height="13" font="14">largely remained stable over the past several decades, with</text>
<text top="541" left="64" width="269" height="18" font="14">&gt;650,000 new HF cases diagnosed annually</text>
<text top="545" left="341" width="19" height="13" font="15"><a href="e147.full.html#65">(51</a></text>
<text top="541" left="359" width="26" height="18" font="15"><a href="e147.full.html#65">–53)</a></text>
<text top="545" left="385" width="29" height="13" font="14">. HF</text>
<text top="563" left="64" width="350" height="13" font="14">incidence increases with age, rising from approximately 20</text>
<text top="580" left="64" width="262" height="13" font="14">per 1,000 individuals 65 to 69 years of age to</text>
<text top="577" left="330" width="83" height="18" font="14">&gt;80 per 1,000</text>
<text top="598" left="64" width="144" height="13" font="14">individuals among those</text>
<text top="595" left="215" width="106" height="18" font="14">85 years of age</text>
<text top="598" left="329" width="23" height="13" font="15"><a href="e147.full.html#65">(52)</a></text>
<text top="598" left="352" width="62" height="13" font="14"><a href="e147.full.html#65">. </a>Approxi-</text>
<text top="616" left="64" width="350" height="13" font="14">mately 5.1 million persons in the United States have clinically</text>
<text top="634" left="64" width="282" height="13" font="14">manifest HF, and the prevalence continues to rise</text>
<text top="634" left="350" width="23" height="13" font="15"><a href="e147.full.html#65">(51)</a></text>
<text top="634" left="373" width="41" height="13" font="14">. In the</text>
<text top="652" left="64" width="350" height="13" font="14">Medicare-eligible population, HF prevalence increased from</text>
<text top="670" left="64" width="153" height="13" font="14">90 to 121 per 1,000 bene</text>
<text top="666" left="218" width="163" height="18" font="14">ﬁciaries from 1994 to 2003</text>
<text top="670" left="387" width="23" height="13" font="15"><a href="e147.full.html#65">(52)</a></text>
<text top="670" left="410" width="4" height="13" font="14">.</text>
<text top="688" left="64" width="350" height="13" font="14">HFrEF and HFpEF each make up about half of the overall HF</text>
<text top="706" left="64" width="39" height="13" font="14">burden</text>
<text top="706" left="107" width="23" height="13" font="15"><a href="e147.full.html#65">(54)</a></text>
<text top="706" left="131" width="164" height="13" font="14"><a href="e147.full.html#65">. </a>One in 5 Americans will be</text>
<text top="702" left="298" width="115" height="18" font="14">&gt;65 years of age by</text>
<text top="724" left="64" width="28" height="13" font="14">2050</text>
<text top="724" left="96" width="23" height="13" font="15"><a href="e147.full.html#65">(55)</a></text>
<text top="724" left="119" width="295" height="13" font="14">. Because HF prevalence is highest in this group, the</text>
<text top="742" left="64" width="308" height="13" font="14">number of Americans with HF is expected to signi</text>
<text top="738" left="372" width="42" height="18" font="14">ﬁcantly</text>
<text top="760" left="64" width="350" height="13" font="14">worsen in the future. Disparities in the epidemiology of HF</text>
<text top="778" left="64" width="92" height="13" font="14">have been identi</text>
<text top="774" left="156" width="227" height="18" font="14">ﬁed. Blacks have the highest risk for HF</text>
<text top="778" left="387" width="23" height="13" font="15"><a href="e147.full.html#65">(56)</a></text>
<text top="778" left="410" width="4" height="13" font="14">.</text>
<text top="796" left="64" width="350" height="13" font="14">In the ARIC (Atherosclerosis Risk in Communities) study,</text>
<text top="814" left="64" width="350" height="13" font="14">incidence rate per 1,000 person-years was lowest among</text>
<text top="832" left="64" width="76" height="13" font="14">white women</text>
<text top="832" left="144" width="41" height="13" font="15"><a href="e147.full.html#65">(52,53)</a></text>
<text top="832" left="188" width="167" height="13" font="14">and highest among black men</text>
<text top="832" left="359" width="23" height="13" font="15"><a href="e147.full.html#65">(57)</a></text>
<text top="832" left="382" width="32" height="13" font="14">, with</text>
<text top="849" left="64" width="319" height="13" font="14">blacks having a greater 5-year mortality rate than whites</text>
<text top="849" left="387" width="23" height="13" font="15"><a href="e147.full.html#65">(58)</a></text>
<text top="849" left="410" width="4" height="13" font="14">.</text>
<text top="867" left="64" width="350" height="13" font="14">HF in non-Hispanic black males and females has a prevalence</text>
<text top="885" left="64" width="350" height="13" font="14">of 4.5% and 3.8%, respectively, versus 2.7% and 1.8% in</text>
<text top="903" left="64" width="298" height="13" font="14">non-Hispanic white males and females, respectively</text>
<text top="903" left="367" width="23" height="13" font="15"><a href="e147.full.html#65">(51)</a></text>
<text top="903" left="390" width="4" height="13" font="14"><a href="e147.full.html#65">.</a></text>
<text top="945" left="64" width="103" height="14" font="16">4.1. Mortality</text>
<text top="964" left="65" width="349" height="13" font="14">Although survival has improved, the absolute mortality rates</text>
<text top="982" left="64" width="350" height="13" font="14">for HF remain approximately 50% within 5 years of diagnosis</text>
<text top="1000" left="64" width="41" height="13" font="15"><a href="e147.full.html#65">(53,59)</a></text>
<text top="1000" left="105" width="309" height="13" font="14">. In the ARIC study, the 30-day, 1-year, and 5-year</text>
<text top="1018" left="64" width="350" height="13" font="14">case fatality rates after hospitalization for HF were 10.4%,</text>
<text top="1036" left="64" width="179" height="13" font="14">22%, and 42.3%, respectively</text>
<text top="1036" left="251" width="23" height="13" font="15"><a href="e147.full.html#65">(58)</a></text>
<text top="1036" left="274" width="140" height="13" font="14">. In another population</text>
<text top="1054" left="64" width="350" height="13" font="14">cohort study with 5-year mortality data, survival for stage A,</text>
<text top="1072" left="64" width="350" height="13" font="14">B, C, and D HF was 97%, 96%, 75%, and 20%, respectively</text>
<text top="1090" left="64" width="23" height="13" font="15"><a href="e147.full.html#65">(47)</a></text>
<text top="1090" left="88" width="326" height="13" font="14"><a href="e147.full.html#65">. </a>Thirty-day postadmission mortality rates decreased from</text>
<text top="103" left="450" width="350" height="13" font="14">12.6% to 10.8% from 1993 to 2005; however, this was due to</text>
<text top="121" left="450" width="350" height="13" font="14">lower in-hospital death rates. Postdischarge mortality actually</text>
<text top="139" left="450" width="319" height="13" font="14">increased from 4.3% to 6.4% during the same time frame</text>
<text top="139" left="773" width="23" height="13" font="15"><a href="e147.full.html#65">(60)</a></text>
<text top="139" left="796" width="4" height="13" font="14"><a href="e147.full.html#65">.</a></text>
<text top="157" left="450" width="350" height="13" font="14">These observed temporal trends in HF survival are primarily</text>
<text top="175" left="450" width="350" height="13" font="14">restricted to patients with reduced EF and are not seen in those</text>
<text top="193" left="450" width="105" height="13" font="14">with preserved EF</text>
<text top="193" left="560" width="23" height="13" font="15"><a href="e147.full.html#65">(40)</a></text>
<text top="193" left="583" width="4" height="13" font="14">.</text>
<text top="211" left="465" width="20" height="13" font="14">See</text>
<text top="211" left="492" width="163" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 3</a></text>
<text top="211" left="663" width="137" height="13" font="14">for additional data on</text>
<text top="229" left="450" width="55" height="13" font="14">mortality.</text>
<text top="263" left="450" width="156" height="14" font="16">4.2. Hospitalizations</text>
<text top="282" left="451" width="184" height="13" font="14">HF is the primary diagnosis in</text>
<text top="278" left="641" width="159" height="18" font="14">&gt;1 million hospitalizations</text>
<text top="300" left="450" width="48" height="13" font="14">annually</text>
<text top="300" left="502" width="23" height="13" font="15"><a href="e147.full.html#65">(51)</a></text>
<text top="300" left="525" width="274" height="13" font="14">. Patients hospitalized for HF are at high risk for</text>
<text top="318" left="450" width="350" height="13" font="14">all-cause rehospitalization, with a 1-month readmission rate of</text>
<text top="336" left="450" width="26" height="13" font="14">25%</text>
<text top="336" left="481" width="23" height="13" font="15"><a href="e147.full.html#65">(61)</a></text>
<text top="336" left="505" width="135" height="13" font="14"><a href="e147.full.html#65">. </a>In 2013, physician of</text>
<text top="332" left="640" width="160" height="18" font="14">ﬁce visits for HF cost $1.8</text>
<text top="354" left="450" width="350" height="13" font="14">billion. The total cost of HF care in the United States exceeds</text>
<text top="372" left="450" width="350" height="13" font="14">$30 billion annually, with over half of these costs spent on</text>
<text top="390" left="450" width="88" height="13" font="14">hospitalizations</text>
<text top="390" left="543" width="23" height="13" font="15"><a href="e147.full.html#65">(51)</a></text>
<text top="390" left="566" width="4" height="13" font="14"><a href="e147.full.html#65">.</a></text>
<text top="424" left="450" width="260" height="14" font="16">4.3. Asymptomatic LV Dysfunction</text>
<text top="443" left="451" width="349" height="13" font="14">The prevalence of asymptomatic LV systolic or diastolic</text>
<text top="461" left="450" width="350" height="13" font="14">dysfunction ranges from 6% to 21% and increases with age</text>
<text top="479" left="450" width="19" height="13" font="15"><a href="e147.full.html#65">(62</a></text>
<text top="475" left="469" width="26" height="18" font="15"><a href="e147.full.html#65">–64)</a></text>
<text top="479" left="494" width="305" height="13" font="14">. In the Left Ventricular Dysfunction Prevention</text>
<text top="497" left="450" width="34" height="13" font="14">study,</text>
<text top="497" left="499" width="65" height="13" font="14">participants</text>
<text top="497" left="579" width="25" height="13" font="14">with</text>
<text top="497" left="620" width="52" height="13" font="14">untreated</text>
<text top="497" left="687" width="79" height="13" font="14">asymptomatic</text>
<text top="497" left="781" width="19" height="13" font="14">LV</text>
<text top="515" left="450" width="350" height="13" font="14">dysfunction had a 10% risk for developing HF symptoms and</text>
<text top="533" left="450" width="300" height="13" font="14">an 8% risk of death or HF hospitalization annually</text>
<text top="533" left="755" width="23" height="13" font="15"><a href="e147.full.html#66">(65)</a></text>
<text top="533" left="779" width="21" height="13" font="14"><a href="e147.full.html#66">. </a>In</text>
<text top="551" left="450" width="350" height="13" font="14">a community-based population, asymptomatic mild LV dia-</text>
<text top="569" left="450" width="350" height="13" font="14">stolic dysfunction was seen in 21% and moderate or severe</text>
<text top="587" left="450" width="350" height="13" font="14">diastolic dysfunction in 7%, and both were associated with an</text>
<text top="604" left="450" width="276" height="13" font="14">increased risk of symptomatic HF and mortality</text>
<text top="604" left="730" width="23" height="13" font="15"><a href="e147.full.html#66">(64)</a></text>
<text top="604" left="754" width="4" height="13" font="14"><a href="e147.full.html#66">.</a></text>
<text top="639" left="450" width="291" height="14" font="16">4.4. Health-Related Quality of Life and</text>
<text top="658" left="450" width="132" height="14" font="16">Functional Status</text>
<text top="677" left="451" width="56" height="13" font="14">HF signi</text>
<text top="673" left="506" width="293" height="18" font="14">ﬁcantly decreases health-related quality of life</text>
<text top="695" left="450" width="350" height="13" font="14">(HRQOL), especially in the areas of physical functioning</text>
<text top="713" left="450" width="66" height="13" font="14">and vitality</text>
<text top="713" left="521" width="41" height="13" font="15"><a href="e147.full.html#66">(66,67)</a></text>
<text top="713" left="562" width="237" height="13" font="14">. Lack of improvement in HRQOL after</text>
<text top="731" left="450" width="350" height="13" font="14">discharge from the hospital is a powerful predictor of reho-</text>
<text top="749" left="450" width="155" height="13" font="14">spitalization and mortality</text>
<text top="749" left="612" width="41" height="13" font="15"><a href="e147.full.html#66">(68,69)</a></text>
<text top="749" left="653" width="147" height="13" font="14"><a href="e147.full.html#66">. </a>Women with HF have</text>
<text top="767" left="450" width="350" height="13" font="14">consistently been found to have poorer HRQOL than men</text>
<text top="785" left="450" width="41" height="13" font="15"><a href="e147.full.html#66">(67,70)</a></text>
<text top="785" left="491" width="309" height="13" font="14"><a href="e147.full.html#66">. </a>Ethnic differences also have been found, with</text>
<text top="803" left="450" width="350" height="13" font="14">Mexican Hispanics reporting better HRQOL than other ethnic</text>
<text top="821" left="450" width="157" height="13" font="14">groups in the United States</text>
<text top="821" left="612" width="23" height="13" font="15"><a href="e147.full.html#66">(71)</a></text>
<text top="821" left="635" width="164" height="13" font="14">. Other determinants of poor</text>
<text top="839" left="450" width="350" height="13" font="14">HRQOL include depression, younger age, higher body mass</text>
<text top="857" left="450" width="350" height="13" font="14">index (BMI), greater symptom burden, lower systolic blood</text>
<text top="874" left="450" width="350" height="13" font="14">pressure, sleep apnea, low perceived control, and uncertainty</text>
<text top="892" left="450" width="95" height="13" font="14">about prognosis</text>
<text top="892" left="553" width="37" height="13" font="15"><a href="e147.full.html#66">(70,72</a></text>
<text top="889" left="589" width="26" height="18" font="15"><a href="e147.full.html#66">–76)</a></text>
<text top="892" left="615" width="185" height="13" font="14">. Memory problems may also</text>
<text top="910" left="450" width="156" height="13" font="14">contribute to poor HRQOL</text>
<text top="910" left="611" width="23" height="13" font="15"><a href="e147.full.html#66">(76)</a></text>
<text top="910" left="634" width="4" height="13" font="14">.</text>
<text top="928" left="465" width="335" height="13" font="14">Pharmacological therapy is not a consistent determinant of</text>
<text top="946" left="450" width="350" height="13" font="14">HRQOL; therapies such as angiotensin-converting enzyme</text>
<text top="964" left="450" width="350" height="13" font="14">(ACE) inhibitors and angiotensin-receptor blockers (ARBs)</text>
<text top="982" left="450" width="350" height="13" font="14">improve HRQOL only modestly or delay the progressive</text>
<text top="1000" left="450" width="167" height="13" font="14">worsening of HRQOL in HF</text>
<text top="1000" left="622" width="23" height="13" font="15"><a href="e147.full.html#66">(77)</a></text>
<text top="1000" left="645" width="154" height="13" font="14">. At present, the only ther-</text>
<text top="1018" left="450" width="350" height="13" font="14">apies shown to improve HRQOL are cardiac resynchroniza-</text>
<text top="1036" left="450" width="109" height="13" font="14">tion therapy (CRT)</text>
<text top="1036" left="563" width="23" height="13" font="15"><a href="e147.full.html#66">(78)</a></text>
<text top="1036" left="591" width="208" height="13" font="14">and certain disease management and</text>
<text top="1054" left="450" width="133" height="13" font="14">educational approaches</text>
<text top="1054" left="589" width="19" height="13" font="15"><a href="e147.full.html#66">(79</a></text>
<text top="1050" left="608" width="26" height="18" font="15"><a href="e147.full.html#66">–82)</a></text>
<text top="1054" left="633" width="166" height="13" font="14">. Self-care and exercise may</text>
<text top="1072" left="450" width="350" height="13" font="14">improve HRQOL, but the results of studies evaluating these</text>
<text top="1090" left="450" width="138" height="13" font="14">interventions are mixed</text>
<text top="1090" left="594" width="19" height="13" font="15"><a href="e147.full.html#66">(83</a></text>
<text top="1086" left="612" width="26" height="18" font="15"><a href="e147.full.html#66">–86)</a></text>
<text top="1090" left="638" width="161" height="13" font="14">. Throughout this guideline</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e156</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">we refer to meaningful survival as a state in which HRQOL is</text>
<text top="121" left="64" width="148" height="13" font="14">satisfactory to the patient.</text>
<text top="139" left="79" width="20" height="13" font="14">See</text>
<text top="139" left="106" width="163" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 4</a></text>
<text top="139" left="277" width="137" height="13" font="14">for additional data on</text>
<text top="157" left="64" width="191" height="13" font="14">HRQOL and functional capacity.</text>
<text top="207" left="64" width="210" height="14" font="16">4.5. Economic Burden of HF</text>
<text top="226" left="65" width="349" height="13" font="14">In 1 in 9 deaths in the United States, HF is mentioned on the</text>
<text top="244" left="64" width="60" height="13" font="14">death certi</text>
<text top="240" left="124" width="289" height="18" font="14">ﬁcate. The number of deaths with any mention of</text>
<text top="262" left="64" width="231" height="13" font="14">HF was as high in 2006 as it was in 1995</text>
<text top="262" left="298" width="23" height="13" font="15"><a href="e147.full.html#65">(51)</a></text>
<text top="262" left="322" width="92" height="13" font="14"><a href="e147.full.html#65">. </a>Approximately</text>
<text top="280" left="64" width="269" height="13" font="14">7% of all cardiovascular deaths are due to HF.</text>
<text top="298" left="79" width="335" height="13" font="14">As previously noted, in 2013, HF costs in the United States</text>
<text top="316" left="64" width="125" height="13" font="14">exceeded $30 billion</text>
<text top="316" left="196" width="23" height="13" font="15"><a href="e147.full.html#65">(51)</a></text>
<text top="316" left="219" width="195" height="13" font="14">. This total includes the cost of</text>
<text top="334" left="64" width="350" height="13" font="14">healthcare services, medications, and lost productivity. The</text>
<text top="351" left="64" width="350" height="13" font="14">mean cost of HF-related hospitalizations was $23,077 per</text>
<text top="369" left="64" width="350" height="13" font="14">patient and was higher when HF was a secondary rather than</text>
<text top="387" left="64" width="350" height="13" font="14">the primary diagnosis. Among patients with HF in 1 large</text>
<text top="405" left="64" width="350" height="13" font="14">population study, hospitalizations were common after HF</text>
<text top="423" left="64" width="350" height="13" font="14">diagnosis, with 83% of patients hospitalized at least once and</text>
<text top="441" left="64" width="350" height="13" font="14">43% hospitalized at least 4 times. More than half of the</text>
<text top="459" left="64" width="350" height="13" font="14">hospitalizations were related to noncardiovascular causes</text>
<text top="477" left="64" width="19" height="13" font="15"><a href="e147.full.html#66">(87</a></text>
<text top="473" left="83" width="26" height="18" font="15"><a href="e147.full.html#66">–89)</a></text>
<text top="477" left="109" width="4" height="13" font="14"><a href="e147.full.html#66">.</a></text>
<text top="527" left="64" width="257" height="14" font="16">4.6. Important Risk Factors for HF</text>
<text top="546" left="64" width="329" height="14" font="16">(Hypertension, Diabetes Mellitus, Metabolic</text>
<text top="566" left="64" width="302" height="14" font="16">Syndrome, and Atherosclerotic Disease)</text>
<text top="585" left="65" width="349" height="13" font="14">Many conditions or comorbidities are associated with an</text>
<text top="603" left="64" width="350" height="13" font="14">increased propensity for structural heart disease. The expe-</text>
<text top="620" left="64" width="66" height="13" font="14">dient identi</text>
<text top="617" left="131" width="283" height="18" font="14">ﬁcation and treatment of these comorbid condi-</text>
<text top="638" left="64" width="205" height="13" font="14">tions may forestall the onset of HF</text>
<text top="638" left="275" width="59" height="13" font="15"><a href="e147.full.html#64">(14,27,90)</a></text>
<text top="638" left="333" width="80" height="13" font="14">. A list of the</text>
<text top="656" left="64" width="55" height="13" font="14">important</text>
<text top="656" left="132" width="61" height="13" font="14">documents</text>
<text top="656" left="206" width="21" height="13" font="14">that</text>
<text top="656" left="240" width="36" height="13" font="14">codify</text>
<text top="656" left="290" width="53" height="13" font="14">treatment</text>
<text top="656" left="356" width="16" height="13" font="14">for</text>
<text top="656" left="385" width="29" height="13" font="14">these</text>
<text top="674" left="64" width="196" height="13" font="14">concomitant conditions appears in</text>
<text top="674" left="265" width="44" height="13" font="15"><a href="e147.full.html#8">Table 2</a></text>
<text top="674" left="309" width="4" height="13" font="14"><a href="e147.full.html#8">.</a></text>
<text top="700" left="64" width="86" height="15" font="14">Hypertension</text>
<text top="721" left="65" width="318" height="13" font="14">Hypertension may be the single most important modi</text>
<text top="717" left="383" width="31" height="18" font="14">ﬁable</text>
<text top="738" left="64" width="350" height="13" font="14">risk factor for HF in the United States. Hypertensive men and</text>
<text top="756" left="64" width="350" height="13" font="14">women have a substantially greater risk for developing HF</text>
<text top="774" left="64" width="208" height="13" font="14">than normotensive men and women</text>
<text top="774" left="278" width="23" height="13" font="15"><a href="e147.full.html#66">(91)</a></text>
<text top="774" left="301" width="113" height="13" font="14">. Elevated levels of</text>
<text top="792" left="64" width="350" height="13" font="14">diastolic and especially systolic blood pressure are major risk</text>
<text top="810" left="64" width="198" height="13" font="14">factors for the development of HF</text>
<text top="810" left="267" width="41" height="13" font="15"><a href="e147.full.html#66">(91,92)</a></text>
<text top="810" left="308" width="105" height="13" font="14">. The incidence of</text>
<text top="828" left="64" width="350" height="13" font="14">HF is greater with higher levels of blood pressure, older age,</text>
<text top="846" left="64" width="350" height="13" font="14">and longer duration of hypertension. Long-term treatment of</text>
<text top="864" left="64" width="350" height="13" font="14">both systolic and diastolic hypertension reduces the risk of HF</text>
<text top="882" left="64" width="131" height="13" font="14">by approximately 50%</text>
<text top="882" left="200" width="19" height="13" font="15"><a href="e147.full.html#66">(93</a></text>
<text top="878" left="218" width="26" height="18" font="15"><a href="e147.full.html#66">–96)</a></text>
<text top="882" left="244" width="170" height="13" font="14">. With nearly a quarter of the</text>
<text top="900" left="64" width="138" height="13" font="14">American population af</text>
<text top="896" left="202" width="212" height="18" font="14">ﬂicted by hypertension and the life-</text>
<text top="918" left="64" width="227" height="13" font="14">time risk of developing hypertension at</text>
<text top="914" left="296" width="118" height="18" font="14">&gt;75% in the United</text>
<text top="936" left="64" width="33" height="13" font="14">States</text>
<text top="936" left="102" width="23" height="13" font="15"><a href="e147.full.html#66">(97)</a></text>
<text top="936" left="126" width="288" height="13" font="14"><a href="e147.full.html#66">, </a>strategies to control hypertension are a vital part</text>
<text top="954" left="64" width="240" height="13" font="14">of any public health effort to prevent HF.</text>
<text top="979" left="64" width="113" height="15" font="14">Diabetes Mellitus</text>
<text top="1000" left="65" width="349" height="13" font="14">Obesity and insulin resistance are important risk factors for</text>
<text top="1018" left="64" width="143" height="13" font="14">the development of HF</text>
<text top="1018" left="215" width="41" height="13" font="15"><a href="e147.full.html#66">(98,99)</a></text>
<text top="1018" left="256" width="158" height="13" font="14"><a href="e147.full.html#66">. </a>The presence of clinical</text>
<text top="1036" left="64" width="350" height="13" font="14">diabetes mellitus markedly increases the likelihood of devel-</text>
<text top="1054" left="64" width="292" height="13" font="14">oping HF in patients without structural heart disease</text>
<text top="1054" left="360" width="30" height="13" font="15"><a href="e147.full.html#66">(100)</a></text>
<text top="1054" left="394" width="20" height="13" font="14">and</text>
<text top="1072" left="64" width="350" height="13" font="14">adversely affects the outcomes of patients with established HF</text>
<text top="1090" left="64" width="55" height="13" font="15"><a href="e147.full.html#66">(101,102)</a></text>
<text top="1090" left="120" width="4" height="13" font="14"><a href="e147.full.html#66">.</a></text>
<text top="103" left="450" width="132" height="15" font="14">Metabolic Syndrome</text>
<text top="123" left="451" width="349" height="13" font="14">The metabolic syndrome includes any 3 of the following:</text>
<text top="141" left="450" width="350" height="13" font="14">abdominal adiposity, hypertriglyceridemia, low high-density</text>
<text top="159" left="450" width="350" height="13" font="14">lipoprotein, hypertension, and fasting hyperglycemia. The</text>
<text top="177" left="450" width="350" height="13" font="14">prevalence of metabolic syndrome in the United States</text>
<text top="195" left="450" width="139" height="13" font="14">exceeds 20% of persons</text>
<text top="191" left="593" width="206" height="18" font="14">20 years of age and 40% of those</text>
<text top="209" left="450" width="100" height="18" font="14">&gt;40 years of age</text>
<text top="213" left="555" width="30" height="13" font="15"><a href="e147.full.html#66">(103)</a></text>
<text top="213" left="585" width="214" height="13" font="14">. The appropriate treatment of hyper-</text>
<text top="231" left="450" width="277" height="13" font="14">tension, diabetes mellitus, and dyslipidemia</text>
<text top="231" left="738" width="30" height="13" font="15"><a href="e147.full.html#66">(104)</a></text>
<text top="231" left="780" width="20" height="13" font="14">can</text>
<text top="249" left="450" width="27" height="13" font="14">signi</text>
<text top="245" left="477" width="226" height="18" font="14">ﬁcantly reduce the development of HF.</text>
<text top="274" left="450" width="149" height="15" font="14">Atherosclerotic Disease</text>
<text top="295" left="451" width="349" height="13" font="14">Patients with known atherosclerotic disease (e.g., of the</text>
<text top="313" left="450" width="350" height="13" font="14">coronary, cerebral, or peripheral blood vessels) are likely to</text>
<text top="331" left="450" width="350" height="13" font="14">develop HF, and clinicians should seek to control vascular</text>
<text top="349" left="450" width="296" height="13" font="14">risk factors in such patients according to guidelines</text>
<text top="349" left="751" width="23" height="13" font="15"><a href="e147.full.html#64">(13)</a></text>
<text top="349" left="774" width="4" height="13" font="14">.</text>
<text top="396" left="450" width="292" height="15" font="13">5. Cardiac Structural Abnormalities</text>
<text top="416" left="450" width="195" height="15" font="13">and Other Causes of HF</text>
<text top="458" left="450" width="228" height="14" font="16">5.1. Dilated Cardiomyopathies</text>
<text top="485" left="450" width="61" height="15" font="14">5.1.1. De</text>
<text top="481" left="511" width="182" height="19" font="14">ﬁnition and Classiﬁcation of</text>
<text top="503" left="450" width="167" height="15" font="14">Dilated Cardiomyopathies</text>
<text top="523" left="451" width="349" height="13" font="14">Dilated cardiomyopathy (DCM) refers to a large group of</text>
<text top="541" left="450" width="350" height="13" font="14">heterogeneous myocardial disorders that are characterized by</text>
<text top="559" left="450" width="350" height="13" font="14">ventricular dilation and depressed myocardial contractility in</text>
<text top="577" left="450" width="350" height="13" font="14">the absence of abnormal loading conditions such as hyper-</text>
<text top="595" left="450" width="350" height="13" font="14">tension or valvular disease. In clinical practice and multicenter</text>
<text top="613" left="450" width="350" height="13" font="14">HF trials, the etiology of HF has often been categorized into</text>
<text top="631" left="450" width="350" height="13" font="14">ischemic or nonischemic cardiomyopathy, with the term</text>
<text top="649" left="450" width="350" height="13" font="14">DCM used interchangeably with nonischemic cardiomyop-</text>
<text top="667" left="450" width="264" height="13" font="14">athy. This approach fails to recognize that</text>
<text top="663" left="722" width="77" height="18" font="14">“nonischemic</text>
<text top="685" left="450" width="91" height="13" font="14">cardiomyopathy</text>
<text top="681" left="541" width="258" height="18" font="14">” may include cardiomyopathies due to</text>
<text top="703" left="450" width="350" height="13" font="14">volume or pressure overload, such as hypertension or valvular</text>
<text top="721" left="450" width="350" height="13" font="14">heart disease, which are not conventionally accepted as DCM</text>
<text top="738" left="450" width="30" height="13" font="15"><a href="e147.full.html#66">(105)</a></text>
<text top="738" left="480" width="101" height="13" font="14">. With the identi</text>
<text top="735" left="581" width="218" height="18" font="14">ﬁcation of genetic defects in several</text>
<text top="756" left="450" width="226" height="13" font="14">forms of cardiomyopathies, a new classi</text>
<text top="753" left="676" width="123" height="18" font="14">ﬁcation scheme based</text>
<text top="774" left="450" width="207" height="13" font="14">on genomics was proposed in 2006</text>
<text top="774" left="662" width="23" height="13" font="15"><a href="e147.full.html#64">(23)</a></text>
<text top="774" left="685" width="114" height="13" font="14">. We recognize that</text>
<text top="792" left="450" width="31" height="13" font="14">classi</text>
<text top="789" left="481" width="319" height="18" font="14">ﬁcation of cardiomyopathies is challenging, mixing</text>
<text top="810" left="450" width="350" height="13" font="14">anatomic designations (i.e., hypertrophic and dilated) with</text>
<text top="828" left="450" width="350" height="13" font="14">functional designations (i.e., restrictive), and is unlikely to</text>
<text top="846" left="450" width="350" height="13" font="14">satisfy all users. The aim of the present guideline is to target</text>
<text top="864" left="450" width="350" height="13" font="14">appropriate diagnostic and treatment strategies for preventing</text>
<text top="882" left="450" width="350" height="13" font="14">the development and progression of HF in patients with</text>
<text top="900" left="450" width="250" height="13" font="14">cardiomyopathies; we do not wish to rede</text>
<text top="896" left="700" width="100" height="18" font="14">ﬁne new classiﬁ-</text>
<text top="918" left="450" width="221" height="13" font="14">cation strategies for cardiomyopathies.</text>
<text top="943" left="450" width="324" height="15" font="14">5.1.2. Epidemiology and Natural History of DCM</text>
<text top="964" left="451" width="349" height="13" font="14">The age-adjusted prevalence of DCM in the United States</text>
<text top="982" left="450" width="350" height="13" font="14">averages 36 cases per 100,000 population, and DCM accounts</text>
<text top="1000" left="450" width="171" height="13" font="14">for 10,000 deaths annually</text>
<text top="1000" left="631" width="30" height="13" font="15"><a href="e147.full.html#66">(106)</a></text>
<text top="1000" left="662" width="138" height="13" font="14"><a href="e147.full.html#66">. </a>In most multicenter</text>
<text top="1018" left="450" width="350" height="13" font="14">RCTs and registries in HF, approximately 30% to 40% of</text>
<text top="1036" left="450" width="176" height="13" font="14">enrolled patients have DCM</text>
<text top="1036" left="635" width="26" height="13" font="15"><a href="e147.full.html#66">(107</a></text>
<text top="1032" left="661" width="33" height="18" font="15"><a href="e147.full.html#66">–109)</a></text>
<text top="1036" left="694" width="106" height="13" font="14"><a href="e147.full.html#66">. </a>Compared with</text>
<text top="1054" left="450" width="350" height="13" font="14">whites, African Americans have almost a 3-fold increased risk</text>
<text top="1072" left="450" width="350" height="13" font="14">for developing DCM, irrespective of comorbidities or socio-</text>
<text top="1090" left="450" width="99" height="13" font="14">economic factors</text>
<text top="1090" left="556" width="26" height="13" font="15"><a href="e147.full.html#66">(108</a></text>
<text top="1086" left="582" width="33" height="18" font="15"><a href="e147.full.html#66">–110)</a></text>
<text top="1090" left="615" width="185" height="13" font="14"><a href="e147.full.html#66">. </a>Sex-related differences in the</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e157</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="238" height="13" font="14">incidence and prognosis of DCM are con</text>
<text top="100" left="302" width="112" height="18" font="14">ﬂicting and may be</text>
<text top="121" left="64" width="199" height="13" font="14">confounded by differing etiologies</text>
<text top="121" left="268" width="80" height="13" font="15"><a href="e147.full.html#66">(108,109,111)</a></text>
<text top="121" left="348" width="66" height="13" font="14">. The prog-</text>
<text top="139" left="64" width="350" height="13" font="14">nosis in patients with symptomatic HF and DCM is relatively</text>
<text top="157" left="64" width="350" height="13" font="14">poor, with 25% mortality at 1 year and 50% mortality at 5</text>
<text top="175" left="64" width="30" height="13" font="14">years</text>
<text top="175" left="99" width="30" height="13" font="15"><a href="e147.full.html#67">(112)</a></text>
<text top="175" left="129" width="285" height="13" font="14"><a href="e147.full.html#67">. </a>Approximately 25% of patients with DCM with</text>
<text top="193" left="64" width="350" height="13" font="14">recent onset of HF symptoms will improve within a short time</text>
<text top="211" left="64" width="215" height="13" font="14">even in the absence of optimal GDMT</text>
<text top="211" left="283" width="30" height="13" font="15"><a href="e147.full.html#67">(113)</a></text>
<text top="211" left="314" width="100" height="13" font="14"><a href="e147.full.html#67">, </a>but patients with</text>
<text top="229" left="64" width="99" height="13" font="14">symptoms lasting</text>
<text top="225" left="167" width="247" height="18" font="14">&gt;3 months who present with severe clinical</text>
<text top="247" left="64" width="312" height="13" font="14">decompensation generally have less chance of recovery</text>
<text top="247" left="380" width="30" height="13" font="15"><a href="e147.full.html#67">(113)</a></text>
<text top="247" left="410" width="4" height="13" font="14">.</text>
<text top="265" left="64" width="350" height="13" font="14">Patients with idiopathic DCM have a lower total mortality rate</text>
<text top="283" left="64" width="244" height="13" font="14">than patients with other types of DCM</text>
<text top="283" left="317" width="30" height="13" font="15"><a href="e147.full.html#67">(114)</a></text>
<text top="283" left="347" width="67" height="13" font="14">. However,</text>
<text top="301" left="64" width="87" height="13" font="14">GDMT is bene</text>
<text top="297" left="151" width="153" height="18" font="14">ﬁcial in all forms of DCM</text>
<text top="301" left="309" width="68" height="13" font="15"><a href="e147.full.html#66">(78,109,115</a></text>
<text top="297" left="377" width="33" height="18" font="15"><a href="e147.full.html#66">–117)</a></text>
<text top="301" left="410" width="4" height="13" font="14"><a href="e147.full.html#66">.</a></text>
<text top="334" left="64" width="233" height="14" font="16">5.2. Familial Cardiomyopathies</text>
<text top="353" left="65" width="349" height="13" font="14">Increasingly, it is recognized that many (20% to 35%) patients</text>
<text top="371" left="64" width="350" height="13" font="14">with an idiopathic DCM have a familial cardiomyopathy</text>
<text top="389" left="64" width="18" height="13" font="14">(de</text>
<text top="385" left="82" width="332" height="18" font="14">ﬁned as 2 closely related family members who meet the</text>
<text top="407" left="64" width="174" height="13" font="14">criteria for idiopathic DCM)</text>
<text top="407" left="247" width="55" height="13" font="15"><a href="e147.full.html#67">(118,119)</a></text>
<text top="407" left="303" width="111" height="13" font="14"><a href="e147.full.html#67">. </a>Consideration of</text>
<text top="425" left="64" width="350" height="13" font="14">familial cardiomyopathies includes the increasingly important</text>
<text top="443" left="64" width="350" height="13" font="14">discovery of noncompaction cardiomyopathies. Advances in</text>
<text top="461" left="64" width="350" height="13" font="14">technology permitting high-throughput sequencing and gen-</text>
<text top="479" left="64" width="350" height="13" font="14">otyping at reduced costs have brought genetic screening to the</text>
<text top="497" left="64" width="350" height="13" font="14">clinical arena. For further information on this topic, the reader</text>
<text top="515" left="64" width="350" height="13" font="14">is referred to published guidelines, position statements, and</text>
<text top="533" left="64" width="161" height="13" font="14">expert consensus statements</text>
<text top="533" left="230" width="51" height="13" font="15"><a href="e147.full.html#67">(118,120</a></text>
<text top="529" left="280" width="33" height="18" font="15"><a href="e147.full.html#67">–123)</a></text>
<text top="533" left="318" width="5" height="13" font="14">(</text>
<text top="533" left="323" width="44" height="13" font="15"><a href="e147.full.html#12">Table 5</a></text>
<text top="533" left="366" width="8" height="13" font="14">).</text>
<text top="566" left="64" width="280" height="14" font="16">5.3. Endocrine and Metabolic Causes</text>
<text top="586" left="64" width="141" height="14" font="16">of Cardiomyopathy</text>
<text top="612" left="64" width="91" height="15" font="14">5.3.1. Obesity</text>
<text top="633" left="65" width="178" height="13" font="14">Obesity cardiomyopathy is de</text>
<text top="629" left="243" width="171" height="18" font="14">ﬁned as cardiomyopathy due</text>
<text top="651" left="64" width="249" height="13" font="14">entirely or predominantly to obesity <a href="e147.full.html#26">(</a></text>
<text top="651" left="313" width="92" height="13" font="15"><a href="e147.full.html#26">Section 7.3.1.5</a></text>
<text top="651" left="406" width="8" height="13" font="14"><a href="e147.full.html#26">).</a></text>
<text top="669" left="64" width="350" height="13" font="14">Although the precise mechanisms causing obesity-related HF</text>
<text top="687" left="64" width="350" height="13" font="14">are not known, excessive adipose accumulation results in an</text>
<text top="705" left="64" width="350" height="13" font="14">increase in circulating blood volume. A subsequent, persistent</text>
<text top="723" left="64" width="350" height="13" font="14">increase in cardiac output, cardiac work, and systemic blood</text>
<text top="741" left="64" width="47" height="13" font="14">pressure</text>
<text top="741" left="116" width="30" height="13" font="15"><a href="e147.full.html#67">(124)</a></text>
<text top="741" left="152" width="262" height="13" font="14">along with lipotoxicity-induced cardiac myo-</text>
<text top="759" left="64" width="350" height="13" font="14">cyte injury and myocardial lipid accumulation have been</text>
<text top="777" left="64" width="205" height="13" font="14">implicated as potential mechanisms</text>
<text top="777" left="274" width="55" height="13" font="15"><a href="e147.full.html#67">(125,126)</a></text>
<text top="777" left="329" width="85" height="13" font="14">. A study with</text>
<text top="794" left="64" width="350" height="13" font="14">participants from the Framingham Heart Study reported that</text>
<text top="812" left="64" width="350" height="13" font="14">after adjustment for established risk factors, obesity was</text>
<text top="830" left="64" width="120" height="13" font="14">associated with signi</text>
<text top="827" left="184" width="230" height="18" font="14">ﬁcant future risk of development of HF</text>
<text top="848" left="64" width="23" height="13" font="15"><a href="e147.full.html#66">(99)</a></text>
<text top="848" left="88" width="293" height="13" font="14"><a href="e147.full.html#66">. </a>There are no large-scale studies of the safety or ef</text>
<text top="844" left="380" width="34" height="18" font="14">ﬁcacy</text>
<text top="103" left="450" width="350" height="13" font="14">of weight loss with diet, exercise, or bariatric surgery in obese</text>
<text top="121" left="450" width="100" height="13" font="14">patients with HF.</text>
<text top="151" left="450" width="205" height="15" font="14">5.3.2. Diabetic Cardiomyopathy</text>
<text top="172" left="451" width="349" height="13" font="14">Diabetes mellitus is now well recognized as a risk factor for</text>
<text top="190" left="450" width="350" height="13" font="14">the development of HF independent of age, hypertension,</text>
<text top="208" left="450" width="350" height="13" font="14">obesity, hypercholesterolemia, or CAD. The association</text>
<text top="226" left="450" width="350" height="13" font="14">between mortality and hemoglobin A1c (HbA1c) in patients</text>
<text top="244" left="450" width="350" height="13" font="14">with diabetes mellitus and HF appears U-shaped, with the</text>
<text top="262" left="450" width="350" height="13" font="14">lowest risk of death in those patients with modest glucose</text>
<text top="280" left="450" width="80" height="13" font="14">control (7.1%</text>
<text top="276" left="529" width="270" height="18" font="14">&lt;HbA1c7.8%) and with increased risk with</text>
<text top="298" left="450" width="227" height="13" font="14">extremely high or low HbA1c levels</text>
<text top="298" left="685" width="30" height="13" font="15"><a href="e147.full.html#67">(127)</a></text>
<text top="298" left="715" width="84" height="13" font="14">. The optimal</text>
<text top="316" left="450" width="350" height="13" font="14">treatment strategy in patients with diabetes mellitus and HF is</text>
<text top="334" left="450" width="350" height="13" font="14">controversial; some studies have suggested potential harm</text>
<text top="352" left="450" width="253" height="13" font="14">with several glucose-lowering medications</text>
<text top="352" left="711" width="55" height="13" font="15"><a href="e147.full.html#67">(127,128)</a></text>
<text top="352" left="766" width="33" height="13" font="14">. The</text>
<text top="370" left="450" width="81" height="13" font="14">safety and ef</text>
<text top="366" left="531" width="269" height="18" font="14">ﬁcacy of diabetes mellitus therapies in HF,</text>
<text top="387" left="450" width="350" height="13" font="14">including metformin, sulfonylureas, insulin, and glucagon-</text>
<text top="405" left="450" width="350" height="13" font="14">like peptide analogues, await further data from prospective</text>
<text top="423" left="450" width="75" height="13" font="14">clinical trials</text>
<text top="423" left="532" width="26" height="13" font="15"><a href="e147.full.html#67">(129</a></text>
<text top="420" left="558" width="33" height="18" font="15"><a href="e147.full.html#67">–131)</a></text>
<text top="423" left="591" width="209" height="13" font="14"><a href="e147.full.html#67">. </a>Treatment with thiazolidinediones</text>
<text top="441" left="450" width="235" height="13" font="14">(e.g., rosiglitazone) is associated with</text>
<text top="437" left="694" width="105" height="18" font="14">ﬂuid retention in</text>
<text top="459" left="450" width="95" height="13" font="14">patients with HF</text>
<text top="459" left="549" width="55" height="13" font="15"><a href="e147.full.html#67">(129,132)</a></text>
<text top="459" left="608" width="191" height="13" font="14">and should be avoided in patients</text>
<text top="477" left="450" width="211" height="13" font="14">with NYHA class II through IV HF.</text>
<text top="507" left="450" width="147" height="15" font="14">5.3.3. Thyroid Disease</text>
<text top="528" left="451" width="349" height="13" font="14">Hyperthyroidism has been implicated in causing DCM but</text>
<text top="546" left="450" width="350" height="13" font="14">most commonly occurs with persistent sinus tachycardia or</text>
<text top="564" left="450" width="213" height="13" font="14">AF and may be related to tachycardia</text>
<text top="564" left="667" width="30" height="13" font="15"><a href="e147.full.html#67">(133)</a></text>
<text top="564" left="697" width="103" height="13" font="14"><a href="e147.full.html#67">. </a>Abnormalities in</text>
<text top="582" left="450" width="350" height="13" font="14">cardiac systolic and diastolic performance have been reported</text>
<text top="600" left="450" width="11" height="13" font="14">in</text>
<text top="600" left="474" width="93" height="13" font="14">hypothyroidism.</text>
<text top="600" left="580" width="55" height="13" font="14">However,</text>
<text top="600" left="648" width="17" height="13" font="14">the</text>
<text top="600" left="679" width="37" height="13" font="14">classic</text>
<text top="596" left="729" width="70" height="18" font="14">ﬁndings of</text>
<text top="618" left="450" width="350" height="13" font="14">myxedema do not usually indicate cardiomyopathy. The low</text>
<text top="636" left="450" width="350" height="13" font="14">cardiac output results from bradycardia, decreased ventricular</text>
<text top="650" left="450" width="350" height="18" font="14">ﬁlling, reduced cardiac contractility, and diminished</text>
<text top="671" left="450" width="97" height="13" font="14">myocardial work</text>
<text top="671" left="551" width="55" height="13" font="15"><a href="e147.full.html#67">(133,134)</a></text>
<text top="671" left="607" width="4" height="13" font="14"><a href="e147.full.html#67">.</a></text>
<text top="702" left="450" width="289" height="15" font="14">5.3.4. Acromegaly and Growth Hormone De</text>
<text top="699" left="739" width="47" height="19" font="14">ﬁciency</text>
<text top="722" left="451" width="349" height="13" font="14">Impaired cardiovascular function has been associated with</text>
<text top="740" left="450" width="350" height="13" font="14">reduced life expectancy in patients with growth hormone</text>
<text top="758" left="450" width="13" height="13" font="14">de</text>
<text top="755" left="463" width="336" height="18" font="14">ﬁciency and excess. Experimental and clinical studies</text>
<text top="776" left="450" width="350" height="13" font="14">implicate growth hormone and insulin-like growth factor I in</text>
<text top="794" left="450" width="118" height="13" font="14">cardiac development</text>
<text top="794" left="573" width="30" height="13" font="15"><a href="e147.full.html#67">(135)</a></text>
<text top="794" left="603" width="196" height="13" font="14">. Cardiomyopathy associated with</text>
<text top="812" left="450" width="350" height="13" font="14">acromegaly is characterized by myocardial hypertrophy with</text>
<text top="830" left="450" width="56" height="13" font="14">interstitial</text>
<text top="826" left="510" width="289" height="18" font="14">ﬁbrosis, lympho-mononuclear inﬁltration, myocyte</text>
<text top="848" left="450" width="288" height="13" font="14">necrosis, and biventricular concentric hypertrophy</text>
<text top="848" left="742" width="30" height="13" font="15"><a href="e147.full.html#67">(135)</a></text>
<text top="848" left="772" width="4" height="13" font="14">.</text>
<text top="894" left="64" width="564" height="12" font="9">Table 5. Screening of Family Members and Genetic Testing in Patients With Idiopathic or Familial DCM</text>
<text top="925" left="64" width="41" height="11" font="4">Condition</text>
<text top="925" left="248" width="135" height="11" font="4">Screening of Family Members</text>
<text top="925" left="614" width="69" height="11" font="4">Genetic Testing</text>
<text top="945" left="64" width="60" height="11" font="4">Familial DCM</text>
<text top="942" left="145" width="340" height="16" font="4"> First-degree relatives not known to be affected should undergo periodic,</text>
<text top="960" left="169" width="302" height="11" font="4">serial echocardiographic screening with assessment of LV function</text>
<text top="975" left="169" width="40" height="11" font="4">and size.</text>
<text top="987" left="145" width="264" height="16" font="4"> Frequency of screening is uncertain, but every 3–5 y is</text>
<text top="1005" left="169" width="48" height="11" font="4">reasonable</text>
<text top="1005" left="222" width="23" height="11" font="5"><a href="e147.full.html#67">(118)</a></text>
<text top="1005" left="244" width="3" height="11" font="4">.</text>
<text top="942" left="498" width="295" height="16" font="4"> Genetic testing may be considered in conjunction with genetic</text>
<text top="960" left="522" width="48" height="11" font="4">counseling</text>
<text top="960" left="574" width="66" height="11" font="5"><a href="e147.full.html#67">(118,121–123)</a></text>
<text top="960" left="640" width="3" height="11" font="4"><a href="e147.full.html#67">.</a></text>
<text top="1025" left="64" width="68" height="11" font="4">Idiopathic DCM</text>
<text top="1022" left="145" width="294" height="16" font="4"> Patients should inform first-degree relatives of their diagnosis.</text>
<text top="1037" left="145" width="308" height="16" font="4"> Relatives should update their clinicians and discuss whether they</text>
<text top="1054" left="169" width="215" height="11" font="4">should undergo screening by echocardiography.</text>
<text top="1022" left="498" width="292" height="16" font="4"> The utility of genetic testing in this setting remains uncertain.</text>
<text top="1037" left="498" width="259" height="16" font="4"> Yield of genetic testing may be higher in patients with</text>
<text top="1054" left="522" width="277" height="11" font="4">significant cardiac conduction disease and/or a family history</text>
<text top="1069" left="522" width="159" height="11" font="4">of premature sudden cardiac death</text>
<text top="1069" left="685" width="66" height="11" font="5"><a href="e147.full.html#67">(118,121–123)</a></text>
<text top="1069" left="751" width="3" height="11" font="4"><a href="e147.full.html#67">.</a></text>
<text top="1091" left="76" width="285" height="11" font="4">DCM indicates dilated cardiomyopathy; and LV, left ventricular.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e158</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="200" height="14" font="16">5.4. Toxic Cardiomyopathy</text>
<text top="130" left="64" width="212" height="15" font="14">5.4.1. Alcoholic Cardiomyopathy</text>
<text top="151" left="65" width="349" height="13" font="14">Chronic alcoholism is one of the most important causes of</text>
<text top="169" left="64" width="32" height="13" font="14">DCM</text>
<text top="169" left="107" width="30" height="13" font="15"><a href="e147.full.html#67">(136)</a></text>
<text top="169" left="137" width="277" height="13" font="14">. The clinical diagnosis is suspected when</text>
<text top="187" left="64" width="350" height="13" font="14">biventricular dysfunction and dilatation are persistently</text>
<text top="205" left="64" width="350" height="13" font="14">observed in a heavy drinker in the absence of other known</text>
<text top="222" left="64" width="350" height="13" font="14">causes for myocardial disease. Alcoholic cardiomyopathy</text>
<text top="240" left="64" width="350" height="13" font="14">most commonly occurs in men 30 to 55 years of age who</text>
<text top="258" left="64" width="246" height="13" font="14">have been heavy consumers of alcohol for</text>
<text top="255" left="315" width="60" height="18" font="14">&gt;10 years</text>
<text top="258" left="380" width="30" height="13" font="15"><a href="e147.full.html#67">(137)</a></text>
<text top="258" left="410" width="4" height="13" font="14">.</text>
<text top="276" left="64" width="350" height="13" font="14">Women represent approximately 14% of the alcoholic</text>
<text top="294" left="64" width="350" height="13" font="14">cardiomyopathy cases but may be more vulnerable with less</text>
<text top="312" left="64" width="168" height="13" font="14">lifetime alcohol consumption</text>
<text top="312" left="238" width="55" height="13" font="15"><a href="e147.full.html#67">(136,138)</a></text>
<text top="312" left="293" width="121" height="13" font="14">. The risk of asymp-</text>
<text top="330" left="64" width="350" height="13" font="14">tomatic alcoholic cardiomyopathy is increased in those</text>
<text top="348" left="64" width="62" height="13" font="14">consuming</text>
<text top="344" left="132" width="282" height="18" font="14">&gt;90 g of alcohol per day (approximately 7 to 8</text>
<text top="366" left="64" width="160" height="13" font="14">standard drinks per day) for</text>
<text top="362" left="229" width="52" height="18" font="14">&gt;5 years</text>
<text top="366" left="286" width="30" height="13" font="15"><a href="e147.full.html#67">(137)</a></text>
<text top="366" left="316" width="98" height="13" font="14">. Interestingly, in</text>
<text top="384" left="64" width="350" height="13" font="14">the general population, mild to moderate alcohol consumption</text>
<text top="402" left="64" width="350" height="13" font="14">has been reported to be protective against development of HF</text>
<text top="420" left="64" width="55" height="13" font="15"><a href="e147.full.html#67">(139,140)</a></text>
<text top="420" left="120" width="110" height="13" font="14"><a href="e147.full.html#67">. </a>These paradoxical</text>
<text top="416" left="233" width="181" height="18" font="14">ﬁndings suggest that duration of</text>
<text top="438" left="64" width="350" height="13" font="14">exposure and individual genetic susceptibility play an</text>
<text top="456" left="64" width="350" height="13" font="14">important role in pathogenesis. Recovery of LV function after</text>
<text top="474" left="64" width="234" height="13" font="14">cessation of drinking has been reported</text>
<text top="474" left="305" width="30" height="13" font="15"><a href="e147.full.html#67">(141)</a></text>
<text top="474" left="335" width="79" height="13" font="14">. Even if LV</text>
<text top="491" left="64" width="350" height="13" font="14">dysfunction persists, the symptoms and signs of HF improve</text>
<text top="509" left="64" width="89" height="13" font="14">after abstinence</text>
<text top="509" left="158" width="30" height="13" font="15"><a href="e147.full.html#67">(141)</a></text>
<text top="509" left="189" width="4" height="13" font="14"><a href="e147.full.html#67">.</a></text>
<text top="545" left="64" width="203" height="15" font="14">5.4.2. Cocaine Cardiomyopathy</text>
<text top="566" left="65" width="349" height="13" font="14">Long-term abuse of cocaine may result in DCM even without</text>
<text top="584" left="64" width="350" height="13" font="14">CAD, vasculitis, or MI. Depressed LV function has been</text>
<text top="602" left="64" width="350" height="13" font="14">reported in 4% to 18% of asymptomatic cocaine abusers</text>
<text top="620" left="64" width="26" height="13" font="15"><a href="e147.full.html#67">(142</a></text>
<text top="616" left="90" width="33" height="18" font="15"><a href="e147.full.html#67">–144)</a></text>
<text top="620" left="123" width="124" height="13" font="14">. The safety and ef</text>
<text top="616" left="247" width="167" height="18" font="14">ﬁcacy of beta blockers for</text>
<text top="638" left="64" width="256" height="13" font="14">chronic HF due to cocaine use are unknown</text>
<text top="638" left="325" width="30" height="13" font="15"><a href="e147.full.html#67">(145)</a></text>
<text top="638" left="355" width="4" height="13" font="14">.</text>
<text top="674" left="64" width="319" height="15" font="14">5.4.3. Cardiotoxicity Related to Cancer Therapies</text>
<text top="695" left="65" width="349" height="13" font="14">Several cytotoxic antineoplastic drugs, especially the anthra-</text>
<text top="713" left="64" width="350" height="13" font="14">cyclines, are cardiotoxic and can lead to long-term cardiac</text>
<text top="731" left="64" width="350" height="13" font="14">morbidity. Iron-chelating agents that prevent generation of</text>
<text top="749" left="64" width="350" height="13" font="14">oxygen free radicals, such as dexrazoxane, are car-</text>
<text top="766" left="64" width="74" height="13" font="14">dioprotective</text>
<text top="766" left="148" width="55" height="13" font="15"><a href="e147.full.html#67">(146,147)</a></text>
<text top="766" left="204" width="210" height="13" font="14"><a href="e147.full.html#67">, </a>and reduce the occurrence and</text>
<text top="784" left="64" width="350" height="13" font="14">severity of anthracycline-induced cardiotoxicity and devel-</text>
<text top="802" left="64" width="85" height="13" font="14">opment of HF.</text>
<text top="820" left="79" width="335" height="13" font="14">Other antineoplastic chemotherapies with cardiac toxicity</text>
<text top="838" left="64" width="350" height="13" font="14">are the monoclonal antibody trastuzumab (Herceptin), high-</text>
<text top="856" left="64" width="281" height="13" font="14">dose cyclophosphamide, taxoids, mitomycin-C, 5-</text>
<text top="852" left="346" width="68" height="18" font="14">ﬂuorouracil,</text>
<text top="874" left="64" width="118" height="13" font="14">and the interferons</text>
<text top="874" left="192" width="31" height="13" font="15"><a href="e147.full.html#67">(148)</a></text>
<text top="874" left="223" width="191" height="13" font="14">. In contrast to anthracycline-</text>
<text top="892" left="64" width="350" height="13" font="14">induced cardiac toxicity, trastuzumab-related cardiac dys-</text>
<text top="910" left="64" width="350" height="13" font="14">function does not appear to increase with cumulative dose,</text>
<text top="928" left="64" width="350" height="13" font="14">nor is it associated with ultrastructural changes in the</text>
<text top="946" left="64" width="350" height="13" font="14">myocardium. However, concomitant anthracycline therapy</text>
<text top="964" left="64" width="28" height="13" font="14">signi</text>
<text top="960" left="92" width="322" height="18" font="14">ﬁcantly increases the risk for cardiotoxicity during</text>
<text top="982" left="64" width="350" height="13" font="14">trastuzumab treatment. The cardiac dysfunction associated</text>
<text top="1000" left="64" width="350" height="13" font="14">with trastuzumab is most often reversible on discontinuation</text>
<text top="1018" left="64" width="350" height="13" font="14">of treatment and initiation of standard medical therapy for HF</text>
<text top="1035" left="64" width="31" height="13" font="15"><a href="e147.full.html#67">(149)</a></text>
<text top="1035" left="95" width="319" height="13" font="14">. The true incidence and reversibility of chemotherapy-</text>
<text top="1053" left="64" width="350" height="13" font="14">related cardiotoxicity are not well documented, and mean-</text>
<text top="1071" left="64" width="350" height="13" font="14">ingful interventions to prevent injury have not yet been</text>
<text top="1089" left="64" width="62" height="13" font="14">elucidated.</text>
<text top="103" left="450" width="233" height="15" font="14">5.4.4. Other Myocardial Toxins and</text>
<text top="120" left="450" width="247" height="15" font="14">Nutritional Causes of Cardiomyopathy</text>
<text top="141" left="451" width="349" height="13" font="14">In addition to the classic toxins described above, a number of</text>
<text top="159" left="450" width="350" height="13" font="14">other toxic agents may lead to LV dysfunction and HF,</text>
<text top="177" left="450" width="350" height="13" font="14">including ephedra, cobalt, anabolic steroids, chloroquine,</text>
<text top="195" left="450" width="350" height="13" font="14">clozapine, amphetamine, methylphenidate, and catechol-</text>
<text top="213" left="450" width="40" height="13" font="14">amines</text>
<text top="213" left="497" width="30" height="13" font="15"><a href="e147.full.html#67">(150)</a></text>
<text top="213" left="528" width="272" height="13" font="14"><a href="e147.full.html#67">. </a>Ephedra, which has been used for athletic</text>
<text top="231" left="450" width="350" height="13" font="14">performance enhancement and weight loss, was ultimately</text>
<text top="249" left="450" width="350" height="13" font="14">banned by the U.S. Food and Drug Administration for its high</text>
<text top="267" left="450" width="350" height="13" font="14">rate of adverse cardiovascular outcomes, including LV</text>
<text top="285" left="450" width="350" height="13" font="14">systolic dysfunction, development of HF, and sudden cardiac</text>
<text top="303" left="450" width="72" height="13" font="14">death (SCD)</text>
<text top="303" left="526" width="30" height="13" font="15"><a href="e147.full.html#67">(151)</a></text>
<text top="303" left="557" width="4" height="13" font="14"><a href="e147.full.html#67">.</a></text>
<text top="321" left="465" width="211" height="13" font="14">Primary and secondary nutritional de</text>
<text top="317" left="676" width="124" height="18" font="14">ﬁciencies may lead to</text>
<text top="338" left="450" width="350" height="13" font="14">cardiomyopathy. Chronic alcoholism, anorexia nervosa,</text>
<text top="356" left="450" width="350" height="13" font="14">AIDS, and pregnancy can account for other rare causes of</text>
<text top="374" left="450" width="69" height="13" font="14">thiamine de</text>
<text top="371" left="519" width="280" height="18" font="14">ﬁciency–related cardiomyopathy in the western</text>
<text top="392" left="450" width="33" height="13" font="14">world</text>
<text top="392" left="489" width="30" height="13" font="15"><a href="e147.full.html#67">(152)</a></text>
<text top="392" left="519" width="26" height="13" font="14"><a href="e147.full.html#67">. </a>De</text>
<text top="389" left="545" width="61" height="18" font="14">ﬁciency in</text>
<text top="395" left="612" width="6" height="9" font="12">L</text>
<text top="392" left="618" width="181" height="13" font="14">-carnitine, a necessary cofactor</text>
<text top="410" left="450" width="350" height="13" font="14">for fatty acid oxidation, may be associated with a syndrome of</text>
<text top="428" left="450" width="295" height="13" font="14">progressive skeletal myopathy and cardiomyopathy</text>
<text top="428" left="749" width="30" height="13" font="15"><a href="e147.full.html#67">(153)</a></text>
<text top="428" left="779" width="4" height="13" font="14">.</text>
<text top="465" left="450" width="312" height="14" font="16">5.5. Tachycardia-Induced Cardiomyopathy</text>
<text top="484" left="451" width="349" height="13" font="14">Tachycardia-induced cardiomyopathy is a reversible cause of</text>
<text top="502" left="450" width="350" height="13" font="14">HF characterized by LV myocardial dysfunction caused by</text>
<text top="520" left="450" width="350" height="13" font="14">increased ventricular rate. The degree of dysfunction corre-</text>
<text top="538" left="450" width="350" height="13" font="14">lates with the duration and rate of the tachyarrhythmia.</text>
<text top="556" left="450" width="350" height="13" font="14">Virtually any supraventricular tachycardia with a rapid</text>
<text top="574" left="450" width="350" height="13" font="14">ventricular response may induce cardiomyopathy. Ventricular</text>
<text top="592" left="450" width="350" height="13" font="14">arrhythmias, including frequent premature ventricular com-</text>
<text top="609" left="450" width="350" height="13" font="14">plexes, may also induce cardiomyopathy. Maintenance of</text>
<text top="627" left="450" width="350" height="13" font="14">sinus rhythm or control of ventricular rate is critical to treating</text>
<text top="645" left="450" width="305" height="13" font="14">patients with tachycardia-induced cardiomyopathy</text>
<text top="645" left="766" width="30" height="13" font="15"><a href="e147.full.html#67">(154)</a></text>
<text top="645" left="796" width="4" height="13" font="14"><a href="e147.full.html#67">.</a></text>
<text top="663" left="450" width="350" height="13" font="14">Reversibility of the cardiomyopathy with treatment of the</text>
<text top="681" left="450" width="350" height="13" font="14">arrhythmia is the rule, although this may not be complete in</text>
<text top="699" left="450" width="350" height="13" font="14">all cases. The underlying mechanisms for this are not well</text>
<text top="717" left="450" width="66" height="13" font="14">understood.</text>
<text top="735" left="465" width="335" height="13" font="14">Ventricular pacing at high rates may cause cardiomyop-</text>
<text top="753" left="450" width="350" height="13" font="14">athy. Additionally, right ventricular pacing alone may exac-</text>
<text top="771" left="450" width="350" height="13" font="14">erbate HF symptoms, increase hospitalization for HF, and</text>
<text top="789" left="450" width="104" height="13" font="14">increase mortality</text>
<text top="789" left="560" width="55" height="13" font="15"><a href="e147.full.html#67">(155,156)</a></text>
<text top="789" left="616" width="184" height="13" font="14"><a href="e147.full.html#67">. </a>Use of CRT in patients with</text>
<text top="807" left="450" width="350" height="13" font="14">a conduction delay due to pacing may result in improved LV</text>
<text top="825" left="450" width="189" height="13" font="14">function and functional capacity.</text>
<text top="861" left="450" width="294" height="14" font="16">5.6. Myocarditis and Cardiomyopathies</text>
<text top="881" left="450" width="69" height="14" font="16">Due to In</text>
<text top="877" left="519" width="83" height="20" font="16">ﬂammation</text>
<text top="907" left="450" width="117" height="15" font="14">5.6.1. Myocarditis</text>
<text top="928" left="451" width="12" height="13" font="14">In</text>
<text top="924" left="462" width="337" height="18" font="14">ﬂammation of the heart may cause HF in about 10% of</text>
<text top="946" left="450" width="269" height="13" font="14">cases of initially unexplained cardiomyopathy</text>
<text top="946" left="725" width="55" height="13" font="15"><a href="e147.full.html#66">(105,157)</a></text>
<text top="946" left="780" width="20" height="13" font="14"><a href="e147.full.html#66">. </a>A</text>
<text top="964" left="450" width="350" height="13" font="14">variety of infectious organisms, as well as toxins and medi-</text>
<text top="982" left="450" width="350" height="13" font="14">cations, most often postviral in origin, may cause myocarditis.</text>
<text top="1000" left="450" width="350" height="13" font="14">In addition, myocarditis is also seen as part of other systemic</text>
<text top="1018" left="450" width="350" height="13" font="14">diseases such as systemic lupus erythematosus and other</text>
<text top="1036" left="450" width="350" height="13" font="14">myocardial muscle diseases such as HIV cardiomyopathy and</text>
<text top="1054" left="450" width="350" height="13" font="14">possibly peripartum cardiomyopathy. Presentation may be</text>
<text top="1072" left="450" width="350" height="13" font="14">acute, with a distinct onset, severe hemodynamic compro-</text>
<text top="1090" left="450" width="350" height="13" font="14">mise, and severe LV dysfunction as seen in acute fulminant</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e159</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">myocarditis, or it may be subacute, with an indistinct onset</text>
<text top="121" left="64" width="207" height="13" font="14">and better-tolerated LV dysfunction</text>
<text top="121" left="277" width="30" height="13" font="15"><a href="e147.full.html#68">(158)</a></text>
<text top="121" left="307" width="107" height="13" font="14">. Prognosis varies,</text>
<text top="139" left="64" width="350" height="13" font="14">with spontaneous complete resolution (paradoxically most</text>
<text top="157" left="64" width="269" height="13" font="14">often seen with acute fulminant myocarditis)</text>
<text top="157" left="341" width="30" height="13" font="15"><a href="e147.full.html#68">(158)</a></text>
<text top="157" left="379" width="35" height="13" font="14">to the</text>
<text top="175" left="64" width="350" height="13" font="14">development of DCM despite immunosuppressive therapy</text>
<text top="193" left="64" width="30" height="13" font="15"><a href="e147.full.html#68">(159)</a></text>
<text top="193" left="95" width="319" height="13" font="14"><a href="e147.full.html#68">. </a>The role of immunosuppressive therapy is controversial</text>
<text top="211" left="64" width="30" height="13" font="15"><a href="e147.full.html#68">(159)</a></text>
<text top="211" left="95" width="185" height="13" font="14"><a href="e147.full.html#68">. </a>Targeting such therapy to speci</text>
<text top="207" left="280" width="134" height="18" font="14">ﬁc individuals based on</text>
<text top="229" left="64" width="350" height="13" font="14">the presence or absence of viral genome in myocardial biopsy</text>
<text top="247" left="64" width="350" height="13" font="14">samples may improve response to immunosuppressive</text>
<text top="265" left="64" width="42" height="13" font="14">therapy</text>
<text top="265" left="111" width="30" height="13" font="15"><a href="e147.full.html#68">(160)</a></text>
<text top="265" left="142" width="4" height="13" font="14"><a href="e147.full.html#68">.</a></text>
<text top="283" left="79" width="335" height="13" font="14">Giant cell myocarditis is a rare form of myocardial</text>
<text top="301" left="64" width="11" height="13" font="14">in</text>
<text top="297" left="75" width="339" height="18" font="14">ﬂammation characterized by fulminant HF, often associated</text>
<text top="319" left="64" width="350" height="13" font="14">with refractory ventricular arrhythmias and a poor prognosis</text>
<text top="337" left="64" width="55" height="13" font="15"><a href="e147.full.html#68">(161,162)</a></text>
<text top="337" left="120" width="71" height="13" font="14"><a href="e147.full.html#68">. </a>Histologic</text>
<text top="333" left="199" width="215" height="18" font="14">ﬁndings include diffuse myocardial</text>
<text top="354" left="64" width="350" height="13" font="14">necrosis with numerous multinucleated giant cells without</text>
<text top="372" left="64" width="350" height="13" font="14">granuloma formation. Consideration for advanced HF thera-</text>
<text top="390" left="64" width="350" height="13" font="14">pies, including immunosuppression, mechanical circulatory</text>
<text top="408" left="64" width="284" height="13" font="14">support (MCS), and transplantation, is warranted.</text>
<text top="438" left="64" width="174" height="15" font="14">5.6.2. Acquired Immunode</text>
<text top="435" left="239" width="116" height="19" font="14">ﬁciency Syndrome</text>
<text top="459" left="65" width="144" height="13" font="14">The extent of immunode</text>
<text top="455" left="209" width="205" height="18" font="14">ﬁciency inﬂuences the incidence of</text>
<text top="477" left="64" width="126" height="13" font="14">HIV-associated DCM</text>
<text top="477" left="198" width="26" height="13" font="15"><a href="e147.full.html#68">(163</a></text>
<text top="473" left="223" width="33" height="18" font="15"><a href="e147.full.html#68">–165)</a></text>
<text top="477" left="256" width="158" height="13" font="14">. In long-term echocardio-</text>
<text top="495" left="64" width="103" height="13" font="14">graphic follow-up</text>
<text top="495" left="172" width="30" height="13" font="15"><a href="e147.full.html#68">(166)</a></text>
<text top="495" left="202" width="211" height="13" font="14">, 8% of initially asymptomatic HIV-</text>
<text top="513" left="64" width="350" height="13" font="14">positive patients were diagnosed with DCM during the</text>
<text top="531" left="64" width="350" height="13" font="14">5-year follow-up. Whether early treatment with ACE inhibi-</text>
<text top="549" left="64" width="350" height="13" font="14">tors and/or beta blockers will prevent or delay disease</text>
<text top="567" left="64" width="307" height="13" font="14">progression in these patients is unknown at this time.</text>
<text top="597" left="64" width="141" height="15" font="14">5.6.3. Chagas Disease</text>
<text top="617" left="65" width="349" height="13" font="14">Although Chagas disease is a relatively uncommon cause of</text>
<text top="635" left="64" width="350" height="13" font="14">DCM in North America, it remains an important cause of</text>
<text top="653" left="64" width="225" height="13" font="14">death in Central and South America</text>
<text top="653" left="297" width="30" height="13" font="15"><a href="e147.full.html#68">(167)</a></text>
<text top="653" left="327" width="86" height="13" font="14">. Symptomatic</text>
<text top="671" left="64" width="350" height="13" font="14">chronic Chagas disease develops in an estimated 10% to 30%</text>
<text top="689" left="64" width="350" height="13" font="14">of infected persons, years or even decades after the Trypa-</text>
<text top="707" left="64" width="350" height="13" font="14">nosoma cruzi infection. Cardiac changes may include biven-</text>
<text top="725" left="64" width="350" height="13" font="14">tricular enlargement, thinning or thickening of ventricular</text>
<text top="743" left="64" width="350" height="13" font="14">walls, apical aneurysms, and mural thrombi. The conduction</text>
<text top="761" left="64" width="350" height="13" font="14">system is often affected, typically resulting in right bundle-</text>
<text top="779" left="64" width="350" height="13" font="14">branch block, left anterior fascicular block, or complete</text>
<text top="797" left="64" width="126" height="13" font="14">atrioventricular block.</text>
<text top="844" left="64" width="49" height="14" font="16">5.7. In</text>
<text top="839" left="114" width="276" height="20" font="16">ﬂammation-Induced Cardiomyopathy:</text>
<text top="863" left="64" width="164" height="14" font="16">Noninfectious Causes</text>
<text top="890" left="64" width="224" height="15" font="14">5.7.1. Hypersensitivity Myocarditis</text>
<text top="910" left="65" width="349" height="13" font="14">Hypersensitivity to a variety of agents may result in allergic</text>
<text top="928" left="64" width="350" height="13" font="14">reactions that involve the myocardium, characterized by</text>
<text top="946" left="64" width="261" height="13" font="14">peripheral eosinophilia and a perivascular in</text>
<text top="942" left="325" width="89" height="18" font="14">ﬁltration of the</text>
<text top="964" left="64" width="350" height="13" font="14">myocardium by eosinophils, lymphocytes, and histiocytes. A</text>
<text top="982" left="64" width="350" height="13" font="14">variety of drugs, most commonly the sulfonamides, penicil-</text>
<text top="1000" left="64" width="350" height="13" font="14">lins, methyldopa, and other agents such as amphotericin B,</text>
<text top="1018" left="64" width="350" height="13" font="14">streptomycin, phenytoin, isoniazid, tetanus toxoid, hydro-</text>
<text top="1036" left="64" width="350" height="13" font="14">chlorothiazide, dobutamine, and chlorthalidone, have been</text>
<text top="1054" left="64" width="311" height="13" font="14">reported to cause allergic hypersensitivity myocarditis</text>
<text top="1054" left="380" width="30" height="13" font="15"><a href="e147.full.html#68">(168)</a></text>
<text top="1054" left="410" width="4" height="13" font="14">.</text>
<text top="1072" left="64" width="350" height="13" font="14">Most patients are not clinically ill but may die suddenly,</text>
<text top="1090" left="64" width="231" height="13" font="14">presumably secondary to an arrhythmia.</text>
<text top="103" left="450" width="339" height="15" font="14">5.7.2. Rheumatological/Connective Tissue Disorders</text>
<text top="123" left="451" width="349" height="13" font="14">Along with a number of cardiac abnormalities (e.g., pericar-</text>
<text top="141" left="450" width="350" height="13" font="14">ditis, pericardial effusion, conduction system abnormalities,</text>
<text top="159" left="450" width="350" height="13" font="14">including complete atrioventricular heart block), DCM can be</text>
<text top="177" left="450" width="350" height="13" font="14">a rare manifestation of systemic lupus erythematosus and</text>
<text top="195" left="450" width="219" height="13" font="14">usually correlates with disease activity</text>
<text top="195" left="673" width="30" height="13" font="15"><a href="e147.full.html#68">(169)</a></text>
<text top="195" left="704" width="96" height="13" font="14"><a href="e147.full.html#68">. </a>Studies suggest</text>
<text top="213" left="450" width="282" height="13" font="14">that echocardiographic evidence of abnormal LV</text>
<text top="209" left="737" width="63" height="18" font="14">ﬁlling may</text>
<text top="231" left="450" width="11" height="13" font="14">re</text>
<text top="227" left="461" width="339" height="18" font="14">ﬂect the presence of myocardial ﬁbrosis and could be</text>
<text top="249" left="450" width="350" height="13" font="14">a marker of subclinical myocardial involvement in systemic</text>
<text top="267" left="450" width="165" height="13" font="14">lupus erythematosus patients</text>
<text top="267" left="619" width="30" height="13" font="15"><a href="e147.full.html#68">(170)</a></text>
<text top="267" left="650" width="4" height="13" font="14"><a href="e147.full.html#68">.</a></text>
<text top="285" left="465" width="335" height="13" font="14">Scleroderma is a rare cause of DCM. One echocardio-</text>
<text top="303" left="450" width="350" height="13" font="14">graphic study showed that despite normal LV dimensions or</text>
<text top="321" left="450" width="350" height="13" font="14">fractional shortening, subclinical systolic impairment was</text>
<text top="338" left="450" width="309" height="13" font="14">present in the majority of patients with scleroderma</text>
<text top="338" left="766" width="30" height="13" font="15"><a href="e147.full.html#68">(171)</a></text>
<text top="338" left="796" width="4" height="13" font="14"><a href="e147.full.html#68">.</a></text>
<text top="356" left="450" width="350" height="13" font="14">Cardiac involvement in rheumatoid arthritis generally is</text>
<text top="374" left="450" width="350" height="13" font="14">in the form of myocarditis and/or pericarditis, and develop-</text>
<text top="392" left="450" width="136" height="13" font="14">ment of DCM is rare</text>
<text top="392" left="594" width="30" height="13" font="15"><a href="e147.full.html#68">(172)</a></text>
<text top="392" left="625" width="175" height="13" font="14"><a href="e147.full.html#68">. </a>Myocardial involvement in</text>
<text top="410" left="450" width="350" height="13" font="14">rheumatoid arthritis is thought to be secondary to micro-</text>
<text top="428" left="450" width="350" height="13" font="14">vasculitis and subsequent microcirculatory disturbances.</text>
<text top="446" left="450" width="350" height="13" font="14">Myocardial disease in rheumatoid arthritis can occur in the</text>
<text top="464" left="450" width="350" height="13" font="14">absence of clinical symptoms or abnormalities of the elec-</text>
<text top="482" left="450" width="121" height="13" font="14">trocardiogram (ECG)</text>
<text top="482" left="576" width="30" height="13" font="15"><a href="e147.full.html#68">(173)</a></text>
<text top="482" left="606" width="4" height="13" font="14">.</text>
<text top="515" left="450" width="244" height="14" font="16">5.8. Peripartum Cardiomyopathy</text>
<text top="534" left="451" width="349" height="13" font="14">Peripartum cardiomyopathy is a disease of unknown cause in</text>
<text top="552" left="450" width="350" height="13" font="14">which LV dysfunction occurs during the last trimester of</text>
<text top="570" left="450" width="350" height="13" font="14">pregnancy or the early puerperium. It is reported in 1:1300 to</text>
<text top="588" left="450" width="103" height="13" font="14">1:4000 live births</text>
<text top="588" left="558" width="30" height="13" font="15"><a href="e147.full.html#68">(174)</a></text>
<text top="588" left="588" width="211" height="13" font="14">. Risk factors for peripartum cardio-</text>
<text top="606" left="450" width="350" height="13" font="14">myopathy include advanced maternal age, multiparity,</text>
<text top="624" left="450" width="350" height="13" font="14">African descent, and long-term tocolysis. Although its</text>
<text top="642" left="450" width="350" height="13" font="14">etiology remains unknown, most theories have focused on</text>
<text top="660" left="450" width="226" height="13" font="14">hemodynamic and immunologic causes</text>
<text top="660" left="680" width="30" height="13" font="15"><a href="e147.full.html#68">(174)</a></text>
<text top="660" left="710" width="89" height="13" font="14">. The prognosis</text>
<text top="677" left="450" width="350" height="13" font="14">of peripartum cardiomyopathy is related to the recovery of</text>
<text top="695" left="450" width="152" height="13" font="14">ventricular function. Signi</text>
<text top="692" left="602" width="197" height="18" font="14">ﬁcant improvement in myocardial</text>
<text top="713" left="450" width="307" height="13" font="14">function is seen in 30% to 50% of patients in the</text>
<text top="710" left="764" width="36" height="18" font="14">ﬁrst 6</text>
<text top="731" left="450" width="146" height="13" font="14">months after presentation</text>
<text top="731" left="601" width="30" height="13" font="15"><a href="e147.full.html#68">(174)</a></text>
<text top="731" left="631" width="168" height="13" font="14"><a href="e147.full.html#68">. </a>However, for those patients</text>
<text top="749" left="450" width="350" height="13" font="14">who do not recover to normal or near-normal function, the</text>
<text top="767" left="450" width="275" height="13" font="14">prognosis is similar to other forms of DCM</text>
<text top="767" left="733" width="30" height="13" font="15"><a href="e147.full.html#68">(175)</a></text>
<text top="767" left="763" width="36" height="13" font="14">. Car-</text>
<text top="785" left="450" width="157" height="13" font="14">diomegaly that persists for</text>
<text top="781" left="613" width="187" height="18" font="14">&gt;4 to 6 months after diagnosis</text>
<text top="803" left="450" width="350" height="13" font="14">indicates a poor prognosis, with a 50% mortality rate at 6</text>
<text top="821" left="450" width="350" height="13" font="14">years. Subsequent pregnancy in women with a history of</text>
<text top="839" left="450" width="350" height="13" font="14">peripartum cardiomyopathy may be associated with a further</text>
<text top="857" left="450" width="350" height="13" font="14">decrease in LV function and can result in clinical deteriora-</text>
<text top="875" left="450" width="350" height="13" font="14">tion, including death. However, if ventricular function has</text>
<text top="893" left="450" width="350" height="13" font="14">normalized in women with a history of peripartum cardio-</text>
<text top="911" left="450" width="182" height="13" font="14">myopathy, the risk may be less</text>
<text top="911" left="637" width="30" height="13" font="15"><a href="e147.full.html#68">(174)</a></text>
<text top="911" left="667" width="132" height="13" font="14">. There is an increased</text>
<text top="929" left="450" width="350" height="13" font="14">risk of venous thromboembolism, and anticoagulation is</text>
<text top="947" left="450" width="83" height="13" font="14">recommended,</text>
<text top="947" left="546" width="56" height="13" font="14">especially</text>
<text top="947" left="615" width="8" height="13" font="14">if</text>
<text top="947" left="637" width="61" height="13" font="14">ventricular</text>
<text top="947" left="711" width="66" height="13" font="14">dysfunction</text>
<text top="947" left="790" width="9" height="13" font="14">is</text>
<text top="964" left="450" width="57" height="13" font="14">persistent.</text>
<text top="997" left="450" width="239" height="14" font="16">5.9. Cardiomyopathy Caused by</text>
<text top="1017" left="450" width="101" height="14" font="16">Iron Overload</text>
<text top="1036" left="451" width="349" height="13" font="14">Iron overload cardiomyopathy manifests itself as systolic or</text>
<text top="1054" left="450" width="350" height="13" font="14">diastolic dysfunction secondary to increased deposition of</text>
<text top="1072" left="450" width="350" height="13" font="14">iron in the heart and occurs with common genetic disorders</text>
<text top="1090" left="450" width="350" height="13" font="14">such as primary hemochromatosis or with lifetime transfusion</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e160</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="17" size="7" family="Times" color="#a70c2f"/>
	<fontspec id="18" size="9" family="Times" color="#005c58"/>
<text top="103" left="64" width="304" height="13" font="14">requirements as seen in beta-thalassemia major</text>
<text top="103" left="380" width="30" height="13" font="15"><a href="e147.full.html#68">(176)</a></text>
<text top="103" left="410" width="4" height="13" font="14">.</text>
<text top="121" left="64" width="350" height="13" font="14">Hereditary hemochromatosis, an autosomal recessive dis-</text>
<text top="139" left="64" width="350" height="13" font="14">order, is the most common hereditary disease of Northern</text>
<text top="157" left="64" width="350" height="13" font="14">Europeans, with a prevalence of approximately 5 per 1,000.</text>
<text top="175" left="64" width="350" height="13" font="14">The actuarial survival rates of persons who are homozygous</text>
<text top="193" left="64" width="350" height="13" font="14">for the mutation of the hemochromatosis gene C282Y have</text>
<text top="211" left="64" width="350" height="13" font="14">been reported to be 95%, 93%, and 66%, at 5, 10, and 20</text>
<text top="229" left="64" width="107" height="13" font="14">years, respectively</text>
<text top="229" left="177" width="30" height="13" font="15"><a href="e147.full.html#68">(177)</a></text>
<text top="229" left="208" width="206" height="13" font="14"><a href="e147.full.html#68">. </a>Similarly, in patients with thalas-</text>
<text top="247" left="64" width="350" height="13" font="14">semia major, cardiac failure is one of the most frequent causes</text>
<text top="265" left="64" width="350" height="13" font="14">of death. Chelation therapy, including newer forms of oral</text>
<text top="283" left="64" width="350" height="13" font="14">chelators, such as deferoxamine, and phlebotomy, have</text>
<text top="301" left="64" width="350" height="13" font="14">dramatically improved the outcome of hemochromatosis, and</text>
<text top="319" left="64" width="350" height="13" font="14">the roles of gene therapy, hepcidin, and calcium channel</text>
<text top="337" left="64" width="227" height="13" font="14">blockers are being actively investigated</text>
<text top="337" left="296" width="30" height="13" font="15"><a href="e147.full.html#68">(178)</a></text>
<text top="337" left="326" width="4" height="13" font="14">.</text>
<text top="371" left="64" width="135" height="14" font="16">5.10. Amyloidosis</text>
<text top="390" left="65" width="349" height="13" font="14">Cardiac amyloidosis involves the deposition of insoluble</text>
<text top="408" left="64" width="61" height="13" font="14">proteins as</text>
<text top="404" left="129" width="285" height="18" font="14">ﬁbrils in the heart, resulting in HF. Primary or AL</text>
<text top="426" left="64" width="350" height="13" font="14">amyloidosis (monoclonal kappa or lambda light chains),</text>
<text top="444" left="64" width="350" height="13" font="14">secondary amyloidosis (protein A), familial TTR amyloidosis</text>
<text top="462" left="64" width="350" height="13" font="14">(mutant transthyretin), dialysis-associated amyloidosis (beta-</text>
<text top="480" left="64" width="350" height="13" font="14">2-microglobulin), or senile TTR amyloidosis (wild-type</text>
<text top="498" left="64" width="350" height="13" font="14">transthyretin) can affect the heart, but cardiac involvement is</text>
<text top="516" left="64" width="287" height="13" font="14">primarily encountered in AL and TTR amyloidosis</text>
<text top="516" left="355" width="30" height="13" font="15"><a href="e147.full.html#68">(179)</a></text>
<text top="516" left="385" width="29" height="13" font="14"><a href="e147.full.html#68">. </a>The</text>
<text top="534" left="64" width="350" height="13" font="14">disease can be rapidly progressive, and in patients with</text>
<text top="552" left="64" width="168" height="13" font="14">ventricular septum thickness</text>
<text top="548" left="239" width="175" height="18" font="14">&gt;15 mm, LVEF &lt;40%, and</text>
<text top="570" left="64" width="242" height="13" font="14">symptoms of HF, median survival may be</text>
<text top="566" left="311" width="64" height="18" font="14">&lt;6 months</text>
<text top="570" left="380" width="30" height="13" font="15"><a href="e147.full.html#68">(180)</a></text>
<text top="570" left="410" width="4" height="13" font="14">.</text>
<text top="588" left="64" width="350" height="13" font="14">Cardiac biomarkers (e.g., B-type natriuretic peptide [BNP],</text>
<text top="605" left="64" width="350" height="13" font="14">cardiac troponin) have been reported to predict response and</text>
<text top="623" left="64" width="207" height="13" font="14">progression of disease and survival</text>
<text top="623" left="277" width="30" height="13" font="15"><a href="e147.full.html#68">(181)</a></text>
<text top="623" left="308" width="106" height="13" font="14"><a href="e147.full.html#68">. </a>Three percent to</text>
<text top="641" left="64" width="350" height="13" font="14">4% of African Americans carry an amyloidogenic allele of the</text>
<text top="659" left="64" width="350" height="13" font="14">human serum protein transthyretin (TTR V122I), which</text>
<text top="677" left="64" width="350" height="13" font="14">appears to increase risk for cardiac amyloid deposition after</text>
<text top="695" left="64" width="89" height="13" font="14">65 years of age</text>
<text top="695" left="158" width="30" height="13" font="15"><a href="e147.full.html#68">(182)</a></text>
<text top="695" left="188" width="4" height="13" font="14">.</text>
<text top="730" left="64" width="193" height="14" font="16">5.11. Cardiac Sarcoidosis</text>
<text top="749" left="65" width="349" height="13" font="14">Cardiac sarcoidosis is an underdiagnosed disease that may</text>
<text top="767" left="64" width="350" height="13" font="14">affect as many as 25% of patients with systemic sarcoidosis.</text>
<text top="785" left="64" width="350" height="13" font="14">Although most commonly recognized in patients with other</text>
<text top="803" left="64" width="350" height="13" font="14">manifestations of sarcoidosis, cardiac involvement may occur</text>
<text top="821" left="64" width="350" height="13" font="14">in isolation and go undetected. Cardiac sarcoidosis may</text>
<text top="839" left="64" width="350" height="13" font="14">present as asymptomatic LV dysfunction, HF, atrioventricular</text>
<text top="857" left="64" width="306" height="13" font="14">block, atrial or ventricular arrhythmia, and SCD</text>
<text top="857" left="380" width="30" height="13" font="15"><a href="e147.full.html#68">(183)</a></text>
<text top="857" left="410" width="4" height="13" font="14">.</text>
<text top="874" left="64" width="350" height="13" font="14">Although untested in clinical trials, early use of high-dose</text>
<text top="892" left="64" width="309" height="13" font="14">steroid therapy may halt or reverse cardiac damage</text>
<text top="892" left="380" width="30" height="13" font="15"><a href="e147.full.html#68">(184)</a></text>
<text top="892" left="410" width="4" height="13" font="14">.</text>
<text top="910" left="64" width="350" height="13" font="14">Cardiac magnetic resonance and cardiac positron emission</text>
<text top="928" left="64" width="350" height="13" font="14">tomographic scanning can identify cardiac involvement with</text>
<text top="946" left="64" width="172" height="13" font="14">patchy areas of myocardial in</text>
<text top="942" left="236" width="178" height="18" font="14">ﬂammation and ﬁbrosis. In the</text>
<text top="964" left="64" width="350" height="13" font="14">setting of ventricular tachyarrhythmia, patients may require</text>
<text top="982" left="64" width="258" height="13" font="14">placement of an implantable cardioverter-de</text>
<text top="978" left="322" width="92" height="18" font="14">ﬁbrillator (ICD)</text>
<text top="1000" left="64" width="179" height="13" font="14">for primary prevention of SCD</text>
<text top="1000" left="248" width="30" height="13" font="15"><a href="e147.full.html#68">(185)</a></text>
<text top="1000" left="278" width="4" height="13" font="14">.</text>
<text top="1035" left="64" width="313" height="14" font="16">5.12. Stress (Takotsubo) Cardiomyopathy</text>
<text top="1054" left="65" width="349" height="13" font="14">Stress cardiomyopathy is characterized by acute reversible</text>
<text top="1072" left="64" width="225" height="13" font="14">LV dysfunction in the absence of signi</text>
<text top="1068" left="289" width="124" height="18" font="14">ﬁcant CAD, triggered</text>
<text top="1090" left="64" width="211" height="13" font="14">by acute emotional or physical stress</text>
<text top="1090" left="280" width="23" height="13" font="15"><a href="e147.full.html#64">(23)</a></text>
<text top="1090" left="304" width="110" height="13" font="14"><a href="e147.full.html#64">. </a>This phenomenon</text>
<text top="103" left="450" width="47" height="13" font="14">is identi</text>
<text top="100" left="497" width="302" height="18" font="14">ﬁed by a distinctive pattern of “apical ballooning,”</text>
<text top="117" left="450" width="350" height="18" font="14">ﬁrst described in Japan as takotsubo, and often affects post-</text>
<text top="139" left="450" width="112" height="13" font="14">menopausal women</text>
<text top="139" left="566" width="30" height="13" font="15"><a href="e147.full.html#68">(186)</a></text>
<text top="139" left="596" width="203" height="13" font="14">. A majority of patients have a clini-</text>
<text top="157" left="450" width="350" height="13" font="14">cal presentation similar to that of acute coronary syndrome</text>
<text top="175" left="450" width="332" height="13" font="14">(ACS) and may have transiently elevated cardiac enzymes.</text>
<text top="213" left="450" width="251" height="15" font="13">6. Initial and Serial Evaluation</text>
<text top="233" left="450" width="141" height="15" font="13">of the HF Patient</text>
<text top="276" left="450" width="174" height="14" font="16">6.1. Clinical Evaluation</text>
<text top="293" left="450" width="264" height="15" font="14">6.1.1. History and Physical Examination:</text>
<text top="311" left="450" width="117" height="15" font="14">Recommendations</text>
<text top="338" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="350" left="468" width="10" height="10" font="18">1.</text>
<text top="350" left="485" width="314" height="10" font="18">A thorough history and physical examination should be ob-</text>
<text top="366" left="485" width="314" height="10" font="18">tained/performed in patients presenting with HF to identify</text>
<text top="383" left="485" width="314" height="10" font="18">cardiac and noncardiac disorders or behaviors that might</text>
<text top="399" left="485" width="314" height="10" font="18">cause or accelerate the development or progression of HF.</text>
<text top="416" left="485" width="113" height="12" font="18">(Level of Evidence: C)</text>
<text top="432" left="468" width="10" height="10" font="18">2.</text>
<text top="432" left="485" width="314" height="10" font="18">In patients with idiopathic DCM, a 3-generational family</text>
<text top="449" left="485" width="314" height="10" font="18">history should be obtained to aid in establishing the diag-</text>
<text top="465" left="485" width="233" height="12" font="18">nosis of familial DCM. (Level of Evidence: C)</text>
<text top="482" left="468" width="10" height="10" font="18">3.</text>
<text top="481" left="485" width="314" height="10" font="18">Volume status and vital signs should be assessed at each</text>
<text top="498" left="485" width="314" height="10" font="18">patient encounter. This includes serial assessment of</text>
<text top="514" left="485" width="314" height="10" font="18">weight, as well as estimates of jugular venous pressure and</text>
<text top="531" left="485" width="250" height="10" font="18">the presence of peripheral edema or orthopnea</text>
<text top="531" left="739" width="26" height="10" font="5"><a href="e147.full.html#68">(187</a></text>
<text top="528" left="765" width="32" height="16" font="5"><a href="e147.full.html#68">–190)</a></text>
<text top="531" left="797" width="3" height="10" font="18"><a href="e147.full.html#68">.</a></text>
<text top="547" left="485" width="113" height="12" font="18">(Level of Evidence: B)</text>
<text top="573" left="465" width="335" height="13" font="14">Despite advances in imaging technology and increasing</text>
<text top="591" left="450" width="350" height="13" font="14">availability of diagnostic laboratory testing, a careful history</text>
<text top="608" left="450" width="350" height="13" font="14">and physical examination remain the cornerstones in the</text>
<text top="626" left="450" width="350" height="13" font="14">assessment of patients with HF. The components of a focused</text>
<text top="644" left="450" width="350" height="13" font="14">history and physical examination for the patient with HF are</text>
<text top="662" left="450" width="45" height="13" font="14">listed in</text>
<text top="662" left="499" width="43" height="13" font="15"><a href="e147.full.html#16">Table 6</a></text>
<text top="662" left="541" width="258" height="13" font="14">. The history provides clues to the etiology of</text>
<text top="680" left="450" width="350" height="13" font="14">the cardiomyopathy, including the diagnosis of familial</text>
<text top="698" left="450" width="118" height="13" font="14">cardiomyopathy (de</text>
<text top="694" left="568" width="231" height="18" font="14">ﬁned as 2 relatives with idiopathic</text>
<text top="716" left="450" width="350" height="13" font="14">DCM). Familial syndromes are now recognized to occur in 20%</text>
<text top="734" left="450" width="281" height="13" font="14">to 35% of patients with apparent idiopathic DCM</text>
<text top="734" left="734" width="30" height="13" font="15"><a href="e147.full.html#67">(118)</a></text>
<text top="734" left="765" width="35" height="13" font="14"><a href="e147.full.html#67">; </a>thus,</text>
<text top="752" left="450" width="350" height="13" font="14">a 3-generation family history should be obtained. The history</text>
<text top="770" left="450" width="350" height="13" font="14">also provides information about the severity of the disease and</text>
<text top="788" left="450" width="60" height="13" font="14">the patient</text>
<text top="784" left="510" width="289" height="18" font="14">’s prognosis and identiﬁes opportunities for thera-</text>
<text top="806" left="450" width="350" height="13" font="14">peutic interventions. The physical examination provides</text>
<text top="824" left="450" width="350" height="13" font="14">information about the severity of illness and allows assessment</text>
<text top="842" left="450" width="350" height="13" font="14">of volume status and adequacy of perfusion. In advanced</text>
<text top="860" left="450" width="350" height="13" font="14">HFrEF, orthopnea and jugular venous pressure are useful</text>
<text top="874" left="450" width="262" height="18" font="14">ﬁndings to detect elevated LV ﬁlling pressures</text>
<text top="877" left="716" width="80" height="13" font="15"><a href="e147.full.html#68">(187,189,190)</a></text>
<text top="877" left="796" width="4" height="13" font="14"><a href="e147.full.html#68">.</a></text>
<text top="895" left="465" width="20" height="13" font="14">See</text>
<text top="895" left="490" width="223" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplements 5, 6, and 7</a></text>
<text top="895" left="719" width="80" height="13" font="14">for additional</text>
<text top="913" left="450" width="263" height="13" font="14">data on stress testing and clinical evaluation.</text>
<text top="939" left="450" width="245" height="15" font="14">6.1.2. Risk Scoring: Recommendation</text>
<text top="966" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="978" left="468" width="10" height="10" font="18">1.</text>
<text top="978" left="485" width="314" height="10" font="18">Validated multivariable risk scores can be useful to estimate</text>
<text top="994" left="485" width="314" height="10" font="18">subsequent risk of mortality in ambulatory or hospitalized</text>
<text top="1010" left="485" width="88" height="10" font="18">patients with HF</text>
<text top="1010" left="577" width="26" height="10" font="5"><a href="e147.full.html#68">(199</a></text>
<text top="1007" left="603" width="32" height="16" font="5"><a href="e147.full.html#68">–207)</a></text>
<text top="1010" left="635" width="121" height="12" font="18"><a href="e147.full.html#68">. </a>(Level of Evidence: B)</text>
<text top="1036" left="465" width="335" height="13" font="14">In the course of standard evaluation, clinicians should</text>
<text top="1054" left="450" width="157" height="13" font="14">routinely assess the patient</text>
<text top="1050" left="607" width="193" height="18" font="14">’s potential for adverse outcome,</text>
<text top="1072" left="450" width="151" height="13" font="14">because accurate risk strati</text>
<text top="1068" left="600" width="199" height="18" font="14">ﬁcation may help guide therapeutic</text>
<text top="1090" left="450" width="350" height="13" font="14">decision making, including a more rapid transition to advanced</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e161</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="19" size="5" family="Times" color="#000000"/>
<text top="1000" left="64" width="350" height="13" font="14">HF therapies. A number of methods objectively assess risk,</text>
<text top="1018" left="64" width="159" height="13" font="14">including biomarker testing <a href="e147.full.html#17">(</a></text>
<text top="1018" left="223" width="62" height="13" font="15"><a href="e147.full.html#17">Section 6.3</a></text>
<text top="1018" left="285" width="129" height="13" font="14"><a href="e147.full.html#17">), </a>as well as a variety of</text>
<text top="1036" left="64" width="185" height="13" font="14">multivariable clinical risk scores (</text>
<text top="1036" left="252" width="42" height="13" font="15"><a href="e147.full.html#17">Table 7</a></text>
<text top="1036" left="293" width="120" height="13" font="14">); these risk scores are</text>
<text top="1053" left="64" width="122" height="13" font="14">for use in ambulatory</text>
<text top="1053" left="191" width="127" height="13" font="15"><a href="e147.full.html#68">(199,203,205,206,208)</a></text>
<text top="1053" left="323" width="91" height="13" font="14">and hospitalized</text>
<text top="1071" left="64" width="43" height="13" font="14">patients</text>
<text top="1071" left="113" width="127" height="13" font="15"><a href="e147.full.html#68">(200,202,204,205,209)</a></text>
<text top="1071" left="240" width="117" height="13" font="14">. Risk models speci</text>
<text top="1068" left="357" width="57" height="18" font="14">ﬁcally for</text>
<text top="1089" left="64" width="255" height="13" font="14">patients with HFpEF have also been described</text>
<text top="1089" left="323" width="30" height="13" font="15"><a href="e147.full.html#68">(201)</a></text>
<text top="1089" left="353" width="4" height="13" font="14"><a href="e147.full.html#68">.</a></text>
<text top="1000" left="465" width="335" height="13" font="14">One well-validated risk score, the Seattle Heart Failure</text>
<text top="1018" left="450" width="350" height="13" font="14">Model, is available in an interactive application on the</text>
<text top="1036" left="450" width="43" height="13" font="14">Internet</text>
<text top="1036" left="498" width="30" height="13" font="15"><a href="e147.full.html#69">(210)</a></text>
<text top="1036" left="534" width="265" height="13" font="14">and provides robust information about risk of</text>
<text top="1053" left="450" width="350" height="13" font="14">mortality in ambulatory patients with HF. For patients</text>
<text top="1071" left="450" width="350" height="13" font="14">hospitalized with acutely decompensated HF, the model</text>
<text top="1089" left="450" width="350" height="13" font="14">developed by ADHERE (Acute Decompensated Heart Failure</text>
<text top="103" left="64" width="264" height="12" font="9">Table 6. History and Physical Examination in HF</text>
<text top="135" left="596" width="48" height="11" font="4">Comments</text>
<text top="154" left="64" width="31" height="11" font="4">History</text>
<text top="174" left="76" width="184" height="11" font="4">Potential clues suggesting etiology of HF</text>
<text top="174" left="441" width="350" height="11" font="4">A careful family history may identify an underlying familial cardiomyopathy in</text>
<text top="189" left="460" width="130" height="11" font="4">patients with idiopathic DCM</text>
<text top="189" left="594" width="23" height="11" font="5"><a href="e147.full.html#67">(118)</a></text>
<text top="189" left="617" width="128" height="11" font="4"><a href="e147.full.html#67">. </a>Other etiologies outlined in</text>
<text top="189" left="749" width="42" height="11" font="5"><a href="e147.full.html#11">Section 5</a></text>
<text top="204" left="460" width="135" height="11" font="4">should be considered as well.</text>
<text top="223" left="76" width="82" height="11" font="4">Duration of illness</text>
<text top="223" left="441" width="282" height="11" font="4">A patient with recent-onset systolic HF may recover over time</text>
<text top="223" left="726" width="23" height="11" font="5"><a href="e147.full.html#67">(113)</a></text>
<text top="223" left="749" width="3" height="11" font="4">.</text>
<text top="243" left="76" width="314" height="11" font="4">Severity and triggers of dyspnea and fatigue, presence of chest pain,</text>
<text top="257" left="88" width="226" height="11" font="4">exercise capacity, physical activity, sexual activity</text>
<text top="243" left="441" width="346" height="11" font="4">To determine NYHA class; identify potential symptoms of coronary ischemia.</text>
<text top="277" left="76" width="175" height="11" font="4">Anorexia and early satiety, weight loss</text>
<text top="277" left="441" width="359" height="11" font="4">Gastrointestinal symptoms are common in patients with HF. Cardiac cachexia is</text>
<text top="292" left="460" width="155" height="11" font="4">associated with adverse prognosis</text>
<text top="292" left="619" width="23" height="11" font="5"><a href="e147.full.html#68">(191)</a></text>
<text top="292" left="642" width="3" height="11" font="4">.</text>
<text top="311" left="76" width="53" height="11" font="4">Weight gain</text>
<text top="311" left="441" width="205" height="11" font="4">Rapid weight gain suggests volume overload.</text>
<text top="331" left="76" width="171" height="11" font="4">Palpitations, (pre)syncope, ICD shocks</text>
<text top="331" left="441" width="359" height="11" font="4">Palpitations may be indications of paroxysmal AF or ventricular tachycardia. ICD</text>
<text top="346" left="460" width="208" height="11" font="4">shocks are associated with adverse prognosis</text>
<text top="346" left="672" width="23" height="11" font="5"><a href="e147.full.html#68">(192)</a></text>
<text top="346" left="695" width="3" height="11" font="4">.</text>
<text top="365" left="76" width="312" height="11" font="4">Symptoms suggesting transient ischemic attack or thromboembolism</text>
<text top="365" left="441" width="239" height="11" font="4">Affects consideration of the need for anticoagulation.</text>
<text top="384" left="76" width="200" height="11" font="4">Development of peripheral edema or ascites</text>
<text top="384" left="441" width="121" height="11" font="4">Suggests volume overload.</text>
<text top="404" left="76" width="207" height="11" font="4">Disordered breathing at night, sleep problems</text>
<text top="404" left="441" width="322" height="11" font="4">Treatment for sleep apnea may improve cardiac function and decrease</text>
<text top="419" left="460" width="107" height="11" font="4">pulmonary hypertension</text>
<text top="419" left="571" width="23" height="11" font="5"><a href="e147.full.html#68">(193)</a></text>
<text top="419" left="594" width="3" height="11" font="4">.</text>
<text top="438" left="76" width="212" height="11" font="4">Recent or frequent prior hospitalizations for HF</text>
<text top="438" left="441" width="156" height="11" font="4">Associated with adverse prognosis</text>
<text top="438" left="601" width="23" height="11" font="5"><a href="e147.full.html#68">(194)</a></text>
<text top="438" left="623" width="3" height="11" font="4">.</text>
<text top="458" left="76" width="215" height="11" font="4">History of discontinuation of medications for HF</text>
<text top="458" left="441" width="359" height="11" font="4">Determine whether lack of GDMT in patients with HFrEF reflects intolerance, an</text>
<text top="473" left="460" width="328" height="11" font="4">adverse event, or perceived contraindication to use. Withdrawal of these</text>
<text top="488" left="460" width="258" height="11" font="4">medications has been associated with adverse prognosis</text>
<text top="488" left="722" width="43" height="11" font="5"><a href="e147.full.html#68">(195,196)</a></text>
<text top="488" left="765" width="3" height="11" font="4"><a href="e147.full.html#68">.</a></text>
<text top="507" left="76" width="165" height="11" font="4">Medications that may exacerbate HF</text>
<text top="507" left="441" width="321" height="11" font="4">Removal of such medications may represent a therapeutic opportunity.</text>
<text top="526" left="76" width="18" height="11" font="4">Diet</text>
<text top="526" left="441" width="335" height="11" font="4">Awareness and restriction of sodium and fluid intake should be assessed.</text>
<text top="546" left="76" width="138" height="11" font="4">Adherence to medical regimen</text>
<text top="546" left="441" width="355" height="11" font="4">Access to medications; family support; access to follow-up; cultural sensitivity</text>
<text top="565" left="64" width="94" height="11" font="4">Physical Examination</text>
<text top="585" left="76" width="148" height="11" font="4">BMI and evidence of weight loss</text>
<text top="585" left="441" width="359" height="11" font="4">Obesity may be a contributing cause of HF; cachexia may correspond with poor</text>
<text top="600" left="460" width="46" height="11" font="4">prognosis.</text>
<text top="619" left="76" width="161" height="11" font="4">Blood pressure (supine and upright)</text>
<text top="619" left="441" width="345" height="11" font="4">Assess for hypertension or hypotension. Width of pulse pressure may reflect</text>
<text top="634" left="460" width="308" height="11" font="4">adequacy of cardiac output. Response of blood pressure to Valsalva</text>
<text top="649" left="460" width="188" height="11" font="4">maneuver may reflect LV filling pressures</text>
<text top="649" left="652" width="23" height="11" font="5"><a href="e147.full.html#68">(197)</a></text>
<text top="649" left="675" width="3" height="11" font="4"><a href="e147.full.html#68">.</a></text>
<text top="668" left="76" width="24" height="11" font="4">Pulse</text>
<text top="668" left="441" width="297" height="11" font="4">Manual palpation will reveal strength and regularity of pulse rate.</text>
<text top="688" left="76" width="312" height="11" font="4">Examination for orthostatic changes in blood pressure and heart rate</text>
<text top="688" left="441" width="338" height="11" font="4">Consistent with volume depletion or excess vasodilation from medications.</text>
<text top="707" left="76" width="317" height="11" font="4">Jugular venous pressure at rest and following abdominal compression</text>
<text top="722" left="88" width="3" height="11" font="4">(</text>
<text top="722" left="91" width="227" height="11" font="5"><a href="http://wn.com/jugular_venous_distension_example">http://wn.com/jugular_venous_distension_example</a></text>
<text top="722" left="318" width="3" height="11" font="4"><a href="http://wn.com/jugular_venous_distension_example">)</a></text>
<text top="707" left="441" width="299" height="11" font="4">Most useful finding on physical examination to identify congestion</text>
<text top="722" left="460" width="66" height="11" font="5"><a href="e147.full.html#68">(187–190,198)</a></text>
<text top="722" left="526" width="3" height="11" font="4">.</text>
<text top="742" left="76" width="205" height="11" font="4">Presence of extra heart sounds and murmurs</text>
<text top="742" left="441" width="6" height="11" font="4">S</text>
<text top="746" left="447" width="4" height="7" font="19">3</text>
<text top="742" left="455" width="208" height="11" font="4">is associated with adverse prognosis in HFrEF</text>
<text top="742" left="667" width="23" height="11" font="5"><a href="e147.full.html#68">(188)</a></text>
<text top="742" left="690" width="84" height="11" font="4">. Murmurs may be</text>
<text top="757" left="460" width="165" height="11" font="4">suggestive of valvular heart disease.</text>
<text top="776" left="76" width="208" height="11" font="4">Size and location of point of maximal impulse</text>
<text top="776" left="441" width="317" height="11" font="4">Enlarged and displaced point of maximal impulse suggests ventricular</text>
<text top="791" left="460" width="58" height="11" font="4">enlargement.</text>
<text top="810" left="76" width="158" height="11" font="4">Presence of right ventricular heave</text>
<text top="810" left="441" width="359" height="11" font="4">Suggests significant right ventricular dysfunction and/or pulmonary hypertension.</text>
<text top="830" left="76" width="257" height="11" font="4">Pulmonary status: respiratory rate, rales, pleural effusion</text>
<text top="830" left="441" width="328" height="11" font="4">In advanced chronic HF, rales are often absent despite major pulmonary</text>
<text top="845" left="460" width="51" height="11" font="4">congestion.</text>
<text top="864" left="76" width="131" height="11" font="4">Hepatomegaly and/or ascites</text>
<text top="864" left="441" width="165" height="11" font="4">Usually markers of volume overload.</text>
<text top="884" left="76" width="79" height="11" font="4">Peripheral edema</text>
<text top="884" left="441" width="359" height="11" font="4">Many patients, particularly those who are young, may be not edematous despite</text>
<text top="899" left="460" width="339" height="11" font="4">intravascular volume overload. In obese patients and elderly patients, edema</text>
<text top="913" left="460" width="226" height="11" font="4">may reflect peripheral rather than cardiac causes.</text>
<text top="933" left="76" width="150" height="11" font="4">Temperature of lower extremities</text>
<text top="933" left="441" width="279" height="11" font="4">Cool lower extremities may reflect inadequate cardiac output.</text>
<text top="954" left="76" width="723" height="11" font="4">AF indicates atrial fibrillation; BMI, body mass index; DCM, dilated cardiomyopathy; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF, heart failure</text>
<text top="969" left="64" width="601" height="11" font="4">with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LV, left ventricular; and NYHA, New York Heart Association.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e162</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1160" width="864">
<text top="578" left="64" width="350" height="13" font="14">National Registry) incorporates 3 routinely measured variables</text>
<text top="596" left="64" width="350" height="13" font="14">on hospital admission (i.e., systolic blood pressure, blood urea</text>
<text top="614" left="64" width="249" height="13" font="14">nitrogen, and serum creatinine) and strati</text>
<text top="610" left="313" width="101" height="18" font="14">ﬁes subjects into</text>
<text top="632" left="64" width="350" height="13" font="14">categories with a 10-fold range of crude in-hospital mortality</text>
<text top="650" left="64" width="123" height="13" font="14">(from 2.1% to 21.9%)</text>
<text top="650" left="191" width="30" height="13" font="15"><a href="e147.full.html#68">(200)</a></text>
<text top="650" left="221" width="193" height="13" font="14">. Notably, clinical risk scores have</text>
<text top="668" left="64" width="350" height="13" font="14">not performed as well in estimating risk of hospital read-</text>
<text top="686" left="64" width="44" height="13" font="14">mission</text>
<text top="686" left="111" width="30" height="13" font="15"><a href="e147.full.html#69">(211)</a></text>
<text top="686" left="142" width="272" height="13" font="14"><a href="e147.full.html#69">. </a>For this purpose, biomarkers such as natriuretic</text>
<text top="704" left="64" width="200" height="13" font="14">peptides hold considerable promise</text>
<text top="704" left="269" width="55" height="13" font="15"><a href="e147.full.html#69">(212,213)</a></text>
<text top="704" left="328" width="5" height="13" font="14">(</text>
<text top="704" left="333" width="64" height="13" font="15"><a href="e147.full.html#17">Section 6.3</a></text>
<text top="704" left="397" width="8" height="13" font="14"><a href="e147.full.html#17">).</a></text>
<text top="722" left="79" width="20" height="13" font="14">See</text>
<text top="722" left="106" width="163" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 8</a></text>
<text top="722" left="277" width="137" height="13" font="14">for additional data on</text>
<text top="740" left="64" width="182" height="13" font="14">clinical evaluation risk scoring.</text>
<text top="770" left="64" width="307" height="14" font="16">6.2. Diagnostic Tests: Recommendations</text>
<text top="797" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="809" left="82" width="10" height="10" font="18">1.</text>
<text top="809" left="100" width="314" height="10" font="18">Initial laboratory evaluation of patients presenting with HF</text>
<text top="825" left="100" width="314" height="10" font="18">should include complete blood count, urinalysis, serum</text>
<text top="842" left="100" width="314" height="10" font="18">electrolytes (including calcium and magnesium), blood urea</text>
<text top="858" left="100" width="295" height="10" font="18">nitrogen, serum creatinine, glucose, fasting lipid pro</text>
<text top="855" left="395" width="19" height="16" font="18">ﬁle,</text>
<text top="874" left="100" width="314" height="12" font="18">liver function tests, and thyroid-stimulating hormone. (Level</text>
<text top="891" left="100" width="79" height="12" font="18">of Evidence: C)</text>
<text top="908" left="82" width="10" height="10" font="18">2.</text>
<text top="907" left="100" width="314" height="10" font="18">Serial monitoring, when indicated, should include serum</text>
<text top="924" left="100" width="282" height="12" font="18">electrolytes and renal function. (Level of Evidence: C)</text>
<text top="940" left="82" width="10" height="10" font="18">3.</text>
<text top="940" left="100" width="314" height="10" font="18">A 12-lead ECG should be performed initially on all patients</text>
<text top="957" left="100" width="220" height="12" font="18">presenting with HF. (Level of Evidence: C)</text>
<text top="981" left="64" width="45" height="8" font="17">CLASS IIa</text>
<text top="993" left="82" width="10" height="10" font="18">1.</text>
<text top="993" left="100" width="314" height="10" font="18">Screening for hemochromatosis or HIV is reasonable in</text>
<text top="1009" left="100" width="220" height="10" font="18">selected patients who present with HF</text>
<text top="1009" left="326" width="30" height="10" font="5"><a href="e147.full.html#69">(216)</a></text>
<text top="1009" left="357" width="57" height="12" font="18"><a href="e147.full.html#69">. </a>(Level of</text>
<text top="1026" left="100" width="65" height="12" font="18">Evidence: C)</text>
<text top="1042" left="82" width="10" height="10" font="18">2.</text>
<text top="1042" left="100" width="314" height="10" font="18">Diagnostic tests for rheumatologic diseases, amyloidosis, or</text>
<text top="1058" left="100" width="314" height="10" font="18">pheochromocytoma are reasonable in patients presenting</text>
<text top="1075" left="100" width="314" height="10" font="18">with HF in whom there is a clinical suspicion of these</text>
<text top="1091" left="100" width="166" height="12" font="18">diseases. (Level of Evidence: C)</text>
<text top="578" left="450" width="268" height="14" font="16">6.3. Biomarkers: Recommendations</text>
<text top="597" left="450" width="170" height="15" font="14">A. Ambulatory/Outpatient</text>
<text top="623" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="635" left="468" width="10" height="10" font="18">1.</text>
<text top="635" left="485" width="314" height="10" font="18">In ambulatory patients with dyspnea, measurement of BNP</text>
<text top="652" left="485" width="314" height="10" font="18">or N-terminal pro-B-type natriuretic peptide (NT-proBNP) is</text>
<text top="668" left="485" width="314" height="10" font="18">useful to support clinical decision making regarding the</text>
<text top="685" left="485" width="314" height="10" font="18">diagnosis of HF, especially in the setting of clinical uncer-</text>
<text top="701" left="485" width="30" height="10" font="18">tainty</text>
<text top="701" left="520" width="26" height="10" font="5"><a href="e147.full.html#69">(217</a></text>
<text top="698" left="545" width="32" height="16" font="5"><a href="e147.full.html#69">–223)</a></text>
<text top="701" left="577" width="120" height="12" font="18"><a href="e147.full.html#69">. </a>(Level of Evidence: A)</text>
<text top="718" left="468" width="10" height="10" font="18">2.</text>
<text top="717" left="485" width="314" height="10" font="18">Measurement of BNP or NT-proBNP is useful for establishing</text>
<text top="734" left="485" width="225" height="10" font="18">prognosis or disease severity in chronic HF</text>
<text top="734" left="714" width="50" height="10" font="5"><a href="e147.full.html#69">(222,224</a></text>
<text top="731" left="764" width="32" height="16" font="5"><a href="e147.full.html#69">–229)</a></text>
<text top="734" left="796" width="3" height="10" font="18">.</text>
<text top="751" left="485" width="113" height="12" font="18">(Level of Evidence: A)</text>
<text top="774" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="786" left="468" width="10" height="10" font="18">1.</text>
<text top="786" left="485" width="106" height="10" font="18">BNP- or NT-proBNP</text>
<text top="783" left="591" width="208" height="16" font="18">–guided HF therapy can be useful to</text>
<text top="803" left="485" width="314" height="10" font="18">achieve optimal dosing of GDMT in select clinically euvole-</text>
<text top="819" left="485" width="314" height="10" font="18">mic patients followed in a well-structured HF disease</text>
<text top="835" left="485" width="116" height="10" font="18">management program</text>
<text top="835" left="605" width="26" height="10" font="5"><a href="e147.full.html#69">(230</a></text>
<text top="832" left="631" width="32" height="16" font="5"><a href="e147.full.html#69">–237)</a></text>
<text top="835" left="662" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="859" left="450" width="45" height="8" font="17">CLASS IIb</text>
<text top="872" left="468" width="10" height="10" font="18">1.</text>
<text top="871" left="485" width="314" height="10" font="18">The usefulness of serial measurement of BNP or NT-proBNP</text>
<text top="888" left="485" width="314" height="10" font="18">to reduce hospitalization or mortality in patients with HF is</text>
<text top="904" left="485" width="107" height="10" font="18">not well established</text>
<text top="904" left="596" width="26" height="10" font="5"><a href="e147.full.html#69">(230</a></text>
<text top="901" left="621" width="32" height="16" font="5"><a href="e147.full.html#69">–237)</a></text>
<text top="904" left="653" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="921" left="468" width="10" height="10" font="18">2.</text>
<text top="921" left="485" width="314" height="10" font="18">Measurement of other clinically available tests such as</text>
<text top="937" left="485" width="184" height="10" font="18">biomarkers of myocardial injury or</text>
<text top="934" left="675" width="125" height="16" font="18">ﬁbrosis may be consid-</text>
<text top="954" left="485" width="144" height="10" font="18">ered for additive risk strati</text>
<text top="950" left="629" width="171" height="16" font="18">ﬁcation in patients with chronic</text>
<text top="970" left="485" width="14" height="10" font="18">HF</text>
<text top="970" left="503" width="26" height="10" font="5"><a href="e147.full.html#69">(238</a></text>
<text top="967" left="529" width="32" height="16" font="5"><a href="e147.full.html#69">–244)</a></text>
<text top="970" left="561" width="121" height="12" font="18"><a href="e147.full.html#69">. </a>(Level of Evidence: B)</text>
<text top="1003" left="450" width="142" height="15" font="14">B. Hospitalized/Acute</text>
<text top="1030" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="1042" left="468" width="10" height="10" font="18">1.</text>
<text top="1042" left="485" width="314" height="10" font="18">Measurement of BNP or NT-proBNP is useful to support clin-</text>
<text top="1058" left="485" width="314" height="10" font="18">ical judgment for the diagnosis of acutely decompensated</text>
<text top="1075" left="485" width="314" height="10" font="18">HF, especially in the setting of uncertainty for the diagnosis</text>
<text top="1091" left="485" width="50" height="10" font="5"><a href="e147.full.html#69">(212,245</a></text>
<text top="1088" left="536" width="32" height="16" font="5"><a href="e147.full.html#69">–250)</a></text>
<text top="1091" left="567" width="116" height="12" font="18">. (Level of Evidence: A)</text>
<text top="103" left="64" width="380" height="12" font="9">Table 7. Selected Multivariable Risk Scores to Predict Outcome in HF</text>
<text top="135" left="64" width="48" height="11" font="4">Risk Score</text>
<text top="135" left="559" width="67" height="11" font="4">Reference/Link</text>
<text top="154" left="64" width="49" height="11" font="4">Chronic HF</text>
<text top="174" left="76" width="125" height="11" font="4">All patients with chronic HF</text>
<text top="193" left="88" width="123" height="11" font="4">Seattle Heart Failure Model</text>
<text top="193" left="386" width="182" height="11" font="5"><a href="e147.full.html#69">(203) </a><a href="http://SeattleHeartFailureModel.org">http://SeattleHeartFailureModel.org</a></text>
<text top="213" left="88" width="126" height="11" font="4">Heart Failure Survival Score</text>
<text top="213" left="386" width="366" height="11" font="5"><a href="e147.full.html#68">(199) </a><a href="http://handheld.softpedia.com/get/Health/Calculator/HFSS-Calc-37354.shtml">http://handheld.softpedia.com/get/Health/Calculator/HFSS-Calc-37354.shtml</a></text>
<text top="232" left="88" width="85" height="11" font="4">CHARM Risk Score</text>
<text top="232" left="581" width="23" height="11" font="5"><a href="e147.full.html#69">(206)</a></text>
<text top="251" left="88" width="90" height="11" font="4">CORONA Risk Score</text>
<text top="251" left="581" width="23" height="11" font="5"><a href="e147.full.html#69">(207)</a></text>
<text top="271" left="76" width="116" height="11" font="4">Specific to chronic HFpEF</text>
<text top="290" left="88" width="82" height="11" font="4">I-PRESERVE Score</text>
<text top="290" left="581" width="23" height="11" font="5"><a href="e147.full.html#68">(201)</a></text>
<text top="310" left="76" width="122" height="11" font="4">Acutely decompensated HF</text>
<text top="329" left="88" width="260" height="11" font="4">ADHERE Classification and Regression Tree (CART) Model</text>
<text top="329" left="581" width="23" height="11" font="5"><a href="e147.full.html#68">(200)</a></text>
<text top="349" left="88" width="265" height="11" font="4">American Heart Association Get With The Guidelines Score</text>
<text top="349" left="386" width="414" height="11" font="5"><a href="e147.full.html#69">(205) </a><a href="http://www.heart.org/HEARTORG/HealthcareProfessional/GetWithTheGuidelinesHFStroke/GetWithTheGuidelinesHeartFailureHomePage/Get-With-The-Guidelines-Heart-Failure-Home-%2520Page_UCM_306087_SubHomePage.jsp">http://www.heart.org/HEARTORG/HealthcareProfessional/GetWithTheGuidelinesHFStroke/</a></text>
<text top="364" left="386" width="401" height="11" font="5"><a href="http://www.heart.org/HEARTORG/HealthcareProfessional/GetWithTheGuidelinesHFStroke/GetWithTheGuidelinesHeartFailureHomePage/Get-With-The-Guidelines-Heart-Failure-Home-%2520Page_UCM_306087_SubHomePage.jsp">GetWithTheGuidelinesHeartFailureHomePage/Get-With-The-Guidelines-Heart-Failure-Home-</a></text>
<text top="378" left="386" width="193" height="11" font="5"><a href="http://www.heart.org/HEARTORG/HealthcareProfessional/GetWithTheGuidelinesHFStroke/GetWithTheGuidelinesHeartFailureHomePage/Get-With-The-Guidelines-Heart-Failure-Home-%2520Page_UCM_306087_SubHomePage.jsp">%20Page_UCM_306087_SubHomePage.jsp</a></text>
<text top="398" left="88" width="85" height="11" font="4">EFFECT Risk Score</text>
<text top="398" left="386" width="250" height="11" font="5"><a href="e147.full.html#68">(202) </a><a href="http://www.ccort.ca/Research/CHFRiskModel.aspx">http://www.ccort.ca/Research/CHFRiskModel.aspx</a></text>
<text top="417" left="88" width="186" height="11" font="4">ESCAPE Risk Model and Discharge Score</text>
<text top="417" left="581" width="23" height="11" font="5"><a href="e147.full.html#69">(214)</a></text>
<text top="437" left="88" width="181" height="11" font="4">OPTIMIZE HF Risk-Prediction Nomogram</text>
<text top="437" left="581" width="23" height="11" font="5"><a href="e147.full.html#69">(215)</a></text>
<text top="458" left="76" width="723" height="11" font="4">ADHERE indicates Acute Decompensated Heart Failure National Registry; CHARM, Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity;</text>
<text top="473" left="64" width="735" height="11" font="4">CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; EFFECT, Enhanced Feedback for Effective Cardiac Treatment; ESCAPE, Evaluation Study of</text>
<text top="488" left="64" width="735" height="11" font="4">Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; I-PRESERVE,</text>
<text top="503" left="64" width="735" height="11" font="4">Irbesartan in Heart Failure with Preserved Ejection Fraction Study; and OPTIMIZE, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart</text>
<text top="518" left="64" width="33" height="11" font="4">Failure.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e163</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="82" width="10" height="10" font="18">2.</text>
<text top="103" left="100" width="314" height="10" font="18">Measurement of BNP or NT-proBNP and/or cardiac troponin</text>
<text top="120" left="100" width="314" height="10" font="18">is useful for establishing prognosis or disease severity</text>
<text top="136" left="100" width="167" height="10" font="18">in acutely decompensated HF</text>
<text top="136" left="274" width="50" height="10" font="5"><a href="e147.full.html#70">(248,251</a></text>
<text top="133" left="324" width="32" height="16" font="5"><a href="e147.full.html#70">–258)</a></text>
<text top="136" left="356" width="58" height="12" font="18"><a href="e147.full.html#70">. </a>(Level of</text>
<text top="153" left="100" width="65" height="12" font="18">Evidence: A)</text>
<text top="177" left="64" width="45" height="8" font="17">CLASS IIb</text>
<text top="189" left="82" width="10" height="10" font="18">1.</text>
<text top="188" left="100" width="208" height="10" font="18">The usefulness of BNP- or NT-proBNP</text>
<text top="185" left="308" width="106" height="16" font="18">–guided therapy for</text>
<text top="205" left="100" width="39" height="10" font="18">acutely</text>
<text top="205" left="150" width="84" height="10" font="18">decompensated</text>
<text top="205" left="245" width="14" height="10" font="18">HF</text>
<text top="205" left="271" width="9" height="10" font="18">is</text>
<text top="205" left="292" width="17" height="10" font="18">not</text>
<text top="205" left="321" width="21" height="10" font="18">well</text>
<text top="205" left="354" width="60" height="10" font="18">established</text>
<text top="221" left="100" width="55" height="10" font="5"><a href="e147.full.html#70">(259,260)</a></text>
<text top="221" left="155" width="120" height="12" font="18"><a href="e147.full.html#70">. </a>(Level of Evidence: C)</text>
<text top="238" left="82" width="10" height="10" font="18">2.</text>
<text top="238" left="100" width="314" height="10" font="18">Measurement of other clinically available tests such as</text>
<text top="254" left="100" width="184" height="10" font="18">biomarkers of myocardial injury or</text>
<text top="251" left="289" width="125" height="16" font="18">ﬁbrosis may be consid-</text>
<text top="271" left="100" width="144" height="10" font="18">ered for additive risk strati</text>
<text top="267" left="243" width="171" height="16" font="18">ﬁcation in patients with acutely</text>
<text top="287" left="100" width="102" height="10" font="18">decompensated HF</text>
<text top="287" left="206" width="125" height="10" font="5"><a href="e147.full.html#70">(248,253,256,257,261</a></text>
<text top="284" left="330" width="32" height="16" font="5"><a href="e147.full.html#70">–267)</a></text>
<text top="287" left="362" width="52" height="12" font="18"><a href="e147.full.html#70">. </a>(Level of</text>
<text top="304" left="100" width="65" height="12" font="18">Evidence: A)</text>
<text top="327" left="79" width="335" height="13" font="14">In addition to routine clinical laboratory tests, other</text>
<text top="345" left="64" width="350" height="13" font="14">biomarkers are gaining greater attention for their utility in</text>
<text top="363" left="64" width="274" height="13" font="14">HF management. These biomarkers may re</text>
<text top="359" left="339" width="75" height="18" font="14">ﬂect various</text>
<text top="381" left="64" width="350" height="13" font="14">pathophysiological aspects of HF, including myocardial wall</text>
<text top="399" left="64" width="227" height="13" font="14">stress, hemodynamic abnormalities, in</text>
<text top="395" left="291" width="123" height="18" font="14">ﬂammation, myocyte</text>
<text top="417" left="64" width="350" height="13" font="14">injury, neurohormonal upregulation, and myocardial remod-</text>
<text top="435" left="64" width="350" height="13" font="14">eling, as well as extracellular matrix turnover. Thus, these</text>
<text top="453" left="64" width="350" height="13" font="14">biomarkers are potentially powerful adjuncts to current stan-</text>
<text top="471" left="64" width="350" height="13" font="14">dards for the diagnosis, prognosis, and treatment of acute and</text>
<text top="489" left="64" width="68" height="13" font="14">chronic HF.</text>
<text top="513" left="64" width="316" height="15" font="14">6.3.1. Natriuretic Peptides: BNP or NT-proBNP</text>
<text top="534" left="65" width="349" height="13" font="14">BNP or its amino-terminal cleavage equivalent (NT-proBNP)</text>
<text top="552" left="64" width="350" height="13" font="14">is derived from a common 108-amino acid precursor peptide</text>
<text top="570" left="64" width="51" height="13" font="14">(proBNP</text>
<text top="575" left="116" width="16" height="9" font="12">108</text>
<text top="570" left="132" width="282" height="13" font="14">) that is generated by cardiomyocytes in the</text>
<text top="587" left="64" width="350" height="13" font="14">context of numerous triggers, most notably myocardial</text>
<text top="605" left="64" width="350" height="13" font="14">stretch. Following several steps of processing, BNP and NT-</text>
<text top="623" left="64" width="350" height="13" font="14">proBNP are released from the cardiomyocyte, along with</text>
<text top="641" left="64" width="181" height="13" font="14">variable amounts of proBNP</text>
<text top="647" left="245" width="16" height="9" font="12">108</text>
<text top="641" left="261" width="153" height="13" font="14">, the latter of which is</text>
<text top="659" left="64" width="249" height="13" font="14">detected by all assays that measure either</text>
<text top="655" left="320" width="94" height="18" font="14">“BNP” or “NT-</text>
<text top="677" left="64" width="50" height="13" font="14">proBNP.</text>
<text top="673" left="115" width="6" height="18" font="14">”</text>
<text top="695" left="79" width="335" height="13" font="14">Assays for BNP and NT-proBNP have been increasingly</text>
<text top="713" left="64" width="350" height="13" font="14">used to establish the presence and severity of HF. In general,</text>
<text top="731" left="64" width="350" height="13" font="14">BNP and NT-proBNP values are reasonably correlated, and</text>
<text top="749" left="64" width="350" height="13" font="14">either can be used in patient care settings as long as their</text>
<text top="767" left="64" width="350" height="13" font="14">respective absolute values and cut points are not used inter-</text>
<text top="785" left="64" width="350" height="13" font="14">changeably. BNP and NT-proBNP are useful to support</text>
<text top="803" left="64" width="350" height="13" font="14">clinical judgment for the diagnosis or exclusion of HF, in the</text>
<text top="821" left="64" width="217" height="13" font="14">setting of chronic ambulatory HF</text>
<text top="821" left="292" width="26" height="13" font="15"><a href="e147.full.html#69">(217</a></text>
<text top="817" left="318" width="33" height="18" font="15"><a href="e147.full.html#69">–223)</a></text>
<text top="821" left="362" width="52" height="13" font="14">or acute</text>
<text top="839" left="64" width="108" height="13" font="14">decompensated HF</text>
<text top="839" left="176" width="26" height="13" font="15"><a href="e147.full.html#70">(245</a></text>
<text top="835" left="202" width="33" height="18" font="15"><a href="e147.full.html#70">–250)</a></text>
<text top="839" left="235" width="179" height="13" font="14"><a href="e147.full.html#70">; </a>the value of natriuretic peptide</text>
<text top="856" left="64" width="149" height="13" font="14">testing is particularly signi</text>
<text top="853" left="213" width="201" height="18" font="14">ﬁcant when the etiology of dyspnea</text>
<text top="874" left="64" width="59" height="13" font="14">is unclear.</text>
<text top="892" left="79" width="335" height="13" font="14">Although lower values of BNP or NT-proBNP exclude the</text>
<text top="910" left="64" width="350" height="13" font="14">presence of HF and higher values have reasonably high</text>
<text top="928" left="64" width="350" height="13" font="14">positive predictive value to diagnose HF, clinicians should be</text>
<text top="946" left="64" width="350" height="13" font="14">aware that elevated plasma levels for both natriuretic peptides</text>
<text top="964" left="64" width="350" height="13" font="14">have been associated with a wide variety of cardiac and</text>
<text top="982" left="64" width="112" height="13" font="14">noncardiac causes (</text>
<text top="982" left="177" width="44" height="13" font="15"><a href="e147.full.html#18">Table 8</a></text>
<text top="982" left="220" width="5" height="13" font="14">)</text>
<text top="982" left="229" width="26" height="13" font="15"><a href="e147.full.html#70">(268</a></text>
<text top="978" left="255" width="33" height="18" font="15"><a href="e147.full.html#70">–271)</a></text>
<text top="982" left="288" width="4" height="13" font="14">.</text>
<text top="1000" left="79" width="335" height="13" font="14">BNP and NT-proBNP levels improve with treatment of</text>
<text top="1018" left="64" width="64" height="13" font="14">chronic HF</text>
<text top="1018" left="133" width="51" height="13" font="15"><a href="e147.full.html#69">(225,272</a></text>
<text top="1014" left="183" width="33" height="18" font="15"><a href="e147.full.html#69">–274)</a></text>
<text top="1018" left="216" width="198" height="13" font="14">, with lowering of levels over time</text>
<text top="1036" left="64" width="350" height="13" font="14">in general, correlating with improved clinical outcomes</text>
<text top="1054" left="64" width="105" height="13" font="15"><a href="e147.full.html#70">(248,251,254,260)</a></text>
<text top="1054" left="169" width="184" height="13" font="14">. Thus, BNP or NT-proBNP</text>
<text top="1050" left="363" width="51" height="18" font="14">“guided”</text>
<text top="1072" left="64" width="350" height="13" font="14">therapy has been studied against standard care without natri-</text>
<text top="1090" left="64" width="350" height="13" font="14">uretic peptide measurement to determine whether guided</text>
<text top="505" left="450" width="350" height="13" font="14">therapy renders superior achievement of GDMT in patients</text>
<text top="523" left="450" width="343" height="13" font="14">with HF. However, RCTs have yielded inconsistent results.</text>
<text top="541" left="465" width="289" height="13" font="14">The positive and negative natriuretic peptide</text>
<text top="537" left="754" width="46" height="18" font="14">–guided</text>
<text top="559" left="450" width="350" height="13" font="14">therapy trials differ primarily in their study populations, with</text>
<text top="577" left="450" width="350" height="13" font="14">successful trials enrolling younger patients and only those</text>
<text top="595" left="450" width="350" height="13" font="14">with HFrEF. In addition, a lower natriuretic peptide goal and/</text>
<text top="613" left="450" width="350" height="13" font="14">or a substantial reduction in natriuretic peptides during treat-</text>
<text top="631" left="450" width="249" height="13" font="14">ment are consistently present in the positive</text>
<text top="627" left="703" width="97" height="18" font="14">“guided” therapy</text>
<text top="649" left="450" width="28" height="13" font="14">trials</text>
<text top="649" left="483" width="30" height="13" font="15"><a href="e147.full.html#70">(275)</a></text>
<text top="649" left="514" width="286" height="13" font="14"><a href="e147.full.html#70">. </a>Although most trials examining the strategy of</text>
<text top="667" left="450" width="58" height="13" font="14">biomarker</text>
<text top="663" left="513" width="287" height="18" font="14">“guided” HF management were small and under-</text>
<text top="685" left="450" width="350" height="13" font="14">powered, 2 comprehensive meta-analyses concluded that</text>
<text top="703" left="450" width="350" height="13" font="14">BNP-guided therapy reduces all-cause mortality in patients</text>
<text top="721" left="450" width="287" height="13" font="14">with chronic HF compared with usual clinical care</text>
<text top="721" left="741" width="55" height="13" font="15"><a href="e147.full.html#69">(231,232)</a></text>
<text top="721" left="796" width="4" height="13" font="14">,</text>
<text top="739" left="450" width="120" height="13" font="14">especially in patients</text>
<text top="735" left="574" width="225" height="18" font="14">&lt;75 years of age. This survival beneﬁt</text>
<text top="756" left="450" width="350" height="13" font="14">may be attributed to increased achievement of GDMT. In</text>
<text top="774" left="450" width="350" height="13" font="14">some cases, BNP or NT-proBNP levels may not be easily</text>
<text top="792" left="450" width="29" height="13" font="14">modi</text>
<text top="789" left="479" width="321" height="18" font="14">ﬁable. If the BNP or NT-proBNP value does not fall</text>
<text top="810" left="450" width="350" height="13" font="14">after aggressive HF care, risk for death or hospitalization for</text>
<text top="828" left="450" width="70" height="13" font="14">HF is signi</text>
<text top="824" left="520" width="280" height="18" font="14">ﬁcant. On the other hand, some patients with</text>
<text top="846" left="450" width="350" height="13" font="14">advanced HF have normal BNP or NT-proBNP levels or have</text>
<text top="864" left="450" width="350" height="13" font="14">falsely low BNP levels because of obesity and HFpEF. All of</text>
<text top="882" left="450" width="308" height="13" font="14">these patients should still receive appropriate GDMT.</text>
<text top="907" left="450" width="255" height="15" font="14">6.3.2. Biomarkers of Myocardial Injury:</text>
<text top="925" left="450" width="160" height="15" font="14">Cardiac Troponin T or I</text>
<text top="946" left="451" width="349" height="13" font="14">Abnormal concentrations of circulating cardiac troponin are</text>
<text top="964" left="450" width="350" height="13" font="14">found in patients with HF, often without obvious myocardial</text>
<text top="982" left="450" width="350" height="13" font="14">ischemia and frequently in those without underlying CAD.</text>
<text top="1000" left="450" width="350" height="13" font="14">This suggests ongoing myocyte injury or necrosis in these</text>
<text top="1018" left="450" width="44" height="13" font="14">patients</text>
<text top="1018" left="497" width="26" height="13" font="15"><a href="e147.full.html#69">(238</a></text>
<text top="1014" left="523" width="58" height="18" font="15"><a href="e147.full.html#69">–241,276)</a></text>
<text top="1018" left="581" width="218" height="13" font="14">. In chronic HF, elaboration of cardiac</text>
<text top="1036" left="450" width="310" height="13" font="14">troponins is associated with impaired hemodynamics</text>
<text top="1036" left="766" width="30" height="13" font="15"><a href="e147.full.html#69">(238)</a></text>
<text top="1036" left="796" width="4" height="13" font="14"><a href="e147.full.html#69">,</a></text>
<text top="1054" left="450" width="164" height="13" font="14">progressive LV dysfunction</text>
<text top="1054" left="620" width="30" height="13" font="15"><a href="e147.full.html#69">(239)</a></text>
<text top="1054" left="651" width="149" height="13" font="14"><a href="e147.full.html#69">, </a>and increased mortality</text>
<text top="1072" left="450" width="26" height="13" font="14">rates</text>
<text top="1072" left="488" width="26" height="13" font="15"><a href="e147.full.html#69">(238</a></text>
<text top="1068" left="514" width="58" height="18" font="15"><a href="e147.full.html#69">–241,276)</a></text>
<text top="1072" left="572" width="228" height="13" font="14"><a href="e147.full.html#69">. </a>Similarly, in patients with acute</text>
<text top="1090" left="450" width="350" height="13" font="14">decompensated HF, elevated cardiac troponin levels are</text>
<text top="103" left="450" width="309" height="12" font="9">Table 8. Selected Causes of Elevated Natriuretic Peptide</text>
<text top="119" left="450" width="81" height="12" font="9">Concentrations</text>
<text top="150" left="450" width="33" height="11" font="4">Cardiac</text>
<text top="167" left="450" width="182" height="16" font="4"> Heart failure, including RV syndromes</text>
<text top="182" left="450" width="127" height="16" font="4"> Acute coronary syndrome</text>
<text top="197" left="450" width="177" height="16" font="4"> Heart muscle disease, including LVH</text>
<text top="212" left="450" width="112" height="16" font="4"> Valvular heart disease</text>
<text top="227" left="450" width="97" height="16" font="4"> Pericardial disease</text>
<text top="242" left="450" width="83" height="16" font="4"> Atrial fibrillation</text>
<text top="257" left="450" width="63" height="16" font="4"> Myocarditis</text>
<text top="272" left="450" width="83" height="16" font="4"> Cardiac surgery</text>
<text top="287" left="450" width="73" height="16" font="4"> Cardioversion</text>
<text top="309" left="450" width="50" height="11" font="4">Noncardiac</text>
<text top="325" left="450" width="78" height="16" font="4"> Advancing age</text>
<text top="340" left="450" width="46" height="16" font="4"> Anemia</text>
<text top="355" left="450" width="69" height="16" font="4"> Renal failure</text>
<text top="370" left="450" width="315" height="16" font="4"> Pulmonary: obstructive sleep apnea, severe pneumonia, pulmonary</text>
<text top="388" left="474" width="57" height="11" font="4">hypertension</text>
<text top="400" left="450" width="75" height="16" font="4"> Critical illness</text>
<text top="415" left="450" width="83" height="16" font="4"> Bacterial sepsis</text>
<text top="430" left="450" width="71" height="16" font="4"> Severe burns</text>
<text top="445" left="450" width="349" height="16" font="4"> Toxic-metabolic insults, including cancer chemotherapy and envenomation</text>
<text top="469" left="462" width="304" height="11" font="4">LVH indicates left ventricular hypertrophy; and RV, right ventricular.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e164</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1160" width="864">
<text top="408" left="64" width="350" height="13" font="14">associated with worse clinical outcomes and mortality</text>
<text top="426" left="64" width="80" height="13" font="15"><a href="e147.full.html#70">(253,257,263)</a></text>
<text top="426" left="144" width="270" height="13" font="14">; decrease in troponin levels over time with</text>
<text top="444" left="64" width="350" height="13" font="14">treatment is associated with a better prognosis than persistent</text>
<text top="462" left="64" width="197" height="13" font="14">elevation in patients with chronic</text>
<text top="462" left="267" width="30" height="13" font="15"><a href="e147.full.html#69">(239)</a></text>
<text top="462" left="303" width="71" height="13" font="14">or acute HF</text>
<text top="462" left="380" width="30" height="13" font="15"><a href="e147.full.html#70">(277)</a></text>
<text top="462" left="410" width="4" height="13" font="14">.</text>
<text top="480" left="64" width="350" height="13" font="14">Given the tight association with ACS and troponin elevation as</text>
<text top="498" left="64" width="350" height="13" font="14">well as the link between MI and the development of acute HF</text>
<text top="516" left="64" width="30" height="13" font="15"><a href="e147.full.html#70">(278)</a></text>
<text top="516" left="95" width="319" height="13" font="14"><a href="e147.full.html#70">, </a>the measurement of troponin I or T should be routine in</text>
<text top="534" left="64" width="350" height="13" font="14">patients presenting with acutely decompensated HF syndromes.</text>
<text top="568" left="64" width="225" height="15" font="14">6.3.3. Other Emerging Biomarkers</text>
<text top="589" left="65" width="349" height="13" font="14">Besides natriuretic peptides or troponins, multiple other</text>
<text top="607" left="64" width="170" height="13" font="14">biomarkers, including those re</text>
<text top="603" left="234" width="179" height="18" font="14">ﬂecting inﬂammation, oxidative</text>
<text top="625" left="64" width="350" height="13" font="14">stress, neurohormonal disarray, and myocardial and matrix</text>
<text top="643" left="64" width="350" height="13" font="14">remodeling, have been widely examined for their prognostic</text>
<text top="661" left="64" width="227" height="13" font="14">value in HF. Biomarkers of myocardial</text>
<text top="657" left="296" width="118" height="18" font="14">ﬁbrosis, soluble ST2</text>
<text top="679" left="64" width="350" height="13" font="14">and galectin-3 are not only predictive of hospitalization and</text>
<text top="697" left="64" width="350" height="13" font="14">death in patients with HF but also additive to natriuretic</text>
<text top="715" left="64" width="350" height="13" font="14">peptide levels in their prognostic value. Markers of renal</text>
<text top="733" left="64" width="350" height="13" font="14">injury may also offer additional prognostic value because</text>
<text top="750" left="64" width="350" height="13" font="14">renal function or injury may be involved in the pathogenesis,</text>
<text top="768" left="64" width="350" height="13" font="14">progression, decompensation, or complications in chronic or</text>
<text top="786" left="64" width="146" height="13" font="14">acute decompensated HF</text>
<text top="786" left="216" width="26" height="13" font="15"><a href="e147.full.html#70">(242</a></text>
<text top="783" left="242" width="108" height="18" font="15"><a href="e147.full.html#70">–244,264,265,279)</a></text>
<text top="786" left="349" width="64" height="13" font="14">. Strategies</text>
<text top="408" left="450" width="350" height="13" font="14">that combine multiple biomarkers may ultimately prove</text>
<text top="426" left="450" width="27" height="13" font="14">bene</text>
<text top="422" left="476" width="240" height="18" font="14">ﬁcial in guiding HF therapy in the future.</text>
<text top="444" left="449" width="20" height="13" font="14">See</text>
<text top="444" left="476" width="45" height="13" font="15"><a href="e147.full.html#19">Table 9</a></text>
<text top="444" left="528" width="272" height="13" font="14">for a summary of recommendations from this</text>
<text top="462" left="450" width="43" height="13" font="14">section.</text>
<text top="497" left="450" width="256" height="14" font="16">6.4. Noninvasive Cardiac Imaging:</text>
<text top="516" left="450" width="138" height="14" font="16">Recommendations</text>
<text top="535" left="451" width="20" height="13" font="14">See</text>
<text top="535" left="476" width="52" height="13" font="15"><a href="e147.full.html#19">Table 10</a></text>
<text top="535" left="533" width="266" height="13" font="14">for a summary of recommendations from this</text>
<text top="553" left="450" width="43" height="13" font="14">section.</text>
<text top="579" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="591" left="468" width="10" height="10" font="18">1.</text>
<text top="591" left="485" width="314" height="10" font="18">Patients with suspected or new-onset HF, or those pre-</text>
<text top="607" left="485" width="314" height="10" font="18">senting with acute decompensated HF, should undergo</text>
<text top="624" left="485" width="314" height="10" font="18">a chest x-ray to assess heart size and pulmonary congestion</text>
<text top="640" left="485" width="314" height="10" font="18">and to detect alternative cardiac, pulmonary, and other</text>
<text top="656" left="485" width="305" height="10" font="18">diseases that may cause or contribute to the patient</text>
<text top="653" left="790" width="9" height="16" font="18">’s</text>
<text top="673" left="485" width="174" height="12" font="18">symptoms. (Level of Evidence: C)</text>
<text top="690" left="468" width="10" height="10" font="18">2.</text>
<text top="689" left="485" width="314" height="10" font="18">A 2-dimensional echocardiogram with Doppler should be</text>
<text top="706" left="485" width="314" height="10" font="18">performed during initial evaluation of patients presenting</text>
<text top="722" left="485" width="314" height="10" font="18">with HF to assess ventricular function, size, wall thickness,</text>
<text top="739" left="485" width="285" height="12" font="18">wall motion, and valve function. (Level of Evidence: C)</text>
<text top="755" left="468" width="10" height="10" font="18">3.</text>
<text top="755" left="485" width="314" height="10" font="18">Repeat measurement of EF and measurement of the severity</text>
<text top="772" left="485" width="314" height="10" font="18">of structural remodeling are useful to provide information in</text>
<text top="788" left="485" width="223" height="10" font="18">patients with HF who have had a signi</text>
<text top="785" left="709" width="91" height="16" font="18">ﬁcant change in</text>
<text top="103" left="108" width="267" height="12" font="9">Table 9. Recommendations for Biomarkers in HF</text>
<text top="135" left="108" width="101" height="11" font="4">Biomarker, Application</text>
<text top="135" left="335" width="31" height="11" font="4">Setting</text>
<text top="135" left="446" width="19" height="11" font="4">COR</text>
<text top="135" left="520" width="17" height="11" font="4">LOE</text>
<text top="135" left="650" width="49" height="11" font="4">References</text>
<text top="154" left="108" width="87" height="11" font="4">Natriuretic peptides</text>
<text top="171" left="120" width="129" height="11" font="4">Diagnosis or exclusion of HF</text>
<text top="171" left="309" width="82" height="11" font="4">Ambulatory, Acute</text>
<text top="171" left="455" width="2" height="11" font="4">I</text>
<text top="171" left="526" width="6" height="11" font="4">A</text>
<text top="171" left="623" width="17" height="11" font="5"><a href="e147.full.html#69">212</a></text>
<text top="171" left="640" width="3" height="11" font="4">,</text>
<text top="171" left="643" width="40" height="11" font="5"><a href="e147.full.html#69">217–223</a></text>
<text top="171" left="683" width="3" height="11" font="4">,</text>
<text top="171" left="686" width="40" height="11" font="5"><a href="e147.full.html#70">245–250</a></text>
<text top="192" left="120" width="71" height="11" font="4">Prognosis of HF</text>
<text top="192" left="309" width="82" height="11" font="4">Ambulatory, Acute</text>
<text top="192" left="455" width="2" height="11" font="4">I</text>
<text top="192" left="526" width="6" height="11" font="4">A</text>
<text top="192" left="613" width="17" height="11" font="5"><a href="e147.full.html#69">222</a></text>
<text top="192" left="630" width="3" height="11" font="4"><a href="e147.full.html#69">,</a></text>
<text top="192" left="633" width="40" height="11" font="5"><a href="e147.full.html#69">224–229</a></text>
<text top="192" left="673" width="3" height="11" font="4">,</text>
<text top="192" left="676" width="17" height="11" font="5"><a href="e147.full.html#70">248</a></text>
<text top="192" left="693" width="3" height="11" font="4">,</text>
<text top="192" left="696" width="40" height="11" font="5"><a href="e147.full.html#70">251–258</a></text>
<text top="213" left="120" width="65" height="11" font="4">Achieve GDMT</text>
<text top="213" left="325" width="50" height="11" font="4">Ambulatory</text>
<text top="213" left="451" width="10" height="11" font="4">IIa</text>
<text top="213" left="526" width="6" height="11" font="4">B</text>
<text top="213" left="654" width="40" height="11" font="5"><a href="e147.full.html#69">230–237</a></text>
<text top="233" left="120" width="93" height="11" font="4">Guidance for acutely</text>
<text top="248" left="131" width="123" height="11" font="4">decompensated HF therapy</text>
<text top="233" left="338" width="25" height="11" font="4">Acute</text>
<text top="233" left="451" width="10" height="11" font="4">IIb</text>
<text top="233" left="526" width="6" height="11" font="4">C</text>
<text top="233" left="656" width="17" height="11" font="5"><a href="e147.full.html#70">259</a></text>
<text top="233" left="673" width="3" height="11" font="4">,</text>
<text top="233" left="676" width="17" height="11" font="5"><a href="e147.full.html#70">260</a></text>
<text top="268" left="108" width="143" height="11" font="4">Biomarkers of myocardial injury</text>
<text top="284" left="120" width="114" height="11" font="4">Additive risk stratification</text>
<text top="284" left="309" width="82" height="11" font="4">Acute, Ambulatory</text>
<text top="284" left="455" width="2" height="11" font="4">I</text>
<text top="284" left="526" width="6" height="11" font="4">A</text>
<text top="284" left="613" width="40" height="11" font="5"><a href="e147.full.html#69">238–241</a></text>
<text top="284" left="653" width="3" height="11" font="4"><a href="e147.full.html#70">,</a></text>
<text top="284" left="656" width="17" height="11" font="5"><a href="e147.full.html#70">248</a></text>
<text top="284" left="673" width="3" height="11" font="4">,</text>
<text top="284" left="676" width="17" height="11" font="5"><a href="e147.full.html#70">253</a></text>
<text top="284" left="693" width="3" height="11" font="4">,</text>
<text top="284" left="696" width="40" height="11" font="5"><a href="e147.full.html#70">256–267</a></text>
<text top="308" left="108" width="151" height="11" font="4">Biomarkers of myocardial fibrosis</text>
<text top="325" left="120" width="114" height="11" font="4">Additive risk stratification</text>
<text top="325" left="325" width="50" height="11" font="4">Ambulatory</text>
<text top="325" left="451" width="10" height="11" font="4">IIb</text>
<text top="325" left="526" width="6" height="11" font="4">B</text>
<text top="325" left="654" width="40" height="11" font="5"><a href="e147.full.html#69">242–244</a></text>
<text top="346" left="338" width="25" height="11" font="4">Acute</text>
<text top="346" left="451" width="10" height="11" font="4">IIb</text>
<text top="346" left="526" width="6" height="11" font="4">A</text>
<text top="346" left="593" width="17" height="11" font="5"><a href="e147.full.html#70">248</a></text>
<text top="346" left="610" width="3" height="11" font="4">,</text>
<text top="346" left="613" width="17" height="11" font="5"><a href="e147.full.html#70">253</a></text>
<text top="346" left="630" width="3" height="11" font="4">,</text>
<text top="346" left="633" width="17" height="11" font="5"><a href="e147.full.html#70">256</a></text>
<text top="346" left="650" width="3" height="11" font="4">,</text>
<text top="346" left="653" width="40" height="11" font="5"><a href="e147.full.html#70">258–260</a></text>
<text top="346" left="693" width="3" height="11" font="4"><a href="e147.full.html#70">,</a></text>
<text top="346" left="696" width="17" height="11" font="5"><a href="e147.full.html#70">262</a></text>
<text top="346" left="713" width="3" height="11" font="4">,</text>
<text top="346" left="716" width="40" height="11" font="5"><a href="e147.full.html#70">264–267</a></text>
<text top="372" left="120" width="593" height="11" font="4">COR indicates Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; and LOE, Level of Evidence.</text>
<text top="825" left="109" width="338" height="12" font="9">Table 10. Recommendations for Noninvasive Cardiac Imaging</text>
<text top="857" left="109" width="82" height="11" font="4">Recommendations</text>
<text top="857" left="624" width="19" height="11" font="4">COR</text>
<text top="857" left="696" width="17" height="11" font="4">LOE</text>
<text top="878" left="109" width="357" height="11" font="4">Patients with suspected, acute, or new-onset HF should undergo a chest x-ray</text>
<text top="878" left="633" width="2" height="11" font="4">I</text>
<text top="878" left="706" width="6" height="11" font="4">C</text>
<text top="899" left="109" width="427" height="11" font="4">A 2-dimensional echocardiogram with Doppler should be performed for initial evaluation of HF</text>
<text top="899" left="633" width="2" height="11" font="4">I</text>
<text top="899" left="706" width="6" height="11" font="4">C</text>
<text top="920" left="109" width="428" height="11" font="4">Repeat measurement of EF is useful in patients with HF who have had a significant change in</text>
<text top="935" left="121" width="409" height="11" font="4">clinical status or received treatment that might affect cardiac function or for consideration</text>
<text top="950" left="121" width="78" height="11" font="4">of device therapy</text>
<text top="920" left="633" width="2" height="11" font="4">I</text>
<text top="920" left="706" width="6" height="11" font="4">C</text>
<text top="966" left="109" width="424" height="11" font="4">Noninvasive imaging to detect myocardial ischemia and viability is reasonable in HF and CAD</text>
<text top="966" left="629" width="10" height="11" font="4">IIa</text>
<text top="966" left="706" width="6" height="11" font="4">C</text>
<text top="987" left="109" width="377" height="11" font="4">Viability assessment is reasonable before revascularization in HF patients with CAD</text>
<text top="987" left="629" width="10" height="11" font="4">IIa</text>
<text top="987" left="681" width="56" height="11" font="4">B <a href="e147.full.html#70">(281–285)</a></text>
<text top="1008" left="109" width="361" height="11" font="4">Radionuclide ventriculography or MRI can be useful to assess LVEF and volume</text>
<text top="1008" left="629" width="10" height="11" font="4">IIa</text>
<text top="1008" left="706" width="6" height="11" font="4">C</text>
<text top="1029" left="109" width="292" height="11" font="4">MRI is reasonable when assessing myocardial infiltration or scar</text>
<text top="1029" left="629" width="10" height="11" font="4">IIa</text>
<text top="1029" left="681" width="56" height="11" font="4">B <a href="e147.full.html#71">(286–288)</a></text>
<text top="1050" left="109" width="368" height="11" font="4">Routine repeat measurement of LV function assessment should not be performed</text>
<text top="1050" left="603" width="61" height="11" font="4">III: No Benefit</text>
<text top="1050" left="682" width="53" height="11" font="4">B <a href="e147.full.html#71">(289,290)</a></text>
<text top="1076" left="121" width="634" height="11" font="4">CAD indicates coronary artery disease; COR, Class of Recommendation; EF, ejection fraction; HF, heart failure; LOE, Level of Evidence; LV, left</text>
<text top="1091" left="109" width="406" height="11" font="4">ventricular; LVEF, left ventricular ejection fraction; and MRI, magnetic resonance imaging.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e165</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="100" width="314" height="10" font="18">clinical status; who have experienced or recovered from</text>
<text top="120" left="100" width="314" height="10" font="18">a clinical event; or who have received treatment, including</text>
<text top="136" left="100" width="189" height="10" font="18">GDMT, that might have had a signi</text>
<text top="133" left="289" width="125" height="16" font="18">ﬁcant effect on cardiac</text>
<text top="153" left="100" width="314" height="10" font="18">function; or who may be candidates for device therapy.</text>
<text top="169" left="100" width="113" height="12" font="18">(Level of Evidence: C)</text>
<text top="196" left="64" width="45" height="8" font="17">CLASS IIa</text>
<text top="208" left="82" width="10" height="10" font="18">1.</text>
<text top="208" left="100" width="314" height="10" font="18">Noninvasive imaging to detect myocardial ischemia and</text>
<text top="224" left="100" width="314" height="10" font="18">viability is reasonable in patients presenting with de novo</text>
<text top="241" left="100" width="314" height="10" font="18">HF, who have known CAD and no angina, unless the patient</text>
<text top="257" left="100" width="314" height="12" font="18">is not eligible for revascularization of any kind. (Level of</text>
<text top="274" left="100" width="65" height="12" font="18">Evidence: C)</text>
<text top="290" left="82" width="10" height="10" font="18">2.</text>
<text top="290" left="100" width="314" height="10" font="18">Viability assessment is reasonable in select situations</text>
<text top="306" left="100" width="314" height="10" font="18">when planning revascularization in HF patients with CAD</text>
<text top="323" left="100" width="26" height="10" font="5"><a href="e147.full.html#70">(281</a></text>
<text top="320" left="126" width="32" height="16" font="5"><a href="e147.full.html#70">–285)</a></text>
<text top="323" left="157" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="340" left="82" width="10" height="10" font="18">3.</text>
<text top="339" left="100" width="67" height="10" font="18">Radionuclide</text>
<text top="339" left="179" width="87" height="10" font="18">ventriculography</text>
<text top="339" left="277" width="10" height="10" font="18">or</text>
<text top="339" left="299" width="49" height="10" font="18">magnetic</text>
<text top="339" left="360" width="54" height="10" font="18">resonance</text>
<text top="356" left="100" width="314" height="10" font="18">imaging can be useful to assess LVEF and volume when</text>
<text top="372" left="100" width="288" height="12" font="18">echocardiography is inadequate. (Level of Evidence: C)</text>
<text top="389" left="82" width="10" height="10" font="18">4.</text>
<text top="389" left="100" width="314" height="10" font="18">Magnetic resonance imaging is reasonable when assessing</text>
<text top="405" left="100" width="70" height="10" font="18">myocardial in</text>
<text top="402" left="170" width="180" height="16" font="18">ﬁltrative processes or scar burden</text>
<text top="405" left="353" width="26" height="10" font="5"><a href="e147.full.html#71">(286</a></text>
<text top="402" left="379" width="32" height="16" font="5"><a href="e147.full.html#71">–288)</a></text>
<text top="405" left="410" width="3" height="10" font="18">.</text>
<text top="422" left="100" width="113" height="12" font="18">(Level of Evidence: B)</text>
<text top="447" left="64" width="88" height="8" font="17">CLASS III: No Bene</text>
<text top="444" left="152" width="10" height="13" font="17">ﬁt</text>
<text top="459" left="82" width="10" height="10" font="18">1.</text>
<text top="459" left="100" width="314" height="10" font="18">Routine repeat measurement of LV function assessment in</text>
<text top="475" left="100" width="314" height="10" font="18">the absence of clinical status change or treatment inter-</text>
<text top="492" left="100" width="192" height="10" font="18">ventions should not be performed</text>
<text top="492" left="300" width="55" height="10" font="5"><a href="e147.full.html#71">(289,290)</a></text>
<text top="492" left="355" width="59" height="12" font="18"><a href="e147.full.html#71">. </a>(Level of</text>
<text top="508" left="100" width="65" height="12" font="18">Evidence: B)</text>
<text top="534" left="79" width="335" height="13" font="14">The chest x-ray is important for the evaluation of patients</text>
<text top="552" left="64" width="350" height="13" font="14">presenting with signs and symptoms of HF because it assesses</text>
<text top="570" left="64" width="350" height="13" font="14">cardiomegaly and pulmonary congestion and may reveal</text>
<text top="587" left="64" width="350" height="13" font="14">alternative causes, cardiopulmonary or otherwise, of the</text>
<text top="605" left="64" width="38" height="13" font="14">patient</text>
<text top="602" left="102" width="312" height="18" font="14">’s symptoms. Apart from congestion, however, other</text>
<text top="619" left="64" width="350" height="18" font="14">ﬁndings on chest x-ray are associated with HF only in the</text>
<text top="641" left="64" width="350" height="13" font="14">context of clinical presentation. Cardiomegaly may be absent</text>
<text top="659" left="64" width="350" height="13" font="14">in HF. A chest x-ray may also show other cardiac chamber</text>
<text top="677" left="64" width="350" height="13" font="14">enlargement, increased pulmonary venous pressure, interstitial</text>
<text top="695" left="64" width="285" height="13" font="14">or alveolar edema, valvular or pericardial calci</text>
<text top="691" left="349" width="65" height="18" font="14">ﬁcation, or</text>
<text top="713" left="64" width="350" height="13" font="14">coexisting thoracic diseases. Considering its low sensitivity</text>
<text top="731" left="64" width="54" height="13" font="14">and speci</text>
<text top="727" left="119" width="295" height="18" font="14">ﬁcity, the chest x-ray should not be the sole deter-</text>
<text top="749" left="64" width="110" height="13" font="14">minant of the speci</text>
<text top="745" left="174" width="240" height="18" font="14">ﬁc cause of HF. Moreover, a supine chest</text>
<text top="767" left="64" width="296" height="13" font="14">x-ray has limited value in acute decompensated HF.</text>
<text top="785" left="79" width="335" height="13" font="14">Although a complete history and physical examination are</text>
<text top="803" left="64" width="55" height="13" font="14">important</text>
<text top="799" left="125" width="289" height="18" font="14">ﬁrst steps, the most useful diagnostic test in the</text>
<text top="821" left="64" width="350" height="13" font="14">evaluation of patients with or at risk for HF (e.g., postacute MI)</text>
<text top="839" left="64" width="350" height="13" font="14">is a comprehensive 2-dimensional echocardiogram; coupled</text>
<text top="856" left="64" width="76" height="13" font="14">with Doppler</text>
<text top="853" left="146" width="268" height="18" font="14">ﬂow studies, the transthoracic echocardiogram</text>
<text top="874" left="64" width="350" height="13" font="14">can identify abnormalities of myocardium, heart valves, and</text>
<text top="892" left="64" width="350" height="13" font="14">pericardium. Echocardiography can reveal subclinical HF and</text>
<text top="910" left="64" width="188" height="13" font="14">predict risk of subsequent events</text>
<text top="910" left="257" width="26" height="13" font="15"><a href="e147.full.html#71">(291</a></text>
<text top="906" left="282" width="33" height="18" font="15"><a href="e147.full.html#71">–295)</a></text>
<text top="910" left="315" width="99" height="13" font="14">. Use of echocar-</text>
<text top="928" left="64" width="350" height="13" font="14">diograms in patients with suspected HF improves disease</text>
<text top="946" left="64" width="32" height="13" font="14">identi</text>
<text top="942" left="96" width="280" height="18" font="14">ﬁcation and provision of appropriate medical care</text>
<text top="946" left="380" width="30" height="13" font="15"><a href="e147.full.html#71">(296)</a></text>
<text top="946" left="410" width="4" height="13" font="14">.</text>
<text top="964" left="79" width="335" height="13" font="14">Echocardiographic evaluation should address whether</text>
<text top="982" left="64" width="350" height="13" font="14">LVEF is reduced, LV structure is abnormal, and other struc-</text>
<text top="1000" left="64" width="350" height="13" font="14">tural abnormalities are present that could account for the</text>
<text top="1018" left="64" width="325" height="13" font="14">clinical presentation. This information should be quanti</text>
<text top="1014" left="389" width="25" height="18" font="14">ﬁed,</text>
<text top="1036" left="64" width="350" height="13" font="14">including numerical estimates of EF measurement, ventricular</text>
<text top="1054" left="64" width="350" height="13" font="14">dimensions, wall thickness, calculations of ventricular</text>
<text top="1072" left="64" width="350" height="13" font="14">volumes, and evaluation of chamber geometry and regional</text>
<text top="1090" left="64" width="350" height="13" font="14">wall motion. Documentation of LVEF is an HF quality-</text>
<text top="103" left="450" width="172" height="13" font="14">of-care performance measure</text>
<text top="103" left="629" width="30" height="13" font="15"><a href="e147.full.html#71">(297)</a></text>
<text top="103" left="660" width="140" height="13" font="14"><a href="e147.full.html#71">. </a>Right ventricular size</text>
<text top="121" left="450" width="350" height="13" font="14">and function as well as atrial size and dimensions should also</text>
<text top="139" left="450" width="350" height="13" font="14">be measured. All valves should be evaluated for anatomic</text>
<text top="157" left="450" width="20" height="13" font="14">and</text>
<text top="153" left="476" width="324" height="18" font="14">ﬂow abnormalities. Secondary changes, particularly the</text>
<text top="175" left="450" width="242" height="13" font="14">severity of mitral and tricuspid valve insuf</text>
<text top="171" left="692" width="107" height="18" font="14">ﬁciency, should be</text>
<text top="193" left="450" width="67" height="13" font="14">determined.</text>
<text top="193" left="530" width="71" height="13" font="14">Noninvasive</text>
<text top="193" left="615" width="80" height="13" font="14">hemodynamic</text>
<text top="193" left="708" width="23" height="13" font="14">data</text>
<text top="193" left="745" width="55" height="13" font="14">constitute</text>
<text top="211" left="450" width="278" height="13" font="14">important additional information. Mitral valve in</text>
<text top="207" left="728" width="72" height="18" font="14">ﬂow pattern,</text>
<text top="229" left="450" width="120" height="13" font="14">pulmonary venous in</text>
<text top="225" left="570" width="229" height="18" font="14">ﬂow pattern, and mitral annular velocity</text>
<text top="247" left="450" width="137" height="13" font="14">provide data about LV</text>
<text top="243" left="593" width="206" height="18" font="14">ﬁlling and left atrial pressure. The</text>
<text top="265" left="450" width="350" height="13" font="14">tricuspid valve regurgitant gradient, coupled with measure-</text>
<text top="283" left="450" width="350" height="13" font="14">ment of inferior vena cava diameter and its response during</text>
<text top="301" left="450" width="350" height="13" font="14">respiration, provides estimates of systolic pulmonary artery</text>
<text top="319" left="450" width="350" height="13" font="14">pressure and central venous pressure. Many of these abnor-</text>
<text top="337" left="450" width="350" height="13" font="14">malities are prognostically important and can be present</text>
<text top="354" left="450" width="122" height="13" font="14">without manifest HF.</text>
<text top="372" left="465" width="335" height="13" font="14">Serial echocardiographic evaluations are useful because</text>
<text top="390" left="450" width="350" height="13" font="14">evidence of cardiac reverse remodeling can provide important</text>
<text top="408" left="450" width="350" height="13" font="14">information in patients who have had a change in clinical</text>
<text top="426" left="450" width="350" height="13" font="14">status or have experienced or recovered from an event or</text>
<text top="444" left="450" width="350" height="13" font="14">treatment that affects cardiac function. However, the routine</text>
<text top="462" left="450" width="350" height="13" font="14">repeat assessment of ventricular function in the absence of</text>
<text top="480" left="450" width="350" height="13" font="14">changing clinical status or a change in treatment intervention</text>
<text top="498" left="450" width="92" height="13" font="14">is not indicated.</text>
<text top="516" left="465" width="335" height="13" font="14">The preference for echocardiography as an imaging</text>
<text top="534" left="450" width="350" height="13" font="14">modality is due to its widespread availability and lack of</text>
<text top="552" left="450" width="350" height="13" font="14">ionizing radiation; however, other imaging modalities may be</text>
<text top="570" left="450" width="350" height="13" font="14">of use. Magnetic resonance imaging assesses LV volume and</text>
<text top="588" left="450" width="350" height="13" font="14">EF measurements at least as accurately as echocardiography.</text>
<text top="606" left="450" width="350" height="13" font="14">However, additional information about myocardial perfusion,</text>
<text top="624" left="450" width="76" height="13" font="14">viability, and</text>
<text top="620" left="531" width="268" height="18" font="14">ﬁbrosis from magnetic resonance imaging can</text>
<text top="641" left="450" width="305" height="13" font="14">help identify HF etiology and assess prognosis</text>
<text top="641" left="766" width="30" height="13" font="15"><a href="e147.full.html#71">(298)</a></text>
<text top="641" left="796" width="4" height="13" font="14"><a href="e147.full.html#71">.</a></text>
<text top="659" left="450" width="350" height="13" font="14">Magnetic resonance imaging provides high anatomical reso-</text>
<text top="677" left="450" width="350" height="13" font="14">lution of all aspects of the heart and surrounding structure,</text>
<text top="695" left="450" width="350" height="13" font="14">leading to its recommended use in known or suspected</text>
<text top="713" left="450" width="142" height="13" font="14">congenital heart diseases</text>
<text top="713" left="597" width="16" height="13" font="15"><a href="e147.full.html#64">(5)</a></text>
<text top="713" left="614" width="186" height="13" font="14"><a href="e147.full.html#64">. </a>Cardiac computed tomography</text>
<text top="731" left="450" width="350" height="13" font="14">can also provide accurate assessment of cardiac structure and</text>
<text top="749" left="450" width="229" height="13" font="14">function, including the coronary arteries</text>
<text top="749" left="683" width="30" height="13" font="15"><a href="e147.full.html#71">(299)</a></text>
<text top="749" left="713" width="86" height="13" font="14">. An advantage</text>
<text top="767" left="450" width="350" height="13" font="14">of cardiac computed tomography over echocardiography may</text>
<text top="785" left="450" width="350" height="13" font="14">be its ability to characterize the myocardium, but studies have</text>
<text top="803" left="450" width="350" height="13" font="14">yet to demonstrate the importance of this factor. Reports of</text>
<text top="821" left="450" width="350" height="13" font="14">cardiac computed tomography in patients with suspected HF</text>
<text top="839" left="450" width="350" height="13" font="14">are limited. Furthermore, both cardiac computed tomography</text>
<text top="857" left="450" width="350" height="13" font="14">and magnetic resonance imaging lose accuracy with high</text>
<text top="875" left="450" width="350" height="13" font="14">heart rates. Radionuclide ventriculography may also be used</text>
<text top="893" left="450" width="350" height="13" font="14">for evaluation of cardiac function when other tests are</text>
<text top="910" left="450" width="350" height="13" font="14">unavailable or inadequate. However, as a planar technique,</text>
<text top="928" left="450" width="350" height="13" font="14">radionuclide ventriculography cannot directly assess valvular</text>
<text top="946" left="450" width="350" height="13" font="14">structure, function, or ventricular wall thickness; it may be</text>
<text top="964" left="450" width="350" height="13" font="14">more useful for assessing LV volumes in patients with</text>
<text top="982" left="450" width="27" height="13" font="14">signi</text>
<text top="978" left="477" width="322" height="18" font="14">ﬁcant baseline wall motion abnormalities or distorted</text>
<text top="1000" left="450" width="307" height="13" font="14">geometry. Ventriculography is highly reproducible</text>
<text top="1000" left="766" width="30" height="13" font="15"><a href="e147.full.html#71">(300)</a></text>
<text top="1000" left="796" width="4" height="13" font="14"><a href="e147.full.html#71">.</a></text>
<text top="1018" left="450" width="350" height="13" font="14">Single photon emission computed tomography or positron</text>
<text top="1036" left="450" width="350" height="13" font="14">emission tomography scans are not primarily used to deter-</text>
<text top="1054" left="450" width="350" height="13" font="14">mine LV systolic global and regional function unless these</text>
<text top="1072" left="450" width="127" height="13" font="14">parameters are quanti</text>
<text top="1068" left="576" width="223" height="18" font="14">ﬁed from the resultant images during</text>
<text top="1090" left="450" width="285" height="13" font="14">myocardial perfusion and/or viability assessment</text>
<text top="1090" left="741" width="55" height="13" font="15"><a href="e147.full.html#71">(301,302)</a></text>
<text top="1090" left="796" width="4" height="13" font="14"><a href="e147.full.html#71">.</a></text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e166</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">Candidates for coronary revascularization who present with</text>
<text top="121" left="64" width="350" height="13" font="14">a high suspicion for obstructive CAD should undergo coro-</text>
<text top="139" left="64" width="350" height="13" font="14">nary angiography. Stress nuclear imaging or echocardiog-</text>
<text top="157" left="64" width="350" height="13" font="14">raphy may be an acceptable option for assessing ischemia in</text>
<text top="175" left="64" width="350" height="13" font="14">patients presenting with HF who have known CAD and no</text>
<text top="193" left="64" width="310" height="13" font="14">angina unless they are ineligible for revascularization</text>
<text top="193" left="380" width="30" height="13" font="15"><a href="e147.full.html#71">(303)</a></text>
<text top="193" left="410" width="4" height="13" font="14">.</text>
<text top="211" left="64" width="350" height="13" font="14">Although the results of the STICH (Surgical Treatment for</text>
<text top="229" left="64" width="350" height="13" font="14">Ischemic Heart Failure) trial have cast doubt on the role of</text>
<text top="247" left="64" width="350" height="13" font="14">myocardial viability assessment to determine the mode of</text>
<text top="265" left="64" width="42" height="13" font="14">therapy</text>
<text top="265" left="111" width="30" height="13" font="15"><a href="e147.full.html#71">(304)</a></text>
<text top="265" left="142" width="272" height="13" font="14"><a href="e147.full.html#71">, </a>the data are nevertheless predictive of a posi-</text>
<text top="283" left="64" width="350" height="13" font="14">tive outcome. When these data are taken into consideration</text>
<text top="301" left="64" width="350" height="13" font="14">with multiple previous studies demonstrating the usefulness</text>
<text top="319" left="64" width="105" height="13" font="14">of this approach</text>
<text top="319" left="180" width="26" height="13" font="15"><a href="e147.full.html#70">(281</a></text>
<text top="315" left="206" width="33" height="18" font="15"><a href="e147.full.html#70">–285)</a></text>
<text top="319" left="239" width="175" height="13" font="14">, it becomes reasonable to</text>
<text top="337" left="64" width="350" height="13" font="14">recommend viability assessment when treating patients with</text>
<text top="354" left="64" width="178" height="13" font="14">HFrEF who have known CAD</text>
<text top="354" left="247" width="23" height="13" font="15"><a href="e147.full.html#64">(14)</a></text>
<text top="354" left="270" width="4" height="13" font="14">.</text>
<text top="372" left="79" width="20" height="13" font="14">See</text>
<text top="372" left="106" width="163" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 9</a></text>
<text top="372" left="277" width="137" height="13" font="14">for additional data on</text>
<text top="390" left="64" width="46" height="13" font="14">imaging</text>
<text top="386" left="111" width="118" height="18" font="14">echocardiography.</text>
<text top="425" left="64" width="329" height="14" font="16">6.5. Invasive Evaluation: Recommendations</text>
<text top="444" left="65" width="20" height="13" font="14">See</text>
<text top="444" left="91" width="52" height="13" font="15"><a href="e147.full.html#21">Table 11</a></text>
<text top="444" left="148" width="266" height="13" font="14">for a summary of recommendations from this</text>
<text top="462" left="64" width="43" height="13" font="14">section.</text>
<text top="487" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="499" left="82" width="10" height="10" font="18">1.</text>
<text top="499" left="100" width="314" height="10" font="18">Invasive hemodynamic monitoring with a pulmonary artery</text>
<text top="515" left="100" width="314" height="10" font="18">catheter should be performed to guide therapy in patients</text>
<text top="532" left="100" width="314" height="10" font="18">who have respiratory distress or clinical evidence of</text>
<text top="548" left="100" width="314" height="10" font="18">impaired perfusion in whom the adequacy or excess of</text>
<text top="565" left="100" width="63" height="10" font="18">intracardiac</text>
<text top="562" left="169" width="245" height="16" font="18">ﬁlling pressures cannot be determined from</text>
<text top="581" left="100" width="225" height="12" font="18">clinical assessment. (Level of Evidence: C)</text>
<text top="605" left="64" width="45" height="8" font="17">CLASS IIa</text>
<text top="617" left="82" width="10" height="10" font="18">1.</text>
<text top="617" left="100" width="314" height="10" font="18">Invasive hemodynamic monitoring can be useful for carefully</text>
<text top="634" left="100" width="314" height="10" font="18">selected patients with acute HF who have persistent symp-</text>
<text top="650" left="100" width="309" height="10" font="18">toms despite empiric adjustment of standard therapies and</text>
<text top="667" left="100" width="9" height="10" font="18">a.</text>
<text top="666" left="115" width="34" height="10" font="18">whose</text>
<text top="663" left="153" width="260" height="16" font="18">ﬂuid status, perfusion, or systemic or pulmonary</text>
<text top="683" left="115" width="173" height="10" font="18">vascular resistance is uncertain;</text>
<text top="700" left="100" width="9" height="10" font="18">b.</text>
<text top="699" left="115" width="299" height="10" font="18">whose systolic pressure remains low, or is associated</text>
<text top="716" left="115" width="207" height="10" font="18">with symptoms, despite initial therapy;</text>
<text top="732" left="101" width="8" height="10" font="18">c.</text>
<text top="732" left="115" width="254" height="10" font="18">whose renal function is worsening with therapy;</text>
<text top="749" left="100" width="9" height="10" font="18">d.</text>
<text top="749" left="115" width="237" height="10" font="18">who require parenteral vasoactive agents; or</text>
<text top="765" left="100" width="9" height="10" font="18">e.</text>
<text top="765" left="115" width="299" height="10" font="18">who may need consideration for MCS or transplantation.</text>
<text top="782" left="115" width="113" height="12" font="18">(Level of Evidence: C)</text>
<text top="798" left="82" width="10" height="10" font="18">2.</text>
<text top="798" left="100" width="314" height="10" font="18">When ischemia may be contributing to HF, coronary arteri-</text>
<text top="814" left="100" width="314" height="10" font="18">ography is reasonable for patients eligible for revasculari-</text>
<text top="831" left="100" width="152" height="12" font="18">zation. (Level of Evidence: C)</text>
<text top="103" left="468" width="10" height="10" font="18">3.</text>
<text top="103" left="485" width="314" height="10" font="18">Endomyocardial biopsy can be useful in patients presenting</text>
<text top="120" left="485" width="115" height="10" font="18">with HF when a speci</text>
<text top="117" left="601" width="199" height="16" font="18">ﬁc diagnosis is suspected that would</text>
<text top="136" left="485" width="9" height="10" font="18">in</text>
<text top="133" left="495" width="202" height="16" font="18">ﬂuence therapy. (Level of Evidence: C)</text>
<text top="160" left="450" width="88" height="8" font="17">CLASS III: No Bene</text>
<text top="157" left="538" width="10" height="13" font="17">ﬁt</text>
<text top="172" left="468" width="10" height="10" font="18">1.</text>
<text top="172" left="485" width="314" height="10" font="18">Routine use of invasive hemodynamic monitoring is not</text>
<text top="188" left="485" width="314" height="10" font="18">recommended in normotensive patients with acute decom-</text>
<text top="205" left="485" width="314" height="10" font="18">pensated HF and congestion with symptomatic response to</text>
<text top="221" left="485" width="136" height="10" font="18">diuretics and vasodilators</text>
<text top="221" left="626" width="30" height="10" font="5"><a href="e147.full.html#71">(305)</a></text>
<text top="221" left="656" width="121" height="12" font="18"><a href="e147.full.html#71">. </a>(Level of Evidence: B)</text>
<text top="245" left="450" width="73" height="8" font="17">CLASS III: Harm</text>
<text top="257" left="468" width="10" height="10" font="18">1.</text>
<text top="257" left="485" width="314" height="10" font="18">Endomyocardial biopsy should not be performed in the</text>
<text top="274" left="485" width="314" height="12" font="18">routine evaluation of patients with HF. (Level of Evidence: C)</text>
<text top="306" left="450" width="224" height="15" font="14">6.5.1. Right-Heart Catheterization</text>
<text top="327" left="451" width="349" height="13" font="14">There has been no established role for routine or periodic</text>
<text top="345" left="450" width="350" height="13" font="14">invasive hemodynamic measurements in the management of</text>
<text top="363" left="450" width="350" height="13" font="14">HF. Most drugs used for the treatment of HF are prescribed on</text>
<text top="381" left="450" width="350" height="13" font="14">the basis of their ability to improve symptoms or survival</text>
<text top="399" left="450" width="350" height="13" font="14">rather than their effect on hemodynamic variables. The initial</text>
<text top="417" left="450" width="350" height="13" font="14">and target doses of these drugs are generally selected on the</text>
<text top="435" left="450" width="350" height="13" font="14">basis of controlled trial experience rather than changes</text>
<text top="453" left="450" width="350" height="13" font="14">produced in cardiac output or pulmonary capillary wedge</text>
<text top="471" left="450" width="350" height="13" font="14">pressure. Hemodynamic monitoring is indicated in patients</text>
<text top="488" left="450" width="350" height="13" font="14">with clinically indeterminate volume status and those refrac-</text>
<text top="506" left="450" width="279" height="13" font="14">tory to initial therapy, particularly if intracardiac</text>
<text top="503" left="733" width="66" height="18" font="14">ﬁlling pres-</text>
<text top="524" left="450" width="350" height="13" font="14">sures and cardiac output are unclear. Patients with clinically</text>
<text top="542" left="450" width="27" height="13" font="14">signi</text>
<text top="539" left="477" width="322" height="18" font="14">ﬁcant hypotension (systolic blood pressure typically &lt;90</text>
<text top="560" left="450" width="350" height="13" font="14">mm Hg or symptomatic low systolic blood pressure) and/or</text>
<text top="578" left="450" width="350" height="13" font="14">worsening renal function during initial therapy might also</text>
<text top="596" left="450" width="27" height="13" font="14">bene</text>
<text top="592" left="476" width="261" height="18" font="14">ﬁt from invasive hemodynamic measurements</text>
<text top="596" left="741" width="55" height="13" font="15"><a href="e147.full.html#71">(305,306)</a></text>
<text top="596" left="796" width="4" height="13" font="14"><a href="e147.full.html#71">.</a></text>
<text top="614" left="450" width="350" height="13" font="14">Patients being considered for cardiac transplantation or</text>
<text top="632" left="450" width="350" height="13" font="14">placement of an MCS device are also candidates for complete</text>
<text top="650" left="450" width="59" height="13" font="14">right-heart</text>
<text top="650" left="522" width="86" height="13" font="14">catheterization,</text>
<text top="650" left="620" width="53" height="13" font="14">including</text>
<text top="650" left="686" width="13" height="13" font="14">an</text>
<text top="650" left="713" width="62" height="13" font="14">assessment</text>
<text top="650" left="788" width="12" height="13" font="14">of</text>
<text top="668" left="450" width="350" height="13" font="14">pulmonary vascular resistance, a necessary part of the initial</text>
<text top="686" left="450" width="350" height="13" font="14">transplantation evaluation. Invasive hemodynamic monitoring</text>
<text top="704" left="450" width="350" height="13" font="14">should be performed in patients with 1) presumed cardiogenic</text>
<text top="722" left="450" width="350" height="13" font="14">shock requiring escalating pressor therapy and consideration</text>
<text top="740" left="450" width="350" height="13" font="14">of MCS; 2) severe clinical decompensation in which therapy</text>
<text top="757" left="450" width="306" height="13" font="14">is limited by uncertain contributions of elevated</text>
<text top="754" left="766" width="34" height="18" font="14">ﬁlling</text>
<text top="775" left="450" width="350" height="13" font="14">pressures, hypoperfusion, and vascular tone; 3) apparent</text>
<text top="793" left="450" width="350" height="13" font="14">dependence on intravenous inotropic infusions after initial</text>
<text top="811" left="450" width="350" height="13" font="14">clinical improvement; or 4) persistent severe symptoms</text>
<text top="829" left="450" width="350" height="13" font="14">despite adjustment of recommended therapies. On the other</text>
<text top="865" left="109" width="284" height="12" font="9">Table 11. Recommendations for Invasive Evaluation</text>
<text top="897" left="109" width="82" height="11" font="4">Recommendations</text>
<text top="897" left="620" width="19" height="11" font="4">COR</text>
<text top="897" left="702" width="17" height="11" font="4">LOE</text>
<text top="918" left="109" width="421" height="11" font="4">Monitoring with a pulmonary artery catheter should be performed in patients with respiratory</text>
<text top="933" left="121" width="361" height="11" font="4">distress or impaired systemic perfusion when clinical assessment is inadequate</text>
<text top="918" left="628" width="2" height="11" font="4">I</text>
<text top="918" left="707" width="6" height="11" font="4">C</text>
<text top="950" left="109" width="406" height="11" font="4">Invasive hemodynamic monitoring can be useful for carefully selected patients with acute</text>
<text top="965" left="121" width="326" height="11" font="4">HF with persistent symptoms and/or when hemodynamics are uncertain</text>
<text top="950" left="624" width="10" height="11" font="4">IIa</text>
<text top="950" left="707" width="6" height="11" font="4">C</text>
<text top="981" left="109" width="362" height="11" font="4">When ischemia may be contributing to HF, coronary arteriography is reasonable</text>
<text top="981" left="624" width="10" height="11" font="4">IIa</text>
<text top="981" left="707" width="6" height="11" font="4">C</text>
<text top="1002" left="109" width="389" height="11" font="4">Endomyocardial biopsy can be useful in patients with HF when a specific diagnosis is</text>
<text top="1017" left="121" width="177" height="11" font="4">suspected that would influence therapy</text>
<text top="1002" left="624" width="10" height="11" font="4">IIa</text>
<text top="1002" left="707" width="6" height="11" font="4">C</text>
<text top="1033" left="109" width="394" height="11" font="4">Routine use of invasive hemodynamic monitoring is not recommended in normotensive</text>
<text top="1048" left="121" width="102" height="11" font="4">patients with acute HF</text>
<text top="1033" left="599" width="61" height="11" font="4">III: No Benefit</text>
<text top="1033" left="694" width="33" height="11" font="4">B <a href="e147.full.html#71">(305)</a></text>
<text top="1065" left="109" width="359" height="11" font="4">Endomyocardial biopsy should not be performed in the routine evaluation of HF</text>
<text top="1065" left="610" width="38" height="11" font="4">III: Harm</text>
<text top="1065" left="707" width="6" height="11" font="4">C</text>
<text top="1091" left="121" width="397" height="11" font="4">COR indicates Class of Recommendation; HF, heart failure; and LOE, Level of Evidence.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e167</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">hand, routine use of invasive hemodynamic monitoring is not</text>
<text top="121" left="64" width="350" height="13" font="14">recommended in normotensive patients with acute decom-</text>
<text top="139" left="64" width="350" height="13" font="14">pensated HF who have a symptomatic response to diuretics and</text>
<text top="157" left="64" width="350" height="13" font="14">vasodilators. This reinforces the concept that right-heart cath-</text>
<text top="175" left="64" width="350" height="13" font="14">eterization is best reserved for those situations where a</text>
<text top="193" left="64" width="29" height="13" font="14">speci</text>
<text top="189" left="93" width="321" height="18" font="14">ﬁc clinical or therapeutic question needs to be addressed.</text>
<text top="219" left="64" width="214" height="15" font="14">6.5.2. Left-Heart Catheterization</text>
<text top="239" left="65" width="349" height="13" font="14">Left-heart catheterization or coronary angiography is indi-</text>
<text top="257" left="64" width="350" height="13" font="14">cated for patients with HF and angina and may be useful for</text>
<text top="275" left="64" width="350" height="13" font="14">those patients without angina but with LV dysfunction.</text>
<text top="293" left="64" width="350" height="13" font="14">Invasive coronary angiography should be used in accordance</text>
<text top="311" left="64" width="350" height="13" font="14">with the ACCF/AHA coronary artery bypass graft (CABG)</text>
<text top="329" left="64" width="301" height="13" font="14">and percutaneous coronary intervention guidelines</text>
<text top="329" left="373" width="41" height="13" font="15"><a href="e147.full.html#64">(10,12)</a></text>
<text top="347" left="64" width="350" height="13" font="14">and should only be performed in patients who are poten-</text>
<text top="365" left="64" width="193" height="13" font="14">tially eligible for revascularization</text>
<text top="365" left="261" width="26" height="13" font="15"><a href="e147.full.html#71">(307</a></text>
<text top="361" left="287" width="33" height="18" font="15"><a href="e147.full.html#71">–309)</a></text>
<text top="365" left="320" width="94" height="13" font="14"><a href="e147.full.html#71">. </a>In patients with</text>
<text top="383" left="64" width="257" height="13" font="14">known CAD and angina or with signi</text>
<text top="379" left="322" width="92" height="18" font="14">ﬁcant ischemia</text>
<text top="401" left="64" width="350" height="13" font="14">diagnosed by ECG or noninvasive testing and impaired</text>
<text top="419" left="64" width="350" height="13" font="14">ventricular function, coronary angiography is indicated.</text>
<text top="437" left="64" width="350" height="13" font="14">Among those without a prior diagnosis, CAD should be</text>
<text top="455" left="64" width="350" height="13" font="14">considered as a potential etiology of impaired LV function</text>
<text top="472" left="64" width="350" height="13" font="14">and should be excluded wherever possible. Coronary angi-</text>
<text top="490" left="64" width="350" height="13" font="14">ography may be considered in these circumstances to detect</text>
<text top="508" left="64" width="350" height="13" font="14">and localize large-vessel coronary obstructions. In patients in</text>
<text top="526" left="64" width="350" height="13" font="14">whom CAD has been excluded as the cause of LV dysfunction,</text>
<text top="544" left="64" width="350" height="13" font="14">coronary angiography is generally not indicated unless a</text>
<text top="562" left="64" width="350" height="13" font="14">change in clinical status suggests interim development of</text>
<text top="580" left="64" width="97" height="13" font="14">ischemic disease.</text>
<text top="606" left="64" width="192" height="15" font="14">6.5.3. Endomyocardial Biopsy</text>
<text top="626" left="65" width="335" height="13" font="14">Endomyocardial biopsy can be useful when seeking a speci</text>
<text top="623" left="400" width="14" height="18" font="14">ﬁc</text>
<text top="644" left="64" width="141" height="13" font="14">diagnosis that would in</text>
<text top="641" left="205" width="209" height="18" font="14">ﬂuence therapy, and biopsy should</text>
<text top="662" left="64" width="350" height="13" font="14">thus be considered in patients with rapidly progressive clinical</text>
<text top="680" left="64" width="350" height="13" font="14">HF or worsening ventricular dysfunction that persists despite</text>
<text top="698" left="64" width="350" height="13" font="14">appropriate medical therapy. Endomyocardial biopsy should</text>
<text top="716" left="64" width="350" height="13" font="14">also be considered in patients suspected of having acute</text>
<text top="734" left="64" width="350" height="13" font="14">cardiac rejection status after heart transplantation or having</text>
<text top="752" left="64" width="81" height="13" font="14">myocardial in</text>
<text top="748" left="145" width="268" height="18" font="14">ﬁltrative processes. A speciﬁc example is to</text>
<text top="770" left="64" width="350" height="13" font="14">determine chemotherapy for primary cardiac amyloidosis.</text>
<text top="788" left="64" width="350" height="13" font="14">Additional other indications for endomyocardial biopsy</text>
<text top="806" left="64" width="350" height="13" font="14">include in patients with rapidly progressive and unexplained</text>
<text top="824" left="64" width="350" height="13" font="14">cardiomyopathy, those in whom active myocarditis, espe-</text>
<text top="842" left="64" width="306" height="13" font="14">cially giant cell myocarditis, is being considered</text>
<text top="842" left="380" width="30" height="13" font="15"><a href="e147.full.html#71">(310)</a></text>
<text top="842" left="410" width="4" height="13" font="14">.</text>
<text top="860" left="64" width="350" height="13" font="14">Routine endomyocardial biopsy is not recommended in all</text>
<text top="877" left="64" width="350" height="13" font="14">cases of HF, given limited diagnostic yield and the risk of</text>
<text top="895" left="64" width="186" height="13" font="14">procedure-related complications.</text>
<text top="913" left="79" width="20" height="13" font="14">See</text>
<text top="913" left="106" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 10</a></text>
<text top="913" left="280" width="134" height="13" font="14">for additional data on</text>
<text top="931" left="64" width="40" height="13" font="14">biopsy.</text>
<text top="978" left="64" width="250" height="15" font="13">7. Treatment of Stages A to D</text>
<text top="1020" left="64" width="242" height="14" font="16">7.1. Stage A: Recommendations</text>
<text top="1046" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="1059" left="82" width="10" height="10" font="18">1.</text>
<text top="1058" left="100" width="314" height="10" font="18">Hypertension and lipid disorders should be controlled in</text>
<text top="1075" left="100" width="314" height="10" font="18">accordance with contemporary guidelines to lower the risk</text>
<text top="1091" left="100" width="28" height="10" font="18">of HF</text>
<text top="1091" left="132" width="61" height="10" font="5"><a href="e147.full.html#65">(27,94,311</a></text>
<text top="1088" left="193" width="32" height="16" font="5"><a href="e147.full.html#65">–314)</a></text>
<text top="1091" left="224" width="120" height="12" font="18">. (Level of Evidence: A)</text>
<text top="103" left="468" width="10" height="10" font="18">2.</text>
<text top="103" left="485" width="314" height="10" font="18">Other conditions that may lead to or contribute to HF, such</text>
<text top="120" left="485" width="314" height="10" font="18">as obesity, diabetes mellitus, tobacco use, and known car-</text>
<text top="136" left="485" width="314" height="12" font="18">diotoxic agents, should be controlled or avoided. (Level of</text>
<text top="153" left="485" width="65" height="12" font="18">Evidence: C)</text>
<text top="186" left="450" width="237" height="15" font="14">7.1.1. Recognition and Treatment of</text>
<text top="204" left="450" width="156" height="15" font="14">Elevated Blood Pressure</text>
<text top="224" left="451" width="349" height="13" font="14">The lifetime risk for development of hypertension is consid-</text>
<text top="242" left="450" width="313" height="13" font="14">erable and represents a major public health issue</text>
<text top="242" left="773" width="23" height="13" font="15"><a href="e147.full.html#66">(97)</a></text>
<text top="242" left="796" width="4" height="13" font="14"><a href="e147.full.html#66">.</a></text>
<text top="260" left="450" width="350" height="13" font="14">Elevated blood pressure is a major risk factor for the devel-</text>
<text top="278" left="450" width="197" height="13" font="14">opment of both HFpEF and HFrEF</text>
<text top="278" left="650" width="41" height="13" font="15"><a href="e147.full.html#66">(91,92)</a></text>
<text top="278" left="692" width="108" height="13" font="14"><a href="e147.full.html#66">, </a>a risk that extends</text>
<text top="296" left="450" width="350" height="13" font="14">across all age ranges. Long-term treatment of both systolic</text>
<text top="314" left="450" width="350" height="13" font="14">and diastolic hypertension has been shown to reduce the risk</text>
<text top="332" left="450" width="224" height="13" font="14">of incident HF by approximately 50%</text>
<text top="332" left="680" width="44" height="13" font="15"><a href="e147.full.html#66">(94,311</a></text>
<text top="328" left="723" width="33" height="18" font="15"><a href="e147.full.html#66">–314)</a></text>
<text top="332" left="756" width="43" height="13" font="14">. Treat-</text>
<text top="350" left="450" width="262" height="13" font="14">ment of hypertension is particularly bene</text>
<text top="346" left="712" width="87" height="18" font="14">ﬁcial in older</text>
<text top="368" left="450" width="44" height="13" font="14">patients</text>
<text top="368" left="498" width="30" height="13" font="15"><a href="e147.full.html#71">(311)</a></text>
<text top="368" left="529" width="271" height="13" font="14"><a href="e147.full.html#71">. </a>One trial of a diuretic-based program demon-</text>
<text top="386" left="450" width="350" height="13" font="14">strated a number needed to treat of 52 to prevent 1 HF event</text>
<text top="404" left="450" width="64" height="13" font="14">in 2 years</text>
<text top="404" left="522" width="30" height="13" font="15"><a href="e147.full.html#71">(311)</a></text>
<text top="404" left="552" width="247" height="13" font="14">. In another study, elderly patients with</text>
<text top="422" left="450" width="278" height="13" font="14">a history or ECG evidence of prior MI had a</text>
<text top="418" left="735" width="65" height="18" font="14">&gt;80% risk</text>
<text top="440" left="450" width="350" height="13" font="14">reduction for incident HF with aggressive blood pressure</text>
<text top="457" left="450" width="40" height="13" font="14">control</text>
<text top="457" left="494" width="23" height="13" font="15"><a href="e147.full.html#66">(94)</a></text>
<text top="457" left="518" width="282" height="13" font="14"><a href="e147.full.html#66">. </a>Given the robust outcomes with blood pressure</text>
<text top="475" left="450" width="350" height="13" font="14">reduction, clinicians should lower both systolic and diastolic</text>
<text top="493" left="450" width="318" height="13" font="14">blood pressure in accordance with published guidelines</text>
<text top="493" left="773" width="23" height="13" font="15"><a href="e147.full.html#65">(27)</a></text>
<text top="493" left="796" width="4" height="13" font="14"><a href="e147.full.html#65">.</a></text>
<text top="511" left="465" width="335" height="13" font="14">Choice of antihypertensive therapy should also follow</text>
<text top="529" left="450" width="58" height="13" font="14">guidelines</text>
<text top="529" left="512" width="23" height="13" font="15"><a href="e147.full.html#65">(27)</a></text>
<text top="529" left="536" width="67" height="13" font="14"><a href="e147.full.html#65">, </a>with speci</text>
<text top="525" left="602" width="197" height="18" font="14">ﬁc options tailored to concomitant</text>
<text top="547" left="450" width="350" height="13" font="14">medical problems, such as diabetes mellitus or CAD.</text>
<text top="565" left="450" width="350" height="13" font="14">Diuretic-based antihypertensive therapy has repeatedly been</text>
<text top="583" left="450" width="350" height="13" font="14">shown to prevent HF in a wide range of patients; ACE</text>
<text top="601" left="450" width="350" height="13" font="14">inhibitors, ARBs, and beta blockers are also effective. Data</text>
<text top="619" left="450" width="350" height="13" font="14">are less clear for calcium antagonists and alpha blockers in</text>
<text top="637" left="450" width="194" height="13" font="14">reducing the risk for incident HF.</text>
<text top="662" left="450" width="335" height="15" font="14">7.1.2. Treatment of Dyslipidemia and Vascular Risk</text>
<text top="683" left="451" width="349" height="13" font="14">Patients with known atherosclerotic disease are likely to</text>
<text top="701" left="450" width="350" height="13" font="14">develop HF. Clinicians should seek to control vascular risk</text>
<text top="719" left="450" width="311" height="13" font="14">factors in such patients according to guidelines</text>
<text top="719" left="773" width="23" height="13" font="15"><a href="e147.full.html#65">(28)</a></text>
<text top="719" left="796" width="4" height="13" font="14"><a href="e147.full.html#65">.</a></text>
<text top="737" left="450" width="350" height="13" font="14">Aggressive treatment of hyperlipidemia with statins reduces</text>
<text top="755" left="450" width="222" height="13" font="14">the likelihood of HF in at-risk patients</text>
<text top="755" left="676" width="55" height="13" font="15"><a href="e147.full.html#71">(315,316)</a></text>
<text top="755" left="731" width="68" height="13" font="14">. Long-term</text>
<text top="773" left="450" width="350" height="13" font="14">treatment with ACE inhibitors in similar patients may also</text>
<text top="791" left="450" width="135" height="13" font="14">decrease the risk of HF</text>
<text top="791" left="589" width="55" height="13" font="15"><a href="e147.full.html#71">(314,317)</a></text>
<text top="791" left="645" width="4" height="13" font="14"><a href="e147.full.html#71">.</a></text>
<text top="818" left="450" width="237" height="15" font="14">7.1.3. Obesity and Diabetes Mellitus</text>
<text top="838" left="451" width="349" height="13" font="14">Obesity and overweight have been repeatedly linked to an</text>
<text top="856" left="450" width="132" height="13" font="14">increased risk for HF</text>
<text top="856" left="590" width="73" height="13" font="15"><a href="e147.full.html#66">(99,318,319)</a></text>
<text top="856" left="663" width="136" height="13" font="14">. Presumably, the link</text>
<text top="874" left="450" width="350" height="13" font="14">between obesity and risk for HF is explained by the clustering</text>
<text top="892" left="450" width="350" height="13" font="14">of risk factors for heart disease in those with elevated BMI</text>
<text top="910" left="450" width="350" height="13" font="14">(i.e., the metabolic syndrome). Similarly, insulin resistance,</text>
<text top="928" left="450" width="350" height="13" font="14">with or without diabetes mellitus, is also an important risk</text>
<text top="946" left="450" width="206" height="13" font="14">factor for the development of HF</text>
<text top="946" left="663" width="44" height="13" font="15"><a href="e147.full.html#66">(92,320</a></text>
<text top="942" left="707" width="33" height="18" font="15"><a href="e147.full.html#66">–323)</a></text>
<text top="946" left="739" width="60" height="13" font="14">. Diabetes</text>
<text top="964" left="450" width="350" height="13" font="14">mellitus is an especially important risk factor for women and</text>
<text top="982" left="450" width="290" height="13" font="14">may, in fact, triple the risk for developing HF</text>
<text top="982" left="748" width="48" height="13" font="15"><a href="e147.full.html#66">(91,324)</a></text>
<text top="982" left="796" width="4" height="13" font="14"><a href="e147.full.html#66">.</a></text>
<text top="1000" left="450" width="350" height="13" font="14">Dysglycemia appears to be directly linked to risk, with</text>
<text top="1018" left="450" width="350" height="13" font="14">HbA1c concentrations powerfully predicting incident HF.</text>
<text top="1036" left="450" width="111" height="13" font="14">Those with HbA1c</text>
<text top="1032" left="566" width="233" height="18" font="14">&gt;10.5% had a nearly 4-fold increase in</text>
<text top="1054" left="450" width="305" height="13" font="14">the risk for HF compared with those with a value of</text>
<text top="1050" left="759" width="40" height="18" font="14">&lt;6.5%</text>
<text top="1072" left="450" width="30" height="13" font="15"><a href="e147.full.html#71">(322)</a></text>
<text top="1072" left="480" width="319" height="13" font="14">. Current consensus advocates that clinicians should</text>
<text top="1090" left="450" width="350" height="13" font="14">make every effort to control hyperglycemia, although such</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e168</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">control has not yet been shown to reduce the subsequent risk</text>
<text top="121" left="64" width="350" height="13" font="14">of HF. Additionally, standard therapies for diabetes mellitus,</text>
<text top="139" left="64" width="350" height="13" font="14">such as use of ACE inhibitors or ARBs, can prevent the</text>
<text top="157" left="64" width="350" height="13" font="14">development of other risk factors for HF, such as renal</text>
<text top="175" left="64" width="66" height="13" font="14">dysfunction</text>
<text top="175" left="134" width="55" height="13" font="15"><a href="e147.full.html#71">(325,326)</a></text>
<text top="175" left="190" width="224" height="13" font="14"><a href="e147.full.html#71">, </a>and may themselves directly lower the</text>
<text top="193" left="64" width="100" height="13" font="14">likelihood of HF</text>
<text top="193" left="171" width="26" height="13" font="15"><a href="e147.full.html#72">(327</a></text>
<text top="189" left="196" width="33" height="18" font="15"><a href="e147.full.html#72">–329)</a></text>
<text top="193" left="229" width="184" height="13" font="14">. Although risk models for the</text>
<text top="211" left="64" width="350" height="13" font="14">development of incident HF in patients with diabetes mellitus</text>
<text top="229" left="64" width="123" height="13" font="14">have been developed</text>
<text top="229" left="193" width="30" height="13" font="15"><a href="e147.full.html#71">(323)</a></text>
<text top="229" left="224" width="190" height="13" font="14"><a href="e147.full.html#71">, </a>their prospective use to reduce</text>
<text top="247" left="64" width="350" height="13" font="14">risk has not been validated. Despite the lack of supportive,</text>
<text top="265" left="64" width="350" height="13" font="14">prospective, randomized data, consensus exists that risk factor</text>
<text top="283" left="64" width="125" height="13" font="14">recognition and modi</text>
<text top="279" left="189" width="224" height="18" font="14">ﬁcation are vital for the prevention of</text>
<text top="301" left="64" width="350" height="13" font="14">HF among at-risk patients (e.g., obese patients or patients with</text>
<text top="319" left="64" width="104" height="13" font="14">diabetes mellitus).</text>
<text top="352" left="64" width="339" height="15" font="14">7.1.4. Recognition and Control of Other Conditions</text>
<text top="370" left="64" width="145" height="15" font="14">That May Lead to HF</text>
<text top="390" left="65" width="349" height="13" font="14">A substantial genetic risk exists in some patients for the</text>
<text top="408" left="64" width="199" height="13" font="14">development of HF. As noted in</text>
<text top="408" left="270" width="67" height="13" font="15"><a href="e147.full.html#15">Section 6.1</a></text>
<text top="408" left="337" width="77" height="13" font="14">, obtaining a</text>
<text top="426" left="64" width="350" height="13" font="14">3-generation family history of HF is recommended. Adequate</text>
<text top="444" left="64" width="350" height="13" font="14">therapy of AF is advisable, given a clear association between</text>
<text top="462" left="64" width="350" height="13" font="14">uncontrolled heart rate and development of HF. Many thera-</text>
<text top="480" left="64" width="350" height="13" font="14">peutic agents can exert important cardiotoxic effects, with</text>
<text top="498" left="64" width="350" height="13" font="14">consequent risk for HF, and clinicians should be aware of</text>
<text top="516" left="64" width="350" height="13" font="14">such risk. For example, cardiotoxic chemotherapy regimens</text>
<text top="534" left="64" width="350" height="13" font="14">(particularly anthracycline based) and trastuzumab may</text>
<text top="552" left="64" width="242" height="13" font="14">increase the risk for HF in certain patients</text>
<text top="552" left="310" width="26" height="13" font="15"><a href="e147.full.html#72">(330</a></text>
<text top="548" left="336" width="33" height="18" font="15"><a href="e147.full.html#72">–332)</a></text>
<text top="552" left="369" width="45" height="13" font="14">; it may</text>
<text top="570" left="64" width="350" height="13" font="14">be reasonable to evaluate those who are receiving (or who</text>
<text top="588" left="64" width="350" height="13" font="14">have received) such agents for LV dysfunction. The use of</text>
<text top="605" left="64" width="350" height="13" font="14">advanced echocardiographic techniques or biomarkers to</text>
<text top="623" left="64" width="350" height="13" font="14">identify increased HF risk in those receiving chemotherapy</text>
<text top="641" left="64" width="256" height="13" font="14">may be useful but remain unvalidated as yet</text>
<text top="641" left="325" width="30" height="13" font="15"><a href="e147.full.html#72">(333)</a></text>
<text top="641" left="355" width="4" height="13" font="14">.</text>
<text top="659" left="79" width="335" height="13" font="14">Tobacco use is strongly associated with risk for incident HF</text>
<text top="677" left="64" width="72" height="13" font="15"><a href="e147.full.html#66">(92,320,334)</a></text>
<text top="677" left="136" width="278" height="13" font="14">, and patients should be strongly advised about the</text>
<text top="695" left="64" width="350" height="13" font="14">hazards of smoking, with attendant efforts at quitting. Cocaine</text>
<text top="713" left="64" width="350" height="13" font="14">and amphetamines are anecdotally but strongly associated with</text>
<text top="731" left="64" width="350" height="13" font="14">HF, and their avoidance is mandatory. Although it is recognized</text>
<text top="749" left="64" width="350" height="13" font="14">that alcohol consumption is associated with subsequent devel-</text>
<text top="767" left="64" width="77" height="13" font="14">opment of HF</text>
<text top="767" left="144" width="72" height="13" font="15"><a href="e147.full.html#66">(92,139,140)</a></text>
<text top="767" left="216" width="198" height="13" font="14">, there is some uncertainty about the</text>
<text top="103" left="450" width="350" height="13" font="14">amount of alcohol ingested and the likelihood of developing</text>
<text top="121" left="450" width="350" height="13" font="14">HF, and there may be sex differences as well. Nevertheless, the</text>
<text top="139" left="450" width="350" height="13" font="14">heavy use of alcohol has repeatedly been associated with</text>
<text top="157" left="450" width="350" height="13" font="14">heightened risk for development of HF. Therefore, patients</text>
<text top="175" left="450" width="265" height="13" font="14">should be counseled about their alcohol intake.</text>
<text top="193" left="465" width="335" height="13" font="14">Although several epidemiological studies have revealed an</text>
<text top="211" left="450" width="350" height="13" font="14">independent link between risk for incident HF and biomarkers</text>
<text top="229" left="450" width="174" height="13" font="14">such as natriuretic peptides</text>
<text top="229" left="634" width="55" height="13" font="15"><a href="e147.full.html#72">(335,336)</a></text>
<text top="229" left="690" width="110" height="13" font="14">, highly sensitive</text>
<text top="247" left="450" width="48" height="13" font="14">troponin</text>
<text top="247" left="502" width="30" height="13" font="15"><a href="e147.full.html#72">(337)</a></text>
<text top="247" left="532" width="267" height="13" font="14">, and measures of renal function such as creat-</text>
<text top="265" left="450" width="350" height="13" font="14">inine, phosphorus, urinary albumin, or albumin-creatinine</text>
<text top="283" left="450" width="26" height="13" font="14">ratio</text>
<text top="283" left="480" width="125" height="13" font="15"><a href="e147.full.html#71">(320,323,334,336,338</a></text>
<text top="279" left="605" width="33" height="18" font="15"><a href="e147.full.html#71">–340)</a></text>
<text top="283" left="638" width="161" height="13" font="14">, it remains unclear whether</text>
<text top="301" left="450" width="101" height="13" font="14">the risk for HF re</text>
<text top="297" left="550" width="249" height="18" font="14">ﬂected by any of these biomarkers is modi-</text>
<text top="315" left="450" width="350" height="18" font="14">ﬁable. Although routine screening with BNP before echocar-</text>
<text top="337" left="450" width="350" height="13" font="14">diography may be a cost-effective strategy to identify high-risk</text>
<text top="354" left="450" width="44" height="13" font="14">patients</text>
<text top="354" left="497" width="30" height="13" font="15"><a href="e147.full.html#72">(341)</a></text>
<text top="354" left="528" width="272" height="13" font="14"><a href="e147.full.html#72">, </a>routine measurement of biomarkers in stage A</text>
<text top="372" left="450" width="129" height="13" font="14">patients is not yet justi</text>
<text top="369" left="578" width="25" height="18" font="14">ﬁed.</text>
<text top="390" left="465" width="20" height="13" font="14">See</text>
<text top="390" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 11</a></text>
<text top="390" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="408" left="450" width="70" height="13" font="14">stage A HF.</text>
<text top="448" left="450" width="243" height="14" font="16">7.2. Stage B: Recommendations</text>
<text top="467" left="451" width="20" height="13" font="14">See</text>
<text top="467" left="476" width="52" height="13" font="15"><a href="e147.full.html#23">Table 12</a></text>
<text top="467" left="533" width="266" height="13" font="14">for a summary of recommendations from this</text>
<text top="485" left="450" width="43" height="13" font="14">section.</text>
<text top="510" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="522" left="468" width="10" height="10" font="18">1.</text>
<text top="522" left="485" width="314" height="10" font="18">In all patients with a recent or remote history of MI or ACS</text>
<text top="539" left="485" width="314" height="10" font="18">and reduced EF, ACE inhibitors should be used to prevent</text>
<text top="555" left="485" width="224" height="10" font="18">symptomatic HF and reduce mortality</text>
<text top="555" left="719" width="26" height="10" font="5"><a href="e147.full.html#72">(342</a></text>
<text top="552" left="745" width="32" height="16" font="5"><a href="e147.full.html#72">–344)</a></text>
<text top="555" left="776" width="23" height="10" font="18">. In</text>
<text top="571" left="485" width="314" height="10" font="18">patients intolerant of ACE inhibitors, ARBs are appropriate</text>
<text top="588" left="485" width="120" height="10" font="18">unless contraindicated</text>
<text top="588" left="609" width="55" height="10" font="5"><a href="e147.full.html#71">(314,345)</a></text>
<text top="588" left="664" width="120" height="12" font="18">. (Level of Evidence: A)</text>
<text top="605" left="468" width="10" height="10" font="18">2.</text>
<text top="604" left="485" width="314" height="10" font="18">In all patients with a recent or remote history of MI or ACS</text>
<text top="621" left="485" width="314" height="10" font="18">and reduced EF, evidence-based beta blockers should be</text>
<text top="637" left="485" width="130" height="10" font="18">used to reduce mortality</text>
<text top="637" left="620" width="26" height="10" font="5"><a href="e147.full.html#72">(346</a></text>
<text top="634" left="645" width="32" height="16" font="5"><a href="e147.full.html#72">–348)</a></text>
<text top="637" left="677" width="121" height="12" font="18"><a href="e147.full.html#72">. </a>(Level of Evidence: B)</text>
<text top="654" left="468" width="10" height="10" font="18">3.</text>
<text top="654" left="485" width="314" height="10" font="18">In all patients with a recent or remote history of MI or ACS,</text>
<text top="670" left="485" width="314" height="10" font="18">statins should be used to prevent symptomatic HF and</text>
<text top="687" left="485" width="113" height="10" font="18">cardiovascular events</text>
<text top="687" left="601" width="50" height="10" font="5"><a href="e147.full.html#66">(104,349</a></text>
<text top="683" left="652" width="32" height="16" font="5"><a href="e147.full.html#66">–354)</a></text>
<text top="687" left="684" width="116" height="12" font="18"><a href="e147.full.html#66">. </a>(Level of Evidence: A)</text>
<text top="703" left="468" width="10" height="10" font="18">4.</text>
<text top="703" left="485" width="314" height="10" font="18">In patients with structural cardiac abnormalities, including</text>
<text top="719" left="485" width="314" height="10" font="18">LV hypertrophy, in the absence of a history of MI or ACS,</text>
<text top="736" left="485" width="314" height="10" font="18">blood pressure should be controlled in accordance with</text>
<text top="752" left="485" width="314" height="10" font="18">clinical practice guidelines for hypertension to prevent</text>
<text top="769" left="485" width="86" height="10" font="18">symptomatic HF</text>
<text top="769" left="576" width="61" height="10" font="5"><a href="e147.full.html#65">(27,94,311</a></text>
<text top="766" left="637" width="32" height="16" font="5"><a href="e147.full.html#65">–313)</a></text>
<text top="769" left="668" width="120" height="12" font="18">. (Level of Evidence: A)</text>
<text top="804" left="64" width="314" height="12" font="9">Table 12. Recommendations for Treatment of Stage B HF</text>
<text top="836" left="64" width="82" height="11" font="4">Recommendations</text>
<text top="836" left="524" width="19" height="11" font="4">COR</text>
<text top="836" left="642" width="17" height="11" font="4">LOE</text>
<text top="836" left="740" width="49" height="11" font="4">References</text>
<text top="857" left="64" width="323" height="11" font="4">In patients with a history of MI and reduced EF, ACE inhibitors or ARBs</text>
<text top="872" left="77" width="134" height="11" font="4">should be used to prevent HF</text>
<text top="857" left="532" width="2" height="11" font="4">I</text>
<text top="857" left="648" width="6" height="11" font="4">A</text>
<text top="857" left="735" width="17" height="11" font="5"><a href="e147.full.html#71">314</a></text>
<text top="857" left="752" width="3" height="11" font="4">,</text>
<text top="857" left="755" width="40" height="11" font="5"><a href="e147.full.html#72">342–345</a></text>
<text top="889" left="64" width="301" height="11" font="4">In patients with MI and reduced EF, evidence-based beta blockers</text>
<text top="903" left="77" width="134" height="11" font="4">should be used to prevent HF</text>
<text top="889" left="532" width="2" height="11" font="4">I</text>
<text top="889" left="647" width="6" height="11" font="4">B</text>
<text top="889" left="745" width="40" height="11" font="5"><a href="e147.full.html#72">346–348</a></text>
<text top="920" left="64" width="258" height="11" font="4">In patients with MI, statins should be used to prevent HF</text>
<text top="920" left="532" width="2" height="11" font="4">I</text>
<text top="920" left="648" width="6" height="11" font="4">A</text>
<text top="920" left="735" width="17" height="11" font="5"><a href="e147.full.html#66">104</a></text>
<text top="920" left="752" width="3" height="11" font="4">,</text>
<text top="920" left="755" width="40" height="11" font="5"><a href="e147.full.html#72">349–354</a></text>
<text top="941" left="64" width="288" height="11" font="4">Blood pressure should be controlled to prevent symptomatic HF</text>
<text top="941" left="532" width="2" height="11" font="4">I</text>
<text top="941" left="648" width="6" height="11" font="4">A</text>
<text top="941" left="731" width="11" height="11" font="5"><a href="e147.full.html#65">27</a></text>
<text top="941" left="742" width="3" height="11" font="4">,</text>
<text top="941" left="745" width="11" height="11" font="5"><a href="e147.full.html#66">94</a></text>
<text top="941" left="756" width="3" height="11" font="4"><a href="e147.full.html#71">,</a></text>
<text top="941" left="759" width="40" height="11" font="5"><a href="e147.full.html#71">311–313</a></text>
<text top="962" left="64" width="352" height="11" font="4">ACE inhibitors should be used in all patients with a reduced EF to prevent HF</text>
<text top="962" left="532" width="2" height="11" font="4">I</text>
<text top="962" left="648" width="6" height="11" font="4">A</text>
<text top="962" left="749" width="11" height="11" font="5"><a href="e147.full.html#66">65</a></text>
<text top="962" left="761" width="3" height="11" font="4"><a href="e147.full.html#66">,</a></text>
<text top="962" left="764" width="17" height="11" font="5"><a href="e147.full.html#72">344</a></text>
<text top="983" left="64" width="351" height="11" font="4">Beta blockers should be used in all patients with a reduced EF to prevent HF</text>
<text top="983" left="532" width="2" height="11" font="4">I</text>
<text top="983" left="647" width="6" height="11" font="4">C</text>
<text top="983" left="757" width="16" height="11" font="4">N/A</text>
<text top="1004" left="64" width="351" height="11" font="4">An ICD is reasonable in patients with asymptomatic ischemic cardiomyopathy</text>
<text top="1018" left="77" width="205" height="11" font="4">who are at least 40 d post-MI, have an LVEF</text>
<text top="1016" left="285" width="98" height="16" font="4">30%, and on GDMT</text>
<text top="1004" left="528" width="10" height="11" font="4">IIa</text>
<text top="1004" left="647" width="6" height="11" font="4">B</text>
<text top="1004" left="756" width="17" height="11" font="5"><a href="e147.full.html#72">355</a></text>
<text top="1035" left="64" width="389" height="11" font="4">Nondihydropyridine calcium channel blockers may be harmful in patients with low LVEF</text>
<text top="1035" left="514" width="38" height="11" font="4">III: Harm</text>
<text top="1035" left="647" width="6" height="11" font="4">C</text>
<text top="1035" left="757" width="16" height="11" font="4">N/A</text>
<text top="1061" left="76" width="723" height="11" font="4">ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; COR, Class of Recommendation; EF, ejection fraction; GDMT, guideline-directed</text>
<text top="1076" left="64" width="735" height="11" font="4">medical therapy; HF, heart failure; ICD, implantable cardioverter-defibrillator; LOE, Level of Evidence; LVEF, left ventricular ejection fraction; MI, myocardial infarction;</text>
<text top="1091" left="64" width="103" height="11" font="4">and N/A, not available.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e169</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="82" width="10" height="10" font="18">5.</text>
<text top="103" left="100" width="314" height="10" font="18">ACE inhibitors should be used in all patients with a reduced</text>
<text top="120" left="100" width="314" height="10" font="18">EF to prevent symptomatic HF, even if they do not have</text>
<text top="136" left="100" width="78" height="10" font="18">a history of MI</text>
<text top="136" left="181" width="48" height="10" font="5"><a href="e147.full.html#66">(65,344)</a></text>
<text top="136" left="229" width="120" height="12" font="18">. (Level of Evidence: A)</text>
<text top="153" left="82" width="10" height="10" font="18">6.</text>
<text top="153" left="100" width="314" height="10" font="18">Beta blockers should be used in all patients with a reduced</text>
<text top="169" left="100" width="314" height="10" font="18">EF to prevent symptomatic HF, even if they do not have</text>
<text top="185" left="100" width="198" height="12" font="18">a history of MI. (Level of Evidence: C)</text>
<text top="209" left="64" width="45" height="8" font="17">CLASS IIa</text>
<text top="222" left="82" width="10" height="10" font="18">1.</text>
<text top="221" left="100" width="314" height="10" font="18">To prevent sudden death, placement of an ICD is reasonable</text>
<text top="238" left="100" width="314" height="10" font="18">in patients with asymptomatic ischemic cardiomyopathy</text>
<text top="254" left="100" width="314" height="10" font="18">who are at least 40 days post-MI, have an LVEF of 30% or</text>
<text top="271" left="100" width="314" height="10" font="18">less, are on appropriate medical therapy, and have reason-</text>
<text top="287" left="100" width="314" height="10" font="18">able expectation of survival with a good functional status for</text>
<text top="303" left="100" width="91" height="10" font="18">more than 1 year</text>
<text top="303" left="195" width="30" height="10" font="5"><a href="e147.full.html#72">(355)</a></text>
<text top="303" left="225" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="327" left="64" width="73" height="8" font="17">CLASS III: Harm</text>
<text top="340" left="82" width="10" height="10" font="18">1.</text>
<text top="339" left="100" width="314" height="10" font="18">Nondihydropyridine calcium channel blockers with negative</text>
<text top="356" left="100" width="314" height="10" font="18">inotropic effects may be harmful in asymptomatic patients</text>
<text top="372" left="100" width="314" height="12" font="18">with low LVEF and no symptoms of HF after MI. (Level of</text>
<text top="389" left="100" width="65" height="12" font="18">Evidence: C)</text>
<text top="414" left="79" width="335" height="13" font="14">Patients with reduced LVEF may not have HF symptoms</text>
<text top="432" left="64" width="141" height="13" font="14">and are most often identi</text>
<text top="428" left="206" width="208" height="18" font="14">ﬁed during an evaluation for another</text>
<text top="450" left="64" width="350" height="13" font="14">disorder (e.g., abnormal heart sounds, abnormal ECG,</text>
<text top="468" left="64" width="350" height="13" font="14">abnormal chest x-ray, hypertension or hypotension, an</text>
<text top="486" left="64" width="350" height="13" font="14">arrhythmia, acute MI, or pulmonary or systemic thrombo-</text>
<text top="504" left="64" width="350" height="13" font="14">embolic event). However, the cost-effectiveness of routine</text>
<text top="522" left="64" width="350" height="13" font="14">periodic population screening for asymptomatic reduced</text>
<text top="540" left="64" width="350" height="13" font="14">LVEF is not recommended at this time. Echocardiographic</text>
<text top="558" left="64" width="350" height="13" font="14">evaluation should be performed in selected patients who are at</text>
<text top="575" left="64" width="350" height="13" font="14">high risk of reduced LVEF (e.g., those with a strong family</text>
<text top="593" left="64" width="350" height="13" font="14">history of cardiomyopathy, long-standing hypertension,</text>
<text top="611" left="64" width="350" height="13" font="14">previous MI, or those receiving cardiotoxic therapies). In</text>
<text top="629" left="64" width="350" height="13" font="14">addition, it should be acknowledged that many adults may</text>
<text top="647" left="64" width="350" height="13" font="14">have asymptomatic valvular abnormalities or congenital heart</text>
<text top="665" left="64" width="350" height="13" font="14">lesions that if unrecognized could lead to the development of</text>
<text top="683" left="64" width="350" height="13" font="14">clinical HF. Although these asymptomatic patients are in</text>
<text top="701" left="64" width="350" height="13" font="14">stage B as well, the management of valvular and congenital</text>
<text top="719" left="64" width="294" height="13" font="14">heart disease is beyond the scope of this guideline.</text>
<text top="746" left="64" width="270" height="15" font="14">7.2.1. Management Strategies for Stage B</text>
<text top="767" left="65" width="349" height="13" font="14">In general, all recommendations for patients with stage A HF</text>
<text top="785" left="64" width="350" height="13" font="14">also apply to those with stage B HF, particularly with respect to</text>
<text top="803" left="64" width="350" height="13" font="14">control of blood pressure in the patient with LV hypertrophy</text>
<text top="821" left="64" width="91" height="13" font="15"><a href="e147.full.html#65">(27,94,311,312)</a></text>
<text top="821" left="162" width="252" height="13" font="14">and the optimization of lipids with statins</text>
<text top="838" left="64" width="55" height="13" font="15"><a href="e147.full.html#72">(349,356)</a></text>
<text top="838" left="120" width="294" height="13" font="14"><a href="e147.full.html#72">. </a>CAD is a major risk factor for the development of</text>
<text top="856" left="64" width="350" height="13" font="14">HF and a key target for prevention of HF. The 5-year risk</text>
<text top="874" left="64" width="350" height="13" font="14">of developing HF after acute MI is 7% and 12% for men and</text>
<text top="892" left="64" width="350" height="13" font="14">women, respectively; for men and women between the ages of</text>
<text top="910" left="64" width="110" height="13" font="14">40 and 69 and those</text>
<text top="906" left="177" width="237" height="18" font="14">&gt;70 years of age, the risk is 22% and 25%,</text>
<text top="928" left="64" width="68" height="13" font="14">respectively</text>
<text top="928" left="137" width="23" height="13" font="15"><a href="e147.full.html#65">(51)</a></text>
<text top="928" left="160" width="254" height="13" font="14">. Current evidence supports the use of ACE</text>
<text top="946" left="64" width="350" height="13" font="14">inhibitors and (to a lower level of evidence) beta-blocker</text>
<text top="964" left="64" width="350" height="13" font="14">therapy to impede maladaptive LV remodeling in patients</text>
<text top="982" left="64" width="350" height="13" font="14">with stage B HF and low LVEF to improve mortality and</text>
<text top="1000" left="64" width="55" height="13" font="14">morbidity</text>
<text top="1000" left="125" width="30" height="13" font="15"><a href="e147.full.html#72">(344)</a></text>
<text top="1000" left="156" width="258" height="13" font="14"><a href="e147.full.html#72">. </a>At 3-year follow-up, those patients treated</text>
<text top="1018" left="64" width="350" height="13" font="14">with ACE inhibitors demonstrated combined endpoints of</text>
<text top="1036" left="64" width="225" height="13" font="14">reduced hospitalization or death, a bene</text>
<text top="1032" left="290" width="124" height="18" font="14">ﬁt that extended up to</text>
<text top="1054" left="64" width="117" height="13" font="14">a 12-year follow-up</text>
<text top="1054" left="187" width="23" height="13" font="15"><a href="e147.full.html#66">(65)</a></text>
<text top="1054" left="210" width="204" height="13" font="14">. ARBs are reasonable alternatives</text>
<text top="1072" left="64" width="350" height="13" font="14">to ACE inhibitors. In 1 study, losartan reduced adverse</text>
<text top="1090" left="64" width="264" height="13" font="14">outcomes in a population with hypertension</text>
<text top="1090" left="335" width="30" height="13" font="15"><a href="e147.full.html#72">(357)</a></text>
<text top="1090" left="365" width="49" height="13" font="14">, and in</text>
<text top="103" left="450" width="350" height="13" font="14">another study of patients post-MI with low LVEF, valsartan</text>
<text top="121" left="450" width="153" height="13" font="14">was equivalent to captopril</text>
<text top="121" left="607" width="30" height="13" font="15"><a href="e147.full.html#72">(345)</a></text>
<text top="121" left="637" width="162" height="13" font="14">. Data with beta blockers are</text>
<text top="139" left="450" width="350" height="13" font="14">less convincing in a population with known CAD, although in</text>
<text top="157" left="450" width="32" height="13" font="14">1 trial</text>
<text top="157" left="485" width="30" height="13" font="15"><a href="e147.full.html#72">(346)</a></text>
<text top="157" left="518" width="281" height="13" font="14">carvedilol therapy in patients with stage B and low</text>
<text top="175" left="450" width="350" height="13" font="14">LVEF was associated with a 31% relative risk reduction in</text>
<text top="193" left="450" width="350" height="13" font="14">adverse long-term outcomes. In patients with previously</text>
<text top="211" left="450" width="350" height="13" font="14">established structural heart disease, the administration of agents</text>
<text top="229" left="450" width="350" height="13" font="14">known to have negative inotropic properties such as non-</text>
<text top="247" left="450" width="350" height="13" font="14">dihydropyridine calcium channel blockers and certain antiar-</text>
<text top="265" left="450" width="166" height="13" font="14">rhythmics should be avoided.</text>
<text top="283" left="465" width="335" height="13" font="14">Elevations in both systolic and diastolic blood pressure are</text>
<text top="301" left="450" width="350" height="13" font="14">major risk factors for developing LV hypertrophy, another</text>
<text top="319" left="450" width="93" height="13" font="14">form of stage B</text>
<text top="319" left="548" width="41" height="13" font="15"><a href="e147.full.html#66">(91,92)</a></text>
<text top="319" left="589" width="198" height="13" font="14">. Although the magnitude of bene</text>
<text top="315" left="788" width="12" height="18" font="14">ﬁt</text>
<text top="337" left="450" width="350" height="13" font="14">varies with the trial selection criteria, target blood pressure</text>
<text top="354" left="450" width="350" height="13" font="14">reduction, and HF criteria, effective hypertension treatment</text>
<text top="372" left="450" width="350" height="13" font="14">invariably reduces HF events. Consequently, long-term</text>
<text top="390" left="450" width="350" height="13" font="14">treatment of both systolic and diastolic hypertension reduces</text>
<text top="408" left="450" width="350" height="13" font="14">the risk of moving from stage A or B to stage C HF</text>
<text top="426" left="450" width="91" height="13" font="15"><a href="e147.full.html#66">(93,94,311,329)</a></text>
<text top="426" left="541" width="259" height="13" font="14"><a href="e147.full.html#66">. </a>Several large controlled studies have</text>
<text top="444" left="450" width="350" height="13" font="14">uniformly demonstrated that optimal blood pressure control</text>
<text top="462" left="450" width="295" height="13" font="14">decreases the risk of new HF by approximately 50%</text>
<text top="462" left="748" width="23" height="13" font="15"><a href="e147.full.html#66">(96)</a></text>
<text top="462" left="771" width="28" height="13" font="14">. It is</text>
<text top="480" left="450" width="350" height="13" font="14">imperative that strategies to control hypertension be part of</text>
<text top="498" left="450" width="145" height="13" font="14">any effort to prevent HF.</text>
<text top="516" left="465" width="335" height="13" font="14">Clinicians should lower both systolic and diastolic blood</text>
<text top="534" left="450" width="278" height="13" font="14">pressure in accordance with published guidelines</text>
<text top="534" left="732" width="23" height="13" font="15"><a href="e147.full.html#65">(27)</a></text>
<text top="534" left="755" width="44" height="13" font="14">. Target</text>
<text top="552" left="450" width="350" height="13" font="14">levels of blood pressure lowering depend on major cardio-</text>
<text top="570" left="450" width="350" height="13" font="14">vascular risk factors, (e.g., CAD, diabetes mellitus, or renal</text>
<text top="588" left="450" width="45" height="13" font="14">disease)</text>
<text top="588" left="502" width="30" height="13" font="15"><a href="e147.full.html#72">(358)</a></text>
<text top="588" left="532" width="267" height="13" font="14"><a href="e147.full.html#72">. </a>Thus, when an antihypertensive regimen is</text>
<text top="606" left="450" width="350" height="13" font="14">devised, optimal control of blood pressure should remain the</text>
<text top="623" left="450" width="350" height="13" font="14">primary goal, with the choice of drugs determined by the</text>
<text top="641" left="450" width="179" height="13" font="14">concomitant medical problems.</text>
<text top="659" left="465" width="335" height="13" font="14">Diuretic-based antihypertensive therapy has been shown to</text>
<text top="677" left="450" width="286" height="13" font="14">prevent HF in a wide range of target populations</text>
<text top="677" left="741" width="55" height="13" font="15"><a href="e147.full.html#72">(359,360)</a></text>
<text top="677" left="796" width="4" height="13" font="14"><a href="e147.full.html#72">.</a></text>
<text top="695" left="450" width="350" height="13" font="14">In refractory hypertensive patients, spironolactone (25 mg)</text>
<text top="713" left="450" width="247" height="13" font="14">should be considered as an additional agent</text>
<text top="713" left="701" width="23" height="13" font="15"><a href="e147.full.html#65">(27)</a></text>
<text top="713" left="724" width="75" height="13" font="14">. Eplerenone,</text>
<text top="731" left="450" width="350" height="13" font="14">in synergy with enalapril, has also demonstrated reduction in</text>
<text top="749" left="450" width="52" height="13" font="14">LV mass</text>
<text top="749" left="506" width="30" height="13" font="15"><a href="e147.full.html#72">(361)</a></text>
<text top="749" left="536" width="4" height="13" font="14"><a href="e147.full.html#72">.</a></text>
<text top="767" left="465" width="335" height="13" font="14">ACE inhibitors and beta blockers are also effective in the</text>
<text top="785" left="450" width="100" height="13" font="14">prevention of HF</text>
<text top="785" left="555" width="23" height="13" font="15"><a href="e147.full.html#65">(27)</a></text>
<text top="785" left="578" width="221" height="13" font="14">. Nevertheless, neither ACE inhibitors</text>
<text top="803" left="450" width="350" height="13" font="14">nor beta blockers as single therapies are superior to other</text>
<text top="821" left="450" width="350" height="13" font="14">antihypertensive drug classes, including calcium channel</text>
<text top="839" left="450" width="350" height="13" font="14">blockers, in the reduction of all cardiovascular outcomes.</text>
<text top="857" left="450" width="350" height="13" font="14">However, in patients with type 2 diabetes mellitus, ACE</text>
<text top="875" left="450" width="146" height="13" font="14">inhibitors and ARBs signi</text>
<text top="871" left="596" width="204" height="18" font="14">ﬁcantly reduced the incidence of HF</text>
<text top="892" left="450" width="60" height="13" font="14">in patients</text>
<text top="892" left="515" width="26" height="13" font="15"><a href="e147.full.html#72">(327</a></text>
<text top="889" left="541" width="33" height="18" font="15"><a href="e147.full.html#72">–329)</a></text>
<text top="892" left="574" width="226" height="13" font="14"><a href="e147.full.html#72">. </a>In contrast, calcium channel blockers</text>
<text top="910" left="450" width="350" height="13" font="14">and alpha blockers were less effective in preventing the HF</text>
<text top="928" left="450" width="189" height="13" font="14">syndrome, particularly in HFrEF</text>
<text top="928" left="643" width="30" height="13" font="15"><a href="e147.full.html#72">(359)</a></text>
<text top="928" left="673" width="4" height="13" font="14">.</text>
<text top="946" left="465" width="335" height="13" font="14">The Framingham studies have shown a 60% increased risk</text>
<text top="964" left="450" width="350" height="13" font="14">of death in patients with asymptomatic low LVEF compared</text>
<text top="982" left="450" width="350" height="13" font="14">with those with normal LVEF; almost half of these patients</text>
<text top="1000" left="450" width="230" height="13" font="14">remained free of HF before their death</text>
<text top="1000" left="686" width="19" height="13" font="15"><a href="e147.full.html#65">(62</a></text>
<text top="996" left="704" width="26" height="18" font="15"><a href="e147.full.html#65">–65)</a></text>
<text top="1000" left="730" width="69" height="13" font="14">. MADIT-II</text>
<text top="1018" left="450" width="161" height="13" font="14">(Multicenter Automatic De</text>
<text top="1014" left="611" width="189" height="18" font="14">ﬁbrillator Implantation Trial II)</text>
<text top="1036" left="450" width="30" height="13" font="15"><a href="e147.full.html#72">(362)</a></text>
<text top="1036" left="485" width="315" height="13" font="14">demonstrated a 31% relative risk reduction in all-cause</text>
<text top="1054" left="450" width="302" height="13" font="14">mortality in patients with post-MI with LVEF</text>
<text top="1050" left="763" width="37" height="18" font="14">30%</text>
<text top="1072" left="450" width="350" height="13" font="14">receiving a prophylactic ICD compared with standard of</text>
<text top="1090" left="450" width="23" height="13" font="14">care</text>
<text top="1090" left="480" width="30" height="13" font="15"><a href="e147.full.html#72">(355)</a></text>
<text top="1090" left="510" width="44" height="13" font="14">. These</text>
<text top="1086" left="561" width="238" height="18" font="14">ﬁndings provided justiﬁcation for broad</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e170</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="20" size="8" family="Times" color="#000000"/>
<text top="464" left="64" width="350" height="13" font="14">adoption of ICDs for primary prevention of SCD in the post-</text>
<text top="482" left="64" width="350" height="13" font="14">MI setting with reduced LVEF, even in the absence of HF</text>
<text top="500" left="64" width="242" height="13" font="14">symptoms, that is, patients in stage B HF.</text>
<text top="518" left="79" width="335" height="13" font="14">Several other ACCF/AHA guidelines addressing the</text>
<text top="536" left="64" width="350" height="15" font="14">appropriate management of patients with stage Bdthose with</text>
<text top="554" left="64" width="350" height="15" font="14">cardiac structural abnormalities but no symptoms of HFdare</text>
<text top="572" left="64" width="46" height="13" font="14">listed in</text>
<text top="572" left="115" width="51" height="13" font="15"><a href="e147.full.html#25">Table 13</a></text>
<text top="572" left="166" width="4" height="13" font="14"><a href="e147.full.html#25">.</a></text>
<text top="590" left="79" width="20" height="13" font="14">See</text>
<text top="590" left="106" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 12</a></text>
<text top="590" left="280" width="134" height="13" font="14">for additional data on</text>
<text top="608" left="64" width="70" height="13" font="14">stage B HF.</text>
<text top="651" left="64" width="95" height="14" font="16">7.3. Stage C</text>
<text top="670" left="65" width="20" height="13" font="14">See</text>
<text top="670" left="93" width="172" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 13</a></text>
<text top="670" left="274" width="140" height="13" font="14">for additional data on</text>
<text top="688" left="64" width="71" height="13" font="14">stage C HF.</text>
<text top="713" left="64" width="263" height="15" font="14">7.3.1. Nonpharmacological Interventions</text>
<text top="740" left="64" width="46" height="15" font="14">7.3.1.1.</text>
<text top="743" left="118" width="68" height="11" font="20">EDUCATION</text>
<text top="740" left="186" width="4" height="15" font="14">:</text>
<text top="743" left="195" width="114" height="11" font="20">RECOMMENDATION</text>
<text top="767" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="779" left="82" width="10" height="10" font="18">1.</text>
<text top="779" left="100" width="201" height="10" font="18">Patients with HF should receive speci</text>
<text top="776" left="301" width="113" height="16" font="18">ﬁc education to facil-</text>
<text top="795" left="100" width="91" height="10" font="18">itate HF self-care</text>
<text top="795" left="195" width="26" height="10" font="5"><a href="e147.full.html#72">(363</a></text>
<text top="792" left="221" width="32" height="16" font="5"><a href="e147.full.html#72">–368)</a></text>
<text top="795" left="252" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="821" left="79" width="335" height="13" font="14">The self-care regimen for patients with HF is complex and</text>
<text top="839" left="64" width="70" height="13" font="14">multifaceted</text>
<text top="839" left="144" width="30" height="13" font="15"><a href="e147.full.html#72">(363)</a></text>
<text top="839" left="174" width="240" height="13" font="14">. Patients need to understand how to</text>
<text top="857" left="64" width="204" height="13" font="14">monitor their symptoms and weight</text>
<text top="853" left="272" width="142" height="18" font="14">ﬂuctuations, restrict their</text>
<text top="874" left="64" width="350" height="13" font="14">sodium intake, take their medications as prescribed, and stay</text>
<text top="892" left="64" width="350" height="13" font="14">physically active. Education regarding these recommenda-</text>
<text top="910" left="64" width="223" height="13" font="14">tions is necessary, albeit not always suf</text>
<text top="907" left="287" width="127" height="18" font="14">ﬁcient, to signiﬁcantly</text>
<text top="928" left="64" width="350" height="13" font="14">improve outcomes. After discharge, many patients with HF</text>
<text top="946" left="64" width="350" height="13" font="14">need disease management programs, which are reviewed in</text>
<text top="964" left="64" width="65" height="13" font="14">Section 11.</text>
<text top="982" left="79" width="335" height="13" font="14">A systematic review of 35 educational intervention studies</text>
<text top="1000" left="64" width="350" height="13" font="14">for patients with HF demonstrated that education improved</text>
<text top="1018" left="64" width="350" height="13" font="14">knowledge, self-monitoring, medication adherence, time to</text>
<text top="1036" left="64" width="231" height="13" font="14">hospitalization, and days in the hospital</text>
<text top="1036" left="301" width="30" height="13" font="15"><a href="e147.full.html#72">(363)</a></text>
<text top="1036" left="331" width="83" height="13" font="14">. Patients who</text>
<text top="1054" left="64" width="350" height="13" font="14">receive in-hospital education have higher knowledge scores at</text>
<text top="1072" left="64" width="350" height="13" font="14">discharge and 1 year later when compared with those who</text>
<text top="1090" left="64" width="210" height="13" font="14">did not receive in-hospital education</text>
<text top="1090" left="279" width="30" height="13" font="15"><a href="e147.full.html#72">(364)</a></text>
<text top="1090" left="310" width="104" height="13" font="14"><a href="e147.full.html#72">. </a>Data have called</text>
<text top="103" left="450" width="193" height="13" font="14">into question the survival bene</text>
<text top="100" left="642" width="157" height="18" font="14">ﬁt of discharge education</text>
<text top="121" left="450" width="55" height="13" font="15"><a href="e147.full.html#73">(369,370)</a></text>
<text top="121" left="505" width="294" height="13" font="14">. However, prior data have suggested that discharge</text>
<text top="139" left="450" width="350" height="13" font="14">education may result in fewer days of hospitalization, lower</text>
<text top="157" left="450" width="350" height="13" font="14">costs, and lower mortality rates within a 6-month follow-up</text>
<text top="175" left="450" width="30" height="13" font="15"><a href="e147.full.html#72">(365)</a></text>
<text top="175" left="480" width="319" height="13" font="14">. Patients educated in all 6 categories of the HF core</text>
<text top="193" left="450" width="282" height="13" font="14">measures from The Joint Commission were signi</text>
<text top="189" left="732" width="68" height="18" font="14">ﬁcantly less</text>
<text top="211" left="450" width="309" height="13" font="14">likely to be readmitted for any cause, including HF</text>
<text top="211" left="766" width="30" height="13" font="15"><a href="e147.full.html#72">(366)</a></text>
<text top="211" left="796" width="4" height="13" font="14"><a href="e147.full.html#72">.</a></text>
<text top="229" left="450" width="350" height="13" font="14">Even a single home-based educational intervention for</text>
<text top="247" left="450" width="350" height="13" font="14">patients and families has been shown to decrease emergency</text>
<text top="265" left="450" width="312" height="13" font="14">visits and unplanned hospitalizations in adults with HF</text>
<text top="265" left="766" width="30" height="13" font="15"><a href="e147.full.html#73">(367)</a></text>
<text top="265" left="796" width="4" height="13" font="14"><a href="e147.full.html#73">.</a></text>
<text top="283" left="465" width="20" height="13" font="14">See</text>
<text top="283" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 14</a></text>
<text top="283" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="301" left="450" width="127" height="13" font="14">patient nonadherence.</text>
<text top="327" left="450" width="46" height="15" font="14">7.3.1.2.</text>
<text top="330" left="503" width="98" height="11" font="20">SOCIAL SUPPORT</text>
<text top="346" left="451" width="349" height="13" font="14">Social support is thought to buffer stress and promote treat-</text>
<text top="364" left="450" width="229" height="13" font="14">ment adherence and a healthy lifestyle</text>
<text top="364" left="685" width="30" height="13" font="15"><a href="e147.full.html#73">(371)</a></text>
<text top="364" left="716" width="84" height="13" font="14"><a href="e147.full.html#73">. </a>Most studies</text>
<text top="382" left="450" width="350" height="13" font="14">examining the relationship between social support and</text>
<text top="400" left="450" width="350" height="13" font="14">hospitalization in adults with HF have found that a lack of</text>
<text top="418" left="450" width="350" height="13" font="14">social support is associated with higher hospitalization rates</text>
<text top="436" left="450" width="55" height="13" font="15"><a href="e147.full.html#73">(372,373)</a></text>
<text top="436" left="510" width="102" height="13" font="14">and mortality risk</text>
<text top="436" left="617" width="55" height="13" font="15"><a href="e147.full.html#73">(374,375)</a></text>
<text top="436" left="672" width="4" height="13" font="14"><a href="e147.full.html#73">.</a></text>
<text top="473" left="450" width="46" height="15" font="14">7.3.1.3.</text>
<text top="476" left="503" width="128" height="11" font="20">SODIUM RESTRICTION</text>
<text top="473" left="632" width="4" height="15" font="14">:</text>
<text top="476" left="641" width="114" height="11" font="20">RECOMMENDATION</text>
<text top="499" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="511" left="468" width="10" height="10" font="18">1.</text>
<text top="511" left="485" width="314" height="10" font="18">Sodium restriction is reasonable for patients with symp-</text>
<text top="528" left="485" width="314" height="12" font="18">tomatic HF to reduce congestive symptoms. (Level of</text>
<text top="544" left="485" width="65" height="12" font="18">Evidence: C)</text>
<text top="570" left="465" width="335" height="13" font="14">Dietary sodium restriction is commonly recommended to</text>
<text top="587" left="450" width="350" height="13" font="14">patients with HF and is endorsed by many guidelines</text>
<text top="605" left="450" width="73" height="13" font="15"><a href="e147.full.html#64">(18,376,377)</a></text>
<text top="605" left="523" width="277" height="13" font="14"><a href="e147.full.html#64">. </a>The data on which this recommendation is</text>
<text top="623" left="450" width="350" height="13" font="14">drawn upon, however, are modest, and variances in protocols,</text>
<text top="637" left="450" width="350" height="18" font="14">ﬂuid intake, measurement of sodium intake and compliance,</text>
<text top="659" left="450" width="350" height="13" font="14">and other clinical and therapeutic characteristics among these</text>
<text top="677" left="450" width="330" height="13" font="14">studies make it challenging to compare data and draw de</text>
<text top="673" left="780" width="19" height="18" font="14">ﬁn-</text>
<text top="695" left="450" width="350" height="13" font="14">itive conclusions. Observational data suggest an association</text>
<text top="713" left="450" width="200" height="13" font="14">between dietary sodium intake with</text>
<text top="709" left="653" width="147" height="18" font="14">ﬂuid retention and risk for</text>
<text top="731" left="450" width="83" height="13" font="14">hospitalization</text>
<text top="731" left="543" width="55" height="13" font="15"><a href="e147.full.html#73">(378,379)</a></text>
<text top="731" left="599" width="201" height="13" font="14"><a href="e147.full.html#73">. </a>Other studies, however, have</text>
<text top="749" left="450" width="249" height="13" font="14">signaled a worsening neurohormonal pro</text>
<text top="745" left="699" width="101" height="18" font="14">ﬁle with sodium</text>
<text top="767" left="450" width="93" height="13" font="14">restriction in HF</text>
<text top="767" left="547" width="26" height="13" font="15"><a href="e147.full.html#73">(380</a></text>
<text top="763" left="573" width="33" height="18" font="15"><a href="e147.full.html#73">–390)</a></text>
<text top="767" left="606" width="194" height="13" font="14"><a href="e147.full.html#73">. </a>Sodium homeostasis is altered in</text>
<text top="785" left="450" width="350" height="13" font="14">patients with HF as opposed to healthy individuals, which</text>
<text top="803" left="450" width="350" height="13" font="14">may partially explain these trends. In most of these studies,</text>
<text top="821" left="450" width="350" height="13" font="14">patients were not receiving GDMT; no study to date has</text>
<text top="839" left="450" width="350" height="13" font="14">evaluated the effects of sodium restriction on neurohor-</text>
<text top="856" left="450" width="350" height="13" font="14">monal activation and outcomes in optimally treated patients</text>
<text top="874" left="450" width="350" height="13" font="14">with HF. With the exception of 1 observational study that</text>
<text top="892" left="450" width="181" height="13" font="14">evaluated patients with HFpEF</text>
<text top="892" left="636" width="31" height="13" font="15"><a href="e147.full.html#73">(383)</a></text>
<text top="892" left="667" width="133" height="13" font="14"><a href="e147.full.html#73">, </a>all other studies have</text>
<text top="910" left="450" width="350" height="13" font="14">focused on patients with HFrEF. These data are mostly from</text>
<text top="928" left="450" width="350" height="13" font="14">white patients; when the differences in cardiovascular and</text>
<text top="946" left="450" width="350" height="13" font="14">renal pathophysiology among races are considered, the</text>
<text top="964" left="450" width="350" height="13" font="14">effects of sodium restriction in nonwhite patients with HF</text>
<text top="982" left="450" width="350" height="13" font="14">cannot be ascertained from these studies. To make this</text>
<text top="1000" left="450" width="350" height="13" font="14">more complicated, the 3 RCTs that assessed outcomes with</text>
<text top="1018" left="450" width="350" height="13" font="14">sodium restriction have all shown that lower sodium intake is</text>
<text top="1036" left="450" width="350" height="13" font="14">associated with worse outcomes in patients with HFrEF</text>
<text top="1054" left="450" width="26" height="13" font="15"><a href="e147.full.html#73">(384</a></text>
<text top="1050" left="476" width="34" height="18" font="15"><a href="e147.full.html#73">–386)</a></text>
<text top="1054" left="510" width="4" height="13" font="14"><a href="e147.full.html#73">.</a></text>
<text top="1072" left="465" width="169" height="13" font="14">These limitations make it dif</text>
<text top="1068" left="634" width="165" height="18" font="14">ﬁcult to give precise recom-</text>
<text top="1090" left="450" width="350" height="13" font="14">mendations about daily sodium intake and whether it should</text>
<text top="103" left="64" width="318" height="12" font="9">Table 13. Other ACCF/AHA Guidelines Addressing Patients</text>
<text top="119" left="64" width="89" height="12" font="9">With Stage B HF</text>
<text top="151" left="64" width="60" height="11" font="4">Consideration</text>
<text top="151" left="317" width="45" height="11" font="4">Reference</text>
<text top="171" left="64" width="179" height="11" font="4">Patients with an acute MI who have not</text>
<text top="186" left="77" width="145" height="11" font="4">developed HF symptoms treated</text>
<text top="201" left="77" width="87" height="11" font="4">according to GDMT</text>
<text top="171" left="264" width="122" height="11" font="4">2013 UA/NSTEMI Guideline</text>
<text top="171" left="390" width="17" height="11" font="5"><a href="e147.full.html#64">(16)</a></text>
<text top="186" left="265" width="100" height="11" font="4">2013 STEMI Guideline</text>
<text top="186" left="368" width="17" height="11" font="5"><a href="e147.full.html#64">(15)</a></text>
<text top="220" left="64" width="173" height="11" font="4">Coronary revascularization for patients</text>
<text top="235" left="77" width="122" height="11" font="4">without symptoms of HF in</text>
<text top="250" left="77" width="105" height="11" font="4">accordance with GDMT</text>
<text top="220" left="264" width="86" height="11" font="4">2011 PCI Guideline</text>
<text top="220" left="355" width="17" height="11" font="5"><a href="e147.full.html#64">(12)</a></text>
<text top="235" left="265" width="97" height="11" font="4">2011 CABG Guideline</text>
<text top="235" left="365" width="17" height="11" font="5"><a href="e147.full.html#64">(10)</a></text>
<text top="250" left="265" width="93" height="11" font="4">2012 SIHD Guideline</text>
<text top="250" left="362" width="17" height="11" font="5"><a href="e147.full.html#64">(14)</a></text>
<text top="269" left="64" width="179" height="11" font="4">Valve replacement or repair for patients</text>
<text top="284" left="77" width="149" height="11" font="4">with hemodynamically significant</text>
<text top="299" left="77" width="167" height="11" font="4">valvular stenosis or regurgitation and</text>
<text top="314" left="77" width="155" height="11" font="4">no symptoms of HF in accordance</text>
<text top="329" left="77" width="50" height="11" font="4">with GDMT</text>
<text top="269" left="264" width="99" height="11" font="4">2008 Focused Update</text>
<text top="284" left="277" width="94" height="11" font="4">incorporated into the</text>
<text top="299" left="277" width="90" height="11" font="4">2006 VHD Guideline</text>
<text top="299" left="371" width="17" height="11" font="5"><a href="e147.full.html#64">(17)</a></text>
<text top="351" left="76" width="338" height="11" font="4">ACCF indicates American College of Cardiology Foundation; AHA, American</text>
<text top="366" left="64" width="350" height="11" font="4">Heart Association; CABG, coronary artery bypass graft; GDMT, guideline-</text>
<text top="381" left="64" width="350" height="11" font="4">directed medical therapy; HF, heart failure; MI, myocardial infarction; PCI,</text>
<text top="396" left="64" width="350" height="11" font="4">percutaneous coronary intervention; SIHD, stable ischemic heart disease;</text>
<text top="410" left="64" width="350" height="11" font="4">STEMI, ST-elevation myocardial infarction; UA/NSTEMI, unstable angina/non–</text>
<text top="425" left="64" width="307" height="11" font="4">ST-elevation myocardial infarction; and VHD, valvular heart disease.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e171</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">vary with respect to the type of HF (e.g., HFrEF versus</text>
<text top="121" left="64" width="350" height="13" font="14">HFpEF), disease severity (e.g., NYHA class), HF-related</text>
<text top="139" left="64" width="350" height="13" font="14">comorbidities (e.g., renal dysfunction), or other characteris-</text>
<text top="157" left="64" width="350" height="13" font="14">tics (e.g., age or race). Because of the association between</text>
<text top="175" left="64" width="350" height="13" font="14">sodium intake and hypertension, LV hypertrophy, and</text>
<text top="193" left="64" width="350" height="13" font="14">cardiovascular disease, the AHA recommendation for restric-</text>
<text top="211" left="64" width="350" height="13" font="14">tion of sodium to 1500 mg/d appears to be appropriate for most</text>
<text top="229" left="64" width="196" height="13" font="14">patients with stage A and B HF</text>
<text top="229" left="267" width="26" height="13" font="15"><a href="e147.full.html#73">(387</a></text>
<text top="225" left="293" width="33" height="18" font="15"><a href="e147.full.html#73">–392)</a></text>
<text top="229" left="326" width="88" height="13" font="14"><a href="e147.full.html#73">. </a>However, for</text>
<text top="247" left="64" width="315" height="13" font="14">patients with stage C and D HF, currently there are insuf</text>
<text top="243" left="379" width="35" height="18" font="14">ﬁcient</text>
<text top="265" left="64" width="146" height="13" font="14">data to endorse any speci</text>
<text top="261" left="211" width="203" height="18" font="14">ﬁc level of sodium intake. Because</text>
<text top="283" left="64" width="189" height="13" font="14">sodium intake is typically high (</text>
<text top="279" left="253" width="161" height="18" font="14">&gt;4 g/d) in the general pop-</text>
<text top="301" left="64" width="301" height="13" font="14">ulation, clinicians should consider some degree (e.g.,</text>
<text top="297" left="369" width="45" height="18" font="14">&lt;3 g/d)</text>
<text top="319" left="64" width="350" height="13" font="14">of sodium restriction in patients with stage C and D HF for</text>
<text top="337" left="64" width="135" height="13" font="14">symptom improvement.</text>
<text top="366" left="64" width="46" height="15" font="14">7.3.1.4.</text>
<text top="370" left="118" width="201" height="11" font="20">TREATMENT OF SLEEP DISORDERS</text>
<text top="366" left="319" width="4" height="15" font="14">:</text>
<text top="387" left="64" width="114" height="11" font="20">RECOMMENDATION</text>
<text top="411" left="64" width="45" height="8" font="17">CLASS IIa</text>
<text top="423" left="82" width="10" height="10" font="18">1.</text>
<text top="423" left="100" width="272" height="10" font="18">Continuous positive airway pressure can be bene</text>
<text top="420" left="372" width="42" height="16" font="18">ﬁcial to</text>
<text top="439" left="100" width="314" height="10" font="18">increase LVEF and improve functional status in patients with</text>
<text top="456" left="100" width="105" height="10" font="18">HF and sleep apnea</text>
<text top="456" left="208" width="4" height="10" font="5"><a href="e147.full.html#73">(</a></text>
<text top="456" left="212" width="21" height="10" font="5"><a href="e147.full.html#73">393</a></text>
<text top="453" left="233" width="31" height="16" font="5"><a href="e147.full.html#73">–396)</a></text>
<text top="456" left="264" width="121" height="12" font="18"><a href="e147.full.html#73">. </a>(Level of Evidence: B)</text>
<text top="481" left="79" width="335" height="13" font="14">Sleep disorders are common in patients with HF. A study</text>
<text top="499" left="64" width="350" height="13" font="14">of adults with chronic HF treated with evidence-based ther-</text>
<text top="517" left="64" width="350" height="13" font="14">apies found that 61% had either central or obstructive sleep</text>
<text top="535" left="64" width="33" height="13" font="14">apnea</text>
<text top="535" left="103" width="30" height="13" font="15"><a href="e147.full.html#73">(397)</a></text>
<text top="535" left="134" width="268" height="13" font="14"><a href="e147.full.html#73">. </a>Despite having less sleep time and sleep ef</text>
<text top="531" left="402" width="12" height="18" font="14">ﬁ-</text>
<text top="553" left="64" width="350" height="13" font="14">ciency compared with those without HF, patients with HF,</text>
<text top="571" left="64" width="350" height="13" font="14">including those with documented sleep disorders, rarely report</text>
<text top="589" left="64" width="168" height="13" font="14">excessive daytime sleepiness</text>
<text top="589" left="238" width="30" height="13" font="15"><a href="e147.full.html#73">(398)</a></text>
<text top="589" left="268" width="145" height="13" font="14">. Thus, a high degree of</text>
<text top="607" left="64" width="350" height="13" font="14">suspicion for sleep disorders should be maintained for these</text>
<text top="625" left="64" width="350" height="13" font="14">patients. The decision to refer a patient to a sleep study should</text>
<text top="643" left="64" width="176" height="13" font="14">be based on clinical judgment.</text>
<text top="660" left="79" width="335" height="13" font="14">The primary treatment for obstructive sleep apnea is</text>
<text top="678" left="64" width="350" height="13" font="14">nocturnal continuous positive airway pressure. In a major</text>
<text top="696" left="64" width="350" height="13" font="14">trial, continuous positive airway pressure for obstructive sleep</text>
<text top="714" left="64" width="249" height="13" font="14">apnea was effective in decreasing the apnea</text>
<text top="710" left="313" width="101" height="18" font="14">–hypopnea index,</text>
<text top="732" left="64" width="350" height="13" font="14">improving nocturnal oxygenation, increasing LVEF, lowering</text>
<text top="750" left="64" width="350" height="13" font="14">norepinephrine levels, and increasing the distance walked in</text>
<text top="768" left="64" width="130" height="13" font="14">6 minutes; these bene</text>
<text top="764" left="194" width="220" height="18" font="14">ﬁts were sustained for up to 2 years</text>
<text top="786" left="64" width="30" height="13" font="15"><a href="e147.full.html#73">(394)</a></text>
<text top="786" left="95" width="319" height="13" font="14"><a href="e147.full.html#73">. </a>Smaller studies suggest that continuous positive airway</text>
<text top="804" left="64" width="350" height="13" font="14">pressure can improve cardiac function, sympathetic activity,</text>
<text top="822" left="64" width="350" height="13" font="14">and HRQOL in patients with HF and obstructive sleep apnea</text>
<text top="840" left="64" width="55" height="13" font="15"><a href="e147.full.html#73">(395,396)</a></text>
<text top="840" left="120" width="4" height="13" font="14"><a href="e147.full.html#73">.</a></text>
<text top="858" left="79" width="20" height="13" font="14">See</text>
<text top="858" left="103" width="159" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 15</a></text>
<text top="858" left="266" width="148" height="13" font="14">for additional data on the</text>
<text top="876" left="64" width="164" height="13" font="14">treatment of sleep disorders.</text>
<text top="906" left="64" width="46" height="15" font="14">7.3.1.5.</text>
<text top="909" left="118" width="81" height="11" font="20">WEIGHT LOSS</text>
<text top="926" left="65" width="78" height="13" font="14">Obesity is de</text>
<text top="922" left="143" width="157" height="18" font="14">ﬁned as a BMI 30 kg/m</text>
<text top="923" left="300" width="5" height="9" font="12">2</text>
<text top="926" left="305" width="109" height="13" font="14">. Patients with HF</text>
<text top="944" left="64" width="270" height="13" font="14">who have a BMI between 30 and 35 kg/m</text>
<text top="940" left="335" width="5" height="9" font="12">2</text>
<text top="944" left="348" width="66" height="13" font="14">have lower</text>
<text top="961" left="64" width="350" height="13" font="14">mortality and hospitalization rates than those with a BMI in</text>
<text top="979" left="64" width="104" height="13" font="14">the normal range</text>
<text top="979" left="176" width="23" height="13" font="15"><a href="e147.full.html#66">(99)</a></text>
<text top="979" left="199" width="133" height="13" font="14">. Weight loss may re</text>
<text top="976" left="333" width="81" height="18" font="14">ﬂect cachexia</text>
<text top="997" left="64" width="350" height="13" font="14">caused by the higher total energy expenditure associated with</text>
<text top="1015" left="64" width="310" height="13" font="14">HF compared with that of healthy sedentary subjects</text>
<text top="1015" left="380" width="30" height="13" font="15"><a href="e147.full.html#73">(399)</a></text>
<text top="1015" left="410" width="4" height="13" font="14">.</text>
<text top="1033" left="64" width="350" height="13" font="14">The diagnosis of cardiac cachexia independently predicts</text>
<text top="1051" left="64" width="104" height="13" font="14">a worse prognosis</text>
<text top="1051" left="173" width="30" height="13" font="15"><a href="e147.full.html#68">(191)</a></text>
<text top="1051" left="204" width="210" height="13" font="14"><a href="e147.full.html#68">. </a>At the other end of the continuum,</text>
<text top="1069" left="64" width="350" height="13" font="14">morbidly obese patients may have worse outcomes compared</text>
<text top="1087" left="64" width="350" height="13" font="14">with patients within the normal weight range and those who</text>
<text top="103" left="450" width="350" height="13" font="14">are obese. A U-shaped distribution curve has been suggested</text>
<text top="121" left="450" width="350" height="13" font="14">in which mortality is greatest in cachectic patients; lower in</text>
<text top="139" left="450" width="350" height="13" font="14">normal, overweight, and mildly obese patients; and higher</text>
<text top="157" left="450" width="216" height="13" font="14">again in more severely obese patients</text>
<text top="157" left="671" width="30" height="13" font="15"><a href="e147.full.html#73">(400)</a></text>
<text top="157" left="701" width="4" height="13" font="14"><a href="e147.full.html#73">.</a></text>
<text top="175" left="465" width="335" height="13" font="14">Although there are anecdotal reports about symptomatic</text>
<text top="193" left="450" width="350" height="13" font="14">improvement after weight reduction in obese patients with HF</text>
<text top="211" left="450" width="55" height="13" font="15"><a href="e147.full.html#73">(401,402)</a></text>
<text top="211" left="505" width="294" height="13" font="14">, large-scale clinical trials on the role of weight loss</text>
<text top="229" left="450" width="350" height="13" font="14">in patients with HF with obesity have not been performed.</text>
<text top="247" left="450" width="350" height="13" font="14">Because of reports of development of cardiomyopathy,</text>
<text top="265" left="450" width="210" height="13" font="14">sibutramine is contraindicated in HF</text>
<text top="265" left="664" width="30" height="13" font="15"><a href="e147.full.html#73">(403)</a></text>
<text top="265" left="695" width="4" height="13" font="14"><a href="e147.full.html#73">.</a></text>
<text top="303" left="450" width="46" height="15" font="14">7.3.1.6.</text>
<text top="306" left="503" width="53" height="11" font="20">ACTIVITY</text>
<text top="303" left="556" width="4" height="15" font="14">,</text>
<text top="306" left="565" width="143" height="11" font="20">EXERCISE PRESCRIPTION</text>
<text top="303" left="708" width="4" height="15" font="14">,</text>
<text top="306" left="717" width="25" height="11" font="20">AND</text>
<text top="324" left="450" width="155" height="11" font="20">CARDIAC REHABILITATION</text>
<text top="320" left="605" width="4" height="15" font="14">:</text>
<text top="324" left="614" width="120" height="11" font="20">RECOMMENDATIONS</text>
<text top="347" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="359" left="468" width="10" height="10" font="18">1.</text>
<text top="359" left="485" width="314" height="10" font="18">Exercise training (or regular physical activity) is recom-</text>
<text top="376" left="485" width="314" height="10" font="18">mended as safe and effective for patients with HF who are</text>
<text top="392" left="485" width="250" height="10" font="18">able to participate to improve functional status</text>
<text top="392" left="739" width="26" height="10" font="5"><a href="e147.full.html#73">(404</a></text>
<text top="389" left="764" width="32" height="16" font="5"><a href="e147.full.html#73">–407)</a></text>
<text top="392" left="796" width="3" height="10" font="18">.</text>
<text top="409" left="485" width="113" height="12" font="18">(Level of Evidence: A)</text>
<text top="432" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="445" left="468" width="10" height="10" font="18">1.</text>
<text top="444" left="478" width="322" height="10" font="18">Cardiac rehabilitation can be useful in clinically stable</text>
<text top="461" left="468" width="332" height="10" font="18">patients with HF to improve functional capacity, exercise</text>
<text top="477" left="468" width="180" height="10" font="18">duration, HRQOL, and mortality</text>
<text top="477" left="656" width="50" height="10" font="5"><a href="e147.full.html#73">(404,406</a></text>
<text top="474" left="707" width="32" height="16" font="5"><a href="e147.full.html#73">–411)</a></text>
<text top="477" left="738" width="61" height="12" font="18">. (Level of</text>
<text top="494" left="468" width="65" height="12" font="18">Evidence: B)</text>
<text top="519" left="465" width="335" height="13" font="14">Exercise training in patients with HF is safe and has</text>
<text top="537" left="450" width="87" height="13" font="14">numerous bene</text>
<text top="533" left="537" width="263" height="18" font="14">ﬁts. Meta-analyses show that cardiac rehabili-</text>
<text top="555" left="450" width="350" height="13" font="14">tation reduces mortality; improves functional capacity, exer-</text>
<text top="573" left="450" width="313" height="13" font="14">cise duration, and HRQOL; and reduces hospitalizations</text>
<text top="573" left="766" width="30" height="13" font="15"><a href="e147.full.html#73">(409)</a></text>
<text top="573" left="796" width="4" height="13" font="14"><a href="e147.full.html#73">.</a></text>
<text top="591" left="450" width="62" height="13" font="14">Other bene</text>
<text top="587" left="512" width="287" height="18" font="14">ﬁts include improved endothelial function, blunted</text>
<text top="609" left="450" width="350" height="13" font="14">catecholamine spillover, increased peripheral oxygen extrac-</text>
<text top="627" left="450" width="208" height="13" font="14">tion, and reduced hospital admission</text>
<text top="627" left="662" width="105" height="13" font="15"><a href="e147.full.html#73">(405,407,410,411)</a></text>
<text top="627" left="767" width="4" height="13" font="14">.</text>
<text top="645" left="465" width="335" height="13" font="14">Many RCTs of exercise training in HF have been con-</text>
<text top="663" left="450" width="294" height="13" font="14">ducted, but the statistical power of most was low</text>
<text top="663" left="749" width="30" height="13" font="15"><a href="e147.full.html#73">(408)</a></text>
<text top="663" left="780" width="20" height="13" font="14"><a href="e147.full.html#73">. </a>A</text>
<text top="680" left="450" width="350" height="13" font="14">major trial of exercise and HF randomly assigned 2331</text>
<text top="698" left="450" width="350" height="13" font="14">patients (mean EF, 25%; ischemic etiology, 52%) to either</text>
<text top="716" left="450" width="256" height="13" font="14">exercise training for 3 months or usual care</text>
<text top="716" left="711" width="30" height="13" font="15"><a href="e147.full.html#73">(406)</a></text>
<text top="716" left="742" width="58" height="13" font="14"><a href="e147.full.html#73">. </a>In unad-</text>
<text top="734" left="450" width="197" height="13" font="14">justed analyses, there was no signi</text>
<text top="731" left="647" width="152" height="18" font="14">ﬁcant difference at the end</text>
<text top="752" left="450" width="350" height="13" font="14">of the study in either total mortality or hospitalizations. When</text>
<text top="770" left="450" width="350" height="13" font="14">adjusted for coronary heart disease risk factors, there was an</text>
<text top="788" left="450" width="350" height="13" font="14">11% reduction in all-cause mortality, cardiovascular disease</text>
<text top="806" left="450" width="178" height="13" font="14">mortality, or hospitalizations (P</text>
<text top="802" left="628" width="172" height="18" font="14">&lt;0.03) in the exercise training</text>
<text top="824" left="450" width="33" height="13" font="14">group</text>
<text top="824" left="489" width="30" height="13" font="15"><a href="e147.full.html#73">(406)</a></text>
<text top="824" left="520" width="280" height="13" font="14"><a href="e147.full.html#73">. </a>A meta-analysis demonstrated improved peak</text>
<text top="842" left="450" width="350" height="13" font="14">oxygen consumption and decreased all-cause mortality with</text>
<text top="860" left="450" width="46" height="13" font="14">exercise</text>
<text top="860" left="500" width="30" height="13" font="15"><a href="e147.full.html#73">(409)</a></text>
<text top="860" left="531" width="4" height="13" font="14"><a href="e147.full.html#73">.</a></text>
<text top="878" left="465" width="20" height="13" font="14">See</text>
<text top="878" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 16</a></text>
<text top="878" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="896" left="450" width="97" height="13" font="14">cardiac exercise.</text>
<text top="933" left="450" width="320" height="15" font="14">7.3.2. Pharmacological Treatment for Stage C HF</text>
<text top="930" left="770" width="29" height="19" font="14">rEF:</text>
<text top="951" left="450" width="117" height="15" font="14">Recommendations</text>
<text top="978" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="990" left="468" width="10" height="10" font="18">1.</text>
<text top="990" left="485" width="314" height="10" font="18">Measures listed as Class I recommendations for patients in</text>
<text top="1006" left="485" width="314" height="10" font="18">stages A and B are recommended where appropriate for</text>
<text top="1023" left="485" width="314" height="12" font="18">patients in stage C. (Levels of Evidence: A, B, and C as</text>
<text top="1039" left="485" width="64" height="12" font="18">appropriate)</text>
<text top="1056" left="468" width="10" height="10" font="18">2.</text>
<text top="1056" left="485" width="116" height="10" font="18">GDMT as depicted in</text>
<text top="1056" left="606" width="45" height="10" font="5"><a href="e147.full.html#27">Figure 1</a></text>
<text top="1056" left="656" width="143" height="10" font="18">should be the mainstay of</text>
<text top="1072" left="485" width="201" height="12" font="18">pharmacological therapy for HFrEF</text>
<text top="1072" left="696" width="103" height="10" font="5"><a href="e147.full.html#66">(108,343,345,346,</a></text>
<text top="1088" left="485" width="21" height="10" font="5"><a href="e147.full.html#66">412</a></text>
<text top="1085" left="507" width="32" height="16" font="5"><a href="e147.full.html#66">–426)</a></text>
<text top="1088" left="538" width="120" height="12" font="18">. (Level of Evidence: A)</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e172</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="21" size="10" family="Times" color="#121211"/>
	<fontspec id="22" size="10" family="Times" color="#121211"/>
	<fontspec id="23" size="10" family="Times" color="#121211"/>
	<fontspec id="24" size="7" family="Times" color="#121211"/>
	<fontspec id="25" size="7" family="Times" color="#121211"/>
	<fontspec id="26" size="7" family="Times" color="#121211"/>
<text top="634" left="64" width="46" height="15" font="14">7.3.2.1.</text>
<text top="637" left="118" width="61" height="11" font="20">DIURETICS</text>
<text top="634" left="179" width="4" height="15" font="14">:</text>
<text top="637" left="188" width="114" height="11" font="20">RECOMMENDATION</text>
<text top="661" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="673" left="82" width="10" height="10" font="18">1.</text>
<text top="673" left="100" width="314" height="12" font="18">Diuretics are recommended in patients with HFrEF who have</text>
<text top="689" left="100" width="65" height="10" font="18">evidence of</text>
<text top="686" left="174" width="240" height="16" font="18">ﬂuid retention, unless contraindicated, to</text>
<text top="706" left="100" width="220" height="12" font="18">improve symptoms. (Level of Evidence: C)</text>
<text top="731" left="79" width="335" height="13" font="14">Diuretics inhibit the reabsorption of sodium or chloride at</text>
<text top="749" left="64" width="29" height="13" font="14">speci</text>
<text top="745" left="93" width="321" height="18" font="14">ﬁc sites in the renal tubules. Bumetanide, furosemide,</text>
<text top="767" left="64" width="350" height="13" font="14">and torsemide act at the loop of Henle (thus, the term loop</text>
<text top="785" left="64" width="350" height="13" font="14">diuretics), whereas thiazides, metolazone, and potassium-</text>
<text top="803" left="64" width="350" height="13" font="14">sparing agents (e.g., spironolactone) act in the distal portion</text>
<text top="821" left="64" width="74" height="13" font="14">of the tubule</text>
<text top="821" left="143" width="55" height="13" font="15"><a href="e147.full.html#74">(427,428)</a></text>
<text top="821" left="199" width="215" height="13" font="14"><a href="e147.full.html#74">. </a>Loop diuretics have emerged as the</text>
<text top="839" left="64" width="350" height="13" font="14">preferred diuretic agents for use in most patients with HF.</text>
<text top="857" left="64" width="350" height="13" font="14">Thiazide diuretics may be considered in hypertensive patients</text>
<text top="874" left="64" width="106" height="13" font="14">with HF and mild</text>
<text top="871" left="176" width="238" height="18" font="14">ﬂuid retention because they confer more</text>
<text top="892" left="64" width="196" height="13" font="14">persistent antihypertensive effects.</text>
<text top="910" left="79" width="335" height="13" font="14">Controlled trials have demonstrated the ability of diuretic</text>
<text top="928" left="64" width="350" height="13" font="14">drugs to increase urinary sodium excretion and decrease</text>
<text top="946" left="64" width="94" height="13" font="14">physical signs of</text>
<text top="942" left="162" width="190" height="18" font="14">ﬂuid retention in patients with HF</text>
<text top="946" left="355" width="55" height="13" font="15"><a href="e147.full.html#74">(429,430)</a></text>
<text top="946" left="410" width="4" height="13" font="14">.</text>
<text top="964" left="64" width="350" height="13" font="14">In intermediate-term studies, diuretics have been shown to</text>
<text top="982" left="64" width="350" height="13" font="14">improve symptoms and exercise tolerance in patients with HF</text>
<text top="1000" left="64" width="26" height="13" font="15"><a href="e147.full.html#74">(431</a></text>
<text top="996" left="90" width="33" height="18" font="15"><a href="e147.full.html#74">–433)</a></text>
<text top="1000" left="123" width="291" height="13" font="14">; however, diuretic effects on morbidity and</text>
<text top="1018" left="64" width="350" height="13" font="14">mortality are not known. Diuretics are the only drugs used for</text>
<text top="1036" left="64" width="316" height="13" font="14">the treatment of HF that can adequately control the</text>
<text top="1032" left="388" width="26" height="18" font="14">ﬂuid</text>
<text top="1054" left="64" width="350" height="13" font="14">retention of HF. Appropriate use of diuretics is a key element</text>
<text top="1072" left="64" width="350" height="13" font="14">in the success of other drugs used for the treatment of HF. The</text>
<text top="1090" left="64" width="350" height="13" font="14">use of inappropriately low doses of diuretics will result in</text>
<text top="631" left="450" width="350" height="18" font="14">ﬂuid retention. Conversely, the use of inappropriately high</text>
<text top="653" left="450" width="350" height="13" font="14">doses of diuretics will lead to volume contraction, which can</text>
<text top="671" left="450" width="274" height="13" font="14">increase the risk of hypotension and renal insuf</text>
<text top="667" left="724" width="48" height="18" font="14">ﬁciency.</text>
<text top="699" left="450" width="350" height="15" font="14">7.3.2.1.1. Diuretics: Selection of Patients. Diuretics</text>
<text top="718" left="450" width="350" height="13" font="14">should be prescribed to all patients who have evidence of, and</text>
<text top="736" left="450" width="254" height="13" font="14">to most patients with a prior history of,</text>
<text top="733" left="712" width="88" height="18" font="14">ﬂuid retention.</text>
<text top="754" left="450" width="350" height="13" font="14">Diuretics should generally be combined with an ACE inhib-</text>
<text top="772" left="450" width="350" height="13" font="14">itor, beta blocker, and aldosterone antagonist. Few patients</text>
<text top="790" left="450" width="350" height="13" font="14">with HF will be able to maintain target weight without the use</text>
<text top="808" left="450" width="68" height="13" font="14">of diuretics.</text>
<text top="837" left="450" width="350" height="15" font="14">7.3.2.1.2. Diuretics: Initiation and Maintenance. The</text>
<text top="856" left="450" width="350" height="13" font="14">most commonly used loop diuretic for the treatment of HF is</text>
<text top="874" left="450" width="350" height="13" font="14">furosemide, but some patients respond more favorably to</text>
<text top="892" left="450" width="350" height="13" font="14">other agents in this category (e.g., bumetanide, torsemide)</text>
<text top="910" left="450" width="282" height="13" font="14">because of their increased oral bioavailability</text>
<text top="910" left="741" width="55" height="13" font="15"><a href="e147.full.html#74">(434,435)</a></text>
<text top="910" left="796" width="4" height="13" font="14"><a href="e147.full.html#74">.</a></text>
<text top="928" left="450" width="54" height="13" font="15"><a href="e147.full.html#28">Table 14</a></text>
<text top="928" left="511" width="288" height="13" font="14">lists oral diuretics recommended for use in the</text>
<text top="946" left="450" width="350" height="13" font="14">treatment of chronic HF. In outpatients with HF, diuretic</text>
<text top="964" left="450" width="350" height="13" font="14">therapy is commonly initiated with low doses, and the dose is</text>
<text top="982" left="450" width="350" height="13" font="14">increased until urine output increases and weight decreases,</text>
<text top="999" left="450" width="350" height="13" font="14">generally by 0.5 to 1.0 kg daily. Further increases in the dose</text>
<text top="1017" left="450" width="350" height="13" font="14">or frequency (i.e., twice-daily dosing) of diuretic administra-</text>
<text top="1035" left="450" width="350" height="13" font="14">tion may be required to maintain an active diuresis and sustain</text>
<text top="1053" left="450" width="350" height="13" font="14">weight loss. The ultimate goal of diuretic treatment is to</text>
<text top="1071" left="450" width="175" height="13" font="14">eliminate clinical evidence of</text>
<text top="1067" left="632" width="168" height="18" font="14">ﬂuid retention. Diuretics are</text>
<text top="1089" left="450" width="350" height="13" font="14">generally combined with moderate dietary sodium restriction.</text>
<text top="123" left="392" width="81" height="11" font="21"><b>HF<i>r</i></b><b>EF Stage C</b></text>
<text top="137" left="382" width="100" height="11" font="21"><b>NYHA Class I </b>– <b>IV</b></text>
<text top="152" left="404" width="56" height="11" font="22"><i><b>Treatment:</b></i></text>
<text top="328" left="547" width="121" height="9" font="24">For NYHA class II-IV patients.</text>
<text top="340" left="549" width="116" height="9" font="24">Provided estimated creatinine</text>
<text top="351" left="541" width="133" height="9" font="24">&gt;30 mL/min and K+ &lt;5.0 mEq/dL</text>
<text top="328" left="376" width="112" height="9" font="24">For persistently symptomatic</text>
<text top="340" left="394" width="75" height="9" font="24">African Americans,</text>
<text top="351" left="396" width="74" height="9" font="24">NYHA class III-IV</text>
<text top="233" left="402" width="60" height="9" font="25"><i><b>Class I, LOE A</b></i></text>
<text top="245" left="393" width="78" height="9" font="24">ACEI or ARB <b>AND</b></text>
<text top="256" left="407" width="50" height="9" font="24">Beta Blocker</text>
<text top="486" left="226" width="60" height="9" font="25"><i><b>Class I, LOE C</b></i></text>
<text top="497" left="228" width="58" height="9" font="24">Loop Diuretics</text>
<text top="486" left="402" width="60" height="9" font="25"><i><b>Class I, LOE A</b></i></text>
<text top="497" left="402" width="60" height="9" font="24">Hydral-Nitrates</text>
<text top="480" left="577" width="60" height="9" font="25"><i><b>Class I, LOE A</b></i></text>
<text top="492" left="584" width="47" height="9" font="24">Aldosterone</text>
<text top="503" left="586" width="42" height="9" font="24">Antagonist</text>
<text top="407" left="424" width="16" height="9" font="24">Add</text>
<text top="407" left="248" width="16" height="9" font="24">Add</text>
<text top="407" left="599" width="16" height="9" font="24">Add</text>
<text top="334" left="209" width="95" height="9" font="24">For all volume overload,</text>
<text top="346" left="205" width="103" height="9" font="24">NYHA class II-IV patients</text>
<text top="543" left="64" width="725" height="16" font="4">Figure 1. Stage C HFrEF: evidence-based, guideline-directed medical therapy. ACEI indicates angiotensin-converting enzyme inhibitor;</text>
<text top="559" left="64" width="205" height="11" font="4">ARB, angiotensin-receptor blocker; HF</text>
<text top="556" left="269" width="531" height="16" font="4">rEF, heart failure with reduced ejection fraction; Hydral-Nitrates, hydralazine and isosorbide dinitrate;</text>
<text top="573" left="64" width="349" height="11" font="4">LOE, Level of Evidence; and NYHA, New York Heart Association.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e173</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1160" width="864">
<text top="756" left="64" width="30" height="13" font="14">Once</text>
<text top="752" left="99" width="315" height="18" font="14">ﬂuid retention has resolved, treatment with the diuretic</text>
<text top="774" left="64" width="350" height="13" font="14">should be maintained in some patients to prevent the recurrence</text>
<text top="791" left="64" width="318" height="13" font="14">of volume overload. Patients are commonly prescribed a</text>
<text top="788" left="386" width="28" height="18" font="14">ﬁxed</text>
<text top="809" left="64" width="350" height="13" font="14">dose of diuretic, but the dose of these drugs frequently may need</text>
<text top="827" left="64" width="350" height="13" font="14">adjustment. In many cases, this adjustment can be accom-</text>
<text top="845" left="64" width="350" height="13" font="14">plished by having patients record their weight each day and</text>
<text top="863" left="64" width="350" height="13" font="14">adjusting the diuretic dosage if weight increases or decreases</text>
<text top="881" left="64" width="82" height="13" font="14">beyond a speci</text>
<text top="877" left="146" width="268" height="18" font="14">ﬁed range. Patients may become unresponsive to</text>
<text top="899" left="64" width="350" height="13" font="14">high doses of diuretic drugs if they consume large amounts</text>
<text top="917" left="64" width="350" height="13" font="14">of dietary sodium, are taking agents that can block the effects</text>
<text top="935" left="64" width="242" height="13" font="14">of diuretics (e.g., nonsteroidal anti-in</text>
<text top="931" left="306" width="108" height="18" font="14">ﬂammatory drugs</text>
<text top="953" left="64" width="287" height="13" font="14">[NSAIDs], including cyclooxygenase-2 inhibitors)</text>
<text top="953" left="355" width="26" height="13" font="15"><a href="e147.full.html#74">(436</a></text>
<text top="949" left="381" width="33" height="18" font="15"><a href="e147.full.html#74">–438)</a></text>
<text top="971" left="64" width="88" height="13" font="14">or have a signi</text>
<text top="967" left="153" width="261" height="18" font="14">ﬁcant impairment of renal function or perfu-</text>
<text top="989" left="64" width="23" height="13" font="14">sion</text>
<text top="989" left="90" width="30" height="13" font="15"><a href="e147.full.html#74">(434)</a></text>
<text top="989" left="120" width="293" height="13" font="14">. Diuretic resistance can generally be overcome by the</text>
<text top="1007" left="64" width="350" height="13" font="14">intravenous administration of diuretics (including the use of</text>
<text top="1025" left="64" width="120" height="13" font="14">continuous infusions)</text>
<text top="1025" left="187" width="30" height="13" font="15"><a href="e147.full.html#74">(439)</a></text>
<text top="1025" left="220" width="194" height="13" font="14">or combination of different diuretic</text>
<text top="1043" left="64" width="257" height="13" font="14">classes (e.g., metolazone with a loop diuretic)</text>
<text top="1043" left="325" width="26" height="13" font="15"><a href="e147.full.html#74">(440</a></text>
<text top="1039" left="351" width="33" height="18" font="15"><a href="e147.full.html#74">–443)</a></text>
<text top="1043" left="384" width="4" height="13" font="14"><a href="e147.full.html#74">.</a></text>
<text top="1067" left="64" width="350" height="15" font="14">7.3.2.1.3. Diuretics: Risks of Treatment. The principal</text>
<text top="1086" left="64" width="315" height="13" font="14">adverse effects of diuretics include electrolyte and</text>
<text top="1082" left="388" width="26" height="18" font="14">ﬂuid</text>
<text top="103" left="450" width="350" height="13" font="14">depletion, as well as hypotension and azotemia. Diuretics can</text>
<text top="121" left="450" width="350" height="13" font="14">cause the depletion of potassium and magnesium, which can</text>
<text top="139" left="450" width="285" height="13" font="14">predispose patients to serious cardiac arrhythmias</text>
<text top="139" left="739" width="30" height="13" font="15"><a href="e147.full.html#74">(444)</a></text>
<text top="139" left="770" width="30" height="13" font="14"><a href="e147.full.html#74">. </a>The</text>
<text top="157" left="450" width="350" height="13" font="14">risk of electrolyte depletion is markedly enhanced when 2</text>
<text top="175" left="450" width="195" height="13" font="14">diuretics are used in combination.</text>
<text top="193" left="465" width="20" height="13" font="14">See</text>
<text top="193" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 17</a></text>
<text top="193" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="211" left="450" width="53" height="13" font="14">diuretics.</text>
<text top="242" left="450" width="46" height="15" font="14">7.3.2.2.</text>
<text top="245" left="503" width="95" height="11" font="20">ACE INHIBITORS</text>
<text top="242" left="599" width="4" height="15" font="14">:</text>
<text top="245" left="608" width="114" height="11" font="20">RECOMMENDATION</text>
<text top="268" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="280" left="468" width="10" height="10" font="18">1.</text>
<text top="280" left="485" width="314" height="12" font="18">ACE inhibitors are recommended in patients with HFrEF and</text>
<text top="297" left="485" width="314" height="10" font="18">current or prior symptoms, unless contraindicated, to</text>
<text top="313" left="485" width="169" height="10" font="18">reduce morbidity and mortality</text>
<text top="313" left="661" width="50" height="10" font="5"><a href="e147.full.html#72">(343,412</a></text>
<text top="310" left="711" width="32" height="16" font="5"><a href="e147.full.html#72">–414)</a></text>
<text top="313" left="743" width="56" height="12" font="18">. (Level of</text>
<text top="330" left="485" width="65" height="12" font="18">Evidence: A)</text>
<text top="361" left="450" width="350" height="15" font="14">7.3.2.2.1. ACE Inhibitors: Selection of Patients. ACE</text>
<text top="380" left="450" width="350" height="13" font="14">inhibitors can reduce the risk of death and reduce hospitali-</text>
<text top="398" left="450" width="152" height="13" font="14">zation in HFrEF. The bene</text>
<text top="395" left="602" width="197" height="18" font="14">ﬁts of ACE inhibition were seen in</text>
<text top="416" left="450" width="350" height="13" font="14">patients with mild, moderate, or severe symptoms of HF and in</text>
<text top="434" left="450" width="350" height="13" font="14">patients with or without CAD. ACE inhibitors should be</text>
<text top="452" left="450" width="350" height="13" font="14">prescribed to all patients with HFrEF. Unless there is</text>
<text top="470" left="450" width="350" height="13" font="14">a contraindication, ACE inhibitors are used together with a beta</text>
<text top="488" left="450" width="350" height="13" font="14">blocker. Patients should not be given an ACE inhibitor if they</text>
<text top="506" left="450" width="350" height="13" font="14">have experienced life-threatening adverse reactions (i.e.,</text>
<text top="524" left="450" width="350" height="13" font="14">angioedema) during previous medication exposure or if they</text>
<text top="542" left="450" width="350" height="13" font="14">are pregnant or plan to become pregnant. Clinicians should</text>
<text top="560" left="450" width="350" height="13" font="14">prescribe an ACE inhibitor with caution if the patient has</text>
<text top="578" left="450" width="350" height="13" font="14">very low systemic blood pressures (systolic blood pressure</text>
<text top="592" left="450" width="350" height="18" font="14">&lt;80 mm Hg), markedly increased serum levels of creatinine</text>
<text top="614" left="450" width="5" height="13" font="14">(</text>
<text top="610" left="454" width="345" height="18" font="14">&gt;3 mg/dL), bilateral renal artery stenosis, or elevated levels of</text>
<text top="632" left="450" width="99" height="13" font="14">serum potassium (</text>
<text top="628" left="549" width="77" height="18" font="14">&gt;5.0 mEq/L).</text>
<text top="660" left="450" width="349" height="15" font="14">7.3.2.2.2. ACE Inhibitors: Initiation and Maintenance.</text>
<text top="680" left="450" width="350" height="13" font="14">The available data suggest that there are no differences among</text>
<text top="697" left="450" width="350" height="13" font="14">available ACE inhibitors in their effects on symptoms or</text>
<text top="715" left="450" width="45" height="13" font="14">survival</text>
<text top="715" left="501" width="30" height="13" font="15"><a href="e147.full.html#74">(414)</a></text>
<text top="715" left="531" width="268" height="13" font="14">. Treatment with an ACE inhibitor should be</text>
<text top="733" left="450" width="135" height="13" font="14">initiated at low doses <a href="e147.full.html#29">(</a></text>
<text top="733" left="585" width="52" height="13" font="15"><a href="e147.full.html#29">Table 15</a></text>
<text top="733" left="637" width="163" height="13" font="14"><a href="e147.full.html#29">), </a>followed by gradual dose</text>
<text top="751" left="450" width="350" height="13" font="14">increments if lower doses have been well tolerated. Renal</text>
<text top="769" left="450" width="350" height="13" font="14">function and serum potassium should be assessed within 1 to</text>
<text top="787" left="450" width="350" height="13" font="14">2 weeks of initiation of therapy and periodically thereafter,</text>
<text top="805" left="450" width="350" height="13" font="14">especially in patients with preexisting hypotension, hypona-</text>
<text top="823" left="450" width="350" height="13" font="14">tremia, diabetes mellitus, azotemia, or in those taking potas-</text>
<text top="841" left="450" width="350" height="13" font="14">sium supplements. In controlled clinical trials that were</text>
<text top="859" left="450" width="350" height="13" font="14">designed to evaluate survival, the dose of the ACE inhibitor</text>
<text top="877" left="450" width="192" height="13" font="14">was not determined by a patient</text>
<text top="873" left="642" width="158" height="18" font="14">’s therapeutic response but</text>
<text top="895" left="450" width="350" height="13" font="14">was increased until the predetermined target dose was reached</text>
<text top="913" left="450" width="80" height="13" font="15"><a href="e147.full.html#72">(343,413,414)</a></text>
<text top="913" left="530" width="270" height="13" font="14"><a href="e147.full.html#72">. </a>Clinicians should attempt to use doses that</text>
<text top="931" left="450" width="350" height="13" font="14">have been shown to reduce the risk of cardiovascular events in</text>
<text top="949" left="450" width="350" height="13" font="14">clinical trials. If these target doses of an ACE inhibitor cannot</text>
<text top="966" left="450" width="350" height="13" font="14">be used or are poorly tolerated, intermediate doses should be</text>
<text top="984" left="450" width="350" height="13" font="14">used with the expectation that there are likely to be only small</text>
<text top="1002" left="450" width="95" height="13" font="14">differences in ef</text>
<text top="999" left="545" width="255" height="18" font="14">ﬁcacy between low and high doses. Abrupt</text>
<text top="1020" left="450" width="350" height="13" font="14">withdrawal of treatment with an ACE inhibitor can lead to</text>
<text top="1038" left="450" width="256" height="13" font="14">clinical deterioration and should be avoided.</text>
<text top="1066" left="450" width="350" height="15" font="14">7.3.2.2.3. ACE Inhibitors: Risks of Treatment. The</text>
<text top="1085" left="450" width="350" height="13" font="14">majority of the adverse reactions of ACE inhibitors can be</text>
<text top="103" left="64" width="293" height="12" font="9">Table 14. Oral Diuretics Recommended for Use in the</text>
<text top="119" left="64" width="133" height="12" font="9">Treatment of Chronic HF</text>
<text top="181" left="64" width="21" height="11" font="4">Drug</text>
<text top="181" left="189" width="86" height="11" font="4">Initial Daily Dose(s)</text>
<text top="151" left="302" width="44" height="11" font="4">Maximum</text>
<text top="166" left="313" width="22" height="11" font="4">Total</text>
<text top="181" left="300" width="48" height="11" font="4">Daily Dose</text>
<text top="166" left="371" width="37" height="11" font="4">Duration</text>
<text top="181" left="370" width="40" height="11" font="4">of Action</text>
<text top="201" left="64" width="63" height="11" font="4">Loop diuretics</text>
<text top="220" left="76" width="53" height="11" font="4">Bumetanide</text>
<text top="220" left="188" width="88" height="11" font="4">0.5 to 1.0 mg once</text>
<text top="235" left="211" width="37" height="11" font="4">or twice</text>
<text top="220" left="309" width="29" height="11" font="4">10 mg</text>
<text top="220" left="371" width="37" height="11" font="4">4 to 6 h</text>
<text top="254" left="76" width="52" height="11" font="4">Furosemide</text>
<text top="254" left="184" width="95" height="11" font="4">20 to 40 mg once or</text>
<text top="269" left="218" width="24" height="11" font="4">twice</text>
<text top="254" left="307" width="35" height="11" font="4">600 mg</text>
<text top="254" left="371" width="37" height="11" font="4">6 to 8 h</text>
<text top="289" left="76" width="46" height="11" font="4">Torsemide</text>
<text top="289" left="191" width="82" height="11" font="4">10 to 20 mg once</text>
<text top="289" left="307" width="35" height="11" font="4">200 mg</text>
<text top="289" left="365" width="49" height="11" font="4">12 to 16 h</text>
<text top="308" left="64" width="78" height="11" font="4">Thiazide diuretics</text>
<text top="328" left="76" width="63" height="11" font="4">Chlorothiazide</text>
<text top="328" left="185" width="94" height="11" font="4">250 to 500 mg once</text>
<text top="343" left="211" width="37" height="11" font="4">or twice</text>
<text top="328" left="302" width="44" height="11" font="4">1,000 mg</text>
<text top="328" left="368" width="43" height="11" font="4">6 to 12 h</text>
<text top="362" left="76" width="64" height="11" font="4">Chlorthalidone</text>
<text top="362" left="182" width="100" height="11" font="4">12.5 to 25.0 mg once</text>
<text top="362" left="307" width="35" height="11" font="4">100 mg</text>
<text top="362" left="365" width="49" height="11" font="4">24 to 72 h</text>
<text top="381" left="76" width="87" height="11" font="4">Hydrochlorothiazide</text>
<text top="381" left="184" width="95" height="11" font="4">25 mg once or twice</text>
<text top="381" left="307" width="35" height="11" font="4">200 mg</text>
<text top="381" left="368" width="43" height="11" font="4">6 to 12 h</text>
<text top="401" left="76" width="51" height="11" font="4">Indapamide</text>
<text top="401" left="203" width="57" height="11" font="4">2.5 mg once</text>
<text top="401" left="312" width="24" height="11" font="4">5 mg</text>
<text top="401" left="379" width="21" height="11" font="4">36 h</text>
<text top="420" left="76" width="51" height="11" font="4">Metolazone</text>
<text top="420" left="203" width="57" height="11" font="4">2.5 mg once</text>
<text top="420" left="309" width="29" height="11" font="4">20 mg</text>
<text top="420" left="365" width="49" height="11" font="4">12 to 24 h</text>
<text top="440" left="64" width="124" height="11" font="4">Potassium-sparing <a href="e147.full.html#28">diuretics</a></text>
<text top="440" left="188" width="4" height="11" font="5"><a href="e147.full.html#28">*</a></text>
<text top="459" left="76" width="42" height="11" font="4">Amiloride</text>
<text top="459" left="207" width="49" height="11" font="4">5 mg once</text>
<text top="459" left="309" width="29" height="11" font="4">20 mg</text>
<text top="459" left="379" width="21" height="11" font="4">24 h</text>
<text top="479" left="76" width="66" height="11" font="4">Spironolactone</text>
<text top="479" left="182" width="100" height="11" font="4">12.5 to 25.0 mg once</text>
<text top="479" left="307" width="29" height="11" font="4">50 <a href="e147.full.html#28">mg</a></text>
<text top="476" left="336" width="5" height="16" font="5"><a href="e147.full.html#28">y</a></text>
<text top="479" left="371" width="37" height="11" font="4">1 to 3 h</text>
<text top="498" left="76" width="53" height="11" font="4">Triamterene</text>
<text top="498" left="189" width="85" height="11" font="4">50 to 75 mg twice</text>
<text top="498" left="307" width="35" height="11" font="4">200 mg</text>
<text top="498" left="371" width="37" height="11" font="4">7 to 9 h</text>
<text top="517" left="64" width="130" height="11" font="4">Sequential nephron blockade</text>
<text top="537" left="76" width="51" height="11" font="4"><a href="e147.full.html#28">Metolazone</a></text>
<text top="534" left="127" width="5" height="16" font="5"><a href="e147.full.html#28">z</a></text>
<text top="537" left="185" width="94" height="11" font="4">2.5 to 10.0 mg once</text>
<text top="552" left="191" width="78" height="11" font="4">plus loop diuretic</text>
<text top="537" left="316" width="16" height="11" font="4">N/A</text>
<text top="537" left="382" width="16" height="11" font="4">N/A</text>
<text top="571" left="76" width="87" height="11" font="4">Hydrochlorothiazide</text>
<text top="571" left="188" width="88" height="11" font="4">25 to 100 mg once</text>
<text top="586" left="189" width="81" height="11" font="4">or twice plus loop</text>
<text top="601" left="213" width="33" height="11" font="4">diuretic</text>
<text top="571" left="316" width="16" height="11" font="4">N/A</text>
<text top="571" left="382" width="16" height="11" font="4">N/A</text>
<text top="621" left="76" width="80" height="11" font="4">Chlorothiazide (IV)</text>
<text top="621" left="181" width="102" height="11" font="4">500 to 1,000 mg once</text>
<text top="636" left="192" width="78" height="11" font="4">plus loop diuretic</text>
<text top="621" left="316" width="16" height="11" font="4">N/A</text>
<text top="621" left="382" width="16" height="11" font="4">N/A</text>
<text top="657" left="76" width="305" height="11" font="4">*Eplerenone, although also a diuretic, is primarily used in chronic HF.</text>
<text top="669" left="75" width="288" height="16" font="4"><a href="e147.full.html#28">yHigher </a>doses may occasionally be used with close monitoring.</text>
<text top="684" left="76" width="22" height="16" font="4"><a href="e147.full.html#28">zSee</a></text>
<text top="687" left="101" width="51" height="11" font="5"><a href="e147.full.html#49">Section 8.4</a></text>
<text top="687" left="152" width="3" height="11" font="4">.</text>
<text top="702" left="78" width="302" height="11" font="4">HF indicates heart failure; IV, intravenous; and N/A, not applicable.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e174</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1160" width="864">
<text top="789" left="64" width="350" height="13" font="14">attributed to the 2 principal pharmacological actions of these</text>
<text top="807" left="64" width="350" height="13" font="14">drugs: those related to angiotensin suppression and those</text>
<text top="825" left="64" width="350" height="13" font="14">related to kinin potentiation. Other types of adverse effects</text>
<text top="843" left="64" width="350" height="13" font="14">may also occur (e.g., rash and taste disturbances). Up to 20% of</text>
<text top="861" left="64" width="252" height="13" font="14">patients will experience an ACE inhibitor</text>
<text top="857" left="317" width="97" height="18" font="14">–induced cough.</text>
<text top="879" left="64" width="350" height="13" font="14">With the use of ACE inhibitors, particular care should be given</text>
<text top="896" left="64" width="73" height="13" font="14">to the patient</text>
<text top="893" left="137" width="277" height="18" font="14">’s volume status, renal function, and concomitant</text>
<text top="914" left="64" width="76" height="13" font="14">medications (</text>
<text top="914" left="140" width="90" height="13" font="15"><a href="e147.full.html#27">Sections 7.3.2.1</a></text>
<text top="914" left="233" width="20" height="13" font="14">and</text>
<text top="914" left="257" width="39" height="13" font="15"><a href="e147.full.html#36">7.3.2.9</a></text>
<text top="914" left="296" width="118" height="13" font="14"><a href="e147.full.html#36">). </a>However, most HF</text>
<text top="932" left="64" width="269" height="13" font="14">patients (85% to 90%) can tolerate these drugs.</text>
<text top="950" left="79" width="20" height="13" font="14">See</text>
<text top="950" left="106" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 18</a></text>
<text top="950" left="280" width="134" height="13" font="14">for additional data on</text>
<text top="968" left="64" width="89" height="13" font="14">ACE inhibitors.</text>
<text top="996" left="64" width="46" height="15" font="14">7.3.2.3.</text>
<text top="999" left="118" width="28" height="11" font="20">ARBS</text>
<text top="996" left="146" width="4" height="15" font="14">:</text>
<text top="999" left="155" width="120" height="11" font="20">RECOMMENDATIONS</text>
<text top="1022" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="1034" left="82" width="10" height="10" font="18">1.</text>
<text top="1034" left="100" width="314" height="12" font="18">ARBs are recommended in patients with HFrEF with current</text>
<text top="1051" left="100" width="314" height="10" font="18">or prior symptoms who are ACE inhibitor intolerant, unless</text>
<text top="1067" left="100" width="86" height="10" font="18">contraindicated,</text>
<text top="1067" left="199" width="11" height="10" font="18">to</text>
<text top="1067" left="223" width="36" height="10" font="18">reduce</text>
<text top="1067" left="272" width="49" height="10" font="18">morbidity</text>
<text top="1067" left="335" width="19" height="10" font="18">and</text>
<text top="1067" left="367" width="47" height="10" font="18">mortality</text>
<text top="1084" left="100" width="104" height="10" font="5"><a href="e147.full.html#66">(108,345,415,450)</a></text>
<text top="1084" left="204" width="120" height="12" font="18">. (Level of Evidence: A)</text>
<text top="792" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="804" left="468" width="10" height="10" font="18">1.</text>
<text top="804" left="485" width="314" height="10" font="18">ARBs are reasonable to reduce morbidity and mortality as</text>
<text top="820" left="485" width="192" height="10" font="18">alternatives to ACE inhibitors as</text>
<text top="817" left="686" width="113" height="16" font="18">ﬁrst-line therapy for</text>
<text top="836" left="485" width="314" height="12" font="18">patients with HFrEF, especially for patients already taking</text>
<text top="853" left="485" width="29" height="10" font="18">ARBs</text>
<text top="853" left="528" width="14" height="10" font="18">for</text>
<text top="853" left="555" width="28" height="10" font="18">other</text>
<text top="853" left="596" width="61" height="10" font="18">indications,</text>
<text top="853" left="670" width="34" height="10" font="18">unless</text>
<text top="853" left="717" width="82" height="10" font="18">contraindicated</text>
<text top="869" left="485" width="26" height="10" font="5"><a href="e147.full.html#74">(451</a></text>
<text top="866" left="511" width="32" height="16" font="5"><a href="e147.full.html#74">–456)</a></text>
<text top="869" left="543" width="120" height="12" font="18"><a href="e147.full.html#74">. </a>(Level of Evidence: A)</text>
<text top="893" left="450" width="45" height="8" font="17">CLASS IIb</text>
<text top="905" left="468" width="10" height="10" font="18">1.</text>
<text top="905" left="485" width="314" height="10" font="18">Addition of an ARB may be considered in persistently</text>
<text top="922" left="485" width="314" height="12" font="18">symptomatic patients with HFrEF who are already being</text>
<text top="938" left="485" width="314" height="10" font="18">treated with an ACE inhibitor and a beta blocker in whom an</text>
<text top="955" left="485" width="62" height="10" font="18">aldosterone</text>
<text top="955" left="558" width="56" height="10" font="18">antagonist</text>
<text top="955" left="625" width="9" height="10" font="18">is</text>
<text top="955" left="644" width="17" height="10" font="18">not</text>
<text top="955" left="672" width="49" height="10" font="18">indicated</text>
<text top="955" left="731" width="10" height="10" font="18">or</text>
<text top="955" left="752" width="48" height="10" font="18">tolerated</text>
<text top="971" left="485" width="55" height="10" font="5"><a href="e147.full.html#74">(420,457)</a></text>
<text top="971" left="540" width="120" height="12" font="18">. (Level of Evidence: A)</text>
<text top="995" left="450" width="73" height="8" font="17">CLASS III: Harm</text>
<text top="1007" left="468" width="10" height="10" font="18">1.</text>
<text top="1007" left="485" width="314" height="12" font="18">Routine combined use of an ACE inhibitor, ARB, and aldo-</text>
<text top="1023" left="485" width="314" height="10" font="18">sterone antagonist is potentially harmful for patients with</text>
<text top="1040" left="485" width="152" height="12" font="18">HFrEF. (Level of Evidence: C)</text>
<text top="1065" left="465" width="335" height="13" font="14">ARBs were developed with the rationale that a) angiotensin</text>
<text top="1083" left="450" width="350" height="13" font="14">II production continues in the presence of ACE inhibition,</text>
<text top="103" left="64" width="264" height="12" font="9">Table 15. Drugs Commonly Used for Stage C HF</text>
<text top="100" left="328" width="17" height="17" font="9">rEF</text>
<text top="149" left="64" width="21" height="11" font="4">Drug</text>
<text top="149" left="325" width="86" height="11" font="4">Initial Daily Dose(s)</text>
<text top="149" left="514" width="80" height="11" font="4">Maximum Dose(s)</text>
<text top="134" left="677" width="111" height="11" font="4">Mean Doses Achieved in</text>
<text top="149" left="702" width="60" height="11" font="4">Clinical Trials</text>
<text top="169" left="64" width="62" height="11" font="4">ACE inhibitors</text>
<text top="189" left="76" width="39" height="11" font="4">Captopril</text>
<text top="189" left="330" width="76" height="11" font="4">6.25 mg 3 times</text>
<text top="189" left="521" width="67" height="11" font="4">50 mg 3 times</text>
<text top="189" left="693" width="53" height="11" font="4">122.7 mg/d</text>
<text top="189" left="749" width="23" height="11" font="5"><a href="e147.full.html#74">(422)</a></text>
<text top="208" left="76" width="38" height="11" font="4">Enalapril</text>
<text top="208" left="338" width="60" height="11" font="4">2.5 mg twice</text>
<text top="208" left="512" width="85" height="11" font="4">10 to 20 mg twice</text>
<text top="208" left="696" width="47" height="11" font="4">16.6 mg/d</text>
<text top="208" left="746" width="23" height="11" font="5"><a href="e147.full.html#74">(413)</a></text>
<text top="228" left="76" width="43" height="11" font="4">Fosinopril</text>
<text top="228" left="329" width="77" height="11" font="4">5 to 10 mg once</text>
<text top="228" left="527" width="55" height="11" font="4">40 mg once</text>
<text top="228" left="725" width="16" height="11" font="4">N/A</text>
<text top="247" left="76" width="40" height="11" font="4">Lisinopril</text>
<text top="247" left="328" width="80" height="11" font="4">2.5 to 5 mg once</text>
<text top="247" left="513" width="82" height="11" font="4">20 to 40 mg once</text>
<text top="247" left="678" width="83" height="11" font="4">32.5 to 35.0 mg/d</text>
<text top="247" left="765" width="23" height="11" font="5"><a href="e147.full.html#74">(445)</a></text>
<text top="266" left="76" width="47" height="11" font="4">Perindopril</text>
<text top="266" left="343" width="49" height="11" font="4">2 mg once</text>
<text top="266" left="516" width="77" height="11" font="4">8 to 16 mg once</text>
<text top="266" left="725" width="16" height="11" font="4">N/A</text>
<text top="286" left="76" width="39" height="11" font="4">Quinapril</text>
<text top="286" left="342" width="51" height="11" font="4">5 mg twice</text>
<text top="286" left="526" width="57" height="11" font="4">20 mg twice</text>
<text top="286" left="725" width="16" height="11" font="4">N/A</text>
<text top="305" left="76" width="37" height="11" font="4">Ramipril</text>
<text top="305" left="321" width="94" height="11" font="4">1.25 to 2.5 mg once</text>
<text top="305" left="527" width="55" height="11" font="4">10 mg once</text>
<text top="305" left="725" width="16" height="11" font="4">N/A</text>
<text top="325" left="76" width="52" height="11" font="4">Trandolapril</text>
<text top="325" left="343" width="49" height="11" font="4">1 mg once</text>
<text top="325" left="530" width="49" height="11" font="4">4 mg once</text>
<text top="325" left="725" width="16" height="11" font="4">N/A</text>
<text top="344" left="64" width="23" height="11" font="4">ARBs</text>
<text top="364" left="76" width="55" height="11" font="4">Candesartan</text>
<text top="364" left="332" width="71" height="11" font="4">4 to 8 mg once</text>
<text top="364" left="527" width="55" height="11" font="4">32 mg once</text>
<text top="364" left="700" width="38" height="11" font="4">24 mg/d</text>
<text top="364" left="742" width="23" height="11" font="5"><a href="e147.full.html#74">(420)</a></text>
<text top="383" left="76" width="38" height="11" font="4">Losartan</text>
<text top="383" left="326" width="82" height="11" font="4">25 to 50 mg once</text>
<text top="383" left="510" width="88" height="11" font="4">50 to 150 mg once</text>
<text top="383" left="697" width="44" height="11" font="4">129 mg/d</text>
<text top="383" left="745" width="23" height="11" font="5"><a href="e147.full.html#74">(421)</a></text>
<text top="402" left="76" width="41" height="11" font="4">Valsartan</text>
<text top="402" left="325" width="85" height="11" font="4">20 to 40 mg twice</text>
<text top="402" left="523" width="63" height="11" font="4">160 mg twice</text>
<text top="402" left="697" width="44" height="11" font="4">254 mg/d</text>
<text top="402" left="745" width="23" height="11" font="5"><a href="e147.full.html#66">(108)</a></text>
<text top="422" left="64" width="107" height="11" font="4">Aldosterone antagonists</text>
<text top="441" left="76" width="66" height="11" font="4">Spironolactone</text>
<text top="441" left="318" width="100" height="11" font="4">12.5 to 25.0 mg once</text>
<text top="441" left="507" width="95" height="11" font="4">25 mg once or twice</text>
<text top="441" left="700" width="38" height="11" font="4">26 mg/d</text>
<text top="441" left="742" width="23" height="11" font="5"><a href="e147.full.html#74">(425)</a></text>
<text top="461" left="76" width="49" height="11" font="4">Eplerenone</text>
<text top="461" left="340" width="55" height="11" font="4">25 mg once</text>
<text top="461" left="527" width="55" height="11" font="4">50 mg once</text>
<text top="461" left="696" width="47" height="11" font="4">42.6 mg/d</text>
<text top="461" left="746" width="23" height="11" font="5"><a href="e147.full.html#74">(446)</a></text>
<text top="480" left="64" width="61" height="11" font="4">Beta blockers</text>
<text top="500" left="76" width="44" height="11" font="4">Bisoprolol</text>
<text top="500" left="336" width="63" height="11" font="4">1.25 mg once</text>
<text top="500" left="527" width="55" height="11" font="4">10 mg once</text>
<text top="500" left="699" width="41" height="11" font="4">8.6 mg/d</text>
<text top="500" left="744" width="23" height="11" font="5"><a href="e147.full.html#67">(117)</a></text>
<text top="519" left="76" width="44" height="11" font="4">Carvedilol</text>
<text top="519" left="332" width="71" height="11" font="4">3.125 mg twice</text>
<text top="519" left="526" width="57" height="11" font="4">50 mg twice</text>
<text top="519" left="700" width="38" height="11" font="4">37 mg/d</text>
<text top="519" left="742" width="23" height="11" font="5"><a href="e147.full.html#74">(447)</a></text>
<text top="538" left="76" width="60" height="11" font="4">Carvedilol CR</text>
<text top="538" left="340" width="55" height="11" font="4">10 mg once</text>
<text top="538" left="527" width="55" height="11" font="4">80 mg once</text>
<text top="538" left="725" width="16" height="11" font="4">N/A</text>
<text top="558" left="76" width="173" height="11" font="4">Metoprolol succinate extended release</text>
<text top="573" left="88" width="83" height="11" font="4">(metoprolol CR/XL)</text>
<text top="558" left="322" width="91" height="11" font="4">12.5 to 25 mg once</text>
<text top="558" left="524" width="60" height="11" font="4">200 mg once</text>
<text top="558" left="697" width="44" height="11" font="4">159 mg/d</text>
<text top="558" left="745" width="23" height="11" font="5"><a href="e147.full.html#74">(448)</a></text>
<text top="592" left="64" width="161" height="11" font="4">Hydralazine and isosorbide dinitrate</text>
<text top="612" left="76" width="107" height="11" font="4">Fixed-dose combination</text>
<text top="612" left="187" width="23" height="11" font="5"><a href="e147.full.html#74">(424)</a></text>
<text top="612" left="305" width="125" height="11" font="4">37.5 mg hydralazine/20 mg</text>
<text top="627" left="326" width="85" height="11" font="4">isosorbide dinitrate</text>
<text top="642" left="339" width="59" height="11" font="4">3 times daily</text>
<text top="612" left="472" width="165" height="11" font="4">75 mg hydralazine/40 mg isosorbide</text>
<text top="627" left="506" width="99" height="11" font="4">dinitrate 3 times daily</text>
<text top="609" left="665" width="134" height="16" font="4">w175 mg hydralazine/90 mg</text>
<text top="627" left="678" width="110" height="11" font="4">isosorbide dinitrate daily</text>
<text top="661" left="76" width="161" height="11" font="4">Hydralazine and isosorbide dinitrate</text>
<text top="661" left="241" width="23" height="11" font="5"><a href="e147.full.html#74">(449)</a></text>
<text top="661" left="309" width="118" height="11" font="4">Hydralazine: 25 to 50 mg,</text>
<text top="676" left="318" width="101" height="11" font="4">3 or 4 times daily and</text>
<text top="691" left="294" width="149" height="11" font="4">isosorbide dinitrate: 20 to 30 mg</text>
<text top="706" left="328" width="81" height="11" font="4">3 or 4 times daily</text>
<text top="661" left="472" width="165" height="11" font="4">Hydralazine: 300 mg daily in divided</text>
<text top="676" left="486" width="138" height="11" font="4">doses and isosorbide dinitrate:</text>
<text top="691" left="487" width="137" height="11" font="4">120 mg daily in divided doses</text>
<text top="661" left="724" width="16" height="11" font="4">N/A</text>
<text top="727" left="76" width="723" height="11" font="4">ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CR, controlled release; CR/XL, controlled release/extended release; HFrEF, heart</text>
<text top="742" left="64" width="281" height="11" font="4">failure with reduced ejection fraction; and N/A, not applicable.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e175</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">driven through alternative enzyme pathways and b) interfer-</text>
<text top="121" left="64" width="350" height="13" font="14">ence with the renin-angiotensin system without inhibition of</text>
<text top="139" left="64" width="225" height="13" font="14">kininase would produce all of the bene</text>
<text top="135" left="289" width="125" height="18" font="14">ﬁts of ACE inhibitors</text>
<text top="157" left="64" width="350" height="13" font="14">while minimizing the risk of adverse reactions to them.</text>
<text top="175" left="64" width="283" height="13" font="14">However, it is now known that some of the bene</text>
<text top="171" left="348" width="66" height="18" font="14">ﬁts of ACE</text>
<text top="193" left="64" width="350" height="13" font="14">inhibitors may be related to the accumulation of kinins rather</text>
<text top="211" left="64" width="350" height="13" font="14">than to the suppression of angiotensin II formation, whereas</text>
<text top="229" left="64" width="350" height="13" font="14">some of the adverse effects of ACE inhibitors in HF are</text>
<text top="247" left="64" width="310" height="13" font="14">related to the suppression of angiotensin II formation.</text>
<text top="265" left="79" width="335" height="13" font="14">In several placebo-controlled studies, long-term therapy</text>
<text top="283" left="64" width="350" height="13" font="14">with ARBs produced hemodynamic, neurohormonal, and</text>
<text top="301" left="64" width="350" height="13" font="14">clinical effects consistent with those expected after interfer-</text>
<text top="319" left="64" width="350" height="13" font="14">ence with the renin-angiotensin system. Reduced hospitali-</text>
<text top="337" left="64" width="350" height="13" font="14">zation and mortality have been demonstrated. ACE inhibitors</text>
<text top="354" left="64" width="61" height="13" font="14">remain the</text>
<text top="351" left="130" width="284" height="18" font="14">ﬁrst choice for inhibition of the renin-angiotensin</text>
<text top="372" left="64" width="350" height="13" font="14">system in systolic HF, but ARBs can now be considered</text>
<text top="390" left="64" width="138" height="13" font="14">a reasonable alternative.</text>
<text top="413" left="64" width="350" height="15" font="14">7.3.2.3.1. ARBs: Selection of Patients. ARBs are used in</text>
<text top="432" left="64" width="350" height="13" font="14">patients with HFrEF who are ACE inhibitor intolerant; an</text>
<text top="450" left="64" width="350" height="13" font="14">ACE-inhibition intolerance primarily related to cough is the</text>
<text top="468" left="64" width="350" height="13" font="14">most common indication. In addition, an ARB may be used as</text>
<text top="486" left="64" width="350" height="13" font="14">an alternative to an ACE inhibitor in patients who are already</text>
<text top="504" left="64" width="350" height="13" font="14">taking an ARB for another reason, such as hypertension, and</text>
<text top="522" left="64" width="302" height="13" font="14">who subsequently develop HF. Angioedema occurs in</text>
<text top="518" left="369" width="45" height="18" font="14">&lt;1% of</text>
<text top="540" left="64" width="350" height="13" font="14">patients who take an ACE inhibitor, but it occurs more</text>
<text top="558" left="64" width="350" height="13" font="14">frequently in blacks. Because its occurrence may be life-</text>
<text top="576" left="64" width="306" height="13" font="14">threatening, clinical suspicion of this reaction justi</text>
<text top="572" left="370" width="44" height="18" font="14">ﬁes the</text>
<text top="594" left="64" width="350" height="13" font="14">subsequent avoidance of all ACE inhibitors for the lifetime of</text>
<text top="611" left="64" width="350" height="13" font="14">the patient. ACE inhibitors should not be initiated in any patient</text>
<text top="629" left="64" width="350" height="13" font="14">with a history of angioedema. Although ARBs may be consid-</text>
<text top="647" left="64" width="350" height="13" font="14">ered as alternative therapy for patients who have developed</text>
<text top="665" left="64" width="350" height="13" font="14">angioedema while taking an ACE inhibitor, there are some</text>
<text top="683" left="64" width="350" height="13" font="14">patients who have also developed angioedema with ARBs, and</text>
<text top="701" left="64" width="350" height="13" font="14">caution is advised when substituting an ARB in a patient who</text>
<text top="719" left="64" width="350" height="13" font="14">has had angioedema associated with use of an ACE inhibitor</text>
<text top="737" left="64" width="26" height="13" font="15"><a href="e147.full.html#75">(458</a></text>
<text top="733" left="90" width="33" height="18" font="15"><a href="e147.full.html#75">–461)</a></text>
<text top="737" left="122" width="4" height="13" font="14">.</text>
<text top="760" left="64" width="350" height="15" font="14">7.3.2.3.2. ARBs: Initiation and Maintenance. When</text>
<text top="779" left="64" width="350" height="13" font="14">used, ARBs should be initiated with the starting doses shown</text>
<text top="797" left="64" width="11" height="13" font="14">in</text>
<text top="797" left="80" width="51" height="13" font="15"><a href="e147.full.html#29">Table 15</a></text>
<text top="797" left="130" width="283" height="13" font="14">. Many of the considerations with initiation of an</text>
<text top="815" left="64" width="350" height="13" font="14">ARB are similar to those with initiation of an ACE inhibitor,</text>
<text top="833" left="64" width="350" height="13" font="14">as discussed previously. Blood pressure (including postural</text>
<text top="851" left="64" width="350" height="13" font="14">blood pressure changes), renal function, and potassium should</text>
<text top="869" left="64" width="350" height="13" font="14">be reassessed within 1 to 2 weeks after initiation and followed</text>
<text top="886" left="64" width="350" height="13" font="14">closely after changes in dose. Patients with systolic blood</text>
<text top="904" left="64" width="47" height="13" font="14">pressure</text>
<text top="901" left="116" width="298" height="18" font="14">&lt;80 mm Hg, low serum sodium, diabetes mellitus,</text>
<text top="922" left="64" width="350" height="13" font="14">and impaired renal function merit close surveillance during</text>
<text top="940" left="64" width="350" height="13" font="14">therapy with inhibitors of the renin angiotensin-aldosterone</text>
<text top="958" left="64" width="350" height="13" font="14">system. Titration is generally achieved by doubling doses.</text>
<text top="976" left="64" width="350" height="13" font="14">For stable patients, it is reasonable to add therapy with beta-</text>
<text top="994" left="64" width="350" height="13" font="14">blocking agents before full target doses of either ACE</text>
<text top="1012" left="64" width="183" height="13" font="14">inhibitors or ARBs are reached.</text>
<text top="1035" left="64" width="350" height="15" font="14">7.3.2.3.3. ARBs: Risks of Treatment. The risks of ARBs</text>
<text top="1054" left="64" width="350" height="13" font="14">are attributed to suppression of angiotensin stimulation. These</text>
<text top="1072" left="64" width="350" height="13" font="14">risks of hypotension, renal dysfunction, and hyperkalemia</text>
<text top="1090" left="64" width="350" height="13" font="14">are greater when combined with another inhibitor of this</text>
<text top="103" left="450" width="350" height="13" font="14">neurohormonal axis, such as ACE inhibitors or aldosterone</text>
<text top="121" left="450" width="67" height="13" font="14">antagonists.</text>
<text top="139" left="465" width="20" height="13" font="14">See</text>
<text top="139" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 19</a></text>
<text top="139" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="157" left="450" width="35" height="13" font="14">ARBs.</text>
<text top="182" left="450" width="46" height="15" font="14">7.3.2.4.</text>
<text top="186" left="503" width="94" height="11" font="20">BETA BLOCKERS</text>
<text top="182" left="598" width="4" height="15" font="14">:</text>
<text top="186" left="607" width="114" height="11" font="20">RECOMMENDATION</text>
<text top="209" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="221" left="468" width="10" height="10" font="18">1.</text>
<text top="221" left="485" width="314" height="10" font="18">Use of 1 of the 3 beta blockers proven to reduce mortality</text>
<text top="237" left="485" width="314" height="10" font="18">(e.g., bisoprolol, carvedilol, and sustained-release metopro-</text>
<text top="254" left="485" width="314" height="10" font="18">lol succinate) is recommended for all patients with current</text>
<text top="270" left="485" width="314" height="12" font="18">or prior symptoms of HFrEF, unless contraindicated, to</text>
<text top="287" left="485" width="164" height="10" font="18">reduce morbidity and mortality</text>
<text top="287" left="654" width="50" height="10" font="5"><a href="e147.full.html#72">(346,416</a></text>
<text top="284" left="705" width="56" height="16" font="5"><a href="e147.full.html#72">–419,448)</a></text>
<text top="287" left="761" width="38" height="12" font="18">. (Level</text>
<text top="303" left="485" width="79" height="12" font="18">of Evidence: A)</text>
<text top="329" left="465" width="335" height="13" font="14">Long-term treatment with beta blockers can lessen the</text>
<text top="346" left="450" width="224" height="13" font="14">symptoms of HF, improve the patient</text>
<text top="343" left="674" width="126" height="18" font="14">’s clinical status, and</text>
<text top="364" left="450" width="111" height="13" font="14">enhance the patient</text>
<text top="361" left="561" width="171" height="18" font="14">’s overall sense of well-being</text>
<text top="364" left="737" width="26" height="13" font="15"><a href="e147.full.html#75">(462</a></text>
<text top="361" left="763" width="33" height="18" font="15"><a href="e147.full.html#75">–469)</a></text>
<text top="364" left="796" width="4" height="13" font="14"><a href="e147.full.html#75">.</a></text>
<text top="382" left="450" width="350" height="13" font="14">In addition, like ACE inhibitors, beta blockers can reduce the</text>
<text top="400" left="450" width="350" height="13" font="14">risk of death and the combined risk of death or hospitalization</text>
<text top="418" left="450" width="130" height="13" font="15"><a href="e147.full.html#67">(117,447,448,470,471)</a></text>
<text top="418" left="580" width="73" height="13" font="14"><a href="e147.full.html#67">. </a>These bene</text>
<text top="414" left="653" width="146" height="18" font="14">ﬁts of beta blockers were</text>
<text top="436" left="450" width="350" height="13" font="14">seen in patients with or without CAD and in patients with or</text>
<text top="454" left="450" width="350" height="13" font="14">without diabetes mellitus, as well as in women and blacks.</text>
<text top="472" left="450" width="350" height="13" font="14">The favorable effects of beta blockers were also observed in</text>
<text top="490" left="450" width="224" height="13" font="14">patients already taking ACE inhibitors.</text>
<text top="508" left="465" width="335" height="13" font="14">Three beta blockers have been shown to be effective in</text>
<text top="526" left="450" width="350" height="13" font="14">reducing the risk of death in patients with chronic HFrEF:</text>
<text top="544" left="450" width="350" height="13" font="14">bisoprolol and sustained-release metoprolol (succinate), which</text>
<text top="562" left="450" width="145" height="13" font="14">selectively block beta-1</text>
<text top="558" left="595" width="205" height="18" font="14">–receptors; and carvedilol, which</text>
<text top="580" left="450" width="83" height="13" font="14">blocks alpha-1</text>
<text top="576" left="533" width="267" height="18" font="14">–, beta-1–, and beta-2–receptors. Positive ﬁnd-</text>
<text top="598" left="450" width="350" height="13" font="14">ings with these 3 agents, however, should not be considered</text>
<text top="615" left="450" width="350" height="13" font="14">a beta-blocker class effect. Bucindolol lacked uniform effec-</text>
<text top="633" left="450" width="350" height="13" font="14">tiveness across different populations, and short-acting meto-</text>
<text top="651" left="450" width="350" height="13" font="14">prolol tartrate was less effective in HF clinical trials. Beta-1</text>
<text top="669" left="450" width="350" height="13" font="14">selective blocker nebivolol demonstrated a modest reduction</text>
<text top="687" left="450" width="350" height="13" font="14">in the primary endpoint of all-cause mortality or cardiovascular</text>
<text top="705" left="450" width="350" height="13" font="14">hospitalization but did not affect mortality alone in an elderly</text>
<text top="723" left="450" width="261" height="13" font="14">population that included patients with HFpEF</text>
<text top="723" left="714" width="30" height="13" font="15"><a href="e147.full.html#75">(472)</a></text>
<text top="723" left="745" width="4" height="13" font="14"><a href="e147.full.html#75">.</a></text>
<text top="747" left="450" width="350" height="15" font="14">7.3.2.4.1. Beta Blockers: Selection of Patients. Beta</text>
<text top="766" left="450" width="350" height="13" font="14">blockers should be prescribed to all patients with stable</text>
<text top="784" left="450" width="350" height="13" font="14">HFrEF unless they have a contraindication to their use or are</text>
<text top="802" left="450" width="350" height="13" font="14">intolerant of these drugs. Because of its favorable effects on</text>
<text top="820" left="450" width="276" height="13" font="14">survival and disease progression, a clinical trial</text>
<text top="816" left="725" width="74" height="18" font="14">–proven beta</text>
<text top="838" left="450" width="350" height="13" font="14">blocker should be initiated as soon as HFrEF is diagnosed.</text>
<text top="856" left="450" width="350" height="13" font="14">Even when symptoms are mild or improve with other</text>
<text top="874" left="450" width="350" height="13" font="14">therapies, beta-blocker therapy is important and should not be</text>
<text top="892" left="450" width="350" height="13" font="14">delayed until symptoms return or disease progression is</text>
<text top="910" left="450" width="350" height="13" font="14">documented. Therefore, even if patients have little disability</text>
<text top="928" left="450" width="306" height="13" font="14">and experience seemingly minimal symptomatic bene</text>
<text top="924" left="756" width="44" height="18" font="14">ﬁt, they</text>
<text top="946" left="450" width="350" height="13" font="14">should still be treated with a beta blocker to reduce the</text>
<text top="964" left="450" width="350" height="13" font="14">risks of disease progression, clinical deterioration, and sudden</text>
<text top="982" left="450" width="30" height="13" font="14">death</text>
<text top="982" left="484" width="76" height="13" font="15"><a href="e147.full.html#67">(117,448,469</a></text>
<text top="978" left="559" width="33" height="18" font="15"><a href="e147.full.html#67">–471)</a></text>
<text top="982" left="592" width="4" height="13" font="14">.</text>
<text top="1000" left="465" width="335" height="13" font="14">Patients need not take high doses of ACE inhibitors before</text>
<text top="1018" left="450" width="350" height="13" font="14">initiation of beta-blocker therapy. In patients taking a low</text>
<text top="1035" left="450" width="350" height="13" font="14">dose of an ACE inhibitor, the addition of a beta blocker</text>
<text top="1053" left="450" width="350" height="13" font="14">produces a greater improvement in symptoms and reduction</text>
<text top="1071" left="450" width="350" height="13" font="14">in the risk of death than does an increase in the dose of</text>
<text top="1089" left="450" width="350" height="13" font="14">the ACE inhibitor, even to the target doses used in clinical</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e176</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="27" size="5" family="Times" color="#005c58"/>
<text top="103" left="64" width="28" height="13" font="14">trials</text>
<text top="103" left="96" width="55" height="13" font="15"><a href="e147.full.html#74">(445,473)</a></text>
<text top="103" left="151" width="263" height="13" font="14">. In patients with a current or recent history of</text>
<text top="117" left="64" width="350" height="18" font="14">ﬂuid retention, beta blockers should not be prescribed without</text>
<text top="139" left="64" width="350" height="13" font="14">diuretics, because diuretics are needed to maintain sodium and</text>
<text top="153" left="64" width="350" height="18" font="14">ﬂuid balance and prevent the exacerbation of ﬂuid retention</text>
<text top="175" left="64" width="350" height="13" font="14">that can accompany the initiation of beta-blocker therapy</text>
<text top="193" left="64" width="55" height="13" font="15"><a href="e147.full.html#75">(474,475)</a></text>
<text top="193" left="120" width="294" height="13" font="14"><a href="e147.full.html#75">. </a>Beta blockers may be considered in patients who</text>
<text top="211" left="64" width="350" height="13" font="14">have reactive airway disease or asymptomatic bradycardia but</text>
<text top="229" left="64" width="350" height="13" font="14">should be used cautiously in patients with persistent symp-</text>
<text top="247" left="64" width="142" height="13" font="14">toms of either condition.</text>
<text top="272" left="64" width="349" height="15" font="14">7.3.2.4.2. Beta Blockers: Initiation and Maintenance.</text>
<text top="292" left="64" width="350" height="13" font="14">Treatment with a beta blocker should be initiated at very low</text>
<text top="310" left="64" width="41" height="13" font="14">doses <a href="e147.full.html#29">(</a></text>
<text top="310" left="105" width="51" height="13" font="15"><a href="e147.full.html#29">Table 15</a></text>
<text top="310" left="157" width="257" height="13" font="14"><a href="e147.full.html#29">), </a>followed by gradual increments in dose if</text>
<text top="327" left="64" width="350" height="13" font="14">lower doses have been well tolerated. Patients should be</text>
<text top="345" left="64" width="350" height="13" font="14">monitored closely for changes in vital signs and symptoms</text>
<text top="363" left="64" width="350" height="13" font="14">during this uptitration period. Planned increments in the dose</text>
<text top="381" left="64" width="350" height="13" font="14">of a beta blocker should be delayed until any adverse effects</text>
<text top="399" left="64" width="350" height="13" font="14">observed with lower doses have disappeared. When such</text>
<text top="417" left="64" width="350" height="13" font="14">a cautious approach was used, most patients (approximately</text>
<text top="435" left="64" width="350" height="13" font="14">85%) enrolled in clinical trials who received beta blockers</text>
<text top="453" left="64" width="350" height="13" font="14">were able to tolerate short- and long-term treatment with these</text>
<text top="471" left="64" width="31" height="13" font="14">drugs</text>
<text top="471" left="108" width="20" height="13" font="14">and</text>
<text top="471" left="141" width="42" height="13" font="14">achieve</text>
<text top="471" left="197" width="87" height="13" font="14">the maximum</text>
<text top="471" left="296" width="79" height="13" font="14">planned trial</text>
<text top="471" left="388" width="26" height="13" font="14">dose</text>
<text top="489" left="64" width="104" height="13" font="15"><a href="e147.full.html#67">(117,447,448,470)</a></text>
<text top="489" left="168" width="246" height="13" font="14">. Data show that beta blockers can be safely</text>
<text top="507" left="64" width="350" height="13" font="14">started before discharge even in patients hospitalized for HF,</text>
<text top="525" left="64" width="350" height="13" font="14">provided they do not require intravenous inotropic therapy for</text>
<text top="543" left="64" width="18" height="13" font="14">HF</text>
<text top="543" left="90" width="30" height="13" font="15"><a href="e147.full.html#75">(476)</a></text>
<text top="543" left="120" width="294" height="13" font="14"><a href="e147.full.html#75">. </a>Clinicians should make every effort to achieve</text>
<text top="561" left="64" width="350" height="13" font="14">the target doses of the beta blockers shown to be effective in</text>
<text top="579" left="64" width="350" height="13" font="14">major clinical trials. Even if symptoms do not improve, long-</text>
<text top="596" left="64" width="350" height="13" font="14">term treatment should be maintained to reduce the risk of</text>
<text top="614" left="64" width="350" height="13" font="14">major clinical events. Abrupt withdrawal of treatment with</text>
<text top="632" left="64" width="350" height="13" font="14">a beta blocker can lead to clinical deterioration and should be</text>
<text top="650" left="64" width="44" height="13" font="14">avoided</text>
<text top="650" left="113" width="30" height="13" font="15"><a href="e147.full.html#75">(477)</a></text>
<text top="650" left="143" width="4" height="13" font="14">.</text>
<text top="676" left="64" width="350" height="15" font="14">7.3.2.4.3. Beta Blockers: Risks of Treatment. Initiation</text>
<text top="695" left="64" width="350" height="13" font="14">of treatment with a beta blocker may produce 4 types of</text>
<text top="713" left="64" width="350" height="13" font="14">adverse reactions that require attention and management:</text>
<text top="727" left="64" width="350" height="18" font="14">ﬂuid retention and worsening HF; fatigue; bradycardia or heart</text>
<text top="749" left="64" width="248" height="13" font="14">block; and hypotension. The occurrence of</text>
<text top="745" left="317" width="97" height="18" font="14">ﬂuid retention or</text>
<text top="767" left="64" width="350" height="13" font="14">worsening HF is not generally a reason for the permanent</text>
<text top="785" left="64" width="350" height="13" font="14">withdrawal of treatment. Such patients generally respond</text>
<text top="803" left="64" width="110" height="13" font="14">favorably to intensi</text>
<text top="799" left="174" width="239" height="18" font="14">ﬁcation of conventional therapy, and once</text>
<text top="821" left="64" width="350" height="13" font="14">treated, they remain excellent candidates for long-term treat-</text>
<text top="839" left="64" width="350" height="13" font="14">ment with a beta blocker. The slowing of heart rate and cardiac</text>
<text top="857" left="64" width="350" height="13" font="14">conduction produced by beta blockers is generally asymp-</text>
<text top="874" left="64" width="350" height="13" font="14">tomatic and thus requires no treatment; however, if the</text>
<text top="892" left="64" width="350" height="13" font="14">bradycardia is accompanied by dizziness or lightheadedness or</text>
<text top="910" left="64" width="350" height="13" font="14">if second- or third-degree heart block occurs, clinicians should</text>
<text top="928" left="64" width="350" height="13" font="14">decrease the dose of the beta blocker. Clinicians may mini-</text>
<text top="946" left="64" width="350" height="13" font="14">mize the risk of hypotension by administering the beta</text>
<text top="964" left="64" width="350" height="13" font="14">blocker and ACE inhibitor at different times during the day.</text>
<text top="982" left="64" width="350" height="13" font="14">Hypotensive symptoms may also resolve after a decrease in</text>
<text top="1000" left="64" width="350" height="13" font="14">the dose of diuretics in patients who are volume depleted. If</text>
<text top="1018" left="64" width="350" height="13" font="14">hypotension is accompanied by other clinical evidence of</text>
<text top="1036" left="64" width="350" height="13" font="14">hypoperfusion, beta-blocker therapy should be decreased or</text>
<text top="1054" left="64" width="350" height="13" font="14">discontinued pending further patient evaluation. The symptom</text>
<text top="1072" left="64" width="350" height="13" font="14">of fatigue is multifactorial and is perhaps the hardest symptom</text>
<text top="1090" left="64" width="113" height="13" font="14">to address with con</text>
<text top="1086" left="177" width="237" height="18" font="14">ﬁdence. Although fatigue may be related</text>
<text top="103" left="450" width="350" height="13" font="14">to beta blockers, other causes of fatigue should be considered,</text>
<text top="121" left="450" width="288" height="13" font="14">including sleep apnea, overdiuresis, or depression.</text>
<text top="139" left="465" width="20" height="13" font="14">See</text>
<text top="139" left="488" width="157" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 20</a></text>
<text top="139" left="648" width="152" height="13" font="14">for additional data on beta</text>
<text top="157" left="450" width="51" height="13" font="14">blockers.</text>
<text top="191" left="450" width="46" height="15" font="14">7.3.2.5.</text>
<text top="194" left="503" width="237" height="11" font="20">ALDOSTERONE RECEPTOR ANTAGONISTS</text>
<text top="191" left="741" width="4" height="15" font="14">:</text>
<text top="212" left="450" width="120" height="11" font="20">RECOMMENDATIONS</text>
<text top="236" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="248" left="468" width="10" height="10" font="18">1.</text>
<text top="248" left="485" width="314" height="10" font="18">Aldosterone receptor antagonists (or mineralocorticoid</text>
<text top="264" left="485" width="314" height="10" font="18">receptor antagonists) are recommended in patients with</text>
<text top="281" left="485" width="76" height="10" font="18">NYHA class II</text>
<text top="277" left="561" width="238" height="16" font="18">–IV HF and who have LVEF of 35% or less,</text>
<text top="297" left="485" width="314" height="10" font="18">unless contraindicated, to reduce morbidity and mortality.</text>
<text top="313" left="485" width="314" height="10" font="18">Patients with NYHA class II HF should have a history of prior</text>
<text top="330" left="485" width="314" height="10" font="18">cardiovascular hospitalization or elevated plasma natriuretic</text>
<text top="346" left="485" width="314" height="10" font="18">peptide levels to be considered for aldosterone receptor</text>
<text top="363" left="485" width="314" height="10" font="18">antagonists. Creatinine should be 2.5 mg/dL or less in men</text>
<text top="379" left="485" width="314" height="10" font="18">or 2.0 mg/dL or less in women (or estimated glomerular</text>
<text top="393" left="485" width="183" height="16" font="18">ﬁltration rate &gt;30 mL/min/1.73 m</text>
<text top="393" left="668" width="5" height="7" font="27">2</text>
<text top="396" left="674" width="126" height="10" font="18">), and potassium should</text>
<text top="412" left="485" width="314" height="10" font="18">be less than 5.0 mEq/L. Careful monitoring of potassium,</text>
<text top="429" left="485" width="314" height="10" font="18">renal function, and diuretic dosing should be performed at</text>
<text top="445" left="485" width="314" height="10" font="18">initiation and closely followed thereafter to minimize risk of</text>
<text top="461" left="485" width="152" height="10" font="18">hyperkalemia and renal insuf</text>
<text top="458" left="637" width="41" height="16" font="18">ﬁciency</text>
<text top="461" left="682" width="80" height="10" font="5"><a href="e147.full.html#74">(425,426,478)</a></text>
<text top="461" left="762" width="38" height="12" font="18"><a href="e147.full.html#74">. </a>(Level</text>
<text top="478" left="485" width="79" height="12" font="18">of Evidence: A)</text>
<text top="495" left="468" width="10" height="10" font="18">2.</text>
<text top="494" left="485" width="314" height="10" font="18">Aldosterone receptor antagonists are recommended to</text>
<text top="511" left="485" width="314" height="10" font="18">reduce morbidity and mortality following an acute MI in</text>
<text top="527" left="485" width="314" height="10" font="18">patients who have LVEF of 40% or less who develop symp-</text>
<text top="544" left="485" width="314" height="10" font="18">toms of HF or who have a history of diabetes mellitus, unless</text>
<text top="560" left="485" width="82" height="10" font="18">contraindicated</text>
<text top="560" left="572" width="28" height="10" font="5"><a href="e147.full.html#74">(446)</a></text>
<text top="560" left="600" width="121" height="12" font="18"><a href="e147.full.html#74">. </a>(Level of Evidence: B)</text>
<text top="584" left="450" width="73" height="8" font="17">CLASS III: Harm</text>
<text top="596" left="468" width="10" height="10" font="18">1.</text>
<text top="596" left="485" width="314" height="10" font="18">Inappropriate use of aldosterone receptor antagonists is</text>
<text top="612" left="485" width="314" height="10" font="18">potentially harmful because of life-threatening hyperkalemia</text>
<text top="629" left="485" width="69" height="10" font="18">or renal insuf</text>
<text top="626" left="554" width="246" height="16" font="18">ﬁciency when serum creatinine is greater than</text>
<text top="645" left="485" width="314" height="10" font="18">2.5 mg/dL in men or greater than 2.0 mg/dL in women</text>
<text top="662" left="485" width="124" height="10" font="18">(or estimated glomerular</text>
<text top="659" left="612" width="175" height="16" font="18">ﬁltration rate &lt;30 mL/min/1.73 m</text>
<text top="659" left="787" width="5" height="7" font="27">2</text>
<text top="662" left="792" width="8" height="10" font="18">),</text>
<text top="678" left="485" width="217" height="10" font="18">and/or potassium greater than 5.0 mEq/L</text>
<text top="678" left="706" width="55" height="10" font="5"><a href="e147.full.html#75">(479,480)</a></text>
<text top="678" left="761" width="38" height="12" font="18">. (Level</text>
<text top="695" left="485" width="79" height="12" font="18">of Evidence: B)</text>
<text top="720" left="465" width="335" height="13" font="14">The landmark RALES trial (Randomized Aldactone Evalu-</text>
<text top="738" left="450" width="74" height="13" font="14">ation Study)</text>
<text top="738" left="532" width="30" height="13" font="15"><a href="e147.full.html#74">(425)</a></text>
<text top="738" left="570" width="229" height="13" font="14">showed a 30% reduction in all-cause</text>
<text top="756" left="450" width="350" height="13" font="14">mortality as well as a reduced risk of SCD and HF hospitali-</text>
<text top="774" left="450" width="350" height="13" font="14">zations with the use of spironolactone in patients with chronic</text>
<text top="792" left="450" width="110" height="13" font="14">HFrEF and LVEF</text>
<text top="788" left="567" width="233" height="18" font="14">&lt;35%. Eplerenone has been shown to</text>
<text top="810" left="450" width="350" height="13" font="14">reduce all-cause deaths, cardiovascular deaths, or HF hospi-</text>
<text top="828" left="450" width="286" height="13" font="14">talizations in a wider range of patients with HFrEF</text>
<text top="828" left="740" width="55" height="13" font="15"><a href="e147.full.html#74">(426,446)</a></text>
<text top="828" left="795" width="4" height="13" font="14"><a href="e147.full.html#74">.</a></text>
<text top="855" left="450" width="350" height="15" font="14">7.3.2.5.1. Aldosterone Receptor Antagonists: Selection</text>
<text top="873" left="450" width="350" height="15" font="14">of Patients. Clinicians should strongly consider the addition</text>
<text top="892" left="450" width="350" height="13" font="14">of the aldosterone receptor antagonists spironolactone or</text>
<text top="910" left="450" width="350" height="13" font="14">eplerenone for all patients with HFrEF who are already on</text>
<text top="928" left="450" width="350" height="13" font="14">ACE inhibitors (or ARBs) and beta blockers. Although the</text>
<text top="946" left="450" width="350" height="13" font="14">entry criteria for the trials of aldosterone receptor antagonists</text>
<text top="964" left="450" width="198" height="13" font="14">excluded patients with a creatinine</text>
<text top="960" left="652" width="147" height="18" font="14">&gt;2.5 mg/dL, the majority</text>
<text top="982" left="450" width="350" height="13" font="14">of patients had much lower creatinine (95% of patients had</text>
<text top="1000" left="450" width="55" height="13" font="14">creatinine</text>
<text top="996" left="510" width="76" height="18" font="14">1.7 mg/dL)</text>
<text top="1000" left="590" width="80" height="13" font="15"><a href="e147.full.html#74">(425,426,446)</a></text>
<text top="1000" left="670" width="129" height="13" font="14">. In contrast, one third</text>
<text top="1018" left="450" width="350" height="13" font="14">of patients in EMPHASIS-HF (Eplerenone in Mild Patients</text>
<text top="1036" left="450" width="350" height="13" font="14">Hospitalization and Survival Study in Heart Failure) had an</text>
<text top="1054" left="450" width="121" height="13" font="14">estimated glomerular</text>
<text top="1050" left="576" width="218" height="18" font="14">ﬁltration rate of &lt;60 mL/min/1.73 m</text>
<text top="1051" left="794" width="5" height="9" font="12">2</text>
<text top="1072" left="450" width="30" height="13" font="15"><a href="e147.full.html#74">(426)</a></text>
<text top="1072" left="480" width="319" height="13" font="14">. Note also that the entry criteria for the EMPHASIS-HF</text>
<text top="1090" left="450" width="133" height="13" font="14">trial were age of at least</text>
<text top="1086" left="586" width="214" height="18" font="14">55 years, NYHA class II symptoms,</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e177</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1160" width="864">
<text top="309" left="64" width="219" height="13" font="14">and an EF of no more than 30% (or, if</text>
<text top="305" left="287" width="127" height="18" font="14">&gt;30% to 35%, a QRS</text>
<text top="327" left="64" width="63" height="13" font="14">duration of</text>
<text top="323" left="132" width="282" height="18" font="14">&gt;130 ms on ECG). To minimize the risk of life-</text>
<text top="345" left="64" width="350" height="13" font="14">threatening hyperkalemia in euvolemic patients with HFrEF,</text>
<text top="363" left="64" width="253" height="13" font="14">patients should have initial serum creatinine</text>
<text top="359" left="322" width="92" height="18" font="14">&lt;2.5 mg/dL (or</text>
<text top="381" left="64" width="138" height="13" font="14">an estimated glomerular</text>
<text top="377" left="207" width="198" height="18" font="14">ﬁltration rate &gt;30 mL/min/1.73 m</text>
<text top="378" left="404" width="5" height="9" font="12">2</text>
<text top="381" left="409" width="5" height="13" font="14">)</text>
<text top="399" left="64" width="272" height="13" font="14">without recent worsening and serum potassium</text>
<text top="395" left="341" width="73" height="18" font="14">&lt;5.0 mEq/L</text>
<text top="417" left="64" width="350" height="13" font="14">without a history of severe hyperkalemia. Careful patient</text>
<text top="435" left="64" width="350" height="13" font="14">selection and risk assessment with availability of close</text>
<text top="452" left="64" width="350" height="13" font="14">monitoring is essential in initiating the use of aldosterone</text>
<text top="470" left="64" width="117" height="13" font="14">receptor antagonists.</text>
<text top="494" left="64" width="350" height="15" font="14">7.3.2.5.2. Aldosterone Receptor Antagonists: Initiation</text>
<text top="512" left="64" width="350" height="15" font="14">and Maintenance. Spironolactone should be initiated at</text>
<text top="532" left="64" width="350" height="13" font="14">a dose of 12.5 to 25 mg daily, while eplerenone should be</text>
<text top="550" left="64" width="350" height="13" font="14">initiated at a dose of 25 mg/d, increasing to 50 mg daily.</text>
<text top="568" left="64" width="350" height="13" font="14">For those with concerns of hyperkalemia or marginal renal</text>
<text top="586" left="64" width="173" height="13" font="14">function (estimated glomerular</text>
<text top="582" left="240" width="173" height="18" font="14">ﬁltration rate 30 to 49 mL/min/</text>
<text top="603" left="64" width="43" height="13" font="14">1.73 m</text>
<text top="600" left="108" width="5" height="9" font="12">2</text>
<text top="603" left="113" width="301" height="13" font="14">), an initial regimen of every-other-day dosing is</text>
<text top="621" left="64" width="54" height="13" font="14">advised <a href="e147.full.html#32">(</a></text>
<text top="621" left="118" width="53" height="13" font="15"><a href="e147.full.html#32">Table 16</a></text>
<text top="621" left="171" width="243" height="13" font="14">). After initiation of aldosterone receptor</text>
<text top="639" left="64" width="350" height="13" font="14">antagonists, potassium supplementation should be discon-</text>
<text top="657" left="64" width="350" height="13" font="14">tinued (or reduced and carefully monitored in those with</text>
<text top="675" left="64" width="149" height="13" font="14">a history of hypokalemia;</text>
<text top="675" left="219" width="51" height="13" font="15"><a href="e147.full.html#32">Table 17</a></text>
<text top="675" left="270" width="144" height="13" font="14"><a href="e147.full.html#32">), </a>and patients should be</text>
<text top="693" left="64" width="350" height="13" font="14">counseled to avoid foods high in potassium and NSAIDs.</text>
<text top="711" left="64" width="350" height="13" font="14">Potassium levels and renal function should be rechecked</text>
<text top="729" left="64" width="350" height="13" font="14">within 2 to 3 days and again at 7 days after initiation of an</text>
<text top="747" left="64" width="350" height="13" font="14">aldosterone receptor antagonist. Subsequent monitoring should</text>
<text top="765" left="64" width="350" height="13" font="14">be dictated by the general clinical stability of renal function</text>
<text top="783" left="64" width="20" height="13" font="14">and</text>
<text top="779" left="89" width="325" height="18" font="14">ﬂuid status but should occur at least monthly for the ﬁrst</text>
<text top="801" left="64" width="350" height="13" font="14">3 months and every 3 months thereafter. The addition or an</text>
<text top="819" left="64" width="350" height="13" font="14">increase in dosage of ACE inhibitors or ARBs should trigger</text>
<text top="837" left="64" width="151" height="13" font="14">a new cycle of monitoring.</text>
<text top="309" left="465" width="335" height="13" font="14">There are limited data to support or refute that spi-</text>
<text top="327" left="450" width="350" height="13" font="14">ronolactone and eplerenone are interchangeable. The per-</text>
<text top="345" left="450" width="350" height="13" font="14">ceived difference between eplerenone and spironolactone is</text>
<text top="363" left="450" width="350" height="13" font="14">the selectivity of aldosterone receptor antagonism and not</text>
<text top="381" left="450" width="350" height="13" font="14">the effectiveness of blocking mineralocorticoid activity. In</text>
<text top="399" left="450" width="350" height="13" font="14">RALES, there was increased incidence (10%) of gyneco-</text>
<text top="417" left="450" width="350" height="13" font="14">mastia or breast pain with use of spironolactone (a nonse-</text>
<text top="435" left="450" width="350" height="13" font="14">lective antagonist). The incidence of these adverse events</text>
<text top="453" left="450" width="22" height="13" font="14">was</text>
<text top="449" left="477" width="323" height="18" font="14">&lt;1% in EPHESUS (Eplerenone Post-Acute Myocardial</text>
<text top="470" left="450" width="161" height="13" font="14">Infarction Heart Failure Ef</text>
<text top="467" left="611" width="189" height="18" font="14">ﬁcacy and Survival Study) and</text>
<text top="488" left="450" width="350" height="13" font="14">EMPHASIS-HF without any difference in adverse events</text>
<text top="506" left="450" width="209" height="13" font="14">between the eplerenone and placebo</text>
<text top="506" left="663" width="55" height="13" font="15"><a href="e147.full.html#74">(426,446)</a></text>
<text top="506" left="718" width="4" height="13" font="14">.</text>
<text top="530" left="450" width="350" height="15" font="14">7.3.2.5.3. Aldosterone Receptor Antagonists: Risks of</text>
<text top="548" left="450" width="350" height="15" font="14">Treatment. The major risk associated with use of aldoste-</text>
<text top="568" left="450" width="350" height="13" font="14">rone receptor antagonists is hyperkalemia due to inhibition of</text>
<text top="585" left="450" width="350" height="13" font="14">potassium excretion, ranging from 2% to 5% in large clinical</text>
<text top="603" left="450" width="28" height="13" font="14">trials</text>
<text top="603" left="486" width="84" height="13" font="15"><a href="e147.full.html#74">(425,426,446)</a></text>
<text top="603" left="578" width="221" height="13" font="14">to 24% to 36% in population-based</text>
<text top="621" left="450" width="51" height="13" font="14">registries</text>
<text top="621" left="507" width="55" height="13" font="15"><a href="e147.full.html#75">(479,480)</a></text>
<text top="621" left="562" width="237" height="13" font="14">. Routine triple combination of an ACE</text>
<text top="639" left="450" width="350" height="13" font="14">inhibitor, ARB, and aldosterone receptor antagonist should be</text>
<text top="657" left="450" width="48" height="13" font="14">avoided.</text>
<text top="675" left="465" width="243" height="13" font="14">The development of potassium levels</text>
<text top="671" left="720" width="80" height="18" font="14">&gt;5.5 mEq/L</text>
<text top="693" left="450" width="252" height="13" font="14">(approximately 12% in EMPHASIS-HF</text>
<text top="693" left="714" width="30" height="13" font="15"><a href="e147.full.html#74">[426]</a></text>
<text top="693" left="745" width="55" height="13" font="14"><a href="e147.full.html#74">) </a>should</text>
<text top="711" left="450" width="350" height="13" font="14">generally trigger discontinuation or dose reduction of the</text>
<text top="729" left="450" width="350" height="13" font="14">aldosterone receptor antagonist unless other causes are iden-</text>
<text top="747" left="450" width="8" height="13" font="14">ti</text>
<text top="743" left="458" width="342" height="18" font="14">ﬁed. The development of worsening renal function should</text>
<text top="765" left="450" width="350" height="13" font="14">lead to careful evaluation of the entire medical regimen and</text>
<text top="783" left="450" width="350" height="13" font="14">consideration for stopping the aldosterone receptor antagonist.</text>
<text top="801" left="450" width="199" height="13" font="14">Patients should be instructed speci</text>
<text top="797" left="649" width="151" height="18" font="14">ﬁcally to stop the aldoste-</text>
<text top="819" left="450" width="350" height="13" font="14">rone receptor antagonist during an episode of diarrhea or</text>
<text top="837" left="450" width="327" height="13" font="14">dehydration or while loop diuretic therapy is interrupted.</text>
<text top="103" left="64" width="331" height="12" font="9">Table 16. Drug Dosing for Aldosterone Receptor Antagonists</text>
<text top="135" left="335" width="49" height="11" font="4">Eplerenone</text>
<text top="135" left="610" width="66" height="11" font="4">Spironolactone</text>
<text top="154" left="64" width="100" height="11" font="4">eGFR (mL/min/1.73 m</text>
<text top="152" left="164" width="4" height="7" font="19">2</text>
<text top="154" left="168" width="3" height="11" font="4">)</text>
<text top="151" left="277" width="21" height="16" font="4">50</text>
<text top="154" left="382" width="24" height="11" font="4">30 to</text>
<text top="151" left="410" width="21" height="16" font="4">49</text>
<text top="151" left="538" width="21" height="16" font="4">50</text>
<text top="154" left="693" width="39" height="11" font="4">30 to 49</text>
<text top="174" left="64" width="93" height="11" font="4">Initial dose (only if K</text>
<text top="169" left="157" width="7" height="10" font="19">þ</text>
<text top="171" left="168" width="50" height="16" font="4">5 mEq/L)</text>
<text top="174" left="248" width="79" height="11" font="4">25 mg once daily</text>
<text top="174" left="342" width="129" height="11" font="4">25 mg once every other day</text>
<text top="174" left="486" width="124" height="11" font="4">12.5 to 25.0 mg once daily</text>
<text top="174" left="625" width="175" height="11" font="4">12.5 mg once daily or every other day</text>
<text top="193" left="64" width="161" height="11" font="4">Maintenance dose (after 4 wk for K</text>
<text top="189" left="226" width="7" height="10" font="19">þ</text>
<text top="205" left="77" width="50" height="16" font="4">5 mEq/L)</text>
<text top="208" left="127" width="4" height="11" font="5"><a href="e147.full.html#32">*</a></text>
<text top="193" left="248" width="79" height="11" font="4">50 mg once daily</text>
<text top="193" left="367" width="79" height="11" font="4">25 mg once daily</text>
<text top="193" left="488" width="120" height="11" font="4">25 mg once or twice daily</text>
<text top="193" left="650" width="124" height="11" font="4">12.5 to 25.0 mg once daily</text>
<text top="230" left="76" width="121" height="11" font="4">*After dose initiation for K</text>
<text top="225" left="197" width="7" height="10" font="19">þ</text>
<text top="230" left="204" width="45" height="11" font="4">, increase</text>
<text top="227" left="253" width="248" height="16" font="4">6.0 mEq/L or worsening renal function, hold until K</text>
<text top="225" left="501" width="7" height="10" font="19">þ</text>
<text top="227" left="508" width="292" height="16" font="4">&lt;5.0 mEq/L. Consider restarting reduced dose after confirming</text>
<text top="245" left="64" width="285" height="11" font="4">resolution of hyperkalemia/renal insufficiency for at least 72 h.</text>
<text top="259" left="76" width="260" height="11" font="4">eGFR indicates estimated glomerular filtration rate; and K</text>
<text top="255" left="336" width="7" height="10" font="19">þ</text>
<text top="259" left="343" width="55" height="11" font="4">, potassium.</text>
<text top="274" left="76" width="118" height="11" font="4">Adapted from Butler et al.</text>
<text top="274" left="198" width="23" height="11" font="5"><a href="e147.full.html#75">(481)</a></text>
<text top="274" left="221" width="3" height="11" font="4"><a href="e147.full.html#75">.</a></text>
<text top="877" left="64" width="592" height="12" font="9">Table 17. Strategies to Minimize the Risk of Hyperkalemia in Patients Treated With Aldosterone Antagonists</text>
<text top="905" left="64" width="735" height="11" font="4">1. Impaired renal function is a risk factor for hyperkalemia during treatment with aldosterone antagonists. The risk of hyperkalemia increases progressively</text>
<text top="920" left="93" width="114" height="11" font="4">when serum creatinine is</text>
<text top="917" left="210" width="58" height="16" font="4">&gt;1.6 <a href="e147.full.html#32">mg/dL.</a></text>
<text top="920" left="268" width="4" height="11" font="5"><a href="e147.full.html#32">*</a></text>
<text top="920" left="276" width="524" height="11" font="4">In elderly patients or others with low muscle mass in whom serum creatinine does not accurately reflect glomerular</text>
<text top="935" left="93" width="377" height="11" font="4">filtration rate, determination that glomerular filtration rate or creatinine clearance is</text>
<text top="932" left="474" width="94" height="16" font="4">&gt;30 mL/min/1.73 m</text>
<text top="932" left="568" width="4" height="7" font="19">2</text>
<text top="935" left="576" width="78" height="11" font="4">is recommended.</text>
<text top="950" left="64" width="466" height="11" font="4">2. Aldosterone antagonists would not ordinarily be initiated in patients with baseline serum potassium</text>
<text top="947" left="534" width="58" height="16" font="4">&gt;5.0 mEq/L.</text>
<text top="965" left="64" width="735" height="11" font="4">3. An initial dose of spironolactone of 12.5 mg or eplerenone 25 mg is typical, after which the dose may be increased to spironolactone 25 mg or eplerenone 50 mg if</text>
<text top="980" left="93" width="53" height="11" font="4">appropriate.</text>
<text top="995" left="64" width="485" height="11" font="4">4. The risk of hyperkalemia is increased with concomitant use of higher doses of ACE inhibitors (captopril</text>
<text top="992" left="553" width="234" height="16" font="4">75 mg daily; enalapril or lisinopril 10 mg daily).</text>
<text top="1010" left="64" width="544" height="11" font="4">5. In most circumstances, potassium supplements are discontinued or reduced when initiating aldosterone antagonists.</text>
<text top="1025" left="64" width="735" height="11" font="4">6. Close monitoring of serum potassium is required; potassium levels and renal function are most typically checked in 3 d and at 1 wk after initiating therapy and at</text>
<text top="1039" left="93" width="145" height="11" font="4">least monthly for the first 3 mo.</text>
<text top="1061" left="76" width="388" height="11" font="4">*Although the entry criteria for the trials of aldosterone antagonists included creatinine</text>
<text top="1058" left="467" width="332" height="16" font="4">&lt;2.5 mg/dL, the majority of patients had much lower creatinine; in 1 trial</text>
<text top="1076" left="64" width="23" height="11" font="5"><a href="e147.full.html#74">(425)</a></text>
<text top="1076" left="87" width="147" height="11" font="4">, 95% of patients had creatinine</text>
<text top="1073" left="238" width="58" height="16" font="4">1.7 mg/dL.</text>
<text top="1091" left="76" width="207" height="11" font="4">ACE indicates angiotensin-converting enzyme.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e178</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="46" height="15" font="14">7.3.2.6.</text>
<text top="106" left="118" width="253" height="11" font="20">HYDRALAZINE AND ISOSORBIDE DINITRATE</text>
<text top="103" left="371" width="4" height="15" font="14">:</text>
<text top="124" left="64" width="120" height="11" font="20">RECOMMENDATIONS</text>
<text top="147" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="159" left="82" width="10" height="10" font="18">1.</text>
<text top="159" left="100" width="314" height="10" font="18">The combination of hydralazine and isosorbide dinitrate is</text>
<text top="176" left="100" width="314" height="10" font="18">recommended to reduce morbidity and mortality for patients</text>
<text top="192" left="100" width="298" height="10" font="18">self-described as African Americans with NYHA class III</text>
<text top="189" left="397" width="17" height="16" font="18">–IV</text>
<text top="208" left="100" width="314" height="12" font="18">HFrEF receiving optimal therapy with ACE inhibitors and</text>
<text top="225" left="100" width="202" height="10" font="18">beta blockers, unless contraindicated</text>
<text top="225" left="306" width="55" height="10" font="5"><a href="e147.full.html#74">(423,424)</a></text>
<text top="225" left="361" width="53" height="12" font="18"><a href="e147.full.html#74">. </a>(Level of</text>
<text top="242" left="100" width="65" height="12" font="18">Evidence: A)</text>
<text top="265" left="64" width="45" height="8" font="17">CLASS IIa</text>
<text top="277" left="82" width="10" height="10" font="18">1.</text>
<text top="277" left="100" width="314" height="10" font="18">A combination of hydralazine and isosorbide dinitrate can be</text>
<text top="294" left="100" width="314" height="10" font="18">useful to reduce morbidity or mortality in patients with</text>
<text top="310" left="100" width="314" height="12" font="18">current or prior symptomatic HFrEF who cannot be given an</text>
<text top="327" left="100" width="314" height="10" font="18">ACE inhibitor or ARB because of drug intolerance, hypoten-</text>
<text top="343" left="100" width="103" height="10" font="18">sion, or renal insuf</text>
<text top="340" left="203" width="172" height="16" font="18">ﬁciency, unless contraindicated</text>
<text top="343" left="380" width="30" height="10" font="5"><a href="e147.full.html#74">(449)</a></text>
<text top="343" left="410" width="3" height="10" font="18">.</text>
<text top="360" left="100" width="113" height="12" font="18">(Level of Evidence: B)</text>
<text top="385" left="79" width="335" height="13" font="14">In a large-scale trial that compared the vasodilator combi-</text>
<text top="403" left="64" width="350" height="13" font="14">nation with placebo, the use of hydralazine and isosorbide</text>
<text top="421" left="64" width="350" height="13" font="14">dinitrate reduced mortality but not hospitalizations in patients</text>
<text top="439" left="64" width="350" height="13" font="14">with HF treated with digoxin and diuretics but not an ACE</text>
<text top="457" left="64" width="137" height="13" font="14">inhibitor or beta blocker</text>
<text top="457" left="206" width="30" height="13" font="15"><a href="e147.full.html#74">(449)</a></text>
<text top="457" left="236" width="178" height="13" font="14"><a href="e147.full.html#74">. </a>However, in 2 other trials that</text>
<text top="475" left="64" width="350" height="13" font="14">compared the vasodilator combination with an ACE inhibitor,</text>
<text top="492" left="64" width="350" height="13" font="14">the ACE inhibitor produced more favorable effects on</text>
<text top="510" left="64" width="45" height="13" font="14">survival</text>
<text top="510" left="114" width="55" height="13" font="15"><a href="e147.full.html#73">(412,482)</a></text>
<text top="510" left="169" width="245" height="13" font="14"><a href="e147.full.html#73">. </a>A post hoc retrospective analysis of these</text>
<text top="528" left="64" width="266" height="13" font="14">vasodilator trials demonstrated particular ef</text>
<text top="524" left="330" width="84" height="18" font="14">ﬁcacy of iso-</text>
<text top="546" left="64" width="350" height="13" font="14">sorbide dinitrate and hydralazine in the African American</text>
<text top="564" left="64" width="36" height="13" font="14">cohort</text>
<text top="564" left="108" width="30" height="13" font="15"><a href="e147.full.html#74">(423)</a></text>
<text top="564" left="138" width="276" height="13" font="14">. In a subsequent trial, which was limited to</text>
<text top="582" left="64" width="350" height="13" font="14">patients self-described as African American, the addition of</text>
<text top="600" left="64" width="6" height="13" font="14">a</text>
<text top="596" left="80" width="334" height="18" font="14">ﬁxed-dose combination of hydralazine and isosorbide</text>
<text top="618" left="64" width="350" height="13" font="14">dinitrate to standard therapy with an ACE inhibitor or ARB,</text>
<text top="636" left="64" width="337" height="13" font="14">a beta blocker, and an aldosterone antagonist offered signi</text>
<text top="632" left="402" width="12" height="18" font="14">ﬁ-</text>
<text top="654" left="64" width="55" height="13" font="14">cant bene</text>
<text top="650" left="119" width="12" height="18" font="14">ﬁt</text>
<text top="654" left="135" width="30" height="13" font="15"><a href="e147.full.html#74">(424)</a></text>
<text top="654" left="166" width="4" height="13" font="14"><a href="e147.full.html#74">.</a></text>
<text top="681" left="64" width="350" height="15" font="14">7.3.2.6.1. Hydralazine and Isosorbide Dinitrate: Selec-</text>
<text top="699" left="64" width="350" height="15" font="14">tion of Patients. The combination of hydralazine and iso-</text>
<text top="718" left="64" width="350" height="13" font="14">sorbide dinitrate is recommended for African Americans with</text>
<text top="736" left="64" width="350" height="13" font="14">HFrEF who remain symptomatic despite concomitant use of</text>
<text top="754" left="64" width="350" height="13" font="14">ACE inhibitors, beta blockers, and aldosterone antagonists.</text>
<text top="772" left="64" width="109" height="13" font="14">Whether this bene</text>
<text top="768" left="174" width="240" height="18" font="14">ﬁt is evident in non–African Americans</text>
<text top="790" left="64" width="350" height="13" font="14">with HFrEF remains to be investigated. The combination of</text>
<text top="808" left="64" width="350" height="13" font="14">hydralazine and isosorbide dinitrate should not be used for the</text>
<text top="826" left="64" width="350" height="13" font="14">treatment of HFrEF in patients who have no prior use of</text>
<text top="844" left="64" width="350" height="13" font="14">standard neurohumoral antagonist therapy and should not be</text>
<text top="862" left="64" width="350" height="13" font="14">substituted for ACE inhibitor or ARB therapy in patients who</text>
<text top="879" left="64" width="193" height="13" font="14">are tolerating therapy without dif</text>
<text top="876" left="257" width="156" height="18" font="14">ﬁculty. Despite the lack of</text>
<text top="897" left="64" width="350" height="13" font="14">data with the vasodilator combination in patients who are</text>
<text top="915" left="64" width="350" height="13" font="14">intolerant of ACE inhibitors or ARBs, the combined use of</text>
<text top="933" left="64" width="350" height="13" font="14">hydralazine and isosorbide dinitrate may be considered as</text>
<text top="951" left="64" width="212" height="13" font="14">a therapeutic option in such patients.</text>
<text top="975" left="64" width="350" height="15" font="14">7.3.2.6.2. Hydralazine and Isosorbide Dinitrate: Initia-</text>
<text top="993" left="64" width="191" height="15" font="14">tion and Maintenance. If the</text>
<text top="991" left="262" width="152" height="18" font="14">ﬁxed-dose combination is</text>
<text top="1012" left="64" width="350" height="13" font="14">available, the initial dose should be 1 tablet containing 37.5</text>
<text top="1030" left="64" width="350" height="13" font="14">mg of hydralazine hydrochloride and 20 mg of isosorbide</text>
<text top="1048" left="64" width="350" height="13" font="14">dinitrate 3 times daily. The dose can be increased to 2 tablets</text>
<text top="1066" left="64" width="350" height="13" font="14">3 times daily for a total daily dose of 225 mg of hydralazine</text>
<text top="1084" left="64" width="350" height="13" font="14">hydrochloride and 120 mg of isosorbide dinitrate. When the 2</text>
<text top="392" left="450" width="350" height="13" font="14">drugs are used separately, both pills should be administered at</text>
<text top="410" left="450" width="350" height="13" font="14">least 3 times daily. Initial low doses of the drugs given sepa-</text>
<text top="428" left="450" width="350" height="13" font="14">rately may be progressively increased to a goal similar to that</text>
<text top="446" left="450" width="86" height="13" font="14">achieved in the</text>
<text top="442" left="540" width="160" height="18" font="14">ﬁxed-dose combination trial</text>
<text top="446" left="704" width="30" height="13" font="15"><a href="e147.full.html#74">(424)</a></text>
<text top="446" left="734" width="4" height="13" font="14">.</text>
<text top="470" left="450" width="350" height="15" font="14">7.3.2.6.3. Hydralazine and Isosorbide Dinitrate: Risks</text>
<text top="487" left="450" width="350" height="15" font="14">of Treatment. Adherence to this combination has generally</text>
<text top="507" left="450" width="350" height="13" font="14">been poor because of the large number of tablets required,</text>
<text top="525" left="450" width="350" height="13" font="14">frequency of administration, and the high incidence of</text>
<text top="543" left="450" width="98" height="13" font="14">adverse reactions</text>
<text top="543" left="552" width="55" height="13" font="15"><a href="e147.full.html#73">(412,449)</a></text>
<text top="543" left="607" width="192" height="13" font="14">. Frequent adverse effects include</text>
<text top="561" left="450" width="350" height="13" font="14">headache, dizziness, and gastrointestinal complaints. Never-</text>
<text top="579" left="450" width="90" height="13" font="14">theless, the bene</text>
<text top="575" left="540" width="259" height="18" font="14">ﬁt of these drugs can be substantial and warrant</text>
<text top="596" left="450" width="350" height="13" font="14">a slower titration of the drugs to enhance tolerance of the</text>
<text top="614" left="450" width="46" height="13" font="14">therapy.</text>
<text top="632" left="449" width="20" height="13" font="14">See</text>
<text top="632" left="473" width="49" height="13" font="15"><a href="e147.full.html#33">Table 18</a></text>
<text top="632" left="525" width="203" height="13" font="14">for a summary of the treatment bene</text>
<text top="628" left="728" width="71" height="18" font="14">ﬁt of GDMT</text>
<text top="650" left="450" width="59" height="13" font="14">in HFrEF.</text>
<text top="676" left="450" width="46" height="15" font="14">7.3.2.7.</text>
<text top="679" left="503" width="51" height="11" font="20">DIGOXIN</text>
<text top="676" left="554" width="4" height="15" font="14">:</text>
<text top="679" left="563" width="114" height="11" font="20">RECOMMENDATION</text>
<text top="703" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="715" left="468" width="10" height="10" font="18">1.</text>
<text top="715" left="485" width="105" height="10" font="18">Digoxin can be bene</text>
<text top="712" left="591" width="209" height="16" font="18">ﬁcial in patients with HFrEF, unless con-</text>
<text top="731" left="485" width="252" height="10" font="18">traindicated, to decrease hospitalizations for HF</text>
<text top="731" left="741" width="25" height="10" font="5"><a href="e147.full.html#75">(484</a></text>
<text top="728" left="766" width="30" height="16" font="5"><a href="e147.full.html#75">–491)</a></text>
<text top="731" left="796" width="3" height="10" font="18">.</text>
<text top="748" left="485" width="111" height="12" font="18">(Level of Evidence: B)</text>
<text top="773" left="465" width="335" height="13" font="14">Several placebo-controlled trials have shown that treatment</text>
<text top="791" left="450" width="350" height="13" font="14">with digoxin for 1 to 3 months can improve symptoms,</text>
<text top="809" left="450" width="350" height="13" font="14">HRQOL, and exercise tolerance in patients with mild to</text>
<text top="827" left="450" width="79" height="13" font="14">moderate HF</text>
<text top="827" left="538" width="26" height="13" font="15"><a href="e147.full.html#75">(485</a></text>
<text top="823" left="563" width="33" height="18" font="15"><a href="e147.full.html#75">–491)</a></text>
<text top="827" left="596" width="81" height="13" font="14">. These bene</text>
<text top="823" left="678" width="122" height="18" font="14">ﬁts have been seen</text>
<text top="845" left="450" width="350" height="13" font="14">regardless of the underlying rhythm (normal sinus rhythm or</text>
<text top="863" left="450" width="350" height="13" font="14">AF), cause of HF (ischemic or nonischemic cardiomyopathy),</text>
<text top="881" left="450" width="350" height="13" font="14">or concomitant therapy (with or without ACE inhibitors). In</text>
<text top="899" left="450" width="350" height="13" font="14">a long-term trial that primarily enrolled patients with NYHA</text>
<text top="917" left="450" width="350" height="13" font="14">class II or III HF, treatment with digoxin for 2 to 5 years had</text>
<text top="935" left="450" width="350" height="13" font="14">no effect on mortality but modestly reduced the combined risk</text>
<text top="952" left="450" width="159" height="13" font="14">of death and hospitalization</text>
<text top="952" left="614" width="30" height="13" font="15"><a href="e147.full.html#75">(484)</a></text>
<text top="952" left="644" width="4" height="13" font="14">.</text>
<text top="976" left="450" width="350" height="15" font="14">7.3.2.7.1. Digoxin: Selection of Patients. Clinicians may</text>
<text top="996" left="450" width="350" height="13" font="14">consider adding digoxin in patients with persistent symptoms</text>
<text top="1014" left="450" width="350" height="13" font="14">of HFrEF during GDMT. Digoxin may also be added to the</text>
<text top="1032" left="450" width="350" height="13" font="14">initial regimen in patients with severe symptoms who have</text>
<text top="1050" left="450" width="292" height="13" font="14">not yet responded symptomatically during GDMT.</text>
<text top="1068" left="465" width="335" height="13" font="14">Alternatively, treatment with digoxin may be delayed until</text>
<text top="1085" left="450" width="59" height="13" font="14">the patient</text>
<text top="1082" left="509" width="291" height="18" font="14">’s response to GDMT has been deﬁned and may be</text>
<text top="103" left="450" width="230" height="12" font="9">Table 18. Medical Therapy for Stage C HF</text>
<text top="100" left="680" width="98" height="17" font="9">rEF: Magnitude of</text>
<text top="119" left="450" width="163" height="12" font="9">Benefit Demonstrated in RCTs</text>
<text top="196" left="450" width="27" height="11" font="4">GDMT</text>
<text top="181" left="562" width="72" height="11" font="4">RR Reduction in</text>
<text top="196" left="569" width="57" height="11" font="4">Mortality (%)</text>
<text top="151" left="644" width="77" height="11" font="4">NNT for Mortality</text>
<text top="166" left="660" width="44" height="11" font="4">Reduction</text>
<text top="181" left="652" width="60" height="11" font="4">(Standardized</text>
<text top="196" left="660" width="44" height="11" font="4">to 36 mo)</text>
<text top="151" left="735" width="60" height="11" font="4">RR Reduction</text>
<text top="166" left="753" width="24" height="11" font="4">in HF</text>
<text top="181" left="730" width="69" height="11" font="4">Hospitalizations</text>
<text top="196" left="758" width="15" height="11" font="4">(%)</text>
<text top="216" left="450" width="92" height="11" font="4">ACE inhibitor or ARB</text>
<text top="216" left="592" width="11" height="11" font="4">17</text>
<text top="216" left="676" width="11" height="11" font="4">26</text>
<text top="216" left="759" width="11" height="11" font="4">31</text>
<text top="235" left="450" width="57" height="11" font="4">Beta blocker</text>
<text top="235" left="592" width="11" height="11" font="4">34</text>
<text top="235" left="682" width="6" height="11" font="4">9</text>
<text top="235" left="759" width="11" height="11" font="4">41</text>
<text top="254" left="450" width="102" height="11" font="4">Aldosterone antagonist</text>
<text top="254" left="592" width="11" height="11" font="4">30</text>
<text top="254" left="682" width="6" height="11" font="4">6</text>
<text top="254" left="759" width="11" height="11" font="4">35</text>
<text top="274" left="450" width="83" height="11" font="4">Hydralazine/nitrate</text>
<text top="274" left="592" width="11" height="11" font="4">43</text>
<text top="274" left="682" width="6" height="11" font="4">7</text>
<text top="274" left="759" width="11" height="11" font="4">33</text>
<text top="295" left="462" width="338" height="11" font="4">ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor</text>
<text top="310" left="450" width="350" height="11" font="4">blocker; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF,</text>
<text top="325" left="450" width="350" height="11" font="4">heart failure with reduced ejection fraction; NNT, number needed to treat;</text>
<text top="340" left="450" width="256" height="11" font="4">RCTs, randomized controlled trials; and RR, relative risk.</text>
<text top="355" left="462" width="204" height="11" font="4">Adapted with permission from Fonarow et al.</text>
<text top="355" left="670" width="23" height="11" font="5"><a href="e147.full.html#75">(483)</a></text>
<text top="355" left="693" width="3" height="11" font="4">.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e179</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">used only in patients who remain symptomatic despite therapy</text>
<text top="121" left="64" width="350" height="13" font="14">with the neurohormonal antagonists. If a patient is taking</text>
<text top="139" left="64" width="350" height="13" font="14">digoxin but not an ACE inhibitor or a beta blocker, treatment</text>
<text top="157" left="64" width="350" height="13" font="14">with digoxin should not be withdrawn, but appropriate</text>
<text top="175" left="64" width="350" height="13" font="14">therapy with the neurohormonal antagonists should be insti-</text>
<text top="193" left="64" width="350" height="13" font="14">tuted. Digoxin is prescribed occasionally in patients with HF</text>
<text top="211" left="64" width="350" height="13" font="14">and AF, but beta blockers are usually more effective when</text>
<text top="229" left="64" width="350" height="13" font="14">added to digoxin in controlling the ventricular response,</text>
<text top="247" left="64" width="156" height="13" font="14">particularly during exercise</text>
<text top="247" left="225" width="26" height="13" font="15"><a href="e147.full.html#75">(492</a></text>
<text top="243" left="251" width="33" height="18" font="15"><a href="e147.full.html#75">–495)</a></text>
<text top="247" left="284" width="4" height="13" font="14">.</text>
<text top="265" left="79" width="322" height="13" font="14">Patients should not be given digoxin if they have signi</text>
<text top="261" left="402" width="12" height="18" font="14">ﬁ-</text>
<text top="283" left="64" width="350" height="13" font="14">cant sinus or atrioventricular block unless the block has been</text>
<text top="301" left="64" width="350" height="13" font="14">addressed with a permanent pacemaker. The drug should be</text>
<text top="319" left="64" width="350" height="13" font="14">used cautiously in patients taking other drugs that can depress</text>
<text top="337" left="64" width="350" height="13" font="14">sinus or atrioventricular nodal function or affect digoxin</text>
<text top="354" left="64" width="350" height="13" font="14">levels (e.g., amiodarone or a beta blocker), even though such</text>
<text top="372" left="64" width="251" height="13" font="14">patients usually tolerate digoxin without dif</text>
<text top="369" left="316" width="39" height="18" font="14">ﬁculty.</text>
<text top="398" left="64" width="120" height="15" font="14">7.3.2.7.2. Digoxin:</text>
<text top="398" left="204" width="60" height="15" font="14">Initiation</text>
<text top="398" left="284" width="23" height="15" font="14">and</text>
<text top="398" left="327" width="86" height="15" font="14">Maintenance.</text>
<text top="417" left="64" width="350" height="13" font="14">Therapy with digoxin is commonly initiated and maintained</text>
<text top="435" left="64" width="350" height="13" font="14">at a dose of 0.125 to 0.25 mg daily. Low doses (0.125 mg</text>
<text top="453" left="64" width="350" height="13" font="14">daily or every other day) should be used initially if the patient</text>
<text top="471" left="64" width="9" height="13" font="14">is</text>
<text top="467" left="77" width="337" height="18" font="14">&gt;70 years of age, has impaired renal function, or has a low</text>
<text top="489" left="64" width="91" height="13" font="14">lean body mass</text>
<text top="489" left="161" width="30" height="13" font="15"><a href="e147.full.html#75">(496)</a></text>
<text top="489" left="192" width="222" height="13" font="14"><a href="e147.full.html#75">. </a>Higher doses (e.g., digoxin 0.375 to</text>
<text top="507" left="64" width="350" height="13" font="14">0.50 mg daily) are rarely used or needed in the management</text>
<text top="525" left="64" width="350" height="13" font="14">of patients with HF. There is no reason to use loading doses</text>
<text top="543" left="64" width="285" height="13" font="14">of digoxin to initiate therapy in patients with HF.</text>
<text top="561" left="79" width="335" height="13" font="14">Doses of digoxin that achieve a plasma concentration of</text>
<text top="579" left="64" width="350" height="13" font="14">drug in the range of 0.5 to 0.9 ng/mL are suggested, given the</text>
<text top="596" left="64" width="350" height="13" font="14">limited evidence currently available. There has been no</text>
<text top="614" left="64" width="300" height="13" font="14">prospective, randomized evaluation of the relative ef</text>
<text top="611" left="364" width="49" height="18" font="14">ﬁcacy or</text>
<text top="632" left="64" width="350" height="13" font="14">safety of different plasma concentrations of digoxin. Retro-</text>
<text top="650" left="64" width="350" height="13" font="14">spective analysis of 2 studies of digoxin withdrawal found</text>
<text top="668" left="64" width="350" height="13" font="14">that prevention of worsening HF by digoxin at lower</text>
<text top="686" left="64" width="350" height="13" font="14">concentrations in plasma (0.5 to 0.9 ng/mL) was as great as</text>
<text top="704" left="64" width="217" height="13" font="14">that achieved at higher concentrations</text>
<text top="704" left="286" width="55" height="13" font="15"><a href="e147.full.html#75">(497,498)</a></text>
<text top="704" left="342" width="4" height="13" font="14"><a href="e147.full.html#75">.</a></text>
<text top="730" left="64" width="350" height="15" font="14">7.3.2.7.3. Digoxin: Risks of Treatment. When adminis-</text>
<text top="749" left="64" width="350" height="13" font="14">tered with attention to dose and factors that alter its metabo-</text>
<text top="767" left="64" width="312" height="13" font="14">lism, digoxin is well tolerated by most patients with HF</text>
<text top="767" left="380" width="30" height="13" font="15"><a href="e147.full.html#75">(499)</a></text>
<text top="767" left="410" width="4" height="13" font="14">.</text>
<text top="785" left="64" width="350" height="13" font="14">The principal adverse reactions occur primarily when digoxin</text>
<text top="803" left="64" width="350" height="13" font="14">is administered in large doses, especially in the elderly, but</text>
<text top="821" left="64" width="265" height="13" font="14">large doses are not necessary for clinical bene</text>
<text top="817" left="330" width="17" height="18" font="14">ﬁts</text>
<text top="821" left="352" width="26" height="13" font="15"><a href="e147.full.html#76">(500</a></text>
<text top="817" left="377" width="33" height="18" font="15"><a href="e147.full.html#76">–502)</a></text>
<text top="821" left="410" width="4" height="13" font="14">.</text>
<text top="839" left="64" width="350" height="13" font="14">The major adverse effects include cardiac arrhythmias (e.g.,</text>
<text top="857" left="64" width="350" height="13" font="14">ectopic and re-entrant cardiac rhythms and heart block),</text>
<text top="874" left="64" width="350" height="13" font="14">gastrointestinal symptoms (e.g., anorexia, nausea, and vom-</text>
<text top="892" left="64" width="350" height="13" font="14">iting), and neurological complaints (e.g., visual disturbances,</text>
<text top="910" left="64" width="350" height="13" font="14">disorientation, and confusion). Overt digoxin toxicity is</text>
<text top="928" left="64" width="276" height="13" font="14">commonly associated with serum digoxin levels</text>
<text top="924" left="345" width="64" height="18" font="14">&gt;2 ng/mL.</text>
<text top="946" left="79" width="335" height="13" font="14">However, toxicity may also occur with lower digoxin</text>
<text top="964" left="64" width="350" height="13" font="14">levels, especially if hypokalemia, hypomagnesemia, or</text>
<text top="982" left="64" width="140" height="13" font="14">hypothyroidism coexists</text>
<text top="982" left="210" width="55" height="13" font="15"><a href="e147.full.html#76">(503,504)</a></text>
<text top="982" left="266" width="148" height="13" font="14"><a href="e147.full.html#76">. </a>The concomitant use of</text>
<text top="1000" left="64" width="350" height="13" font="14">clarithromycin, dronedarone, erythromycin, amiodarone, itra-</text>
<text top="1018" left="64" width="350" height="13" font="14">conazole, cyclosporine, propafenone, verapamil, or quinidine</text>
<text top="1036" left="64" width="350" height="13" font="14">can increase serum digoxin concentrations and may increase</text>
<text top="1054" left="64" width="200" height="13" font="14">the likelihood of digoxin toxicity</text>
<text top="1054" left="271" width="26" height="13" font="15"><a href="e147.full.html#76">(505</a></text>
<text top="1050" left="297" width="33" height="18" font="15"><a href="e147.full.html#76">–507)</a></text>
<text top="1054" left="330" width="84" height="13" font="14"><a href="e147.full.html#76">. </a>The dose of</text>
<text top="1072" left="64" width="350" height="13" font="14">digoxin should be reduced if treatment with these drugs is</text>
<text top="1090" left="64" width="350" height="13" font="14">initiated. In addition, a low lean body mass and impaired renal</text>
<text top="103" left="450" width="350" height="13" font="14">function can also elevate serum digoxin levels, which may</text>
<text top="121" left="450" width="350" height="13" font="14">explain the increased risk of digoxin toxicity in elderly patients.</text>
<text top="154" left="450" width="46" height="15" font="14">7.3.2.8.</text>
<text top="157" left="503" width="154" height="11" font="20">OTHER DRUG TREATMENT</text>
<text top="172" left="450" width="293" height="15" font="14">7.3.2.8.1. Anticoagulation: Recommendations</text>
<text top="199" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="211" left="468" width="10" height="10" font="18">1.</text>
<text top="211" left="485" width="314" height="10" font="18">Patients with chronic HF with permanent/persistent/</text>
<text top="227" left="485" width="314" height="10" font="18">paroxysmal AF and an additional risk factor for car-</text>
<text top="243" left="485" width="314" height="10" font="18">dioembolic stroke (history of hypertension, diabetes melli-</text>
<text top="260" left="485" width="288" height="10" font="18">tus, previous stroke or transient ischemic attack, or</text>
<text top="257" left="778" width="21" height="16" font="18">‡75</text>
<text top="276" left="485" width="314" height="10" font="18">years of age) should receive chronic anticoagulant therapy*</text>
<text top="293" left="485" width="4" height="10" font="18">(</text>
<text top="293" left="490" width="21" height="10" font="5"><a href="e147.full.html#76">508</a></text>
<text top="290" left="511" width="27" height="16" font="5"><a href="e147.full.html#76">–514</a></text>
<text top="293" left="538" width="125" height="12" font="18">). (Level of Evidence: A)</text>
<text top="309" left="468" width="10" height="10" font="18">2.</text>
<text top="309" left="485" width="314" height="10" font="18">The selection of an anticoagulant agent (warfarin, dabigatran,</text>
<text top="326" left="485" width="314" height="10" font="18">apixaban, or rivaroxaban) for permanent/persistent/parox-</text>
<text top="342" left="485" width="314" height="10" font="18">ysmal AF should be individualized on the basis of risk factors,</text>
<text top="359" left="485" width="314" height="10" font="18">cost, tolerability, patient preference, potential for drug inter-</text>
<text top="375" left="485" width="314" height="10" font="18">actions, and other clinical characteristics, including time in</text>
<text top="391" left="485" width="314" height="10" font="18">the international normalized ratio therapeutic range if the</text>
<text top="408" left="485" width="285" height="12" font="18">patient has been taking warfarin. (Level of Evidence: C)</text>
<text top="432" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="444" left="468" width="10" height="10" font="18">1.</text>
<text top="444" left="485" width="314" height="10" font="18">Chronic anticoagulation is reasonable for patients with</text>
<text top="460" left="485" width="314" height="10" font="18">chronic HF who have permanent/persistent/paroxysmal AF</text>
<text top="477" left="485" width="314" height="10" font="18">but are without an additional risk factor for cardioembolic</text>
<text top="493" left="485" width="34" height="10" font="18"><a href="e147.full.html#34">stroke</a></text>
<text top="493" left="519" width="6" height="10" font="5"><a href="e147.full.html#34">*</a></text>
<text top="493" left="529" width="4" height="10" font="18">(</text>
<text top="493" left="534" width="21" height="10" font="5"><a href="e147.full.html#76">509</a></text>
<text top="490" left="555" width="79" height="16" font="5"><a href="e147.full.html#76">–511,515–517</a></text>
<text top="493" left="634" width="125" height="12" font="18">). (Level of Evidence: B)</text>
<text top="517" left="450" width="88" height="8" font="17">CLASS III: No Bene</text>
<text top="514" left="538" width="10" height="13" font="17">ﬁt</text>
<text top="529" left="468" width="10" height="10" font="18">1.</text>
<text top="529" left="485" width="314" height="10" font="18">Anticoagulation is not recommended in patients with</text>
<text top="545" left="485" width="314" height="12" font="18">chronic HFrEF without AF, a prior thromboembolic event, or</text>
<text top="562" left="485" width="123" height="10" font="18">a cardioembolic source</text>
<text top="562" left="612" width="26" height="10" font="5"><a href="e147.full.html#76">(518</a></text>
<text top="559" left="638" width="32" height="16" font="5"><a href="e147.full.html#76">–520)</a></text>
<text top="562" left="669" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="587" left="465" width="335" height="13" font="14">Patients with chronic HFrEF are at an increased risk of</text>
<text top="605" left="450" width="350" height="13" font="14">thromboembolic events due to stasis of blood in dilated</text>
<text top="623" left="450" width="350" height="13" font="14">hypokinetic cardiac chambers and in peripheral blood vessels</text>
<text top="641" left="450" width="55" height="13" font="15"><a href="e147.full.html#76">(521,522)</a></text>
<text top="641" left="511" width="288" height="13" font="14">and perhaps due to increased activity of procoa-</text>
<text top="659" left="450" width="78" height="13" font="14">gulant factors</text>
<text top="659" left="532" width="30" height="13" font="15"><a href="e147.full.html#76">(523)</a></text>
<text top="659" left="562" width="237" height="13" font="14">. However, in large-scale studies, the risk</text>
<text top="677" left="450" width="350" height="13" font="14">of thromboembolism in clinically stable patients has been low</text>
<text top="695" left="450" width="350" height="13" font="14">(1% to 3% per year), even in those with a very depressed</text>
<text top="713" left="450" width="350" height="13" font="14">EF and echocardiographic evidence of intracardiac thrombi</text>
<text top="731" left="450" width="26" height="13" font="15"><a href="e147.full.html#76">(524</a></text>
<text top="727" left="476" width="33" height="18" font="15"><a href="e147.full.html#76">–528)</a></text>
<text top="731" left="509" width="133" height="13" font="14"><a href="e147.full.html#76">. </a>These rates are suf</text>
<text top="727" left="642" width="157" height="18" font="14">ﬁciently low to limit the</text>
<text top="749" left="450" width="88" height="13" font="14">detectable bene</text>
<text top="745" left="538" width="220" height="18" font="14">ﬁt of anticoagulation in these patients.</text>
<text top="766" left="465" width="335" height="13" font="14">In several retrospective analyses, the risk of thromboem-</text>
<text top="784" left="450" width="350" height="13" font="14">bolic events was not lower in patients with HF taking warfarin</text>
<text top="802" left="450" width="350" height="13" font="14">than in patients not treated with antithrombotic drugs</text>
<text top="820" left="450" width="80" height="13" font="15"><a href="e147.full.html#76">(524,526,527)</a></text>
<text top="820" left="530" width="270" height="13" font="14"><a href="e147.full.html#76">. </a>The use of warfarin was associated with a</text>
<text top="838" left="450" width="350" height="13" font="14">reduction in major cardiovascular events and death in patients</text>
<text top="856" left="450" width="240" height="13" font="14">with HF in some studies but not in others</text>
<text top="856" left="694" width="80" height="13" font="15"><a href="e147.full.html#76">(518,529,530)</a></text>
<text top="856" left="774" width="25" height="13" font="14">. An</text>
<text top="874" left="450" width="350" height="13" font="14">RCT that compared the outcome of patients with HFrEF</text>
<text top="892" left="450" width="350" height="13" font="14">assigned to aspirin, warfarin, or clopidogrel was completed</text>
<text top="910" left="450" width="30" height="13" font="15"><a href="e147.full.html#76">(519)</a></text>
<text top="910" left="480" width="319" height="13" font="14">, but no therapy appeared to be superior. Another trial</text>
<text top="928" left="450" width="350" height="13" font="14">compared aspirin with warfarin in patients with reduced LVEF,</text>
<text top="946" left="450" width="350" height="13" font="14">sinus rhythm, and no cardioembolic source and demonstrated</text>
<text top="964" left="450" width="350" height="13" font="14">no difference in either the primary outcome of death, stroke, or</text>
<text top="982" left="450" width="142" height="13" font="14">intracerebral hemorrhage</text>
<text top="982" left="596" width="30" height="13" font="15"><a href="e147.full.html#76">(520)</a></text>
<text top="982" left="626" width="173" height="13" font="14">. There was also no difference</text>
<text top="1000" left="450" width="350" height="13" font="14">in the combined outcome of death, ischemic stroke, intrace-</text>
<text top="1018" left="450" width="350" height="13" font="14">rebral hemorrhage, MI, or HF hospitalization. There was</text>
<text top="1035" left="450" width="38" height="13" font="14">a signi</text>
<text top="1032" left="488" width="312" height="18" font="14">ﬁcant increase in major bleeding with warfarin. Given</text>
<text top="1092" left="450" width="235" height="9" font="20">*In the absence of contraindications to anticoagulation.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e180</text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="153" height="13" font="14">that there is no overall bene</text>
<text top="100" left="217" width="196" height="18" font="14">ﬁt of warfarin and an increased risk</text>
<text top="121" left="64" width="350" height="13" font="14">of bleeding, there is no compelling evidence to use warfarin or</text>
<text top="139" left="64" width="336" height="13" font="14">aspirin in patients with HFrEF in the absence of a speci</text>
<text top="135" left="400" width="14" height="18" font="14">ﬁc</text>
<text top="157" left="64" width="60" height="13" font="14">indication.</text>
<text top="175" left="79" width="39" height="13" font="14">The ef</text>
<text top="171" left="118" width="296" height="18" font="14">ﬁcacy of long-term warfarin for the prevention of</text>
<text top="193" left="64" width="350" height="13" font="14">stroke in patients with AF is well established. However, the</text>
<text top="211" left="64" width="184" height="13" font="14">ACCF/AHA guidelines for AF</text>
<text top="211" left="256" width="16" height="13" font="15"><a href="e147.full.html#64">(6)</a></text>
<text top="211" left="279" width="135" height="13" font="14">recommend use of the</text>
<text top="229" left="64" width="48" height="13" font="14">CHADS</text>
<text top="234" left="112" width="5" height="9" font="12">2</text>
<text top="229" left="123" width="260" height="13" font="14">[Congestive heart failure, Hypertension, Age</text>
<text top="225" left="389" width="25" height="18" font="14">75</text>
<text top="247" left="64" width="350" height="13" font="14">years, Diabetes mellitus, previous Stroke/transient ischemic</text>
<text top="265" left="64" width="350" height="13" font="14">attack (doubled risk weight)] score to assess patient risk for</text>
<text top="283" left="64" width="350" height="13" font="14">adverse outcomes before initiating anticoagulation therapy.</text>
<text top="301" left="64" width="350" height="13" font="14">More recently, a revised score, CHADS2-VASc, has been</text>
<text top="319" left="64" width="350" height="13" font="14">suggested as more applicable to a wider range of patients</text>
<text top="337" left="64" width="30" height="13" font="15"><a href="e147.full.html#76">(531)</a></text>
<text top="337" left="95" width="319" height="13" font="14"><a href="e147.full.html#76">, </a>but this revised score has not yet been fully studied in</text>
<text top="354" left="64" width="350" height="13" font="14">patients with HF. Regardless of whether patients receive</text>
<text top="372" left="64" width="350" height="13" font="14">rhythm or rate control, anticoagulation is recommended for</text>
<text top="390" left="64" width="350" height="13" font="14">patients with HF and AF for stroke prevention in the presence</text>
<text top="408" left="64" width="350" height="13" font="14">of at least 1 additional risk factor. For patients with HF and</text>
<text top="426" left="64" width="350" height="13" font="14">AF in the absence of another cardioembolic risk factor, anti-</text>
<text top="444" left="64" width="148" height="13" font="14">coagulation is reasonable.</text>
<text top="462" left="79" width="301" height="13" font="14">Trials of newer oral anticoagulants have compared ef</text>
<text top="458" left="380" width="34" height="18" font="14">ﬁcacy</text>
<text top="480" left="64" width="350" height="13" font="14">and safety with warfarin therapy rather than placebo. Several</text>
<text top="498" left="64" width="350" height="13" font="14">new oral anticoagulants are now available, including the</text>
<text top="516" left="64" width="350" height="13" font="14">factor Xa inhibitors apixaban and rivaroxaban and the direct</text>
<text top="534" left="64" width="174" height="13" font="14">thrombin inhibitor dabigatran</text>
<text top="534" left="247" width="51" height="13" font="15"><a href="e147.full.html#76">(508,512</a></text>
<text top="530" left="297" width="33" height="18" font="15"><a href="e147.full.html#76">–514)</a></text>
<text top="534" left="330" width="84" height="13" font="14">. These drugs</text>
<text top="552" left="64" width="350" height="13" font="14">have few food and drug interactions compared with warfarin</text>
<text top="570" left="64" width="350" height="13" font="14">and no need for routine coagulation monitoring or dose</text>
<text top="588" left="64" width="91" height="13" font="14">adjustment. The</text>
<text top="584" left="160" width="254" height="18" font="14">ﬁxed dosing together with fewer interactions</text>
<text top="606" left="64" width="350" height="13" font="14">may simplify patient management, particularly with the</text>
<text top="623" left="64" width="350" height="13" font="14">polypharmacy commonly seen in HF. These drugs have</text>
<text top="641" left="64" width="183" height="13" font="14">a potential for an improved bene</text>
<text top="638" left="247" width="167" height="18" font="14">ﬁt–risk proﬁle compared with</text>
<text top="659" left="64" width="350" height="13" font="14">warfarin, which may increase their use in practice, especially in</text>
<text top="677" left="64" width="350" height="13" font="14">those at increased bleeding risk. However, important adverse</text>
<text top="695" left="64" width="350" height="13" font="14">effects have been noted with these new anticoagulants,</text>
<text top="713" left="64" width="350" height="13" font="14">including gastrointestinal distress, which may limit compli-</text>
<text top="731" left="64" width="350" height="13" font="14">ance. At present, there is no commercially available agent to</text>
<text top="749" left="64" width="350" height="13" font="14">reverse the effect of these newer drugs. Trials comparing new</text>
<text top="767" left="64" width="246" height="13" font="14">anticoagulants with warfarin have enrolled</text>
<text top="763" left="315" width="99" height="18" font="14">&gt;10,000 patients</text>
<text top="785" left="64" width="350" height="13" font="14">with HF. As more detailed evaluations of the comparative</text>
<text top="803" left="64" width="27" height="13" font="14">bene</text>
<text top="799" left="91" width="323" height="18" font="14">ﬁts and risks of these newer agents in patients with HF are</text>
<text top="821" left="64" width="350" height="13" font="14">still pending, the writing committee considered their use in</text>
<text top="839" left="64" width="350" height="13" font="14">patients with HF and nonvalvular AF as an alternative to</text>
<text top="857" left="64" width="147" height="13" font="14">warfarin to be reasonable.</text>
<text top="875" left="79" width="54" height="13" font="14">The bene</text>
<text top="871" left="133" width="281" height="18" font="14">ﬁt afforded by low-dose aspirin in patients with</text>
<text top="892" left="64" width="337" height="13" font="14">systolic HF but no previous MI or known CAD (or speci</text>
<text top="889" left="402" width="12" height="18" font="14">ﬁ-</text>
<text top="910" left="64" width="350" height="13" font="14">cally in patients proven free of CAD) remains unknown. A</text>
<text top="928" left="64" width="143" height="13" font="14">Cochrane review failed to</text>
<text top="924" left="210" width="204" height="18" font="14">ﬁnd sufﬁcient evidence to support its</text>
<text top="946" left="64" width="19" height="13" font="14">use</text>
<text top="946" left="88" width="30" height="13" font="15"><a href="e147.full.html#76">(532)</a></text>
<text top="946" left="118" width="296" height="13" font="14">. Retrospective and observational studies again had</text>
<text top="964" left="64" width="20" height="13" font="14">con</text>
<text top="960" left="85" width="329" height="18" font="14">ﬂicting results and used very different criteria to identify</text>
<text top="982" left="64" width="350" height="13" font="14">patients as nonischemic, with some demonstrating protection</text>
<text top="1000" left="64" width="111" height="13" font="14">from aspirin overall</text>
<text top="1000" left="179" width="30" height="13" font="15"><a href="e147.full.html#76">(532)</a></text>
<text top="1000" left="213" width="201" height="13" font="14">or only in patients with more severe</text>
<text top="1018" left="64" width="171" height="13" font="14">depression of systolic function</text>
<text top="1018" left="239" width="30" height="13" font="15"><a href="e147.full.html#76">(518)</a></text>
<text top="1018" left="270" width="144" height="13" font="14"><a href="e147.full.html#76">, </a>whereas others found no</text>
<text top="1036" left="64" width="27" height="13" font="14">bene</text>
<text top="1032" left="91" width="90" height="18" font="14">ﬁt from aspirin</text>
<text top="1036" left="188" width="30" height="13" font="15"><a href="e147.full.html#76">(530)</a></text>
<text top="1036" left="218" width="195" height="13" font="14">. The high incidence of diabetes</text>
<text top="1054" left="64" width="350" height="13" font="14">mellitus and hypertension in most HF studies, combined with</text>
<text top="1072" left="64" width="350" height="13" font="14">a failure to use objective methods to exclude CAD in enrolled</text>
<text top="1090" left="64" width="350" height="13" font="14">patients, may leave this question unanswered. Currently, data</text>
<text top="103" left="450" width="52" height="13" font="14">are insuf</text>
<text top="100" left="502" width="297" height="18" font="14">ﬁcient to recommend aspirin for empiric primary</text>
<text top="121" left="450" width="350" height="13" font="14">prevention in HF patients known to be free of atherosclerotic</text>
<text top="139" left="450" width="243" height="13" font="14">disease and without additional risk factors.</text>
<text top="157" left="465" width="20" height="13" font="14">See</text>
<text top="157" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 21</a></text>
<text top="157" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="175" left="450" width="87" height="13" font="14">anticoagulants.</text>
<text top="205" left="450" width="229" height="15" font="14">7.3.2.8.2. Statins: Recommendation</text>
<text top="232" left="450" width="88" height="8" font="17">CLASS III: No Bene</text>
<text top="229" left="538" width="10" height="13" font="17">ﬁt</text>
<text top="244" left="468" width="10" height="10" font="18">1.</text>
<text top="244" left="485" width="122" height="10" font="18">Statins are not bene</text>
<text top="241" left="607" width="192" height="16" font="18">ﬁcial as adjunctive therapy when</text>
<text top="260" left="485" width="314" height="10" font="18">prescribed solely for the diagnosis of HF in the absence of</text>
<text top="277" left="485" width="141" height="10" font="18">other indications for their use</text>
<text top="277" left="629" width="25" height="10" font="5"><a href="e147.full.html#76">(533</a></text>
<text top="274" left="653" width="30" height="16" font="5"><a href="e147.full.html#76">–538)</a></text>
<text top="277" left="684" width="116" height="12" font="18"><a href="e147.full.html#76">. </a>(Level of Evidence: A)</text>
<text top="302" left="465" width="335" height="13" font="14">Statin therapy has been broadly implicated in prevention of</text>
<text top="320" left="450" width="350" height="13" font="14">adverse cardiovascular events, including new-onset HF.</text>
<text top="338" left="450" width="350" height="13" font="14">Originally designed to lower cholesterol in patients with</text>
<text top="356" left="450" width="350" height="13" font="14">cardiovascular disease, statins are increasingly recognized for</text>
<text top="374" left="450" width="160" height="13" font="14">their favorable effects on in</text>
<text top="370" left="610" width="190" height="18" font="14">ﬂammation, oxidative stress, and</text>
<text top="392" left="450" width="350" height="13" font="14">vascular performance. Several observational and post hoc</text>
<text top="410" left="450" width="350" height="13" font="14">analyses from large clinical trials have implied that statin</text>
<text top="428" left="450" width="209" height="13" font="14">therapy may provide clinical bene</text>
<text top="424" left="659" width="141" height="18" font="14">ﬁt to patients with HF</text>
<text top="446" left="450" width="26" height="13" font="15"><a href="e147.full.html#76">(533</a></text>
<text top="442" left="476" width="33" height="18" font="15"><a href="e147.full.html#76">–536)</a></text>
<text top="446" left="509" width="291" height="13" font="14"><a href="e147.full.html#76">. </a>However, 2 large RCTs have demonstrated that</text>
<text top="463" left="450" width="350" height="13" font="14">rosuvastatin has neutral effects on long-term outcomes in</text>
<text top="481" left="450" width="350" height="13" font="14">patients with chronic HFrEF when added to standard GDMT</text>
<text top="499" left="450" width="55" height="13" font="15"><a href="e147.full.html#76">(537,538)</a></text>
<text top="499" left="505" width="294" height="13" font="14">. At present, statin therapy should not be prescribed</text>
<text top="517" left="450" width="350" height="13" font="14">primarily for the treatment of HF to improve clinical outcomes.</text>
<text top="535" left="465" width="20" height="13" font="14">See</text>
<text top="535" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 22</a></text>
<text top="535" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="553" left="450" width="82" height="13" font="14">statin therapy.</text>
<text top="583" left="450" width="323" height="15" font="14">7.3.2.8.3. Omega-3 Fatty Acids: Recommendation</text>
<text top="610" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="622" left="468" width="10" height="10" font="18">1.</text>
<text top="622" left="485" width="314" height="10" font="18">Omega-3 polyunsaturated fatty acid (PUFA) supplementa-</text>
<text top="638" left="485" width="314" height="10" font="18">tion is reasonable to use as adjunctive therapy in patients</text>
<text top="655" left="485" width="109" height="10" font="18">with NYHA class II</text>
<text top="652" left="595" width="205" height="16" font="18">–IV symptoms and HFrEF or HFpEF,</text>
<text top="671" left="485" width="314" height="10" font="18">unless contraindicated, to reduce mortality and cardiovas-</text>
<text top="688" left="485" width="112" height="10" font="18">cular hospitalizations</text>
<text top="688" left="601" width="55" height="10" font="5"><a href="e147.full.html#76">(539,540)</a></text>
<text top="688" left="656" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="713" left="465" width="335" height="13" font="14">Supplementation with omega-3 PUFA has been evaluated</text>
<text top="731" left="450" width="350" height="13" font="14">as an adjunctive therapy for cardiovascular disease and HF</text>
<text top="749" left="450" width="30" height="13" font="15"><a href="e147.full.html#76">(541)</a></text>
<text top="749" left="480" width="319" height="13" font="14">. Trials in primary and secondary prevention of coronary</text>
<text top="767" left="450" width="350" height="13" font="14">heart disease showed that omega-3 PUFA supplementation</text>
<text top="785" left="450" width="350" height="13" font="14">results in a 10% to 20% risk reduction in fatal and nonfatal</text>
<text top="803" left="450" width="350" height="13" font="14">cardiovascular events. The GISSI (Gruppo Italiano per lo</text>
<text top="821" left="450" width="197" height="13" font="14">Studio della Sopravvivenza nell</text>
<text top="817" left="647" width="153" height="18" font="14">’Infarto miocardico) Pre-</text>
<text top="839" left="450" width="350" height="13" font="14">venzione trial demonstrated a 21% reduction in death among</text>
<text top="857" left="450" width="350" height="13" font="14">post-MI patients taking 1 g of omega-3 PUFA (850 mg to 882</text>
<text top="874" left="450" width="350" height="13" font="14">mg of eicosapentaenoic acid [EPA] and docosahexaenoic acid</text>
<text top="892" left="450" width="254" height="13" font="14">[DHA] as ethyl esters in the ratio of 1:1.2)</text>
<text top="892" left="710" width="30" height="13" font="15"><a href="e147.full.html#76">(542)</a></text>
<text top="892" left="740" width="59" height="13" font="14">. Post hoc</text>
<text top="910" left="450" width="350" height="13" font="14">subgroup analysis revealed that this reduction in mortality and</text>
<text top="928" left="450" width="350" height="13" font="14">SCD was concentrated in the approximately 2000 patients</text>
<text top="946" left="450" width="125" height="13" font="14">with reduced LVEF</text>
<text top="946" left="584" width="30" height="13" font="15"><a href="e147.full.html#76">(539)</a></text>
<text top="946" left="615" width="185" height="13" font="14"><a href="e147.full.html#76">. </a>The GISSI-HF investigators</text>
<text top="964" left="450" width="258" height="13" font="14">randomized 6,975 patients in NYHA class II</text>
<text top="960" left="708" width="91" height="18" font="14">–IV chronic HF</text>
<text top="982" left="450" width="350" height="13" font="14">to 1 g daily of omega-3 PUFA (850 mg to 882 mg EPA/DHA)</text>
<text top="1000" left="450" width="350" height="13" font="14">or matching placebo. Death from any cause was reduced from</text>
<text top="1018" left="450" width="350" height="13" font="14">29% with placebo to 27% in those treated with omega-3 PUFA</text>
<text top="1036" left="450" width="30" height="13" font="15"><a href="e147.full.html#76">(540)</a></text>
<text top="1036" left="480" width="319" height="13" font="14">. The outcome of death or admission to hospital for</text>
<text top="1054" left="450" width="217" height="13" font="14">a cardiovascular event was also signi</text>
<text top="1050" left="666" width="133" height="18" font="14">ﬁcantly reduced. In re-</text>
<text top="1072" left="450" width="350" height="13" font="14">ported studies, this therapy has been safe and very well toler-</text>
<text top="1090" left="450" width="23" height="13" font="14">ated</text>
<text top="1090" left="480" width="26" height="13" font="15"><a href="e147.full.html#76">(540</a></text>
<text top="1086" left="505" width="33" height="18" font="15"><a href="e147.full.html#76">–543)</a></text>
<text top="1090" left="538" width="261" height="13" font="14">. Further investigations are needed to better</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e181</text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="13" height="13" font="14">de</text>
<text top="100" left="78" width="336" height="18" font="14">ﬁne optimal dosing and formulation of omega-3 PUFA</text>
<text top="121" left="64" width="350" height="13" font="14">supplements. The use of omega-3 PUFA supplementation is</text>
<text top="139" left="64" width="348" height="13" font="14">reasonable as adjunctive therapy in patients with chronic HF.</text>
<text top="157" left="79" width="20" height="13" font="14">See</text>
<text top="157" left="106" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 23</a></text>
<text top="157" left="280" width="134" height="13" font="14">for additional data on</text>
<text top="175" left="64" width="117" height="13" font="14">omega-3 fatty acids.</text>
<text top="205" left="64" width="46" height="15" font="14">7.3.2.9.</text>
<text top="209" left="118" width="255" height="11" font="20">DRUGS OF UNPROVEN VALUE OR THAT MAY</text>
<text top="227" left="64" width="70" height="11" font="20">WORSEN HF</text>
<text top="223" left="134" width="4" height="15" font="14">:</text>
<text top="227" left="143" width="120" height="11" font="20">RECOMMENDATIONS</text>
<text top="250" left="64" width="88" height="8" font="17">CLASS III: No Bene</text>
<text top="248" left="152" width="10" height="13" font="17">ﬁt</text>
<text top="262" left="82" width="10" height="10" font="18">1.</text>
<text top="262" left="100" width="314" height="10" font="18">Nutritional supplements as treatment for HF are not rec-</text>
<text top="278" left="100" width="314" height="10" font="18">ommended in patients with current or prior symptoms of</text>
<text top="295" left="100" width="31" height="12" font="18">HFrEF</text>
<text top="295" left="135" width="55" height="10" font="5"><a href="e147.full.html#76">(544,545)</a></text>
<text top="295" left="190" width="121" height="12" font="18"><a href="e147.full.html#76">. </a>(Level of Evidence: B)</text>
<text top="312" left="82" width="10" height="10" font="18">2.</text>
<text top="311" left="100" width="242" height="10" font="18">Hormonal therapies other than to correct de</text>
<text top="308" left="342" width="72" height="16" font="18">ﬁciencies are</text>
<text top="328" left="100" width="314" height="10" font="18">not recommended for patients with current or prior symp-</text>
<text top="344" left="100" width="196" height="12" font="18">toms of HFrEF. (Level of Evidence: C)</text>
<text top="368" left="64" width="73" height="8" font="17">CLASS III: Harm</text>
<text top="380" left="82" width="10" height="10" font="18">1.</text>
<text top="380" left="100" width="314" height="10" font="18">Drugs known to adversely affect the clinical status of</text>
<text top="397" left="100" width="314" height="12" font="18">patients with current or prior symptoms of HFrEF are poten-</text>
<text top="413" left="100" width="314" height="10" font="18">tially harmful and should be avoided or withdrawn whenever</text>
<text top="429" left="100" width="314" height="10" font="18">possible (e.g., most antiarrhythmic drugs, most calcium</text>
<text top="446" left="100" width="41" height="10" font="18">channel</text>
<text top="443" left="141" width="273" height="16" font="18">–blocking drugs [except amlodipine], NSAIDs, or</text>
<text top="462" left="100" width="98" height="10" font="18">thiazolidinediones)</text>
<text top="462" left="202" width="26" height="10" font="5"><a href="e147.full.html#76">(546</a></text>
<text top="459" left="228" width="32" height="16" font="5"><a href="e147.full.html#76">–557)</a></text>
<text top="462" left="259" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="479" left="82" width="10" height="10" font="18">2.</text>
<text top="479" left="100" width="314" height="10" font="18">Long-term use of infused positive inotropic drugs is poten-</text>
<text top="495" left="100" width="314" height="12" font="18">tially harmful for patients with HFrEF, except as palliation for</text>
<text top="512" left="100" width="314" height="10" font="18">patients with end-stage disease who cannot be stabilized</text>
<text top="528" left="100" width="314" height="10" font="18">with standard medical treatment (see recommendations for</text>
<text top="544" left="100" width="166" height="12" font="18">stage D). (Level of Evidence: C)</text>
<text top="576" left="64" width="350" height="15" font="14">7.3.2.9.1. Nutritional Supplements and Hormonal</text>
<text top="594" left="64" width="350" height="15" font="14">Therapies. Patients with HF, particularly those treated with</text>
<text top="613" left="64" width="161" height="13" font="14">diuretics, may become de</text>
<text top="609" left="225" width="189" height="18" font="14">ﬁcient in vitamins and micro-</text>
<text top="631" left="64" width="350" height="13" font="14">nutrients. Several nutritional supplements (e.g., coenzyme</text>
<text top="649" left="64" width="350" height="13" font="14">Q10, carnitine, taurine, and antioxidants) and hormonal</text>
<text top="667" left="64" width="350" height="13" font="14">therapies (e.g., growth hormone or thyroid hormone) have</text>
<text top="685" left="64" width="233" height="13" font="14">been proposed for the treatment of HF</text>
<text top="685" left="304" width="26" height="13" font="15"><a href="e147.full.html#77">(558</a></text>
<text top="681" left="330" width="33" height="18" font="15"><a href="e147.full.html#77">–563)</a></text>
<text top="685" left="363" width="51" height="13" font="14"><a href="e147.full.html#77">. </a>Testos-</text>
<text top="703" left="64" width="247" height="13" font="14">terone has also been evaluated for its bene</text>
<text top="699" left="311" width="103" height="18" font="14">ﬁcial effect in HF</text>
<text top="721" left="64" width="231" height="13" font="14">with modest albeit preliminary effects</text>
<text top="721" left="304" width="30" height="13" font="15"><a href="e147.full.html#77">(564)</a></text>
<text top="721" left="334" width="80" height="13" font="14">. Aside from</text>
<text top="739" left="64" width="198" height="13" font="14">replenishment of documented de</text>
<text top="735" left="263" width="151" height="18" font="14">ﬁciencies, published data</text>
<text top="757" left="64" width="185" height="13" font="14">have failed to demonstrate bene</text>
<text top="753" left="249" width="165" height="18" font="14">ﬁt for routine vitamin, nutri-</text>
<text top="775" left="64" width="212" height="13" font="14">tional, or hormonal supplementation</text>
<text top="775" left="282" width="30" height="13" font="15"><a href="e147.full.html#77">(565)</a></text>
<text top="775" left="313" width="101" height="13" font="14"><a href="e147.full.html#77">. </a>In most data or</text>
<text top="793" left="64" width="350" height="13" font="14">other literature regarding nutraceuticals, there are issues,</text>
<text top="811" left="64" width="350" height="13" font="14">including outcomes analyses, adverse effects, and drug-</text>
<text top="828" left="64" width="285" height="13" font="14">nutraceutical interactions, that remain unresolved.</text>
<text top="846" left="79" width="335" height="13" font="14">No clinical trials have demonstrated improved survival</text>
<text top="864" left="64" width="350" height="13" font="14">rates with use of nutritional or hormonal therapy, with the</text>
<text top="882" left="64" width="350" height="13" font="14">exception of omega-3 fatty acid supplementation as previ-</text>
<text top="900" left="64" width="350" height="13" font="14">ously noted. Some studies have suggested a possible effect for</text>
<text top="918" left="64" width="350" height="13" font="14">coenzyme Q10 in reduced hospitalization rates, dyspnea, and</text>
<text top="936" left="64" width="246" height="13" font="14">edema in patients with HF, but these bene</text>
<text top="932" left="311" width="103" height="18" font="14">ﬁts have not been</text>
<text top="954" left="64" width="91" height="13" font="14">seen uniformly</text>
<text top="954" left="165" width="26" height="13" font="15"><a href="e147.full.html#77">(566</a></text>
<text top="950" left="191" width="33" height="18" font="15"><a href="e147.full.html#77">–569)</a></text>
<text top="954" left="224" width="190" height="13" font="14"><a href="e147.full.html#77">. </a>Because of possible adverse</text>
<text top="972" left="64" width="350" height="13" font="14">effects and drug interactions of nutritional supplements and</text>
<text top="990" left="64" width="350" height="13" font="14">their widespread use, clinicians caring for patients with HF</text>
<text top="1008" left="64" width="350" height="13" font="14">should routinely inquire about their use. Until more data are</text>
<text top="1026" left="64" width="350" height="13" font="14">available, nutritional supplements or hormonal therapies are</text>
<text top="1044" left="64" width="245" height="13" font="14">not recommended for the treatment of HF.</text>
<text top="1069" left="64" width="350" height="15" font="14">7.3.2.9.2. Antiarrhythmic Agents. With atrial and ven-</text>
<text top="1088" left="64" width="350" height="13" font="14">tricular arrhythmias contributing to the morbidity and mortality</text>
<text top="103" left="450" width="350" height="13" font="14">of HF, various classes of antiarrhythmic agents have been</text>
<text top="121" left="450" width="350" height="13" font="14">repeatedly studied in large RCTs. Instead of conferring</text>
<text top="139" left="450" width="79" height="13" font="14">survival bene</text>
<text top="135" left="529" width="271" height="18" font="14">ﬁt, however, nearly all antiarrhythmic agents</text>
<text top="157" left="450" width="243" height="13" font="14">increase mortality in the HF population</text>
<text top="157" left="700" width="26" height="13" font="15"><a href="e147.full.html#77">(548</a></text>
<text top="153" left="726" width="33" height="18" font="15"><a href="e147.full.html#77">–550)</a></text>
<text top="157" left="759" width="40" height="13" font="14">. Most</text>
<text top="175" left="450" width="350" height="13" font="14">antiarrhythmics have some negative inotropic effect and some,</text>
<text top="193" left="450" width="350" height="13" font="14">particularly the class I and class III antiarrhythmic drugs, have</text>
<text top="211" left="450" width="350" height="13" font="14">proarrhythmic effects. Hence, class I sodium channel antago-</text>
<text top="229" left="450" width="350" height="13" font="14">nists and the class III potassium channel blockers d-sotalol and</text>
<text top="247" left="450" width="350" height="13" font="14">dronedarone should be avoided in patients with HF. Amio-</text>
<text top="265" left="450" width="350" height="13" font="14">darone and dofetilide are the only antiarrhythmic agents to</text>
<text top="283" left="450" width="350" height="13" font="14">have neutral effects on mortality in clinical trials of patients</text>
<text top="301" left="450" width="350" height="13" font="14">with HF and thus are the preferred drugs for treating arrhyth-</text>
<text top="319" left="450" width="145" height="13" font="14">mias in this patient group</text>
<text top="319" left="599" width="26" height="13" font="15"><a href="e147.full.html#77">(570</a></text>
<text top="315" left="625" width="33" height="18" font="15"><a href="e147.full.html#77">–573)</a></text>
<text top="319" left="658" width="4" height="13" font="14"><a href="e147.full.html#77">.</a></text>
<text top="337" left="465" width="20" height="13" font="14">See</text>
<text top="337" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 24</a></text>
<text top="337" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="354" left="450" width="129" height="13" font="14">antiarrhythmic agents.</text>
<text top="381" left="450" width="350" height="15" font="14">7.3.2.9.3. Calcium Channel Blockers: Recommendation</text>
<text top="407" left="450" width="88" height="8" font="17">CLASS III: No Bene</text>
<text top="405" left="538" width="10" height="13" font="17">ﬁt</text>
<text top="420" left="468" width="10" height="10" font="18">1.</text>
<text top="419" left="485" width="89" height="10" font="18">Calcium channel</text>
<text top="416" left="574" width="226" height="16" font="18">–blocking drugs are not recommended as</text>
<text top="436" left="485" width="226" height="12" font="18">routine treatment for patients with HFrEF</text>
<text top="436" left="716" width="80" height="10" font="5"><a href="e147.full.html#77">(551,574,575)</a></text>
<text top="436" left="796" width="3" height="10" font="18">.</text>
<text top="452" left="485" width="113" height="12" font="18">(Level of Evidence: A)</text>
<text top="477" left="465" width="335" height="13" font="14">By reducing peripheral vasoconstriction and LV afterload,</text>
<text top="495" left="450" width="350" height="13" font="14">calcium channel blockers were thought to have a potential</text>
<text top="513" left="450" width="314" height="13" font="14">role in the management of chronic HF. However,</text>
<text top="510" left="773" width="26" height="18" font="14">ﬁrst-</text>
<text top="531" left="450" width="350" height="13" font="14">generation dihydropyridine and nondihydropyridine calcium</text>
<text top="549" left="450" width="350" height="13" font="14">channel blockers also have myocardial depressant activity.</text>
<text top="567" left="450" width="350" height="13" font="14">Several clinical trials have demonstrated either no clinical</text>
<text top="585" left="450" width="27" height="13" font="14">bene</text>
<text top="581" left="476" width="323" height="18" font="14">ﬁt or even worse outcomes in patients with HF treated</text>
<text top="603" left="450" width="100" height="13" font="14">with these drugs</text>
<text top="603" left="558" width="76" height="13" font="15"><a href="e147.full.html#76">(546,547,551</a></text>
<text top="599" left="633" width="33" height="18" font="15"><a href="e147.full.html#76">–553)</a></text>
<text top="603" left="666" width="133" height="13" font="14">. Despite their greater</text>
<text top="621" left="450" width="350" height="13" font="14">selectivity for calcium channels in vascular smooth muscle</text>
<text top="639" left="450" width="350" height="13" font="14">cells, second-generation calcium channel blockers, dihy-</text>
<text top="657" left="450" width="350" height="13" font="14">dropyridine derivatives such as amlodipine and felodipine,</text>
<text top="675" left="450" width="338" height="13" font="14">have failed to demonstrate any functional or survival bene</text>
<text top="671" left="788" width="12" height="18" font="14">ﬁt</text>
<text top="693" left="450" width="109" height="13" font="14">in patients with HF</text>
<text top="693" left="562" width="26" height="13" font="15"><a href="e147.full.html#77">(575</a></text>
<text top="689" left="588" width="33" height="18" font="15"><a href="e147.full.html#77">–579)</a></text>
<text top="693" left="621" width="179" height="13" font="14"><a href="e147.full.html#77">. </a>Amlodipine, however, may be</text>
<text top="711" left="450" width="350" height="13" font="14">considered in the management of hypertension or ischemic</text>
<text top="729" left="450" width="350" height="13" font="14">heart disease in patients with HF because it is generally well</text>
<text top="747" left="450" width="350" height="13" font="14">tolerated and had neutral effects on morbidity and mortality in</text>
<text top="764" left="450" width="350" height="13" font="14">large RCTs. In general, calcium channel blockers should be</text>
<text top="782" left="450" width="186" height="13" font="14">avoided in patients with HFrEF.</text>
<text top="800" left="465" width="20" height="13" font="14">See</text>
<text top="800" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 25</a></text>
<text top="800" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="818" left="450" width="150" height="13" font="14">calcium channel blockers.</text>
<text top="844" left="450" width="188" height="15" font="14">7.3.2.9.4. Nonsteroidal Anti-In</text>
<text top="841" left="637" width="163" height="19" font="14">ﬂammatoryDrugs. NSAIDs</text>
<text top="864" left="450" width="350" height="13" font="14">inhibit the synthesis of renal prostaglandins, which mediate</text>
<text top="882" left="450" width="350" height="13" font="14">vasodilation in the kidneys and directly inhibit sodium</text>
<text top="900" left="450" width="350" height="13" font="14">resorption in the thick ascending loop of Henle and collecting</text>
<text top="917" left="450" width="350" height="13" font="14">tubule. Hence, NSAIDs can cause sodium and water retention</text>
<text top="935" left="450" width="350" height="13" font="14">and blunt the effects of diuretics. Several observational cohort</text>
<text top="953" left="450" width="350" height="13" font="14">studies have revealed increased morbidity and mortality in</text>
<text top="971" left="450" width="350" height="13" font="14">patients with HF using either nonselective or selective</text>
<text top="989" left="450" width="48" height="13" font="14">NSAIDs</text>
<text top="989" left="503" width="26" height="13" font="15"><a href="e147.full.html#77">(554</a></text>
<text top="985" left="529" width="86" height="18" font="15"><a href="e147.full.html#77">–556,580–582)</a></text>
<text top="989" left="615" width="4" height="13" font="14">.</text>
<text top="1007" left="465" width="20" height="13" font="14">See</text>
<text top="1007" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 26</a></text>
<text top="1007" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="1025" left="450" width="49" height="13" font="14">NSAIDs.</text>
<text top="1051" left="450" width="350" height="15" font="14">7.3.2.9.5. Thiazolidinediones. Thiazolidinediones increase</text>
<text top="1070" left="450" width="350" height="13" font="14">insulin sensitivity by activating nuclear peroxisome proliferator-</text>
<text top="1088" left="450" width="350" height="13" font="14">activated receptor gamma. Expressed in virtually all tissues,</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e182</text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="28" size="8" family="Times" color="#327eb1"/>
<text top="103" left="64" width="350" height="13" font="14">peroxisome proliferator-activated receptor gamma also regulates</text>
<text top="121" left="64" width="350" height="13" font="14">sodium reabsorption in the collecting ducts of the kidney. In</text>
<text top="139" left="64" width="350" height="13" font="14">clinical trials, thiazolidinediones have been associated with</text>
<text top="157" left="64" width="350" height="13" font="14">increased incidence of HF events, even in those without any prior</text>
<text top="175" left="64" width="115" height="13" font="14">history of clinical HF</text>
<text top="175" left="183" width="49" height="13" font="15"><a href="e147.full.html#77">(557,583</a></text>
<text top="171" left="231" width="32" height="18" font="15"><a href="e147.full.html#77">–588)</a></text>
<text top="175" left="263" width="4" height="13" font="14"><a href="e147.full.html#77">.</a></text>
<text top="193" left="79" width="20" height="13" font="14">See</text>
<text top="193" left="103" width="50" height="13" font="15"><a href="e147.full.html#38">Table 19</a></text>
<text top="193" left="157" width="257" height="13" font="14">for a summary of recommendations from this</text>
<text top="211" left="64" width="68" height="13" font="14">section and</text>
<text top="211" left="140" width="53" height="13" font="15"><a href="e147.full.html#39">Table 20</a></text>
<text top="211" left="200" width="214" height="13" font="14">for strategies for achieving optimal</text>
<text top="229" left="64" width="68" height="13" font="14">GDMT; see</text>
<text top="229" left="137" width="162" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 27</a></text>
<text top="229" left="304" width="110" height="13" font="14">for additional data</text>
<text top="247" left="64" width="126" height="13" font="14">on thiazolidinediones.</text>
<text top="281" left="64" width="319" height="15" font="14">7.3.3. Pharmacological Treatment for Stage C HF</text>
<text top="278" left="383" width="31" height="19" font="14">pEF:</text>
<text top="299" left="64" width="117" height="15" font="14">Recommendations</text>
<text top="320" left="65" width="20" height="13" font="14">See</text>
<text top="320" left="91" width="52" height="13" font="15"><a href="e147.full.html#39">Table 21</a></text>
<text top="320" left="148" width="266" height="13" font="14">for a summary of recommendations from this</text>
<text top="338" left="64" width="43" height="13" font="14">section.</text>
<text top="368" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="380" left="82" width="10" height="10" font="18">1.</text>
<text top="380" left="100" width="314" height="10" font="18">Systolic and diastolic blood pressure should be controlled in</text>
<text top="396" left="100" width="314" height="12" font="18">patients with HFpEF in accordance with published clinical</text>
<text top="413" left="100" width="215" height="10" font="18">practice guidelines to prevent morbidity</text>
<text top="413" left="320" width="41" height="10" font="5"><a href="e147.full.html#65">(27,91)</a></text>
<text top="413" left="360" width="54" height="12" font="18">. (Level of</text>
<text top="429" left="100" width="65" height="12" font="18">Evidence: B)</text>
<text top="446" left="82" width="10" height="10" font="18">2.</text>
<text top="446" left="100" width="314" height="10" font="18">Diuretics should be used for relief of symptoms due to volume</text>
<text top="462" left="100" width="281" height="12" font="18">overload in patients with HFpEF. (Level of Evidence: C)</text>
<text top="489" left="64" width="45" height="8" font="17">CLASS IIa</text>
<text top="501" left="82" width="10" height="10" font="18">1.</text>
<text top="501" left="100" width="314" height="10" font="18">Coronary revascularization is reasonable in patients with</text>
<text top="517" left="100" width="314" height="10" font="18">CAD in whom symptoms (angina) or demonstrable myocar-</text>
<text top="534" left="100" width="314" height="10" font="18">dial ischemia is judged to be having an adverse effect on</text>
<text top="550" left="100" width="305" height="12" font="18">symptomatic HFpEF despite GDMT. (Level of Evidence: C)</text>
<text top="567" left="82" width="10" height="10" font="18">2.</text>
<text top="567" left="100" width="314" height="10" font="18">Management of AF according to published clinical practice</text>
<text top="583" left="100" width="314" height="12" font="18">guidelines in patients with HFpEF is reasonable to improve</text>
<text top="600" left="100" width="281" height="12" font="18">symptomatic HF (Section 9.1). (Level of Evidence: C)</text>
<text top="616" left="82" width="10" height="10" font="18">3.</text>
<text top="616" left="100" width="314" height="10" font="18">The use of beta-blocking agents, ACE inhibitors, and ARBs</text>
<text top="632" left="100" width="314" height="10" font="18">in patients with hypertension is reasonable to control blood</text>
<text top="649" left="100" width="290" height="12" font="18">pressure in patients with HFpEF. (Level of Evidence: C)</text>
<text top="676" left="64" width="45" height="8" font="17">CLASS IIb</text>
<text top="688" left="82" width="10" height="10" font="18">1.</text>
<text top="688" left="100" width="314" height="10" font="18">The use of ARBs might be considered to decrease hospitali-</text>
<text top="704" left="100" width="163" height="12" font="18">zations for patients with HFpEF</text>
<text top="704" left="265" width="30" height="10" font="5"><a href="e147.full.html#78">(589)</a></text>
<text top="704" left="295" width="117" height="12" font="18"><a href="e147.full.html#78">. </a>(Level of Evidence: B)</text>
<text top="731" left="64" width="88" height="8" font="17">CLASS III: No Bene</text>
<text top="728" left="152" width="10" height="13" font="17">ﬁt</text>
<text top="743" left="82" width="10" height="10" font="18">1.</text>
<text top="743" left="100" width="314" height="10" font="18">Routine use of nutritional supplements is not recommended</text>
<text top="759" left="100" width="245" height="12" font="18">for patients with HFpEF. (Level of Evidence: C)</text>
<text top="785" left="79" width="179" height="13" font="14">Trials using comparable and ef</text>
<text top="781" left="258" width="156" height="18" font="14">ﬁcacious agents for HFrEF</text>
<text top="803" left="64" width="350" height="13" font="14">have generally been disappointing when used in patients with</text>
<text top="821" left="64" width="41" height="13" font="14">HFpEF</text>
<text top="821" left="111" width="30" height="13" font="15"><a href="e147.full.html#78">(590)</a></text>
<text top="821" left="141" width="273" height="13" font="14">. Thus, most of the recommended therapies for</text>
<text top="839" left="64" width="350" height="13" font="14">HFpEF are directed at symptoms, especially comorbidities,</text>
<text top="857" left="64" width="324" height="13" font="14">and risk factors that may worsen cardiovascular disease.</text>
<text top="874" left="79" width="335" height="13" font="14">Blood pressure control concordant with existing hyper-</text>
<text top="892" left="64" width="350" height="13" font="14">tension guidelines remains the most important recommenda-</text>
<text top="910" left="64" width="350" height="13" font="14">tion in patients with HFpEF. Evidence from an RCT has</text>
<text top="928" left="64" width="350" height="13" font="14">shown that improved blood pressure control reduces hospi-</text>
<text top="946" left="64" width="96" height="13" font="14">talization for HF</text>
<text top="946" left="165" width="30" height="13" font="15"><a href="e147.full.html#78">(591)</a></text>
<text top="946" left="196" width="218" height="13" font="14"><a href="e147.full.html#78">, </a>decreases cardiovascular events, and</text>
<text top="964" left="64" width="311" height="13" font="14">reduces HF mortality in patients without prevalent HF</text>
<text top="964" left="380" width="30" height="13" font="15"><a href="e147.full.html#71">(311)</a></text>
<text top="964" left="410" width="4" height="13" font="14">.</text>
<text top="982" left="64" width="350" height="13" font="14">In hypertensive patients with HFpEF, aggressive treatment</text>
<text top="1000" left="64" width="350" height="13" font="14">(often with several drugs with complementary mechanisms of</text>
<text top="1018" left="64" width="350" height="13" font="14">action) is recommended. ACE inhibitors and/or ARBs are</text>
<text top="1036" left="64" width="112" height="13" font="14">often considered as</text>
<text top="1032" left="182" width="232" height="18" font="14">ﬁrst-line agents. Speciﬁc blood pressure</text>
<text top="1054" left="64" width="185" height="13" font="14">targets in HFpEF have not been</text>
<text top="1050" left="255" width="159" height="18" font="14">ﬁrmly established; thus, the</text>
<text top="1072" left="64" width="350" height="13" font="14">recommended targets are those used for general hypertensive</text>
<text top="1090" left="64" width="69" height="13" font="14">populations.</text>
<text top="103" left="465" width="237" height="13" font="14">CAD is common in patients with HFpE</text>
<text top="103" left="707" width="30" height="13" font="15"><a href="e147.full.html#78">(592)</a></text>
<text top="103" left="738" width="62" height="13" font="14"><a href="e147.full.html#78">; </a>however,</text>
<text top="121" left="450" width="350" height="13" font="14">there are no studies to determine the impact of revasculari-</text>
<text top="139" left="450" width="222" height="13" font="14">zation on symptoms or outcomes speci</text>
<text top="135" left="672" width="127" height="18" font="14">ﬁcally in patients with</text>
<text top="157" left="450" width="350" height="13" font="14">HFpEF. In general, contemporary revascularization guidelines</text>
<text top="175" left="450" width="41" height="13" font="15"><a href="e147.full.html#64">(10,12)</a></text>
<text top="175" left="491" width="309" height="13" font="14"><a href="e147.full.html#64">, </a>should be used in the care of patients with HFpEF</text>
<text top="193" left="450" width="165" height="13" font="14">and concomitant CAD. Speci</text>
<text top="189" left="615" width="184" height="18" font="14">ﬁc to this population, it might be</text>
<text top="211" left="450" width="350" height="13" font="14">reasonable to consider revascularization in patients for whom</text>
<text top="229" left="450" width="350" height="13" font="14">ischemia appears to contribute to HF symptoms, although this</text>
<text top="247" left="450" width="140" height="13" font="14">determination can be dif</text>
<text top="243" left="590" width="32" height="18" font="14">ﬁcult.</text>
<text top="265" left="465" width="335" height="13" font="14">Theoretical mechanisms for the worsening of HF symp-</text>
<text top="283" left="450" width="350" height="13" font="14">toms by AF among patients with HFpEF include shortened</text>
<text top="301" left="450" width="47" height="13" font="14">diastolic</text>
<text top="297" left="503" width="296" height="18" font="14">ﬁlling time with tachycardia and the loss of atrial</text>
<text top="319" left="450" width="159" height="13" font="14">contribution to LV diastolic</text>
<text top="315" left="614" width="186" height="18" font="14">ﬁlling. Conversely, chronotropic</text>
<text top="337" left="450" width="350" height="13" font="14">incompetence is also a concern. Slowing the heart rate is</text>
<text top="354" left="450" width="350" height="13" font="14">useful in tachycardia but not in normal resting heart rate;</text>
<text top="372" left="450" width="350" height="13" font="14">a slow heart rate prolongs diastasis and worsens chronotropic</text>
<text top="390" left="450" width="257" height="13" font="14">incompetence. Currently, there are no speci</text>
<text top="387" left="707" width="92" height="18" font="14">ﬁc trials of rate</text>
<text top="408" left="450" width="191" height="13" font="14">versus rhythm control in HFpEF.</text>
<text top="441" left="450" width="249" height="15" font="14">7.3.4. Device Therapy for Stage C HF</text>
<text top="438" left="699" width="29" height="19" font="14">rEF:</text>
<text top="459" left="450" width="117" height="15" font="14">Recommendations</text>
<text top="480" left="451" width="20" height="13" font="14">See</text>
<text top="480" left="476" width="52" height="13" font="15"><a href="e147.full.html#40">Table 22</a></text>
<text top="480" left="533" width="266" height="13" font="14">for a summary of recommendations from this</text>
<text top="498" left="450" width="43" height="13" font="14">section.</text>
<text top="523" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="535" left="468" width="10" height="10" font="18">1.</text>
<text top="535" left="485" width="314" height="10" font="18">ICD therapy is recommended for primary prevention of SCD</text>
<text top="552" left="485" width="314" height="10" font="18">to reduce total mortality in selected patients with non-</text>
<text top="568" left="485" width="314" height="10" font="18">ischemic DCM or ischemic heart disease at least 40 days</text>
<text top="585" left="485" width="314" height="10" font="18">post-MI with LVEF of 35% or less and NYHA class II or III</text>
<text top="601" left="485" width="314" height="10" font="18">symptoms on chronic GDMT, who have reasonable expec-</text>
<text top="617" left="485" width="309" height="10" font="18">tation of meaningful survival for more than 1 <a href="e147.full.html#37">year</a></text>
<text top="614" left="794" width="5" height="16" font="5"><a href="e147.full.html#37">y</a></text>
<text top="634" left="485" width="55" height="10" font="5"><a href="e147.full.html#72">(355,593)</a></text>
<text top="634" left="540" width="120" height="12" font="18">. (Level of Evidence: A)</text>
<text top="650" left="468" width="10" height="10" font="18">2.</text>
<text top="650" left="485" width="314" height="10" font="18">CRT is indicated for patients who have LVEF of 35% or less,</text>
<text top="667" left="485" width="314" height="10" font="18">sinus rhythm, left bundle-branch block (LBBB) with a QRS</text>
<text top="683" left="485" width="314" height="10" font="18">duration of 150 ms or greater, and NYHA class II, III, or</text>
<text top="700" left="485" width="314" height="12" font="18">ambulatory IV symptoms on GDMT. (Level of Evidence: A for</text>
<text top="716" left="485" width="89" height="12" font="18">NYHA class III/IV</text>
<text top="716" left="578" width="90" height="10" font="5"><a href="e147.full.html#65">(38,78,116,594)</a></text>
<text top="716" left="668" width="131" height="12" font="18">; Level of Evidence: B for</text>
<text top="733" left="485" width="70" height="12" font="18">NYHA class II</text>
<text top="733" left="559" width="55" height="10" font="5"><a href="e147.full.html#78">(595,596)</a></text>
<text top="733" left="614" width="6" height="10" font="18"><a href="e147.full.html#78">).</a></text>
<text top="749" left="468" width="10" height="10" font="18">3.</text>
<text top="749" left="485" width="314" height="10" font="18">ICD therapy is recommended for primary prevention of SCD</text>
<text top="765" left="485" width="314" height="10" font="18">to reduce total mortality in selected patients at least 40</text>
<text top="782" left="485" width="314" height="10" font="18">days post-MI with LVEF of 30% or less, and NYHA class I</text>
<text top="798" left="485" width="314" height="10" font="18">symptoms while receiving GDMT, who have reasonable</text>
<text top="815" left="485" width="309" height="10" font="18">expectation of meaningful survival for more than 1 <a href="e147.full.html#78">year</a></text>
<text top="812" left="794" width="5" height="16" font="18"><a href="e147.full.html#78">y</a></text>
<text top="831" left="485" width="80" height="10" font="5"><a href="e147.full.html#72">(362,597,598)</a></text>
<text top="831" left="565" width="121" height="12" font="18"><a href="e147.full.html#72">. </a>(Level of Evidence: B)</text>
<text top="855" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="867" left="468" width="10" height="10" font="18">1.</text>
<text top="867" left="485" width="314" height="10" font="18">CRT can be useful for patients who have LVEF of 35% or</text>
<text top="883" left="485" width="314" height="10" font="18">less, sinus rhythm, a non-LBBB pattern with a QRS duration</text>
<text top="900" left="485" width="314" height="10" font="18">of 150 ms or greater, and NYHA class III/ambulatory</text>
<text top="916" left="485" width="158" height="10" font="18">class IV symptoms on GDMT</text>
<text top="916" left="648" width="97" height="10" font="5"><a href="e147.full.html#66">(78,116,594,596)</a></text>
<text top="916" left="745" width="54" height="12" font="18">. (Level of</text>
<text top="933" left="485" width="65" height="12" font="18">Evidence: A)</text>
<text top="1009" left="450" width="350" height="14" font="20"><a href="e147.full.html#66">y</a>Counseling should be speciﬁc to each individual patient and should include</text>
<text top="1025" left="450" width="350" height="9" font="20">documentation of a discussion about the potential for sudden death and nonsudden</text>
<text top="1038" left="450" width="350" height="9" font="20">death from HF or noncardiac conditions. Information should be provided about the</text>
<text top="1052" left="450" width="8" height="9" font="20">ef</text>
<text top="1049" left="458" width="342" height="14" font="20">ﬁcacy, safety, and potential complications of an ICD and the potential for deﬁ-</text>
<text top="1065" left="450" width="350" height="9" font="20">brillation to be inactivated if desired in the future, notably when a patient is</text>
<text top="1079" left="450" width="350" height="9" font="20">approaching end of life. This will facilitate shared decision making between</text>
<text top="1092" left="450" width="241" height="9" font="20">patients, families, and the medical care team about ICDs</text>
<text top="1092" left="694" width="17" height="9" font="28"><a href="e147.full.html#65">(30)</a></text>
<text top="1092" left="711" width="3" height="9" font="20">.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e183</text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1160" width="864">
<text top="102" left="65" width="489" height="12" font="9">Table 19. Recommendations for Pharmacological Therapy for Management of Stage C HF</text>
<text top="99" left="554" width="17" height="17" font="9">rEF</text>
<text top="133" left="65" width="82" height="11" font="4">Recommendations</text>
<text top="133" left="549" width="19" height="11" font="4">COR</text>
<text top="133" left="648" width="17" height="11" font="4">LOE</text>
<text top="133" left="734" width="49" height="11" font="4">References</text>
<text top="153" left="65" width="39" height="11" font="4">Diuretics</text>
<text top="170" left="77" width="317" height="11" font="4">Diuretics are recommended in patients with HFrEF with fluid retention</text>
<text top="170" left="558" width="2" height="11" font="4">I</text>
<text top="170" left="653" width="6" height="11" font="4">C</text>
<text top="170" left="751" width="16" height="11" font="4">N/A</text>
<text top="194" left="65" width="62" height="11" font="4">ACE inhibitors</text>
<text top="210" left="77" width="270" height="11" font="4">ACE inhibitors are recommended for all patients with HFrEF</text>
<text top="210" left="558" width="2" height="11" font="4">I</text>
<text top="210" left="654" width="6" height="11" font="4">A</text>
<text top="210" left="728" width="17" height="11" font="5"><a href="e147.full.html#72">343</a></text>
<text top="210" left="746" width="3" height="11" font="4"><a href="e147.full.html#72">,</a></text>
<text top="210" left="748" width="40" height="11" font="5"><a href="e147.full.html#73">412–414</a></text>
<text top="234" left="65" width="23" height="11" font="4">ARBs</text>
<text top="250" left="77" width="360" height="11" font="4">ARBs are recommended in patients with HFrEF who are ACE inhibitor intolerant</text>
<text top="250" left="558" width="2" height="11" font="4">I</text>
<text top="250" left="654" width="6" height="11" font="4">A</text>
<text top="250" left="720" width="17" height="11" font="5"><a href="e147.full.html#66">108</a></text>
<text top="250" left="737" width="3" height="11" font="4"><a href="e147.full.html#72">,</a></text>
<text top="250" left="740" width="17" height="11" font="5"><a href="e147.full.html#72">345</a></text>
<text top="250" left="757" width="3" height="11" font="4"><a href="e147.full.html#74">,</a></text>
<text top="250" left="760" width="17" height="11" font="5"><a href="e147.full.html#74">415</a></text>
<text top="250" left="777" width="3" height="11" font="4">,</text>
<text top="250" left="780" width="17" height="11" font="5"><a href="e147.full.html#74">450</a></text>
<text top="271" left="77" width="375" height="11" font="4">ARBs are reasonable as alternatives to ACE inhibitors as first-line therapy in HFrEF</text>
<text top="271" left="554" width="10" height="11" font="4">IIa</text>
<text top="271" left="654" width="6" height="11" font="4">A</text>
<text top="271" left="739" width="40" height="11" font="5"><a href="e147.full.html#74">451–456</a></text>
<text top="292" left="77" width="394" height="11" font="4">Addition of an ARB may be considered in persistently symptomatic patients with HFrEF</text>
<text top="307" left="89" width="42" height="11" font="4">on GDMT</text>
<text top="292" left="554" width="10" height="11" font="4">IIb</text>
<text top="292" left="654" width="6" height="11" font="4">A</text>
<text top="292" left="740" width="17" height="11" font="5"><a href="e147.full.html#74">420</a></text>
<text top="292" left="757" width="3" height="11" font="4"><a href="e147.full.html#74">,</a></text>
<text top="292" left="760" width="17" height="11" font="5"><a href="e147.full.html#74">457</a></text>
<text top="324" left="77" width="403" height="11" font="4">Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is potentially</text>
<text top="339" left="89" width="34" height="11" font="4">harmful</text>
<text top="324" left="540" width="38" height="11" font="4">III: Harm</text>
<text top="324" left="653" width="6" height="11" font="4">C</text>
<text top="324" left="751" width="16" height="11" font="4">N/A</text>
<text top="358" left="65" width="61" height="11" font="4">Beta blockers</text>
<text top="374" left="77" width="375" height="11" font="4">Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all</text>
<text top="389" left="89" width="66" height="11" font="4">stable patients</text>
<text top="374" left="558" width="2" height="11" font="4">I</text>
<text top="374" left="654" width="6" height="11" font="4">A</text>
<text top="374" left="718" width="17" height="11" font="5"><a href="e147.full.html#72">346</a></text>
<text top="374" left="736" width="3" height="11" font="4"><a href="e147.full.html#72">,</a></text>
<text top="374" left="739" width="40" height="11" font="5"><a href="e147.full.html#74">416–419</a></text>
<text top="374" left="779" width="3" height="11" font="4"><a href="e147.full.html#74">,</a></text>
<text top="374" left="782" width="17" height="11" font="5"><a href="e147.full.html#74">448</a></text>
<text top="409" left="65" width="148" height="11" font="4">Aldosterone receptor antagonists</text>
<text top="425" left="77" width="384" height="11" font="4">Aldosterone receptor antagonists are recommended in patients with NYHA class II–IV</text>
<text top="440" left="89" width="69" height="11" font="4">who have LVEF</text>
<text top="437" left="162" width="30" height="16" font="4">35%</text>
<text top="425" left="558" width="2" height="11" font="4">I</text>
<text top="425" left="654" width="6" height="11" font="4">A</text>
<text top="425" left="730" width="17" height="11" font="5"><a href="e147.full.html#74">425</a></text>
<text top="425" left="747" width="3" height="11" font="4"><a href="e147.full.html#74">,</a></text>
<text top="425" left="750" width="17" height="11" font="5"><a href="e147.full.html#74">426</a></text>
<text top="425" left="767" width="3" height="11" font="4"><a href="e147.full.html#75">,</a></text>
<text top="425" left="770" width="17" height="11" font="5"><a href="e147.full.html#75">478</a></text>
<text top="457" left="77" width="386" height="11" font="4">Aldosterone receptor antagonists are recommended in patients following an acute MI</text>
<text top="472" left="89" width="69" height="11" font="4">who have LVEF</text>
<text top="469" left="162" width="162" height="16" font="4">40% with symptoms of HF or DM</text>
<text top="457" left="558" width="2" height="11" font="4">I</text>
<text top="457" left="653" width="6" height="11" font="4">B</text>
<text top="457" left="750" width="17" height="11" font="5"><a href="e147.full.html#74">446</a></text>
<text top="488" left="77" width="316" height="11" font="4">Inappropriate use of aldosterone receptor antagonists may be harmful</text>
<text top="488" left="540" width="38" height="11" font="4">III: Harm</text>
<text top="488" left="653" width="6" height="11" font="4">B</text>
<text top="488" left="740" width="17" height="11" font="5"><a href="e147.full.html#75">479</a></text>
<text top="488" left="757" width="3" height="11" font="4"><a href="e147.full.html#75">,</a></text>
<text top="488" left="760" width="17" height="11" font="5"><a href="e147.full.html#75">480</a></text>
<text top="512" left="65" width="161" height="11" font="4">Hydralazine and isosorbide dinitrate</text>
<text top="528" left="77" width="380" height="11" font="4">The combination of hydralazine and isosorbide dinitrate is recommended for African</text>
<text top="543" left="89" width="225" height="11" font="4">Americans with NYHA class III–IV HFrEF on GDMT</text>
<text top="528" left="558" width="2" height="11" font="4">I</text>
<text top="528" left="654" width="6" height="11" font="4">A</text>
<text top="528" left="740" width="17" height="11" font="5"><a href="e147.full.html#74">423</a></text>
<text top="528" left="757" width="3" height="11" font="4"><a href="e147.full.html#74">,</a></text>
<text top="528" left="760" width="17" height="11" font="5"><a href="e147.full.html#74">424</a></text>
<text top="560" left="77" width="356" height="11" font="4">A combination of hydralazine and isosorbide dinitrate can be useful in patients</text>
<text top="575" left="89" width="253" height="11" font="4">with HFrEF who cannot be given ACE inhibitors or ARBs</text>
<text top="560" left="554" width="10" height="11" font="4">IIa</text>
<text top="560" left="653" width="6" height="11" font="4">B</text>
<text top="560" left="750" width="17" height="11" font="5"><a href="e147.full.html#74">449</a></text>
<text top="594" left="65" width="33" height="11" font="4">Digoxin</text>
<text top="611" left="77" width="217" height="11" font="4">Digoxin can be beneficial in patients with HFrEF</text>
<text top="611" left="554" width="10" height="11" font="4">IIa</text>
<text top="611" left="653" width="6" height="11" font="4">B</text>
<text top="611" left="739" width="40" height="11" font="5"><a href="e147.full.html#75">484–491</a></text>
<text top="634" left="65" width="68" height="11" font="4">Anticoagulation</text>
<text top="651" left="77" width="382" height="11" font="4">Patients with chronic HF with permanent/persistent/paroxysmal AF and an additional</text>
<text top="666" left="89" width="364" height="11" font="4">risk factor for cardioembolic stroke should receive chronic anticoagulant <a href="e147.full.html#38">therapy</a></text>
<text top="666" left="453" width="4" height="11" font="5"><a href="e147.full.html#38">*</a></text>
<text top="651" left="558" width="2" height="11" font="4">I</text>
<text top="651" left="654" width="6" height="11" font="4">A</text>
<text top="651" left="739" width="40" height="11" font="5"><a href="e147.full.html#76">508–514</a></text>
<text top="682" left="77" width="290" height="11" font="4">The selection of an anticoagulant agent should be individualized</text>
<text top="682" left="558" width="2" height="11" font="4">I</text>
<text top="682" left="653" width="6" height="11" font="4">C</text>
<text top="682" left="751" width="16" height="11" font="4">N/A</text>
<text top="703" left="77" width="390" height="11" font="4">Chronic anticoagulation is reasonable for patients with chronic HF who have permanent/</text>
<text top="718" left="89" width="399" height="11" font="4">persistent/paroxysmal AF but are without an additional risk factor for cardioembolic <a href="e147.full.html#38">stroke</a></text>
<text top="718" left="488" width="4" height="11" font="5"><a href="e147.full.html#38">*</a></text>
<text top="703" left="554" width="10" height="11" font="4">IIa</text>
<text top="703" left="653" width="6" height="11" font="4">B</text>
<text top="703" left="717" width="40" height="11" font="5"><a href="e147.full.html#76">509–511</a></text>
<text top="703" left="757" width="3" height="11" font="4"><a href="e147.full.html#76">,</a></text>
<text top="703" left="760" width="40" height="11" font="5"><a href="e147.full.html#76">515–517</a></text>
<text top="735" left="77" width="393" height="11" font="4">Anticoagulation is not recommended in patients with chronic HFrEF without AF, a prior</text>
<text top="750" left="89" width="224" height="11" font="4">thromboembolic event, or a cardioembolic source</text>
<text top="735" left="528" width="61" height="11" font="4">III: No Benefit</text>
<text top="735" left="653" width="6" height="11" font="4">B</text>
<text top="735" left="738" width="40" height="11" font="5"><a href="e147.full.html#76">518–520</a></text>
<text top="769" left="65" width="30" height="11" font="4">Statins</text>
<text top="785" left="77" width="352" height="11" font="4">Statins are not beneficial as adjunctive therapy when prescribed solely for HF</text>
<text top="785" left="528" width="61" height="11" font="4">III: No Benefit</text>
<text top="785" left="653" width="6" height="11" font="4">A</text>
<text top="785" left="738" width="40" height="11" font="5"><a href="e147.full.html#76">533–538</a></text>
<text top="809" left="65" width="92" height="11" font="4">Omega-3 fatty acids</text>
<text top="826" left="77" width="383" height="11" font="4">Omega-3 PUFA supplementation is reasonable to use as adjunctive therapy in HFrEF</text>
<text top="841" left="89" width="80" height="11" font="4">or HFpEF patients</text>
<text top="826" left="554" width="10" height="11" font="4">IIa</text>
<text top="826" left="653" width="6" height="11" font="4">B</text>
<text top="826" left="740" width="17" height="11" font="5"><a href="e147.full.html#76">539</a></text>
<text top="826" left="757" width="3" height="11" font="4">,</text>
<text top="826" left="760" width="17" height="11" font="5"><a href="e147.full.html#76">540</a></text>
<text top="860" left="65" width="53" height="11" font="4">Other drugs</text>
<text top="877" left="77" width="343" height="11" font="4">Nutritional supplements as treatment for HF are not recommended in HFrEF</text>
<text top="877" left="528" width="61" height="11" font="4">III: No Benefit</text>
<text top="877" left="653" width="6" height="11" font="4">B</text>
<text top="877" left="740" width="17" height="11" font="5"><a href="e147.full.html#76">544</a></text>
<text top="877" left="757" width="3" height="11" font="4">,</text>
<text top="877" left="760" width="17" height="11" font="5"><a href="e147.full.html#76">545</a></text>
<text top="897" left="77" width="386" height="11" font="4">Hormonal therapies other than to correct deficiencies are not recommended in HFrEF</text>
<text top="897" left="528" width="61" height="11" font="4">III: No Benefit</text>
<text top="897" left="653" width="6" height="11" font="4">C</text>
<text top="897" left="751" width="16" height="11" font="4">N/A</text>
<text top="918" left="77" width="401" height="11" font="4">Drugs known to adversely affect the clinical status of patients with HFrEF are potentially</text>
<text top="933" left="89" width="203" height="11" font="4">harmful and should be avoided or withdrawn</text>
<text top="918" left="540" width="38" height="11" font="4">III: Harm</text>
<text top="918" left="653" width="6" height="11" font="4">B</text>
<text top="918" left="738" width="40" height="11" font="5"><a href="e147.full.html#76">546–557</a></text>
<text top="950" left="77" width="411" height="11" font="4">Long-term use of an infusion of a positive inotropic drug is not recommended and may be</text>
<text top="965" left="89" width="125" height="11" font="4">harmful except as palliation</text>
<text top="950" left="540" width="38" height="11" font="4">III: Harm</text>
<text top="950" left="653" width="6" height="11" font="4">C</text>
<text top="950" left="751" width="16" height="11" font="4">N/A</text>
<text top="984" left="65" width="116" height="11" font="4">Calcium channel blockers</text>
<text top="1001" left="77" width="387" height="11" font="4">Calcium channel–blocking drugs are not recommended as routine treatment in HFrEF</text>
<text top="1001" left="528" width="61" height="11" font="4">III: No Benefit</text>
<text top="1001" left="654" width="6" height="11" font="4">A</text>
<text top="1001" left="730" width="17" height="11" font="5"><a href="e147.full.html#77">551</a></text>
<text top="1001" left="747" width="3" height="11" font="4">,</text>
<text top="1001" left="750" width="17" height="11" font="5"><a href="e147.full.html#77">574</a></text>
<text top="1001" left="767" width="3" height="11" font="4">,</text>
<text top="1001" left="770" width="17" height="11" font="5"><a href="e147.full.html#77">575</a></text>
<text top="1027" left="77" width="249" height="11" font="4">*In the absence of contraindications to anticoagulation.</text>
<text top="1041" left="77" width="723" height="11" font="4">ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin-receptor blocker; COR, Class of Recommendation; DM, diabetes mellitus;</text>
<text top="1056" left="65" width="735" height="11" font="4">GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction;</text>
<text top="1071" left="65" width="735" height="11" font="4">LOE, Level of Evidence; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N/A, not available; NYHA, New York Heart Association; and PUFA, poly-</text>
<text top="1086" left="65" width="106" height="11" font="4">unsaturated fatty acids.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e184</text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1160" width="864">
<text top="860" left="82" width="10" height="10" font="18">2.</text>
<text top="860" left="100" width="314" height="10" font="18">CRT can be useful for patients who have LVEF of 35% or</text>
<text top="876" left="100" width="314" height="10" font="18">less, sinus rhythm, LBBB with a QRS duration of 120 to 149</text>
<text top="893" left="100" width="314" height="10" font="18">ms, and NYHA class II, III, or ambulatory IV symptoms on</text>
<text top="909" left="100" width="32" height="10" font="18">GDMT</text>
<text top="909" left="136" width="68" height="10" font="5"><a href="e147.full.html#66">(78,116,594</a></text>
<text top="906" left="204" width="56" height="16" font="5"><a href="e147.full.html#66">–596,599)</a></text>
<text top="909" left="261" width="121" height="12" font="18"><a href="e147.full.html#66">. </a>(Level of Evidence: B)</text>
<text top="926" left="82" width="10" height="10" font="18">3.</text>
<text top="926" left="100" width="314" height="10" font="18">CRT can be useful in patients with AF and LVEF of 35% or</text>
<text top="942" left="100" width="314" height="10" font="18">less on GDMT if a) the patient requires ventricular pacing or</text>
<text top="958" left="100" width="314" height="10" font="18">otherwise meets CRT criteria and b) atrioventricular nodal</text>
<text top="975" left="100" width="314" height="10" font="18">ablation or pharmacological rate control will allow near</text>
<text top="991" left="100" width="192" height="10" font="18">100% ventricular pacing with CRT</text>
<text top="991" left="299" width="26" height="10" font="5"><a href="e147.full.html#78">(600</a></text>
<text top="988" left="325" width="32" height="16" font="5"><a href="e147.full.html#78">–605)</a></text>
<text top="991" left="356" width="58" height="12" font="18">. (Level of</text>
<text top="1008" left="100" width="65" height="12" font="18">Evidence: B)</text>
<text top="1024" left="82" width="10" height="10" font="18">4.</text>
<text top="1024" left="100" width="314" height="10" font="18">CRT can be useful for patients on GDMT who have LVEF</text>
<text top="1041" left="100" width="314" height="10" font="18">of 35% or less and are undergoing placement of a new</text>
<text top="1057" left="100" width="10" height="10" font="18">or</text>
<text top="1057" left="122" width="65" height="10" font="18">replacement</text>
<text top="1057" left="198" width="34" height="10" font="18">device</text>
<text top="1057" left="244" width="66" height="10" font="18">implantation</text>
<text top="1057" left="321" width="23" height="10" font="18">with</text>
<text top="1057" left="355" width="59" height="10" font="18">anticipated</text>
<text top="1074" left="100" width="63" height="10" font="18">requirement</text>
<text top="1074" left="174" width="14" height="10" font="18">for</text>
<text top="1074" left="198" width="25" height="10" font="18">signi</text>
<text top="1070" left="223" width="191" height="16" font="18">ﬁcant (&gt;40%) ventricular pacing</text>
<text top="1090" left="100" width="104" height="10" font="5"><a href="e147.full.html#67">(155,602,606,607)</a></text>
<text top="1090" left="204" width="120" height="12" font="18">. (Level of Evidence: C)</text>
<text top="863" left="450" width="45" height="8" font="17">CLASS IIb</text>
<text top="875" left="468" width="10" height="10" font="18">1.</text>
<text top="875" left="485" width="314" height="10" font="18">The usefulness of implantation of an ICD is of uncertain</text>
<text top="891" left="485" width="25" height="10" font="18">bene</text>
<text top="888" left="511" width="289" height="16" font="18">ﬁt to prolong meaningful survival in patients with a high</text>
<text top="908" left="485" width="314" height="10" font="18">risk of nonsudden death as predicted by frequent hospitali-</text>
<text top="924" left="485" width="314" height="10" font="18">zations, advanced frailty, or comorbidities such as systemic</text>
<text top="940" left="485" width="209" height="10" font="18">malignancy or severe renal <a href="e147.full.html#39">dysfunction</a></text>
<text top="937" left="694" width="67" height="16" font="5"><a href="e147.full.html#39">y </a><a href="e147.full.html#78">(608–611)</a></text>
<text top="940" left="761" width="38" height="12" font="18">. (Level</text>
<text top="957" left="485" width="79" height="12" font="18">of Evidence: B)</text>
<text top="102" left="65" width="269" height="12" font="9">Table 20. Strategies for Achieving Optimal GDMT</text>
<text top="130" left="71" width="570" height="11" font="4">1. Uptitrate in small increments to the recommended target dose or the highest tolerated dose for those medications listed in</text>
<text top="130" left="645" width="39" height="11" font="5"><a href="e147.full.html#29">Table 15</a></text>
<text top="130" left="688" width="112" height="11" font="4">with an appreciation that</text>
<text top="145" left="87" width="695" height="11" font="4">some patients cannot tolerate the full recommended doses of all medications, particularly patients with low baseline heart rate or blood pressure or with</text>
<text top="160" left="87" width="154" height="11" font="4">a tendency to postural symptoms.</text>
<text top="179" left="71" width="729" height="11" font="4">2. Certain patients (e.g., the elderly, patients with chronic kidney disease) may require more frequent visits and laboratory monitoring during dose titration and more</text>
<text top="194" left="87" width="713" height="11" font="4">gradual dose changes. However, such vulnerable patients may accrue considerable benefits from GDMT. Inability to tolerate optimal doses of GDMT may change</text>
<text top="209" left="87" width="230" height="11" font="4">after disease-modifying interventions such as CRT.</text>
<text top="228" left="71" width="729" height="11" font="4">3. Monitor vital signs closely before and during uptitration, including postural changes in blood pressure or heart rate, particularly in patients with orthostatic</text>
<text top="243" left="87" width="391" height="11" font="4">symptoms, bradycardia, and/or “low” systolic blood pressure (e.g., 80 to 100 mm Hg).</text>
<text top="263" left="71" width="513" height="11" font="4">4. Alternate adjustments of different medication classes (especially ACE inhibitors/ARBs and beta blockers) listed in</text>
<text top="263" left="587" width="38" height="11" font="5"><a href="e147.full.html#29">Table 15</a></text>
<text top="263" left="625" width="175" height="11" font="4">. Patients with elevated or normal blood</text>
<text top="278" left="87" width="353" height="11" font="4">pressure and heart rate may tolerate faster incremental increases in dosages.</text>
<text top="297" left="71" width="729" height="11" font="4">5. Monitor renal function and electrolytes for rising creatinine and hyperkalemia, recognizing that an initial rise in creatinine may be expected and does not</text>
<text top="312" left="87" width="598" height="11" font="4">necessarily require discontinuation of therapy; discuss tolerable levels of creatinine above baseline with a nephrologist if necessary.</text>
<text top="332" left="71" width="729" height="11" font="4">6. Patients may complain of symptoms of fatigue and weakness with dosage increases; in the absence of instability in vital signs, reassure them that these</text>
<text top="347" left="87" width="441" height="11" font="4">symptoms are often transient and usually resolve within a few days of these changes in therapy.</text>
<text top="366" left="71" width="709" height="11" font="4">7. Discourage sudden spontaneous discontinuation of GDMT medications by the patient and/or other clinicians without discussion with managing clinicians.</text>
<text top="385" left="71" width="519" height="11" font="4">8. Carefully review doses of other medications for HF symptom control (e.g., diuretics, nitrates) during uptitration.</text>
<text top="405" left="71" width="709" height="11" font="4">9. Consider temporary adjustments in dosages of GDMT during acute episodes of noncardiac illnesses (e.g., respiratory infections, risk of dehydration, etc).</text>
<text top="424" left="65" width="735" height="11" font="4">10. Educate patients, family members, and other clinicians about the expected benefits of achieving GDMT, including an understanding of the potential benefits of</text>
<text top="439" left="87" width="430" height="11" font="4">myocardial reverse remodeling, increased survival, and improved functional status and HRQOL.</text>
<text top="461" left="77" width="723" height="11" font="4">ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical</text>
<text top="476" left="65" width="305" height="11" font="4">therapy; HF, heart failure; and HRQOL, health-related quality of life.</text>
<text top="530" left="118" width="267" height="12" font="9">Table 21. Recommendations for Treatment of HF</text>
<text top="527" left="385" width="19" height="17" font="9">pEF</text>
<text top="561" left="118" width="82" height="11" font="4">Recommendations</text>
<text top="561" left="605" width="19" height="11" font="4">COR</text>
<text top="561" left="696" width="17" height="11" font="4">LOE</text>
<text top="583" left="118" width="320" height="11" font="4">Systolic and diastolic blood pressure should be controlled according to</text>
<text top="598" left="130" width="165" height="11" font="4">published clinical practice guidelines</text>
<text top="583" left="614" width="2" height="11" font="4">I</text>
<text top="583" left="684" width="42" height="11" font="4">B <a href="e147.full.html#65">(27,91)</a></text>
<text top="614" left="118" width="329" height="11" font="4">Diuretics should be used for relief of symptoms due to volume overload.</text>
<text top="614" left="614" width="2" height="11" font="4">I</text>
<text top="614" left="701" width="6" height="11" font="4">C</text>
<text top="635" left="118" width="307" height="11" font="4">Coronary revascularization for patients with CAD in whom angina or</text>
<text top="650" left="130" width="271" height="11" font="4">demonstrable myocardial ischemia is present despite GDMT</text>
<text top="635" left="610" width="10" height="11" font="4">IIa</text>
<text top="635" left="701" width="6" height="11" font="4">C</text>
<text top="667" left="118" width="315" height="11" font="4">Management of AF according to published clinical practice guidelines</text>
<text top="681" left="130" width="172" height="11" font="4">for HFpEF to improve symptomatic HF</text>
<text top="667" left="610" width="10" height="11" font="4">IIa</text>
<text top="667" left="701" width="6" height="11" font="4">C</text>
<text top="698" left="118" width="366" height="11" font="4">Use of beta-blocking agents, ACE inhibitors, and ARBs for hypertension in HFpEF</text>
<text top="698" left="610" width="10" height="11" font="4">IIa</text>
<text top="698" left="701" width="6" height="11" font="4">C</text>
<text top="719" left="118" width="292" height="11" font="4">ARBs might be considered to decrease hospitalizations in HFpEF</text>
<text top="719" left="610" width="10" height="11" font="4">IIb</text>
<text top="719" left="688" width="33" height="11" font="4">B <a href="e147.full.html#78">(589)</a></text>
<text top="740" left="118" width="263" height="11" font="4">Nutritional supplementation is not recommended in HFpEF</text>
<text top="740" left="584" width="61" height="11" font="4">III: No Benefit</text>
<text top="740" left="701" width="6" height="11" font="4">C</text>
<text top="766" left="130" width="616" height="11" font="4">ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARBs, angiotensin-receptor blockers; CAD, coronary artery disease; COR,</text>
<text top="781" left="118" width="628" height="11" font="4">Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction;</text>
<text top="796" left="118" width="123" height="11" font="4">LOE, and Level of Evidence.</text>
<text top="1009" left="450" width="350" height="14" font="20"><a href="e147.full.html#78">y</a>Counseling should be speciﬁc to each individual patient and should include</text>
<text top="1025" left="450" width="350" height="9" font="20">documentation of a discussion about the potential for sudden death and nonsudden</text>
<text top="1038" left="450" width="350" height="9" font="20">death from HF or noncardiac conditions. Information should be provided about the</text>
<text top="1052" left="450" width="8" height="9" font="20">ef</text>
<text top="1049" left="458" width="342" height="14" font="20">ﬁcacy, safety, and potential complications of an ICD and the potential for deﬁ-</text>
<text top="1065" left="450" width="350" height="9" font="20">brillation to be inactivated if desired in the future, notably when a patient is</text>
<text top="1079" left="450" width="350" height="9" font="20">approaching end of life. This will facilitate shared decision making between</text>
<text top="1092" left="450" width="241" height="9" font="20">patients, families, and the medical care team about ICDs</text>
<text top="1092" left="694" width="17" height="9" font="28"><a href="e147.full.html#65">(30)</a></text>
<text top="1092" left="711" width="3" height="9" font="20">.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e185</text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1160" width="864">
<text top="791" left="82" width="10" height="10" font="18">2.</text>
<text top="791" left="100" width="314" height="10" font="18">CRT may be considered for patients who have LVEF of 35%</text>
<text top="808" left="100" width="314" height="10" font="18">or less, sinus rhythm, a non-LBBB pattern with QRS duration</text>
<text top="824" left="100" width="314" height="10" font="18">of 120 to 149 ms, and NYHA class III/ambulatory class IV</text>
<text top="840" left="100" width="49" height="10" font="18">on GDMT</text>
<text top="840" left="153" width="55" height="10" font="5"><a href="e147.full.html#78">(596,612)</a></text>
<text top="840" left="208" width="121" height="12" font="18"><a href="e147.full.html#78">. </a>(Level of Evidence: B)</text>
<text top="857" left="82" width="10" height="10" font="18">3.</text>
<text top="857" left="100" width="314" height="10" font="18">CRT may be considered for patients who have LVEF of 35%</text>
<text top="873" left="100" width="314" height="10" font="18">or less, sinus rhythm, a non-LBBB pattern with a QRS</text>
<text top="890" left="100" width="314" height="10" font="18">duration of 150 ms or greater, and NYHA class II symptoms</text>
<text top="906" left="100" width="49" height="10" font="18">on GDMT</text>
<text top="906" left="153" width="55" height="10" font="5"><a href="e147.full.html#78">(595,596)</a></text>
<text top="906" left="208" width="121" height="12" font="18"><a href="e147.full.html#78">. </a>(Level of Evidence: B)</text>
<text top="923" left="82" width="10" height="10" font="18">4.</text>
<text top="923" left="100" width="314" height="10" font="18">CRT may be considered for patients who have LVEF of 30%</text>
<text top="939" left="100" width="314" height="10" font="18">or less, ischemic etiology of HF, sinus rhythm, LBBB with</text>
<text top="956" left="100" width="314" height="10" font="18">a QRS duration of 150 ms or greater, and NYHA class I</text>
<text top="972" left="100" width="107" height="10" font="18">symptoms on GDMT</text>
<text top="972" left="211" width="55" height="10" font="5"><a href="e147.full.html#78">(595,596)</a></text>
<text top="972" left="266" width="120" height="12" font="18"><a href="e147.full.html#78">. </a>(Level of Evidence: C)</text>
<text top="996" left="64" width="88" height="8" font="17">CLASS III: No Bene</text>
<text top="993" left="152" width="10" height="13" font="17">ﬁt</text>
<text top="1008" left="82" width="10" height="10" font="18">1.</text>
<text top="1008" left="100" width="314" height="10" font="18">CRT is not recommended for patients with NYHA class I or II</text>
<text top="1024" left="100" width="314" height="10" font="18">symptoms and non-LBBB pattern with QRS duration less</text>
<text top="1041" left="100" width="68" height="10" font="18">than 150 ms</text>
<text top="1041" left="172" width="80" height="10" font="5"><a href="e147.full.html#78">(595,596,612)</a></text>
<text top="1041" left="252" width="121" height="12" font="18"><a href="e147.full.html#78">. </a>(Level of Evidence: B)</text>
<text top="1057" left="82" width="10" height="10" font="18">2.</text>
<text top="1057" left="100" width="314" height="10" font="18">CRT is not indicated for patients whose comorbidities and/</text>
<text top="1074" left="100" width="314" height="10" font="18">or frailty limit survival with good functional capacity to less</text>
<text top="1090" left="100" width="61" height="10" font="18">than 1 year</text>
<text top="1090" left="165" width="23" height="10" font="5"><a href="e147.full.html#65">(38)</a></text>
<text top="1090" left="188" width="120" height="12" font="18"><a href="e147.full.html#65">. </a>(Level of Evidence: C)</text>
<text top="791" left="449" width="20" height="13" font="14">See</text>
<text top="791" left="474" width="48" height="13" font="15"><a href="e147.full.html#41">Figure 2</a></text>
<text top="791" left="522" width="233" height="13" font="14">, indications for CRT therapy algorithm.</text>
<text top="817" left="450" width="46" height="15" font="14">7.3.4.1.</text>
<text top="820" left="503" width="175" height="11" font="20">IMPLANTABLE CARDIOVERTER</text>
<text top="817" left="678" width="6" height="15" font="14">-</text>
<text top="820" left="684" width="91" height="11" font="20">DEFIBRILLATOR</text>
<text top="837" left="451" width="349" height="13" font="14">Patients with reduced LVEF are at increased risk for</text>
<text top="855" left="450" width="350" height="13" font="14">ventricular tachyarrhythmias leading to SCD. Sudden death in</text>
<text top="873" left="450" width="350" height="13" font="14">HFrEF has been substantially decreased by neurohormonal</text>
<text top="891" left="450" width="350" height="13" font="14">antagonists that alter disease progression and also protect</text>
<text top="909" left="450" width="350" height="13" font="14">against arrhythmias. Nonetheless, patients with systolic</text>
<text top="927" left="450" width="350" height="13" font="14">dysfunction remain at increased risk for SCD due to</text>
<text top="944" left="450" width="350" height="13" font="14">ventricular tachyarrhythmias. Patients who have had sustained</text>
<text top="962" left="450" width="204" height="13" font="14">ventricular tachycardia, ventricular</text>
<text top="959" left="661" width="139" height="18" font="14">ﬁbrillation, unexplained</text>
<text top="980" left="450" width="350" height="13" font="14">syncope, or cardiac arrest are at highest risk for recurrence.</text>
<text top="998" left="450" width="350" height="13" font="14">Indications for ICD therapy as secondary prevention of SCD</text>
<text top="1016" left="450" width="350" height="13" font="14">in these patients are also discussed in the ACCF/AHA/HRS</text>
<text top="1034" left="450" width="177" height="13" font="14">device-based therapy guideline</text>
<text top="1034" left="632" width="16" height="13" font="15"><a href="e147.full.html#64">(4)</a></text>
<text top="1034" left="648" width="4" height="13" font="14"><a href="e147.full.html#64">.</a></text>
<text top="1052" left="465" width="335" height="13" font="14">The use of ICDs for primary prevention of SCD in patients</text>
<text top="1070" left="450" width="350" height="13" font="14">with HFrEF without prior history of arrhythmias or syncope</text>
<text top="1088" left="450" width="350" height="13" font="14">has been evaluated in multiple RCTs. ICD therapy for primary</text>
<text top="103" left="64" width="435" height="12" font="9">Table 22. Recommendations for Device Therapy for Management of Stage C HF</text>
<text top="135" left="64" width="82" height="11" font="4">Recommendations</text>
<text top="135" left="512" width="19" height="11" font="4">COR</text>
<text top="135" left="627" width="17" height="11" font="4">LOE</text>
<text top="135" left="728" width="49" height="11" font="4">References</text>
<text top="156" left="64" width="384" height="11" font="4">ICD therapy is recommended for primary prevention of SCD in selected patients with</text>
<text top="171" left="77" width="173" height="11" font="4">HFrEF at least 40 d post-MI with LVEF</text>
<text top="168" left="253" width="200" height="16" font="4">35% and NYHA class II or III symptoms on</text>
<text top="186" left="77" width="182" height="11" font="4">chronic GDMT, who are expected to live</text>
<text top="183" left="263" width="24" height="16" font="4">&gt;1 <a href="e147.full.html#40">y</a></text>
<text top="186" left="286" width="4" height="11" font="5"><a href="e147.full.html#40">*</a></text>
<text top="156" left="521" width="2" height="11" font="4">I</text>
<text top="156" left="633" width="6" height="11" font="4">A</text>
<text top="156" left="734" width="17" height="11" font="5"><a href="e147.full.html#72">355</a></text>
<text top="156" left="751" width="3" height="11" font="4"><a href="e147.full.html#72">,</a></text>
<text top="156" left="754" width="17" height="11" font="5"><a href="e147.full.html#78">593</a></text>
<text top="202" left="64" width="201" height="11" font="4">CRT is indicated for patients who have LVEF</text>
<text top="199" left="269" width="148" height="16" font="4">35%, sinus rhythm, LBBB with</text>
<text top="217" left="74" width="28" height="11" font="4">a QRS</text>
<text top="214" left="106" width="321" height="16" font="4">150 ms, and NYHA class II, III, or ambulatory IV symptoms on GDMT</text>
<text top="202" left="521" width="2" height="11" font="4">I</text>
<text top="202" left="591" width="89" height="11" font="4">A (NYHA class III/IV)</text>
<text top="202" left="719" width="11" height="11" font="5"><a href="e147.full.html#65">38</a></text>
<text top="202" left="731" width="3" height="11" font="4"><a href="e147.full.html#65">,</a></text>
<text top="202" left="734" width="11" height="11" font="5"><a href="e147.full.html#66">78</a></text>
<text top="202" left="745" width="3" height="11" font="4">,</text>
<text top="202" left="748" width="17" height="11" font="5"><a href="e147.full.html#67">116</a></text>
<text top="202" left="765" width="3" height="11" font="4">,</text>
<text top="202" left="768" width="17" height="11" font="5"><a href="e147.full.html#78">594</a></text>
<text top="223" left="598" width="76" height="11" font="4">B (NYHA class II)</text>
<text top="223" left="734" width="17" height="11" font="5"><a href="e147.full.html#78">595</a></text>
<text top="223" left="751" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="223" left="754" width="17" height="11" font="5"><a href="e147.full.html#78">596</a></text>
<text top="244" left="64" width="384" height="11" font="4">ICD therapy is recommended for primary prevention of SCD in selected patients with</text>
<text top="259" left="77" width="174" height="11" font="4">HFrEF at least 40 d post-MI with LVEF</text>
<text top="256" left="255" width="188" height="16" font="4">30% and NYHA class I symptoms while</text>
<text top="274" left="77" width="190" height="11" font="4">receiving GDMT, who are expected to live</text>
<text top="271" left="270" width="24" height="16" font="4">&gt;1 <a href="e147.full.html#40">y</a></text>
<text top="274" left="294" width="4" height="11" font="5"><a href="e147.full.html#40">*</a></text>
<text top="244" left="521" width="2" height="11" font="4">I</text>
<text top="244" left="633" width="6" height="11" font="4">B</text>
<text top="244" left="724" width="17" height="11" font="5"><a href="e147.full.html#72">362</a></text>
<text top="244" left="741" width="3" height="11" font="4"><a href="e147.full.html#72">,</a></text>
<text top="244" left="744" width="17" height="11" font="5"><a href="e147.full.html#78">597</a></text>
<text top="244" left="761" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="244" left="764" width="17" height="11" font="5"><a href="e147.full.html#78">598</a></text>
<text top="290" left="64" width="211" height="11" font="4">CRT can be useful for patients who have LVEF</text>
<text top="287" left="279" width="155" height="16" font="4">35%, sinus rhythm, a non-LBBB</text>
<text top="305" left="77" width="77" height="11" font="4">pattern with QRS</text>
<text top="302" left="157" width="274" height="16" font="4">150 ms, and NYHA class III/ambulatory class IV symptoms</text>
<text top="320" left="77" width="42" height="11" font="4">on GDMT</text>
<text top="290" left="517" width="10" height="11" font="4">IIa</text>
<text top="290" left="633" width="6" height="11" font="4">A</text>
<text top="290" left="717" width="11" height="11" font="5"><a href="e147.full.html#66">78</a></text>
<text top="290" left="728" width="3" height="11" font="4"><a href="e147.full.html#66">,</a></text>
<text top="290" left="731" width="17" height="11" font="5"><a href="e147.full.html#67">116</a></text>
<text top="290" left="748" width="3" height="11" font="4">,</text>
<text top="290" left="751" width="17" height="11" font="5"><a href="e147.full.html#78">594</a></text>
<text top="290" left="768" width="3" height="11" font="4">,</text>
<text top="290" left="771" width="17" height="11" font="5"><a href="e147.full.html#78">596</a></text>
<text top="337" left="64" width="208" height="11" font="4">CRT can be useful for patients who have LVEF</text>
<text top="334" left="275" width="177" height="16" font="4">35%, sinus rhythm, LBBB with a QRS</text>
<text top="352" left="77" width="345" height="11" font="4">120 to 149 ms, and NYHA class II, III, or ambulatory IV symptoms on GDMT</text>
<text top="337" left="517" width="10" height="11" font="4">IIa</text>
<text top="337" left="633" width="6" height="11" font="4">B</text>
<text top="337" left="705" width="11" height="11" font="5"><a href="e147.full.html#66">78</a></text>
<text top="337" left="716" width="3" height="11" font="4"><a href="e147.full.html#67">,</a></text>
<text top="337" left="719" width="17" height="11" font="5"><a href="e147.full.html#67">116</a></text>
<text top="337" left="736" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="337" left="739" width="40" height="11" font="5"><a href="e147.full.html#78">594–596</a></text>
<text top="337" left="780" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="337" left="782" width="17" height="11" font="5"><a href="e147.full.html#78">599</a></text>
<text top="368" left="64" width="218" height="11" font="4">CRT can be useful in patients with AF and LVEF</text>
<text top="365" left="286" width="149" height="16" font="4">35% on GDMT if a) the patient</text>
<text top="383" left="77" width="376" height="11" font="4">requires ventricular pacing or otherwise meets CRT criteria and b) AV nodal ablation</text>
<text top="398" left="77" width="278" height="11" font="4">or rate control allows near 100% ventricular pacing with CRT</text>
<text top="368" left="517" width="10" height="11" font="4">IIa</text>
<text top="368" left="633" width="6" height="11" font="4">B</text>
<text top="368" left="732" width="40" height="11" font="5"><a href="e147.full.html#78">600–605</a></text>
<text top="414" left="64" width="246" height="11" font="4">CRT can be useful for patients on GDMT who have LVEF</text>
<text top="412" left="313" width="140" height="16" font="4">35% and are undergoing new</text>
<text top="429" left="77" width="325" height="11" font="4">or replacement device implantation with anticipated ventricular pacing (</text>
<text top="427" left="401" width="33" height="16" font="4">&gt;40%)</text>
<text top="414" left="517" width="10" height="11" font="4">IIa</text>
<text top="414" left="633" width="6" height="11" font="4">C</text>
<text top="414" left="714" width="17" height="11" font="5"><a href="e147.full.html#67">155</a></text>
<text top="414" left="731" width="3" height="11" font="4"><a href="e147.full.html#67">,</a></text>
<text top="414" left="734" width="17" height="11" font="5"><a href="e147.full.html#78">602</a></text>
<text top="414" left="751" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="414" left="754" width="17" height="11" font="5"><a href="e147.full.html#78">606</a></text>
<text top="414" left="771" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="414" left="774" width="17" height="11" font="5"><a href="e147.full.html#78">607</a></text>
<text top="446" left="64" width="388" height="11" font="4">An ICD is of uncertain benefit to prolong meaningful survival in patients with a high risk</text>
<text top="461" left="77" width="321" height="11" font="4">of nonsudden death such as frequent hospitalizations, frailty, or severe</text>
<text top="476" left="77" width="60" height="11" font="4"><a href="e147.full.html#40">comorbidities</a></text>
<text top="476" left="136" width="4" height="11" font="5"><a href="e147.full.html#40">*</a></text>
<text top="446" left="517" width="10" height="11" font="4">IIb</text>
<text top="446" left="633" width="6" height="11" font="4">B</text>
<text top="446" left="732" width="40" height="11" font="5"><a href="e147.full.html#78">608–611</a></text>
<text top="492" left="64" width="232" height="11" font="4">CRT may be considered for patients who have LVEF</text>
<text top="489" left="300" width="153" height="16" font="4">35%, sinus rhythm, a non-LBBB</text>
<text top="507" left="77" width="376" height="11" font="4">pattern with a QRS duration of 120 to 149 ms, and NYHA class III/ambulatory class IV</text>
<text top="522" left="77" width="42" height="11" font="4">on GDMT</text>
<text top="492" left="517" width="10" height="11" font="4">IIb</text>
<text top="492" left="633" width="6" height="11" font="4">B</text>
<text top="492" left="734" width="17" height="11" font="5"><a href="e147.full.html#78">596</a></text>
<text top="492" left="751" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="492" left="754" width="17" height="11" font="5"><a href="e147.full.html#78">612</a></text>
<text top="538" left="64" width="232" height="11" font="4">CRT may be considered for patients who have LVEF</text>
<text top="536" left="300" width="153" height="16" font="4">35%, sinus rhythm, a non-LBBB</text>
<text top="553" left="77" width="77" height="11" font="4">pattern with QRS</text>
<text top="551" left="157" width="226" height="16" font="4">150 ms, and NYHA class II symptoms on GDMT</text>
<text top="538" left="517" width="10" height="11" font="4">IIb</text>
<text top="538" left="633" width="6" height="11" font="4">B</text>
<text top="538" left="734" width="17" height="11" font="5"><a href="e147.full.html#78">595</a></text>
<text top="538" left="751" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="538" left="754" width="17" height="11" font="5"><a href="e147.full.html#78">596</a></text>
<text top="570" left="64" width="235" height="11" font="4">CRT may be considered for patients who have LVEF</text>
<text top="567" left="304" width="145" height="16" font="4">30%, ischemic etiology of HF,</text>
<text top="585" left="77" width="134" height="11" font="4">sinus rhythm, LBBB with QRS</text>
<text top="582" left="215" width="223" height="16" font="4">150 ms, and NYHA class I symptoms on GDMT</text>
<text top="570" left="517" width="10" height="11" font="4">IIb</text>
<text top="570" left="633" width="6" height="11" font="4">C</text>
<text top="570" left="734" width="17" height="11" font="5"><a href="e147.full.html#78">595</a></text>
<text top="570" left="751" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="570" left="754" width="17" height="11" font="5"><a href="e147.full.html#78">596</a></text>
<text top="601" left="64" width="389" height="11" font="4">CRT is not recommended for patients with NYHA class I or II symptoms and non-LBBB</text>
<text top="616" left="77" width="77" height="11" font="4">pattern with QRS</text>
<text top="613" left="157" width="44" height="16" font="4">&lt;150 ms</text>
<text top="601" left="491" width="61" height="11" font="4">III: No Benefit</text>
<text top="601" left="633" width="6" height="11" font="4">B</text>
<text top="601" left="724" width="17" height="11" font="5"><a href="e147.full.html#78">595</a></text>
<text top="601" left="741" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="601" left="744" width="17" height="11" font="5"><a href="e147.full.html#78">596</a></text>
<text top="601" left="761" width="3" height="11" font="4"><a href="e147.full.html#78">,</a></text>
<text top="601" left="764" width="17" height="11" font="5"><a href="e147.full.html#78">612</a></text>
<text top="633" left="64" width="363" height="11" font="4">CRT is not indicated for patients whose comorbidities and/or frailty limit survival to</text>
<text top="630" left="430" width="23" height="16" font="4">&lt;1 y</text>
<text top="633" left="491" width="61" height="11" font="4">III: No Benefit</text>
<text top="633" left="633" width="6" height="11" font="4">C</text>
<text top="633" left="747" width="11" height="11" font="5"><a href="e147.full.html#65">38</a></text>
<text top="658" left="76" width="723" height="11" font="4">*Counseling should be specific to each individual patient and should include documentation of a discussion about the potential for sudden death and nonsudden</text>
<text top="673" left="64" width="735" height="11" font="4">death from HF or noncardiac conditions. Information should be provided about the efficacy, safety, and potential complications of an ICD and the potential for</text>
<text top="688" left="64" width="735" height="11" font="4">defibrillation to be inactivated if desired in the future, notably when a patient is approaching end of life. This will facilitate shared decision making between patients,</text>
<text top="703" left="64" width="217" height="11" font="4">families, and the medical care team about ICDs</text>
<text top="703" left="285" width="17" height="11" font="5"><a href="e147.full.html#65">(30)</a></text>
<text top="703" left="302" width="3" height="11" font="4"><a href="e147.full.html#65">.</a></text>
<text top="718" left="76" width="723" height="11" font="4">AF indicates atrial fibrillation; AV, atrioventricular; COR, Class of Recommendation; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical</text>
<text top="733" left="64" width="735" height="11" font="4">therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LBBB, left bundle-branch block; LOE, Level of</text>
<text top="748" left="64" width="649" height="11" font="4">Evidence; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; and SCD, sudden cardiac death.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e186</text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1160" width="864">
<text top="677" left="64" width="350" height="13" font="14">prevention was demonstrated to reduce all-cause mortality.</text>
<text top="695" left="64" width="138" height="13" font="14">For patients with LVEF</text>
<text top="691" left="207" width="206" height="18" font="14">30% after remote MI, use of ICD</text>
<text top="713" left="64" width="350" height="13" font="14">therapy led to a 31% decrease in mortality over 20 months, for</text>
<text top="731" left="64" width="166" height="13" font="14">an absolute decrease of 5.6%</text>
<text top="731" left="234" width="30" height="13" font="15"><a href="e147.full.html#72">(362)</a></text>
<text top="731" left="265" width="149" height="13" font="14"><a href="e147.full.html#72">. </a>For patients with mild to</text>
<text top="749" left="64" width="228" height="13" font="14">moderate symptoms of HF with LVEF</text>
<text top="745" left="297" width="116" height="18" font="14">35% due either to</text>
<text top="767" left="64" width="350" height="13" font="14">ischemic or nonischemic etiology, there was a 23% decrease</text>
<text top="785" left="64" width="350" height="13" font="14">in mortality over a 5-year period, for an absolute decrease of</text>
<text top="803" left="64" width="29" height="13" font="14">7.2%</text>
<text top="803" left="97" width="30" height="13" font="15"><a href="e147.full.html#78">(593)</a></text>
<text top="803" left="127" width="221" height="13" font="14">. For both these trials, the survival bene</text>
<text top="799" left="348" width="66" height="18" font="14">ﬁt appeared</text>
<text top="821" left="64" width="48" height="13" font="14">after the</text>
<text top="817" left="118" width="296" height="18" font="14">ﬁrst year. Other smaller trials were consistent with</text>
<text top="839" left="64" width="112" height="13" font="14">this degree of bene</text>
<text top="835" left="176" width="238" height="18" font="14">ﬁt, except for patients within the ﬁrst 40</text>
<text top="857" left="64" width="350" height="13" font="14">days after acute MI, in whom SCD was decreased but there</text>
<text top="874" left="64" width="350" height="13" font="14">was an increase in other events such that there was no net</text>
<text top="892" left="64" width="27" height="13" font="14">bene</text>
<text top="889" left="91" width="83" height="18" font="14">ﬁt for survival</text>
<text top="892" left="179" width="55" height="13" font="15"><a href="e147.full.html#78">(598,614)</a></text>
<text top="892" left="234" width="180" height="13" font="14">. Both SCD and total mortality</text>
<text top="910" left="64" width="350" height="13" font="14">are highest in patients with HFrEF with class IV symptoms, in</text>
<text top="928" left="64" width="350" height="13" font="14">whom ICDs are not expected to prolong meaningful survival</text>
<text top="946" left="64" width="350" height="13" font="14">and are not indicated except in those for whom heart trans-</text>
<text top="964" left="64" width="191" height="13" font="14">plantation or MCS is anticipated.</text>
<text top="982" left="79" width="335" height="13" font="14">The use of ICDs for primary prevention in patients with</text>
<text top="1000" left="64" width="350" height="13" font="14">HFrEF should be considered only in the setting of optimal</text>
<text top="1018" left="64" width="350" height="13" font="14">GDMT and with a minimum of 3 to 6 months of appropriate</text>
<text top="1036" left="64" width="350" height="13" font="14">medical therapy. A repeat assessment of ventricular function</text>
<text top="1054" left="64" width="350" height="13" font="14">is appropriate to assess any recovery of ventricular function</text>
<text top="1072" left="64" width="350" height="13" font="14">on GDMT that would be above the threshold where an ICD is</text>
<text top="1090" left="64" width="350" height="13" font="14">indicated. This therapy will often improve ventricular</text>
<text top="677" left="450" width="350" height="13" font="14">function to a range for which the risk of sudden death is too</text>
<text top="695" left="450" width="350" height="13" font="14">low to warrant placement of an ICD. In addition, the trials of</text>
<text top="713" left="450" width="350" height="13" font="14">ICDs for primary prevention of SCD studied patients who</text>
<text top="731" left="450" width="142" height="13" font="14">were already on GDMT.</text>
<text top="749" left="465" width="335" height="13" font="14">ICDs are highly effective in preventing death from</text>
<text top="767" left="450" width="350" height="13" font="14">ventricular arrhythmias, but frequent shocks can decrease</text>
<text top="785" left="450" width="309" height="13" font="14">HRQOL and lead to posttraumatic stress syndrome</text>
<text top="785" left="766" width="30" height="13" font="15"><a href="e147.full.html#78">(615)</a></text>
<text top="785" left="796" width="4" height="13" font="14"><a href="e147.full.html#78">.</a></text>
<text top="803" left="450" width="350" height="13" font="14">Therapy with antiarrhythmic drugs and catheter ablation for</text>
<text top="821" left="450" width="350" height="13" font="14">ventricular tachycardia can decrease the number of ICD</text>
<text top="839" left="450" width="350" height="13" font="14">shocks given and can sometimes improve ventricular function</text>
<text top="857" left="450" width="350" height="13" font="14">in cases of very frequent ventricular tachyarrhythmias.</text>
<text top="875" left="450" width="16" height="13" font="14">Re</text>
<text top="871" left="466" width="334" height="18" font="14">ﬁned device programming can optimize pacing therapies</text>
<text top="892" left="450" width="350" height="13" font="14">to avert the need for shocks, minimize inappropriate shocks,</text>
<text top="910" left="450" width="350" height="13" font="14">and avoid aggravation of HF by frequent ventricular pacing.</text>
<text top="928" left="450" width="350" height="13" font="14">Although there have been occasional recalls of device</text>
<text top="946" left="450" width="350" height="13" font="14">generators, these are exceedingly rare in comparison to</text>
<text top="964" left="450" width="350" height="13" font="14">complications related to intracardiac device leads, such as</text>
<text top="982" left="450" width="126" height="13" font="14">fracture and infection.</text>
<text top="1000" left="465" width="335" height="13" font="14">ICDs are indicated only in patients with a reasonable</text>
<text top="1018" left="450" width="350" height="13" font="14">expectation of survival with good functional status beyond</text>
<text top="1036" left="450" width="350" height="13" font="14">a year, but the range of uncertainty remains wide. The</text>
<text top="1054" left="450" width="284" height="13" font="14">complex decision about the relative risks and bene</text>
<text top="1050" left="734" width="66" height="18" font="14">ﬁts of ICDs</text>
<text top="1072" left="450" width="350" height="13" font="14">for primary prevention of SCD must be individualized for</text>
<text top="1090" left="450" width="350" height="13" font="14">each patient. Unlike other therapies that can prolong life with</text>
<text top="607" left="64" width="709" height="14" font="4">Figure 2. Indications for CRT therapy algorithm. CRT indicates cardiac resynchronization therapy; CRT-D, cardiac resynchronization</text>
<text top="624" left="64" width="58" height="11" font="4">therapy-de</text>
<text top="621" left="122" width="637" height="16" font="4">ﬁbrillator; GDMT, guideline-directed medical therapy; HF, heart failure; ICD, implantable cardioverter-deﬁbrillator; LBBB,</text>
<text top="637" left="64" width="699" height="11" font="4">left bundle-branch block; LVEF, left ventricular ejection fraction; MI, myocardial infarction; and NYHA, New York Heart Association.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e187</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">HF, the ICD does not modify the disease except in conjunc-</text>
<text top="121" left="64" width="350" height="13" font="14">tion with CRT. Patients with multiple comorbidities have</text>
<text top="139" left="64" width="350" height="13" font="14">a higher rate of implant complications and higher competing</text>
<text top="157" left="64" width="221" height="13" font="14">risks of death from noncardiac causes</text>
<text top="157" left="290" width="30" height="13" font="15"><a href="e147.full.html#78">(616)</a></text>
<text top="157" left="321" width="93" height="13" font="14"><a href="e147.full.html#78">. </a>Older patients,</text>
<text top="175" left="64" width="350" height="13" font="14">who are at a higher risk of nonsudden death, are often</text>
<text top="193" left="64" width="350" height="13" font="14">underrepresented in the pivotal trials where the average</text>
<text top="211" left="64" width="56" height="13" font="14">patient is</text>
<text top="207" left="128" width="111" height="18" font="14">&lt;65 years of age</text>
<text top="211" left="248" width="30" height="13" font="15"><a href="e147.full.html#78">(617)</a></text>
<text top="211" left="278" width="136" height="13" font="14">. The major trials for</text>
<text top="229" left="64" width="273" height="13" font="14">secondary prevention of SCD showed no bene</text>
<text top="225" left="337" width="77" height="18" font="14">ﬁt in patients</text>
<text top="243" left="64" width="109" height="18" font="14">&gt;75 years of age</text>
<text top="247" left="181" width="30" height="13" font="15"><a href="e147.full.html#78">(618)</a></text>
<text top="247" left="212" width="202" height="13" font="14"><a href="e147.full.html#78">, </a>and a meta-analysis of primary</text>
<text top="265" left="64" width="350" height="13" font="14">prevention of SCD also suggested lesser effectiveness of</text>
<text top="283" left="64" width="30" height="13" font="14">ICDs</text>
<text top="283" left="99" width="30" height="13" font="15"><a href="e147.full.html#78">(619)</a></text>
<text top="283" left="129" width="285" height="13" font="14">. Populations of patients with multiple HF hospi-</text>
<text top="301" left="64" width="350" height="13" font="14">talizations, particularly in the setting of chronic kidney</text>
<text top="319" left="64" width="240" height="13" font="14">disease, have a median survival rate of</text>
<text top="315" left="311" width="103" height="18" font="14">&lt;2 years, during</text>
<text top="337" left="64" width="85" height="13" font="14">which the bene</text>
<text top="333" left="150" width="190" height="18" font="14">ﬁt of the ICD may not be realized</text>
<text top="337" left="344" width="30" height="13" font="15"><a href="e147.full.html#78">(608)</a></text>
<text top="337" left="374" width="40" height="13" font="14">. There</text>
<text top="354" left="64" width="350" height="13" font="14">is widespread recognition of the need for further research to</text>
<text top="372" left="64" width="254" height="13" font="14">identify patients most and least likely to bene</text>
<text top="369" left="319" width="95" height="18" font="14">ﬁt from ICDs for</text>
<text top="390" left="64" width="350" height="13" font="14">primary prevention of SCD in HF. Similar considerations</text>
<text top="408" left="64" width="305" height="13" font="14">apply to the decision to replace the device generator.</text>
<text top="426" left="79" width="335" height="13" font="14">Consideration of ICD implantation is highly appropriate for</text>
<text top="444" left="64" width="140" height="13" font="14">shared decision making</text>
<text top="444" left="211" width="23" height="13" font="15"><a href="e147.full.html#65">(30)</a></text>
<text top="444" left="234" width="127" height="13" font="14">. The risks and bene</text>
<text top="440" left="361" width="53" height="18" font="14">ﬁts carry</text>
<text top="462" left="64" width="350" height="13" font="14">different relative values depending on patient goals and pref-</text>
<text top="480" left="64" width="350" height="13" font="14">erences. Discussion should include the potential for SCD and</text>
<text top="498" left="64" width="350" height="13" font="14">nonsudden death from HF or noncardiac conditions. Infor-</text>
<text top="516" left="64" width="350" height="13" font="14">mation should be provided in a format that patients can</text>
<text top="534" left="64" width="193" height="13" font="14">understand about the estimated ef</text>
<text top="530" left="257" width="157" height="18" font="14">ﬁcacy, safety, and potential</text>
<text top="552" left="64" width="291" height="13" font="14">complications of an ICD and the ease with which de</text>
<text top="548" left="355" width="59" height="18" font="14">ﬁbrillation</text>
<text top="570" left="64" width="226" height="13" font="14">can be inactivated if no longer desired</text>
<text top="570" left="295" width="30" height="13" font="15"><a href="e147.full.html#78">(620)</a></text>
<text top="570" left="326" width="88" height="13" font="14"><a href="e147.full.html#78">. </a>As the preva-</text>
<text top="588" left="64" width="350" height="13" font="14">lence of implantable devices increases, it is essential that</text>
<text top="606" left="64" width="56" height="13" font="14">clearly de</text>
<text top="602" left="121" width="293" height="18" font="14">ﬁned processes be in place to support patients and</text>
<text top="623" left="64" width="276" height="13" font="14">families when decisions about deactivation arise</text>
<text top="623" left="345" width="30" height="13" font="15"><a href="e147.full.html#78">(621)</a></text>
<text top="623" left="375" width="4" height="13" font="14">.</text>
<text top="657" left="64" width="46" height="15" font="14">7.3.4.2.</text>
<text top="661" left="118" width="239" height="11" font="20">CARDIAC RESYNCHRONIZATION THERAPY</text>
<text top="677" left="65" width="349" height="13" font="14">In approximately one third of patients, HF progression is</text>
<text top="695" left="64" width="350" height="13" font="14">accompanied by substantial prolongation of the QRS</text>
<text top="713" left="64" width="307" height="13" font="14">interval, which is associated with worse outcome</text>
<text top="713" left="379" width="31" height="13" font="15"><a href="e147.full.html#78">(622)</a></text>
<text top="713" left="410" width="4" height="13" font="14">.</text>
<text top="731" left="64" width="350" height="13" font="14">Multisite ventricular pacing (termed CRT or biventricular</text>
<text top="749" left="64" width="350" height="13" font="14">pacing) can improve ventricular contractile function, di-</text>
<text top="767" left="64" width="350" height="13" font="14">minish secondary mitral regurgitation, reverse ventricular</text>
<text top="785" left="64" width="350" height="13" font="14">remodeling, and sustain improvement in LVEF. Increased</text>
<text top="803" left="64" width="350" height="13" font="14">blood pressure with CRT can allow increased titration of</text>
<text top="821" left="64" width="350" height="13" font="14">neurohormonal antagonist medications that may further</text>
<text top="839" left="64" width="192" height="13" font="14">contribute to improvement. Bene</text>
<text top="835" left="256" width="158" height="18" font="14">ﬁts were proven initially in</text>
<text top="857" left="64" width="350" height="13" font="14">trials of patients with NYHA class III or ambulatory class IV</text>
<text top="874" left="64" width="209" height="13" font="14">HF symptoms and QRS duration of</text>
<text top="871" left="278" width="136" height="18" font="14">120 to 130 ms. These</text>
<text top="892" left="64" width="350" height="13" font="14">results have included a decrease of approximately 30% in</text>
<text top="910" left="64" width="350" height="13" font="14">rehospitalization and reductions in all-cause mortality in the</text>
<text top="928" left="64" width="350" height="13" font="14">range of 24% to 36%. Improvement in survival is evident as</text>
<text top="946" left="64" width="68" height="13" font="14">early as the</text>
<text top="942" left="138" width="276" height="18" font="14">ﬁrst 3 months of therapy. Functional improve-</text>
<text top="964" left="64" width="350" height="13" font="14">ments have been demonstrated on average as a 1 to 2 mL/kg/</text>
<text top="982" left="64" width="350" height="13" font="14">min increase in peak oxygen consumption, 50- to 70-meter</text>
<text top="1000" left="64" width="350" height="13" font="14">increase in 6-minute walk distance, and a reduction of 10</text>
<text top="1018" left="64" width="350" height="13" font="14">points or more in the 0- to 105-point scale of the Minnesota</text>
<text top="1036" left="64" width="350" height="13" font="14">Living With Heart Failure Questionnaire, all considered</text>
<text top="1054" left="64" width="87" height="13" font="14">clinically signi</text>
<text top="1050" left="152" width="262" height="18" font="14">ﬁcant. These results include patients with a</text>
<text top="1072" left="64" width="350" height="13" font="14">wide range of QRS duration and, in most cases, sinus rhythm</text>
<text top="1090" left="64" width="100" height="13" font="15"><a href="e147.full.html#66">(78,116,594,623)</a></text>
<text top="1090" left="164" width="4" height="13" font="14">.</text>
<text top="103" left="465" width="294" height="13" font="14">Although it is still not possible to predict with con</text>
<text top="100" left="759" width="41" height="18" font="14">ﬁdence</text>
<text top="121" left="450" width="350" height="13" font="14">which patients will improve with CRT, further experiences</text>
<text top="139" left="450" width="152" height="13" font="14">have provided some clari</text>
<text top="135" left="601" width="198" height="18" font="14">ﬁcation. Beneﬁt appears conﬁned</text>
<text top="157" left="450" width="350" height="13" font="14">largely to patients with a QRS duration of at least 150 ms and</text>
<text top="175" left="450" width="83" height="13" font="14">LBBB pattern</text>
<text top="175" left="539" width="26" height="13" font="15"><a href="e147.full.html#78">(624</a></text>
<text top="171" left="565" width="33" height="18" font="15"><a href="e147.full.html#78">–628)</a></text>
<text top="175" left="598" width="202" height="13" font="14"><a href="e147.full.html#78">. </a>The weight of the evidence has</text>
<text top="193" left="450" width="350" height="13" font="14">been accumulated from patients with sinus rhythm, with meta-</text>
<text top="211" left="450" width="316" height="13" font="14">analyses indicating substantially less clinical bene</text>
<text top="207" left="766" width="33" height="18" font="14">ﬁt in</text>
<text top="229" left="450" width="171" height="13" font="14">patients with permanent AF</text>
<text top="229" left="629" width="55" height="13" font="15"><a href="e147.full.html#78">(604,605)</a></text>
<text top="229" left="684" width="116" height="13" font="14"><a href="e147.full.html#78">. </a>Because effective</text>
<text top="247" left="450" width="284" height="13" font="14">CRT requires a high rate of ventricular pacing</text>
<text top="247" left="741" width="30" height="13" font="15"><a href="e147.full.html#78">(629)</a></text>
<text top="247" left="772" width="28" height="13" font="14"><a href="e147.full.html#78">, </a>the</text>
<text top="265" left="450" width="27" height="13" font="14">bene</text>
<text top="261" left="476" width="323" height="18" font="14">ﬁt for patients with AF is most evident in patients who</text>
<text top="283" left="450" width="350" height="13" font="14">have undergone atrioventricular nodal ablation, which ensures</text>
<text top="301" left="450" width="153" height="13" font="14">obligate ventricular pacing</text>
<text top="301" left="607" width="26" height="13" font="15"><a href="e147.full.html#78">(601</a></text>
<text top="297" left="633" width="33" height="18" font="15"><a href="e147.full.html#78">–603)</a></text>
<text top="301" left="666" width="4" height="13" font="14">.</text>
<text top="319" left="465" width="335" height="13" font="14">In general, most data derive from patients with class III</text>
<text top="337" left="450" width="350" height="13" font="14">symptoms. Patients labeled as having class IV symptoms</text>
<text top="354" left="450" width="350" height="13" font="14">account for a small minority of patients enrolled. Furthermore,</text>
<text top="372" left="450" width="173" height="13" font="14">these patients, characterized as</text>
<text top="369" left="626" width="173" height="18" font="14">“ambulatory” NYHA class IV,</text>
<text top="390" left="450" width="133" height="13" font="14">are not refractory due to</text>
<text top="387" left="586" width="214" height="18" font="14">ﬂuid retention, frequently hospitalized</text>
<text top="408" left="450" width="350" height="13" font="14">for HF, or dependent on continuous intravenous inotropic</text>
<text top="426" left="450" width="234" height="13" font="14">therapy. CRT should not be considered as</text>
<text top="422" left="687" width="113" height="18" font="14">“rescue” therapy for</text>
<text top="444" left="450" width="252" height="13" font="14">stage D HF. In addition, patients with signi</text>
<text top="440" left="702" width="98" height="18" font="14">ﬁcant noncardiac</text>
<text top="462" left="450" width="253" height="13" font="14">limitations are unlikely to derive major bene</text>
<text top="458" left="703" width="78" height="18" font="14">ﬁt from CRT.</text>
<text top="480" left="465" width="269" height="13" font="14">Since publication of the 2009 HF guideline</text>
<text top="480" left="741" width="23" height="13" font="15"><a href="e147.full.html#65">(38)</a></text>
<text top="480" left="765" width="35" height="13" font="14"><a href="e147.full.html#65">, </a>new</text>
<text top="498" left="450" width="350" height="13" font="14">evidence supports extension of CRT to patients with milder</text>
<text top="516" left="450" width="350" height="13" font="14">symptoms. LV remodeling was consistently reversed or hal-</text>
<text top="534" left="450" width="88" height="13" font="14">ted, with bene</text>
<text top="530" left="537" width="262" height="18" font="14">ﬁt also in reduction of HF hospitalizations</text>
<text top="552" left="450" width="80" height="13" font="15"><a href="e147.full.html#78">(595,596,599)</a></text>
<text top="552" left="530" width="269" height="13" font="14"><a href="e147.full.html#78">. </a>In this population with low 1-year mortality,</text>
<text top="570" left="450" width="350" height="13" font="14">reduction of HF hospitalization dominated the composite</text>
<text top="588" left="450" width="232" height="13" font="14">primary endpoints, but a mortality bene</text>
<text top="584" left="682" width="118" height="18" font="14">ﬁt was subsequently</text>
<text top="606" left="450" width="272" height="13" font="14">observed in a 2-year extended follow-up study</text>
<text top="606" left="727" width="30" height="13" font="15"><a href="e147.full.html#78">(630)</a></text>
<text top="606" left="763" width="37" height="13" font="14">and in</text>
<text top="624" left="450" width="350" height="13" font="14">a meta-analysis of 5 trials of CRT in mild HF that included</text>
<text top="641" left="450" width="215" height="13" font="14">4213 patients with class II symptoms</text>
<text top="641" left="670" width="30" height="13" font="15"><a href="e147.full.html#79">(631)</a></text>
<text top="641" left="701" width="82" height="13" font="14"><a href="e147.full.html#79">. </a>Overall bene</text>
<text top="638" left="782" width="17" height="18" font="14">ﬁts</text>
<text top="659" left="450" width="294" height="13" font="14">in class II HF were noted only in patients with QRS</text>
<text top="656" left="747" width="52" height="18" font="14">150 ms</text>
<text top="677" left="450" width="350" height="13" font="14">and LBBB, with an adverse impact with shorter QRS duration</text>
<text top="695" left="450" width="83" height="13" font="14">or non-LBBB.</text>
<text top="713" left="465" width="335" height="13" font="14">The entry criterion for LVEF in CRT trials has ranged</text>
<text top="731" left="450" width="27" height="13" font="14">from</text>
<text top="727" left="481" width="318" height="18" font="14">30% to 40%. The trials with class III–IV symptoms</text>
<text top="749" left="450" width="176" height="13" font="14">included patients with LVEF</text>
<text top="745" left="634" width="37" height="18" font="14">35%</text>
<text top="749" left="678" width="73" height="13" font="15"><a href="e147.full.html#66">(78,116,594)</a></text>
<text top="749" left="751" width="48" height="13" font="14">. The 2</text>
<text top="767" left="450" width="350" height="13" font="14">individual trials showing improvement in mortality with class</text>
<text top="785" left="450" width="206" height="13" font="14">II HF included patients with LVEF</text>
<text top="781" left="661" width="37" height="18" font="14">30%</text>
<text top="785" left="703" width="55" height="13" font="15"><a href="e147.full.html#79">(632,633)</a></text>
<text top="785" left="758" width="41" height="13" font="14">. Trials</text>
<text top="803" left="450" width="115" height="13" font="14">demonstrating signi</text>
<text top="799" left="564" width="235" height="18" font="14">ﬁcant improvement in LV size and EF</text>
<text top="821" left="450" width="226" height="13" font="14">have included patients with LVEF</text>
<text top="817" left="688" width="37" height="18" font="14">35%</text>
<text top="821" left="737" width="30" height="13" font="15"><a href="e147.full.html#67">(115)</a></text>
<text top="821" left="779" width="20" height="13" font="14">and</text>
<text top="839" left="450" width="35" height="13" font="14">LVEF</text>
<text top="835" left="493" width="37" height="18" font="14">40%</text>
<text top="839" left="537" width="30" height="13" font="15"><a href="e147.full.html#78">(599)</a></text>
<text top="839" left="568" width="232" height="13" font="14"><a href="e147.full.html#78">, </a>which also showed reduction in the</text>
<text top="857" left="450" width="350" height="13" font="14">secondary endpoint of time to hospitalization and a reduction</text>
<text top="874" left="450" width="350" height="13" font="14">in the composite of clinical HF events comparable to that of</text>
<text top="892" left="450" width="115" height="13" font="14">all of the CRT trials</text>
<text top="892" left="569" width="30" height="13" font="15"><a href="e147.full.html#78">(624)</a></text>
<text top="892" left="599" width="200" height="13" font="14">. The congruence of evidence from</text>
<text top="910" left="450" width="350" height="13" font="14">the totality of CRT trials with regard to remodeling and HF</text>
<text top="928" left="450" width="307" height="13" font="14">events supports a common threshold of 35% for bene</text>
<text top="924" left="756" width="43" height="18" font="14">ﬁt from</text>
<text top="946" left="450" width="350" height="13" font="14">CRT in patients with class II, III, and IV HF symptoms. For</text>
<text top="964" left="450" width="350" height="13" font="14">patients with class II HF, all but 1 of the trials tested CRT in</text>
<text top="982" left="450" width="350" height="13" font="14">combination with an ICD, whereas there is evidence for</text>
<text top="1000" left="450" width="27" height="13" font="14">bene</text>
<text top="996" left="476" width="323" height="18" font="14">ﬁt with both CRT-deﬁbrillator and CRT alone in patients</text>
<text top="1018" left="450" width="75" height="13" font="14">with class III</text>
<text top="1014" left="525" width="84" height="18" font="14">–IV symptoms</text>
<text top="1018" left="614" width="48" height="13" font="15"><a href="e147.full.html#66">(78,116)</a></text>
<text top="1018" left="662" width="4" height="13" font="14">.</text>
<text top="1036" left="465" width="335" height="13" font="14">Although the weight of evidence is substantial for patients</text>
<text top="1054" left="450" width="350" height="13" font="14">with class II symptoms, these CRT trials have included only</text>
<text top="1072" left="450" width="350" height="13" font="14">372 patients with class I symptoms, most with concomitant</text>
<text top="1090" left="450" width="212" height="13" font="14">ICD for the postinfarction indication</text>
<text top="1090" left="667" width="55" height="13" font="15"><a href="e147.full.html#78">(595,599)</a></text>
<text top="1090" left="722" width="77" height="13" font="14">. Considering</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e188</text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="29" size="6" family="Times" color="#000000"/>
<text top="103" left="64" width="42" height="13" font="14">the risk</text>
<text top="100" left="106" width="308" height="18" font="14">–beneﬁt ratio for class I, more concern is raised by the</text>
<text top="121" left="64" width="350" height="13" font="14">early adverse events, which in 1 trial occurred in 13% of</text>
<text top="139" left="64" width="350" height="13" font="14">patients with CRT-ICD compared with 6.7% in patients</text>
<text top="157" left="64" width="90" height="13" font="14">with ICD only</text>
<text top="157" left="162" width="30" height="13" font="15"><a href="e147.full.html#78">(596)</a></text>
<text top="157" left="192" width="222" height="13" font="14">. On the basis of limited data from</text>
<text top="175" left="64" width="238" height="13" font="14">MADIT-CRT (Multicenter Automatic De</text>
<text top="171" left="302" width="112" height="18" font="14">ﬁbrillator Implanta-</text>
<text top="193" left="64" width="350" height="13" font="14">tion Trial-Cardiac Resynchronization Therapy), CRT-ICD</text>
<text top="211" left="64" width="319" height="13" font="14">may be considered for patients with class I symptoms</text>
<text top="207" left="389" width="25" height="18" font="14">&gt;40</text>
<text top="229" left="64" width="133" height="13" font="14">days after MI, LVEF</text>
<text top="225" left="205" width="209" height="18" font="14">30%, sinus rhythm, LBBB, and</text>
<text top="247" left="64" width="27" height="13" font="14">QRS</text>
<text top="243" left="96" width="53" height="18" font="14">150 ms</text>
<text top="247" left="154" width="30" height="13" font="15"><a href="e147.full.html#78">(595)</a></text>
<text top="247" left="185" width="4" height="13" font="14"><a href="e147.full.html#78">.</a></text>
<text top="265" left="79" width="335" height="13" font="14">These indications for CRT all include expectation for</text>
<text top="283" left="64" width="316" height="13" font="14">ongoing GDMT and diuretic therapy as needed for</text>
<text top="279" left="388" width="26" height="18" font="14">ﬂuid</text>
<text top="301" left="64" width="350" height="13" font="14">retention. In addition, regular monitoring is required after</text>
<text top="319" left="64" width="350" height="13" font="14">device implantation because adjustment of HF therapies and</text>
<text top="337" left="64" width="350" height="13" font="14">reprogramming of device intervals may be required. The trials</text>
<text top="354" left="64" width="119" height="13" font="14">establishing the bene</text>
<text top="351" left="183" width="231" height="18" font="14">ﬁt of these interventions were conducted</text>
<text top="372" left="64" width="350" height="13" font="14">in centers offering expertise in both implantation and follow-</text>
<text top="390" left="64" width="350" height="13" font="14">up. Recommendations for CRT are made with the expectation</text>
<text top="408" left="64" width="350" height="13" font="14">that they will be performed in centers with expertise and</text>
<text top="426" left="64" width="350" height="13" font="14">outcome comparable to that of the trials that provide the bases of</text>
<text top="444" left="64" width="109" height="13" font="14">evidence. The bene</text>
<text top="440" left="174" width="240" height="18" font="14">ﬁt–risk ratio for this intervention would be</text>
<text top="462" left="64" width="350" height="13" font="14">anticipated to be diminished for patients who do not have</text>
<text top="480" left="64" width="350" height="13" font="14">access to these specialized care settings or who are nonadherent.</text>
<text top="498" left="79" width="20" height="13" font="14">See</text>
<text top="498" left="105" width="221" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplements 28 and 29</a></text>
<text top="498" left="333" width="81" height="13" font="14">for additional</text>
<text top="516" left="64" width="192" height="13" font="14">data on device therapy and CRT.</text>
<text top="548" left="64" width="95" height="14" font="16">7.4. Stage D</text>
<text top="574" left="64" width="61" height="15" font="14">7.4.1. De</text>
<text top="571" left="126" width="158" height="19" font="14">ﬁnition of Advanced HF</text>
<text top="595" left="65" width="349" height="13" font="14">A subset of patients with chronic HF will continue to progress</text>
<text top="613" left="64" width="350" height="13" font="14">and develop persistently severe symptoms despite maximum</text>
<text top="631" left="64" width="350" height="13" font="14">GDMT. Various terminologies have been used to describe</text>
<text top="649" left="64" width="219" height="13" font="14">this group of patients who are classi</text>
<text top="645" left="284" width="130" height="18" font="14">ﬁed with ACCF/AHA</text>
<text top="667" left="64" width="129" height="13" font="14">stage D HF, including</text>
<text top="663" left="198" width="216" height="18" font="14">“advanced HF,” “end-stage HF,” and</text>
<text top="681" left="64" width="350" height="18" font="14">“refractory HF.” In the 2009 ACCF/AHA HF guideline, stage</text>
<text top="703" left="64" width="52" height="13" font="14">D was de</text>
<text top="699" left="116" width="298" height="18" font="14">ﬁned as “patients with truly refractory HF who might</text>
<text top="721" left="64" width="350" height="13" font="14">be eligible for specialized, advanced treatment strategies, such</text>
<text top="738" left="64" width="193" height="13" font="14">as MCS, procedures to facilitate</text>
<text top="735" left="263" width="150" height="18" font="14">ﬂuid removal, continuous</text>
<text top="756" left="64" width="350" height="13" font="14">inotropic infusions, or cardiac transplantation or other inno-</text>
<text top="774" left="64" width="350" height="13" font="14">vative or experimental surgical procedures, or for end-of-life</text>
<text top="792" left="64" width="122" height="13" font="14">care, such as hospice</text>
<text top="789" left="186" width="6" height="18" font="14">”</text>
<text top="792" left="197" width="23" height="13" font="15"><a href="e147.full.html#65">(38)</a></text>
<text top="792" left="221" width="193" height="13" font="14"><a href="e147.full.html#65">. </a>The European Society of Cardi-</text>
<text top="810" left="64" width="165" height="13" font="14">ology has developed a de</text>
<text top="806" left="229" width="185" height="18" font="14">ﬁnition of advanced HF with</text>
<text top="828" left="64" width="198" height="13" font="14">objective criteria that can be useful</text>
<text top="828" left="267" width="23" height="13" font="15"><a href="e147.full.html#65">(32)</a></text>
<text top="828" left="294" width="5" height="13" font="14"><a href="e147.full.html#43">(</a></text>
<text top="828" left="298" width="50" height="13" font="15"><a href="e147.full.html#43">Table 23</a></text>
<text top="828" left="348" width="66" height="13" font="14">). There are</text>
<text top="846" left="64" width="350" height="13" font="14">clinical clues that may assist clinicians in identifying patients</text>
<text top="864" left="64" width="261" height="13" font="14">who are progressing toward advanced HF (</text>
<text top="864" left="325" width="53" height="13" font="15"><a href="e147.full.html#43">Table 24</a></text>
<text top="864" left="377" width="36" height="13" font="14">). The</text>
<text top="882" left="64" width="350" height="13" font="14">Interagency Registry for Mechanically Assisted Circulatory</text>
<text top="900" left="64" width="259" height="13" font="14">Support (INTERMACS) has developed 7 pro</text>
<text top="896" left="323" width="91" height="18" font="14">ﬁles that further</text>
<text top="918" left="64" width="207" height="13" font="14">stratify patients with advanced HF (</text>
<text top="918" left="272" width="51" height="13" font="15"><a href="e147.full.html#44">Table 25</a></text>
<text top="918" left="322" width="5" height="13" font="14">)</text>
<text top="918" left="332" width="30" height="13" font="15"><a href="e147.full.html#79">(635)</a></text>
<text top="918" left="362" width="4" height="13" font="14">.</text>
<text top="943" left="64" width="350" height="15" font="14">7.4.2. Important Considerations in Determining If the</text>
<text top="961" left="64" width="133" height="15" font="14">Patient Is Refractory</text>
<text top="982" left="65" width="349" height="13" font="14">Patients considered to have stage D HF should be thoroughly</text>
<text top="1000" left="64" width="350" height="13" font="14">evaluated to ascertain that the diagnosis is correct and that</text>
<text top="1018" left="64" width="350" height="13" font="14">there are no remediable etiologies or alternative explanations</text>
<text top="1036" left="64" width="350" height="13" font="14">for advanced symptoms. For example, it is important to</text>
<text top="1054" left="64" width="350" height="13" font="14">determine that HF and not a concomitant pulmonary disorder</text>
<text top="1072" left="64" width="350" height="13" font="14">is the basis of dyspnea. Similarly, in those with presumed</text>
<text top="1090" left="64" width="350" height="13" font="14">cardiac cachexia, other causes of weight loss should be ruled</text>
<text top="594" left="450" width="350" height="13" font="14">out. Likewise, other reversible factors such as thyroid disor-</text>
<text top="612" left="450" width="350" height="13" font="14">ders should be treated. Severely symptomatic patients pre-</text>
<text top="630" left="450" width="350" height="13" font="14">senting with a new diagnosis of HF can often improve</text>
<text top="647" left="450" width="350" height="13" font="14">substantially if they are initially stabilized. Patients should</text>
<text top="665" left="450" width="284" height="13" font="14">also be evaluated for nonadherence to medications</text>
<text top="665" left="737" width="26" height="13" font="15"><a href="e147.full.html#79">(636</a></text>
<text top="662" left="763" width="33" height="18" font="15"><a href="e147.full.html#79">–639)</a></text>
<text top="665" left="796" width="4" height="13" font="14"><a href="e147.full.html#79">,</a></text>
<text top="683" left="450" width="107" height="13" font="14">sodium restriction</text>
<text top="683" left="566" width="30" height="13" font="15"><a href="e147.full.html#79">(640)</a></text>
<text top="683" left="596" width="203" height="13" font="14"><a href="e147.full.html#79">, </a>and/or daily weight monitoring</text>
<text top="701" left="450" width="30" height="13" font="15"><a href="e147.full.html#79">(641)</a></text>
<text top="701" left="480" width="319" height="13" font="14">. Finally, a careful review of prior medical management</text>
<text top="103" left="450" width="223" height="12" font="9">Table 23. ESC Definition of Advanced HF</text>
<text top="134" left="450" width="350" height="11" font="4">1. Severe symptoms of HF with dyspnea and/or fatigue at rest or with minimal</text>
<text top="149" left="469" width="132" height="11" font="4">exertion (NYHA class III or IV)</text>
<text top="168" left="450" width="314" height="11" font="4">2. Episodes of fluid retention (pulmonary and/or systemic congestion,</text>
<text top="183" left="469" width="305" height="11" font="4">peripheral edema) and/or reduced cardiac output at rest (peripheral</text>
<text top="198" left="469" width="65" height="11" font="4">hypoperfusion)</text>
<text top="218" left="450" width="350" height="11" font="4">3. Objective evidence of severe cardiac dysfunction shown by at least 1 of the</text>
<text top="233" left="469" width="43" height="11" font="4">following:</text>
<text top="252" left="462" width="34" height="11" font="4">a. LVEF</text>
<text top="249" left="499" width="30" height="16" font="4">&lt;30%</text>
<text top="267" left="462" width="230" height="11" font="4">b. Pseudonormal or restrictive mitral inflow pattern</text>
<text top="282" left="462" width="66" height="11" font="4">c. Mean PCWP</text>
<text top="279" left="532" width="268" height="16" font="4">&gt;16 mm Hg and/or RAP &gt;12 mm Hg by PA catheterization</text>
<text top="297" left="462" width="321" height="11" font="4">d. High BNP or NT-proBNP plasma levels in the absence of noncardiac</text>
<text top="312" left="486" width="31" height="11" font="4">causes</text>
<text top="331" left="450" width="331" height="11" font="4">4. Severe impairment of functional capacity shown by 1 of the following:</text>
<text top="351" left="462" width="99" height="11" font="4">a. Inability to exercise</text>
<text top="366" left="462" width="118" height="11" font="4">b. 6-Minute walk distance</text>
<text top="363" left="584" width="39" height="16" font="4">300 m</text>
<text top="381" left="462" width="48" height="11" font="4">c. Peak _Vo</text>
<text top="385" left="510" width="4" height="8" font="29">2</text>
<text top="378" left="519" width="100" height="16" font="4">&lt;12 to 14 mL/kg/min</text>
<text top="400" left="450" width="55" height="11" font="4">5. History of</text>
<text top="397" left="509" width="160" height="16" font="4">1 HF hospitalization in past 6 mo</text>
<text top="419" left="450" width="350" height="11" font="4">6. Presence of all the previous features despite “attempts to optimize” therapy,</text>
<text top="434" left="469" width="301" height="11" font="4">including diuretics and GDMT, unless these are poorly tolerated or</text>
<text top="449" left="469" width="185" height="11" font="4">contraindicated, and CRT when indicated</text>
<text top="471" left="462" width="338" height="11" font="4">BNP indicates B-type natriuretic peptide; CRT, cardiac resynchronization</text>
<text top="486" left="450" width="350" height="11" font="4">therapy; ESC, European Society of Cardiology; GDMT, guideline-directed</text>
<text top="501" left="450" width="350" height="11" font="4">medical therapy; HF, heart failure; LVEF, left ventricular ejection fraction;</text>
<text top="516" left="450" width="350" height="11" font="4">NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart</text>
<text top="530" left="450" width="350" height="11" font="4">Association; PA, pulmonary artery; PWCP, pulmonary capillary wedge pressure;</text>
<text top="545" left="450" width="136" height="11" font="4">and RAP, right atrial pressure.</text>
<text top="560" left="462" width="117" height="11" font="4">Adapted from Metra et al.</text>
<text top="560" left="583" width="17" height="11" font="5"><a href="e147.full.html#65">(32)</a></text>
<text top="560" left="600" width="3" height="11" font="4">.</text>
<text top="738" left="450" width="329" height="12" font="9">Table 24. Clinical Events and Findings Useful for Identifying</text>
<text top="754" left="450" width="147" height="12" font="9">Patients With Advanced HF</text>
<text top="785" left="450" width="48" height="11" font="4">Repeated (</text>
<text top="783" left="498" width="252" height="16" font="4">2) hospitalizations or ED visits for HF in the past year</text>
<text top="805" left="450" width="340" height="11" font="4">Progressive deterioration in renal function (e.g., rise in BUN and creatinine)</text>
<text top="824" left="450" width="253" height="11" font="4">Weight loss without other cause (e.g., cardiac cachexia)</text>
<text top="844" left="450" width="325" height="11" font="4">Intolerance to ACE inhibitors due to hypotension and/or worsening renal</text>
<text top="859" left="462" width="36" height="11" font="4">function</text>
<text top="878" left="450" width="294" height="11" font="4">Intolerance to beta blockers due to worsening HF or hypotension</text>
<text top="897" left="450" width="146" height="11" font="4">Frequent systolic blood pressure</text>
<text top="895" left="600" width="56" height="16" font="4">&lt;90 mm Hg</text>
<text top="917" left="450" width="262" height="11" font="4">Persistent dyspnea with dressing or bathing requiring rest</text>
<text top="936" left="450" width="321" height="11" font="4">Inability to walk 1 block on the level ground due to dyspnea or fatigue</text>
<text top="956" left="450" width="344" height="11" font="4">Recent need to escalate diuretics to maintain volume status, often reaching</text>
<text top="971" left="462" width="148" height="11" font="4">daily furosemide equivalent dose</text>
<text top="968" left="614" width="181" height="16" font="4">&gt;160 mg/d and/or use of supplemental</text>
<text top="986" left="462" width="88" height="11" font="4">metolazone therapy</text>
<text top="1005" left="450" width="217" height="11" font="4">Progressive decline in serum sodium, usually to</text>
<text top="1002" left="670" width="59" height="16" font="4">&lt;133 mEq/L</text>
<text top="1025" left="450" width="93" height="11" font="4">Frequent ICD shocks</text>
<text top="1046" left="462" width="338" height="11" font="4">ACE indicates angiotensin-converting enzyme; BUN, blood urea nitrogen; ED,</text>
<text top="1061" left="450" width="350" height="11" font="4">emergency department; HF, heart failure; and ICD, implantable cardioverter-</text>
<text top="1076" left="450" width="53" height="11" font="4">defibrillator.</text>
<text top="1091" left="462" width="123" height="11" font="4">Adapted from Russell et al.</text>
<text top="1091" left="589" width="23" height="11" font="5"><a href="e147.full.html#79">(642)</a></text>
<text top="1091" left="612" width="3" height="11" font="4"><a href="e147.full.html#79">.</a></text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e189</text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1160" width="864">
<text top="642" left="64" width="350" height="13" font="14">should be conducted to verify that all evidence-based thera-</text>
<text top="660" left="64" width="340" height="13" font="14">pies likely to improve clinical status have been considered.</text>
<text top="678" left="79" width="20" height="13" font="14">See</text>
<text top="678" left="105" width="221" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplements 30 and 31</a></text>
<text top="678" left="333" width="81" height="13" font="14">for additional</text>
<text top="696" left="64" width="344" height="15" font="14">data on therapiesdimportant considerations and sildenaﬁl.</text>
<text top="723" left="64" width="277" height="15" font="14">7.4.3. Water Restriction: Recommendation</text>
<text top="750" left="64" width="45" height="8" font="17">CLASS IIa</text>
<text top="762" left="82" width="10" height="10" font="18">1.</text>
<text top="762" left="100" width="314" height="10" font="18">Fluid restriction (1.5 to 2 L/d) is reasonable in stage D,</text>
<text top="778" left="100" width="314" height="10" font="18">especially in patients with hyponatremia, to reduce conges-</text>
<text top="795" left="100" width="194" height="12" font="18">tive symptoms. (Level of Evidence: C)</text>
<text top="820" left="79" width="128" height="13" font="14">Recommendations for</text>
<text top="816" left="214" width="200" height="18" font="14">ﬂuid restriction in HF are largely</text>
<text top="838" left="64" width="263" height="13" font="14">driven by clinical experience. Sodium and</text>
<text top="834" left="336" width="77" height="18" font="14">ﬂuid balance</text>
<text top="856" left="64" width="350" height="13" font="14">recommendations are best implemented in the context of</text>
<text top="874" left="64" width="350" height="13" font="14">weight and symptom monitoring programs. Routine strict</text>
<text top="888" left="64" width="350" height="18" font="14">ﬂuid restriction in all patients with HF regardless of symptoms</text>
<text top="910" left="64" width="318" height="13" font="14">or other considerations does not appear to result in signi</text>
<text top="906" left="383" width="31" height="18" font="14">ﬁcant</text>
<text top="928" left="64" width="27" height="13" font="14">bene</text>
<text top="924" left="91" width="12" height="18" font="14">ﬁt</text>
<text top="928" left="107" width="30" height="13" font="15"><a href="e147.full.html#79">(644)</a></text>
<text top="928" left="137" width="57" height="13" font="14">. Limiting</text>
<text top="924" left="198" width="216" height="18" font="14">ﬂuid intake to around 2 L/d is usually</text>
<text top="946" left="64" width="350" height="13" font="14">adequate for most hospitalized patients who are not diuretic</text>
<text top="964" left="64" width="93" height="13" font="14">resistant or signi</text>
<text top="960" left="157" width="257" height="18" font="14">ﬁcantly hyponatremic. In 1 study, patients on</text>
<text top="982" left="64" width="350" height="13" font="14">a similar sodium and diuretic regimen showed higher read-</text>
<text top="1000" left="64" width="149" height="13" font="14">mission rates with higher</text>
<text top="996" left="219" width="195" height="18" font="14">ﬂuid intake, suggesting that ﬂuid</text>
<text top="1018" left="64" width="157" height="13" font="14">intake affects HF outcomes</text>
<text top="1018" left="225" width="30" height="13" font="15"><a href="e147.full.html#73">(385)</a></text>
<text top="1018" left="256" width="38" height="13" font="14"><a href="e147.full.html#73">. </a>Strict</text>
<text top="1014" left="298" width="116" height="18" font="14">ﬂuid restriction may</text>
<text top="1036" left="64" width="350" height="13" font="14">best be used in patients who are either refractory to diuretics</text>
<text top="1053" left="64" width="350" height="13" font="14">or have hyponatremia. Fluid restriction, especially in con-</text>
<text top="1071" left="64" width="350" height="13" font="14">junction with sodium restriction, enhances volume manage-</text>
<text top="1089" left="64" width="350" height="13" font="14">ment with diuretics. Fluid restriction is important to manage</text>
<text top="643" left="450" width="350" height="13" font="14">hyponatremia, which is relatively common with advanced HF</text>
<text top="660" left="450" width="168" height="13" font="14">and portends a poor prognosis</text>
<text top="660" left="621" width="55" height="13" font="15"><a href="e147.full.html#79">(645,646)</a></text>
<text top="660" left="676" width="123" height="13" font="14">. Fluid restriction may</text>
<text top="678" left="450" width="307" height="13" font="14">improve serum sodium concentration; however, it is dif</text>
<text top="675" left="757" width="43" height="18" font="14">ﬁcult to</text>
<text top="696" left="450" width="350" height="13" font="14">achieve and maintain. In hot or low-humidity climates,</text>
<text top="714" left="450" width="54" height="13" font="14">excessive</text>
<text top="710" left="508" width="292" height="18" font="14">ﬂuid restriction predisposes patients with advanced</text>
<text top="732" left="450" width="350" height="13" font="14">HF to the risk of heat stroke. Hyponatremia in HF is primarily</text>
<text top="750" left="450" width="350" height="13" font="14">due to an inability to excrete free water. Norepinephrine and</text>
<text top="768" left="450" width="350" height="13" font="14">angiotensin II activation result in decreased sodium delivery to</text>
<text top="786" left="450" width="350" height="13" font="14">the distal tubule, whereas arginine vasopressin increases water</text>
<text top="804" left="450" width="350" height="13" font="14">absorption from the distal tubule. In addition, angiotensin II</text>
<text top="822" left="450" width="236" height="13" font="14">also promotes thirst. Thus, sodium and</text>
<text top="818" left="692" width="107" height="18" font="14">ﬂuid restriction in</text>
<text top="840" left="450" width="228" height="13" font="14">advanced patients with HF is important.</text>
<text top="869" left="450" width="283" height="15" font="14">7.4.4. Inotropic Support: Recommendations</text>
<text top="895" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="908" left="468" width="10" height="10" font="18">1.</text>
<text top="907" left="485" width="45" height="10" font="18">Until de</text>
<text top="904" left="530" width="270" height="16" font="18">ﬁnitive therapy (e.g., coronary revascularization,</text>
<text top="924" left="485" width="314" height="10" font="18">MCS, heart transplantation) or resolution of the acute</text>
<text top="940" left="485" width="314" height="10" font="18">precipitating problem, patients with cardiogenic shock</text>
<text top="957" left="485" width="314" height="10" font="18">should receive temporary intravenous inotropic support to</text>
<text top="973" left="485" width="314" height="10" font="18">maintain systemic perfusion and preserve end-organ perfor-</text>
<text top="990" left="485" width="155" height="12" font="18">mance. (Level of Evidence: C)</text>
<text top="1013" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="1026" left="468" width="10" height="10" font="18">1.</text>
<text top="1025" left="485" width="314" height="10" font="18">Continuous intravenous inotropic support is reasonable as</text>
<text top="1039" left="485" width="314" height="16" font="18">“bridge therapy” in patients with stage D HF refractory to</text>
<text top="1058" left="485" width="314" height="10" font="18">GDMT and device therapy who are eligible for and awaiting</text>
<text top="1075" left="485" width="185" height="10" font="18">MCS or cardiac transplantation</text>
<text top="1075" left="680" width="55" height="10" font="5"><a href="e147.full.html#79">(647,648)</a></text>
<text top="1075" left="735" width="64" height="12" font="18">. (Level of</text>
<text top="1091" left="485" width="64" height="12" font="18">Evidence: B)</text>
<text top="103" left="64" width="165" height="12" font="9">Table 25. INTERMACS Profiles</text>
<text top="135" left="64" width="28" height="11" font="4"><a href="e147.full.html#44">Profile</a></text>
<text top="135" left="92" width="4" height="11" font="5"><a href="e147.full.html#44">*</a></text>
<text top="135" left="138" width="81" height="11" font="4">Profile Description</text>
<text top="135" left="511" width="38" height="11" font="4">Features</text>
<text top="154" left="64" width="6" height="11" font="4">1</text>
<text top="154" left="119" width="116" height="11" font="4">Critical cardiogenic shock</text>
<text top="169" left="131" width="85" height="11" font="4">(“Crash and burn”)</text>
<text top="154" left="261" width="526" height="11" font="4">Life-threatening hypotension and rapidly escalating inotropic/pressor support, with critical organ hypoperfusion often</text>
<text top="169" left="274" width="234" height="11" font="4">confirmed by worsening acidosis and lactate levels.</text>
<text top="189" left="64" width="6" height="11" font="4">2</text>
<text top="189" left="119" width="87" height="11" font="4">Progressive decline</text>
<text top="204" left="131" width="77" height="11" font="4">(“Sliding fast” on</text>
<text top="219" left="131" width="44" height="11" font="4">inotropes)</text>
<text top="189" left="261" width="538" height="11" font="4">“Dependent” on inotropic support but nonetheless shows signs of continuing deterioration in nutrition, renal function, fluid</text>
<text top="204" left="274" width="524" height="11" font="4">retention, or other major status indicator. Can also apply to a patient with refractory volume overload, perhaps with</text>
<text top="219" left="274" width="523" height="11" font="4">evidence of impaired perfusion, in whom inotropic infusions cannot be maintained due to tachyarrhythmias, clinical</text>
<text top="233" left="274" width="138" height="11" font="4">ischemia, or other intolerance.</text>
<text top="253" left="64" width="6" height="11" font="4">3</text>
<text top="253" left="119" width="86" height="11" font="4">Stable but inotrope</text>
<text top="268" left="131" width="47" height="11" font="4">dependent</text>
<text top="253" left="261" width="536" height="11" font="4">Clinically stable on mild-moderate doses of intravenous inotropes (or has a temporary circulatory support device) after</text>
<text top="268" left="274" width="519" height="11" font="4">repeated documentation of failure to wean without symptomatic hypotension, worsening symptoms, or progressive</text>
<text top="283" left="274" width="149" height="11" font="4">organ dysfunction (usually renal).</text>
<text top="302" left="64" width="6" height="11" font="4">4</text>
<text top="302" left="119" width="97" height="11" font="4">Resting symptoms on</text>
<text top="317" left="131" width="95" height="11" font="4">oral therapy at home</text>
<text top="302" left="261" width="538" height="11" font="4">Patient who is at home on oral therapy but frequently has symptoms of congestion at rest or with activities of daily living</text>
<text top="317" left="274" width="526" height="11" font="4">(dressing or bathing). He or she may have orthopnea, shortness of breath during dressing or bathing, gastrointestinal</text>
<text top="332" left="274" width="497" height="11" font="4">symptoms (abdominal discomfort, nausea, poor appetite), disabling ascites, or severe lower-extremity edema.</text>
<text top="352" left="64" width="6" height="11" font="4">5</text>
<text top="352" left="119" width="81" height="11" font="4">Exertion intolerant</text>
<text top="367" left="131" width="69" height="11" font="4">(“housebound”)</text>
<text top="352" left="261" width="509" height="11" font="4">Patient who is comfortable at rest but unable to engage in any activity, living predominantly within the house or</text>
<text top="367" left="274" width="56" height="11" font="4">housebound.</text>
<text top="386" left="64" width="6" height="11" font="4">6</text>
<text top="386" left="119" width="69" height="11" font="4">Exertion limited</text>
<text top="401" left="131" width="94" height="11" font="4">(“walking wounded”)</text>
<text top="386" left="261" width="538" height="11" font="4">Patient who is comfortable at rest without evidence of fluid overload but who is able to do some mild activity. Activities of</text>
<text top="401" left="274" width="526" height="11" font="4">daily living are comfortable and minor activities outside the home such as visiting friends or going to a restaurant can</text>
<text top="416" left="274" width="438" height="11" font="4">be performed, but fatigue results within a few minutes or with any meaningful physical exertion.</text>
<text top="435" left="64" width="6" height="11" font="4">7</text>
<text top="435" left="119" width="109" height="11" font="4">Advanced NYHA class III</text>
<text top="435" left="261" width="485" height="11" font="4">Patient who is clinically stable with a reasonable level of comfortable activity, despite a history of previous</text>
<text top="450" left="274" width="506" height="11" font="4">decompensation that is not recent. This patient is usually able to walk more than a block. Any decompensation</text>
<text top="465" left="274" width="526" height="11" font="4">requiring intravenous diuretics or hospitalization within the previous month should make this person a Patient Profile 6</text>
<text top="480" left="274" width="40" height="11" font="4">or lower.</text>
<text top="502" left="76" width="723" height="11" font="4">*Modifier options: Profiles 3–6 can be modified with the designation frequent flyer for patients with recurrent decompensations leading to frequent (generally at least</text>
<text top="517" left="64" width="735" height="11" font="4">2 in last 3 mo or 3 in last 6 mo) emergency department visits or hospitalizations for intravenous diuretics, ultrafiltration, or brief inotropic therapy. Profile 3 can be</text>
<text top="531" left="64" width="735" height="11" font="4">modified in this fashion if the patient is usually at home. If a Profile 7 patient meets the definition of frequent flyer, the patient should be moved to Profile 6 or worse.</text>
<text top="546" left="64" width="735" height="11" font="4">Other modifier options include arrhythmia, which should be used in the presence of recurrent ventricular tachyarrhythmias contributing to the overall clinical course</text>
<text top="561" left="64" width="735" height="11" font="4">(e.g., frequent implantable cardioverter-defibrillator shocks or requirement of external defibrillation, usually more than twice weekly); or temporary circulatory support</text>
<text top="576" left="64" width="165" height="11" font="4">for hospitalized patients profiles 1–3</text>
<text top="576" left="233" width="23" height="11" font="5"><a href="e147.full.html#79">(635)</a></text>
<text top="576" left="256" width="3" height="11" font="4"><a href="e147.full.html#79">.</a></text>
<text top="591" left="76" width="586" height="11" font="4">INTERMACS indicates Interagency Registry for Mechanically Assisted Circulatory Support; and NYHA, New York Heart Association.</text>
<text top="606" left="76" width="137" height="11" font="4">Adapted from Stevenson et al.</text>
<text top="606" left="217" width="23" height="11" font="5"><a href="e147.full.html#79">(643)</a></text>
<text top="606" left="240" width="3" height="11" font="4">.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e190</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1160" width="864">
<text top="417" left="64" width="45" height="8" font="17">CLASS IIb</text>
<text top="429" left="82" width="10" height="10" font="18">1.</text>
<text top="429" left="100" width="314" height="10" font="18">Short-term, continuous intravenous inotropic support may</text>
<text top="446" left="100" width="314" height="10" font="18">be reasonable in those hospitalized patients presenting with</text>
<text top="462" left="100" width="314" height="10" font="18">documented severe systolic dysfunction who present with</text>
<text top="478" left="100" width="167" height="10" font="18">low blood pressure and signi</text>
<text top="475" left="267" width="147" height="16" font="18">ﬁcantly depressed cardiac</text>
<text top="495" left="100" width="314" height="10" font="18">output to maintain systemic perfusion and preserve end-</text>
<text top="511" left="100" width="99" height="10" font="18">organ performance</text>
<text top="511" left="203" width="80" height="10" font="5"><a href="e147.full.html#78">(592,649,650)</a></text>
<text top="511" left="282" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="528" left="82" width="10" height="10" font="18">2.</text>
<text top="528" left="100" width="314" height="10" font="18">Long-term, continuous intravenous inotropic support may be</text>
<text top="544" left="100" width="314" height="10" font="18">considered as palliative therapy for symptom control in</text>
<text top="561" left="100" width="314" height="10" font="18">select patients with stage D HF despite optimal GDMT and</text>
<text top="577" left="100" width="314" height="10" font="18">device therapy who are not eligible for either MCS or cardiac</text>
<text top="594" left="100" width="80" height="10" font="18">transplantation</text>
<text top="594" left="184" width="26" height="10" font="5"><a href="e147.full.html#79">(651</a></text>
<text top="590" left="209" width="32" height="16" font="5"><a href="e147.full.html#79">–653)</a></text>
<text top="594" left="241" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="617" left="64" width="73" height="8" font="17">CLASS III: Harm</text>
<text top="630" left="82" width="10" height="10" font="18">1.</text>
<text top="629" left="100" width="314" height="10" font="18">Long-term use of either continuous or intermittent, intrave-</text>
<text top="646" left="100" width="314" height="10" font="18">nous parenteral positive inotropic agents, in the absence of</text>
<text top="662" left="100" width="28" height="10" font="18">speci</text>
<text top="659" left="128" width="286" height="16" font="18">ﬁc indications or for reasons other than palliative care,</text>
<text top="679" left="100" width="225" height="10" font="18">is potentially harmful in the patient with HF</text>
<text top="679" left="328" width="50" height="10" font="5"><a href="e147.full.html#74">(416,654</a></text>
<text top="676" left="379" width="32" height="16" font="5"><a href="e147.full.html#74">–659)</a></text>
<text top="679" left="410" width="3" height="10" font="18">.</text>
<text top="695" left="100" width="113" height="12" font="18">(Level of Evidence: B)</text>
<text top="712" left="82" width="10" height="10" font="18">2.</text>
<text top="712" left="100" width="314" height="10" font="18">Use of parenteral inotropic agents in hospitalized patients</text>
<text top="728" left="100" width="314" height="10" font="18">without documented severe systolic dysfunction, low blood</text>
<text top="744" left="100" width="275" height="10" font="18">pressure, or impaired perfusion and evidence of signi</text>
<text top="741" left="375" width="39" height="16" font="18">ﬁcantly</text>
<text top="761" left="100" width="314" height="10" font="18">depressed cardiac output, with or without congestion, is</text>
<text top="777" left="100" width="98" height="10" font="18">potentially harmful</text>
<text top="777" left="202" width="80" height="10" font="5"><a href="e147.full.html#78">(592,649,650)</a></text>
<text top="777" left="282" width="121" height="12" font="18"><a href="e147.full.html#78">. </a>(Level of Evidence: B)</text>
<text top="803" left="79" width="335" height="13" font="14">Despite improving hemodynamic compromise, positive</text>
<text top="821" left="64" width="350" height="13" font="14">inotropic agents have not demonstrated improved outcomes in</text>
<text top="839" left="64" width="350" height="13" font="14">patients with HF in either the hospital or outpatient setting</text>
<text top="857" left="64" width="51" height="13" font="15"><a href="e147.full.html#74">(416,654</a></text>
<text top="853" left="115" width="33" height="18" font="15"><a href="e147.full.html#74">–658)</a></text>
<text top="857" left="148" width="266" height="13" font="14"><a href="e147.full.html#74">. </a>Regardless of their mechanism of action (e.g.,</text>
<text top="874" left="64" width="350" height="13" font="14">inhibition of phosphodiesterase, stimulation of adrenergic or</text>
<text top="892" left="64" width="350" height="13" font="14">dopaminergic receptors, calcium sensitization), chronic oral</text>
<text top="910" left="64" width="350" height="13" font="14">inotrope treatment increased mortality, mostly related to</text>
<text top="928" left="64" width="350" height="13" font="14">arrhythmic events. Parenteral inotropes, however, remain as</text>
<text top="946" left="64" width="350" height="13" font="14">an option to help the subset of patients with HF who are</text>
<text top="964" left="64" width="350" height="13" font="14">refractory to other therapies and are suffering consequences</text>
<text top="982" left="64" width="350" height="13" font="14">from end-organ hypoperfusion. Inotropes should be consid-</text>
<text top="1000" left="64" width="350" height="13" font="14">ered only in such patients with systolic dysfunction who have</text>
<text top="1018" left="64" width="350" height="13" font="14">low cardiac index and evidence of systemic hypoperfusion</text>
<text top="1036" left="64" width="113" height="13" font="14">and/or congestion (</text>
<text top="1036" left="178" width="52" height="13" font="15"><a href="e147.full.html#45">Table 26</a></text>
<text top="1036" left="230" width="184" height="13" font="14"><a href="e147.full.html#45">). </a>To minimize adverse effects,</text>
<text top="1054" left="64" width="350" height="13" font="14">lower doses are preferred. Similarly, the ongoing need for</text>
<text top="1072" left="64" width="350" height="13" font="14">inotropic support and the possibility of discontinuation should</text>
<text top="1090" left="64" width="124" height="13" font="14">be regularly assessed.</text>
<text top="414" left="465" width="20" height="13" font="14">See</text>
<text top="414" left="491" width="221" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplements 32 and 33</a></text>
<text top="414" left="719" width="81" height="13" font="14">for additional</text>
<text top="432" left="450" width="105" height="13" font="14">data on inotropes.</text>
<text top="458" left="450" width="251" height="15" font="14">7.4.5. Mechanical Circulatory Support:</text>
<text top="476" left="450" width="117" height="15" font="14">Recommendations</text>
<text top="503" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="515" left="468" width="10" height="10" font="18">1.</text>
<text top="515" left="485" width="67" height="10" font="18">MCS is bene</text>
<text top="511" left="552" width="135" height="16" font="18">ﬁcial in carefully selected</text>
<text top="511" left="688" width="5" height="16" font="5"><a href="e147.full.html#45">z</a></text>
<text top="515" left="697" width="103" height="10" font="18">patients with stage</text>
<text top="531" left="485" width="314" height="12" font="18">D HFrEF in whom deﬁnitive management (e.g., cardiac</text>
<text top="547" left="485" width="314" height="10" font="18">transplantation) or cardiac recovery is anticipated or plan-</text>
<text top="564" left="485" width="48" height="10" font="18">ned (660</text>
<text top="561" left="533" width="151" height="16" font="18">–667). (Level of Evidence: B)</text>
<text top="581" left="468" width="10" height="10" font="18">2.</text>
<text top="580" left="485" width="314" height="10" font="18">Nondurable MCS, including the use of percutaneous and</text>
<text top="597" left="485" width="76" height="10" font="18">extracorporeal</text>
<text top="597" left="574" width="56" height="10" font="18">ventricular</text>
<text top="597" left="642" width="32" height="10" font="18">assist</text>
<text top="597" left="685" width="40" height="10" font="18">devices</text>
<text top="597" left="738" width="41" height="10" font="18">(VADs),</text>
<text top="597" left="791" width="9" height="10" font="18">is</text>
<text top="613" left="485" width="83" height="10" font="18">reasonable as a</text>
<text top="610" left="571" width="228" height="16" font="18">“bridge to recovery” or “bridge to decision”</text>
<text top="630" left="485" width="118" height="10" font="18">for carefully selected</text>
<text top="626" left="604" width="196" height="16" font="18"><a href="e147.full.html#45">z </a>patients with HFrEF with acute,</text>
<text top="646" left="485" width="194" height="10" font="18">profound hemodynamic compromise</text>
<text top="646" left="686" width="26" height="10" font="5"><a href="e147.full.html#79">(668</a></text>
<text top="643" left="712" width="32" height="16" font="5"><a href="e147.full.html#79">–671)</a></text>
<text top="646" left="743" width="56" height="12" font="18">. (Level of</text>
<text top="663" left="485" width="65" height="12" font="18">Evidence: B)</text>
<text top="679" left="468" width="10" height="10" font="18">3.</text>
<text top="679" left="485" width="314" height="10" font="18">Durable MCS is reasonable to prolong survival for carefully</text>
<text top="695" left="485" width="45" height="10" font="18"><a href="e147.full.html#79">selected</a></text>
<text top="692" left="530" width="157" height="16" font="18"><a href="e147.full.html#79">z </a>patients with stage D HFrEF</text>
<text top="695" left="691" width="26" height="10" font="5"><a href="e147.full.html#80">(672</a></text>
<text top="692" left="717" width="32" height="16" font="5"><a href="e147.full.html#80">–675)</a></text>
<text top="695" left="749" width="51" height="12" font="18"><a href="e147.full.html#80">. </a>(Level of</text>
<text top="712" left="485" width="65" height="12" font="18">Evidence: B)</text>
<text top="737" left="465" width="335" height="13" font="14">MCS has emerged as a viable therapeutic option for</text>
<text top="755" left="450" width="350" height="13" font="14">patients with advanced stage D HFrEF refractory to optimal</text>
<text top="773" left="450" width="350" height="13" font="14">GDMT and cardiac device intervention. Since its initial use 50</text>
<text top="791" left="450" width="213" height="13" font="14">years ago for postcardiotomy shock</text>
<text top="791" left="669" width="30" height="13" font="15"><a href="e147.full.html#80">(676)</a></text>
<text top="791" left="700" width="100" height="13" font="14"><a href="e147.full.html#80">, </a>the implantable</text>
<text top="809" left="450" width="151" height="13" font="14">VAD continues to evolve.</text>
<text top="827" left="465" width="335" height="13" font="14">Designed to assist the native heart, VADs are differentiated</text>
<text top="845" left="450" width="350" height="13" font="14">by the implant location (intracorporeal versus extracorporeal),</text>
<text top="863" left="450" width="238" height="13" font="14">approach (percutaneous versus surgical),</text>
<text top="859" left="694" width="106" height="18" font="14">ﬂow characteristic</text>
<text top="881" left="450" width="350" height="13" font="14">(pulsatile versus continuous), pump mechanism (volume</text>
<text top="899" left="450" width="350" height="13" font="14">displacement, axial, centrifugal), and the ventricle(s) sup-</text>
<text top="917" left="450" width="350" height="13" font="14">ported (left, right, biventricular). VADs are effective in both</text>
<text top="103" left="64" width="365" height="12" font="9">Table 26. Intravenous Inotropic Agents Used in Management of HF</text>
<text top="155" left="64" width="68" height="11" font="4">Inotropic Agent</text>
<text top="131" left="208" width="65" height="11" font="4">Dose (mcg/kg)</text>
<text top="140" left="336" width="60" height="11" font="4">Drug Kinetics</text>
<text top="155" left="330" width="72" height="11" font="4">and Metabolism</text>
<text top="131" left="491" width="30" height="11" font="4">Effects</text>
<text top="140" left="637" width="35" height="11" font="4">Adverse</text>
<text top="155" left="639" width="30" height="11" font="4">Effects</text>
<text top="140" left="748" width="32" height="11" font="4">Special</text>
<text top="155" left="732" width="65" height="11" font="4">Considerations</text>
<text top="155" left="182" width="24" height="11" font="4">Bolus</text>
<text top="155" left="235" width="64" height="11" font="4">Infusion (/min)</text>
<text top="155" left="433" width="13" height="11" font="4">CO</text>
<text top="155" left="474" width="13" height="11" font="4">HR</text>
<text top="155" left="516" width="18" height="11" font="4">SVR</text>
<text top="155" left="563" width="17" height="11" font="4">PVR</text>
<text top="175" left="64" width="88" height="11" font="4">Adrenergic agonists</text>
<text top="194" left="76" width="45" height="11" font="4">Dopamine</text>
<text top="194" left="186" width="16" height="11" font="4">N/A</text>
<text top="194" left="251" width="33" height="11" font="4">5 to 10</text>
<text top="194" left="328" width="3" height="11" font="4">t</text>
<text top="199" left="332" width="11" height="7" font="19">1/2</text>
<text top="194" left="343" width="61" height="11" font="4">: 2 to 20 min</text>
<text top="191" left="435" width="8" height="16" font="4">[</text>
<text top="191" left="477" width="8" height="16" font="4">[</text>
<text top="191" left="518" width="14" height="16" font="4">4</text>
<text top="191" left="564" width="14" height="16" font="4">4</text>
<text top="194" left="619" width="71" height="11" font="4">T, HA, N, tissue</text>
<text top="209" left="636" width="37" height="11" font="4">necrosis</text>
<text top="194" left="730" width="68" height="11" font="4">Caution: MAO-I</text>
<text top="214" left="186" width="16" height="11" font="4">N/A</text>
<text top="214" left="248" width="39" height="11" font="4">10 to 15</text>
<text top="214" left="354" width="24" height="11" font="4">R,H,P</text>
<text top="211" left="435" width="8" height="16" font="4">[</text>
<text top="211" left="477" width="8" height="16" font="4">[</text>
<text top="211" left="521" width="8" height="16" font="4">[</text>
<text top="211" left="564" width="14" height="16" font="4">4</text>
<text top="233" left="76" width="53" height="11" font="4">Dobutamine</text>
<text top="233" left="186" width="16" height="11" font="4">N/A</text>
<text top="233" left="249" width="36" height="11" font="4">2.5 to 5</text>
<text top="233" left="331" width="3" height="11" font="4">t</text>
<text top="238" left="334" width="11" height="7" font="19">1/2</text>
<text top="233" left="346" width="55" height="11" font="4">: 2 to 3 min</text>
<text top="248" left="357" width="6" height="11" font="4">H</text>
<text top="230" left="435" width="8" height="16" font="4">[</text>
<text top="230" left="477" width="8" height="16" font="4">[</text>
<text top="230" left="521" width="8" height="16" font="4">Y</text>
<text top="230" left="564" width="14" height="16" font="4">4</text>
<text top="230" left="615" width="79" height="16" font="4">[/YBP, HA, T, N,</text>
<text top="248" left="619" width="81" height="11" font="4">F, hypersensitivity</text>
<text top="233" left="729" width="71" height="11" font="4">Caution: MAO-I;</text>
<text top="248" left="724" width="76" height="11" font="4">CI: sulfite allergy</text>
<text top="253" left="186" width="16" height="11" font="4">N/A</text>
<text top="253" left="251" width="33" height="11" font="4">5 to 20</text>
<text top="250" left="435" width="8" height="16" font="4">[</text>
<text top="250" left="477" width="8" height="16" font="4">[</text>
<text top="250" left="518" width="14" height="16" font="4">4</text>
<text top="250" left="564" width="14" height="16" font="4">4</text>
<text top="272" left="64" width="58" height="11" font="4">PDE inhibitor</text>
<text top="291" left="76" width="41" height="11" font="4">Milrinone</text>
<text top="291" left="186" width="16" height="11" font="4">N/R</text>
<text top="291" left="236" width="62" height="11" font="4">0.125 to 0.75</text>
<text top="291" left="338" width="3" height="11" font="4">t</text>
<text top="296" left="342" width="11" height="7" font="19">1/2</text>
<text top="291" left="353" width="41" height="11" font="4">: 2.5 h H</text>
<text top="289" left="435" width="8" height="16" font="4">[</text>
<text top="289" left="477" width="8" height="16" font="4">[</text>
<text top="289" left="521" width="8" height="16" font="4">Y</text>
<text top="289" left="567" width="8" height="16" font="4">Y</text>
<text top="291" left="638" width="8" height="11" font="4">T,</text>
<text top="289" left="651" width="20" height="16" font="4">YBP</text>
<text top="291" left="734" width="61" height="11" font="4">Renal dosing,</text>
<text top="306" left="736" width="59" height="11" font="4">monitor LFTs</text>
<text top="328" left="76" width="723" height="11" font="4">BP indicates blood pressure; CI, contraindication; CO, cardiac output; F, fever; H, hepatic; HA, headache; HF, heart failure; HR, heart rate; LFT, liver function test;</text>
<text top="343" left="64" width="735" height="11" font="4">MAO-I, monoamine oxidase inhibitor; N, nausea; N/A, not applicable; N/R, not recommended; P, plasma; PDE, phosphodiesterase; PVR, pulmonary vascular resistance;</text>
<text top="358" left="64" width="321" height="11" font="4">R, renal; SVR, systemic vascular resistance; and T, tachyarrhythmias; t</text>
<text top="363" left="385" width="11" height="7" font="19">1/2</text>
<text top="358" left="396" width="96" height="11" font="4">, elimination half-life.</text>
<text top="982" left="450" width="350" height="14" font="20"><a href="e147.full.html#80">z</a>Although optimal patient selection for MCS remains an active area of investiga-</text>
<text top="998" left="450" width="350" height="9" font="20">tion, general indications for referral for MCS therapy include patients with</text>
<text top="1012" left="450" width="26" height="9" font="20">LVEF</text>
<text top="1009" left="479" width="320" height="14" font="20">&lt;25% and NYHA class III–IV functional status despite GDMT, including,</text>
<text top="1025" left="450" width="350" height="9" font="20">when indicated, CRT, with either high predicted 1- to 2-year mortality (e.g., as</text>
<text top="1038" left="450" width="350" height="9" font="20">suggested by markedly reduced peak oxygen consumption and clinical prognostic</text>
<text top="1052" left="450" width="350" height="9" font="20">scores) or dependence on continuous parenteral inotropic support. Patient selection</text>
<text top="1065" left="450" width="350" height="9" font="20">requires a multidisciplinary team of experienced advanced HF and transplantation</text>
<text top="1079" left="450" width="350" height="9" font="20">cardiologists, cardiothoracic surgeons, nurses, and ideally, social workers and</text>
<text top="1092" left="450" width="105" height="9" font="20">palliative care clinicians.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e191</text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">the short-term (hours to days) management of acute decom-</text>
<text top="121" left="64" width="350" height="13" font="14">pensated, hemodynamically unstable HFrEF that is refractory</text>
<text top="139" left="64" width="350" height="13" font="14">to inotropic support, and the long-term (months to years)</text>
<text top="157" left="64" width="350" height="13" font="14">management of stage D chronic HFrEF. Nondurable or</text>
<text top="175" left="64" width="350" height="13" font="14">temporary, MCS provides an opportunity for decisions about</text>
<text top="193" left="64" width="231" height="13" font="14">the appropriateness of transition to de</text>
<text top="189" left="295" width="119" height="18" font="14">ﬁnitive management</text>
<text top="211" left="64" width="350" height="13" font="14">such as cardiac surgery or durable, that is, permanent, MCS</text>
<text top="229" left="64" width="350" height="13" font="14">or, in the case of improvement and recovery, suitability for</text>
<text top="247" left="64" width="350" height="13" font="14">device removal. Nondurable MCS thereby may be helpful as</text>
<text top="265" left="64" width="291" height="13" font="14">either a bridge to decision or a bridge to recovery.</text>
<text top="283" left="79" width="335" height="13" font="14">More common scenarios for MCS, however, are long-term</text>
<text top="301" left="64" width="350" height="13" font="14">strategies, including 1) bridge to transplantation, 2) bridge to</text>
<text top="319" left="64" width="350" height="13" font="14">candidacy, and 3) destination therapy. Bridge to transplant</text>
<text top="337" left="64" width="350" height="13" font="14">and destination therapy have the strongest evidence base with</text>
<text top="354" left="64" width="329" height="13" font="14">respect to survival, functional capacity, and HRQOL bene</text>
<text top="351" left="393" width="21" height="18" font="14">ﬁts.</text>
<text top="372" left="79" width="335" height="13" font="14">Data from INTERMACS provides valuable information on</text>
<text top="390" left="64" width="350" height="13" font="14">risk factors and outcomes for patients undergoing MCS. The</text>
<text top="408" left="64" width="350" height="13" font="14">greatest risk factors for death among patients undergoing</text>
<text top="426" left="64" width="350" height="13" font="14">bridge to transplant include acuity and severity of clinical</text>
<text top="444" left="64" width="279" height="13" font="14">condition and evidence of right ventricular failure</text>
<text top="444" left="347" width="30" height="13" font="15"><a href="e147.full.html#80">(677)</a></text>
<text top="444" left="377" width="37" height="13" font="14">. MCS</text>
<text top="462" left="64" width="350" height="13" font="14">may also be used as a bridge to candidacy. Retrospective</text>
<text top="480" left="64" width="350" height="13" font="14">studies have shown reduction in pulmonary pressures with</text>
<text top="498" left="64" width="304" height="13" font="14">MCS therapy in patients with HF considered to have</text>
<text top="494" left="373" width="41" height="18" font="14">“ﬁxed”</text>
<text top="516" left="64" width="139" height="13" font="14">pulmonary hypertension</text>
<text top="516" left="208" width="26" height="13" font="15"><a href="e147.full.html#79">(661</a></text>
<text top="512" left="234" width="33" height="18" font="15"><a href="e147.full.html#79">–663)</a></text>
<text top="516" left="267" width="147" height="13" font="14"><a href="e147.full.html#79">. </a>Thus, patients who may</text>
<text top="534" left="64" width="350" height="13" font="14">be transplant-ineligible due to irreversible severe pulmonary</text>
<text top="103" left="450" width="350" height="13" font="14">hypertension may become eligible with MCS support over</text>
<text top="121" left="450" width="350" height="13" font="14">time. Other bridge-to-candidacy indications may include</text>
<text top="139" left="450" width="350" height="13" font="14">obesity and tobacco use in patients who are otherwise candi-</text>
<text top="157" left="450" width="350" height="13" font="14">dates for cardiac transplantation. There is ongoing interest in</text>
<text top="175" left="450" width="350" height="13" font="14">understanding how MCS facilitates LV reverse remodeling.</text>
<text top="193" left="450" width="83" height="13" font="14">Current scienti</text>
<text top="189" left="533" width="267" height="18" font="14">ﬁc and translational research in the area aims to</text>
<text top="211" left="450" width="350" height="13" font="14">identify clinical, cellular, molecular, and genomic markers of</text>
<text top="229" left="450" width="233" height="13" font="14">cardiac recovery in the patient with VAD</text>
<text top="229" left="686" width="55" height="13" font="15"><a href="e147.full.html#80">(678,679)</a></text>
<text top="229" left="741" width="4" height="13" font="14">.</text>
<text top="247" left="465" width="20" height="13" font="14">See</text>
<text top="247" left="491" width="221" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplements 34 and 35</a></text>
<text top="247" left="719" width="81" height="13" font="14">for additional</text>
<text top="265" left="450" width="166" height="13" font="14">data on MCS and left VADs.</text>
<text top="293" left="450" width="318" height="15" font="14">7.4.6. Cardiac Transplantation: Recommendation</text>
<text top="320" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="332" left="468" width="10" height="10" font="18">1.</text>
<text top="332" left="485" width="314" height="10" font="18">Evaluation for cardiac transplantation is indicated for</text>
<text top="348" left="485" width="314" height="10" font="18">carefully selected patients with stage D HF despite</text>
<text top="365" left="485" width="225" height="10" font="18">GDMT, device, and surgical management</text>
<text top="365" left="715" width="31" height="10" font="5"><a href="e147.full.html#80">(680)</a></text>
<text top="365" left="746" width="54" height="12" font="18"><a href="e147.full.html#80">. </a>(Level of</text>
<text top="382" left="485" width="66" height="12" font="18">Evidence: C)</text>
<text top="407" left="465" width="335" height="13" font="14">Cardiac transplantation is considered the gold standard for</text>
<text top="425" left="450" width="320" height="13" font="14">the treatment of refractory end-stage HF. Since the</text>
<text top="421" left="778" width="22" height="18" font="14">ﬁrst</text>
<text top="443" left="450" width="350" height="13" font="14">successful cardiac transplantation in 1967, advances in</text>
<text top="460" left="450" width="350" height="13" font="14">immunosuppressive therapy have vastly improved the long-</text>
<text top="478" left="450" width="350" height="13" font="14">term survival of transplant recipients with a 1-, 3-, and</text>
<text top="496" left="450" width="350" height="13" font="14">5-year posttransplant survival rate of 87.8%, 78.5%, and</text>
<text top="514" left="450" width="168" height="13" font="14">71.7% in adults, respectively</text>
<text top="514" left="622" width="30" height="13" font="15"><a href="e147.full.html#80">(681)</a></text>
<text top="514" left="653" width="147" height="13" font="14"><a href="e147.full.html#80">. </a>Similarly, cardiac trans-</text>
<text top="532" left="450" width="350" height="13" font="14">plantation has been shown to improve functional status and</text>
<text top="592" left="109" width="467" height="12" font="9">Table 27. Recommendations for Inotropic Support, MCS, and Cardiac Transplantation</text>
<text top="624" left="109" width="82" height="11" font="4">Recommendations</text>
<text top="624" left="541" width="19" height="11" font="4">COR</text>
<text top="624" left="633" width="17" height="11" font="4">LOE</text>
<text top="624" left="700" width="50" height="11" font="4">References</text>
<text top="643" left="109" width="75" height="11" font="4">Inotropic support</text>
<text top="660" left="121" width="262" height="11" font="4">Cardiogenic shock pending definitive therapy or resolution</text>
<text top="660" left="550" width="2" height="11" font="4">I</text>
<text top="660" left="638" width="6" height="11" font="4">C</text>
<text top="660" left="717" width="16" height="11" font="4">N/A</text>
<text top="681" left="121" width="195" height="11" font="4">BTT or MCS in stage D refractory to GDMT</text>
<text top="681" left="546" width="10" height="11" font="4">IIa</text>
<text top="681" left="638" width="6" height="11" font="4">B</text>
<text top="681" left="706" width="17" height="11" font="5"><a href="e147.full.html#79">647</a></text>
<text top="681" left="723" width="3" height="11" font="4">,</text>
<text top="681" left="726" width="17" height="11" font="5"><a href="e147.full.html#79">648</a></text>
<text top="702" left="121" width="377" height="11" font="4">Short-term support for threatened end-organ dysfunction in hospitalized patients with</text>
<text top="717" left="133" width="118" height="11" font="4">stage D and severe HFrEF</text>
<text top="702" left="546" width="10" height="11" font="4">IIb</text>
<text top="702" left="638" width="6" height="11" font="4">B</text>
<text top="702" left="696" width="17" height="11" font="5"><a href="e147.full.html#78">592</a></text>
<text top="702" left="713" width="3" height="11" font="4"><a href="e147.full.html#79">,</a></text>
<text top="702" left="716" width="17" height="11" font="5"><a href="e147.full.html#79">649</a></text>
<text top="702" left="733" width="3" height="11" font="4">,</text>
<text top="702" left="736" width="17" height="11" font="5"><a href="e147.full.html#79">650</a></text>
<text top="733" left="121" width="373" height="11" font="4">Long-term support with continuous infusion palliative therapy in select stage D HF</text>
<text top="733" left="546" width="10" height="11" font="4">IIb</text>
<text top="733" left="638" width="6" height="11" font="4">B</text>
<text top="733" left="704" width="40" height="11" font="5"><a href="e147.full.html#79">651–653</a></text>
<text top="754" left="121" width="373" height="11" font="4">Routine intravenous use, either continuous or intermittent, is potentially harmful in</text>
<text top="769" left="133" width="50" height="11" font="4">stage D HF</text>
<text top="754" left="532" width="38" height="11" font="4">III: Harm</text>
<text top="754" left="638" width="6" height="11" font="4">B</text>
<text top="754" left="694" width="17" height="11" font="5"><a href="e147.full.html#74">416</a></text>
<text top="754" left="712" width="3" height="11" font="4"><a href="e147.full.html#74">,</a></text>
<text top="754" left="714" width="40" height="11" font="5"><a href="e147.full.html#79">654–659</a></text>
<text top="785" left="121" width="365" height="11" font="4">Short-term intravenous use in hospitalized patients without evidence of shock or</text>
<text top="800" left="133" width="255" height="11" font="4">threatened end-organ performance is potentially harmful</text>
<text top="785" left="532" width="38" height="11" font="4">III: Harm</text>
<text top="785" left="638" width="6" height="11" font="4">B</text>
<text top="785" left="696" width="17" height="11" font="5"><a href="e147.full.html#78">592</a></text>
<text top="785" left="713" width="3" height="11" font="4"><a href="e147.full.html#79">,</a></text>
<text top="785" left="716" width="17" height="11" font="5"><a href="e147.full.html#79">649</a></text>
<text top="785" left="733" width="3" height="11" font="4"><a href="e147.full.html#79">,</a></text>
<text top="785" left="736" width="17" height="11" font="5"><a href="e147.full.html#79">650</a></text>
<text top="820" left="109" width="21" height="11" font="4">MCS</text>
<text top="836" left="121" width="171" height="11" font="4">MCS is beneficial in carefully selected</text>
<text top="836" left="293" width="4" height="11" font="5"><a href="e147.full.html#46">*</a></text>
<text top="836" left="300" width="197" height="11" font="4">patients with stage D HF in whom definitive</text>
<text top="851" left="133" width="309" height="11" font="4">management (e.g., cardiac transplantation) is anticipated or planned</text>
<text top="836" left="546" width="10" height="11" font="4">IIa</text>
<text top="836" left="638" width="6" height="11" font="4">B</text>
<text top="836" left="704" width="40" height="11" font="5"><a href="e147.full.html#79">660–667</a></text>
<text top="868" left="121" width="377" height="11" font="4">Nondurable MCS is reasonable as a “bridge to recovery” or “bridge to decision” for</text>
<text top="883" left="133" width="79" height="11" font="4">carefully selected</text>
<text top="883" left="212" width="4" height="11" font="5"><a href="e147.full.html#46">*</a></text>
<text top="883" left="220" width="203" height="11" font="4">patients with HF and acute profound disease</text>
<text top="868" left="546" width="10" height="11" font="4">IIa</text>
<text top="868" left="638" width="6" height="11" font="4">B</text>
<text top="868" left="704" width="40" height="11" font="5"><a href="e147.full.html#79">668–671</a></text>
<text top="899" left="121" width="308" height="11" font="4">Durable MCS is reasonable to prolong survival for carefully selected</text>
<text top="899" left="429" width="4" height="11" font="5"><a href="e147.full.html#46">*</a></text>
<text top="899" left="437" width="58" height="11" font="4">patients with</text>
<text top="914" left="133" width="65" height="11" font="4">stage D HFrEF</text>
<text top="899" left="546" width="10" height="11" font="4">IIa</text>
<text top="899" left="638" width="6" height="11" font="4">B</text>
<text top="899" left="704" width="40" height="11" font="5"><a href="e147.full.html#80">672–675</a></text>
<text top="933" left="109" width="103" height="11" font="4">Cardiac transplantation</text>
<text top="950" left="121" width="377" height="11" font="4">Evaluation for cardiac transplantation is indicated for carefully selected patients with</text>
<text top="965" left="133" width="276" height="11" font="4">stage D HF despite GDMT, device, and surgical management</text>
<text top="950" left="550" width="2" height="11" font="4">I</text>
<text top="950" left="638" width="6" height="11" font="4">C</text>
<text top="950" left="716" width="17" height="11" font="5"><a href="e147.full.html#80">680</a></text>
<text top="986" left="121" width="634" height="11" font="4">*Although optimal patient selection for MCS remains an active area of investigation, general indications for referral for MCS therapy include</text>
<text top="1001" left="109" width="81" height="11" font="4">patients with LVEF</text>
<text top="998" left="193" width="562" height="16" font="4">&lt;25% and NYHA class III–IV functional status despite GDMT, including, when indicated, CRT, with either high predicted 1- to 2-</text>
<text top="1016" left="109" width="646" height="11" font="4">year mortality (e.g., as suggested by markedly reduced peak oxygen consumption and clinical prognostic scores) or dependence on continuous</text>
<text top="1031" left="109" width="646" height="11" font="4">parenteral inotropic support. Patient selection requires a multidisciplinary team of experienced advanced HF and transplantation cardiologists,</text>
<text top="1046" left="109" width="405" height="11" font="4">cardiothoracic surgeons, nurses, and ideally, social workers and palliative care clinicians.</text>
<text top="1061" left="121" width="634" height="11" font="4">BTT indicates bridge to transplant; COR, Class of Recommendation; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical</text>
<text top="1076" left="109" width="646" height="11" font="4">therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LOE, Level of Evidence; LVEF, left ventricular ejection fraction; MCS,</text>
<text top="1091" left="109" width="416" height="11" font="4">mechanical circulatory support; N/A, not applicable; and NYHA, New York Heart Association.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e192</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1160" width="864">
<text top="767" left="64" width="49" height="13" font="14">HRQOL</text>
<text top="767" left="118" width="26" height="13" font="15"><a href="e147.full.html#80">(682</a></text>
<text top="763" left="144" width="33" height="18" font="15"><a href="e147.full.html#80">–688)</a></text>
<text top="767" left="177" width="163" height="13" font="14">. The greatest survival bene</text>
<text top="763" left="340" width="74" height="18" font="14">ﬁt is seen in</text>
<text top="785" left="64" width="350" height="13" font="14">those patients who are at highest risk of death from advanced</text>
<text top="803" left="64" width="18" height="13" font="14">HF</text>
<text top="803" left="91" width="30" height="13" font="15"><a href="e147.full.html#80">(689)</a></text>
<text top="803" left="122" width="271" height="13" font="14"><a href="e147.full.html#80">. </a>Cardiopulmonary exercise testing helps re</text>
<text top="799" left="393" width="21" height="18" font="14">ﬁne</text>
<text top="821" left="64" width="115" height="13" font="14">candidate selection</text>
<text top="821" left="190" width="26" height="13" font="15"><a href="e147.full.html#80">(690</a></text>
<text top="817" left="216" width="33" height="18" font="15"><a href="e147.full.html#80">–696)</a></text>
<text top="821" left="249" width="165" height="13" font="14">. Data suggest acceptable</text>
<text top="839" left="64" width="350" height="13" font="14">posttransplant outcomes in patients with reversible pulmonary</text>
<text top="857" left="64" width="73" height="13" font="14">hypertension</text>
<text top="857" left="148" width="30" height="13" font="15"><a href="e147.full.html#80">(697)</a></text>
<text top="857" left="179" width="190" height="13" font="14"><a href="e147.full.html#80">, </a>hypertrophic cardiomyopathy</text>
<text top="857" left="380" width="30" height="13" font="15"><a href="e147.full.html#80">(698)</a></text>
<text top="857" left="410" width="4" height="13" font="14">,</text>
<text top="874" left="64" width="157" height="13" font="14">peripartum cardiomyopathy</text>
<text top="874" left="225" width="30" height="13" font="15"><a href="e147.full.html#80">(699)</a></text>
<text top="874" left="255" width="158" height="13" font="14">, restrictive cardiomyopathy</text>
<text top="892" left="64" width="55" height="13" font="15"><a href="e147.full.html#80">(700,701)</a></text>
<text top="892" left="120" width="151" height="13" font="14"><a href="e147.full.html#80">, </a>and muscular dystrophy</text>
<text top="892" left="276" width="30" height="13" font="15"><a href="e147.full.html#80">(702)</a></text>
<text top="892" left="307" width="107" height="13" font="14"><a href="e147.full.html#80">. </a>Selected patients</text>
<text top="910" left="64" width="350" height="13" font="14">with stage D HF and poor prognosis should be referred to</text>
<text top="928" left="64" width="350" height="13" font="14">a cardiac transplantation center for evaluation and transplant</text>
<text top="946" left="64" width="350" height="13" font="14">consideration. Determination of HF prognosis is addressed in</text>
<text top="964" left="64" width="82" height="13" font="15"><a href="e147.full.html#15">Sections 6.1.2</a></text>
<text top="964" left="152" width="20" height="13" font="14">and</text>
<text top="964" left="178" width="28" height="13" font="15"><a href="e147.full.html#43">7.4.2</a></text>
<text top="964" left="206" width="208" height="13" font="14">. The listing criteria and evaluation</text>
<text top="982" left="64" width="350" height="13" font="14">and management of patients undergoing cardiac trans-</text>
<text top="1000" left="64" width="350" height="13" font="14">plantation are described in detail by the International Society</text>
<text top="1018" left="64" width="204" height="13" font="14">for Heart and Lung Transplantation</text>
<text top="1018" left="273" width="30" height="13" font="15"><a href="e147.full.html#80">(680)</a></text>
<text top="1018" left="304" width="4" height="13" font="14"><a href="e147.full.html#80">.</a></text>
<text top="1036" left="79" width="20" height="13" font="14">See</text>
<text top="1036" left="103" width="50" height="13" font="15"><a href="e147.full.html#46">Table 27</a></text>
<text top="1036" left="157" width="257" height="13" font="14">for a summary of recommendations from this</text>
<text top="1054" left="64" width="43" height="13" font="14">section,</text>
<text top="1054" left="115" width="53" height="13" font="15"><a href="e147.full.html#47">Figure 3</a></text>
<text top="1054" left="175" width="239" height="13" font="14">for the stages of HF development; and</text>
<text top="1072" left="64" width="38" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online</a></text>
<text top="1072" left="115" width="28" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Data</a></text>
<text top="1072" left="156" width="66" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Supplement</a></text>
<text top="1072" left="235" width="14" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">36</a></text>
<text top="1072" left="262" width="16" height="13" font="14">for</text>
<text top="1072" left="291" width="58" height="13" font="14">additional</text>
<text top="1072" left="362" width="25" height="13" font="14">data</text>
<text top="1072" left="400" width="14" height="13" font="14">on</text>
<text top="1090" left="64" width="90" height="13" font="14">transplantation.</text>
<text top="767" left="450" width="225" height="15" font="13">8. The Hospitalized Patient</text>
<text top="809" left="450" width="80" height="14" font="16">8.1. Classi</text>
<text top="805" left="529" width="270" height="20" font="16">ﬁcation of Acute Decompensated HF</text>
<text top="828" left="451" width="349" height="13" font="14">Hospitalization for HF is a growing and major public health</text>
<text top="846" left="450" width="28" height="13" font="14">issue</text>
<text top="846" left="483" width="30" height="13" font="15"><a href="e147.full.html#80">(703)</a></text>
<text top="846" left="514" width="286" height="13" font="14"><a href="e147.full.html#80">. </a>Presently, HF is the leading cause of hospitali-</text>
<text top="864" left="450" width="131" height="13" font="14">zation among patients</text>
<text top="860" left="588" width="108" height="18" font="14">&gt;65 years of age</text>
<text top="864" left="703" width="23" height="13" font="15"><a href="e147.full.html#65">(51)</a></text>
<text top="864" left="727" width="73" height="13" font="14"><a href="e147.full.html#65">; </a>the largest</text>
<text top="882" left="450" width="350" height="13" font="14">percentage of expenditures related to HF are directly attrib-</text>
<text top="900" left="450" width="350" height="13" font="14">utable to hospital costs. Moreover, in addition to costs,</text>
<text top="918" left="450" width="350" height="13" font="14">hospitalization for acutely decompensated HF represents</text>
<text top="936" left="450" width="350" height="13" font="14">a sentinel prognostic event in the course of many patients with</text>
<text top="954" left="450" width="350" height="13" font="14">HF, with a high risk for recurrent hospitalization (e.g., 50% at</text>
<text top="972" left="450" width="350" height="13" font="14">6 months) and a 1-year mortality rate of approximately 30%</text>
<text top="990" left="450" width="55" height="13" font="15"><a href="e147.full.html#69">(211,704)</a></text>
<text top="990" left="505" width="219" height="13" font="14">. The AHA has published a scienti</text>
<text top="986" left="724" width="75" height="18" font="14">ﬁc statement</text>
<text top="1008" left="450" width="114" height="13" font="14">about this condition</text>
<text top="1008" left="569" width="30" height="13" font="15"><a href="e147.full.html#80">(705)</a></text>
<text top="1008" left="599" width="4" height="13" font="14">.</text>
<text top="1026" left="465" width="335" height="13" font="14">There is no widely accepted nomenclature for HF syndromes</text>
<text top="1043" left="450" width="350" height="13" font="14">requiring hospitalization. Patients are described as having</text>
<text top="1058" left="450" width="350" height="18" font="14">“acute HF,” “acute HF syndromes,” or “acute(ly) decom-</text>
<text top="1079" left="450" width="71" height="13" font="14">pensated HF</text>
<text top="1075" left="521" width="278" height="18" font="14">”; while the third has gained greatest acceptance,</text>
<text top="649" left="64" width="735" height="14" font="4">Figure 3. Stages in the development of HF and recommended therapy by stage. ACEI indicates angiotensin-converting enzyme inhibitor;</text>
<text top="665" left="64" width="46" height="11" font="4">AF, atrial</text>
<text top="663" left="113" width="686" height="16" font="4">ﬁbrillation; ARB, angiotensin-receptor blocker; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; DM, diabetes</text>
<text top="679" left="64" width="501" height="11" font="4">mellitus; EF, ejection fraction; GDMT, guideline-directed medical therapy; HF, heart failure; HF</text>
<text top="676" left="566" width="218" height="16" font="4">pEF, heart failure with preserved ejection</text>
<text top="692" left="64" width="62" height="11" font="4">fraction; HF</text>
<text top="689" left="127" width="652" height="16" font="4">rEF, heart failure with reduced ejection fraction; HRQOL, health-related quality of life; HTN, hypertension; ICD, implantable</text>
<text top="706" left="64" width="81" height="11" font="4">cardioverter-de</text>
<text top="703" left="145" width="642" height="16" font="4">ﬁbrillator; LV, left ventricular; LVH, left ventricular hypertrophy; MCS, mechanical circulatory support; and MI, myocardial</text>
<text top="719" left="64" width="189" height="11" font="4">infarction. Adapted from Hunt et al.</text>
<text top="719" left="257" width="19" height="11" font="5"><a href="e147.full.html#65">(38)</a></text>
<text top="719" left="276" width="3" height="11" font="4">.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e193</text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="30" size="8" family="Times" color="#231f20"/>
	<fontspec id="31" size="11" family="Times" color="#231f20"/>
	<fontspec id="32" size="8" family="Times" color="#231f20"/>
	<fontspec id="33" size="11" family="Times" color="#231f20"/>
<text top="103" left="64" width="350" height="13" font="14">it too has limitations, for it does not make the important</text>
<text top="121" left="64" width="350" height="13" font="14">distinction between those with a de novo presentation of HF</text>
<text top="139" left="64" width="336" height="13" font="14">from those with worsening of previously chronic stable HF.</text>
<text top="157" left="79" width="220" height="13" font="14">Data from HF registries have clari</text>
<text top="153" left="300" width="114" height="18" font="14">ﬁed the proﬁle of</text>
<text top="175" left="64" width="237" height="13" font="14">patients with HF requiring hospitalization</text>
<text top="175" left="305" width="105" height="13" font="15"><a href="e147.full.html#66">(107,704,706,707)</a></text>
<text top="175" left="410" width="4" height="13" font="14">.</text>
<text top="193" left="64" width="350" height="13" font="14">Characteristically, such patients are elderly or near elderly,</text>
<text top="211" left="64" width="350" height="13" font="14">equally male or female, and typically have a history of</text>
<text top="229" left="64" width="350" height="13" font="14">hypertension, as well as other medical comorbidities,</text>
<text top="247" left="64" width="350" height="13" font="14">including chronic kidney disease, hyponatremia, hematologic</text>
<text top="265" left="64" width="350" height="13" font="14">abnormalities, and chronic obstructive pulmonary disease</text>
<text top="283" left="64" width="76" height="13" font="15"><a href="e147.full.html#66">(107,706,708</a></text>
<text top="279" left="140" width="33" height="18" font="15"><a href="e147.full.html#66">–713)</a></text>
<text top="283" left="173" width="241" height="13" font="14"><a href="e147.full.html#66">. </a>A relatively equal percentage of patients</text>
<text top="301" left="64" width="350" height="13" font="14">with acutely decompensated HF have impaired versus</text>
<text top="319" left="64" width="191" height="13" font="14">preserved LV systolic function</text>
<text top="319" left="265" width="80" height="13" font="15"><a href="e147.full.html#80">(707,714,715)</a></text>
<text top="319" left="345" width="69" height="13" font="14">; clinically,</text>
<text top="337" left="64" width="350" height="13" font="14">patients with preserved systolic function are older, more</text>
<text top="354" left="64" width="195" height="13" font="14">likely to be female, to have signi</text>
<text top="351" left="259" width="155" height="18" font="14">ﬁcant hypertension, and to</text>
<text top="372" left="64" width="350" height="13" font="14">have less CAD. The overall morbidity and mortality for both</text>
<text top="390" left="64" width="87" height="13" font="14">groups is high.</text>
<text top="408" left="79" width="282" height="13" font="14">Hospitalized patients with HF can be classi</text>
<text top="404" left="361" width="53" height="18" font="14">ﬁed into</text>
<text top="426" left="64" width="350" height="13" font="14">important subgroups. These include patients with acute</text>
<text top="444" left="64" width="350" height="13" font="14">coronary ischemia, accelerated hypertension and acutely</text>
<text top="462" left="64" width="350" height="13" font="14">decompensated HF, shock, and acutely worsening right HF.</text>
<text top="480" left="64" width="350" height="13" font="14">Patients who develop HF decompensation after surgical</text>
<text top="498" left="64" width="350" height="13" font="14">procedures also bear mention. Each of these various cate-</text>
<text top="516" left="64" width="130" height="13" font="14">gories of HF has speci</text>
<text top="512" left="195" width="219" height="18" font="14">ﬁc etiologic factors leading to decom-</text>
<text top="534" left="64" width="302" height="13" font="14">pensation, presentation, management, and outcomes.</text>
<text top="552" left="79" width="335" height="13" font="14">Noninvasive modalities can be used to classify the patient</text>
<text top="570" left="64" width="350" height="13" font="14">with hospitalized HF. The history and physical examination</text>
<text top="588" left="64" width="171" height="13" font="14">allows estimation of a patient</text>
<text top="584" left="235" width="179" height="18" font="14">’s hemodynamic status, that is,</text>
<text top="606" left="64" width="150" height="13" font="14">the degree of congestion (</text>
<text top="602" left="214" width="200" height="18" font="14">“dry” versus “wet”), as well as the</text>
<text top="623" left="64" width="222" height="13" font="14">adequacy of their peripheral perfusion (</text>
<text top="620" left="286" width="128" height="18" font="14">“warm” versus “cold”)</text>
<text top="641" left="64" width="30" height="13" font="15"><a href="e147.full.html#81">(716)</a></text>
<text top="641" left="102" width="5" height="13" font="14"><a href="e147.full.html#48">(</a></text>
<text top="641" left="106" width="51" height="13" font="15"><a href="e147.full.html#48">Figure 4</a></text>
<text top="641" left="157" width="257" height="13" font="14">). Chest x-ray is variably sensitive for the</text>
<text top="659" left="64" width="350" height="13" font="14">presence of interstitial or alveolar edema, even in the presence</text>
<text top="677" left="64" width="63" height="13" font="14">of elevated</text>
<text top="673" left="132" width="282" height="18" font="14">ﬁlling pressures. Thus, a normal chest x-ray does</text>
<text top="695" left="64" width="238" height="13" font="14">not exclude acutely decompensated HF</text>
<text top="695" left="309" width="30" height="13" font="15"><a href="e147.full.html#81">(717)</a></text>
<text top="695" left="340" width="74" height="13" font="14"><a href="e147.full.html#81">. </a>The utility</text>
<text top="713" left="64" width="350" height="13" font="14">of natriuretic peptides in patients with acutely decom-</text>
<text top="731" left="64" width="263" height="13" font="14">pensated HF has been described in detail in</text>
<text top="731" left="334" width="77" height="13" font="15"><a href="e147.full.html#17">Section 6.3.1</a></text>
<text top="731" left="410" width="4" height="13" font="14">.</text>
<text top="749" left="64" width="307" height="13" font="14">Both BNP and NT-proBNP are useful for the identi</text>
<text top="745" left="372" width="42" height="18" font="14">ﬁcation</text>
<text top="767" left="64" width="350" height="13" font="14">or exclusion of acutely decompensated HF in dyspneic</text>
<text top="103" left="450" width="44" height="13" font="14">patients</text>
<text top="103" left="498" width="130" height="13" font="15"><a href="e147.full.html#70">(247,249,250,718,719)</a></text>
<text top="103" left="628" width="172" height="13" font="14"><a href="e147.full.html#70">, </a>particularly in the context of</text>
<text top="121" left="450" width="111" height="13" font="14">uncertain diagnosis</text>
<text top="121" left="567" width="26" height="13" font="15"><a href="e147.full.html#81">(720</a></text>
<text top="118" left="593" width="33" height="18" font="15"><a href="e147.full.html#81">–722)</a></text>
<text top="121" left="625" width="174" height="13" font="14">. Other options for diagnostic</text>
<text top="139" left="450" width="350" height="13" font="14">evaluation of patients with suspected acutely decompensated</text>
<text top="157" left="450" width="218" height="13" font="14">HF, such as acoustic cardiography</text>
<text top="157" left="677" width="30" height="13" font="15"><a href="e147.full.html#81">(723)</a></text>
<text top="157" left="707" width="92" height="13" font="14">, bioimpedance</text>
<text top="175" left="450" width="108" height="13" font="14">vector monitoring</text>
<text top="175" left="568" width="30" height="13" font="15"><a href="e147.full.html#81">(724)</a></text>
<text top="175" left="598" width="201" height="13" font="14">, or noninvasive cardiac output</text>
<text top="193" left="450" width="62" height="13" font="14">monitoring</text>
<text top="193" left="518" width="30" height="13" font="15"><a href="e147.full.html#81">(725)</a></text>
<text top="193" left="554" width="123" height="13" font="14">are not yet validated.</text>
<text top="238" left="450" width="209" height="14" font="16">8.2. Precipitating Causes of</text>
<text top="258" left="450" width="289" height="14" font="16">Decompensated HF: Recommendations</text>
<text top="284" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="296" left="468" width="10" height="10" font="18">1.</text>
<text top="296" left="485" width="314" height="10" font="18">ACS precipitating acute HF decompensation should be</text>
<text top="313" left="485" width="79" height="10" font="18">promptly identi</text>
<text top="309" left="564" width="236" height="16" font="18">ﬁed by ECG and serum biomarkers, including</text>
<text top="329" left="485" width="314" height="10" font="18">cardiac troponin testing, and treated optimally as appro-</text>
<text top="345" left="485" width="314" height="10" font="18">priate to the overall condition and prognosis of the patient.</text>
<text top="362" left="485" width="113" height="12" font="18">(Level of Evidence: C)</text>
<text top="379" left="468" width="10" height="10" font="18">2.</text>
<text top="378" left="485" width="314" height="10" font="18">Common precipitating factors for acute HF should be</text>
<text top="395" left="485" width="314" height="10" font="18">considered during initial evaluation, as recognition of these</text>
<text top="411" left="485" width="314" height="12" font="18">conditions is critical to guide appropriate therapy. (Level of</text>
<text top="428" left="485" width="65" height="12" font="18">Evidence: C)</text>
<text top="453" left="465" width="335" height="13" font="14">ACS is an important cause of worsening or new-onset HF</text>
<text top="471" left="450" width="30" height="13" font="15"><a href="e147.full.html#81">(726)</a></text>
<text top="471" left="480" width="320" height="13" font="14"><a href="e147.full.html#81">. </a>Although acute ST-segment elevation myocardial</text>
<text top="489" left="450" width="350" height="13" font="14">infarction can be readily apparent on an ECG, other ACS cases</text>
<text top="507" left="450" width="350" height="13" font="14">may be more challenging to diagnose. Complicating the clini-</text>
<text top="525" left="450" width="350" height="13" font="14">cal scenario is that many patients with acute HF, with or without</text>
<text top="543" left="450" width="282" height="13" font="14">CAD, have serum troponin levels that are elevated</text>
<text top="543" left="736" width="30" height="13" font="15"><a href="e147.full.html#81">(727)</a></text>
<text top="543" left="766" width="4" height="13" font="14"><a href="e147.full.html#81">.</a></text>
<text top="561" left="465" width="335" height="13" font="14">However, many other patients may have low levels of</text>
<text top="579" left="450" width="350" height="13" font="14">detectable troponins not meeting criteria for an acute ischemic</text>
<text top="597" left="450" width="30" height="13" font="14">event</text>
<text top="597" left="485" width="55" height="13" font="15"><a href="e147.full.html#70">(278,728)</a></text>
<text top="597" left="540" width="260" height="13" font="14"><a href="e147.full.html#70">. </a>Registry data have suggested that the use of</text>
<text top="614" left="450" width="350" height="13" font="14">coronary angiography is low for patients hospitalized with</text>
<text top="632" left="450" width="350" height="13" font="14">decompensated HF, and opportunities to diagnose important</text>
<text top="650" left="450" width="131" height="13" font="14">CAD may be missed</text>
<text top="650" left="590" width="30" height="13" font="15"><a href="e147.full.html#81">(729)</a></text>
<text top="650" left="620" width="180" height="13" font="14">. For the patient with newly</text>
<text top="668" left="450" width="350" height="13" font="14">discovered HF, clinicians should always consider the possi-</text>
<text top="686" left="450" width="263" height="13" font="14">bility that CAD is an underlying cause of HF</text>
<text top="686" left="717" width="30" height="13" font="15"><a href="e147.full.html#81">(726)</a></text>
<text top="686" left="747" width="4" height="13" font="14">.</text>
<text top="704" left="465" width="335" height="13" font="14">Besides ACS, several other precipitating causes of acute</text>
<text top="722" left="450" width="350" height="13" font="14">HF decompensation must be carefully assessed to inform</text>
<text top="740" left="450" width="350" height="13" font="14">appropriate treatment, optimize outcomes, and prevent future</text>
<text top="758" left="450" width="186" height="13" font="14">acute events in patients with HF</text>
<text top="758" left="641" width="30" height="13" font="15"><a href="e147.full.html#81">(730)</a></text>
<text top="758" left="671" width="93" height="13" font="14">. See list below.</text>
<text top="784" left="450" width="262" height="15" font="14">Common Factors That Precipitate Acute</text>
<text top="801" left="450" width="128" height="15" font="14">Decompensated HF</text>
<text top="817" left="468" width="332" height="18" font="14"> Nonadherence with medication regimen, sodium and/or</text>
<text top="835" left="484" width="87" height="18" font="14">ﬂuid restriction</text>
<text top="853" left="468" width="172" height="18" font="14"> Acute myocardial ischemia</text>
<text top="871" left="468" width="203" height="18" font="14"> Uncorrected high blood pressure</text>
<text top="889" left="468" width="164" height="18" font="14"> AF and other arrhythmias</text>
<text top="907" left="468" width="332" height="18" font="14"> Recent addition of negative inotropic drugs (e.g.,</text>
<text top="928" left="484" width="270" height="13" font="14">verapamil, nifedipine, diltiazem, beta blockers)</text>
<text top="942" left="468" width="130" height="18" font="14"> Pulmonary embolus</text>
<text top="960" left="468" width="332" height="18" font="14"> Initiation of drugs that increase salt retention (e.g.,</text>
<text top="982" left="484" width="216" height="13" font="14">steroids, thiazolidinediones, NSAIDs)</text>
<text top="996" left="468" width="223" height="18" font="14"> Excessive alcohol or illicit drug use</text>
<text top="1014" left="468" width="332" height="18" font="14"> Endocrine abnormalities (e.g., diabetes mellitus,</text>
<text top="1036" left="484" width="195" height="13" font="14">hyperthyroidism, hypothyroidism)</text>
<text top="1050" left="468" width="330" height="18" font="14"> Concurrent infections (e.g., pneumonia, viral illnesses)</text>
<text top="1068" left="468" width="332" height="18" font="14"> Additional acute cardiovascular disorders (e.g., valve</text>
<text top="1090" left="484" width="315" height="13" font="14">disease endocarditis, myopericarditis, aortic dissection)</text>
<text top="888" left="211" width="14" height="10" font="30"><b>No</b></text>
<text top="925" left="136" width="14" height="10" font="30"><b>No</b></text>
<text top="926" left="182" width="71" height="10" font="30"><b>Warm and Dry</b></text>
<text top="1008" left="185" width="65" height="10" font="30"><b>Cold and Dry</b></text>
<text top="888" left="331" width="19" height="10" font="30"><b>Yes</b></text>
<text top="1008" left="135" width="19" height="10" font="30"><b>Yes</b></text>
<text top="926" left="304" width="73" height="10" font="30"><b>Warm and Wet</b></text>
<text top="1008" left="307" width="67" height="10" font="30"><b>Cold and Wet</b></text>
<text top="827" left="207" width="126" height="12" font="31"><b>Congestion at rest?</b></text>
<text top="841" left="144" width="251" height="10" font="30"><b>(e.g. orthopnea, elevated jugular venous pressure,</b></text>
<text top="854" left="182" width="176" height="10" font="30"><b>pulmonary rales, S3 gallop, edema)</b></text>
<text top="1033" left="99" width="0" height="10" font="32"><b>(e.g. narrow pulse pressure,</b></text>
<text top="1039" left="111" width="0" height="10" font="32"><b>cool extremities, hypotension)</b></text>
<text top="1035" left="86" width="0" height="12" font="33"><b>Low perfusion at rest?</b></text>
<text top="1061" left="64" width="315" height="16" font="4">Figure 4. Classiﬁcation of patients presenting with acutely</text>
<text top="1077" left="64" width="320" height="11" font="4">decompensated heart failure. Adapted with permission from</text>
<text top="1091" left="64" width="65" height="11" font="4">Nohria et al.</text>
<text top="1091" left="133" width="26" height="11" font="5"><a href="e147.full.html#81">(716)</a></text>
<text top="1091" left="159" width="3" height="11" font="4"><a href="e147.full.html#81">.</a></text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e194</text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="79" width="335" height="13" font="14">Hypertension is an important contributor to acute HF, par-</text>
<text top="121" left="64" width="312" height="13" font="14">ticularly among blacks, women, and those with HFpEF</text>
<text top="121" left="380" width="30" height="13" font="15"><a href="e147.full.html#81">(731)</a></text>
<text top="121" left="410" width="4" height="13" font="14">.</text>
<text top="139" left="64" width="350" height="13" font="14">In the ADHERE registry, almost 50% of patients admitted</text>
<text top="157" left="64" width="163" height="13" font="14">with HF had blood pressure</text>
<text top="153" left="233" width="97" height="18" font="14">&gt;140/90 mm Hg</text>
<text top="157" left="335" width="30" height="13" font="15"><a href="e147.full.html#66">(107)</a></text>
<text top="157" left="365" width="49" height="13" font="14">. Abrupt</text>
<text top="175" left="64" width="350" height="13" font="14">discontinuation of antihypertensive therapy may precipitate</text>
<text top="193" left="64" width="350" height="13" font="14">worsening HF. The prevalence of AF in patients with acute HF</text>
<text top="211" left="64" width="9" height="13" font="14">is</text>
<text top="207" left="81" width="37" height="18" font="14">&gt;30%</text>
<text top="211" left="126" width="30" height="13" font="15"><a href="e147.full.html#81">(731)</a></text>
<text top="211" left="156" width="258" height="13" font="14"><a href="e147.full.html#81">. </a>Infection increases metabolic demands in</text>
<text top="229" left="64" width="350" height="13" font="14">general. Pulmonary infections, which are common in patients</text>
<text top="247" left="64" width="350" height="13" font="14">with HF, may add hypoxia to the increased metabolic demands</text>
<text top="265" left="64" width="240" height="13" font="14">and are associated with worse outcomes</text>
<text top="265" left="311" width="30" height="13" font="15"><a href="e147.full.html#81">(730)</a></text>
<text top="265" left="342" width="72" height="13" font="14"><a href="e147.full.html#81">. </a>The sepsis</text>
<text top="283" left="64" width="350" height="13" font="14">syndrome is associated with reversible myocardial depression</text>
<text top="301" left="64" width="236" height="13" font="14">that is likely mediated by cytokine release</text>
<text top="301" left="304" width="30" height="13" font="15"><a href="e147.full.html#81">(732)</a></text>
<text top="301" left="334" width="80" height="13" font="14">. Patients with</text>
<text top="319" left="64" width="350" height="13" font="14">HF are hypercoagulable, and the possibility of pulmonary</text>
<text top="337" left="64" width="350" height="13" font="14">embolus as an etiology of acute decompensation should be</text>
<text top="354" left="64" width="350" height="13" font="14">considered. Deterioration of renal function can be both</text>
<text top="372" left="64" width="350" height="13" font="14">a consequence and contributor to decompensated HF. Resto-</text>
<text top="390" left="64" width="350" height="13" font="14">ration of normal thyroid function in those with hypothyroidism</text>
<text top="408" left="64" width="350" height="13" font="14">or hyperthyroidism may reverse abnormal cardiovascular</text>
<text top="426" left="64" width="46" height="13" font="14">function</text>
<text top="426" left="117" width="30" height="13" font="15"><a href="e147.full.html#81">(733)</a></text>
<text top="426" left="147" width="267" height="13" font="14"><a href="e147.full.html#81">. </a>In patients treated with amiodarone, thyroid</text>
<text top="444" left="64" width="191" height="13" font="14">disturbances should be suspected.</text>
<text top="462" left="79" width="131" height="13" font="14">Excessive sodium and</text>
<text top="458" left="216" width="198" height="18" font="14">ﬂuid intake may precipitate acute</text>
<text top="480" left="64" width="18" height="13" font="14">HF</text>
<text top="480" left="86" width="55" height="13" font="15"><a href="e147.full.html#73">(379,384)</a></text>
<text top="480" left="141" width="173" height="13" font="14">. Medication nonadherence for</text>
<text top="476" left="318" width="96" height="18" font="14">ﬁnancial or other</text>
<text top="498" left="64" width="265" height="13" font="14">reasons is a major cause of hospital admission</text>
<text top="498" left="334" width="30" height="13" font="15"><a href="e147.full.html#81">(734)</a></text>
<text top="498" left="364" width="50" height="13" font="14">. Several</text>
<text top="516" left="64" width="350" height="13" font="14">drugs may precipitate acute HF (e.g., calcium channel</text>
<text top="534" left="64" width="350" height="13" font="14">blockers, antiarrhythmic agents, glucocorticoids, NSAIDs and</text>
<text top="552" left="64" width="350" height="13" font="14">cyclooxygenase-2 inhibitors, thiazolidinediones, and over-</text>
<text top="570" left="64" width="350" height="13" font="14">the-counter agents like pseudoephedrine). Finally, excessive</text>
<text top="588" left="64" width="350" height="13" font="14">alcohol intake and use of illicit drugs, such as cocaine and</text>
<text top="606" left="64" width="350" height="13" font="14">methamphetamine, also need to be investigated as potential</text>
<text top="623" left="64" width="175" height="13" font="14">causes of HF decompensation.</text>
<text top="641" left="79" width="20" height="13" font="14">See</text>
<text top="641" left="106" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 37</a></text>
<text top="641" left="280" width="134" height="13" font="14">for additional data on</text>
<text top="659" left="64" width="235" height="13" font="14">comorbidities in the hospitalized patient.</text>
<text top="703" left="64" width="253" height="14" font="16">8.3. Maintenance of GDMT During</text>
<text top="722" left="64" width="260" height="14" font="16">Hospitalization: Recommendations</text>
<text top="749" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="761" left="82" width="10" height="10" font="18">1.</text>
<text top="761" left="100" width="314" height="12" font="18">In patients with HFrEF experiencing a symptomatic exac-</text>
<text top="777" left="100" width="314" height="10" font="18">erbation of HF requiring hospitalization during chronic</text>
<text top="794" left="100" width="314" height="10" font="18">maintenance treatment with GDMT, it is recommended</text>
<text top="810" left="100" width="314" height="10" font="18">that GDMT be continued in the absence of hemodynamic</text>
<text top="827" left="100" width="168" height="10" font="18">instability or contraindications</text>
<text top="827" left="275" width="80" height="10" font="5"><a href="e147.full.html#68">(195,735,736)</a></text>
<text top="827" left="355" width="59" height="12" font="18">. (Level of</text>
<text top="843" left="100" width="65" height="12" font="18">Evidence: B)</text>
<text top="860" left="82" width="10" height="10" font="18">2.</text>
<text top="860" left="100" width="314" height="10" font="18">Initiation of beta-blocker therapy is recommended after</text>
<text top="876" left="100" width="314" height="10" font="18">optimization of volume status and successful discontinua-</text>
<text top="892" left="100" width="314" height="10" font="18">tion of intravenous diuretics, vasodilators, and inotropic</text>
<text top="909" left="100" width="314" height="10" font="18">agents. Beta-blocker therapy should be initiated at a low</text>
<text top="925" left="100" width="314" height="10" font="18">dose and only in stable patients. Caution should be used</text>
<text top="942" left="100" width="314" height="10" font="18">when initiating beta blockers in patients who have required</text>
<text top="958" left="100" width="195" height="10" font="18">inotropes during their hospital course</text>
<text top="958" left="298" width="80" height="10" font="5"><a href="e147.full.html#68">(195,735,736)</a></text>
<text top="958" left="377" width="37" height="12" font="18">. (Level</text>
<text top="975" left="100" width="79" height="12" font="18">of Evidence: B)</text>
<text top="1000" left="79" width="69" height="13" font="14">The patient</text>
<text top="996" left="149" width="265" height="18" font="14">’s maintenance HF medications should be</text>
<text top="1018" left="64" width="350" height="13" font="14">carefully reviewed on admission, and it should be decided</text>
<text top="1036" left="64" width="350" height="13" font="14">whether adjustments should be made as a result of the</text>
<text top="1054" left="64" width="350" height="13" font="14">hospitalization. In the majority of patients with HFrEF who</text>
<text top="1072" left="64" width="350" height="13" font="14">are admitted to the hospital, oral HF therapy should be</text>
<text top="1090" left="64" width="350" height="13" font="14">continued, or even uptitrated, during hospitalization. It has</text>
<text top="103" left="450" width="350" height="13" font="14">been demonstrated that continuation of ACE inhibitors or</text>
<text top="121" left="450" width="350" height="13" font="14">ARBs and beta blockers for most patients is well tolerated and</text>
<text top="139" left="450" width="148" height="13" font="14">results in better outcomes</text>
<text top="139" left="603" width="80" height="13" font="15"><a href="e147.full.html#68">(195,735,736)</a></text>
<text top="139" left="683" width="117" height="13" font="14"><a href="e147.full.html#68">. </a>Withholding of, or</text>
<text top="157" left="450" width="350" height="13" font="14">reduction in, beta-blocker therapy should be considered only</text>
<text top="175" left="450" width="350" height="13" font="14">in patients hospitalized after recent initiation or increase in</text>
<text top="193" left="450" width="350" height="13" font="14">beta-blocker therapy or with marked volume overload or</text>
<text top="211" left="450" width="319" height="13" font="14">marginal/low cardiac output. Patients admitted with signi</text>
<text top="207" left="768" width="31" height="18" font="14">ﬁcant</text>
<text top="229" left="450" width="350" height="13" font="14">worsening of renal function should be considered for a reduc-</text>
<text top="247" left="450" width="350" height="13" font="14">tion in, or temporary discontinuation of ACE inhibitors, ARBs,</text>
<text top="265" left="450" width="350" height="13" font="14">and/or aldosterone antagonists until renal function improves.</text>
<text top="283" left="450" width="350" height="13" font="14">Although it is important to ensure that evidence-based medi-</text>
<text top="301" left="450" width="350" height="13" font="14">cations are instituted before hospital discharge, it is equally</text>
<text top="319" left="450" width="350" height="13" font="14">critical to reassess medications on admission and adjust their</text>
<text top="337" left="450" width="251" height="13" font="14">administration in light of the worsening HF.</text>
<text top="365" left="450" width="291" height="14" font="16">8.4. Diuretics in Hospitalized Patients:</text>
<text top="385" left="450" width="138" height="14" font="16">Recommendations</text>
<text top="411" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="423" left="468" width="10" height="10" font="18">1.</text>
<text top="423" left="485" width="284" height="10" font="18">Patients with HF admitted with evidence of signi</text>
<text top="420" left="769" width="30" height="16" font="18">ﬁcant</text>
<text top="436" left="485" width="314" height="16" font="18">ﬂuid overload should be promptly treated with intravenous</text>
<text top="456" left="485" width="193" height="10" font="18">loop diuretics to reduce morbidity</text>
<text top="456" left="686" width="55" height="10" font="5"><a href="e147.full.html#81">(737,738)</a></text>
<text top="456" left="741" width="59" height="12" font="18"><a href="e147.full.html#81">. </a>(Level of</text>
<text top="473" left="485" width="65" height="12" font="18">Evidence: B)</text>
<text top="489" left="468" width="10" height="10" font="18">2.</text>
<text top="489" left="485" width="314" height="10" font="18">If patients are already receiving loop diuretic therapy, the</text>
<text top="505" left="485" width="314" height="10" font="18">initial intravenous dose should equal or exceed their chronic</text>
<text top="522" left="485" width="314" height="10" font="18">oral daily dose and should be given as either intermittent</text>
<text top="538" left="485" width="314" height="10" font="18">boluses or continuous infusion. Urine output and signs and</text>
<text top="555" left="485" width="314" height="10" font="18">symptoms of congestion should be serially assessed, and</text>
<text top="571" left="485" width="314" height="10" font="18">the diuretic dose should be adjusted accordingly to relieve</text>
<text top="588" left="485" width="314" height="10" font="18">symptoms, reduce volume excess, and avoid hypotension</text>
<text top="604" left="485" width="30" height="10" font="5"><a href="e147.full.html#81">(739)</a></text>
<text top="604" left="516" width="121" height="12" font="18"><a href="e147.full.html#81">. </a>(Level of Evidence: B)</text>
<text top="621" left="468" width="10" height="10" font="18">3.</text>
<text top="620" left="485" width="314" height="10" font="18">The effect of HF treatment should be monitored with careful</text>
<text top="637" left="485" width="87" height="10" font="18">measurement of</text>
<text top="634" left="577" width="222" height="16" font="18">ﬂuid intake and output, vital signs, body</text>
<text top="653" left="485" width="314" height="10" font="18">weight that is determined at the same time each day,</text>
<text top="670" left="485" width="314" height="10" font="18">and clinical signs and symptoms of systemic perfusion and</text>
<text top="686" left="485" width="314" height="10" font="18">congestion. Daily serum electrolytes, urea nitrogen, and</text>
<text top="703" left="485" width="314" height="10" font="18">creatinine concentrations should be measured during the</text>
<text top="719" left="485" width="314" height="10" font="18">use of intravenous diuretics or active titration of HF medi-</text>
<text top="735" left="485" width="159" height="12" font="18">cations. (Level of Evidence: C)</text>
<text top="759" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="772" left="468" width="10" height="10" font="18">1.</text>
<text top="771" left="485" width="314" height="10" font="18">When diuresis is inadequate to relieve symptoms, it is</text>
<text top="788" left="485" width="302" height="10" font="18">reasonable to intensify the diuretic regimen using either:</text>
<text top="804" left="485" width="9" height="10" font="18">a.</text>
<text top="804" left="501" width="243" height="10" font="18">higher doses of intravenous loop diuretics</text>
<text top="804" left="752" width="48" height="10" font="5"><a href="e147.full.html#65">(38,739)</a></text>
<text top="821" left="501" width="131" height="12" font="18">(Level of Evidence: B); or</text>
<text top="837" left="485" width="9" height="10" font="18">b.</text>
<text top="837" left="501" width="234" height="10" font="18">addition of a second (e.g., thiazide) diuretic</text>
<text top="837" left="739" width="26" height="10" font="5"><a href="e147.full.html#81">(740</a></text>
<text top="834" left="764" width="32" height="16" font="5"><a href="e147.full.html#81">–743)</a></text>
<text top="837" left="796" width="3" height="10" font="18">.</text>
<text top="854" left="501" width="116" height="12" font="18">(Level of Evidence: B).</text>
<text top="877" left="450" width="45" height="8" font="17">CLASS IIb</text>
<text top="890" left="468" width="10" height="10" font="18">1.</text>
<text top="889" left="485" width="314" height="10" font="18">Low-dose dopamine infusion may be considered in addition</text>
<text top="906" left="485" width="314" height="10" font="18">to loop diuretic therapy to improve diuresis and better</text>
<text top="922" left="485" width="221" height="10" font="18">preserve renal function and renal blood</text>
<text top="919" left="713" width="22" height="16" font="18">ﬂow</text>
<text top="922" left="741" width="55" height="10" font="5"><a href="e147.full.html#81">(744,745)</a></text>
<text top="922" left="796" width="3" height="10" font="18">.</text>
<text top="939" left="485" width="113" height="12" font="18">(Level of Evidence: B)</text>
<text top="964" left="465" width="107" height="13" font="14">Patients with signi</text>
<text top="960" left="572" width="227" height="18" font="14">ﬁcant ﬂuid overload should be initially</text>
<text top="982" left="450" width="350" height="13" font="14">treated with loop diuretics given intravenously during hospi-</text>
<text top="1000" left="450" width="350" height="13" font="14">talization. Therapy should begin in the emergency department</text>
<text top="1018" left="450" width="350" height="13" font="14">without delay, as early therapy has been associated with better</text>
<text top="1036" left="450" width="54" height="13" font="14">outcomes</text>
<text top="1036" left="510" width="48" height="13" font="15"><a href="e147.full.html#65">(37,738)</a></text>
<text top="1036" left="558" width="241" height="13" font="14">. Patients should be carefully monitored,</text>
<text top="1054" left="450" width="350" height="13" font="14">including serial evaluation of volume status and systemic</text>
<text top="1072" left="450" width="350" height="13" font="14">perfusion. Monitoring of daily weight, supine and standing</text>
<text top="1090" left="450" width="88" height="13" font="14">vital signs, and</text>
<text top="1086" left="543" width="256" height="18" font="14">ﬂuid input and output is necessary for daily</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e195</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">management. Assessment of daily electrolytes and renal</text>
<text top="121" left="64" width="350" height="13" font="14">function should be performed while intravenous diuretics are</text>
<text top="139" left="64" width="350" height="13" font="14">administered or HF medications are actively titrated. Intra-</text>
<text top="157" left="64" width="350" height="13" font="14">venous loop diuretics have the potential to reduce glomerular</text>
<text top="171" left="64" width="350" height="18" font="14">ﬁltration rate, further worsen neurohumoral activation, and</text>
<text top="193" left="64" width="350" height="13" font="14">produce electrolyte disturbances. Thus, although the use of</text>
<text top="211" left="64" width="350" height="13" font="14">diuretics may relieve symptoms, their impact on mortality has</text>
<text top="229" left="64" width="350" height="13" font="14">not been well studied. Diuretics should be administered at</text>
<text top="247" left="64" width="53" height="13" font="14">doses suf</text>
<text top="243" left="117" width="297" height="18" font="14">ﬁcient to achieve optimal volume status and relieve</text>
<text top="265" left="64" width="350" height="13" font="14">congestion without inducing an excessively rapid reduction in</text>
<text top="283" left="64" width="350" height="13" font="14">intravascular volume, which could result in hypotension, renal</text>
<text top="301" left="64" width="350" height="13" font="14">dysfunction, or both. Because loop diuretics have a relatively</text>
<text top="319" left="64" width="350" height="13" font="14">short half-life, sodium reabsorption in the tubules will occur</text>
<text top="337" left="64" width="350" height="13" font="14">once the tubular concentration of the diuretics declines.</text>
<text top="354" left="64" width="350" height="13" font="14">Therefore, limiting sodium intake and dosing the diuretic</text>
<text top="372" left="64" width="350" height="13" font="14">continuously or multiple times per day will enhance diuretic</text>
<text top="390" left="64" width="73" height="13" font="14">effectiveness</text>
<text top="390" left="142" width="76" height="13" font="15"><a href="e147.full.html#74">(434,737,746</a></text>
<text top="386" left="218" width="33" height="18" font="15"><a href="e147.full.html#74">–748)</a></text>
<text top="390" left="250" width="4" height="13" font="14">.</text>
<text top="408" left="79" width="335" height="13" font="14">Some patients may present with moderate to severe renal</text>
<text top="426" left="64" width="350" height="13" font="14">dysfunction such that the diuretic response may be blunted,</text>
<text top="444" left="64" width="350" height="13" font="14">necessitating higher initial diuretic doses. In many cases,</text>
<text top="462" left="64" width="73" height="13" font="14">reduction of</text>
<text top="458" left="145" width="269" height="18" font="14">ﬂuid overload may improve congestion and</text>
<text top="480" left="64" width="270" height="13" font="14">improve renal function, particularly if signi</text>
<text top="476" left="334" width="80" height="18" font="14">ﬁcant venous</text>
<text top="498" left="64" width="123" height="13" font="14">congestion is reduced</text>
<text top="498" left="191" width="30" height="13" font="15"><a href="e147.full.html#81">(749)</a></text>
<text top="498" left="221" width="193" height="13" font="14">. Clinical experience suggests it is</text>
<text top="516" left="64" width="16" height="13" font="14">dif</text>
<text top="512" left="80" width="334" height="18" font="14">ﬁcult to determine whether congestion has been adequately</text>
<text top="534" left="64" width="289" height="13" font="14">treated in many patients, and registry data have con</text>
<text top="530" left="353" width="61" height="18" font="14">ﬁrmed that</text>
<text top="552" left="64" width="350" height="13" font="14">patients are frequently discharged after a net weight loss of only</text>
<text top="570" left="64" width="350" height="13" font="14">a few pounds. Although patients may rapidly improve symp-</text>
<text top="588" left="64" width="350" height="13" font="14">tomatically, they may remain congested or hemodynamically</text>
<text top="606" left="64" width="350" height="13" font="14">compromised. Routine use of serial natriuretic peptide</text>
<text top="623" left="64" width="350" height="13" font="14">measurement or Swan-Ganz catheter has not been conclusively</text>
<text top="641" left="64" width="350" height="13" font="14">shown to improve outcomes among these patients. Neverthe-</text>
<text top="659" left="64" width="229" height="13" font="14">less, careful evaluation of all physical</text>
<text top="655" left="300" width="114" height="18" font="14">ﬁndings, laboratory</text>
<text top="677" left="64" width="208" height="13" font="14">parameters, weight change, and net</text>
<text top="673" left="279" width="135" height="18" font="14">ﬂuid change should be</text>
<text top="695" left="64" width="162" height="13" font="14">considered before discharge.</text>
<text top="713" left="79" width="335" height="13" font="14">When a patient does not respond to initial intravenous</text>
<text top="731" left="64" width="350" height="13" font="14">diuretics, several options may be considered. Efforts should</text>
<text top="749" left="64" width="350" height="13" font="14">be made to make certain that congestion persists and that</text>
<text top="767" left="64" width="152" height="13" font="14">another hemodynamic pro</text>
<text top="763" left="216" width="198" height="18" font="14">ﬁle or alternate disease process is</text>
<text top="785" left="64" width="230" height="13" font="14">not evident. If there is doubt about the</text>
<text top="781" left="300" width="114" height="18" font="14">ﬂuid status, consid-</text>
<text top="803" left="64" width="233" height="13" font="14">eration should be given for assessment of</text>
<text top="799" left="301" width="113" height="18" font="14">ﬁlling pressures and</text>
<text top="821" left="64" width="350" height="13" font="14">cardiac output using right-heart catheterization. If volume</text>
<text top="839" left="64" width="87" height="13" font="14">overload is con</text>
<text top="835" left="151" width="263" height="18" font="14">ﬁrmed, the dose of the loop diuretic should be</text>
<text top="857" left="64" width="350" height="13" font="14">increased to ensure that adequate drug levels reach the kidney.</text>
<text top="875" left="64" width="350" height="13" font="14">Adding a second diuretic, typically a thiazide, can improve</text>
<text top="892" left="64" width="132" height="13" font="14">diuretic responsiveness</text>
<text top="892" left="202" width="80" height="13" font="15"><a href="e147.full.html#74">(435,442,443)</a></text>
<text top="892" left="282" width="132" height="13" font="14"><a href="e147.full.html#74">. </a>Theoretically, contin-</text>
<text top="910" left="64" width="350" height="13" font="14">uous diuretic infusion may enhance diuresis because contin-</text>
<text top="928" left="64" width="350" height="13" font="14">uous diuretic delivery to the nephron avoids rebound sodium</text>
<text top="946" left="64" width="20" height="13" font="14">and</text>
<text top="942" left="95" width="106" height="18" font="14">ﬂuid reabsorption</text>
<text top="946" left="212" width="105" height="13" font="15"><a href="e147.full.html#74">(440,441,750,751)</a></text>
<text top="946" left="317" width="97" height="13" font="14">. However, the</text>
<text top="964" left="64" width="350" height="13" font="14">DOSE (Diuretic Optimization Strategies Evaluation) trial did</text>
<text top="982" left="64" width="18" height="13" font="14">not</text>
<text top="978" left="88" width="326" height="18" font="14">ﬁnd any signiﬁcant difference between continuous infu-</text>
<text top="1000" left="64" width="350" height="13" font="14">sion versus intermittent bolus strategies for symptoms,</text>
<text top="1018" left="64" width="120" height="13" font="14">diuresis, or outcomes</text>
<text top="1018" left="188" width="30" height="13" font="15"><a href="e147.full.html#81">(739)</a></text>
<text top="1018" left="219" width="195" height="13" font="14"><a href="e147.full.html#81">. </a>It is reasonable to try an alternate</text>
<text top="1036" left="64" width="350" height="13" font="14">approach of using either bolus or continuous infusion therapy</text>
<text top="1054" left="64" width="350" height="13" font="14">different from the initial strategy among patients who are</text>
<text top="1072" left="64" width="350" height="13" font="14">resistant to diuresis. Finally, some data suggest that low-dose</text>
<text top="1090" left="64" width="350" height="13" font="14">dopamine infusion in addition to loop diuretics may improve</text>
<text top="103" left="450" width="350" height="13" font="14">diuresis and better preserve renal function, although ongoing</text>
<text top="121" left="450" width="253" height="13" font="14">trials will provide further data on this effect</text>
<text top="121" left="707" width="30" height="13" font="15"><a href="e147.full.html#81">(744)</a></text>
<text top="121" left="738" width="4" height="13" font="14"><a href="e147.full.html#81">.</a></text>
<text top="139" left="465" width="20" height="13" font="14">See</text>
<text top="139" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 17</a></text>
<text top="139" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="157" left="450" width="53" height="13" font="14">diuretics.</text>
<text top="188" left="450" width="260" height="16" font="16">8.5. Renal Replacement Therapyd</text>
<text top="208" left="450" width="36" height="14" font="16">Ultra</text>
<text top="203" left="486" width="212" height="20" font="16">ﬁltration: Recommendations</text>
<text top="234" left="450" width="45" height="8" font="17">CLASS IIb</text>
<text top="246" left="468" width="10" height="10" font="18">1.</text>
<text top="246" left="485" width="26" height="10" font="18">Ultra</text>
<text top="243" left="511" width="289" height="16" font="18">ﬁltration may be considered for patients with obvious</text>
<text top="262" left="485" width="289" height="10" font="18">volume overload to alleviate congestive symptoms and</text>
<text top="259" left="777" width="22" height="16" font="18">ﬂuid</text>
<text top="279" left="485" width="36" height="10" font="18">weight</text>
<text top="279" left="525" width="30" height="10" font="5"><a href="e147.full.html#81">(752)</a></text>
<text top="279" left="555" width="121" height="12" font="18"><a href="e147.full.html#81">. </a>(Level of Evidence: B)</text>
<text top="296" left="468" width="10" height="10" font="18">2.</text>
<text top="295" left="485" width="26" height="10" font="18">Ultra</text>
<text top="292" left="511" width="289" height="16" font="18">ﬁltration may be considered for patients with refractory</text>
<text top="312" left="485" width="314" height="12" font="18">congestion not responding to medical therapy. (Level of</text>
<text top="328" left="485" width="65" height="12" font="18">Evidence: C)</text>
<text top="354" left="465" width="259" height="13" font="14">If all diuretic strategies are unsuccessful, ultra</text>
<text top="350" left="723" width="76" height="18" font="14">ﬁltration may</text>
<text top="372" left="450" width="124" height="13" font="14">be considered. Ultra</text>
<text top="368" left="574" width="226" height="18" font="14">ﬁltration moves water and small- to</text>
<text top="390" left="450" width="350" height="13" font="14">medium-weight solutes across a semipermeable membrane to</text>
<text top="407" left="450" width="350" height="13" font="14">reduce volume overload. Because the electrolyte concentra-</text>
<text top="425" left="450" width="350" height="13" font="14">tion is similar to plasma, relatively more sodium can be</text>
<text top="443" left="450" width="159" height="13" font="14">removed than by diuretics</text>
<text top="443" left="617" width="26" height="13" font="15"><a href="e147.full.html#81">(753</a></text>
<text top="440" left="643" width="33" height="18" font="15"><a href="e147.full.html#81">–755)</a></text>
<text top="443" left="676" width="124" height="13" font="14"><a href="e147.full.html#81">. </a>Initial studies sup-</text>
<text top="461" left="450" width="113" height="13" font="14">porting use of ultra</text>
<text top="457" left="563" width="236" height="18" font="14">ﬁltration in HF were small but provided</text>
<text top="479" left="450" width="81" height="13" font="14">safety and ef</text>
<text top="475" left="531" width="148" height="18" font="14">ﬁcacy data in acute HF</text>
<text top="479" left="687" width="26" height="13" font="15"><a href="e147.full.html#81">(755</a></text>
<text top="475" left="713" width="33" height="18" font="15"><a href="e147.full.html#81">–757)</a></text>
<text top="479" left="746" width="53" height="13" font="14">. Use of</text>
<text top="497" left="450" width="26" height="13" font="14">ultra</text>
<text top="493" left="475" width="324" height="18" font="14">ﬁltration in HF has been shown to reduce neurohormone</text>
<text top="515" left="450" width="350" height="13" font="14">levels and increase diuretic responsiveness. In a larger trial of</text>
<text top="533" left="450" width="275" height="13" font="14">200 unselected patients with acute HF, ultra</text>
<text top="529" left="725" width="74" height="18" font="14">ﬁltration did</text>
<text top="551" left="450" width="350" height="13" font="14">reduce weight compared with bolus or continuous diuretics at</text>
<text top="569" left="450" width="350" height="13" font="14">48 hours, had similar effects on the dyspnea score compared</text>
<text top="587" left="450" width="350" height="13" font="14">with diuretics, and improved readmission rate at 90 days</text>
<text top="605" left="450" width="30" height="13" font="15"><a href="e147.full.html#81">(752)</a></text>
<text top="605" left="480" width="319" height="13" font="14">. A randomized acute HF trial in patients with car-</text>
<text top="623" left="450" width="350" height="13" font="14">diorenal syndrome and persistent congestion has failed to</text>
<text top="641" left="450" width="118" height="13" font="14">demonstrate a signi</text>
<text top="637" left="568" width="231" height="18" font="14">ﬁcant advantage of ultraﬁltration over</text>
<text top="659" left="450" width="129" height="13" font="14">bolus diuretic therapy</text>
<text top="659" left="585" width="55" height="13" font="15"><a href="e147.full.html#82">(758,759)</a></text>
<text top="659" left="641" width="159" height="13" font="14"><a href="e147.full.html#82">. </a>Cost, the need for veno-</text>
<text top="677" left="450" width="350" height="13" font="14">venous access, provider experience, and nursing support</text>
<text top="694" left="450" width="298" height="13" font="14">remain concerns about the routine use of ultra</text>
<text top="691" left="748" width="52" height="18" font="14">ﬁltration.</text>
<text top="712" left="450" width="350" height="13" font="14">Consultation with a nephrologist is appropriate before initi-</text>
<text top="730" left="450" width="61" height="13" font="14">ating ultra</text>
<text top="726" left="511" width="288" height="18" font="14">ﬁltration, especially in circumstances where the</text>
<text top="748" left="450" width="249" height="13" font="14">non-nephrology provider does not have suf</text>
<text top="744" left="699" width="101" height="18" font="14">ﬁcient experience</text>
<text top="766" left="450" width="55" height="13" font="14">with ultra</text>
<text top="762" left="505" width="52" height="18" font="14">ﬁltration.</text>
<text top="784" left="465" width="20" height="13" font="14">See</text>
<text top="784" left="491" width="221" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplements 17 and 38</a></text>
<text top="784" left="718" width="81" height="13" font="14">for additional</text>
<text top="802" left="450" width="189" height="13" font="14">data on diuretics versus ultra</text>
<text top="798" left="639" width="160" height="18" font="14">ﬁltration in acute decom-</text>
<text top="820" left="450" width="334" height="13" font="14">pensated HF and worsening renal function and mortality.</text>
<text top="851" left="450" width="322" height="14" font="16">8.6. Parenteral Therapy in Hospitalized HF:</text>
<text top="870" left="450" width="130" height="14" font="16">Recommendation</text>
<text top="897" left="450" width="45" height="8" font="17">CLASS IIb</text>
<text top="909" left="468" width="10" height="10" font="18">1.</text>
<text top="909" left="485" width="314" height="10" font="18">If symptomatic hypotension is absent, intravenous nitro-</text>
<text top="925" left="485" width="314" height="10" font="18">glycerin, nitroprusside, or nesiritide may be considered an</text>
<text top="942" left="485" width="314" height="10" font="18">adjuvant to diuretic therapy for relief of dyspnea in patients</text>
<text top="958" left="485" width="217" height="10" font="18">admitted with acutely decompensated HF</text>
<text top="958" left="705" width="26" height="10" font="5"><a href="e147.full.html#82">(760</a></text>
<text top="955" left="731" width="32" height="16" font="5"><a href="e147.full.html#82">–763)</a></text>
<text top="958" left="763" width="37" height="12" font="18"><a href="e147.full.html#82">. </a>(Level</text>
<text top="975" left="485" width="79" height="12" font="18">of Evidence: A)</text>
<text top="1000" left="465" width="335" height="13" font="14">The different vasodilators include 1) intravenous nitro-</text>
<text top="1018" left="450" width="295" height="13" font="14">glycerin, 2) sodium nitroprusside, and 3) nesiritide.</text>
<text top="1036" left="465" width="335" height="13" font="14">Intravenous nitroglycerin acts primarily through venodila-</text>
<text top="1054" left="450" width="350" height="13" font="14">tion, lowers preload, and may help to rapidly reduce pulmonary</text>
<text top="1072" left="450" width="61" height="13" font="14">congestion</text>
<text top="1072" left="518" width="55" height="13" font="15"><a href="e147.full.html#82">(764,765)</a></text>
<text top="1072" left="574" width="226" height="13" font="14"><a href="e147.full.html#82">. </a>Patients with HF and hypertension,</text>
<text top="1090" left="450" width="153" height="13" font="14">coronary ischemia, or signi</text>
<text top="1086" left="603" width="197" height="18" font="14">ﬁcant mitral regurgitation are often</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e196</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">cited as ideal candidates for the use of intravenous nitroglyc-</text>
<text top="121" left="64" width="350" height="13" font="14">erin. However, tachyphylaxis to nitroglycerin may develop</text>
<text top="139" left="64" width="350" height="13" font="14">within 24 hours, and up to 20% of those with HF may develop</text>
<text top="157" left="64" width="165" height="13" font="14">resistance to even high doses</text>
<text top="157" left="233" width="26" height="13" font="15"><a href="e147.full.html#82">(766</a></text>
<text top="153" left="259" width="33" height="18" font="15"><a href="e147.full.html#82">–768)</a></text>
<text top="157" left="292" width="4" height="13" font="14">.</text>
<text top="175" left="79" width="335" height="13" font="14">Sodium nitroprusside is a balanced preload-reducing</text>
<text top="193" left="64" width="350" height="13" font="14">venodilator and afterload-reducing arteriodilator that also</text>
<text top="211" left="64" width="194" height="13" font="14">dilates the pulmonary vasculature</text>
<text top="211" left="263" width="30" height="13" font="15"><a href="e147.full.html#82">(769)</a></text>
<text top="211" left="293" width="120" height="13" font="14">. Data demonstrating</text>
<text top="229" left="64" width="11" height="13" font="14">ef</text>
<text top="225" left="75" width="339" height="18" font="14">ﬁcacy are limited, and invasive hemodynamic blood pressure</text>
<text top="247" left="64" width="350" height="13" font="14">monitoring (such as an arterial line) is typically required; in</text>
<text top="265" left="64" width="350" height="13" font="14">such cases, blood pressure and volume status should be</text>
<text top="283" left="64" width="350" height="13" font="14">monitored frequently. Nitroprusside has the potential for</text>
<text top="301" left="64" width="350" height="13" font="14">producing marked hypotension and is usually used in the</text>
<text top="319" left="64" width="350" height="13" font="14">intensive care setting as well; longer infusions of the drug have</text>
<text top="337" left="64" width="350" height="13" font="14">been rarely associated with thiocyanate toxicity, particularly in</text>
<text top="354" left="64" width="133" height="13" font="14">the setting of renal insuf</text>
<text top="351" left="197" width="216" height="18" font="14">ﬁciency. Nitroprusside is potentially of</text>
<text top="372" left="64" width="350" height="13" font="14">value in severely congested patients with hypertension or</text>
<text top="390" left="64" width="350" height="13" font="14">severe mitral valve regurgitation complicating LV dysfunction.</text>
<text top="408" left="79" width="217" height="13" font="14">Nesiritide (human BNP) reduces LV</text>
<text top="404" left="303" width="111" height="18" font="14">ﬁlling pressure but</text>
<text top="426" left="64" width="350" height="13" font="14">has variable effects on cardiac output, urinary output, and</text>
<text top="444" left="64" width="350" height="13" font="14">sodium excretion. An initial study demonstrated that the</text>
<text top="462" left="64" width="350" height="13" font="14">severity of dyspnea is reduced more rapidly compared with</text>
<text top="480" left="64" width="82" height="13" font="14">diuretics alone</text>
<text top="480" left="150" width="30" height="13" font="15"><a href="e147.full.html#82">(760)</a></text>
<text top="480" left="180" width="234" height="13" font="14">. A large randomized trial in patients with</text>
<text top="498" left="64" width="350" height="13" font="14">acute decompensated HF demonstrated nesiritide had no</text>
<text top="516" left="64" width="350" height="13" font="14">impact on mortality, rehospitalization, or renal function,</text>
<text top="534" left="64" width="162" height="13" font="14">a small but statistically signi</text>
<text top="530" left="226" width="188" height="18" font="14">ﬁcant impact on dyspnea, and an</text>
<text top="552" left="64" width="173" height="13" font="14">increased risk of hypotension</text>
<text top="552" left="244" width="30" height="13" font="15"><a href="e147.full.html#82">(762)</a></text>
<text top="552" left="274" width="140" height="13" font="14">. Because nesiritide has</text>
<text top="570" left="64" width="350" height="13" font="14">a longer effective half-life than nitroglycerin or nitroprusside,</text>
<text top="588" left="64" width="350" height="13" font="14">adverse effects such as hypotension may persist longer.</text>
<text top="606" left="64" width="350" height="13" font="14">Overall, presently there are no data that suggest that intrave-</text>
<text top="623" left="64" width="350" height="13" font="14">nous vasodilators improve outcomes in the patient hospitalized</text>
<text top="641" left="64" width="350" height="13" font="14">with HF; as such, use of intravenous vasodilators is limited</text>
<text top="659" left="64" width="350" height="13" font="14">to the relief of dyspnea in the hospitalized HF patient with</text>
<text top="677" left="64" width="350" height="13" font="14">intact blood pressure. Administration of intravenous vasodi-</text>
<text top="695" left="64" width="350" height="13" font="14">lators in patients with HFpEF should be done with caution</text>
<text top="713" left="64" width="335" height="13" font="14">because these patients are typically more volume sensitive.</text>
<text top="731" left="79" width="335" height="13" font="14">The use of inotropic support as indicated for hospitalized</text>
<text top="749" left="64" width="350" height="13" font="14">HF with shock or impending shock and/or end-organ perfu-</text>
<text top="767" left="64" width="173" height="13" font="14">sion limitations is addressed in</text>
<text top="767" left="240" width="74" height="13" font="15"><a href="e147.full.html#44">Section 7.4.4</a></text>
<text top="767" left="314" width="27" height="13" font="14">. See</text>
<text top="767" left="345" width="50" height="13" font="15"><a href="e147.full.html#45">Table 26</a></text>
<text top="767" left="398" width="16" height="13" font="14">for</text>
<text top="785" left="64" width="108" height="13" font="14">drug therapies and</text>
<text top="785" left="177" width="215" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplements 32 and 33</a></text>
<text top="785" left="398" width="16" height="13" font="14">for</text>
<text top="803" left="64" width="252" height="13" font="14">additional information on inotropic support.</text>
<text top="821" left="79" width="20" height="13" font="14">See</text>
<text top="821" left="106" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 39</a></text>
<text top="821" left="280" width="134" height="13" font="14">for additional data on</text>
<text top="839" left="64" width="56" height="13" font="14">nesiritide.</text>
<text top="885" left="64" width="324" height="14" font="16">8.7. Venous Thromboembolism Prophylaxis</text>
<text top="905" left="64" width="318" height="14" font="16">in Hospitalized Patients: Recommendation</text>
<text top="931" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="943" left="82" width="10" height="10" font="18">1.</text>
<text top="943" left="100" width="314" height="10" font="18">A patient admitted to the hospital with decompensated HF</text>
<text top="960" left="100" width="314" height="10" font="18">should receive venous thromboembolism prophylaxis with</text>
<text top="976" left="100" width="224" height="10" font="18">an anticoagulant medication if the risk</text>
<text top="973" left="323" width="91" height="16" font="18">–beneﬁt ratio is</text>
<text top="993" left="100" width="48" height="10" font="18">favorable</text>
<text top="993" left="152" width="48" height="10" font="5"><a href="e147.full.html#64">(21,770)</a></text>
<text top="993" left="199" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="1018" left="79" width="335" height="13" font="14">HF has long been recognized as affording additional risk</text>
<text top="1036" left="64" width="350" height="13" font="14">for venous thromboembolic disease, associated with a number</text>
<text top="1054" left="64" width="350" height="13" font="14">of pathophysiologic changes, including reduced cardiac</text>
<text top="1072" left="64" width="350" height="13" font="14">output, increased systemic venous pressure, and chemical</text>
<text top="1090" left="64" width="350" height="13" font="14">changes promoting blood clotting. When patients are</text>
<text top="103" left="450" width="350" height="13" font="14">hospitalized for decompensated HF or when patients with</text>
<text top="121" left="450" width="350" height="13" font="14">chronic stable HF are hospitalized for other reasons, they are</text>
<text top="139" left="450" width="350" height="13" font="14">at increased risk for venous thromboembolic disease, although</text>
<text top="157" left="450" width="328" height="13" font="14">accurate numerical estimates are lacking in the literature.</text>
<text top="175" left="465" width="335" height="13" font="14">Most early data on the effectiveness of different anticoag-</text>
<text top="193" left="450" width="350" height="13" font="14">ulant regimens to reduce the incidence of venous thrombo-</text>
<text top="211" left="450" width="45" height="13" font="14">embolic</text>
<text top="211" left="509" width="40" height="13" font="14">disease</text>
<text top="211" left="563" width="11" height="13" font="14">in</text>
<text top="211" left="588" width="68" height="13" font="14">hospitalized</text>
<text top="211" left="669" width="44" height="13" font="14">patients</text>
<text top="211" left="727" width="27" height="13" font="14">were</text>
<text top="211" left="768" width="32" height="13" font="14">either</text>
<text top="229" left="450" width="201" height="13" font="14">observational, retrospective reports</text>
<text top="229" left="657" width="55" height="13" font="15"><a href="e147.full.html#82">(776,777)</a></text>
<text top="229" left="718" width="82" height="13" font="14">or prospective</text>
<text top="247" left="450" width="286" height="13" font="14">studies using a variety of drugs and differing de</text>
<text top="243" left="736" width="63" height="18" font="14">ﬁnitions of</text>
<text top="265" left="450" width="200" height="13" font="14">therapeutic effect and endpoints</text>
<text top="265" left="660" width="51" height="13" font="15"><a href="e147.full.html#82">(774,778</a></text>
<text top="261" left="711" width="33" height="18" font="15"><a href="e147.full.html#82">–780)</a></text>
<text top="265" left="744" width="56" height="13" font="14">, making</text>
<text top="283" left="450" width="141" height="13" font="14">summary conclusions dif</text>
<text top="279" left="591" width="208" height="18" font="14">ﬁcult. Early studies involved patients</text>
<text top="301" left="450" width="350" height="13" font="14">with far longer hospital lengths of stay than occur pre-</text>
<text top="319" left="450" width="350" height="13" font="14">sently and were performed well before present standard-</text>
<text top="337" left="450" width="350" height="13" font="14">of-care treatments and diagnostic tests were available</text>
<text top="354" left="450" width="51" height="13" font="15"><a href="e147.full.html#82">(774,778</a></text>
<text top="351" left="501" width="33" height="18" font="15"><a href="e147.full.html#82">–780)</a></text>
<text top="354" left="533" width="266" height="13" font="14">. Newer trials using presently available antith-</text>
<text top="372" left="450" width="350" height="13" font="14">rombotic drugs often were not limited to patients with HF but</text>
<text top="390" left="450" width="350" height="13" font="14">included those with other acute illnesses, severe respiratory</text>
<text top="408" left="450" width="350" height="13" font="14">diseases, or simply a broad spectrum of hospitalized medical</text>
<text top="426" left="450" width="44" height="13" font="14">patients</text>
<text top="426" left="499" width="26" height="13" font="15"><a href="e147.full.html#82">(771</a></text>
<text top="422" left="525" width="58" height="18" font="15"><a href="e147.full.html#82">–774,781)</a></text>
<text top="426" left="583" width="217" height="13" font="14"><a href="e147.full.html#82">. </a>In most studies, patients were cate-</text>
<text top="444" left="450" width="350" height="13" font="14">gorized as having HF by admitting diagnosis, clinical signs, or</text>
<text top="462" left="450" width="220" height="13" font="14">functional class, whereas only 1 study</text>
<text top="462" left="674" width="30" height="13" font="15"><a href="e147.full.html#82">(782)</a></text>
<text top="462" left="710" width="90" height="13" font="14">provided LVEF</text>
<text top="480" left="450" width="350" height="13" font="14">data on enrolled study patients. All included trials tried to</text>
<text top="498" left="450" width="350" height="13" font="14">exclude patients perceived to have an elevated risk of</text>
<text top="516" left="450" width="350" height="13" font="14">bleeding complications or with an elevated risk of toxicity</text>
<text top="534" left="450" width="87" height="13" font="14">from the speci</text>
<text top="530" left="536" width="263" height="18" font="14">ﬁc agent tested (e.g., enoxaparin in patients</text>
<text top="552" left="450" width="350" height="13" font="14">with compromised renal function). Patients with HF typically</text>
<text top="570" left="450" width="293" height="13" font="14">made up a minority of the study cohort, and signi</text>
<text top="566" left="743" width="57" height="18" font="14">ﬁcance of</text>
<text top="588" left="450" width="350" height="13" font="14">results were not always reported by the authors, making</text>
<text top="606" left="450" width="251" height="13" font="14">ACCF/AHA class I recommendations dif</text>
<text top="602" left="701" width="98" height="18" font="14">ﬁcult to support</text>
<text top="623" left="450" width="350" height="13" font="14">using this guideline methodology. In some trials, concurrent</text>
<text top="641" left="450" width="350" height="13" font="14">aspirin was allowed but not controlled for as a confounding</text>
<text top="659" left="450" width="45" height="13" font="14">variable</text>
<text top="659" left="500" width="55" height="13" font="15"><a href="e147.full.html#82">(772,783)</a></text>
<text top="659" left="555" width="4" height="13" font="14"><a href="e147.full.html#82">.</a></text>
<text top="677" left="465" width="160" height="13" font="14">For patients admitted speci</text>
<text top="673" left="625" width="175" height="18" font="14">ﬁcally for decompensated HF</text>
<text top="695" left="450" width="290" height="13" font="14">and with adequate renal function (serum creatinine</text>
<text top="691" left="745" width="55" height="18" font="14">&lt;2.0 mg/</text>
<text top="713" left="450" width="350" height="13" font="14">dL), randomized trials suggest that enoxaparin 40 mg</text>
<text top="731" left="450" width="156" height="13" font="14">subcutaneously once daily</text>
<text top="731" left="613" width="105" height="13" font="15"><a href="e147.full.html#82">(770,773,774,783)</a></text>
<text top="731" left="725" width="74" height="13" font="14">or unfractio-</text>
<text top="749" left="450" width="315" height="13" font="14">nated heparin 5,000 units subcutaneously every 8 hours</text>
<text top="749" left="769" width="30" height="13" font="15"><a href="e147.full.html#82">(771)</a></text>
<text top="767" left="450" width="350" height="13" font="14">will reduce radiographically demonstrable venous thrombosis.</text>
<text top="785" left="450" width="247" height="13" font="14">Effects on mortality or clinically signi</text>
<text top="781" left="697" width="102" height="18" font="14">ﬁcant pulmonary</text>
<text top="803" left="450" width="350" height="13" font="14">embolism rates are unclear. Lower doses of enoxaparin do not</text>
<text top="821" left="450" width="161" height="13" font="14">appear superior to placebo</text>
<text top="821" left="619" width="55" height="13" font="15"><a href="e147.full.html#82">(770,773)</a></text>
<text top="821" left="674" width="125" height="13" font="14">, whereas continuing</text>
<text top="839" left="450" width="350" height="13" font="14">weight-based enoxaparin therapy up to 3 months after</text>
<text top="857" left="450" width="350" height="13" font="14">hospital discharge does not appear to provide additional</text>
<text top="875" left="450" width="27" height="13" font="14">bene</text>
<text top="871" left="476" width="12" height="18" font="14">ﬁt</text>
<text top="875" left="493" width="30" height="13" font="15"><a href="e147.full.html#82">(782)</a></text>
<text top="875" left="524" width="4" height="13" font="14"><a href="e147.full.html#82">.</a></text>
<text top="892" left="465" width="335" height="13" font="14">A single prospective study failed to demonstrate certoparin</text>
<text top="910" left="450" width="256" height="13" font="14">to be noninferior to unfractionated heparin</text>
<text top="910" left="713" width="30" height="13" font="15"><a href="e147.full.html#82">(783)</a></text>
<text top="910" left="743" width="56" height="13" font="14">, whereas</text>
<text top="928" left="450" width="350" height="13" font="14">retrospective analysis of a prospective trial of dalteparin was</text>
<text top="946" left="450" width="194" height="13" font="14">underpowered to determine bene</text>
<text top="942" left="643" width="116" height="18" font="14">ﬁt in its HF cohort</text>
<text top="946" left="766" width="30" height="13" font="15"><a href="e147.full.html#82">(776)</a></text>
<text top="946" left="796" width="4" height="13" font="14"><a href="e147.full.html#82">.</a></text>
<text top="964" left="450" width="216" height="13" font="14">Fondaparinux failed to show signi</text>
<text top="960" left="666" width="134" height="18" font="14">ﬁcant difference from</text>
<text top="982" left="450" width="350" height="13" font="14">placebo in an RCT that included a subgroup of 160 patients</text>
<text top="1000" left="450" width="48" height="13" font="14">with HF</text>
<text top="1000" left="502" width="30" height="13" font="15"><a href="e147.full.html#82">(781)</a></text>
<text top="1000" left="533" width="4" height="13" font="14"><a href="e147.full.html#82">.</a></text>
<text top="1018" left="465" width="307" height="13" font="14">No adequate trials have evaluated anticoagulant bene</text>
<text top="1014" left="772" width="28" height="18" font="14">ﬁt in</text>
<text top="1036" left="450" width="350" height="13" font="14">patients with chronic but stable HF admitted to the hospital</text>
<text top="1054" left="450" width="350" height="13" font="14">for other reasons. However, the MEDENOX (Medical</text>
<text top="1072" left="450" width="321" height="13" font="14">Patients with Enoxaparin) trial suggested that the bene</text>
<text top="1068" left="771" width="29" height="18" font="14">ﬁt of</text>
<text top="1090" left="450" width="239" height="13" font="14">enoxaparin may extend to this population</text>
<text top="1090" left="694" width="80" height="13" font="15"><a href="e147.full.html#82">(770,773,774)</a></text>
<text top="1090" left="774" width="4" height="13" font="14"><a href="e147.full.html#82">.</a></text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e197</text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="79" width="119" height="13" font="14">A systematic review</text>
<text top="103" left="204" width="30" height="13" font="15"><a href="e147.full.html#82">(784)</a></text>
<text top="103" left="240" width="173" height="13" font="14">failed to demonstrate prophy-</text>
<text top="121" left="64" width="48" height="13" font="14">lactic ef</text>
<text top="117" left="112" width="302" height="18" font="14">ﬁcacy of graded compression stockings in general</text>
<text top="139" left="64" width="165" height="13" font="14">medical patients, but signi</text>
<text top="135" left="229" width="185" height="18" font="14">ﬁcant cutaneous complications</text>
<text top="157" left="64" width="350" height="13" font="14">were associated with their use. No studies were performed</text>
<text top="175" left="64" width="350" height="13" font="14">exclusively on patients with HF. Two RCTs in patients with</text>
<text top="193" left="64" width="106" height="13" font="14">stroke found no ef</text>
<text top="189" left="171" width="130" height="18" font="14">ﬁcacy of these devices</text>
<text top="193" left="305" width="55" height="13" font="15"><a href="e147.full.html#82">(785,786)</a></text>
<text top="193" left="361" width="4" height="13" font="14"><a href="e147.full.html#82">.</a></text>
<text top="211" left="79" width="20" height="13" font="14">See</text>
<text top="211" left="106" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 20</a></text>
<text top="211" left="280" width="134" height="13" font="14">for additional data on</text>
<text top="229" left="64" width="93" height="13" font="14">anticoagulation.</text>
<text top="274" left="64" width="292" height="14" font="16">8.8. Arginine Vasopressin Antagonists:</text>
<text top="294" left="64" width="130" height="14" font="16">Recommendation</text>
<text top="320" left="64" width="45" height="8" font="17">CLASS IIb</text>
<text top="332" left="82" width="10" height="10" font="18">1.</text>
<text top="332" left="100" width="314" height="10" font="18">In patients hospitalized with volume overload, including HF,</text>
<text top="348" left="100" width="314" height="10" font="18">who have persistent severe hyponatremia and are at risk for</text>
<text top="365" left="100" width="314" height="10" font="18">or having active cognitive symptoms despite water restric-</text>
<text top="381" left="100" width="314" height="10" font="18">tion and maximization of GDMT, vasopressin antagonists</text>
<text top="398" left="100" width="314" height="10" font="18">may be considered in the short term to improve serum</text>
<text top="414" left="100" width="314" height="10" font="18">sodium concentration in hypervolemic, hyponatremic states</text>
<text top="431" left="100" width="80" height="10" font="18">with either a V</text>
<text top="435" left="180" width="5" height="7" font="27">2</text>
<text top="431" left="190" width="224" height="10" font="18">receptor selective or a nonselective vaso-</text>
<text top="447" left="100" width="98" height="10" font="18">pressin antagonist</text>
<text top="447" left="202" width="55" height="10" font="5"><a href="e147.full.html#82">(787,788)</a></text>
<text top="447" left="257" width="121" height="12" font="18"><a href="e147.full.html#82">. </a>(Level of Evidence: B)</text>
<text top="472" left="79" width="335" height="13" font="14">Even mild hyponatremia may be associated with neuro-</text>
<text top="490" left="64" width="322" height="13" font="14">cognitive problems, including falls and attention de</text>
<text top="487" left="387" width="27" height="18" font="14">ﬁcits</text>
<text top="508" left="64" width="30" height="13" font="15"><a href="e147.full.html#82">(789)</a></text>
<text top="508" left="95" width="309" height="13" font="14"><a href="e147.full.html#82">. </a>Treatment of hypervolemic hyponatremia with a V</text>
<text top="514" left="404" width="5" height="9" font="12">2</text>
<text top="508" left="409" width="5" height="13" font="14">-</text>
<text top="526" left="64" width="350" height="13" font="14">selective vasopressin antagonist (tolvaptan) was associated</text>
<text top="544" left="64" width="70" height="13" font="14">with a signi</text>
<text top="540" left="134" width="280" height="18" font="14">ﬁcant improvement in the mental component of</text>
<text top="562" left="64" width="350" height="13" font="14">the Medical Outcomes Study Short Form General Health</text>
<text top="580" left="64" width="40" height="13" font="14">Survey</text>
<text top="580" left="113" width="30" height="13" font="15"><a href="e147.full.html#82">(788)</a></text>
<text top="580" left="144" width="270" height="13" font="14"><a href="e147.full.html#82">. </a>Hyponatremia may be treated with water</text>
<text top="598" left="64" width="350" height="13" font="14">restriction and maximization of GDMT that modulate angio-</text>
<text top="616" left="64" width="350" height="13" font="14">tensin II, leading to improved renal perfusion and decreased</text>
<text top="103" left="450" width="350" height="13" font="14">thirst. Alternative causes of hyponatremia (e.g., syndrome of</text>
<text top="121" left="450" width="350" height="13" font="14">inappropriate antidiuretic hormone, hypothyroidism, and</text>
<text top="139" left="450" width="350" height="13" font="14">hypoaldosteronism) should be assessed. Vasopressin antago-</text>
<text top="157" left="450" width="350" height="13" font="14">nists improve serum sodium in hypervolemic, hyponatremic</text>
<text top="175" left="450" width="31" height="13" font="14">states</text>
<text top="175" left="488" width="55" height="13" font="15"><a href="e147.full.html#82">(787,788)</a></text>
<text top="175" left="543" width="247" height="13" font="14">; however, longer-term therapy with a V</text>
<text top="181" left="790" width="5" height="9" font="12">2</text>
<text top="175" left="795" width="5" height="13" font="14">-</text>
<text top="193" left="450" width="350" height="13" font="14">selective vasopressin antagonist did not improve mortality in</text>
<text top="211" left="450" width="98" height="13" font="14">patients with HF</text>
<text top="211" left="553" width="55" height="13" font="15"><a href="e147.full.html#82">(790,791)</a></text>
<text top="211" left="608" width="191" height="13" font="14">. Currently, 2 vasopressin antag-</text>
<text top="229" left="450" width="350" height="13" font="14">onists are available for clinical use: conivaptan and tolvaptan.</text>
<text top="247" left="450" width="350" height="13" font="14">It may be reasonable to use a nonselective vasopressin</text>
<text top="265" left="450" width="350" height="13" font="14">antagonist to treat hyponatremia in patients with HF with</text>
<text top="283" left="450" width="350" height="13" font="14">cognitive symptoms due to hyponatremia. However, the long-</text>
<text top="301" left="450" width="119" height="13" font="14">term safety and bene</text>
<text top="297" left="568" width="231" height="18" font="14">ﬁt of this approach remains unknown. A</text>
<text top="319" left="450" width="350" height="13" font="14">summary of the recommendations for the hospitalized patient</text>
<text top="337" left="450" width="59" height="13" font="14">appears in</text>
<text top="337" left="513" width="51" height="13" font="15"><a href="e147.full.html#52">Table 28</a></text>
<text top="337" left="564" width="4" height="13" font="14"><a href="e147.full.html#52">.</a></text>
<text top="392" left="450" width="287" height="14" font="16">8.9. Inpatient and Transitions of Care:</text>
<text top="412" left="450" width="138" height="14" font="16">Recommendations</text>
<text top="431" left="451" width="20" height="13" font="14">See</text>
<text top="431" left="476" width="52" height="13" font="15"><a href="e147.full.html#53">Table 29</a></text>
<text top="431" left="533" width="266" height="13" font="14">for a summary of recommendations from this</text>
<text top="449" left="450" width="43" height="13" font="14">section.</text>
<text top="474" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="486" left="468" width="10" height="10" font="18">1.</text>
<text top="486" left="485" width="314" height="10" font="18">The use of performance improvement systems and/or</text>
<text top="502" left="485" width="314" height="10" font="18">evidence-based systems of care is recommended in the</text>
<text top="519" left="485" width="314" height="10" font="18">hospital and early postdischarge outpatient setting to</text>
<text top="535" left="485" width="314" height="10" font="18">identify appropriate HF patients for GDMT, provide clinicians</text>
<text top="552" left="485" width="314" height="10" font="18">with useful reminders to advance GDMT, and assess</text>
<text top="568" left="485" width="120" height="10" font="18">the clinical response</text>
<text top="568" left="614" width="93" height="10" font="5"><a href="e147.full.html#66">(82,365,706,792</a></text>
<text top="565" left="706" width="32" height="16" font="5"><a href="e147.full.html#66">–796)</a></text>
<text top="568" left="738" width="61" height="12" font="18">. (Level of</text>
<text top="585" left="485" width="65" height="12" font="18">Evidence: B)</text>
<text top="601" left="468" width="10" height="10" font="18">2.</text>
<text top="601" left="485" width="60" height="10" font="18">Throughout</text>
<text top="601" left="555" width="17" height="10" font="18">the</text>
<text top="601" left="583" width="76" height="10" font="18">hospitalization</text>
<text top="601" left="670" width="12" height="10" font="18">as</text>
<text top="601" left="693" width="63" height="10" font="18">appropriate,</text>
<text top="601" left="767" width="33" height="10" font="18">before</text>
<text top="617" left="485" width="140" height="10" font="18">hospital discharge, at the</text>
<text top="614" left="630" width="170" height="16" font="18">ﬁrst postdischarge visit, and in</text>
<text top="668" left="100" width="397" height="12" font="9">Table 28. Recommendations for Therapies in the Hospitalized HF Patient</text>
<text top="700" left="100" width="82" height="11" font="4">Recommendations</text>
<text top="700" left="559" width="19" height="11" font="4">COR</text>
<text top="700" left="648" width="17" height="11" font="4">LOE</text>
<text top="700" left="710" width="49" height="11" font="4">References</text>
<text top="721" left="100" width="397" height="11" font="4">HF patients hospitalized with fluid overload should be treated with intravenous diuretics</text>
<text top="721" left="568" width="2" height="11" font="4">I</text>
<text top="721" left="653" width="6" height="11" font="4">B</text>
<text top="721" left="717" width="17" height="11" font="5"><a href="e147.full.html#81">737</a></text>
<text top="721" left="734" width="3" height="11" font="4"><a href="e147.full.html#81">,</a></text>
<text top="721" left="737" width="17" height="11" font="5"><a href="e147.full.html#81">738</a></text>
<text top="742" left="100" width="412" height="11" font="4">HF patients receiving loop diuretic therapy should receive an initial parenteral dose greater</text>
<text top="757" left="113" width="378" height="11" font="4">than or equal to their chronic oral daily dose; then dose should be serially adjusted</text>
<text top="742" left="568" width="2" height="11" font="4">I</text>
<text top="742" left="653" width="6" height="11" font="4">B</text>
<text top="742" left="727" width="17" height="11" font="5"><a href="e147.full.html#81">739</a></text>
<text top="773" left="100" width="419" height="11" font="4">HFrEF patients requiring HF hospitalization on GDMT should continue GDMT except in cases of</text>
<text top="788" left="113" width="224" height="11" font="4">hemodynamic instability or where contraindicated</text>
<text top="773" left="568" width="2" height="11" font="4">I</text>
<text top="773" left="653" width="6" height="11" font="4">B</text>
<text top="773" left="707" width="17" height="11" font="5"><a href="e147.full.html#68">195</a></text>
<text top="773" left="724" width="3" height="11" font="4"><a href="e147.full.html#68">,</a></text>
<text top="773" left="727" width="17" height="11" font="5"><a href="e147.full.html#81">735</a></text>
<text top="773" left="744" width="3" height="11" font="4"><a href="e147.full.html#81">,</a></text>
<text top="773" left="747" width="17" height="11" font="5"><a href="e147.full.html#81">736</a></text>
<text top="805" left="100" width="418" height="11" font="4">Initiation of beta-blocker therapy at a low dose is recommended after optimization of volume</text>
<text top="820" left="113" width="219" height="11" font="4">status and discontinuation of intravenous agents</text>
<text top="805" left="568" width="2" height="11" font="4">I</text>
<text top="805" left="653" width="6" height="11" font="4">B</text>
<text top="805" left="707" width="17" height="11" font="5"><a href="e147.full.html#68">195</a></text>
<text top="805" left="724" width="3" height="11" font="4"><a href="e147.full.html#68">,</a></text>
<text top="805" left="727" width="17" height="11" font="5"><a href="e147.full.html#81">735</a></text>
<text top="805" left="744" width="3" height="11" font="4"><a href="e147.full.html#81">,</a></text>
<text top="805" left="747" width="17" height="11" font="5"><a href="e147.full.html#81">736</a></text>
<text top="836" left="100" width="417" height="11" font="4">Thrombosis/thromboembolism prophylaxis is recommended for patients hospitalized with HF</text>
<text top="836" left="568" width="2" height="11" font="4">I</text>
<text top="836" left="653" width="6" height="11" font="4">B</text>
<text top="836" left="708" width="11" height="11" font="5"><a href="e147.full.html#64">21</a></text>
<text top="836" left="719" width="3" height="11" font="4"><a href="e147.full.html#82">,</a></text>
<text top="836" left="722" width="40" height="11" font="5"><a href="e147.full.html#82">770–774</a></text>
<text top="857" left="100" width="414" height="11" font="4">Serum electrolytes, urea nitrogen, and creatinine should be measured during titration of HF</text>
<text top="872" left="113" width="142" height="11" font="4">medications, including diuretics</text>
<text top="857" left="568" width="2" height="11" font="4">I</text>
<text top="857" left="653" width="6" height="11" font="4">C</text>
<text top="857" left="727" width="16" height="11" font="4">N/A</text>
<text top="889" left="100" width="216" height="11" font="4">When diuresis is inadequate, it is reasonable to</text>
<text top="903" left="122" width="241" height="11" font="4">a. give higher doses of intravenous loop diuretics; or</text>
<text top="918" left="122" width="180" height="11" font="4">b. add a second diuretic (e.g., thiazide)</text>
<text top="903" left="564" width="10" height="11" font="4">IIa</text>
<text top="903" left="653" width="6" height="11" font="4">B</text>
<text top="903" left="720" width="11" height="11" font="5"><a href="e147.full.html#65">38</a></text>
<text top="903" left="731" width="3" height="11" font="4">,</text>
<text top="903" left="734" width="17" height="11" font="5"><a href="e147.full.html#81">739</a></text>
<text top="924" left="653" width="6" height="11" font="4">B</text>
<text top="924" left="715" width="40" height="11" font="5"><a href="e147.full.html#81">740–743</a></text>
<text top="945" left="100" width="397" height="11" font="4">Low-dose dopamine infusion may be considered with loop diuretics to improve diuresis</text>
<text top="945" left="564" width="10" height="11" font="4">IIb</text>
<text top="945" left="653" width="6" height="11" font="4">B</text>
<text top="945" left="717" width="17" height="11" font="5"><a href="e147.full.html#81">744</a></text>
<text top="945" left="734" width="3" height="11" font="4"><a href="e147.full.html#81">,</a></text>
<text top="945" left="737" width="17" height="11" font="5"><a href="e147.full.html#81">745</a></text>
<text top="966" left="100" width="340" height="11" font="4">Ultrafiltration may be considered for patients with obvious volume overload</text>
<text top="966" left="564" width="10" height="11" font="4">IIb</text>
<text top="966" left="653" width="6" height="11" font="4">B</text>
<text top="966" left="727" width="17" height="11" font="5"><a href="e147.full.html#81">752</a></text>
<text top="987" left="100" width="323" height="11" font="4">Ultrafiltration may be considered for patients with refractory congestion</text>
<text top="987" left="564" width="10" height="11" font="4">IIb</text>
<text top="987" left="653" width="6" height="11" font="4">C</text>
<text top="987" left="727" width="16" height="11" font="4">N/A</text>
<text top="1008" left="100" width="419" height="11" font="4">Intravenous nitroglycerin, nitroprusside, or nesiritide may be considered an adjuvant to diuretic</text>
<text top="1023" left="113" width="157" height="11" font="4">therapy for stable patients with HF</text>
<text top="1008" left="564" width="10" height="11" font="4">IIb</text>
<text top="1008" left="653" width="6" height="11" font="4">A</text>
<text top="1008" left="715" width="40" height="11" font="5"><a href="e147.full.html#82">760–763</a></text>
<text top="1039" left="100" width="380" height="11" font="4">In patients hospitalized with volume overload and severe hyponatremia, vasopressin</text>
<text top="1054" left="113" width="141" height="11" font="4">antagonists may be considered</text>
<text top="1039" left="565" width="10" height="11" font="4">IIb</text>
<text top="1039" left="653" width="6" height="11" font="4">B</text>
<text top="1039" left="717" width="17" height="11" font="5"><a href="e147.full.html#82">787</a></text>
<text top="1039" left="734" width="3" height="11" font="4"><a href="e147.full.html#82">,</a></text>
<text top="1039" left="737" width="17" height="11" font="5"><a href="e147.full.html#82">788</a></text>
<text top="1076" left="112" width="652" height="11" font="4">COR indicates Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection</text>
<text top="1091" left="100" width="253" height="11" font="4">fraction; LOE, Level of Evidence; and N/A, not available.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e198</text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1160" width="864">
<text top="510" left="100" width="61" height="10" font="18">subsequent</text>
<text top="510" left="171" width="47" height="10" font="18">follow-up</text>
<text top="510" left="228" width="32" height="10" font="18">visits,</text>
<text top="510" left="271" width="17" height="10" font="18">the</text>
<text top="510" left="299" width="47" height="10" font="18">following</text>
<text top="510" left="356" width="34" height="10" font="18">should</text>
<text top="510" left="401" width="13" height="10" font="18">be</text>
<text top="526" left="100" width="54" height="10" font="18">addressed</text>
<text top="526" left="158" width="75" height="10" font="5"><a href="e147.full.html#69">(204,795,797</a></text>
<text top="523" left="233" width="32" height="16" font="5"><a href="e147.full.html#69">–799)</a></text>
<text top="526" left="264" width="124" height="12" font="18">. (Level of Evidence: B):</text>
<text top="543" left="100" width="9" height="10" font="18">a.</text>
<text top="543" left="115" width="299" height="10" font="18">initiation of GDMT if not previously established and not</text>
<text top="559" left="115" width="86" height="10" font="18">contraindicated;</text>
<text top="576" left="100" width="9" height="10" font="18">b.</text>
<text top="576" left="115" width="299" height="10" font="18">precipitant causes of HF, barriers to optimal care tran-</text>
<text top="592" left="115" width="260" height="10" font="18">sitions, and limitations in postdischarge support;</text>
<text top="609" left="101" width="8" height="10" font="18">c.</text>
<text top="608" left="115" width="299" height="10" font="18">assessment of volume status and supine/upright hypo-</text>
<text top="625" left="115" width="287" height="10" font="18">tension with adjustment of HF therapy as appropriate;</text>
<text top="642" left="100" width="9" height="10" font="18">d.</text>
<text top="641" left="115" width="278" height="10" font="18">titration and optimization of chronic oral HF therapy;</text>
<text top="658" left="100" width="9" height="10" font="18">e.</text>
<text top="658" left="115" width="299" height="10" font="18">assessment of renal function and electrolytes where</text>
<text top="674" left="115" width="63" height="10" font="18">appropriate;</text>
<text top="691" left="103" width="7" height="10" font="18">f.</text>
<text top="691" left="115" width="286" height="10" font="18">assessment and management of comorbid conditions;</text>
<text top="707" left="100" width="9" height="10" font="18">g.</text>
<text top="707" left="115" width="299" height="10" font="18">reinforcement of HF education, self-care, emergency</text>
<text top="724" left="115" width="186" height="10" font="18">plans, and need for adherence; and</text>
<text top="740" left="100" width="9" height="10" font="18">h.</text>
<text top="740" left="115" width="299" height="10" font="18">consideration for palliative care or hospice care in</text>
<text top="756" left="115" width="96" height="10" font="18">selected patients.</text>
<text top="773" left="82" width="10" height="10" font="18">3.</text>
<text top="773" left="100" width="314" height="10" font="18">Multidisciplinary HF disease-management programs are</text>
<text top="789" left="100" width="314" height="10" font="18">recommended for patients at high risk for hospital read-</text>
<text top="806" left="100" width="314" height="10" font="18">mission, to facilitate the implementation of GDMT, to</text>
<text top="822" left="100" width="314" height="10" font="18">address different barriers to behavioral change, and to</text>
<text top="839" left="100" width="314" height="10" font="18">reduce the risk of subsequent rehospitalization for HF</text>
<text top="855" left="100" width="43" height="10" font="5"><a href="e147.full.html#66">(82,800</a></text>
<text top="852" left="143" width="32" height="16" font="5"><a href="e147.full.html#66">–802)</a></text>
<text top="855" left="175" width="121" height="12" font="18"><a href="e147.full.html#66">. </a>(Level of Evidence: B)</text>
<text top="879" left="64" width="45" height="8" font="17">CLASS IIa</text>
<text top="891" left="82" width="10" height="10" font="18">1.</text>
<text top="891" left="100" width="314" height="10" font="18">Scheduling an early follow-up visit (within 7 to 14 days) and</text>
<text top="907" left="100" width="314" height="10" font="18">early telephone follow-up (within 3 days) of hospital</text>
<text top="924" left="100" width="133" height="10" font="18">discharge are reasonable</text>
<text top="924" left="237" width="55" height="10" font="5"><a href="e147.full.html#66">(101,803)</a></text>
<text top="924" left="292" width="121" height="12" font="18"><a href="e147.full.html#66">. </a>(Level of Evidence: B)</text>
<text top="940" left="82" width="10" height="10" font="18">2.</text>
<text top="940" left="100" width="314" height="10" font="18">Use of clinical risk-prediction tools and/or biomarkers to</text>
<text top="957" left="100" width="314" height="10" font="18">identify patients at higher risk for postdischarge clinical</text>
<text top="973" left="100" width="117" height="10" font="18">events are reasonable</text>
<text top="973" left="221" width="30" height="10" font="5"><a href="e147.full.html#69">(215)</a></text>
<text top="973" left="251" width="121" height="12" font="18"><a href="e147.full.html#69">. </a>(Level of Evidence: B)</text>
<text top="999" left="79" width="55" height="13" font="14">Decisions</text>
<text top="999" left="148" width="31" height="13" font="14">about</text>
<text top="999" left="192" width="94" height="13" font="14">pharmacological</text>
<text top="999" left="298" width="51" height="13" font="14">therapies</text>
<text top="999" left="362" width="52" height="13" font="14">delivered</text>
<text top="1016" left="64" width="350" height="13" font="14">during hospitalization likely can impact postdischarge</text>
<text top="1034" left="64" width="350" height="13" font="14">outcome. Continuation or initiation of HF GDMT prior to</text>
<text top="1052" left="64" width="350" height="13" font="14">hospital discharge is associated with substantially improved</text>
<text top="1070" left="64" width="350" height="13" font="14">clinical outcomes for patients with HFrEF. However, caution</text>
<text top="1088" left="64" width="350" height="13" font="14">should be used when initiating beta blockers in patients who</text>
<text top="510" left="450" width="350" height="13" font="14">have required inotropes during their hospital course or when</text>
<text top="528" left="450" width="350" height="13" font="14">initiating ACE inhibitors, ARBs, or aldosterone antagonists in</text>
<text top="546" left="450" width="350" height="13" font="14">those patients who have experienced marked azotemia or are</text>
<text top="564" left="450" width="350" height="13" font="14">at risk for hyperkalemia. The patient should be transitioned to</text>
<text top="582" left="450" width="350" height="13" font="14">oral diuretic therapy to verify its effectiveness. Similarly,</text>
<text top="600" left="450" width="350" height="13" font="14">optimal volume status should be achieved. Blood pressure</text>
<text top="618" left="450" width="350" height="13" font="14">should be adequately controlled, and, in patients with AF,</text>
<text top="636" left="450" width="350" height="13" font="14">ventricular response should also be well controlled. The</text>
<text top="653" left="450" width="110" height="13" font="14">hospitalization is a</text>
<text top="650" left="565" width="234" height="18" font="14">“teachable moment” to reinforce patient</text>
<text top="671" left="450" width="350" height="13" font="14">and family education and develop a plan of care, which</text>
<text top="689" left="450" width="347" height="13" font="14">should be communicated to the appropriate healthcare team.</text>
<text top="707" left="465" width="335" height="13" font="14">Safety for patients hospitalized with HF is crucial. System</text>
<text top="725" left="450" width="350" height="13" font="14">changes necessary to achieve safer care include the adoption</text>
<text top="743" left="450" width="279" height="13" font="14">by all U.S. hospitals of a standardized set of 30</text>
<text top="739" left="734" width="66" height="18" font="14">“Safe Prac-</text>
<text top="761" left="450" width="26" height="13" font="14">tices</text>
<text top="757" left="475" width="259" height="18" font="14">” endorsed by the National Quality Forum</text>
<text top="761" left="742" width="30" height="13" font="15"><a href="e147.full.html#83">(804)</a></text>
<text top="761" left="779" width="20" height="13" font="14">and</text>
<text top="779" left="450" width="350" height="13" font="14">National Patient Safety Goals espoused by The Joint</text>
<text top="797" left="450" width="71" height="13" font="14">Commission</text>
<text top="797" left="526" width="30" height="13" font="15"><a href="e147.full.html#83">(805)</a></text>
<text top="797" left="557" width="243" height="13" font="14"><a href="e147.full.html#83">. </a>Improved communication between clini-</text>
<text top="815" left="450" width="350" height="13" font="14">cians and nurses, medication reconciliation, carefully planned</text>
<text top="833" left="450" width="350" height="13" font="14">transitions between care settings, and consistent documenta-</text>
<text top="851" left="450" width="350" height="13" font="14">tion are examples of patient safety standards that should be</text>
<text top="869" left="450" width="337" height="13" font="14">ensured for patients with HF discharged from the hospital.</text>
<text top="887" left="465" width="335" height="13" font="14">The prognosis of patients hospitalized with HF, and espe-</text>
<text top="905" left="450" width="350" height="13" font="14">cially those with serial readmissions, is suboptimal. Hence,</text>
<text top="922" left="450" width="350" height="13" font="14">appropriate levels of symptomatic relief, support, and pallia-</text>
<text top="940" left="450" width="350" height="13" font="14">tive care for patients with chronic HF should be addressed as</text>
<text top="958" left="450" width="350" height="13" font="14">an ongoing key component of the plan of care, especially</text>
<text top="976" left="450" width="350" height="13" font="14">when patients are hospitalized with acute decompensation</text>
<text top="994" left="450" width="30" height="13" font="15"><a href="e147.full.html#83">(806)</a></text>
<text top="994" left="480" width="319" height="13" font="14">. The appropriateness of discussion about advanced</text>
<text top="1012" left="450" width="278" height="13" font="14">therapy or end-of-life preferences is reviewed in</text>
<text top="1012" left="732" width="61" height="13" font="15"><a href="e147.full.html#59">Section 11</a></text>
<text top="1012" left="793" width="4" height="13" font="14">.</text>
<text top="1030" left="465" width="335" height="13" font="14">For patients with HF, the transition from inpatient to</text>
<text top="1048" left="450" width="350" height="13" font="14">outpatient care can be an especially vulnerable period because</text>
<text top="1066" left="450" width="350" height="13" font="14">of the progressive nature of the disease state, complex medical</text>
<text top="1084" left="450" width="350" height="13" font="14">regimens, the large number of comorbid conditions, and the</text>
<text top="103" left="100" width="281" height="12" font="9">Table 29. Recommendations for Hospital Discharge</text>
<text top="135" left="100" width="146" height="11" font="4">Recommendations or Indications</text>
<text top="135" left="517" width="19" height="11" font="4">COR</text>
<text top="135" left="608" width="17" height="11" font="4">LOE</text>
<text top="135" left="692" width="50" height="11" font="4">References</text>
<text top="156" left="100" width="338" height="11" font="4">Performance improvement systems in the hospital and early postdischarge</text>
<text top="171" left="113" width="189" height="11" font="4">outpatient setting to identify HF for GDMT</text>
<text top="156" left="525" width="2" height="11" font="4">I</text>
<text top="156" left="613" width="6" height="11" font="4">B</text>
<text top="156" left="669" width="11" height="11" font="5"><a href="e147.full.html#66">82</a></text>
<text top="156" left="681" width="3" height="11" font="4"><a href="e147.full.html#66">,</a></text>
<text top="156" left="683" width="17" height="11" font="5"><a href="e147.full.html#72">365</a></text>
<text top="156" left="701" width="3" height="11" font="4"><a href="e147.full.html#72">,</a></text>
<text top="156" left="703" width="17" height="11" font="5"><a href="e147.full.html#80">706</a></text>
<text top="156" left="721" width="3" height="11" font="4"><a href="e147.full.html#80">,</a></text>
<text top="156" left="723" width="40" height="11" font="5"><a href="e147.full.html#82">792–796</a></text>
<text top="187" left="100" width="345" height="11" font="4">Before hospital discharge, at the first postdischarge visit, and in subsequent</text>
<text top="202" left="113" width="233" height="11" font="4">follow-up visits, the following should be addressed:</text>
<text top="217" left="124" width="236" height="11" font="4">a. initiation of GDMT if not done or contraindicated;</text>
<text top="232" left="124" width="274" height="11" font="4">b. causes of HF, barriers to care, and limitations in support;</text>
<text top="247" left="125" width="312" height="11" font="4">c. assessment of volume status and blood pressure with adjustment</text>
<text top="262" left="138" width="64" height="11" font="4">of HF therapy;</text>
<text top="277" left="124" width="193" height="11" font="4">d. optimization of chronic oral HF therapy;</text>
<text top="292" left="124" width="154" height="11" font="4">e. renal function and electrolytes;</text>
<text top="307" left="127" width="179" height="11" font="4">f. management of comorbid conditions;</text>
<text top="322" left="124" width="299" height="11" font="4">g. HF education, self-care, emergency plans, and adherence; and</text>
<text top="337" left="124" width="128" height="11" font="4">h. palliative or hospice care</text>
<text top="187" left="525" width="2" height="11" font="4">I</text>
<text top="187" left="613" width="6" height="11" font="4">B</text>
<text top="187" left="676" width="17" height="11" font="5"><a href="e147.full.html#69">204</a></text>
<text top="187" left="693" width="3" height="11" font="4"><a href="e147.full.html#82">,</a></text>
<text top="187" left="696" width="17" height="11" font="5"><a href="e147.full.html#82">795</a></text>
<text top="187" left="713" width="3" height="11" font="4"><a href="e147.full.html#82">,</a></text>
<text top="187" left="716" width="40" height="11" font="5"><a href="e147.full.html#82">797–799</a></text>
<text top="353" left="100" width="324" height="11" font="4">Multidisciplinary HF disease-management programs for patients at high</text>
<text top="368" left="116" width="214" height="11" font="4">risk for hospital readmission are recommended</text>
<text top="353" left="525" width="2" height="11" font="4">I</text>
<text top="353" left="613" width="6" height="11" font="4">B</text>
<text top="353" left="689" width="11" height="11" font="5"><a href="e147.full.html#66">82</a></text>
<text top="353" left="701" width="3" height="11" font="4"><a href="e147.full.html#66">,</a></text>
<text top="353" left="703" width="40" height="11" font="5"><a href="e147.full.html#83">800–802</a></text>
<text top="384" left="100" width="335" height="11" font="4">A follow-up visit within 7 to 14 d and/or a telephone follow-up within 3 d</text>
<text top="399" left="113" width="164" height="11" font="4">of hospital discharge are reasonable</text>
<text top="384" left="521" width="10" height="11" font="4">IIa</text>
<text top="384" left="613" width="6" height="11" font="4">B</text>
<text top="384" left="698" width="17" height="11" font="5"><a href="e147.full.html#66">101</a></text>
<text top="384" left="715" width="3" height="11" font="4"><a href="e147.full.html#66">,</a></text>
<text top="384" left="718" width="17" height="11" font="5"><a href="e147.full.html#83">803</a></text>
<text top="416" left="100" width="291" height="11" font="4">Use of clinical risk-prediction tools and/or biomarkers to identify</text>
<text top="431" left="113" width="158" height="11" font="4">higher-risk patients are reasonable</text>
<text top="416" left="521" width="10" height="11" font="4">IIa</text>
<text top="416" left="613" width="6" height="11" font="4">B</text>
<text top="416" left="708" width="17" height="11" font="5"><a href="e147.full.html#69">215</a></text>
<text top="452" left="112" width="593" height="11" font="4">COR indicates Class of Recommendation; GDMT, guideline-directed medical therapy; HF, heart failure; and LOE, Level of Evidence.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e199</text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="34" size="13" family="Times" color="#327eb1"/>
<text top="103" left="64" width="350" height="13" font="14">multiple clinicians who may be involved. Patient education</text>
<text top="121" left="64" width="350" height="13" font="14">and written discharge instructions or educational material</text>
<text top="139" left="64" width="350" height="13" font="14">given to the patient, family members, and/or caregiver during</text>
<text top="157" left="64" width="350" height="13" font="14">the hospital stay or at discharge to home are essential</text>
<text top="175" left="64" width="350" height="13" font="14">components of transition care. These should address all of</text>
<text top="193" left="64" width="350" height="13" font="14">the following: activity level, diet, discharge medications,</text>
<text top="211" left="64" width="350" height="13" font="14">follow-up appointment, weight monitoring, and what to do if</text>
<text top="229" left="64" width="105" height="13" font="14">symptoms worsen</text>
<text top="229" left="175" width="30" height="13" font="15"><a href="e147.full.html#71">(297)</a></text>
<text top="229" left="206" width="208" height="13" font="14"><a href="e147.full.html#71">. </a>Thorough discharge planning that</text>
<text top="247" left="64" width="350" height="13" font="14">includes special emphasis on ensuring adherence to an</text>
<text top="265" left="64" width="206" height="13" font="14">evidence-based medication regimen</text>
<text top="265" left="275" width="30" height="13" font="15"><a href="e147.full.html#82">(795)</a></text>
<text top="265" left="311" width="103" height="13" font="14">is associated with</text>
<text top="283" left="64" width="162" height="13" font="14">improved patient outcomes</text>
<text top="283" left="234" width="80" height="13" font="15"><a href="e147.full.html#82">(792,797,807)</a></text>
<text top="283" left="314" width="100" height="13" font="14"><a href="e147.full.html#82">. </a>More intensive</text>
<text top="301" left="64" width="350" height="13" font="14">delivery of discharge instructions, coupled tightly with</text>
<text top="319" left="64" width="350" height="13" font="14">subsequent well-coordinated follow-up care for patients</text>
<text top="337" left="64" width="350" height="13" font="14">hospitalized with HF, has produced positive results in several</text>
<text top="354" left="64" width="39" height="13" font="14">studies</text>
<text top="354" left="106" width="72" height="13" font="15"><a href="e147.full.html#66">(82,793,800)</a></text>
<text top="354" left="178" width="229" height="13" font="14">. The addition of a 1-hour, nurse educator</text>
<text top="351" left="407" width="7" height="18" font="14">–</text>
<text top="372" left="64" width="350" height="13" font="14">delivered teaching session at the time of hospital discharge,</text>
<text top="390" left="64" width="350" height="13" font="14">using standardized instructions, resulted in improved clinical</text>
<text top="408" left="64" width="350" height="13" font="14">outcomes, increased self-care and treatment adherence, and</text>
<text top="426" left="64" width="350" height="13" font="14">reduced cost of care. Patients receiving the education inter-</text>
<text top="444" left="64" width="350" height="13" font="14">vention also had a lower risk of rehospitalization or death and</text>
<text top="462" left="64" width="107" height="13" font="14">lower costs of care</text>
<text top="462" left="175" width="30" height="13" font="15"><a href="e147.full.html#72">(365)</a></text>
<text top="462" left="205" width="209" height="13" font="14">. There are ongoing efforts to further</text>
<text top="480" left="64" width="319" height="13" font="14">develop evidence-based interventions in this population.</text>
<text top="498" left="79" width="335" height="13" font="14">Transitional care extends beyond patient education. Care</text>
<text top="516" left="64" width="350" height="13" font="14">information, especially changes in orders and new diagnostic</text>
<text top="534" left="64" width="350" height="13" font="14">information, must be transmitted in a timely and clearly</text>
<text top="552" left="64" width="228" height="13" font="14">understandable form to all of the patient</text>
<text top="548" left="292" width="122" height="18" font="14">’s clinicians who will</text>
<text top="570" left="64" width="350" height="13" font="14">be delivering follow-up care. Other important components of</text>
<text top="588" left="64" width="350" height="13" font="14">transitional care include preparation of the patient and care-</text>
<text top="606" left="64" width="350" height="13" font="14">giver for what to expect at the next site of care, reconciliation</text>
<text top="623" left="64" width="350" height="13" font="14">of medications, follow-up plans for outstanding tests, and</text>
<text top="641" left="64" width="350" height="13" font="14">discussions about monitoring signs and symptoms of wors-</text>
<text top="659" left="64" width="350" height="13" font="14">ening conditions. Early outpatient follow-up, a central</text>
<text top="677" left="64" width="236" height="13" font="14">element of transitional care, varies signi</text>
<text top="673" left="300" width="114" height="18" font="14">ﬁcantly across U.S.</text>
<text top="695" left="64" width="350" height="13" font="14">hospitals. Early postdischarge follow-up may help minimize</text>
<text top="713" left="64" width="350" height="13" font="14">gaps in understanding of changes to the care plan or knowl-</text>
<text top="731" left="64" width="350" height="13" font="14">edge of test results and has been associated with a lower risk</text>
<text top="749" left="64" width="187" height="13" font="14">of subsequent rehospitalization</text>
<text top="749" left="261" width="30" height="13" font="15"><a href="e147.full.html#83">(803)</a></text>
<text top="749" left="292" width="122" height="13" font="14"><a href="e147.full.html#83">. </a>A follow-up visit</text>
<text top="767" left="64" width="350" height="13" font="14">within 7 to 14 days and/or a telephone follow-up within 3</text>
<text top="785" left="64" width="318" height="13" font="14">days of hospital discharge are reasonable goals of care.</text>
<text top="803" left="79" width="20" height="13" font="14">See</text>
<text top="803" left="102" width="157" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 40</a></text>
<text top="803" left="263" width="151" height="13" font="14">for additional data on oral</text>
<text top="821" left="64" width="231" height="13" font="14">medications for the hospitalized patient.</text>
<text top="869" left="64" width="270" height="15" font="13">9. Important Comorbidities in HF</text>
<text top="911" left="64" width="161" height="14" font="16">9.1. Atrial Fibrillation</text>
<text top="907" left="225" width="7" height="20" font="34"><a href="e147.full.html#54">x</a></text>
<text top="930" left="65" width="349" height="13" font="14">Patients with HF are more likely than the general population</text>
<text top="948" left="64" width="84" height="13" font="14">to develop AF</text>
<text top="948" left="154" width="30" height="13" font="15"><a href="e147.full.html#83">(808)</a></text>
<text top="948" left="185" width="229" height="13" font="14"><a href="e147.full.html#83">. </a>There is a direct relationship between</text>
<text top="966" left="64" width="350" height="13" font="14">the NYHA class and prevalence of AF in patients with HF</text>
<text top="984" left="64" width="350" height="13" font="14">progressing from 4% in those who are NYHA class I to 40%</text>
<text top="103" left="450" width="195" height="13" font="14">in those who are NYHA class IV</text>
<text top="103" left="649" width="30" height="13" font="15"><a href="e147.full.html#83">(809)</a></text>
<text top="103" left="680" width="120" height="13" font="14"><a href="e147.full.html#83">. </a>AF is also a strong</text>
<text top="121" left="450" width="350" height="13" font="14">independent risk factor for subsequent development of HF</text>
<text top="139" left="450" width="55" height="13" font="15"><a href="e147.full.html#73">(376,808)</a></text>
<text top="139" left="505" width="294" height="13" font="14">. In addition to those with HFrEF, patients with</text>
<text top="157" left="450" width="350" height="13" font="14">HFpEF are also at greater risk for AF than the general age-</text>
<text top="175" left="450" width="111" height="13" font="14">matched population</text>
<text top="175" left="565" width="30" height="13" font="15"><a href="e147.full.html#83">(811)</a></text>
<text top="175" left="595" width="204" height="13" font="14">. HF and AF can interact to promote</text>
<text top="193" left="450" width="350" height="13" font="14">their perpetuation and worsening through mechanisms such</text>
<text top="211" left="450" width="276" height="13" font="14">as rate-dependent worsening of cardiac function,</text>
<text top="207" left="730" width="69" height="18" font="14">ﬁbrosis, and</text>
<text top="229" left="450" width="350" height="13" font="14">activation of neurohumoral vasoconstrictors. AF can worsen</text>
<text top="247" left="450" width="350" height="13" font="14">symptoms in patients with HF, and, conversely, worsened HF</text>
<text top="265" left="450" width="269" height="13" font="14">can promote a rapid ventricular response in AF.</text>
<text top="283" left="465" width="335" height="13" font="14">Similar to other patient populations, for those with AF and</text>
<text top="301" left="450" width="350" height="13" font="14">HF, the main goals of therapy are prevention of thrombo-</text>
<text top="319" left="450" width="350" height="13" font="14">embolism and symptom control. Most patients with AF and</text>
<text top="337" left="450" width="350" height="13" font="14">HF would be expected to be candidates for systemic anti-</text>
<text top="354" left="450" width="350" height="13" font="14">coagulation unless otherwise contraindicated. General prin-</text>
<text top="372" left="450" width="350" height="13" font="14">ciples of management include correction of underlying causes</text>
<text top="390" left="450" width="350" height="13" font="14">of AF and HF as well as optimization of HF management</text>
<text top="408" left="450" width="5" height="13" font="14"><a href="e147.full.html#55">(</a></text>
<text top="408" left="454" width="51" height="13" font="15"><a href="e147.full.html#55">Table 30</a></text>
<text top="408" left="506" width="294" height="13" font="14"><a href="e147.full.html#55">). </a>As in other patient populations, the issue of rate</text>
<text top="426" left="450" width="350" height="13" font="14">control versus rhythm control has been investigated. For</text>
<text top="444" left="450" width="350" height="13" font="14">patients who develop HF as a result of AF, a rhythm control</text>
<text top="462" left="450" width="350" height="13" font="14">strategy should be pursued. It is important to recognize that</text>
<text top="480" left="450" width="350" height="13" font="14">AF with a rapid ventricular response is one of the few</text>
<text top="498" left="450" width="350" height="13" font="14">potentially reversible causes of HF. Because of this, a patient</text>
<text top="516" left="450" width="350" height="13" font="14">who presents with newly detected HF in the presence of AF</text>
<text top="534" left="450" width="350" height="13" font="14">with a rapid ventricular response should be presumed to have</text>
<text top="552" left="450" width="350" height="13" font="14">a rate-related cardiomyopathy until proved otherwise. In this</text>
<text top="570" left="450" width="350" height="13" font="14">situation, 2 strategies can be considered. One is rate control of</text>
<text top="588" left="450" width="59" height="13" font="14">the patient</text>
<text top="584" left="508" width="291" height="18" font="14">’s AF and see if HF and EF improve. The other is to</text>
<text top="606" left="450" width="350" height="13" font="14">try to restore and maintain sinus rhythm. In this situation, it is</text>
<text top="623" left="450" width="350" height="13" font="14">common practice to initiate amiodarone and then arrange for</text>
<text top="641" left="450" width="350" height="13" font="14">cardioversion 1 month later. Amiodarone has the advantage of</text>
<text top="659" left="450" width="350" height="13" font="14">being both an effective rate-control medication and the most</text>
<text top="677" left="450" width="350" height="13" font="14">effective antiarrhythmic medication with a lower risk of</text>
<text top="695" left="450" width="120" height="13" font="14">proarrhythmic effect.</text>
<text top="713" left="465" width="335" height="13" font="14">In patients with HF who develop AF, a rhythm-control</text>
<text top="731" left="450" width="350" height="13" font="14">strategy has not been shown to be superior to a rate-control</text>
<text top="749" left="450" width="44" height="13" font="14">strategy</text>
<text top="749" left="503" width="30" height="13" font="15"><a href="e147.full.html#83">(812)</a></text>
<text top="749" left="533" width="267" height="13" font="14"><a href="e147.full.html#83">. </a>If rhythm control is chosen, limited data</text>
<text top="767" left="450" width="350" height="13" font="14">suggest that AF catheter ablation in HF patients may lead to</text>
<text top="785" left="450" width="350" height="13" font="14">improvement in LV function and quality of life but is less</text>
<text top="803" left="450" width="350" height="13" font="14">likely to be effective than in patients with intact cardiac</text>
<text top="821" left="450" width="47" height="13" font="14">function</text>
<text top="821" left="505" width="55" height="13" font="15"><a href="e147.full.html#83">(813,814)</a></text>
<text top="821" left="561" width="239" height="13" font="14"><a href="e147.full.html#83">. </a>Because of their favorable effect on</text>
<text top="839" left="450" width="350" height="13" font="14">morbidity and mortality in patients with systolic HF, beta-</text>
<text top="857" left="450" width="350" height="13" font="14">adrenergic blockers are the preferred agents for achieving</text>
<text top="875" left="450" width="350" height="13" font="14">rate control unless otherwise contraindicated. Digoxin may be</text>
<text top="892" left="450" width="350" height="13" font="14">an effective adjunct to a beta blocker. The nondihydropyridine</text>
<text top="910" left="450" width="350" height="13" font="14">calcium antagonists, such as diltiazem, should be used with</text>
<text top="928" left="450" width="350" height="13" font="14">caution in those with depressed EF because of their negative</text>
<text top="946" left="450" width="350" height="13" font="14">inotropic effect. For those with HFpEF, nondihydropyridine</text>
<text top="964" left="450" width="350" height="13" font="14">calcium antagonists can be effective for achieving rate control</text>
<text top="982" left="450" width="350" height="13" font="14">but may be more effective when used in combination with</text>
<text top="1000" left="450" width="350" height="13" font="14">digoxin. For those for whom a rate-control strategy is chosen,</text>
<text top="1018" left="450" width="350" height="13" font="14">when rate control cannot be achieved either because of drug</text>
<text top="1036" left="450" width="22" height="13" font="14">inef</text>
<text top="1032" left="472" width="328" height="18" font="14">ﬁcacy or intolerance, atrioventricular node ablation and</text>
<text top="1054" left="450" width="217" height="13" font="14">CRT device placement can be useful</text>
<text top="1054" left="672" width="98" height="13" font="15"><a href="e147.full.html#66">(78,116,595,596)</a></text>
<text top="1054" left="770" width="29" height="13" font="14">. See</text>
<text top="1072" left="450" width="54" height="13" font="15"><a href="e147.full.html#56">Figures 5</a></text>
<text top="1072" left="508" width="20" height="13" font="14">and</text>
<text top="1072" left="533" width="7" height="13" font="15"><a href="e147.full.html#56">6</a></text>
<text top="1072" left="545" width="165" height="13" font="14">for AF treatment algorithms.</text>
<text top="1090" left="465" width="20" height="13" font="14">See</text>
<text top="1090" left="488" width="158" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 41</a></text>
<text top="1090" left="650" width="150" height="13" font="14">for additional data on AF.</text>
<text top="1036" left="64" width="350" height="14" font="20"><a href="e147.full.html#56">xThe </a>“ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial</text>
<text top="1052" left="64" width="46" height="9" font="20">Fibrillation</text>
<text top="1049" left="111" width="214" height="14" font="20">” and the 2 subsequent focused updates from 2011</text>
<text top="1052" left="328" width="9" height="9" font="28"><a href="e147.full.html#83">(6</a></text>
<text top="1049" left="336" width="14" height="14" font="28"><a href="e147.full.html#83">–8)</a></text>
<text top="1052" left="353" width="61" height="9" font="20">are considered</text>
<text top="1065" left="64" width="350" height="9" font="20">policy at the time of publication of the present HF Guideline; however, a fully</text>
<text top="1079" left="64" width="350" height="9" font="20">revised AF guideline, which will include updated recommendations on AF, is in</text>
<text top="1092" left="64" width="244" height="9" font="20">development, with publication expected in 2013 or 2014.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e200</text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1160" width="864">
<text top="873" left="64" width="91" height="14" font="16">9.2. Anemia</text>
<text top="892" left="65" width="128" height="13" font="14">Anemia is a common</text>
<text top="888" left="199" width="215" height="18" font="14">ﬁnding in patients with chronic HF.</text>
<text top="910" left="64" width="350" height="13" font="14">Although variably reported, in part due to the lack of</text>
<text top="927" left="64" width="125" height="13" font="14">consensus on the de</text>
<text top="924" left="189" width="225" height="18" font="14">ﬁnition of anemia, the prevalence of</text>
<text top="945" left="64" width="350" height="13" font="14">anemia among patients with HF increases with HF severity.</text>
<text top="963" left="64" width="350" height="13" font="14">Anemia is also more common in women and is seen in both</text>
<text top="981" left="64" width="204" height="13" font="14">patients with HFrEF and HFpEF</text>
<text top="981" left="277" width="26" height="13" font="15"><a href="e147.full.html#83">(818</a></text>
<text top="977" left="303" width="33" height="18" font="15"><a href="e147.full.html#83">–823)</a></text>
<text top="981" left="336" width="78" height="13" font="14"><a href="e147.full.html#83">. </a>The World</text>
<text top="999" left="64" width="137" height="13" font="14">Health Organization de</text>
<text top="995" left="201" width="212" height="18" font="14">ﬁnes anemia as a hemoglobin level</text>
<text top="1017" left="64" width="12" height="13" font="14">of</text>
<text top="1013" left="80" width="334" height="18" font="14">&lt;12 g/dL in women and &lt;13 g/dL in men. Registries have</text>
<text top="1035" left="64" width="350" height="13" font="14">reported anemia to be present in 25% to 40% of HF patients</text>
<text top="1053" left="64" width="26" height="13" font="15"><a href="e147.full.html#83">(818</a></text>
<text top="1049" left="90" width="33" height="18" font="15"><a href="e147.full.html#83">–820)</a></text>
<text top="1053" left="123" width="291" height="13" font="14">. Anemia is associated with an increased mortality</text>
<text top="1071" left="64" width="179" height="13" font="14">risk in HF. In a large study of</text>
<text top="1067" left="249" width="165" height="18" font="14">&gt;150,000 patients, the mor-</text>
<text top="1089" left="64" width="350" height="13" font="14">tality risk was approximately doubled in anemic HF patients</text>
<text top="873" left="450" width="350" height="13" font="14">compared with those without anemia, and this risk persisted</text>
<text top="891" left="450" width="350" height="13" font="14">after controlling for other confounders, including renal</text>
<text top="908" left="450" width="161" height="13" font="14">dysfunction and HF severity</text>
<text top="908" left="615" width="30" height="13" font="15"><a href="e147.full.html#83">(818)</a></text>
<text top="908" left="646" width="154" height="13" font="14"><a href="e147.full.html#83">. </a>Anemia is also associated</text>
<text top="926" left="450" width="350" height="13" font="14">with reduced exercise capacity, impaired HRQOL, and</text>
<text top="944" left="450" width="192" height="13" font="14">a higher risk for hospitalization</text>
<text top="944" left="650" width="105" height="13" font="15"><a href="e147.full.html#69">(225,819,824,825)</a></text>
<text top="944" left="755" width="45" height="13" font="14"><a href="e147.full.html#69">. </a>These</text>
<text top="962" left="450" width="350" height="13" font="14">risks are inversely and linearly associated with hemoglobin</text>
<text top="980" left="450" width="350" height="13" font="14">levels, although a U-shaped risk with the highest hemoglobin</text>
<text top="998" left="450" width="139" height="13" font="14">levels has been reported</text>
<text top="998" left="593" width="55" height="13" font="15"><a href="e147.full.html#83">(822,826)</a></text>
<text top="998" left="649" width="4" height="13" font="14"><a href="e147.full.html#83">.</a></text>
<text top="1016" left="465" width="335" height="13" font="14">Multiple etiological factors, many of which coexist within</text>
<text top="1034" left="450" width="350" height="13" font="14">individual patients, contribute to the development of anemia</text>
<text top="1052" left="450" width="350" height="13" font="14">in HF. Anemia in patients with HF is often normocytic and</text>
<text top="1070" left="450" width="350" height="13" font="14">accompanied by an abnormally low reticulocyte count</text>
<text top="1088" left="450" width="55" height="13" font="15"><a href="e147.full.html#83">(825,827)</a></text>
<text top="1088" left="505" width="294" height="13" font="14">. Evaluation of anemia in HF requires careful</text>
<text top="101" left="64" width="265" height="12" font="9">Table 30. Clinical Evaluation in Patients With AF</text>
<text top="132" left="64" width="91" height="11" font="4">Minimum evaluation</text>
<text top="152" left="76" width="211" height="11" font="4">1. History and physical examination, to define</text>
<text top="149" left="364" width="256" height="16" font="4"> Presence and nature of symptoms associated with AF</text>
<text top="164" left="364" width="272" height="16" font="4"> Clinical type of AF (paroxysmal, persistent, or permanent)</text>
<text top="179" left="364" width="285" height="16" font="4"> Onset of first symptomatic attack or date of discovery of AF</text>
<text top="194" left="364" width="348" height="16" font="4"> Frequency, duration, precipitating factors, and modes of termination of AF</text>
<text top="209" left="364" width="330" height="16" font="4"> Response to any pharmacological agents that have been administered</text>
<text top="224" left="364" width="435" height="16" font="4"> Presence of any underlying heart disease or other reversible conditions (e.g., hyperthyroidism</text>
<text top="241" left="388" width="108" height="11" font="4">or alcohol consumption)</text>
<text top="261" left="76" width="86" height="11" font="4">2. ECG, to identify</text>
<text top="258" left="364" width="95" height="16" font="4"> Rhythm (verify AF)</text>
<text top="273" left="364" width="79" height="16" font="4"> LV hypertrophy</text>
<text top="288" left="364" width="254" height="16" font="4"> P-wave duration and morphology or fibrillatory waves</text>
<text top="303" left="364" width="70" height="16" font="4"> Preexcitation</text>
<text top="318" left="364" width="105" height="16" font="4"> Bundle-branch block</text>
<text top="333" left="364" width="48" height="16" font="4"> Prior MI</text>
<text top="348" left="364" width="119" height="16" font="4"> Other atrial arrhythmias</text>
<text top="363" left="364" width="417" height="16" font="4"> To measure and follow the R-R, QRS, and QT intervals in conjunction with antiarrhythmic</text>
<text top="380" left="388" width="57" height="11" font="4">drug therapy</text>
<text top="400" left="76" width="203" height="11" font="4">3. Transthoracic echocardiogram, to identify</text>
<text top="397" left="364" width="112" height="16" font="4"> Valvular heart disease</text>
<text top="412" left="364" width="81" height="16" font="4"> LA and RA size</text>
<text top="427" left="364" width="140" height="16" font="4"> LV and RV size and function</text>
<text top="442" left="364" width="209" height="16" font="4"> Peak RV pressure (pulmonary hypertension)</text>
<text top="457" left="364" width="79" height="16" font="4"> LV hypertrophy</text>
<text top="472" left="364" width="142" height="16" font="4"> LA thrombus (low sensitivity)</text>
<text top="487" left="364" width="97" height="16" font="4"> Pericardial disease</text>
<text top="509" left="76" width="239" height="11" font="4">4. Blood tests of thyroid, renal, and hepatic function</text>
<text top="506" left="364" width="337" height="16" font="4"> For a first episode of AF, when the ventricular rate is difficult to control</text>
<text top="528" left="64" width="263" height="11" font="4">Additional testing (one or several tests may be necessary)</text>
<text top="548" left="76" width="102" height="11" font="4">1. 6-Minute walk test</text>
<text top="545" left="364" width="215" height="16" font="4"> If the adequacy of rate control is in question</text>
<text top="567" left="76" width="87" height="11" font="4">2. Exercise testing</text>
<text top="564" left="364" width="287" height="16" font="4"> If the adequacy of rate control is in question (permanent AF)</text>
<text top="579" left="364" width="167" height="16" font="4"> To reproduce exercise-induced AF</text>
<text top="594" left="364" width="435" height="16" font="4"> To exclude ischemia before treatment of selected patients with a type IC antiarrhythmic drug</text>
<text top="616" left="76" width="180" height="11" font="4">3. Holter monitoring or event recording</text>
<text top="614" left="364" width="245" height="16" font="4"> If diagnosis of the type of arrhythmia is in question</text>
<text top="629" left="364" width="183" height="16" font="4"> As a means of evaluating rate control</text>
<text top="651" left="76" width="174" height="11" font="4">4. Transesophageal echocardiography</text>
<text top="648" left="364" width="224" height="16" font="4"> To identify LA thrombus (in the LA appendage)</text>
<text top="663" left="364" width="114" height="16" font="4"> To guide cardioversion</text>
<text top="685" left="76" width="131" height="11" font="4">5. Electrophysiological study</text>
<text top="682" left="364" width="284" height="16" font="4"> To clarify the mechanism of wide-QRS-complex tachycardia</text>
<text top="697" left="364" width="343" height="16" font="4"> To identify a predisposing arrhythmia such as atrial flutter or paroxysmal</text>
<text top="715" left="388" width="126" height="11" font="4">supraventricular tachycardia</text>
<text top="727" left="364" width="332" height="16" font="4"> To seek sites for curative ablation or AV conduction block/modification</text>
<text top="749" left="76" width="121" height="11" font="4">6. Chest x-ray to evaluate</text>
<text top="747" left="364" width="306" height="16" font="4"> Lung parenchyma, when clinical findings suggest an abnormality</text>
<text top="762" left="364" width="327" height="16" font="4"> Pulmonary vasculature, when clinical findings suggest an abnormality</text>
<text top="786" left="76" width="350" height="11" font="4">Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs.</text>
<text top="801" left="76" width="723" height="11" font="4">AF indicates atrial fibrillation; AV, atrioventricular; ECG, electrocardiogram; LA, left atrial; LV, left ventricular; MI, myocardial infarction; RA, right atrial; and</text>
<text top="816" left="64" width="92" height="11" font="4">RV, right ventricular.</text>
<text top="831" left="76" width="136" height="11" font="4">Reproduced from Fuster et al.</text>
<text top="831" left="216" width="11" height="11" font="5"><a href="e147.full.html#64">(6)</a></text>
<text top="831" left="227" width="3" height="11" font="4">.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e201</text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1160" width="864">
<text top="558" left="64" width="696" height="16" font="4">Figure 5. Pharmacological management of patients with newly discovered AF. AF indicates atrial ﬁbrillation; and HF, heart failure.</text>
<text top="575" left="64" width="161" height="11" font="4">Reproduced from Fuster et al.</text>
<text top="575" left="229" width="13" height="11" font="5"><a href="e147.full.html#64">(6)</a></text>
<text top="575" left="241" width="3" height="11" font="4">.</text>
<text top="1075" left="64" width="697" height="16" font="4">Figure 6. Pharmacological management of patients with recurrent paroxysmal AF. AF indicates atrial ﬁbrillation. Reproduced from</text>
<text top="1091" left="64" width="63" height="11" font="4">Fuster et al.</text>
<text top="1091" left="132" width="13" height="11" font="5"><a href="e147.full.html#64">(6)</a></text>
<text top="1091" left="144" width="3" height="11" font="4">.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e202</text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">consideration of other causes, the most common being</text>
<text top="121" left="64" width="160" height="13" font="14">secondary causes of iron de</text>
<text top="117" left="224" width="93" height="18" font="14">ﬁciency anemia.</text>
<text top="139" left="79" width="12" height="13" font="14">In</text>
<text top="139" left="105" width="43" height="13" font="14">persons</text>
<text top="139" left="161" width="43" height="13" font="14">without</text>
<text top="139" left="218" width="32" height="13" font="14">identi</text>
<text top="135" left="250" width="164" height="18" font="14">ﬁable causes of anemia,</text>
<text top="157" left="64" width="318" height="13" font="14">erythropoiesis-stimulating agents have gained signi</text>
<text top="153" left="383" width="31" height="18" font="14">ﬁcant</text>
<text top="175" left="64" width="350" height="13" font="14">interest as potential adjunctive therapy in the patient with HF.</text>
<text top="193" left="64" width="350" height="13" font="14">In a retrospective study of erythropoiesis-stimulating agents in</text>
<text top="211" left="64" width="350" height="13" font="14">26 patients with HF and anemia, the hemoglobin level, LVEF,</text>
<text top="229" left="64" width="173" height="13" font="14">and functional class improved</text>
<text top="229" left="242" width="30" height="13" font="15"><a href="e147.full.html#83">(828)</a></text>
<text top="229" left="272" width="142" height="13" font="14">. These patients required</text>
<text top="247" left="64" width="350" height="13" font="14">lower diuretic doses and were hospitalized less often. Similar</text>
<text top="261" left="64" width="350" height="18" font="14">ﬁndings were also observed in a randomized open-label study</text>
<text top="283" left="64" width="79" height="13" font="14">of 32 patients</text>
<text top="283" left="148" width="30" height="13" font="15"><a href="e147.full.html#83">(829)</a></text>
<text top="283" left="179" width="235" height="13" font="14"><a href="e147.full.html#83">. </a>A single-blind RCT showed that eryth-</text>
<text top="301" left="64" width="350" height="13" font="14">ropoietin increased hemoglobin, peak oxygen uptake, and</text>
<text top="319" left="64" width="350" height="13" font="14">exercise duration in patients with severe HF and anemia</text>
<text top="337" left="64" width="30" height="13" font="15"><a href="e147.full.html#83">(830)</a></text>
<text top="337" left="95" width="141" height="13" font="14"><a href="e147.full.html#83">. </a>Two further studies con</text>
<text top="333" left="236" width="178" height="18" font="14">ﬁrmed these ﬁndings; however,</text>
<text top="354" left="64" width="186" height="13" font="14">none of these were double blind</text>
<text top="354" left="255" width="55" height="13" font="15"><a href="e147.full.html#83">(831,832)</a></text>
<text top="354" left="310" width="4" height="13" font="14">.</text>
<text top="372" left="79" width="335" height="13" font="14">These positive data led to 2 larger studies. A 165-patient</text>
<text top="390" left="64" width="350" height="13" font="14">study showed that darbepoetin alfa was associated with</text>
<text top="408" left="64" width="350" height="13" font="14">improvement in several HRQOL measures with a trend</text>
<text top="426" left="64" width="350" height="13" font="14">toward improved exercise capacity (6-minute walking</text>
<text top="444" left="64" width="46" height="13" font="14">distance</text>
<text top="440" left="116" width="240" height="18" font="14">þ347 m versus þ1110 m, P¼0.074)</text>
<text top="444" left="362" width="30" height="13" font="15"><a href="e147.full.html#83">(833)</a></text>
<text top="444" left="393" width="21" height="13" font="14"><a href="e147.full.html#83">. </a>In</text>
<text top="462" left="64" width="350" height="13" font="14">STAMINA-HeFT (Study of Anemia in Heart Failure Trial),</text>
<text top="480" left="64" width="350" height="13" font="14">319 patients were randomly assigned to darbepoetin alfa or</text>
<text top="498" left="64" width="131" height="13" font="14">placebo for 12 months</text>
<text top="498" left="201" width="30" height="13" font="15"><a href="e147.full.html#83">(834)</a></text>
<text top="498" left="231" width="183" height="13" font="14">. Although darbepoetin alfa did</text>
<text top="516" left="64" width="350" height="13" font="14">not improve exercise duration, it was well tolerated, and</text>
<text top="534" left="64" width="350" height="13" font="14">a trend toward improvement in the composite endpoint of all-</text>
<text top="552" left="64" width="112" height="13" font="14">cause mortality or</text>
<text top="548" left="185" width="229" height="18" font="14">ﬁrst hospitalization for HF was seen</text>
<text top="570" left="64" width="172" height="13" font="14">(hazard ratio: 0.68; 95% con</text>
<text top="566" left="236" width="178" height="18" font="14">ﬁdence interval: 0.43 to 1.08;</text>
<text top="588" left="64" width="9" height="13" font="14">P</text>
<text top="584" left="73" width="40" height="18" font="14">¼0.10)</text>
<text top="588" left="119" width="30" height="13" font="15"><a href="e147.full.html#83">(834)</a></text>
<text top="588" left="150" width="264" height="13" font="14"><a href="e147.full.html#83">. </a>These favorable data led to the design and</text>
<text top="606" left="64" width="350" height="13" font="14">initiation of the RED-HF (Phase III Reduction of Events With</text>
<text top="623" left="64" width="222" height="13" font="14">Darbepoetin alfa in Heart Failure) trial</text>
<text top="623" left="291" width="30" height="13" font="15"><a href="e147.full.html#83">(835)</a></text>
<text top="623" left="322" width="4" height="13" font="14"><a href="e147.full.html#83">.</a></text>
<text top="641" left="79" width="335" height="13" font="14">Two trials in erythropoiesis-stimulating agents, however,</text>
<text top="659" left="64" width="25" height="13" font="14">later</text>
<text top="659" left="103" width="33" height="13" font="14">raised</text>
<text top="659" left="151" width="50" height="13" font="14">concerns</text>
<text top="659" left="215" width="21" height="13" font="14">that</text>
<text top="659" left="251" width="44" height="13" font="14">patients</text>
<text top="659" left="309" width="38" height="13" font="14">treated</text>
<text top="659" left="361" width="25" height="13" font="14">with</text>
<text top="659" left="401" width="13" height="13" font="14">an</text>
<text top="677" left="64" width="350" height="13" font="14">erythropoiesis-stimulating agent may have an increased risk</text>
<text top="695" left="64" width="140" height="13" font="14">of cardiovascular events</text>
<text top="695" left="209" width="55" height="13" font="15"><a href="e147.full.html#83">(836,837)</a></text>
<text top="695" left="265" width="149" height="13" font="14"><a href="e147.full.html#83">. </a>Because the populations</text>
<text top="103" left="450" width="350" height="13" font="14">in these trials differed, the RED-HF trial was continued.</text>
<text top="121" left="450" width="350" height="13" font="14">Nevertheless, at the completion of the trial, the investigators</text>
<text top="139" left="450" width="350" height="13" font="14">concluded that treatment with darbepoetin alfa did not</text>
<text top="157" left="450" width="350" height="13" font="14">improve clinical outcomes in patients with systolic HF and</text>
<text top="175" left="450" width="145" height="13" font="14">mild-to-moderate anemia</text>
<text top="175" left="601" width="30" height="13" font="15"><a href="e147.full.html#83">(838)</a></text>
<text top="175" left="632" width="168" height="13" font="14"><a href="e147.full.html#83">. </a>Finally, a trial using intra-</text>
<text top="193" left="450" width="350" height="13" font="14">venous iron as a supplement in patients with HFrEF with iron</text>
<text top="211" left="450" width="13" height="13" font="14">de</text>
<text top="207" left="463" width="298" height="18" font="14">ﬁciency showed an improvement in functional status</text>
<text top="211" left="766" width="30" height="13" font="15"><a href="e147.full.html#83">(840)</a></text>
<text top="211" left="796" width="4" height="13" font="14"><a href="e147.full.html#83">.</a></text>
<text top="229" left="450" width="350" height="13" font="14">There were no untoward adverse effects of iron in this trial. In</text>
<text top="247" left="450" width="133" height="13" font="14">the absence of a de</text>
<text top="243" left="583" width="216" height="18" font="14">ﬁnitive evidence base, the writing</text>
<text top="265" left="450" width="179" height="13" font="14">committee has deferred a speci</text>
<text top="261" left="629" width="171" height="18" font="14">ﬁc treatment recommendation</text>
<text top="283" left="450" width="103" height="13" font="14">regarding anemia.</text>
<text top="318" left="450" width="119" height="14" font="16">9.3. Depression</text>
<text top="337" left="451" width="349" height="13" font="14">Depression is common in patients with HF; those with</text>
<text top="355" left="450" width="350" height="13" font="14">depressive symptoms have lower HRQOL, poorer self-care,</text>
<text top="373" left="450" width="350" height="13" font="14">worse clinical outcomes, and more use of healthcare</text>
<text top="391" left="450" width="45" height="13" font="14">services</text>
<text top="391" left="504" width="26" height="13" font="15"><a href="e147.full.html#83">(841</a></text>
<text top="387" left="530" width="33" height="18" font="15"><a href="e147.full.html#83">–843)</a></text>
<text top="391" left="563" width="236" height="13" font="14">. Although it might be assumed that</text>
<text top="409" left="450" width="308" height="13" font="14">depression occurs only among hospitalized patients</text>
<text top="409" left="766" width="30" height="13" font="15"><a href="e147.full.html#83">(844)</a></text>
<text top="409" left="796" width="4" height="13" font="14"><a href="e147.full.html#83">,</a></text>
<text top="427" left="450" width="350" height="13" font="14">a multicenter study demonstrated that even at least 3 months</text>
<text top="445" left="450" width="350" height="13" font="14">after a hospitalization, 63% of patients with HF reported</text>
<text top="463" left="450" width="145" height="13" font="14">symptoms of depression</text>
<text top="463" left="603" width="30" height="13" font="15"><a href="e147.full.html#83">(845)</a></text>
<text top="463" left="633" width="166" height="13" font="14">. Potential pathophysiologic</text>
<text top="481" left="450" width="350" height="13" font="14">mechanisms proposed to explain the high prevalence of</text>
<text top="499" left="450" width="350" height="13" font="14">depression in HF include autonomic nervous system</text>
<text top="517" left="450" width="87" height="13" font="14">dysfunction, in</text>
<text top="513" left="537" width="262" height="18" font="14">ﬂammation, cardiac arrhythmias, and altered</text>
<text top="534" left="450" width="310" height="13" font="14">platelet function, but the mechanism remains unclear</text>
<text top="534" left="766" width="30" height="13" font="15"><a href="e147.full.html#84">(846)</a></text>
<text top="534" left="796" width="4" height="13" font="14"><a href="e147.full.html#84">.</a></text>
<text top="552" left="450" width="350" height="13" font="14">Although remission from depression may improve cardio-</text>
<text top="570" left="450" width="350" height="13" font="14">vascular outcomes, the most effective intervention strategy is</text>
<text top="588" left="450" width="83" height="13" font="14">not yet known</text>
<text top="588" left="538" width="30" height="13" font="15"><a href="e147.full.html#83">(842)</a></text>
<text top="588" left="568" width="4" height="13" font="14">.</text>
<text top="624" left="450" width="252" height="14" font="16">9.4. Other Multiple Comorbidities</text>
<text top="643" left="451" width="349" height="13" font="14">Although there are additional and important comorbidities</text>
<text top="661" left="450" width="35" height="13" font="14">that af</text>
<text top="657" left="485" width="189" height="18" font="14">ﬂict patients with HF as shown in</text>
<text top="661" left="678" width="50" height="13" font="15"><a href="e147.full.html#57">Table 31</a></text>
<text top="661" left="727" width="72" height="13" font="14">, how best to</text>
<text top="679" left="450" width="82" height="13" font="14">generate speci</text>
<text top="675" left="532" width="268" height="18" font="14">ﬁc recommendations remains uncertain, given</text>
<text top="697" left="450" width="173" height="13" font="14">the status of current evidence.</text>
<text top="759" left="64" width="573" height="12" font="9">Table 31. Ten Most Common Co-Occurring Chronic Conditions Among Medicare Beneficiaries With HF (N</text>
<text top="756" left="637" width="102" height="17" font="9">[4,947,918), 2011</text>
<text top="787" left="144" width="78" height="11" font="4">Beneficiaries Age</text>
<text top="784" left="225" width="101" height="16" font="4">65 y (N¼<a href="e147.full.html#57">4,376,150)</a></text>
<text top="787" left="326" width="4" height="11" font="5"><a href="e147.full.html#57">*</a></text>
<text top="787" left="552" width="78" height="11" font="4">Beneficiaries Age</text>
<text top="784" left="633" width="92" height="16" font="4">&lt;65 y (N¼<a href="e147.full.html#57">571,768)</a></text>
<text top="784" left="725" width="5" height="16" font="5"><a href="e147.full.html#57">y</a></text>
<text top="811" left="290" width="7" height="11" font="4">N</text>
<text top="811" left="395" width="9" height="11" font="4">%</text>
<text top="811" left="680" width="7" height="11" font="4">N</text>
<text top="811" left="783" width="9" height="11" font="4">%</text>
<text top="831" left="64" width="58" height="11" font="4">Hypertension</text>
<text top="831" left="271" width="46" height="11" font="4">3,685,373</text>
<text top="831" left="390" width="20" height="11" font="4">84.2</text>
<text top="831" left="483" width="58" height="11" font="4">Hypertension</text>
<text top="831" left="665" width="37" height="11" font="4">461,235</text>
<text top="831" left="778" width="20" height="11" font="4">80.7</text>
<text top="850" left="64" width="104" height="11" font="4">Ischemic heart disease</text>
<text top="850" left="271" width="46" height="11" font="4">3,145,718</text>
<text top="850" left="390" width="20" height="11" font="4">71.9</text>
<text top="850" left="483" width="104" height="11" font="4">Ischemic heart disease</text>
<text top="850" left="665" width="37" height="11" font="4">365,889</text>
<text top="850" left="778" width="20" height="11" font="4">64.0</text>
<text top="870" left="64" width="66" height="11" font="4">Hyperlipidemia</text>
<text top="870" left="271" width="46" height="11" font="4">2,623,601</text>
<text top="870" left="390" width="20" height="11" font="4">60.0</text>
<text top="870" left="483" width="39" height="11" font="4">Diabetes</text>
<text top="870" left="665" width="37" height="11" font="4">338,687</text>
<text top="870" left="778" width="20" height="11" font="4">59.2</text>
<text top="889" left="64" width="33" height="11" font="4">Anemia</text>
<text top="889" left="271" width="46" height="11" font="4">2,200,674</text>
<text top="889" left="390" width="20" height="11" font="4">50.3</text>
<text top="889" left="483" width="66" height="11" font="4">Hyperlipidemia</text>
<text top="889" left="665" width="37" height="11" font="4">325,498</text>
<text top="889" left="778" width="20" height="11" font="4">56.9</text>
<text top="909" left="64" width="39" height="11" font="4">Diabetes</text>
<text top="909" left="271" width="46" height="11" font="4">2,027,875</text>
<text top="909" left="390" width="20" height="11" font="4">46.3</text>
<text top="909" left="483" width="33" height="11" font="4">Anemia</text>
<text top="909" left="665" width="37" height="11" font="4">284,102</text>
<text top="909" left="778" width="20" height="11" font="4">49.7</text>
<text top="928" left="64" width="34" height="11" font="4">Arthritis</text>
<text top="928" left="271" width="46" height="11" font="4">1,901,447</text>
<text top="928" left="390" width="20" height="11" font="4">43.5</text>
<text top="928" left="483" width="104" height="11" font="4">Chronic kidney disease</text>
<text top="928" left="665" width="37" height="11" font="4">257,015</text>
<text top="928" left="778" width="20" height="11" font="4">45.0</text>
<text top="948" left="64" width="104" height="11" font="4">Chronic kidney disease</text>
<text top="948" left="271" width="46" height="11" font="4">1,851,812</text>
<text top="948" left="390" width="20" height="11" font="4">42.3</text>
<text top="948" left="483" width="49" height="11" font="4">Depression</text>
<text top="948" left="665" width="37" height="11" font="4">207,082</text>
<text top="948" left="778" width="20" height="11" font="4">36.2</text>
<text top="967" left="64" width="25" height="11" font="4">COPD</text>
<text top="967" left="271" width="46" height="11" font="4">1,311,118</text>
<text top="967" left="390" width="20" height="11" font="4">30.0</text>
<text top="967" left="483" width="34" height="11" font="4">Arthritis</text>
<text top="967" left="665" width="37" height="11" font="4">201,964</text>
<text top="967" left="778" width="20" height="11" font="4">35.3</text>
<text top="986" left="64" width="70" height="11" font="4">Atrial fibrillation</text>
<text top="986" left="271" width="46" height="11" font="4">1,247,748</text>
<text top="986" left="390" width="20" height="11" font="4">28.5</text>
<text top="986" left="483" width="25" height="11" font="4">COPD</text>
<text top="986" left="665" width="37" height="11" font="4">191,016</text>
<text top="986" left="778" width="20" height="11" font="4">33.4</text>
<text top="1006" left="64" width="133" height="11" font="4">Alzheimer’s disease/dementia</text>
<text top="1006" left="271" width="46" height="11" font="4">1,207,704</text>
<text top="1006" left="390" width="20" height="11" font="4">27.6</text>
<text top="1006" left="483" width="33" height="11" font="4">Asthma</text>
<text top="1006" left="670" width="31" height="11" font="4">88,816</text>
<text top="1006" left="778" width="20" height="11" font="4">15.5</text>
<text top="1027" left="76" width="202" height="11" font="4">*Mean No. of conditions is 6.1; median is 6.</text>
<text top="1039" left="76" width="203" height="16" font="4"><a href="e147.full.html#57">yMean </a>No. of conditions is 5.5; median is 5.</text>
<text top="1057" left="76" width="458" height="11" font="4">Data source: Centers for Medicare and Medicaid Services administrative claims data, January 2011</text>
<text top="1054" left="534" width="265" height="16" font="4">December 2011, from the Chronic Condition Warehouse</text>
<text top="1072" left="64" width="30" height="11" font="4">(CCW),</text>
<text top="1072" left="98" width="81" height="11" font="5"><a href="http://ccwdata.org">ccwdata.org </a><a href="e147.full.html#84">(847)</a></text>
<text top="1072" left="179" width="3" height="11" font="4"><a href="e147.full.html#84">.</a></text>
<text top="1087" left="76" width="348" height="11" font="4">COPD indicates chronic obstructive pulmonary disease; and HF, heart failure.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e203</text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="348" height="15" font="13">10. Surgical/Percutaneous/Transcatheter</text>
<text top="124" left="64" width="267" height="15" font="13">Interventional Treatments of HF:</text>
<text top="144" left="64" width="151" height="15" font="13">Recommendations</text>
<text top="187" left="65" width="20" height="13" font="14">See</text>
<text top="187" left="91" width="52" height="13" font="15"><a href="e147.full.html#58">Table 32</a></text>
<text top="187" left="148" width="266" height="13" font="14">for a summary of recommendations from this</text>
<text top="205" left="64" width="43" height="13" font="14">section.</text>
<text top="230" left="64" width="37" height="8" font="17">CLASS I</text>
<text top="242" left="82" width="10" height="10" font="18">1.</text>
<text top="242" left="100" width="314" height="10" font="18">Coronary artery revascularization via CABG or percutaneous</text>
<text top="258" left="100" width="314" height="12" font="18">intervention is indicated for patients (HFpEF and HFrEF) on</text>
<text top="275" left="100" width="314" height="10" font="18">GDMT with angina and suitable coronary anatomy, espe-</text>
<text top="291" left="100" width="160" height="10" font="18">cially for a left main stenosis (</text>
<text top="288" left="260" width="155" height="16" font="18">&gt;50%) or left main equivalent</text>
<text top="308" left="100" width="40" height="10" font="18">disease</text>
<text top="308" left="144" width="83" height="10" font="5"><a href="e147.full.html#64">(10,12,14,848)</a></text>
<text top="308" left="227" width="120" height="12" font="18">. (Level of Evidence: C)</text>
<text top="332" left="64" width="45" height="8" font="17">CLASS IIa</text>
<text top="344" left="82" width="10" height="10" font="18">1.</text>
<text top="344" left="100" width="314" height="10" font="18">CABG to improve survival is reasonable in patients with mild</text>
<text top="360" left="100" width="314" height="10" font="18">to moderate LV systolic dysfunction (EF 35% to 50%) and</text>
<text top="377" left="100" width="25" height="10" font="18">signi</text>
<text top="373" left="125" width="289" height="16" font="18">ﬁcant (‡70% diameter stenosis) multivessel CAD or</text>
<text top="393" left="100" width="314" height="10" font="18">proximal left anterior descending coronary artery stenosis</text>
<text top="409" left="100" width="314" height="10" font="18">when viable myocardium is present in the region of intended</text>
<text top="426" left="100" width="89" height="10" font="18">revascularization</text>
<text top="426" left="192" width="26" height="10" font="5"><a href="e147.full.html#84">(848</a></text>
<text top="423" left="218" width="32" height="16" font="5"><a href="e147.full.html#84">–850)</a></text>
<text top="426" left="250" width="121" height="12" font="18"><a href="e147.full.html#84">. </a>(Level of Evidence: B)</text>
<text top="443" left="82" width="10" height="10" font="18">2.</text>
<text top="442" left="100" width="314" height="10" font="18">CABG or medical therapy is reasonable to improve morbidity</text>
<text top="459" left="100" width="314" height="10" font="18">and cardiovascular mortality for patients with severe LV</text>
<text top="475" left="100" width="82" height="10" font="18">dysfunction (EF</text>
<text top="472" left="185" width="166" height="16" font="18">&lt;35%), HF, and signiﬁcant CAD</text>
<text top="475" left="356" width="55" height="10" font="5"><a href="e147.full.html#71">(309,851)</a></text>
<text top="475" left="410" width="3" height="10" font="18">.</text>
<text top="492" left="100" width="113" height="12" font="18">(Level of Evidence: B)</text>
<text top="508" left="82" width="10" height="10" font="18">3.</text>
<text top="508" left="100" width="314" height="10" font="18">Surgical aortic valve replacement is reasonable for patients</text>
<text top="525" left="100" width="314" height="10" font="18">with critical aortic stenosis and a predicted surgical mortality</text>
<text top="541" left="100" width="120" height="10" font="18">of no greater than 10%</text>
<text top="541" left="224" width="30" height="10" font="5"><a href="e147.full.html#84">(852)</a></text>
<text top="541" left="254" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="558" left="82" width="10" height="10" font="18">4.</text>
<text top="557" left="100" width="314" height="10" font="18">Transcatheter aortic valve replacement after careful candi-</text>
<text top="574" left="100" width="314" height="10" font="18">date consideration is reasonable for patients with critical</text>
<text top="590" left="100" width="228" height="10" font="18">aortic stenosis who are deemed inoperable</text>
<text top="590" left="332" width="30" height="10" font="5"><a href="e147.full.html#84">(853)</a></text>
<text top="590" left="362" width="52" height="12" font="18">. (Level of</text>
<text top="607" left="100" width="65" height="12" font="18">Evidence: B)</text>
<text top="631" left="64" width="45" height="8" font="17">CLASS IIb</text>
<text top="643" left="82" width="10" height="10" font="18">1.</text>
<text top="643" left="100" width="314" height="10" font="18">CABG may be considered with the intent of improving</text>
<text top="659" left="100" width="314" height="10" font="18">survival in patients with ischemic heart disease with severe</text>
<text top="103" left="485" width="157" height="10" font="18">LV systolic dysfunction (EF</text>
<text top="100" left="651" width="149" height="16" font="18">&lt;35%) and operable coro-</text>
<text top="120" left="485" width="314" height="10" font="18">nary anatomy whether or not viable myocardium is present</text>
<text top="136" left="485" width="26" height="10" font="5"><a href="e147.full.html#71">(307</a></text>
<text top="133" left="511" width="32" height="16" font="5"><a href="e147.full.html#71">–309)</a></text>
<text top="136" left="543" width="121" height="12" font="18"><a href="e147.full.html#71">. </a>(Level of Evidence: B)</text>
<text top="153" left="468" width="10" height="10" font="18">2.</text>
<text top="153" left="485" width="314" height="10" font="18">Transcatheter mitral valve repair or mitral valve surgery for</text>
<text top="169" left="485" width="120" height="10" font="18">functional mitral insuf</text>
<text top="166" left="605" width="195" height="16" font="18">ﬁciency is of uncertain beneﬁt and</text>
<text top="185" left="485" width="314" height="10" font="18">should only be considered after careful candidate selection</text>
<text top="202" left="485" width="190" height="10" font="18">and with a background of GDMT</text>
<text top="202" left="683" width="26" height="10" font="5"><a href="e147.full.html#84">(854</a></text>
<text top="199" left="709" width="32" height="16" font="5"><a href="e147.full.html#84">–857)</a></text>
<text top="202" left="740" width="59" height="12" font="18">. (Level of</text>
<text top="219" left="485" width="65" height="12" font="18">Evidence: B)</text>
<text top="235" left="468" width="10" height="10" font="18">3.</text>
<text top="235" left="485" width="314" height="10" font="18">Surgical reverse remodeling or LV aneurysmectomy may be</text>
<text top="251" left="485" width="314" height="12" font="18">considered in carefully selected patients with HFrEF for</text>
<text top="268" left="485" width="28" height="10" font="18">speci</text>
<text top="264" left="513" width="286" height="16" font="18">ﬁc indications, including intractable HF and ventricular</text>
<text top="284" left="485" width="62" height="10" font="18">arrhythmias</text>
<text top="284" left="551" width="30" height="10" font="5"><a href="e147.full.html#84">(858)</a></text>
<text top="284" left="582" width="121" height="12" font="18"><a href="e147.full.html#84">. </a>(Level of Evidence: B)</text>
<text top="315" left="465" width="335" height="13" font="14">Surgical therapies and percutaneous interventions that are</text>
<text top="333" left="450" width="350" height="13" font="14">commonly integrated, or at least considered, in HF manage-</text>
<text top="351" left="450" width="350" height="13" font="14">ment include coronary revascularization (e.g, CABG, angio-</text>
<text top="369" left="450" width="350" height="13" font="14">plasty, stenting); aortic valve replacement; mitral valve</text>
<text top="387" left="450" width="350" height="13" font="14">replacement or repair; septal myectomy or alcohol septal</text>
<text top="405" left="450" width="350" height="13" font="14">ablation for hypertrophic cardiomyopathy; surgical ablation of</text>
<text top="423" left="450" width="350" height="13" font="14">ventricular arrhythmia; MCS; and cardiac transplantation</text>
<text top="441" left="450" width="105" height="13" font="15"><a href="e147.full.html#80">(675,680,859,860)</a></text>
<text top="441" left="555" width="245" height="13" font="14"><a href="e147.full.html#80">. </a>Surgical placement of ICDs or LV pacing</text>
<text top="459" left="450" width="350" height="13" font="14">leads is of historical importance but may be considered in</text>
<text top="477" left="450" width="294" height="13" font="14">situations where transvenous access is not feasible.</text>
<text top="495" left="465" width="335" height="13" font="14">The most common reason for intervention is CAD.</text>
<text top="513" left="450" width="350" height="13" font="14">Myocardial viability indicates the likelihood of improved</text>
<text top="531" left="450" width="350" height="13" font="14">outcomes with either surgical or medical therapy but does not</text>
<text top="549" left="450" width="252" height="13" font="14">identify patients with greater survival bene</text>
<text top="545" left="702" width="98" height="18" font="14">ﬁt from revascu-</text>
<text top="566" left="450" width="53" height="13" font="14">larization</text>
<text top="566" left="506" width="30" height="13" font="15"><a href="e147.full.html#71">(304)</a></text>
<text top="566" left="537" width="263" height="13" font="14"><a href="e147.full.html#71">. </a>The dictum of CABG for left main CAD and</text>
<text top="584" left="450" width="350" height="13" font="14">reduced LV function was considered absolute and subse-</text>
<text top="602" left="450" width="350" height="13" font="14">quently extrapolated to all severities of LV dysfunction</text>
<text top="620" left="450" width="82" height="13" font="14">without a con</text>
<text top="617" left="532" width="139" height="18" font="14">ﬁrmatory evidence base</text>
<text top="620" left="677" width="30" height="13" font="15"><a href="e147.full.html#84">(848)</a></text>
<text top="620" left="707" width="92" height="13" font="14">. Newer studies</text>
<text top="638" left="450" width="350" height="13" font="14">have addressed patients with multivessel CAD, HF, and at</text>
<text top="656" left="450" width="350" height="13" font="14">least moderately severe to severe LV systolic dysfunction</text>
<text top="707" left="108" width="556" height="12" font="9">Table 32. Recommendations for Surgical/Percutaneous/Transcatheter Interventional Treatments of HF</text>
<text top="739" left="108" width="82" height="11" font="4">Recommendations</text>
<text top="739" left="541" width="19" height="11" font="4">COR</text>
<text top="739" left="633" width="17" height="11" font="4">LOE</text>
<text top="739" left="701" width="50" height="11" font="4">References</text>
<text top="760" left="108" width="385" height="11" font="4">CABG or percutaneous intervention is indicated for HF patients on GDMT with angina</text>
<text top="775" left="120" width="376" height="11" font="4">and suitable coronary anatomy, especially significant left main stenosis or left main</text>
<text top="790" left="120" width="45" height="11" font="4">equivalent</text>
<text top="760" left="549" width="2" height="11" font="4">I</text>
<text top="760" left="639" width="6" height="11" font="4">C</text>
<text top="760" left="696" width="60" height="11" font="5"><a href="e147.full.html#64">10,12,14,848</a></text>
<text top="806" left="108" width="385" height="11" font="4">CABG to improve survival is reasonable in patients with mild to moderate LV systolic</text>
<text top="821" left="120" width="371" height="11" font="4">dysfunction and significant multivessel CAD or proximal LAD stenosis when viable</text>
<text top="836" left="120" width="103" height="11" font="4">myocardium is present</text>
<text top="806" left="545" width="10" height="11" font="4">IIa</text>
<text top="806" left="639" width="6" height="11" font="4">B</text>
<text top="806" left="706" width="40" height="11" font="5"><a href="e147.full.html#84">848–850</a></text>
<text top="853" left="108" width="389" height="11" font="4">CABG or medical therapy is reasonable to improve morbidity and mortality for patients</text>
<text top="868" left="120" width="139" height="11" font="4">with severe LV dysfunction (EF</text>
<text top="865" left="263" width="146" height="16" font="4">&lt;35%), HF, and significant CAD</text>
<text top="853" left="545" width="10" height="11" font="4">IIa</text>
<text top="853" left="639" width="6" height="11" font="4">B</text>
<text top="853" left="708" width="17" height="11" font="5"><a href="e147.full.html#71">309</a></text>
<text top="853" left="725" width="3" height="11" font="4"><a href="e147.full.html#71">,</a></text>
<text top="853" left="728" width="17" height="11" font="5"><a href="e147.full.html#84">851</a></text>
<text top="884" left="108" width="389" height="11" font="4">Surgical aortic valve replacement is reasonable for patients with critical aortic stenosis</text>
<text top="899" left="120" width="262" height="11" font="4">and a predicted surgical mortality of no greater than 10%</text>
<text top="884" left="545" width="10" height="11" font="4">IIa</text>
<text top="884" left="639" width="6" height="11" font="4">B</text>
<text top="884" left="718" width="17" height="11" font="5"><a href="e147.full.html#84">852</a></text>
<text top="915" left="108" width="379" height="11" font="4">Transcatheter aortic valve replacement is reasonable for patients with critical aortic</text>
<text top="930" left="120" width="166" height="11" font="4">stenosis who are deemed inoperable</text>
<text top="915" left="545" width="10" height="11" font="4">IIa</text>
<text top="915" left="639" width="6" height="11" font="4">B</text>
<text top="915" left="718" width="17" height="11" font="5"><a href="e147.full.html#84">853</a></text>
<text top="947" left="108" width="384" height="11" font="4">CABG may be considered in patients with ischemic heart disease, severe LV systolic</text>
<text top="962" left="120" width="370" height="11" font="4">dysfunction, and operable coronary anatomy whether or not viable myocardium is</text>
<text top="977" left="120" width="33" height="11" font="4">present</text>
<text top="947" left="545" width="10" height="11" font="4">IIb</text>
<text top="947" left="639" width="6" height="11" font="4">B</text>
<text top="947" left="706" width="40" height="11" font="5"><a href="e147.full.html#71">307–309</a></text>
<text top="993" left="108" width="345" height="11" font="4">Transcatheter mitral valve repair or mitral valve surgery for functional mitral</text>
<text top="1008" left="120" width="158" height="11" font="4">insufficiency is of uncertain benefit</text>
<text top="993" left="545" width="10" height="11" font="4">IIb</text>
<text top="993" left="639" width="6" height="11" font="4">B</text>
<text top="993" left="706" width="40" height="11" font="5"><a href="e147.full.html#84">854–857</a></text>
<text top="1025" left="108" width="380" height="11" font="4">Surgical reverse remodeling or LV aneurysmectomy may be considered in HFrEF for</text>
<text top="1039" left="120" width="325" height="11" font="4">specific indications, including intractable HF and ventricular arrhythmias</text>
<text top="1025" left="545" width="10" height="11" font="4">IIb</text>
<text top="1025" left="639" width="6" height="11" font="4">B</text>
<text top="1025" left="718" width="17" height="11" font="5"><a href="e147.full.html#84">858</a></text>
<text top="1061" left="120" width="637" height="11" font="4">CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COR, Class of Recommendation; EF, ejection fraction; GDMT,</text>
<text top="1076" left="108" width="649" height="11" font="4">guideline-directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LAD, left anterior descending; LOE, Level</text>
<text top="1091" left="108" width="164" height="11" font="4">of Evidence; and LV, left ventricular.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e204</text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="55" height="13" font="15"><a href="e147.full.html#84">(861,862)</a></text>
<text top="103" left="120" width="294" height="13" font="14"><a href="e147.full.html#84">. </a>Both surgical and medical therapies have similar</text>
<text top="121" left="64" width="350" height="13" font="14">outcomes, and decisions about revascularization should be</text>
<text top="139" left="64" width="350" height="13" font="14">made jointly by the HF team and cardiothoracic surgeon. The</text>
<text top="157" left="64" width="350" height="13" font="14">most important considerations in the decision to proceed with</text>
<text top="175" left="64" width="350" height="13" font="14">a surgical or interventional approach include coronary</text>
<text top="193" left="64" width="350" height="13" font="14">anatomy that is amenable to revascularization and appropriate</text>
<text top="211" left="64" width="350" height="13" font="14">concomitant GDMT. Valvular heart disease is not an infre-</text>
<text top="229" left="64" width="350" height="13" font="14">quent cause of HF; however, when valvular disease is</text>
<text top="247" left="64" width="350" height="13" font="14">managed correctly and pre-emptively, its adverse conse-</text>
<text top="265" left="64" width="350" height="13" font="14">quences on ventricular mechanics can be ameliorated. The</text>
<text top="283" left="64" width="350" height="13" font="14">advent of effective transcatheter approaches to both mitral and</text>
<text top="301" left="64" width="350" height="13" font="14">aortic disease creates the need for greater considerations of</text>
<text top="319" left="64" width="350" height="13" font="14">structural interventions for patients with LV systolic dys-</text>
<text top="337" left="64" width="350" height="13" font="14">function and valvular heart disease. To date, the surgical or</text>
<text top="354" left="64" width="305" height="13" font="14">transcatheter management of functional mitral insuf</text>
<text top="351" left="369" width="44" height="18" font="14">ﬁciency</text>
<text top="372" left="64" width="350" height="13" font="14">has not been proven superior to medical therapy. A decision</text>
<text top="390" left="64" width="350" height="13" font="14">to intervene in functional mitral regurgitation should be made</text>
<text top="408" left="64" width="350" height="13" font="14">on a case-by-case basis, and consideration should be given to</text>
<text top="426" left="64" width="350" height="13" font="14">participation in clinical trials and/or databases. The surgical or</text>
<text top="444" left="64" width="350" height="13" font="14">transcatheter management of critical aortic stenosis is an</text>
<text top="462" left="64" width="350" height="13" font="14">effective strategy with reasonable outcomes noted even in</text>
<text top="480" left="64" width="163" height="13" font="14">patients with advanced age (</text>
<text top="476" left="227" width="187" height="18" font="14">&gt;80 years). Indications for other</text>
<text top="498" left="64" width="350" height="13" font="14">surgical or percutaneous interventions in the setting of HF are</text>
<text top="516" left="64" width="350" height="13" font="14">driven by other relevant guidelines or other sections of this</text>
<text top="534" left="64" width="350" height="13" font="14">guideline, including myomectomy for hypertrophic cardio-</text>
<text top="552" left="64" width="350" height="13" font="14">myopathy, surgical or electrophysiological procedures for AF,</text>
<text top="570" left="64" width="314" height="13" font="14">nondurable or durable MCS, and heart transplantation.</text>
<text top="588" left="79" width="335" height="13" font="14">Several procedures under evaluation hold promise but are</text>
<text top="606" left="64" width="18" height="13" font="14">not</text>
<text top="606" left="95" width="17" height="13" font="14">yet</text>
<text top="606" left="126" width="64" height="13" font="14">appropriate</text>
<text top="606" left="203" width="16" height="13" font="14">for</text>
<text top="606" left="232" width="6" height="13" font="14">a</text>
<text top="606" left="252" width="93" height="13" font="14">guideline-driven</text>
<text top="606" left="358" width="56" height="13" font="14">indication</text>
<text top="623" left="64" width="5" height="13" font="14">(</text>
<text top="623" left="69" width="53" height="13" font="15"><a href="e147.full.html#59">Table 33</a></text>
<text top="623" left="122" width="292" height="13" font="14">). This includes revascularization as a means to</text>
<text top="103" left="450" width="350" height="13" font="14">support cellular regenerative therapies. For patients willing to</text>
<text top="121" left="450" width="350" height="13" font="14">consider regenerative technologies, the ideal strategy is</text>
<text top="139" left="450" width="350" height="13" font="14">referral to an enrolling clinical trial at a center experienced</text>
<text top="157" left="450" width="350" height="13" font="14">in both high-risk revascularization and cell-based science</text>
<text top="175" left="450" width="26" height="13" font="15"><a href="e147.full.html#84">(863</a></text>
<text top="171" left="476" width="33" height="18" font="15"><a href="e147.full.html#84">–865)</a></text>
<text top="175" left="509" width="291" height="13" font="14"><a href="e147.full.html#84">. </a>Surgical reverse-ventricular remodeling (ventric-</text>
<text top="193" left="450" width="287" height="13" font="14">ular reconstruction) does not appear to be of bene</text>
<text top="189" left="737" width="63" height="18" font="14">ﬁt but may</text>
<text top="211" left="450" width="350" height="13" font="14">be considered in carefully selected patients with HFrEF for</text>
<text top="229" left="450" width="29" height="13" font="14">speci</text>
<text top="225" left="479" width="321" height="18" font="14">ﬁed indications, including retractable HF and ventricular</text>
<text top="247" left="450" width="67" height="13" font="14">arrhythmias</text>
<text top="247" left="521" width="30" height="13" font="15"><a href="e147.full.html#84">(858)</a></text>
<text top="247" left="552" width="4" height="13" font="14"><a href="e147.full.html#84">.</a></text>
<text top="286" left="450" width="286" height="15" font="13">11. Coordinating Care for Patients</text>
<text top="307" left="450" width="131" height="15" font="13">With Chronic HF</text>
<text top="349" left="450" width="313" height="14" font="16">11.1. Coordinating Care for Patients With</text>
<text top="368" left="450" width="228" height="14" font="16">Chronic HF: Recommendations</text>
<text top="395" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="407" left="468" width="10" height="10" font="18">1.</text>
<text top="407" left="485" width="314" height="10" font="18">Effective systems of care coordination with special atten-</text>
<text top="423" left="485" width="314" height="10" font="18">tion to care transitions should be deployed for every patient</text>
<text top="440" left="485" width="314" height="10" font="18">with chronic HF that facilitate and ensure effective care that</text>
<text top="456" left="485" width="314" height="10" font="18">is designed to achieve GDMT and prevent hospitalization</text>
<text top="472" left="485" width="86" height="10" font="5"><a href="e147.full.html#66">(80,82,793,870</a></text>
<text top="469" left="571" width="32" height="16" font="5"><a href="e147.full.html#66">–884)</a></text>
<text top="472" left="603" width="121" height="12" font="18"><a href="e147.full.html#66">. </a>(Level of Evidence: B)</text>
<text top="489" left="468" width="10" height="10" font="18">2.</text>
<text top="489" left="485" width="314" height="10" font="18">Every patient with HF should have a clear, detailed, and</text>
<text top="505" left="485" width="314" height="10" font="18">evidence-based plan of care that ensures the achievement</text>
<text top="522" left="485" width="314" height="10" font="18">of GDMT goals, effective management of comorbid condi-</text>
<text top="538" left="485" width="314" height="10" font="18">tions, timely follow-up with the healthcare team, appropriate</text>
<text top="555" left="485" width="36" height="10" font="18">dietary</text>
<text top="555" left="532" width="19" height="10" font="18">and</text>
<text top="555" left="561" width="135" height="10" font="18">physical activities, and</text>
<text top="555" left="707" width="93" height="10" font="18">compliance with</text>
<text top="571" left="485" width="314" height="10" font="18">secondary prevention guidelines for cardiovascular disease.</text>
<text top="588" left="485" width="314" height="10" font="18">This plan of care should be updated regularly and made</text>
<text top="604" left="485" width="246" height="10" font="18">readily available to all members of each patient</text>
<text top="601" left="731" width="68" height="16" font="18">’s healthcare</text>
<text top="620" left="485" width="27" height="10" font="18">team</text>
<text top="620" left="516" width="23" height="10" font="5"><a href="e147.full.html#64">(13)</a></text>
<text top="620" left="539" width="120" height="12" font="18">. (Level of Evidence: C)</text>
<text top="637" left="468" width="10" height="10" font="18">3.</text>
<text top="637" left="485" width="314" height="10" font="18">Palliative and supportive care is effective for patients with</text>
<text top="653" left="485" width="314" height="10" font="18">symptomatic advanced HF to improve quality of life</text>
<text top="670" left="485" width="43" height="10" font="5"><a href="e147.full.html#65">(30,885</a></text>
<text top="667" left="529" width="32" height="16" font="5"><a href="e147.full.html#65">–888)</a></text>
<text top="670" left="560" width="121" height="12" font="18">. (Level of Evidence: B)</text>
<text top="695" left="465" width="335" height="13" font="14">Education, support, and involvement of patients with HF</text>
<text top="713" left="450" width="350" height="13" font="14">and their families are critical and often complex, especially</text>
<text top="731" left="450" width="350" height="13" font="14">during transitions of care. Failure to understand and follow</text>
<text top="749" left="450" width="350" height="13" font="14">a detailed and often nuanced plan of care likely contributes to</text>
<text top="767" left="450" width="350" height="13" font="14">the high rates of HF 30-day rehospitalization and mortality</text>
<text top="785" left="450" width="177" height="13" font="14">seen across the United States</text>
<text top="785" left="634" width="48" height="13" font="15"><a href="e147.full.html#65">(61,889)</a></text>
<text top="785" left="682" width="117" height="13" font="14">. One critical inter-</text>
<text top="803" left="450" width="350" height="13" font="14">vention to ensure effective care coordination and transition is</text>
<text top="821" left="450" width="350" height="13" font="14">the provision of a comprehensive plan of care, with easily</text>
<text top="839" left="450" width="350" height="13" font="14">understood, culturally sensitive, and evidence-based educa-</text>
<text top="857" left="450" width="350" height="13" font="14">tional materials, to patients with HF and/or caregivers during</text>
<text top="874" left="450" width="117" height="13" font="14">both hospital and of</text>
<text top="871" left="567" width="232" height="18" font="14">ﬁce-based encounters. A comprehensive</text>
<text top="892" left="450" width="350" height="13" font="14">plan of care should promote successful patient self-care</text>
<text top="910" left="450" width="80" height="13" font="15"><a href="e147.full.html#84">(870,884,890)</a></text>
<text top="910" left="530" width="269" height="13" font="14"><a href="e147.full.html#84">. </a>Hence, the plan of care for patients with HF</text>
<text top="928" left="450" width="350" height="13" font="14">should continuously address in detail a number of complex</text>
<text top="946" left="450" width="350" height="13" font="14">issues, including adherence to GDMT, timely follow-up with</text>
<text top="964" left="450" width="294" height="13" font="14">the healthcare professionals who manage the patient</text>
<text top="960" left="744" width="56" height="18" font="14">’s HF and</text>
<text top="982" left="450" width="350" height="13" font="14">associated comorbidities, appropriate dietary and physical</text>
<text top="1000" left="450" width="350" height="13" font="14">activities, including cardiac rehabilitation, and adherence to</text>
<text top="1018" left="450" width="350" height="13" font="14">an extensive list of secondary prevention recommendations</text>
<text top="1036" left="450" width="350" height="13" font="14">based on established guidelines for cardiovascular disease</text>
<text top="1054" left="450" width="5" height="13" font="14"><a href="e147.full.html#60">(</a></text>
<text top="1054" left="454" width="59" height="13" font="15"><a href="e147.full.html#60">Table 34</a></text>
<text top="1054" left="513" width="287" height="13" font="14"><a href="e147.full.html#60">). </a>Clinicians must maintain vigilance about</text>
<text top="1072" left="450" width="350" height="13" font="14">psychosocial, behavioral, and socioeconomic issues that</text>
<text top="1090" left="450" width="350" height="13" font="14">patients with HF and their caregivers face, including</text>
<text top="683" left="64" width="331" height="12" font="9">Table 33. Surgical/Percutaneous/Transcatheter Interventions</text>
<text top="700" left="64" width="104" height="12" font="9">in Patients With HF</text>
<text top="731" left="364" width="50" height="11" font="4">References</text>
<text top="751" left="64" width="243" height="11" font="4">Appropriate Guideline-Directed Surgical/Percutaneous/</text>
<text top="766" left="77" width="153" height="11" font="4">Transcatheter Interventions for HF</text>
<text top="785" left="76" width="207" height="11" font="4">1. Surgical or percutaneous revascularization</text>
<text top="785" left="369" width="11" height="11" font="5"><a href="e147.full.html#64">10</a></text>
<text top="785" left="381" width="3" height="11" font="4"><a href="e147.full.html#64">,</a></text>
<text top="785" left="383" width="11" height="11" font="5"><a href="e147.full.html#64">12</a></text>
<text top="785" left="395" width="3" height="11" font="4"><a href="e147.full.html#64">,</a></text>
<text top="785" left="398" width="11" height="11" font="5"><a href="e147.full.html#64">14</a></text>
<text top="805" left="76" width="242" height="11" font="4">2. Surgical or transcatheter aortic valve replacement</text>
<text top="805" left="371" width="17" height="11" font="5"><a href="e147.full.html#84">852</a></text>
<text top="805" left="388" width="3" height="11" font="4"><a href="e147.full.html#84">,</a></text>
<text top="805" left="391" width="17" height="11" font="5"><a href="e147.full.html#84">853</a></text>
<text top="824" left="76" width="219" height="11" font="4">3. Surgical myomectomy or alcohol ablation for</text>
<text top="839" left="104" width="129" height="11" font="4">hypertrophic cardiomyopathy</text>
<text top="824" left="383" width="11" height="11" font="5"><a href="e147.full.html#64">11</a></text>
<text top="859" left="76" width="192" height="11" font="4">4. Nondurable MCS for cardiogenic shock</text>
<text top="859" left="369" width="40" height="11" font="5"><a href="e147.full.html#79">668–671</a></text>
<text top="878" left="76" width="153" height="11" font="4">5. Durable MCS for advanced HF</text>
<text top="878" left="369" width="40" height="11" font="5"><a href="e147.full.html#80">672–675</a></text>
<text top="897" left="76" width="110" height="11" font="4">6. Heart transplantation</text>
<text top="897" left="381" width="17" height="11" font="5"><a href="e147.full.html#80">680</a></text>
<text top="917" left="76" width="244" height="11" font="4">7. Surgical/electrophysiological ablation of ventricular</text>
<text top="932" left="104" width="51" height="11" font="4">tachycardia</text>
<text top="917" left="381" width="17" height="11" font="5"><a href="e147.full.html#84">866</a></text>
<text top="951" left="64" width="254" height="11" font="4">Surgical/Percutaneous/Transcatheter Interventions Under</text>
<text top="966" left="77" width="136" height="11" font="4">Evaluation in Patients With HF</text>
<text top="986" left="76" width="226" height="11" font="4">1. Transcatheter intervention for functional mitral</text>
<text top="1001" left="104" width="55" height="11" font="4">insufficiency</text>
<text top="986" left="369" width="17" height="11" font="5"><a href="e147.full.html#84">854</a></text>
<text top="986" left="386" width="6" height="11" font="4"><a href="e147.full.html#84">–</a></text>
<text top="986" left="392" width="17" height="11" font="5"><a href="e147.full.html#84">857</a></text>
<text top="1020" left="76" width="242" height="11" font="4">2. Left atrial resection/left atrial appendage removal,</text>
<text top="1035" left="104" width="145" height="11" font="4">surgical or percutaneous, for AF</text>
<text top="1020" left="381" width="17" height="11" font="5"><a href="e147.full.html#84">867</a></text>
<text top="1054" left="76" width="224" height="11" font="4">3. MCS for advanced HF as a bridge to recovery</text>
<text top="1054" left="371" width="17" height="11" font="5"><a href="e147.full.html#84">868</a></text>
<text top="1054" left="388" width="3" height="11" font="4"><a href="e147.full.html#84">,</a></text>
<text top="1054" left="391" width="17" height="11" font="5"><a href="e147.full.html#84">869</a></text>
<text top="1076" left="76" width="338" height="11" font="4">AF indicates atrial fibrillation; HF, heart failure; and MCS, mechanical circulatory</text>
<text top="1091" left="64" width="35" height="11" font="4">support.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e205</text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="283" height="12" font="9">Table 34. Plan of Care for Patients With Chronic HF</text>
<text top="135" left="64" width="56" height="11" font="4">Plan of Care</text>
<text top="135" left="427" width="168" height="11" font="4">Relevant Guideline Section/Reference</text>
<text top="154" left="64" width="209" height="11" font="4">Guideline-directed medical and device therapy</text>
<text top="174" left="76" width="79" height="11" font="4">ACE inhibitor/ARB</text>
<text top="174" left="427" width="73" height="11" font="5"><a href="e147.full.html#28">Sections 7.3.2.2</a></text>
<text top="174" left="504" width="16" height="11" font="4">and</text>
<text top="174" left="524" width="31" height="11" font="5"><a href="e147.full.html#29">7.3.2.3</a></text>
<text top="193" left="76" width="57" height="11" font="4">Beta blocker</text>
<text top="193" left="427" width="68" height="11" font="5"><a href="e147.full.html#30">Section 7.3.2.4</a></text>
<text top="213" left="76" width="143" height="11" font="4">Aldosterone receptor antagonist</text>
<text top="213" left="427" width="68" height="11" font="5"><a href="e147.full.html#31">Section 7.3.2.5</a></text>
<text top="232" left="76" width="34" height="11" font="4">Diuretic</text>
<text top="232" left="427" width="73" height="11" font="5"><a href="e147.full.html#27">Sections 7.3.2.1</a></text>
<text top="232" left="504" width="16" height="11" font="4">and</text>
<text top="232" left="524" width="14" height="11" font="5"><a href="e147.full.html#49">8.4</a></text>
<text top="251" left="76" width="161" height="11" font="4">Hydralazine and isosorbide dinitrate</text>
<text top="251" left="427" width="68" height="11" font="5"><a href="e147.full.html#33">Section 7.3.2.6</a></text>
<text top="271" left="76" width="33" height="11" font="4">Digoxin</text>
<text top="271" left="427" width="68" height="11" font="5"><a href="e147.full.html#33">Section 7.3.2.7</a></text>
<text top="290" left="76" width="205" height="11" font="4">Discontinuation of drugs that may worsen HF</text>
<text top="290" left="427" width="68" height="11" font="5"><a href="e147.full.html#36">Section 7.3.2.9</a></text>
<text top="310" left="76" width="161" height="11" font="4">Biomarker-related therapeutic goals</text>
<text top="310" left="427" width="51" height="11" font="5"><a href="e147.full.html#17">Section 6.3</a></text>
<text top="329" left="76" width="161" height="11" font="4">HF-related devices (MCS, CRT, ICD)</text>
<text top="329" left="427" width="64" height="11" font="5"><a href="e147.full.html#37">Sections 7.3.4</a></text>
<text top="329" left="496" width="16" height="11" font="4">and</text>
<text top="329" left="516" width="23" height="11" font="5"><a href="e147.full.html#45">7.4.5</a></text>
<text top="349" left="64" width="186" height="11" font="4">Management of comorbidities (examples)</text>
<text top="368" left="76" width="104" height="11" font="4">Ischemic heart disease</text>
<text top="368" left="427" width="143" height="11" font="4">2012 ACCF/AHA SIHD Guideline</text>
<text top="368" left="574" width="17" height="11" font="5"><a href="e147.full.html#64">(14)</a></text>
<text top="388" left="76" width="109" height="11" font="4">Antithrombotic therapies</text>
<text top="388" left="427" width="77" height="11" font="5"><a href="e147.full.html#34">Section 7.3.2.8.1</a></text>
<text top="407" left="76" width="119" height="11" font="4">Arrhythmia/arrhythmia risk</text>
<text top="407" left="427" width="82" height="11" font="5"><a href="e147.full.html#36">Sections 7.3.2.9.2</a></text>
<text top="407" left="513" width="16" height="11" font="4">and</text>
<text top="407" left="533" width="14" height="11" font="5"><a href="e147.full.html#54">9.1</a></text>
<text top="426" left="76" width="58" height="11" font="4">Hypertension</text>
<text top="426" left="427" width="60" height="11" font="5"><a href="e147.full.html#22">Section 7.1.1</a></text>
<text top="426" left="487" width="39" height="11" font="4"><a href="e147.full.html#22">, </a>JNC-VII</text>
<text top="426" left="530" width="17" height="11" font="5"><a href="e147.full.html#65">(27)</a></text>
<text top="446" left="76" width="77" height="11" font="4">Diabetes mellitus</text>
<text top="446" left="427" width="94" height="11" font="4">2012 ADA Standards</text>
<text top="446" left="525" width="17" height="11" font="5"><a href="e147.full.html#66">(90)</a></text>
<text top="465" left="76" width="91" height="11" font="4">Chronic renal failure</text>
<text top="465" left="427" width="51" height="11" font="5"><a href="e147.full.html#50">Section 8.5</a></text>
<text top="485" left="76" width="174" height="11" font="4">Chronic obstructive pulmonary disease</text>
<text top="485" left="427" width="138" height="11" font="4">2011 ACCP/ATS/ERS Guideline</text>
<text top="485" left="569" width="23" height="11" font="5"><a href="e147.full.html#85">(908)</a></text>
<text top="504" left="76" width="304" height="11" font="4">Secondary prevention interventions (e.g., lipids, smoking cessation,</text>
<text top="519" left="88" width="173" height="11" font="4">influenza and pneumococcal vaccines)</text>
<text top="504" left="427" width="334" height="11" font="4">2011 AHA/ACCF Secondary Prevention and Risk Reduction Guidelines and</text>
<text top="519" left="447" width="210" height="11" font="4">Centers for Disease Control Adult Vaccinations</text>
<text top="519" left="660" width="57" height="11" font="5"><a href="e147.full.html#64">(13,909,910)</a></text>
<text top="538" left="64" width="108" height="11" font="4">Patient/family education</text>
<text top="558" left="76" width="196" height="11" font="4">Diet and fluid restriction, weight monitoring</text>
<text top="558" left="427" width="149" height="11" font="5"><a href="e147.full.html#25">Sections 7.3.1.1, 7.3.1.3, 7.3.1.5</a></text>
<text top="558" left="577" width="23" height="11" font="4"><a href="e147.full.html#25">, </a>and</text>
<text top="558" left="604" width="23" height="11" font="5"><a href="e147.full.html#44">7.4.3</a></text>
<text top="577" left="76" width="228" height="11" font="4">Recognizing signs and symptoms of worsening HF</text>
<text top="577" left="427" width="39" height="11" font="5"><a href="e147.full.html#43">Table 24</a></text>
<text top="597" left="76" width="142" height="11" font="4">Risk assessment and prognosis</text>
<text top="597" left="427" width="98" height="11" font="5"><a href="e147.full.html#9">Sections 3, 4.6, 6.1.2</a></text>
<text top="616" left="76" width="75" height="11" font="4">QOL assessment</text>
<text top="616" left="427" width="216" height="11" font="4">2012 AHA Scientific Statement on Advanced HF</text>
<text top="616" left="647" width="17" height="11" font="5"><a href="e147.full.html#65">(30)</a></text>
<text top="636" left="76" width="305" height="11" font="4">Advance care planning (e.g., palliative care and advance directives)</text>
<text top="636" left="427" width="98" height="11" font="5"><a href="e147.full.html#61">Section 11.3 </a><a href="e147.full.html#65">(30,888)</a></text>
<text top="655" left="76" width="148" height="11" font="4">CPR training for family members</text>
<text top="655" left="427" width="120" height="11" font="4">AHA Family &amp; Friends CPR</text>
<text top="655" left="551" width="23" height="11" font="5"><a href="e147.full.html#85">(911)</a></text>
<text top="674" left="76" width="64" height="11" font="4">Social support</text>
<text top="674" left="427" width="68" height="11" font="5"><a href="e147.full.html#25">Section 7.3.1.2</a></text>
<text top="694" left="64" width="168" height="11" font="4">Physical activity/cardiac rehabilitation</text>
<text top="713" left="76" width="77" height="11" font="4">Exercise regimen</text>
<text top="713" left="427" width="73" height="11" font="5"><a href="e147.full.html#26">Sections 7.3.1.5</a></text>
<text top="713" left="504" width="16" height="11" font="4">and</text>
<text top="713" left="524" width="31" height="11" font="5"><a href="e147.full.html#26">7.3.1.6</a></text>
<text top="733" left="76" width="104" height="11" font="4">Activities of daily living</text>
<text top="733" left="427" width="68" height="11" font="5"><a href="e147.full.html#26">Section 7.3.1.6</a></text>
<text top="752" left="76" width="214" height="11" font="4">Functional status assessment and classification</text>
<text top="752" left="427" width="42" height="11" font="5"><a href="e147.full.html#9">Section 3</a></text>
<text top="772" left="64" width="91" height="11" font="4">Psychosocial factors</text>
<text top="791" left="76" width="86" height="11" font="4">Sex-specific issues</text>
<text top="791" left="427" width="349" height="11" font="4">2011 AHA Guidelines for the Prevention of Cardiovascular Disease in Women</text>
<text top="791" left="780" width="23" height="11" font="5"><a href="e147.full.html#85">(912)</a></text>
<text top="810" left="76" width="65" height="11" font="4">Sexual activity</text>
<text top="810" left="427" width="223" height="11" font="4">2012 AHA Scientific Statement on Sexual Activity</text>
<text top="810" left="654" width="23" height="11" font="5"><a href="e147.full.html#85">(913)</a></text>
<text top="830" left="76" width="96" height="11" font="4">Depression screening</text>
<text top="830" left="427" width="212" height="11" font="4">U.S. Preventive Services Task Force Guidelines</text>
<text top="830" left="644" width="23" height="11" font="5"><a href="e147.full.html#85">(914)</a></text>
<text top="849" left="64" width="185" height="11" font="4">Clinician follow-up and care coordination</text>
<text top="869" left="76" width="193" height="11" font="4">Cardiologists and other relevant specialists</text>
<text top="869" left="427" width="336" height="11" font="4">2000 AHA Scientific Statement for Team Management of Patients With HF</text>
<text top="869" left="767" width="23" height="11" font="5"><a href="e147.full.html#85">(900)</a></text>
<text top="888" left="76" width="103" height="11" font="4">Primary care physician</text>
<text top="888" left="427" width="207" height="11" font="4">NQF Preferred Practices for Care Coordination</text>
<text top="888" left="638" width="23" height="11" font="5"><a href="e147.full.html#85">(898)</a></text>
<text top="908" left="76" width="111" height="11" font="4">Advanced practice nurse</text>
<text top="908" left="427" width="83" height="11" font="5"><a href="e147.full.html#59">Section 11.1–11.3</a></text>
<text top="908" left="510" width="248" height="11" font="4"><a href="e147.full.html#59">, </a>Joint Commission 2013 National Patient Safety Goals</text>
<text top="908" left="762" width="23" height="11" font="5"><a href="e147.full.html#85">(915)</a></text>
<text top="927" left="64" width="200" height="11" font="4">Other healthcare providers (e.g., home care)</text>
<text top="946" left="76" width="479" height="11" font="4">Medication reconciliation Establishment of electronic personal health records HHS Meaningful Use Criteria</text>
<text top="966" left="64" width="278" height="11" font="4">Socioeconomic and cultural factors Culturally sensitive issues</text>
<text top="966" left="427" width="353" height="11" font="4">NQF: A Comprehensive Framework and Preferred Practices for Measuring and</text>
<text top="981" left="447" width="139" height="11" font="4">Reporting Cultural Competency</text>
<text top="981" left="590" width="23" height="11" font="5"><a href="e147.full.html#85">(916)</a></text>
<text top="1000" left="76" width="131" height="11" font="4">Education and health literacy</text>
<text top="1000" left="427" width="68" height="11" font="5"><a href="e147.full.html#25">Section 7.3.1.1</a></text>
<text top="1020" left="76" width="64" height="11" font="4">Social support</text>
<text top="1020" left="427" width="68" height="11" font="5"><a href="e147.full.html#25">Section 7.3.1.2</a></text>
<text top="1041" left="76" width="723" height="11" font="4">ACCF indicates American College of Cardiology Foundation; ACCP, American College of Chest Physicians; ACE, angiotensin-converting enzyme; ADA, American</text>
<text top="1056" left="64" width="735" height="11" font="4">Diabetes Association; AHA, American Heart Association; ARB, angiotensin-receptor blocker; ATS, American Thoracic Society; CPR, cardiopulmonary resuscitation; CRT,</text>
<text top="1071" left="64" width="735" height="11" font="4">cardiac resynchronization therapy; ERS, European Respiratory Society; HF, heart failure; HHS, Health and Human Services; ICD, implantable cardioverter-defibrillator;</text>
<text top="1086" left="64" width="728" height="11" font="4">JNC, Joint National Committee; MCS, mechanical circulatory support; NQF, National Quality Forum; QOL, quality of life; and SIHD, stable ischemic heart disease.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e206</text>
</page>
<page number="61" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">access to care, risk of depression, and healthcare disparities</text>
<text top="121" left="64" width="51" height="13" font="15"><a href="e147.full.html#79">(639,891</a></text>
<text top="117" left="115" width="33" height="18" font="15"><a href="e147.full.html#79">–895)</a></text>
<text top="121" left="148" width="266" height="13" font="14"><a href="e147.full.html#79">. </a>For example, patients with HF who live in</text>
<text top="139" left="64" width="350" height="13" font="14">skilled nursing facilities are at higher risk for adverse events,</text>
<text top="157" left="64" width="177" height="13" font="14">with a 1-year mortality rate</text>
<text top="153" left="251" width="37" height="18" font="14">&gt;50%</text>
<text top="157" left="297" width="30" height="13" font="15"><a href="e147.full.html#85">(896)</a></text>
<text top="157" left="327" width="87" height="13" font="14">. Furthermore,</text>
<text top="175" left="64" width="350" height="13" font="14">community-dwelling patients with HF are often unable to</text>
<text top="193" left="64" width="350" height="13" font="14">afford the large number of medications prescribed, thereby</text>
<text top="211" left="64" width="253" height="13" font="14">leading to suboptimal medication adherence</text>
<text top="211" left="322" width="30" height="13" font="15"><a href="e147.full.html#85">(897)</a></text>
<text top="211" left="352" width="4" height="13" font="14">.</text>
<text top="245" left="64" width="298" height="14" font="16">11.2. Systems of Care to Promote Care</text>
<text top="264" left="64" width="315" height="14" font="16">Coordination for Patients With Chronic HF</text>
<text top="283" left="65" width="349" height="13" font="14">Improved communication between clinicians and nurses,</text>
<text top="301" left="64" width="62" height="13" font="14">medication</text>
<text top="301" left="140" width="80" height="13" font="14">reconciliation,</text>
<text top="301" left="234" width="50" height="13" font="14">carefully</text>
<text top="301" left="297" width="45" height="13" font="14">planned</text>
<text top="301" left="356" width="58" height="13" font="14">transitions</text>
<text top="319" left="64" width="350" height="13" font="14">between care settings, and consistent documentation are</text>
<text top="337" left="64" width="350" height="13" font="14">examples of patient safety standards that should be ensured</text>
<text top="355" left="64" width="350" height="13" font="14">for all patients with HF. The National Quality Forum has also</text>
<text top="373" left="64" width="203" height="13" font="14">endorsed a set of patient-centered</text>
<text top="369" left="275" width="139" height="18" font="14">“Preferred Practices for</text>
<text top="391" left="64" width="110" height="13" font="14">Care Coordination,</text>
<text top="387" left="174" width="6" height="18" font="14">”</text>
<text top="391" left="186" width="30" height="13" font="15"><a href="e147.full.html#85">(898)</a></text>
<text top="391" left="223" width="191" height="13" font="14">which detail comprehensive spe-</text>
<text top="409" left="64" width="10" height="13" font="14">ci</text>
<text top="405" left="74" width="340" height="18" font="14">ﬁcations for successful care coordination for patients and</text>
<text top="427" left="64" width="79" height="13" font="14">their families.</text>
<text top="445" left="79" width="335" height="13" font="14">Systems of care designed to support patients with HF and</text>
<text top="463" left="64" width="239" height="13" font="14">other cardiac diseases can produce a signi</text>
<text top="459" left="304" width="110" height="18" font="14">ﬁcant improvement</text>
<text top="481" left="64" width="350" height="13" font="14">in outcomes. Furthermore, the Centers for Medicare and</text>
<text top="499" left="64" width="148" height="13" font="14">Medicaid Services is now</text>
<text top="495" left="216" width="198" height="18" font="14">ﬁnancially penalizing hospitals for</text>
<text top="517" left="64" width="350" height="13" font="14">avoidable hospitalizations and readmissions, thereby empha-</text>
<text top="534" left="64" width="350" height="13" font="14">sizing the importance of such systems-based care coordination</text>
<text top="552" left="64" width="109" height="13" font="14">of patients with HF</text>
<text top="552" left="177" width="30" height="13" font="15"><a href="e147.full.html#85">(899)</a></text>
<text top="552" left="207" width="207" height="13" font="14">. However, the quality of evidence is</text>
<text top="570" left="64" width="93" height="13" font="14">mixed for speci</text>
<text top="567" left="157" width="257" height="18" font="14">ﬁc components of HF clinical management</text>
<text top="588" left="64" width="235" height="13" font="14">interventions, such as home-based care</text>
<text top="588" left="307" width="26" height="13" font="15"><a href="e147.full.html#84">(871</a></text>
<text top="588" left="333" width="4" height="13" font="14">,</text>
<text top="588" left="337" width="26" height="13" font="15"><a href="e147.full.html#84">872)</a></text>
<text top="588" left="362" width="51" height="13" font="14">, disease</text>
<text top="606" left="64" width="72" height="13" font="14">management</text>
<text top="606" left="149" width="80" height="13" font="15"><a href="e147.full.html#84">(873,874,880)</a></text>
<text top="606" left="229" width="4" height="13" font="14">,</text>
<text top="606" left="246" width="20" height="13" font="14">and</text>
<text top="606" left="279" width="39" height="13" font="14">remote</text>
<text top="606" left="331" width="83" height="13" font="14">telemonitoring</text>
<text top="624" left="64" width="53" height="13" font="14">programs</text>
<text top="624" left="127" width="98" height="13" font="15"><a href="e147.full.html#66">(80,875,876,878)</a></text>
<text top="624" left="224" width="190" height="13" font="14">. Unfortunately, numerous and</text>
<text top="642" left="64" width="92" height="13" font="14">nonstandardized</text>
<text top="642" left="175" width="13" height="13" font="14">de</text>
<text top="638" left="188" width="46" height="18" font="14">ﬁnitions</text>
<text top="642" left="253" width="12" height="13" font="14">of</text>
<text top="642" left="283" width="40" height="13" font="14">disease</text>
<text top="642" left="342" width="72" height="13" font="14">management</text>
<text top="660" left="64" width="80" height="13" font="15"><a href="e147.full.html#84">(873,879,880)</a></text>
<text top="660" left="144" width="119" height="13" font="14">, including the speci</text>
<text top="656" left="263" width="151" height="18" font="14">ﬁc elements that compose</text>
<text top="678" left="64" width="350" height="13" font="14">disease management, impede efforts to improve the care of</text>
<text top="696" left="64" width="350" height="13" font="14">patients with HF. Hence, more generic multidisciplinary</text>
<text top="714" left="64" width="350" height="13" font="14">strategies for improving the quality and cost-effectiveness of</text>
<text top="732" left="64" width="350" height="13" font="14">systems-based HF care should be evaluated with equal weight</text>
<text top="750" left="64" width="350" height="13" font="14">to those interventions focused on improving adherence to</text>
<text top="768" left="64" width="350" height="13" font="14">GDMT. For example, multidisciplinary approaches can</text>
<text top="786" left="64" width="350" height="13" font="14">reduce rates of hospitalization for HF. Programs involving</text>
<text top="803" left="64" width="350" height="13" font="14">specialized follow-up by a multidisciplinary team decrease</text>
<text top="821" left="64" width="350" height="13" font="14">all-cause hospitalizations and mortality; however, this has not</text>
<text top="839" left="64" width="91" height="13" font="14">been shown for</text>
<text top="836" left="161" width="252" height="18" font="14">“disease management programs” that focus</text>
<text top="857" left="64" width="162" height="13" font="14">only on self-care activities</text>
<text top="857" left="234" width="123" height="13" font="15"><a href="e147.full.html#66">(82,793,881,882,900)</a></text>
<text top="857" left="357" width="57" height="13" font="14"><a href="e147.full.html#66">. </a>Further-</text>
<text top="875" left="64" width="350" height="13" font="14">more, patient characteristics may be important predictors of</text>
<text top="893" left="64" width="170" height="13" font="14">HF and other cardiac disease</text>
<text top="889" left="234" width="180" height="18" font="14">–related survival and hospitali-</text>
<text top="911" left="64" width="187" height="13" font="14">zation. Overall, very few speci</text>
<text top="907" left="252" width="162" height="18" font="14">ﬁc interventions have been</text>
<text top="929" left="64" width="107" height="13" font="14">consistently identi</text>
<text top="925" left="171" width="243" height="18" font="14">ﬁed and successfully applied in clinical</text>
<text top="947" left="64" width="44" height="13" font="14">practice</text>
<text top="947" left="113" width="76" height="13" font="15"><a href="e147.full.html#69">(204,214,901</a></text>
<text top="943" left="189" width="33" height="18" font="15"><a href="e147.full.html#69">–903)</a></text>
<text top="947" left="222" width="4" height="13" font="14"><a href="e147.full.html#69">.</a></text>
<text top="965" left="79" width="20" height="13" font="14">See</text>
<text top="965" left="105" width="221" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplements 42 and 43</a></text>
<text top="965" left="333" width="81" height="13" font="14">for additional</text>
<text top="983" left="64" width="284" height="13" font="14">data on disease management and telemonitoring.</text>
<text top="1017" left="64" width="313" height="14" font="16">11.3. Palliative Care for Patients With HF</text>
<text top="1036" left="65" width="349" height="13" font="14">The core elements of comprehensive palliative care for HF</text>
<text top="1054" left="64" width="350" height="13" font="14">delivered by clinicians include expert symptom assessment</text>
<text top="1072" left="64" width="350" height="13" font="14">and management. Ongoing care should address symptom</text>
<text top="1090" left="64" width="350" height="13" font="14">control, psychosocial distress, HRQOL, preferences about</text>
<text top="103" left="450" width="350" height="13" font="14">end-of-life care, caregiver support, and assurance of access to</text>
<text top="121" left="450" width="350" height="13" font="14">evidence-based disease-modifying interventions. The HF</text>
<text top="139" left="450" width="350" height="13" font="14">team can help patients and their families explore treatment</text>
<text top="157" left="450" width="350" height="13" font="14">options and prognosis. The HF and palliative care teams are</text>
<text top="175" left="450" width="350" height="13" font="14">best suited to help patients and families decide when end-of-</text>
<text top="193" left="450" width="241" height="13" font="14">life care (including hospice) is appropriate</text>
<text top="193" left="695" width="44" height="13" font="15"><a href="e147.full.html#65">(30,885</a></text>
<text top="189" left="738" width="58" height="18" font="15"><a href="e147.full.html#65">–888,904)</a></text>
<text top="193" left="796" width="4" height="13" font="14"><a href="e147.full.html#65">.</a></text>
<text top="211" left="450" width="350" height="13" font="14">Assessment for frailty and dementia is part of this decision</text>
<text top="229" left="450" width="265" height="13" font="14">care process offered to the patient and family.</text>
<text top="247" left="465" width="335" height="13" font="14">Data suggest that advance directives specifying limitations</text>
<text top="265" left="450" width="268" height="13" font="14">in end-of-life care are associated with signi</text>
<text top="261" left="718" width="82" height="18" font="14">ﬁcantly lower</text>
<text top="283" left="450" width="350" height="13" font="14">levels of Medicare spending, lower likelihood of in-hospital</text>
<text top="301" left="450" width="350" height="13" font="14">death, and higher use of hospice care in regions character-</text>
<text top="319" left="450" width="256" height="13" font="14">ized by higher levels of end-of-life spending</text>
<text top="319" left="710" width="30" height="13" font="15"><a href="e147.full.html#85">(905)</a></text>
<text top="319" left="741" width="59" height="13" font="14"><a href="e147.full.html#85">. </a>In newly</text>
<text top="337" left="450" width="350" height="13" font="14">diagnosed cancer patients, palliative care interventions deliv-</text>
<text top="354" left="450" width="350" height="13" font="14">ered early have had a positive impact on survival and HRQOL.</text>
<text top="372" left="450" width="250" height="13" font="14">This approach may also be relevant for HF</text>
<text top="372" left="705" width="30" height="13" font="15"><a href="e147.full.html#85">(906)</a></text>
<text top="372" left="735" width="64" height="13" font="14"><a href="e147.full.html#85">. </a>Access to</text>
<text top="390" left="450" width="350" height="13" font="14">formally trained palliative care specialists may be limited in</text>
<text top="408" left="450" width="350" height="13" font="14">ambulatory settings. Therefore, cardiologists, primary care</text>
<text top="426" left="450" width="350" height="13" font="14">physicians, physician assistants, advanced practice nurses, and</text>
<text top="444" left="450" width="350" height="13" font="14">other members of the HF healthcare team should be familiar</text>
<text top="462" left="450" width="350" height="13" font="14">with these local treatment options. Evaluation for cardiac</text>
<text top="480" left="450" width="350" height="13" font="14">transplantation or MCS in experienced centers should include</text>
<text top="498" left="450" width="350" height="13" font="14">formal palliative care consultation, which can improve</text>
<text top="516" left="450" width="350" height="13" font="14">advanced care planning and enhance the overall quality of</text>
<text top="534" left="450" width="350" height="13" font="14">decision making and integrated care for these patients,</text>
<text top="552" left="450" width="270" height="13" font="14">regardless of the advanced HF therapy selected</text>
<text top="552" left="725" width="30" height="13" font="15"><a href="e147.full.html#85">(907)</a></text>
<text top="552" left="755" width="4" height="13" font="14">.</text>
<text top="590" left="450" width="348" height="15" font="13">12. Quality Metrics/Performance Measures:</text>
<text top="610" left="450" width="144" height="15" font="13">Recommendations</text>
<text top="650" left="450" width="37" height="8" font="17">CLASS I</text>
<text top="662" left="468" width="10" height="10" font="18">1.</text>
<text top="662" left="485" width="314" height="10" font="18">Performance measures based on professionally developed</text>
<text top="679" left="485" width="314" height="10" font="18">clinical practice guidelines should be used with the goal of</text>
<text top="695" left="485" width="174" height="10" font="18">improving quality of care for HF</text>
<text top="695" left="665" width="80" height="10" font="5"><a href="e147.full.html#80">(706,801,917)</a></text>
<text top="695" left="745" width="55" height="12" font="18"><a href="e147.full.html#80">. </a>(Level of</text>
<text top="712" left="485" width="65" height="12" font="18">Evidence: B)</text>
<text top="736" left="450" width="45" height="8" font="17">CLASS IIa</text>
<text top="748" left="468" width="10" height="10" font="18">1.</text>
<text top="747" left="485" width="314" height="10" font="18">Participation in quality improvement programs and patient</text>
<text top="764" left="485" width="314" height="10" font="18">registries based on nationally endorsed, clinical practice</text>
<text top="780" left="485" width="47" height="10" font="18">guideline</text>
<text top="777" left="533" width="267" height="16" font="18">–based quality and performance measures can be</text>
<text top="797" left="485" width="25" height="10" font="18">bene</text>
<text top="794" left="511" width="225" height="16" font="18">ﬁcial in improving the quality of HF care</text>
<text top="797" left="741" width="55" height="10" font="5"><a href="e147.full.html#80">(706,801)</a></text>
<text top="797" left="796" width="3" height="10" font="18">.</text>
<text top="813" left="485" width="113" height="12" font="18">(Level of Evidence: B)</text>
<text top="839" left="465" width="335" height="13" font="14">Quality measurement and accountability have become</text>
<text top="857" left="450" width="350" height="13" font="14">integral parts of medical practice over the past 2 decades. HF</text>
<text top="874" left="450" width="97" height="13" font="14">has been a speci</text>
<text top="871" left="546" width="253" height="18" font="14">ﬁc target of quality measurement, improve-</text>
<text top="892" left="450" width="350" height="13" font="14">ment, and reporting because of its substantial impact on</text>
<text top="910" left="450" width="350" height="13" font="14">population morbidity and mortality. Commonly used perfor-</text>
<text top="928" left="450" width="350" height="13" font="14">mance measures for HF can be considered in 2 distinct</text>
<text top="946" left="450" width="308" height="13" font="14">categories: process measures and outcomes measures.</text>
<text top="964" left="465" width="335" height="13" font="14">Process performance measures focus on the aspects of care</text>
<text top="982" left="450" width="350" height="13" font="14">that are delivered to a patient (e.g., the prescription of</text>
<text top="1000" left="450" width="350" height="13" font="14">a particular drug such as an ACE inhibitor in patients with LV</text>
<text top="1018" left="450" width="350" height="13" font="14">systolic dysfunction and without contraindications). Process</text>
<text top="1036" left="450" width="205" height="13" font="14">measures derive from the most de</text>
<text top="1032" left="655" width="145" height="18" font="14">ﬁnitive guideline recom-</text>
<text top="1054" left="450" width="350" height="13" font="14">mendations (i.e., class I and class III recommendations). A</text>
<text top="1072" left="450" width="350" height="13" font="14">small group of process measures for hospitalized patients with</text>
<text top="1090" left="450" width="350" height="13" font="14">HF have been reported to the public by the Centers for</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e207</text>
</page>
<page number="62" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">Medicare and Medicaid Services as part of the Hospital</text>
<text top="121" left="64" width="104" height="13" font="14">Compare program</text>
<text top="121" left="173" width="30" height="13" font="15"><a href="e147.full.html#85">(918)</a></text>
<text top="121" left="203" width="4" height="13" font="14">.</text>
<text top="139" left="79" width="335" height="13" font="14">Measures used to characterize the care of patients with HF</text>
<text top="157" left="64" width="350" height="13" font="14">should be those developed in a multiorganizational consensus</text>
<text top="175" left="64" width="350" height="13" font="14">process using an explicit methodology focusing on measur-</text>
<text top="193" left="64" width="350" height="13" font="14">ability, validity, reliability, feasibility, and ideally, correlation</text>
<text top="211" left="64" width="139" height="13" font="14">with patient outcomes</text>
<text top="211" left="214" width="55" height="13" font="15"><a href="e147.full.html#85">(919,920)</a></text>
<text top="211" left="270" width="144" height="13" font="14"><a href="e147.full.html#85">, </a>and with transparent</text>
<text top="229" left="64" width="244" height="13" font="14">disclosure and management of possible con</text>
<text top="225" left="309" width="105" height="18" font="14">ﬂicts of interest. In</text>
<text top="247" left="64" width="350" height="13" font="14">the case of HF, several national outcome measures are</text>
<text top="265" left="64" width="103" height="13" font="14">currently in use <a href="e147.full.html#62">(</a></text>
<text top="265" left="167" width="52" height="13" font="15"><a href="e147.full.html#62">Table 35</a></text>
<text top="265" left="220" width="194" height="13" font="14"><a href="e147.full.html#62">), </a>and the ACCF/AHA/American</text>
<text top="283" left="64" width="118" height="13" font="14">Medical Association</text>
<text top="279" left="182" width="232" height="18" font="14">–Physician Consortium for Performance</text>
<text top="301" left="64" width="76" height="13" font="14">Improvement</text>
<text top="301" left="156" width="45" height="13" font="14">recently</text>
<text top="301" left="216" width="55" height="13" font="14">published</text>
<text top="301" left="287" width="40" height="13" font="14">revised</text>
<text top="301" left="343" width="71" height="13" font="14">performance</text>
<text top="319" left="64" width="350" height="13" font="14">measures document includes several process measures for both</text>
<text top="337" left="64" width="188" height="13" font="14">inpatient and outpatient HF care (</text>
<text top="337" left="253" width="49" height="13" font="15"><a href="e147.full.html#63">Table 36</a></text>
<text top="337" left="302" width="5" height="13" font="14">)</text>
<text top="337" left="310" width="30" height="13" font="15"><a href="e147.full.html#85">(921)</a></text>
<text top="337" left="341" width="73" height="13" font="14"><a href="e147.full.html#85">. </a>Of note, the</text>
<text top="354" left="64" width="350" height="13" font="14">ACCF/AHA distinguish between processes of care that can be</text>
<text top="372" left="64" width="61" height="13" font="14">considered</text>
<text top="369" left="130" width="284" height="18" font="14">“Performance Measures” (i.e., suitable for use for</text>
<text top="390" left="64" width="164" height="13" font="14">accountability purposes) and</text>
<text top="386" left="233" width="181" height="18" font="14">“Quality Metrics” (i.e., suitable</text>
<text top="408" left="64" width="312" height="13" font="14">for use for quality improvement but not accountability)</text>
<text top="408" left="380" width="30" height="13" font="15"><a href="e147.full.html#85">(922)</a></text>
<text top="408" left="410" width="4" height="13" font="14">.</text>
<text top="426" left="79" width="291" height="13" font="14">Measures are appealing for several reasons; by de</text>
<text top="422" left="370" width="44" height="18" font="14">ﬁnition,</text>
<text top="444" left="64" width="41" height="13" font="14">they re</text>
<text top="440" left="105" width="309" height="18" font="14">ﬂect the strongest guideline recommendations. When</text>
<text top="462" left="64" width="110" height="13" font="14">appropriately speci</text>
<text top="458" left="174" width="240" height="18" font="14">ﬁed, they are relatively easy to calculate</text>
<text top="480" left="64" width="350" height="13" font="14">and they provide a clear target for improvement. However,</text>
<text top="498" left="64" width="350" height="13" font="14">they do not capture the broader range of care; they apply only</text>
<text top="516" left="64" width="350" height="13" font="14">to those patients without contraindications to therapy.</text>
<text top="534" left="64" width="350" height="13" font="14">Evidence of the relation between better performance with</text>
<text top="552" left="64" width="350" height="13" font="14">respect to process measures and patient outcomes is con-</text>
<text top="566" left="64" width="350" height="18" font="14">ﬂicting, and performance rates for those measures that have</text>
<text top="588" left="64" width="350" height="13" font="14">been used as part of public reporting programs are generally</text>
<text top="606" left="64" width="350" height="13" font="14">high for all institutions, limiting the ability of these measures</text>
<text top="623" left="64" width="260" height="13" font="14">to identify high- and low-performing centers.</text>
<text top="641" left="79" width="335" height="13" font="14">These limitations of process measures have generated</text>
<text top="659" left="64" width="350" height="13" font="14">interest in the use of outcomes measures as a complementary</text>
<text top="677" left="64" width="350" height="13" font="14">approach to characterize quality. With respect to HF, 30-day</text>
<text top="695" left="64" width="350" height="13" font="14">mortality and 30-day readmission are reported by the</text>
<text top="713" left="64" width="350" height="13" font="14">Centers for Medicare and Medicaid Services as part of the</text>
<text top="731" left="64" width="162" height="13" font="14">Hospital Compare program <a href="e147.full.html#62">(</a></text>
<text top="731" left="226" width="50" height="13" font="15"><a href="e147.full.html#62">Table 35</a></text>
<text top="731" left="276" width="138" height="13" font="14"><a href="e147.full.html#62">) </a>and are incorporated in</text>
<text top="749" left="64" width="350" height="13" font="14">the Centers for Medicare and Medicaid Services value-based</text>
<text top="767" left="64" width="114" height="13" font="14">purchasing program</text>
<text top="767" left="182" width="30" height="13" font="15"><a href="e147.full.html#85">(918)</a></text>
<text top="767" left="213" width="201" height="13" font="14"><a href="e147.full.html#85">. </a>Outcomes measures are appealing</text>
<text top="785" left="64" width="350" height="13" font="14">because they apply universally to almost all patients, and they</text>
<text top="803" left="64" width="350" height="13" font="14">provide a perspective on the performance of health systems</text>
<text top="821" left="64" width="30" height="13" font="15"><a href="e147.full.html#85">(923)</a></text>
<text top="821" left="95" width="319" height="13" font="14"><a href="e147.full.html#85">. </a>On the other hand, they are limited by the questionable</text>
<text top="839" left="64" width="350" height="13" font="14">adequacy of risk adjustment and by the challenges of</text>
<text top="103" left="450" width="350" height="13" font="14">improvement. The ACCF and AHA have published criteria</text>
<text top="121" left="450" width="350" height="13" font="14">that characterize the necessary attributes of robust outcomes</text>
<text top="139" left="450" width="52" height="13" font="14">measures</text>
<text top="139" left="507" width="30" height="13" font="15"><a href="e147.full.html#85">(924)</a></text>
<text top="139" left="537" width="4" height="13" font="14">.</text>
<text top="157" left="465" width="20" height="13" font="14">See</text>
<text top="157" left="491" width="167" height="13" font="15"><a href="http://jaccjacc.cardiosource.com/DataSupp/ACCF/2013_HFGL_Evidence_Tables.pdf">Online Data Supplement 44</a></text>
<text top="157" left="665" width="134" height="13" font="14">for additional data on</text>
<text top="175" left="450" width="249" height="13" font="14">quality metrics and performance measures.</text>
<text top="219" left="450" width="189" height="15" font="13">13. Evidence Gaps and</text>
<text top="240" left="450" width="224" height="15" font="13">Future Research Directions</text>
<text top="283" left="451" width="349" height="13" font="14">Despite the objective evidence compiled by the writing</text>
<text top="301" left="450" width="350" height="13" font="14">committee on the basis of hundreds of clinical trials, there are</text>
<text top="319" left="450" width="350" height="13" font="14">huge gaps in our knowledge base about many fundamental</text>
<text top="337" left="450" width="350" height="13" font="14">aspects of HF care. Some key examples include an effective</text>
<text top="354" left="450" width="350" height="13" font="14">management strategy for patients with HFpEF beyond blood</text>
<text top="372" left="450" width="350" height="13" font="14">pressure control; a convincing method to use biomarkers in</text>
<text top="390" left="450" width="350" height="13" font="14">the optimization of medical therapy; the recognition and</text>
<text top="408" left="450" width="350" height="13" font="14">treatment of cardiorenal syndrome; and the critical need for</text>
<text top="426" left="450" width="350" height="13" font="14">improving patient adherence to therapeutic regimens. Even</text>
<text top="444" left="450" width="350" height="13" font="14">the widely embraced dictum of sodium restriction in HF is not</text>
<text top="462" left="450" width="350" height="13" font="14">well supported by current evidence. Moreover, the majority of</text>
<text top="480" left="450" width="350" height="13" font="14">the clinical trials that inform GDMT were designed around the</text>
<text top="498" left="450" width="350" height="13" font="14">primary endpoint of mortality, so that there is less certainty</text>
<text top="516" left="450" width="350" height="13" font="14">about the impact of therapies on the HRQOL of patients. It is</text>
<text top="534" left="450" width="350" height="13" font="14">also of major concern that the majority of RCTs failed to</text>
<text top="552" left="450" width="96" height="13" font="14">randomize a suf</text>
<text top="548" left="546" width="254" height="18" font="14">ﬁcient number of the elderly, women, and</text>
<text top="570" left="450" width="350" height="13" font="14">underrepresented minorities, thus, limiting insight into these</text>
<text top="588" left="450" width="350" height="13" font="14">important patient cohorts. A growing body of studies on</text>
<text top="606" left="450" width="350" height="13" font="14">patient-centered outcomes research is likely to address some</text>
<text top="623" left="450" width="63" height="13" font="14">of these de</text>
<text top="620" left="513" width="208" height="18" font="14">ﬁciencies, but time will be required.</text>
<text top="641" left="465" width="335" height="13" font="14">HF is a syndrome with a high prevalence of comorbidities</text>
<text top="659" left="450" width="350" height="13" font="14">and multiple chronic conditions, but most guidelines are</text>
<text top="677" left="450" width="350" height="13" font="14">developed for patients with a single disease. Nevertheless, the</text>
<text top="695" left="450" width="350" height="13" font="14">coexistence of additional diseases such as arthritis, renal</text>
<text top="713" left="450" width="28" height="13" font="14">insuf</text>
<text top="709" left="478" width="322" height="18" font="14">ﬁciency, diabetes mellitus, or chronic lung disease with</text>
<text top="731" left="450" width="290" height="13" font="14">the HF syndrome should logically require a modi</text>
<text top="727" left="740" width="59" height="18" font="14">ﬁcation of</text>
<text top="749" left="450" width="350" height="13" font="14">treatment, outcome assessment, or follow-up care. About 25%</text>
<text top="767" left="450" width="310" height="13" font="14">of Americans have multiple chronic conditions; this</text>
<text top="763" left="767" width="33" height="18" font="14">ﬁgure</text>
<text top="785" left="450" width="118" height="13" font="14">rises to 75% in those</text>
<text top="781" left="571" width="228" height="18" font="14">&gt;65 years of age, including the diseases</text>
<text top="803" left="450" width="350" height="13" font="14">referred to above, as well as asthma, hypertension, cognitive</text>
<text top="821" left="450" width="135" height="13" font="14">disorders, or depression</text>
<text top="821" left="589" width="30" height="13" font="15"><a href="e147.full.html#84">(847)</a></text>
<text top="821" left="620" width="145" height="13" font="14"><a href="e147.full.html#84">. </a>Most RCTs in HF speci</text>
<text top="817" left="765" width="35" height="18" font="14">ﬁcally</text>
<text top="839" left="450" width="166" height="13" font="14">excluded patients with signi</text>
<text top="835" left="616" width="184" height="18" font="14">ﬁcant other comorbidities from</text>
<text top="857" left="450" width="350" height="13" font="14">enrollment, thus limiting our ability to generalize our recom-</text>
<text top="875" left="450" width="350" height="13" font="14">mendations to many real-world patients. Therefore, the clini-</text>
<text top="892" left="450" width="350" height="13" font="14">cian must, as always, practice the art of using the best of the</text>
<text top="910" left="450" width="290" height="13" font="14">guideline recommendations as they apply to a speci</text>
<text top="907" left="740" width="59" height="18" font="14">ﬁc patient.</text>
<text top="928" left="465" width="335" height="13" font="14">Future research will need to focus on novel pharmacolog-</text>
<text top="946" left="450" width="350" height="13" font="14">ical therapies, especially for hospitalized HF; regenerative</text>
<text top="964" left="450" width="350" height="13" font="14">cell-based therapies to restore myocardium; and new device</text>
<text top="982" left="450" width="350" height="13" font="14">platforms that will either improve existing technologies (e.g.,</text>
<text top="1000" left="450" width="350" height="13" font="14">CRT, ICD, left VAD) or introduce simpler, less morbid</text>
<text top="1018" left="450" width="350" height="13" font="14">devices that are capable of changing the natural history of HF.</text>
<text top="1036" left="450" width="350" height="13" font="14">What is critically needed is an evidence base that clearly</text>
<text top="1054" left="450" width="32" height="13" font="14">identi</text>
<text top="1050" left="482" width="318" height="18" font="14">ﬁes best processes of care, especially in the transition</text>
<text top="1072" left="450" width="350" height="13" font="14">from hospital to home. Finally, preventing the burden of</text>
<text top="1090" left="450" width="304" height="13" font="14">this disease through more successful risk modi</text>
<text top="1086" left="754" width="46" height="18" font="14">ﬁcation,</text>
<text top="885" left="64" width="198" height="12" font="9">Table 35. Outcome Measures for HF</text>
<text top="917" left="64" width="38" height="11" font="4">Measure</text>
<text top="917" left="292" width="44" height="11" font="4">Developer</text>
<text top="936" left="64" width="128" height="11" font="4">Congestive HF mortality rate</text>
<text top="951" left="77" width="69" height="11" font="4">(NQF endorsed)</text>
<text top="936" left="214" width="180" height="11" font="4">Agency for Health Research and Quality</text>
<text top="971" left="64" width="111" height="11" font="4">HF 30-day mortality rate</text>
<text top="986" left="77" width="69" height="11" font="4">(NQF endorsed)</text>
<text top="971" left="214" width="200" height="11" font="4">Centers for Medicare and Medicaid Services</text>
<text top="1005" left="64" width="134" height="11" font="4">Congestive HF admission rate</text>
<text top="1020" left="77" width="69" height="11" font="4">(NQF endorsed)</text>
<text top="1005" left="214" width="180" height="11" font="4">Agency for Health Research and Quality</text>
<text top="1039" left="64" width="128" height="11" font="4">HF 30-day risk-standardized</text>
<text top="1054" left="77" width="91" height="11" font="4">HF readmission rate</text>
<text top="1069" left="77" width="69" height="11" font="4">(NQF endorsed)</text>
<text top="1039" left="214" width="200" height="11" font="4">Centers for Medicare and Medicaid Services</text>
<text top="1091" left="76" width="271" height="11" font="4">HF indicates heart failure; and NQF, National Quality Forum.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e208</text>
</page>
<page number="63" position="absolute" top="0" left="0" height="1160" width="864">
<text top="919" left="64" width="249" height="13" font="14">sophisticated screening, perhaps using speci</text>
<text top="915" left="313" width="101" height="18" font="14">ﬁc omics technol-</text>
<text top="937" left="64" width="350" height="13" font="14">ogies (i.e., systems biology) or effective treatment interventions</text>
<text top="955" left="64" width="350" height="13" font="14">that reduce the progression from stage A to stage B is an urgent</text>
<text top="973" left="64" width="30" height="13" font="14">need.</text>
<text top="1010" left="64" width="170" height="15" font="13">Presidents and Staff</text>
<text top="1053" left="64" width="324" height="14" font="16">American College of Cardiology Foundation</text>
<text top="1072" left="65" width="260" height="13" font="14">John Gordon Harold, MD, MACC, President</text>
<text top="1090" left="64" width="228" height="13" font="14">Shalom Jacobovitz, Chief Executive Of</text>
<text top="1086" left="292" width="25" height="18" font="14">ﬁcer</text>
<text top="919" left="450" width="350" height="13" font="14">William J. Oetgen, MD, MBA, FACC, Senior Vice President,</text>
<text top="937" left="464" width="115" height="13" font="14">Science and Quality</text>
<text top="955" left="450" width="350" height="13" font="14">Charlene L. May, Senior Director, Science and Clinical</text>
<text top="973" left="464" width="37" height="13" font="14">Policy</text>
<text top="1015" left="450" width="332" height="14" font="16">American College of Cardiology Foundation/</text>
<text top="1035" left="450" width="208" height="14" font="16">American Heart Association</text>
<text top="1054" left="451" width="56" height="13" font="14">Lisa Brad</text>
<text top="1050" left="507" width="283" height="18" font="14">ﬁeld, CAE, Director, Science and Clinical Policy</text>
<text top="1072" left="450" width="350" height="13" font="14">Debjani Mukherjee, MPH, Associate Director, Evidence-</text>
<text top="1090" left="464" width="92" height="13" font="14">Based Medicine</text>
<text top="108" left="64" width="318" height="12" font="9">Table 36. ACCF/AHA/AMA-PCPI 2011 HF Measurement Set</text>
<text top="139" left="64" width="38" height="11" font="4">Measure</text>
<text top="139" left="391" width="50" height="11" font="4">Description</text>
<text top="139" left="441" width="4" height="11" font="5"><a href="e147.full.html#63">*</a></text>
<text top="139" left="612" width="55" height="11" font="4">Care Setting</text>
<text top="139" left="695" width="100" height="11" font="4">Level of Measurement</text>
<text top="159" left="64" width="94" height="11" font="4">1. LVEF assessment</text>
<text top="159" left="248" width="127" height="11" font="4">Percentage of patients aged</text>
<text top="156" left="378" width="200" height="16" font="4">18 y with a diagnosis of HF for whom the</text>
<text top="174" left="260" width="328" height="11" font="4">quantitative or qualitative results of a recent or prior (any time in the past)</text>
<text top="189" left="260" width="253" height="11" font="4">LVEF assessment is documented within a 12-mo period</text>
<text top="159" left="610" width="46" height="11" font="4">Outpatient</text>
<text top="159" left="691" width="96" height="11" font="4">Individual practitioner</text>
<text top="208" left="64" width="94" height="11" font="4">2. LVEF assessment</text>
<text top="208" left="248" width="123" height="11" font="4">Percentage of patients aged</text>
<text top="206" left="374" width="215" height="16" font="4">18 y with a principal discharge diagnosis of HF</text>
<text top="223" left="260" width="305" height="11" font="4">with documentation in the hospital record of the results of an LVEF</text>
<text top="238" left="260" width="326" height="11" font="4">assessment performed either before arrival or during hospitalization, OR</text>
<text top="253" left="260" width="328" height="11" font="4">documentation in the hospital record that LVEF assessment is planned for</text>
<text top="268" left="260" width="67" height="11" font="4">after discharge</text>
<text top="208" left="610" width="38" height="11" font="4">Inpatient</text>
<text top="206" left="691" width="108" height="16" font="4"> Individual practitioner</text>
<text top="221" left="691" width="44" height="16" font="4"> Facility</text>
<text top="288" left="64" width="114" height="11" font="4">3. Symptom and activity</text>
<text top="303" left="81" width="53" height="11" font="4">assessment</text>
<text top="288" left="248" width="224" height="11" font="4">Percentage of patient visits for those patients aged</text>
<text top="285" left="474" width="114" height="16" font="4">18 y with a diagnosis of</text>
<text top="303" left="260" width="308" height="11" font="4">HF with quantitative results of an evaluation of both current level of</text>
<text top="318" left="260" width="194" height="11" font="4">activity and clinical symptoms documented</text>
<text top="288" left="610" width="46" height="11" font="4">Outpatient</text>
<text top="288" left="691" width="96" height="11" font="4">Individual practitioner</text>
<text top="337" left="64" width="120" height="11" font="4">4. Symptom managemen<a href="e147.full.html#63">t</a></text>
<text top="334" left="184" width="5" height="16" font="5"><a href="e147.full.html#63">y</a></text>
<text top="337" left="248" width="224" height="11" font="4">Percentage of patient visits for those patients aged</text>
<text top="334" left="474" width="114" height="16" font="4">18 y with a diagnosis of</text>
<text top="352" left="260" width="328" height="11" font="4">HF and with quantitative results of an evaluation of both level of activity</text>
<text top="367" left="260" width="313" height="11" font="4">AND clinical symptoms documented in which patient symptoms have</text>
<text top="382" left="260" width="292" height="11" font="4">improved or remained consistent with treatment goals since last</text>
<text top="397" left="260" width="328" height="11" font="4">assessment OR patient symptoms have demonstrated clinically important</text>
<text top="412" left="260" width="308" height="11" font="4">deterioration since last assessment with a documented plan of care</text>
<text top="337" left="610" width="46" height="11" font="4">Outpatient</text>
<text top="337" left="691" width="96" height="11" font="4">Individual practitioner</text>
<text top="431" left="64" width="137" height="11" font="4">5. Patient self-care <a href="e147.full.html#63">education</a></text>
<text top="428" left="201" width="10" height="16" font="5"><a href="e147.full.html#63">yz</a></text>
<text top="431" left="248" width="123" height="11" font="4">Percentage of patients aged</text>
<text top="428" left="374" width="215" height="16" font="4">18 y with a diagnosis of HF who were provided</text>
<text top="446" left="260" width="124" height="11" font="4">with self-care education on</text>
<text top="443" left="388" width="196" height="16" font="4">3 elements of education during 1 visits</text>
<text top="461" left="260" width="101" height="11" font="4">within a 12-mo period</text>
<text top="431" left="610" width="46" height="11" font="4">Outpatient</text>
<text top="431" left="691" width="96" height="11" font="4">Individual practitioner</text>
<text top="480" left="64" width="153" height="11" font="4">6. Beta-blocker therapy for LVSD</text>
<text top="495" left="93" width="109" height="11" font="4">(outpatient and inpatient</text>
<text top="510" left="93" width="33" height="11" font="4">setting)</text>
<text top="480" left="248" width="126" height="11" font="4">Percentage of patients aged</text>
<text top="478" left="377" width="212" height="16" font="4">18 y with a diagnosis of HF with a current or</text>
<text top="495" left="260" width="46" height="11" font="4">prior LVEF</text>
<text top="493" left="310" width="248" height="16" font="4">&lt;40% who were prescribed beta-blocker therapy with</text>
<text top="510" left="260" width="316" height="11" font="4">bisoprolol, carvedilol, or sustained-release metoprolol succinate either</text>
<text top="525" left="260" width="328" height="11" font="4">within a 12-mo period when seen in the outpatient setting or at hospital</text>
<text top="540" left="260" width="43" height="11" font="4">discharge</text>
<text top="480" left="610" width="58" height="11" font="4">Inpatient and</text>
<text top="495" left="623" width="44" height="11" font="4">outpatient</text>
<text top="478" left="691" width="108" height="16" font="4"> Individual practitioner</text>
<text top="493" left="691" width="44" height="16" font="4"> Facility</text>
<text top="560" left="64" width="146" height="11" font="4">7. ACE inhibitor or ARB therapy</text>
<text top="575" left="93" width="110" height="11" font="4">for LVSD (outpatient and</text>
<text top="590" left="93" width="75" height="11" font="4">inpatient setting)</text>
<text top="560" left="248" width="126" height="11" font="4">Percentage of patients aged</text>
<text top="557" left="377" width="212" height="16" font="4">18 y with a diagnosis of HF with a current or</text>
<text top="575" left="260" width="45" height="11" font="4">prior LVEF</text>
<text top="572" left="308" width="281" height="16" font="4">&lt;40% who were prescribed ACE inhibitor or ARB therapy either</text>
<text top="590" left="260" width="328" height="11" font="4">within a 12-mo period when seen in the outpatient setting or at hospital</text>
<text top="604" left="260" width="43" height="11" font="4">discharge</text>
<text top="560" left="610" width="58" height="11" font="4">Inpatient and</text>
<text top="575" left="623" width="44" height="11" font="4">outpatient</text>
<text top="557" left="691" width="108" height="16" font="4"> Individual practitioner</text>
<text top="572" left="691" width="44" height="16" font="4"> Facility</text>
<text top="624" left="64" width="113" height="11" font="4">8. Counseling about ICD</text>
<text top="639" left="93" width="110" height="11" font="4">implantation for patients</text>
<text top="654" left="93" width="119" height="11" font="4">with LVSD on combination</text>
<text top="669" left="93" width="72" height="11" font="4">medical <a href="e147.full.html#63">therapy</a></text>
<text top="666" left="164" width="10" height="16" font="5"><a href="e147.full.html#63">yz</a></text>
<text top="624" left="248" width="127" height="11" font="4">Percentage of patients aged</text>
<text top="621" left="378" width="193" height="16" font="4">18 y with a diagnosis of HF with current</text>
<text top="639" left="260" width="22" height="11" font="4">LVEF</text>
<text top="636" left="286" width="294" height="16" font="4">35% despite ACE inhibitor/ARB and beta-blocker therapy for at</text>
<text top="654" left="260" width="322" height="11" font="4">least 3 mo who were counseled about ICD implantation as a treatment</text>
<text top="669" left="260" width="192" height="11" font="4">option for the prophylaxis of sudden death</text>
<text top="624" left="610" width="46" height="11" font="4">Outpatient</text>
<text top="624" left="691" width="96" height="11" font="4">Individual practitioner</text>
<text top="688" left="64" width="137" height="11" font="4">9. Postdischarge appointment</text>
<text top="703" left="93" width="67" height="11" font="4">for HF patients</text>
<text top="688" left="248" width="323" height="11" font="4">Percentage of patients, regardless of age, discharged from an inpatient</text>
<text top="703" left="260" width="328" height="11" font="4">facility to ambulatory care or home health care with a principal discharge</text>
<text top="718" left="260" width="322" height="11" font="4">diagnosis of HF for whom a follow-up appointment was scheduled and</text>
<text top="733" left="260" width="328" height="11" font="4">documented, including location, date, and time for a follow-up office visit</text>
<text top="748" left="260" width="154" height="11" font="4">or home health visit (as specified)</text>
<text top="688" left="610" width="38" height="11" font="4">Inpatient</text>
<text top="688" left="691" width="31" height="11" font="4">Facility</text>
<text top="769" left="76" width="705" height="11" font="4">NB, Regarding test measure no. 8, implantation of ICD must be consistent with published guidelines. This measure is intended to promote counseling only.</text>
<text top="784" left="76" width="429" height="11" font="4">*Refer to the complete measures for comprehensive information, including measure exception.</text>
<text top="796" left="75" width="724" height="16" font="4"><a href="e147.full.html#63">yTest </a>measure designated for use in internal quality improvement programs only. These measures are not appropriate for any other purpose (e.g., pay for</text>
<text top="814" left="64" width="282" height="11" font="4">performance, physician ranking, or public reporting programs).</text>
<text top="826" left="75" width="70" height="16" font="4"><a href="e147.full.html#63">z</a>New measure.</text>
<text top="844" left="76" width="723" height="11" font="4">ACCF indicates American College of Cardiology Foundation; ACE, angiotensin-converting enzyme; AHA, American Heart Association; AMA-PCPI, American Medical</text>
<text top="859" left="64" width="50" height="11" font="4">Association</text>
<text top="856" left="115" width="685" height="16" font="4">Physician Consortium for Performance Improvement; ARB, angiotensin-receptor blocker; HF, heart failure; ICD, implantable cardioverter-defibrillator;</text>
<text top="874" left="64" width="385" height="11" font="4">LVEF, left ventricular ejection fraction; and LVSD, left ventricular systolic dysfunction.</text>
<text top="889" left="76" width="122" height="11" font="4">Adapted from Bonow et al.</text>
<text top="889" left="202" width="23" height="11" font="5"><a href="e147.full.html#85">(921)</a></text>
<text top="889" left="225" width="3" height="11" font="4"><a href="e147.full.html#85">.</a></text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e209</text>
</page>
<page number="64" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="13" font="14">Ezaldeen Ramadhan III, Specialist, Science and Clinical</text>
<text top="121" left="78" width="36" height="13" font="14">Policy</text>
<text top="139" left="64" width="341" height="13" font="14">Sarah Jackson, MPH, Specialist, Science and Clinical Policy</text>
<text top="183" left="64" width="208" height="14" font="16">American Heart Association</text>
<text top="202" left="65" width="268" height="13" font="14">Donna K. Arnett, PhD, MD, FAHA, President</text>
<text top="220" left="64" width="200" height="13" font="14">Nancy Brown, Chief Executive Of</text>
<text top="217" left="264" width="25" height="18" font="14">ﬁcer</text>
<text top="238" left="64" width="314" height="13" font="14">Rose Marie Robertson, MD, FAHA, Chief Science Of</text>
<text top="234" left="378" width="25" height="18" font="14">ﬁcer</text>
<text top="256" left="64" width="350" height="13" font="14">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice</text>
<text top="274" left="78" width="75" height="13" font="14">President, Of</text>
<text top="270" left="154" width="151" height="18" font="14">ﬁce of Science Operations</text>
<text top="292" left="64" width="350" height="13" font="14">Judy Bezanson, DSN, RN, CNS-MS, FAHA, Science and</text>
<text top="310" left="78" width="103" height="13" font="14">Medicine Advisor</text>
<text top="328" left="64" width="257" height="13" font="14">Jody Hundley, Production Manager, Scienti</text>
<text top="324" left="321" width="93" height="18" font="14">ﬁc Publications,</text>
<text top="346" left="78" width="15" height="13" font="14">Of</text>
<text top="342" left="93" width="151" height="18" font="14">ﬁce of Science Operations</text>
<text top="402" left="64" width="94" height="15" font="2">References</text>
<text top="430" left="75" width="339" height="10" font="4">1. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual</text>
<text top="444" left="89" width="325" height="10" font="4">and Policies From the ACCF/AHA Task Force on Practice Guidelines.</text>
<text top="458" left="89" width="61" height="10" font="4">Available at:</text>
<text top="458" left="159" width="255" height="10" font="5"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">http://assets.cardiosource.com/Methodology_Manual_for_</a></text>
<text top="472" left="89" width="167" height="10" font="5"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">ACC_AHA_Writing_Committees.pdf</a></text>
<text top="472" left="265" width="16" height="10" font="4">and</text>
<text top="472" left="290" width="124" height="10" font="5"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/sop/documents/downloadable/ucm_319826.pdf">http://my.americanheart.org/</a></text>
<text top="487" left="89" width="325" height="10" font="5"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/sop/documents/downloadable/ucm_319826.pdf">idc/groups/ahamah-public/@wcm/sop/documents/downloadable/ucm_31</a></text>
<text top="501" left="89" width="39" height="10" font="5"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/sop/documents/downloadable/ucm_319826.pdf">9826.pdf</a></text>
<text top="501" left="128" width="286" height="10" font="4">. American College of Cardiology Foundation and American</text>
<text top="515" left="89" width="224" height="10" font="4">Heart Association. 2010. Accessed May 16, 2012.</text>
<text top="529" left="75" width="339" height="10" font="4">2. Committee on Standards for Developing Trustworthy Clinical Practice</text>
<text top="543" left="89" width="325" height="10" font="4">Guidelines; Institute of Medicine. Clinical practice guidelines we can</text>
<text top="558" left="89" width="281" height="10" font="4">trust. Washington, DC: The National Academies Press; 2011.</text>
<text top="572" left="75" width="339" height="10" font="4">3. Committee on Standards for Systematic Reviews of Comparative</text>
<text top="586" left="89" width="325" height="10" font="4">Effectiveness Research, Institute of Medicine. Finding what works in</text>
<text top="600" left="89" width="325" height="10" font="4">health care: standards for systematic reviews. Washington, DC: The</text>
<text top="614" left="89" width="150" height="10" font="4">National Academies Press; 2011.</text>
<text top="629" left="75" width="339" height="10" font="4">4. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused</text>
<text top="643" left="89" width="325" height="10" font="4">update incorporated into the ACCF/AHA/HRS 2008 guidelines for</text>
<text top="657" left="89" width="325" height="10" font="4">device-based therapy of cardiac rhythm abnormalities: a report of the</text>
<text top="671" left="89" width="325" height="10" font="4">American College of Cardiology Foundation/American Heart Associa-</text>
<text top="685" left="89" width="325" height="10" font="4">tion Task Force on Practice Guidelines and the Heart Rhythm Society. J</text>
<text top="700" left="89" width="130" height="10" font="4">Am Coll Cardiol 2013;61:e6</text>
<text top="697" left="220" width="20" height="15" font="4">–75.</text>
<text top="714" left="75" width="339" height="10" font="4">5. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guide-</text>
<text top="728" left="89" width="325" height="10" font="4">lines for the management of adults with congenital heart disease: a report</text>
<text top="742" left="89" width="325" height="10" font="4">of the American College of Cardiology/American Heart Association</text>
<text top="756" left="89" width="325" height="10" font="4">Task Force on Practice Guidelines (Writing Committee to Develop</text>
<text top="770" left="89" width="325" height="10" font="4">Guidelines on the Management of Adults With Congenital Heart</text>
<text top="785" left="89" width="194" height="10" font="4">Disease). J Am Coll Cardiol 2008;52:e143</text>
<text top="782" left="284" width="25" height="15" font="4">–263.</text>
<text top="799" left="75" width="339" height="10" font="4">6. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused</text>
<text top="813" left="89" width="325" height="10" font="4">updates incorporated into the ACC/AHA/ESC 2006 guidelines for the</text>
<text top="827" left="89" width="156" height="10" font="4">management of patients with atrial</text>
<text top="824" left="249" width="165" height="15" font="4">ﬁbrillation: a report of the American</text>
<text top="841" left="89" width="325" height="10" font="4">College of Cardiology Foundation/American Heart Association Task</text>
<text top="856" left="89" width="325" height="10" font="4">Force on Practice Guidelines developed in partnership with the European</text>
<text top="870" left="89" width="256" height="10" font="4">Society of Cardiology. J Am Coll Cardiol 2011;57:e101</text>
<text top="867" left="346" width="20" height="15" font="4">–98.</text>
<text top="884" left="75" width="339" height="10" font="4">7. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused</text>
<text top="898" left="89" width="227" height="10" font="4">update on the management of patients with atrial</text>
<text top="895" left="320" width="94" height="15" font="4">ﬁbrillation (updating</text>
<text top="912" left="89" width="325" height="10" font="4">the 2006 guideline): a report of the American College of Cardiology</text>
<text top="927" left="89" width="325" height="10" font="4">Foundation/American Heart Association Task Force on Practice</text>
<text top="941" left="89" width="199" height="10" font="4">Guidelines. J Am Coll Cardiol 2011;57:223</text>
<text top="938" left="289" width="20" height="15" font="4">–42.</text>
<text top="955" left="75" width="339" height="10" font="4">8. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS</text>
<text top="969" left="89" width="273" height="10" font="4">focused update on the management of patients with atrial</text>
<text top="966" left="367" width="47" height="15" font="4">ﬁbrillation</text>
<text top="983" left="89" width="325" height="10" font="4">(update on dabigatran): a report of the American College of Cardiology</text>
<text top="998" left="89" width="325" height="10" font="4">Foundation/American Heart Association Task Force on practice guide-</text>
<text top="1012" left="89" width="178" height="10" font="4">lines. J Am Coll Cardiol 2011;57:1330</text>
<text top="1009" left="267" width="14" height="15" font="4">–7.</text>
<text top="1026" left="75" width="339" height="10" font="4">9. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline</text>
<text top="1040" left="89" width="325" height="10" font="4">for assessment of cardiovascular risk in asymptomatic adults: a report</text>
<text top="1054" left="89" width="325" height="10" font="4">of the American College of Cardiology Foundation/American Heart</text>
<text top="1069" left="89" width="325" height="10" font="4">Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;</text>
<text top="1083" left="89" width="30" height="10" font="4">56:e50</text>
<text top="1080" left="120" width="25" height="15" font="4">–103.</text>
<text top="103" left="455" width="344" height="10" font="4">10. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for</text>
<text top="117" left="475" width="324" height="10" font="4">coronary artery bypass graft surgery: a report of the American College of</text>
<text top="132" left="475" width="324" height="10" font="4">Cardiology Foundation/American Heart Association Task Force on</text>
<text top="146" left="475" width="244" height="10" font="4">Practice Guidelines. J Am Coll Cardiol 2011;58:e123</text>
<text top="143" left="719" width="25" height="15" font="4">–210.</text>
<text top="160" left="455" width="344" height="10" font="4">11. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for</text>
<text top="174" left="475" width="324" height="10" font="4">the diagnosis and treatment of hypertrophic cardiomyopathy: a report of</text>
<text top="188" left="475" width="324" height="10" font="4">the American College of Cardiology Foundation/American Heart</text>
<text top="203" left="475" width="324" height="10" font="4">Association Task Force on Practice Guidelines Developed in Collabo-</text>
<text top="217" left="475" width="324" height="10" font="4">ration With the American Association for Thoracic Surgery, American</text>
<text top="231" left="475" width="324" height="10" font="4">Society of Echocardiography, American Society of Nuclear Cardiology,</text>
<text top="245" left="475" width="324" height="10" font="4">Heart Failure Society of America, Heart Rhythm Society, Society for</text>
<text top="259" left="475" width="324" height="10" font="4">Cardiovascular Angiography and Interventions, and Society of Thoracic</text>
<text top="274" left="475" width="198" height="10" font="4">Surgeons. J Am Coll Cardiol 2011;58:e212</text>
<text top="271" left="673" width="20" height="15" font="4">–60.</text>
<text top="288" left="455" width="344" height="10" font="4">12. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI</text>
<text top="302" left="475" width="324" height="10" font="4">guideline for percutaneous coronary intervention: a report of the American</text>
<text top="316" left="475" width="324" height="10" font="4">College of Cardiology Foundation/American Heart Association Task</text>
<text top="330" left="475" width="324" height="10" font="4">Force on Practice Guidelines and the Society for Cardiovascular Angi-</text>
<text top="345" left="475" width="263" height="10" font="4">ography and Interventions. J Am Coll Cardiol 2011;58:e44</text>
<text top="342" left="738" width="25" height="15" font="4">–122.</text>
<text top="359" left="455" width="344" height="10" font="4">13. Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary</text>
<text top="373" left="475" width="324" height="10" font="4">prevention and risk reduction therapy for patients with coronary and</text>
<text top="387" left="475" width="324" height="10" font="4">other atherosclerotic vascular disease: 2011 update: a guideline from the</text>
<text top="401" left="475" width="324" height="10" font="4">American Heart Association and American College of Cardiology</text>
<text top="416" left="475" width="208" height="10" font="4">Foundation. J Am Coll Cardiol 2011;58:2432</text>
<text top="413" left="683" width="20" height="15" font="4">–46.</text>
<text top="430" left="455" width="344" height="10" font="4">14. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/</text>
<text top="444" left="475" width="324" height="10" font="4">PCNA/SCAI/STS guideline for the diagnosis and management of patients</text>
<text top="458" left="475" width="324" height="10" font="4">with stable ischemic heart disease: a report of the American College of</text>
<text top="472" left="475" width="324" height="10" font="4">Cardiology Foundation/American Heart Association Task Force on</text>
<text top="486" left="475" width="324" height="10" font="4">Practice Guidelines, and the American College of Physicians, American</text>
<text top="501" left="475" width="324" height="10" font="4">Association for Thoracic Surgery, Preventive Cardiovascular Nurses</text>
<text top="515" left="475" width="324" height="10" font="4">Association, Society for Cardiovascular Angiography and Interventions,</text>
<text top="529" left="475" width="297" height="10" font="4">and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44</text>
<text top="526" left="772" width="25" height="15" font="4">–164.</text>
<text top="543" left="455" width="28" height="10" font="4">15. O</text>
<text top="540" left="483" width="316" height="15" font="4">’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA</text>
<text top="557" left="475" width="324" height="10" font="4">guideline for the management of ST-elevation myocardial infarction:</text>
<text top="572" left="475" width="324" height="10" font="4">executive summary: a report of the American College of Cardiology</text>
<text top="586" left="475" width="324" height="10" font="4">Foundation/American Heart Association Task Force on Practice</text>
<text top="600" left="475" width="199" height="10" font="4">Guidelines. J Am Coll Cardiol 2013;61:485</text>
<text top="597" left="675" width="25" height="15" font="4">–510.</text>
<text top="614" left="455" width="344" height="10" font="4">16. Anderson J, Adams C, Antman E, et al. 2012 ACCF/AHA focused</text>
<text top="628" left="475" width="324" height="10" font="4">update incorporated into the ACCF/AHA 2007 guidelines for the</text>
<text top="643" left="475" width="57" height="10" font="4">management</text>
<text top="643" left="543" width="9" height="10" font="4">of</text>
<text top="643" left="564" width="34" height="10" font="4">patients</text>
<text top="643" left="610" width="20" height="10" font="4">with</text>
<text top="643" left="641" width="37" height="10" font="4">unstable</text>
<text top="643" left="689" width="110" height="10" font="4">angina/non-ST-elevation</text>
<text top="657" left="475" width="324" height="10" font="4">myocardial infarction: a report of the American College of Cardiology</text>
<text top="671" left="475" width="324" height="10" font="4">Foundation/American Heart Association Task Force on Practice</text>
<text top="685" left="475" width="204" height="10" font="4">Guidelines. J Am Coll Cardiol 2013;61:e179</text>
<text top="682" left="680" width="25" height="15" font="4">–347.</text>
<text top="699" left="455" width="344" height="10" font="4">17. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update</text>
<text top="714" left="475" width="324" height="10" font="4">incorporated into the ACC/AHA 2006 guidelines for the management of</text>
<text top="728" left="475" width="324" height="10" font="4">patients with valvular heart disease: a report of the American College of</text>
<text top="742" left="475" width="324" height="10" font="4">Cardiology/American Heart Association Task Force on Practice Guide-</text>
<text top="756" left="475" width="324" height="10" font="4">lines (Writing Committee to revise the 1998 guidelines for the</text>
<text top="770" left="475" width="324" height="10" font="4">management of patients with valvular heart disease). J Am Coll Cardiol</text>
<text top="785" left="475" width="50" height="10" font="4">2008;52:e1</text>
<text top="782" left="525" width="25" height="15" font="4">–142.</text>
<text top="799" left="455" width="344" height="10" font="4">18. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive</text>
<text top="813" left="475" width="249" height="10" font="4">heart failure practice guideline. J Card Fail 2010;16:e1</text>
<text top="810" left="724" width="25" height="15" font="4">–194.</text>
<text top="827" left="455" width="344" height="10" font="4">19. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the</text>
<text top="841" left="475" width="324" height="10" font="4">diagnosis and treatment of acute and chronic heart failure 2012: the Task</text>
<text top="856" left="475" width="324" height="10" font="4">Force for the Diagnosis and Treatment of Acute and Chronic Heart</text>
<text top="870" left="475" width="324" height="10" font="4">Failure 2012 of the European Society of Cardiology. Eur Heart J 2012;</text>
<text top="884" left="475" width="37" height="10" font="4">33:1787</text>
<text top="881" left="512" width="25" height="15" font="4">–847.</text>
<text top="898" left="455" width="344" height="10" font="4">20. National Collaborating Centre for Acute and Chronic Conditions. Chronic</text>
<text top="912" left="475" width="325" height="10" font="4">heart failure: management of chronic heart failure in adults in primary and</text>
<text top="927" left="475" width="251" height="10" font="4">secondary care (NICE clinical guideline 108). Available at:</text>
<text top="927" left="728" width="71" height="10" font="5"><a href="http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf">http://www.nice.</a></text>
<text top="941" left="475" width="199" height="10" font="5"><a href="http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf">org.uk/nicemedia/live/13099/50517/50517.pdf</a></text>
<text top="941" left="674" width="119" height="10" font="4"><a href="http://www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf">. </a>Accessed March 11, 2013.</text>
<text top="955" left="455" width="344" height="10" font="4">21. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antith-</text>
<text top="969" left="475" width="324" height="10" font="4">rombotic Therapy and Prevention of Thrombosis, 9th ed: American</text>
<text top="983" left="475" width="324" height="10" font="4">College of Chest Physicians Evidence-Based Clinical Practice Guide-</text>
<text top="998" left="475" width="114" height="10" font="4">lines. Chest 2012;141:7S</text>
<text top="995" left="589" width="26" height="15" font="4">–47S.</text>
<text top="1012" left="455" width="344" height="10" font="4">22. Costanzo MR, Dipchand A, Starling R, et al. The International Society</text>
<text top="1026" left="475" width="324" height="10" font="4">of Heart and Lung Transplantation guidelines for the care of heart</text>
<text top="1040" left="475" width="268" height="10" font="4">transplant recipients. J Heart Lung Transplant 2010;29:914</text>
<text top="1037" left="743" width="20" height="15" font="4">–56.</text>
<text top="1054" left="455" width="288" height="10" font="4">23. Maron BJ, Towbin JA, Thiene G, et al. Contemporary de</text>
<text top="1051" left="743" width="57" height="15" font="4">ﬁnitions and</text>
<text top="1069" left="475" width="24" height="10" font="4">classi</text>
<text top="1066" left="500" width="300" height="15" font="4">ﬁcation of the cardiomyopathies: an American Heart Association</text>
<text top="1083" left="475" width="31" height="10" font="4">Scienti</text>
<text top="1080" left="506" width="294" height="15" font="4">ﬁc Statement from the Council on Clinical Cardiology, Heart</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e210</text>
</page>
<page number="65" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="90" width="324" height="10" font="4">Failure and Transplantation Committee; Quality of Care and Outcomes</text>
<text top="117" left="90" width="324" height="10" font="4">Research and Functional Genomics and Translational Biology Interdis-</text>
<text top="132" left="90" width="324" height="10" font="4">ciplinary Working Groups; and Council on Epidemiology and Preven-</text>
<text top="146" left="90" width="145" height="10" font="4">tion. Circulation 2006;113:1807</text>
<text top="143" left="235" width="20" height="15" font="4">–16.</text>
<text top="160" left="70" width="344" height="10" font="4">24. Ashley EA, Hershberger RE, Caleshu C, et al. Genetics and cardiovas-</text>
<text top="174" left="90" width="324" height="10" font="4">cular disease: a policy statement from the American Heart Association.</text>
<text top="188" left="90" width="116" height="10" font="4">Circulation 2012;126:142</text>
<text top="185" left="205" width="20" height="15" font="4">–57.</text>
<text top="203" left="70" width="344" height="10" font="4">25. Patel MR, White RD, Abbara S, et al. 2013 ACCF/ACR/ASE/ASNC/</text>
<text top="217" left="90" width="324" height="10" font="4">SCCT/SCMR appropriate utilization of cardiovascular imaging in heart</text>
<text top="231" left="90" width="324" height="10" font="4">failure: a report of the American College of Cardiology Foundation</text>
<text top="245" left="90" width="324" height="10" font="4">Appropriate Use Criteria Task Force. J Am Coll Cardiol 2013;61:</text>
<text top="259" left="90" width="22" height="10" font="4">2207</text>
<text top="256" left="112" width="20" height="15" font="4">–31.</text>
<text top="274" left="70" width="344" height="10" font="4">26. Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/</text>
<text top="288" left="90" width="324" height="10" font="4">AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary</text>
<text top="302" left="90" width="324" height="10" font="4">revascularization focused update: a report of the American College of</text>
<text top="316" left="90" width="324" height="10" font="4">Cardiology Foundation Appropriate Use Criteria Task Force, Society for</text>
<text top="330" left="90" width="324" height="10" font="4">Cardiovascular Angiography and Interventions, Society of Thoracic</text>
<text top="345" left="90" width="324" height="10" font="4">Surgeons, American Association for Thoracic Surgery, American Heart</text>
<text top="359" left="90" width="324" height="10" font="4">Association, American Society of Nuclear Cardiology, and the Society</text>
<text top="373" left="90" width="324" height="10" font="4">of Cardiovascular Computed Tomography. J Am Coll Cardiol 2012;59:</text>
<text top="387" left="90" width="17" height="10" font="4">857</text>
<text top="384" left="106" width="20" height="15" font="4">–81.</text>
<text top="401" left="70" width="344" height="10" font="4">27. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint</text>
<text top="416" left="90" width="324" height="10" font="4">National Committee on Prevention, Detection, Evaluation, and Treat-</text>
<text top="430" left="90" width="266" height="10" font="4">ment of High Blood Pressure. Hypertension 2003;42:1206</text>
<text top="427" left="355" width="20" height="15" font="4">–52.</text>
<text top="444" left="70" width="344" height="10" font="4">28. Third Report of the National Cholesterol Education Program (NCEP)</text>
<text top="458" left="90" width="324" height="10" font="4">Expert Panel on Detection, Evaluation, and Treatment of High Blood</text>
<text top="472" left="90" width="227" height="10" font="4">Cholesterol in Adults (Adult Treatment Panel III)</text>
<text top="469" left="321" width="93" height="15" font="4">ﬁnal report. Circula-</text>
<text top="486" left="90" width="89" height="10" font="4">tion 2002;106:3143</text>
<text top="483" left="178" width="25" height="15" font="4">–421.</text>
<text top="501" left="70" width="344" height="10" font="4">29. Balady GJ, Ades PA, Bittner VA, et al. Referral, enrollment, and</text>
<text top="515" left="90" width="324" height="10" font="4">delivery of cardiac rehabilitation/secondary prevention programs at</text>
<text top="529" left="90" width="324" height="10" font="4">clinical centers and beyond: a presidential advisory from the American</text>
<text top="543" left="90" width="209" height="10" font="4">Heart Association. Circulation 2011;124:2951</text>
<text top="540" left="298" width="20" height="15" font="4">–60.</text>
<text top="557" left="70" width="344" height="10" font="4">30. Allen LA, Stevenson LW, Grady KL, et al. Decision making in</text>
<text top="572" left="90" width="146" height="10" font="4">advanced heart failure: a scienti</text>
<text top="569" left="236" width="178" height="15" font="4">ﬁc statement from the American Heart</text>
<text top="586" left="90" width="180" height="10" font="4">Association. Circulation 2012;125:1928</text>
<text top="583" left="270" width="20" height="15" font="4">–52.</text>
<text top="600" left="70" width="344" height="10" font="4">31. Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the</text>
<text top="614" left="90" width="324" height="10" font="4">use of mechanical circulatory support: device strategies and patient</text>
<text top="628" left="90" width="85" height="10" font="4">selection: a scienti</text>
<text top="625" left="175" width="239" height="15" font="4">ﬁc statement from the American Heart Association.</text>
<text top="643" left="90" width="121" height="10" font="4">Circulation 2012;126:2648</text>
<text top="640" left="211" width="20" height="15" font="4">–67.</text>
<text top="657" left="70" width="344" height="10" font="4">32. Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart</text>
<text top="671" left="90" width="324" height="10" font="4">failure: a position statement from the Study Group on Advanced Heart</text>
<text top="685" left="90" width="324" height="10" font="4">Failure of the Heart Failure Association of the European Society of</text>
<text top="699" left="90" width="184" height="10" font="4">Cardiology. Eur J Heart Fail 2007;9:684</text>
<text top="696" left="274" width="20" height="15" font="4">–94.</text>
<text top="714" left="70" width="344" height="10" font="4">33. Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents</text>
<text top="728" left="90" width="224" height="10" font="4">for the prevention of stroke in nonvalvular atrial</text>
<text top="725" left="318" width="96" height="15" font="4">ﬁbrillation: a science</text>
<text top="742" left="90" width="324" height="10" font="4">advisory for healthcare professionals from the American Heart Associ-</text>
<text top="756" left="90" width="259" height="10" font="4">ation/American Stroke Association. Stroke 2012;43:3442</text>
<text top="753" left="349" width="65" height="15" font="4">–53. Errata in:</text>
<text top="770" left="90" width="209" height="10" font="4">Stroke 2013;44:e20 and Stroke 2012;43:e181.</text>
<text top="785" left="70" width="298" height="10" font="4">34. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal de</text>
<text top="782" left="368" width="46" height="15" font="4">ﬁnition of</text>
<text top="799" left="90" width="254" height="10" font="4">myocardial infarction. J Am Coll Cardiol 2012;60:1581</text>
<text top="796" left="343" width="20" height="15" font="4">–98.</text>
<text top="813" left="70" width="344" height="10" font="4">35. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treat-</text>
<text top="827" left="90" width="324" height="10" font="4">ments, and outcomes of patients with preserved systolic function</text>
<text top="841" left="90" width="324" height="10" font="4">hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.</text>
<text top="856" left="90" width="145" height="10" font="4">J Am Coll Cardiol 2007;50:768</text>
<text top="853" left="234" width="20" height="15" font="4">–77.</text>
<text top="870" left="70" width="344" height="10" font="4">36. Cleland JG, Torabi A, Khan NK. Epidemiology and management of</text>
<text top="884" left="90" width="324" height="10" font="4">heart failure and left ventricular systolic dysfunction in the aftermath of</text>
<text top="898" left="90" width="230" height="10" font="4">a myocardial infarction. Heart 2005;91 Suppl 2:ii7</text>
<text top="895" left="320" width="20" height="15" font="4">–13.</text>
<text top="912" left="70" width="344" height="10" font="4">37. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev</text>
<text top="927" left="90" width="51" height="10" font="4">2000;5:167</text>
<text top="924" left="141" width="20" height="15" font="4">–73.</text>
<text top="941" left="70" width="344" height="10" font="4">38. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incor-</text>
<text top="955" left="90" width="324" height="10" font="4">porated into the ACC/AHA 2005 guidelines for the diagnosis and</text>
<text top="969" left="90" width="324" height="10" font="4">management of heart failure in adults: a report of the American College</text>
<text top="983" left="90" width="324" height="10" font="4">of Cardiology Foundation/American Heart Association Task Force on</text>
<text top="998" left="90" width="232" height="10" font="4">Practice Guidelines. J Am Coll Cardiol 2009;53:e1</text>
<text top="995" left="322" width="20" height="15" font="4">–90.</text>
<text top="1012" left="70" width="344" height="10" font="4">39. Kane GC, Karon BL, Mahoney DW, et al. Progression of left</text>
<text top="1026" left="90" width="324" height="10" font="4">ventricular diastolic dysfunction and risk of heart failure. JAMA 2011;</text>
<text top="1040" left="90" width="37" height="10" font="4">306:856</text>
<text top="1037" left="126" width="20" height="15" font="4">–63.</text>
<text top="1054" left="70" width="344" height="10" font="4">40. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and</text>
<text top="1069" left="90" width="324" height="10" font="4">outcome of heart failure with preserved ejection fraction. N Engl J Med</text>
<text top="1083" left="90" width="62" height="10" font="4">2006;355:251</text>
<text top="1080" left="152" width="14" height="15" font="4">–9.</text>
<text top="103" left="455" width="126" height="10" font="4">41. Vasan RS, Levy D. De</text>
<text top="100" left="581" width="218" height="15" font="4">ﬁning diastolic heart failure: a call for standard-</text>
<text top="117" left="475" width="230" height="10" font="4">ized diagnostic criteria. Circulation 2000;101:2118</text>
<text top="114" left="706" width="20" height="15" font="4">–21.</text>
<text top="132" left="455" width="344" height="10" font="4">42. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospi-</text>
<text top="146" left="475" width="324" height="10" font="4">talized with heart failure and preserved left ventricular ejection fraction:</text>
<text top="160" left="475" width="276" height="10" font="4">prevalence, therapies, and outcomes. Circulation 2012;126:65</text>
<text top="157" left="751" width="20" height="15" font="4">–75.</text>
<text top="174" left="455" width="344" height="10" font="4">43. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and</text>
<text top="188" left="475" width="324" height="10" font="4">risk factors to heart failure with preserved or reduced ejection fraction:</text>
<text top="203" left="475" width="324" height="10" font="4">insights from the Framingham Heart Study of the National Heart, Lung,</text>
<text top="217" left="475" width="215" height="10" font="4">and Blood Institute. Circulation 2009;119:3070</text>
<text top="214" left="690" width="14" height="15" font="4">–7.</text>
<text top="231" left="455" width="344" height="10" font="4">44. Bhuiyan T, Maurer MS. Heart failure with preserved ejection fraction:</text>
<text top="245" left="475" width="324" height="10" font="4">persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep</text>
<text top="259" left="475" width="51" height="10" font="4">2011;5:440</text>
<text top="256" left="526" width="14" height="15" font="4">–9.</text>
<text top="274" left="455" width="344" height="10" font="4">45. Punnoose LR, Givertz MM, Lewis EF, et al. Heart failure with recov-</text>
<text top="288" left="475" width="324" height="10" font="4">ered ejection fraction: a distinct clinical entity. J Card Fail 2011;17:</text>
<text top="302" left="475" width="17" height="10" font="4">527</text>
<text top="299" left="492" width="20" height="15" font="4">–32.</text>
<text top="316" left="455" width="344" height="10" font="4">46. The Criteria Committee of the New York Heart Association. Nomen-</text>
<text top="330" left="475" width="324" height="10" font="4">clature and criteria for diagnosis of diseases of the heart and great vessels.</text>
<text top="345" left="475" width="223" height="10" font="4">9th edition. Boston, Mass: Little &amp; Brown; 1994.</text>
<text top="359" left="455" width="344" height="10" font="4">47. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prog-</text>
<text top="373" left="475" width="52" height="10" font="4">nostic signi</text>
<text top="370" left="528" width="272" height="15" font="4">ﬁcance of heart failure stages: application of the American</text>
<text top="387" left="475" width="324" height="10" font="4">College of Cardiology/American Heart Association heart failure staging</text>
<text top="401" left="475" width="243" height="10" font="4">criteria in the community. Circulation 2007;115:1563</text>
<text top="398" left="718" width="20" height="15" font="4">–70.</text>
<text top="416" left="455" width="344" height="10" font="4">48. Goldman L, Hashimoto B, Cook EF, et al. Comparative reproducibility</text>
<text top="430" left="475" width="324" height="10" font="4">and validity of systems for assessing cardiovascular functional class:</text>
<text top="444" left="475" width="114" height="10" font="4">advantages of a new speci</text>
<text top="441" left="589" width="210" height="15" font="4">ﬁc activity scale. Circulation 1981;64:1227–34.</text>
<text top="458" left="455" width="344" height="10" font="4">49. Madsen BK, Hansen JF, Stokholm KH, et al. Chronic congestive heart</text>
<text top="472" left="475" width="324" height="10" font="4">failure: description and survival of 190 consecutive patients with</text>
<text top="486" left="475" width="324" height="10" font="4">a diagnosis of chronic congestive heart failure based on clinical signs</text>
<text top="501" left="475" width="185" height="10" font="4">and symptoms. Eur Heart J 1994;15:303</text>
<text top="498" left="660" width="20" height="15" font="4">–10.</text>
<text top="515" left="455" width="297" height="10" font="4">50. Djousse L, Driver JA, Gaziano JM. Relation between modi</text>
<text top="512" left="752" width="47" height="15" font="4">ﬁable life-</text>
<text top="529" left="475" width="299" height="10" font="4">style factors and lifetime risk of heart failure. JAMA 2009;302:394</text>
<text top="526" left="774" width="25" height="15" font="4">–400.</text>
<text top="543" left="455" width="344" height="10" font="4">51. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke</text>
<text top="557" left="475" width="38" height="10" font="4">statistics</text>
<text top="555" left="513" width="286" height="15" font="4">–2013 update: a report from the American Heart Association.</text>
<text top="572" left="475" width="109" height="10" font="4">Circulation 2013;127:e6</text>
<text top="569" left="585" width="25" height="15" font="4">–245.</text>
<text top="586" left="455" width="344" height="10" font="4">52. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of</text>
<text top="600" left="475" width="166" height="10" font="4">heart failure in elderly persons, 1994</text>
<text top="597" left="641" width="158" height="15" font="4">–2003. Arch Intern Med 2008;168:</text>
<text top="614" left="475" width="17" height="10" font="4">418</text>
<text top="611" left="492" width="20" height="15" font="4">–24.</text>
<text top="628" left="455" width="155" height="10" font="4">53. Roger VL, Weston SA, Red</text>
<text top="626" left="611" width="189" height="15" font="4">ﬁeld MM, et al. Trends in heart failure</text>
<text top="643" left="475" width="324" height="10" font="4">incidence and survival in a community-based population. JAMA 2004;</text>
<text top="657" left="475" width="37" height="10" font="4">292:344</text>
<text top="654" left="512" width="20" height="15" font="4">–50.</text>
<text top="671" left="455" width="89" height="10" font="4">54. Owan TE, Red</text>
<text top="668" left="544" width="255" height="15" font="4">ﬁeld MM. Epidemiology of diastolic heart failure. Prog</text>
<text top="685" left="475" width="129" height="10" font="4">Cardiovasc Dis 2005;47:320</text>
<text top="682" left="605" width="20" height="15" font="4">–32.</text>
<text top="699" left="455" width="344" height="10" font="4">55. The Booming Dynamics of Aging: From Awareness to Action. The</text>
<text top="714" left="475" width="324" height="10" font="4">White House Conference on Aging. Washington, DC: US Department of</text>
<text top="728" left="475" width="159" height="10" font="4">Health and Human Services; 2011.</text>
<text top="742" left="455" width="344" height="10" font="4">56. Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence</text>
<text top="756" left="475" width="324" height="10" font="4">of congestive heart failure by ethnicity: the Multi-Ethnic Study of</text>
<text top="770" left="475" width="223" height="10" font="4">Atherosclerosis. Arch Intern Med 2008;168:2138</text>
<text top="767" left="699" width="20" height="15" font="4">–45.</text>
<text top="785" left="455" width="344" height="10" font="4">57. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for devel-</text>
<text top="799" left="475" width="324" height="10" font="4">oping congestive heart failure: the Framingham Heart Study. Circulation</text>
<text top="813" left="475" width="68" height="10" font="4">2002;106:3068</text>
<text top="810" left="543" width="20" height="15" font="4">–72.</text>
<text top="827" left="455" width="344" height="10" font="4">58. Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and</text>
<text top="841" left="475" width="324" height="10" font="4">survival (from the Atherosclerosis Risk in Communities study). Am J</text>
<text top="856" left="475" width="105" height="10" font="4">Cardiol 2008;101:1016</text>
<text top="853" left="580" width="20" height="15" font="4">–22.</text>
<text top="870" left="455" width="344" height="10" font="4">59. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the</text>
<text top="884" left="475" width="324" height="10" font="4">incidence of and survival with heart failure. N Engl J Med 2002;347:</text>
<text top="898" left="475" width="22" height="10" font="4">1397</text>
<text top="895" left="498" width="25" height="15" font="4">–402.</text>
<text top="912" left="455" width="344" height="10" font="4">60. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term</text>
<text top="927" left="475" width="319" height="10" font="4">outcomes among Medicare patients hospitalized for heart failure, 1993</text>
<text top="924" left="794" width="6" height="15" font="4">–</text>
<text top="941" left="475" width="131" height="10" font="4">2006. JAMA 2010;303:2141</text>
<text top="938" left="606" width="14" height="15" font="4">–7.</text>
<text top="955" left="455" width="344" height="10" font="4">61. Krumholz HM, Merrill AR, Schone EM, et al. Patterns of hospital</text>
<text top="969" left="475" width="324" height="10" font="4">performance in acute myocardial infarction and heart failure 30-day</text>
<text top="983" left="475" width="324" height="10" font="4">mortality and readmission. Circ Cardiovasc Qual Outcomes 2009;2:</text>
<text top="998" left="475" width="17" height="10" font="4">407</text>
<text top="995" left="492" width="20" height="15" font="4">–13.</text>
<text top="1012" left="455" width="344" height="10" font="4">62. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and</text>
<text top="1026" left="475" width="324" height="10" font="4">asymptomatic left-ventricular systolic dysfunction in an urban pop-</text>
<text top="1040" left="475" width="133" height="10" font="4">ulation. Lancet 1997;350:829</text>
<text top="1037" left="609" width="20" height="15" font="4">–33.</text>
<text top="1054" left="455" width="344" height="10" font="4">63. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure</text>
<text top="1069" left="475" width="324" height="10" font="4">and left ventricular dysfunction in the general population: the Rotterdam</text>
<text top="1083" left="475" width="145" height="10" font="4">Study. Eur Heart J 1999;20:447</text>
<text top="1080" left="620" width="20" height="15" font="4">–55.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e211</text>
</page>
<page number="66" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="70" width="38" height="10" font="4">64. Red</text>
<text top="100" left="108" width="306" height="15" font="4">ﬁeld MM, Jacobsen SJ, Burnett JC Jr., et al. Burden of systolic and</text>
<text top="117" left="90" width="324" height="10" font="4">diastolic ventricular dysfunction in the community: appreciating the</text>
<text top="132" left="90" width="261" height="10" font="4">scope of the heart failure epidemic. JAMA 2003;289:194</text>
<text top="129" left="350" width="25" height="15" font="4">–202.</text>
<text top="146" left="70" width="344" height="10" font="4">65. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year</text>
<text top="160" left="90" width="324" height="10" font="4">survival and life expectancy in patients with left ventricular systolic</text>
<text top="174" left="90" width="248" height="10" font="4">dysfunction: a follow-up study. Lancet 2003;361:1843</text>
<text top="171" left="337" width="14" height="15" font="4">–8.</text>
<text top="188" left="70" width="344" height="10" font="4">66. Heo S, Doering LV, Widener J, et al. Predictors and effect of physical</text>
<text top="203" left="90" width="324" height="10" font="4">symptom status on health-related quality of life in patients with heart</text>
<text top="217" left="90" width="166" height="10" font="4">failure. Am J Crit Care 2008;17:124</text>
<text top="214" left="255" width="20" height="15" font="4">–32.</text>
<text top="231" left="70" width="344" height="10" font="4">67. Lesman-Leegte I, Jaarsma T, Coyne JC, et al. Quality of life and</text>
<text top="245" left="90" width="324" height="10" font="4">depressive symptoms in the elderly: a comparison between patients with</text>
<text top="259" left="90" width="324" height="10" font="4">heart failure and age- and gender-matched community controls. J Card</text>
<text top="274" left="90" width="72" height="10" font="4">Fail 2009;15:17</text>
<text top="271" left="161" width="20" height="15" font="4">–23.</text>
<text top="288" left="70" width="344" height="10" font="4">68. Moser DK, Yamokoski L, Sun JL, et al. Improvement in health-related</text>
<text top="302" left="90" width="324" height="10" font="4">quality of life after hospitalization predicts event-free survival in patients</text>
<text top="316" left="90" width="241" height="10" font="4">with advanced heart failure. J Card Fail 2009;15:763</text>
<text top="313" left="331" width="14" height="15" font="4">–9.</text>
<text top="330" left="70" width="344" height="10" font="4">69. Rodriguez-Artalejo F, Guallar-Castillon P, Pascual CR, et al. Health-</text>
<text top="345" left="90" width="324" height="10" font="4">related quality of life as a predictor of hospital readmission and death</text>
<text top="359" left="90" width="305" height="10" font="4">among patients with heart failure. Arch Intern Med 2005;165:1274</text>
<text top="356" left="394" width="14" height="15" font="4">–9.</text>
<text top="373" left="70" width="344" height="10" font="4">70. Heo S, Moser DK, Widener J. Gender differences in the effects of</text>
<text top="387" left="90" width="324" height="10" font="4">physical and emotional symptoms on health-related quality of life in</text>
<text top="401" left="90" width="280" height="10" font="4">patients with heart failure. Eur J Cardiovasc Nurs 2007;6:146</text>
<text top="398" left="370" width="20" height="15" font="4">–52.</text>
<text top="416" left="70" width="344" height="10" font="4">71. Riegel B, Moser DK, Rayens MK, et al. Ethnic differences in quality of</text>
<text top="430" left="90" width="258" height="10" font="4">life in persons with heart failure. J Card Fail 2008;14:41</text>
<text top="427" left="348" width="14" height="15" font="4">–7.</text>
<text top="444" left="70" width="344" height="10" font="4">72. Bosworth HB, Steinhauser KE, Orr M, et al. Congestive heart failure</text>
<text top="458" left="90" width="34" height="10" font="4">patients</text>
<text top="455" left="124" width="290" height="15" font="4">’ perceptions of quality of life: the integration of physical and</text>
<text top="472" left="90" width="235" height="10" font="4">psychosocial factors. Aging Ment Health 2004;8:83</text>
<text top="469" left="325" width="20" height="15" font="4">–91.</text>
<text top="486" left="70" width="344" height="10" font="4">73. Carmona-Bernal C, Ruiz-Garcia A, Villa-Gil M, et al. Quality of life in</text>
<text top="501" left="90" width="324" height="10" font="4">patients with congestive heart failure and central sleep apnea. Sleep Med</text>
<text top="515" left="90" width="51" height="10" font="4">2008;9:646</text>
<text top="512" left="141" width="20" height="15" font="4">–51.</text>
<text top="529" left="70" width="140" height="10" font="4">74. Lewis EF, Lamas GA, O</text>
<text top="526" left="210" width="204" height="15" font="4">’Meara E, et al. Characterization of health-</text>
<text top="543" left="90" width="324" height="10" font="4">related quality of life in heart failure patients with preserved versus</text>
<text top="557" left="90" width="279" height="10" font="4">low ejection fraction in CHARM. Eur J Heart Fail 2007;9:83</text>
<text top="554" left="369" width="20" height="15" font="4">–91.</text>
<text top="572" left="70" width="344" height="10" font="4">75. Masoudi FA, Rumsfeld JS, Havranek EP, et al. Age, functional capacity,</text>
<text top="586" left="90" width="324" height="10" font="4">and health-related quality of life in patients with heart failure. J Card Fail</text>
<text top="600" left="90" width="57" height="10" font="4">2004;10:368</text>
<text top="597" left="146" width="20" height="15" font="4">–73.</text>
<text top="614" left="70" width="302" height="10" font="4">76. Pressler SJ, Subramanian U, Kareken D, et al. Cognitive de</text>
<text top="611" left="372" width="42" height="15" font="4">ﬁcits and</text>
<text top="628" left="90" width="324" height="10" font="4">health-related quality of life in chronic heart failure. J Cardiovasc Nurs</text>
<text top="643" left="90" width="57" height="10" font="4">2010;25:189</text>
<text top="640" left="146" width="20" height="15" font="4">–98.</text>
<text top="657" left="70" width="344" height="10" font="4">77. Majani G, Giardini A, Opasich C, et al. Effect of valsartan on quality of</text>
<text top="671" left="90" width="324" height="10" font="4">life when added to usual therapy for heart failure: results from the</text>
<text top="685" left="90" width="248" height="10" font="4">Valsartan Heart Failure Trial. J Card Fail 2005;11:253</text>
<text top="682" left="338" width="14" height="15" font="4">–9.</text>
<text top="699" left="70" width="344" height="10" font="4">78. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac</text>
<text top="714" left="90" width="324" height="10" font="4">resynchronization on morbidity and mortality in heart failure. N Engl J</text>
<text top="728" left="90" width="92" height="10" font="4">Med 2005;352:1539</text>
<text top="725" left="181" width="20" height="15" font="4">–49.</text>
<text top="742" left="70" width="344" height="10" font="4">79. Harrison MB, Browne GB, Roberts J, et al. Quality of life of individuals</text>
<text top="756" left="90" width="324" height="10" font="4">with heart failure: a randomized trial of the effectiveness of two models</text>
<text top="770" left="90" width="246" height="10" font="4">of hospital-to-home transition. Med Care 2002;40:271</text>
<text top="767" left="336" width="20" height="15" font="4">–82.</text>
<text top="785" left="70" width="344" height="10" font="4">80. Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support</text>
<text top="799" left="90" width="324" height="10" font="4">or telemonitoring programmes for patients with chronic heart failure.</text>
<text top="813" left="90" width="229" height="10" font="4">Cochrane Database Syst Rev 2010;(8):CD007228.</text>
<text top="827" left="70" width="344" height="10" font="4">81. Johansson P, Dahlstrom U, Brostrom A. Factors and interventions</text>
<text top="841" left="90" width="9" height="10" font="4">in</text>
<text top="838" left="98" width="316" height="15" font="4">ﬂuencing health-related quality of life in patients with heart failure:</text>
<text top="856" left="90" width="265" height="10" font="4">a review of the literature. Eur J Cardiovasc Nurs 2006;5:5</text>
<text top="853" left="355" width="20" height="15" font="4">–15.</text>
<text top="870" left="70" width="344" height="10" font="4">82. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for</text>
<text top="884" left="90" width="324" height="10" font="4">the management of heart failure patients at high risk for admission:</text>
<text top="898" left="90" width="311" height="10" font="4">a systematic review of randomized trials. J Am Coll Cardiol 2004;44:810</text>
<text top="895" left="400" width="14" height="15" font="4">–9.</text>
<text top="912" left="70" width="344" height="10" font="4">83. Ditewig JB, Blok H, Havers J, et al. Effectiveness of self-management</text>
<text top="927" left="90" width="324" height="10" font="4">interventions on mortality, hospital readmissions, chronic heart failure</text>
<text top="941" left="90" width="324" height="10" font="4">hospitalization rate and quality of life in patients with chronic heart</text>
<text top="955" left="90" width="281" height="10" font="4">failure: a systematic review. Patient Educ Couns 2010;78:297</text>
<text top="952" left="371" width="25" height="15" font="4">–315.</text>
<text top="969" left="70" width="344" height="10" font="4">84. Jovicic A, Holroyd-Leduc JM, Straus SE. Effects of self-management</text>
<text top="983" left="90" width="324" height="10" font="4">intervention on health outcomes of patients with heart failure:</text>
<text top="998" left="90" width="324" height="10" font="4">a systematic review of randomized controlled trials. BMC Cardiovasc</text>
<text top="1012" left="90" width="82" height="10" font="4">Disord 2006;6:43.</text>
<text top="1026" left="70" width="344" height="10" font="4">85. Chien CL, Lee CM, Wu YW, et al. Home-based exercise increases</text>
<text top="1040" left="90" width="324" height="10" font="4">exercise capacity but not quality of life in people with chronic heart</text>
<text top="1054" left="90" width="266" height="10" font="4">failure: a systematic review. Aust J Physiother 2008;54:87</text>
<text top="1051" left="356" width="20" height="15" font="4">–93.</text>
<text top="1069" left="70" width="344" height="10" font="4">86. Karapolat H, Demir E, Bozkaya YT, et al. Comparison of hospital-based</text>
<text top="1083" left="90" width="324" height="10" font="4">versus home-based exercise training in patients with heart failure: effects</text>
<text top="103" left="475" width="324" height="10" font="4">on functional capacity, quality of life, psychological symptoms, and</text>
<text top="117" left="475" width="259" height="10" font="4">hemodynamic parameters. Clin Res Cardiol 2009;98:635</text>
<text top="114" left="734" width="20" height="15" font="4">–42.</text>
<text top="132" left="455" width="344" height="10" font="4">87. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future</text>
<text top="146" left="475" width="324" height="10" font="4">of cardiovascular disease in the United States: a policy statement from</text>
<text top="160" left="475" width="268" height="10" font="4">the American Heart Association. Circulation 2011;123:933</text>
<text top="157" left="743" width="20" height="15" font="4">–44.</text>
<text top="174" left="455" width="344" height="10" font="4">88. Titler MG, Jensen GA, Dochterman JM, et al. Cost of hospital care for</text>
<text top="188" left="475" width="324" height="10" font="4">older adults with heart failure: medical, pharmaceutical, and nursing</text>
<text top="203" left="475" width="163" height="10" font="4">costs. Health Serv Res 2008;43:635</text>
<text top="200" left="638" width="20" height="15" font="4">–55.</text>
<text top="217" left="455" width="344" height="10" font="4">89. Wang G, Zhang Z, Ayala C, et al. Costs of heart failure-related hospi-</text>
<text top="231" left="475" width="324" height="10" font="4">talizations in patients aged 18 to 64 years. Am J Manag Care 2010;16:</text>
<text top="245" left="475" width="17" height="10" font="4">769</text>
<text top="242" left="492" width="20" height="15" font="4">–76.</text>
<text top="259" left="455" width="339" height="10" font="4">90. American Diabetes Association. Standards of medical care in diabetes</text>
<text top="256" left="794" width="6" height="15" font="4">–</text>
<text top="274" left="475" width="192" height="10" font="4">2012. Diabetes Care 2012;35 Suppl 1:S11</text>
<text top="271" left="667" width="20" height="15" font="4">–63.</text>
<text top="288" left="455" width="344" height="10" font="4">91. Levy D, Larson MG, Vasan RS, et al. The progression from hyperten-</text>
<text top="302" left="475" width="249" height="10" font="4">sion to congestive heart failure. JAMA 1996;275:1557</text>
<text top="299" left="724" width="20" height="15" font="4">–62.</text>
<text top="316" left="455" width="344" height="10" font="4">92. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the</text>
<text top="330" left="475" width="324" height="10" font="4">general population of men: morbidity, risk factors and prognosis. J Intern</text>
<text top="345" left="475" width="86" height="10" font="4">Med 2001;249:253</text>
<text top="342" left="561" width="20" height="15" font="4">–61.</text>
<text top="359" left="455" width="344" height="10" font="4">93. Effects of treatment on morbidity in hypertension, II: results in patients</text>
<text top="373" left="475" width="324" height="10" font="4">with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA</text>
<text top="387" left="475" width="68" height="10" font="4">1970;213:1143</text>
<text top="384" left="543" width="20" height="15" font="4">–52.</text>
<text top="401" left="455" width="344" height="10" font="4">94. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by</text>
<text top="416" left="475" width="324" height="10" font="4">antihypertensive drug treatment in older persons with isolated systolic</text>
<text top="430" left="475" width="324" height="10" font="4">hypertension: SHEP Cooperative Research Group. JAMA 1997;278:</text>
<text top="444" left="475" width="17" height="10" font="4">212</text>
<text top="441" left="492" width="14" height="15" font="4">–6.</text>
<text top="458" left="455" width="344" height="10" font="4">95. Izzo JL Jr., Gradman AH. Mechanisms and management of hypertensive</text>
<text top="472" left="475" width="324" height="10" font="4">heart disease: from left ventricular hypertrophy to heart failure. Med Clin</text>
<text top="486" left="475" width="112" height="10" font="4">North Am 2004;88:1257</text>
<text top="483" left="587" width="20" height="15" font="4">–71.</text>
<text top="501" left="455" width="306" height="10" font="4">96. Baker DW. Prevention of heart failure. J Card Fail 2002;8:333</text>
<text top="498" left="761" width="20" height="15" font="4">–46.</text>
<text top="515" left="455" width="344" height="10" font="4">97. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for devel-</text>
<text top="529" left="475" width="324" height="10" font="4">oping hypertension in middle-aged women and men: the Framingham</text>
<text top="543" left="475" width="163" height="10" font="4">Heart Study. JAMA 2002;287:1003</text>
<text top="540" left="638" width="20" height="15" font="4">–10.</text>
<text top="557" left="455" width="344" height="10" font="4">98. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of</text>
<text top="572" left="475" width="324" height="10" font="4">the heart in diabetes: part I: general concepts. Circulation 2002;105:</text>
<text top="586" left="475" width="22" height="10" font="4">1727</text>
<text top="583" left="498" width="20" height="15" font="4">–33.</text>
<text top="600" left="455" width="344" height="10" font="4">99. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart</text>
<text top="614" left="475" width="166" height="10" font="4">failure. N Engl J Med 2002;347:305</text>
<text top="611" left="641" width="20" height="15" font="4">–13.</text>
<text top="628" left="450" width="350" height="10" font="4">100. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart</text>
<text top="643" left="475" width="324" height="10" font="4">failure in US men and women: NHANES I epidemiologic follow-up</text>
<text top="657" left="475" width="173" height="10" font="4">study. Arch Intern Med 2001;161:996</text>
<text top="654" left="648" width="31" height="15" font="4">–1002.</text>
<text top="671" left="450" width="350" height="10" font="4">101. Krumholz HM, Chen YT, Wang Y, et al. Predictors of readmission</text>
<text top="685" left="475" width="324" height="10" font="4">among elderly survivors of admission with heart failure. Am Heart J</text>
<text top="699" left="475" width="56" height="10" font="4">2000;139:72</text>
<text top="696" left="532" width="14" height="15" font="4">–7.</text>
<text top="714" left="450" width="350" height="10" font="4">102. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of</text>
<text top="728" left="475" width="324" height="10" font="4">morbidity and mortality in the Studies of Left Ventricular Dysfunction</text>
<text top="742" left="475" width="269" height="10" font="4">(SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017</text>
<text top="739" left="745" width="20" height="15" font="4">–20.</text>
<text top="756" left="450" width="350" height="10" font="4">103. Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation</text>
<text top="770" left="475" width="68" height="10" font="4">2003;108:1552</text>
<text top="767" left="543" width="14" height="15" font="4">–3.</text>
<text top="785" left="450" width="350" height="10" font="4">104. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical</text>
<text top="799" left="475" width="324" height="10" font="4">trials for the National Cholesterol Education Program Adult Treatment</text>
<text top="813" left="475" width="242" height="10" font="4">Panel III Guidelines. J Am Coll Cardiol 2004;44:720</text>
<text top="810" left="718" width="20" height="15" font="4">–32.</text>
<text top="827" left="450" width="350" height="10" font="4">105. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World</text>
<text top="841" left="475" width="324" height="10" font="4">Health Organization/International Society and Federation of Cardiology</text>
<text top="856" left="475" width="103" height="10" font="4">Task Force on the De</text>
<text top="853" left="579" width="221" height="15" font="4">ﬁnition and Classiﬁcation of Cardiomyopathies.</text>
<text top="870" left="475" width="110" height="10" font="4">Circulation 1996;93:841</text>
<text top="867" left="586" width="14" height="15" font="4">–2.</text>
<text top="884" left="450" width="350" height="10" font="4">106. Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology</text>
<text top="898" left="475" width="324" height="10" font="4">of idiopathic dilated cardiomyopathy (summary of a National Heart,</text>
<text top="912" left="475" width="299" height="10" font="4">Lung, and Blood Institute workshop). Am J Cardiol 1992;69:1458</text>
<text top="909" left="775" width="20" height="15" font="4">–66.</text>
<text top="927" left="450" width="350" height="10" font="4">107. Adams KF Jr., Fonarow GC, Emerman CL, et al. Characteristics and</text>
<text top="941" left="475" width="324" height="10" font="4">outcomes of patients hospitalized for heart failure in the United States:</text>
<text top="955" left="475" width="261" height="10" font="4">rationale, design, and preliminary observations from the</text>
<text top="952" left="741" width="58" height="15" font="4">ﬁrst 100,000</text>
<text top="969" left="475" width="324" height="10" font="4">cases in the Acute Decompensated Heart Failure National Registry</text>
<text top="983" left="475" width="178" height="10" font="4">(ADHERE). Am Heart J 2005;149:209</text>
<text top="980" left="653" width="20" height="15" font="4">–16.</text>
<text top="998" left="450" width="350" height="10" font="4">108. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor</text>
<text top="1012" left="475" width="324" height="10" font="4">blocker valsartan in chronic heart failure. N Engl J Med 2001;345:</text>
<text top="1026" left="475" width="22" height="10" font="4">1667</text>
<text top="1023" left="498" width="20" height="15" font="4">–75.</text>
<text top="1040" left="450" width="350" height="10" font="4">109. Ghali JK, Pina IL, Gottlieb SS, et al. Metoprolol CR/XL in female</text>
<text top="1054" left="475" width="324" height="10" font="4">patients with heart failure: analysis of the experience in Metoprolol</text>
<text top="1069" left="475" width="324" height="10" font="4">Extended-Release Randomized Intervention Trial in Heart Failure</text>
<text top="1083" left="475" width="188" height="10" font="4">(MERIT-HF). Circulation 2002;105:1585</text>
<text top="1080" left="663" width="20" height="15" font="4">–91.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e212</text>
</page>
<page number="67" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">110. Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome</text>
<text top="117" left="90" width="273" height="10" font="4">of left ventricular dysfunction. N Engl J Med 1999;340:609</text>
<text top="114" left="363" width="20" height="15" font="4">–16.</text>
<text top="132" left="64" width="350" height="10" font="4">111. Nieminen MS, Harjola VP, Hochadel M, et al. Gender related differ-</text>
<text top="146" left="90" width="324" height="10" font="4">ences in patients presenting with acute heart failure: results from Euro-</text>
<text top="160" left="90" width="246" height="10" font="4">Heart Failure Survey II. Eur J Heart Fail 2008;10:140</text>
<text top="157" left="336" width="14" height="15" font="4">–8.</text>
<text top="174" left="64" width="350" height="10" font="4">112. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med</text>
<text top="188" left="90" width="68" height="10" font="4">1994;331:1564</text>
<text top="185" left="158" width="20" height="15" font="4">–75.</text>
<text top="203" left="64" width="350" height="10" font="4">113. McNamara DM, Starling RC, Cooper LT, et al. Clinical and demo-</text>
<text top="217" left="90" width="324" height="10" font="4">graphic predictors of outcomes in recent onset dilated cardiomyopathy:</text>
<text top="231" left="90" width="29" height="10" font="4">results</text>
<text top="231" left="129" width="140" height="10" font="4">of the IMAC (Intervention</text>
<text top="231" left="279" width="72" height="10" font="4">in Myocarditis</text>
<text top="231" left="361" width="53" height="10" font="4">and Acute</text>
<text top="245" left="90" width="273" height="10" font="4">Cardiomyopathy)-2 study. J Am Coll Cardiol 2011;58:1112</text>
<text top="242" left="363" width="14" height="15" font="4">–8.</text>
<text top="259" left="64" width="350" height="10" font="4">114. Ehlert FA, Cannom DS, Renfroe EG, et al. Comparison of dilated</text>
<text top="274" left="90" width="324" height="10" font="4">cardiomyopathy and coronary artery disease in patients with life-</text>
<text top="288" left="90" width="324" height="10" font="4">threatening ventricular arrhythmias: differences in presentation and</text>
<text top="302" left="90" width="262" height="10" font="4">outcome in the AVID registry. Am Heart J 2001;142:816</text>
<text top="299" left="352" width="20" height="15" font="4">–22.</text>
<text top="316" left="64" width="350" height="10" font="4">115. Abraham WT, Young JB, Leon AR, et al. Effects of cardiac resynch-</text>
<text top="330" left="90" width="324" height="10" font="4">ronization on disease progression in patients with left ventricular systolic</text>
<text top="345" left="90" width="279" height="10" font="4">dysfunction, an indication for an implantable cardioverter-de</text>
<text top="342" left="369" width="44" height="15" font="4">ﬁbrillator,</text>
<text top="359" left="90" width="324" height="10" font="4">and mildly symptomatic chronic heart failure. Circulation 2004;110:</text>
<text top="373" left="90" width="22" height="10" font="4">2864</text>
<text top="370" left="112" width="14" height="15" font="4">–8.</text>
<text top="387" left="64" width="350" height="10" font="4">116. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization</text>
<text top="401" left="90" width="189" height="10" font="4">therapy with or without an implantable de</text>
<text top="398" left="279" width="135" height="15" font="4">ﬁbrillator in advanced chronic</text>
<text top="416" left="90" width="197" height="10" font="4">heart failure. N Engl J Med 2004;350:2140</text>
<text top="413" left="287" width="20" height="15" font="4">–50.</text>
<text top="430" left="64" width="186" height="10" font="4">117. CBIS II Authors. The Cardiac Insuf</text>
<text top="427" left="251" width="163" height="15" font="4">ﬁciency Bisoprolol Study II (CIBIS-</text>
<text top="444" left="90" width="191" height="10" font="4">II): a randomised trial. Lancet 1999;353:9</text>
<text top="441" left="281" width="20" height="15" font="4">–13.</text>
<text top="458" left="64" width="350" height="10" font="4">118. Hershberger RE, Siegfried JD. Update 2011: clinical and genetic issues in</text>
<text top="472" left="90" width="298" height="10" font="4">familial dilated cardiomyopathy. J Am Coll Cardiol 2011;57:1641</text>
<text top="469" left="388" width="14" height="15" font="4">–9.</text>
<text top="486" left="64" width="350" height="10" font="4">119. Petretta M, Pirozzi F, Sasso L, et al. Review and metaanalysis of the</text>
<text top="501" left="90" width="324" height="10" font="4">frequency of familial dilated cardiomyopathy. Am J Cardiol 2011;108:</text>
<text top="515" left="90" width="22" height="10" font="4">1171</text>
<text top="512" left="112" width="14" height="15" font="4">–6.</text>
<text top="529" left="64" width="350" height="10" font="4">120. Judge DP, Rouf R. Use of genetics in the clinical evaluation and</text>
<text top="543" left="90" width="324" height="10" font="4">management of heart failure. Curr Treat Options Cardiovasc Med 2010;</text>
<text top="557" left="90" width="31" height="10" font="4">12:566</text>
<text top="554" left="121" width="20" height="15" font="4">–77.</text>
<text top="572" left="64" width="350" height="10" font="4">121. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of</text>
<text top="586" left="90" width="324" height="10" font="4">cardiomyopathy: a Heart Failure Society of America practice guideline.</text>
<text top="600" left="90" width="105" height="10" font="4">J Card Fail 2009;15:83</text>
<text top="597" left="195" width="20" height="15" font="4">–97.</text>
<text top="614" left="64" width="350" height="10" font="4">122. Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in</text>
<text top="628" left="90" width="324" height="10" font="4">cardiomyopathies: a position statement of the European Society of</text>
<text top="643" left="90" width="324" height="10" font="4">Cardiology Working Group on Myocardial and Pericardial Diseases. Eur</text>
<text top="657" left="90" width="98" height="10" font="4">Heart J 2010;31:2715</text>
<text top="654" left="188" width="20" height="15" font="4">–26.</text>
<text top="671" left="64" width="350" height="10" font="4">123. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert</text>
<text top="685" left="90" width="324" height="10" font="4">consensus statement on the state of genetic testing for the channelo-</text>
<text top="699" left="90" width="324" height="10" font="4">pathies and cardiomyopathies: this document was developed as a</text>
<text top="714" left="90" width="324" height="10" font="4">partnership between the Heart Rhythm Society (HRS) and the Euro-</text>
<text top="728" left="90" width="299" height="10" font="4">pean Heart Rhythm Association (EHRA). Europace 2011;13:1077</text>
<text top="725" left="389" width="25" height="15" font="4">–109.</text>
<text top="742" left="64" width="350" height="10" font="4">124. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of</text>
<text top="756" left="90" width="236" height="10" font="4">the clinical syndrome. Am J Med Sci 2001;321:225</text>
<text top="753" left="326" width="20" height="15" font="4">–36.</text>
<text top="770" left="64" width="350" height="10" font="4">125. Marfella R, Di Filippo C, Portoghese M, et al. Myocardial lipid accu-</text>
<text top="785" left="90" width="324" height="10" font="4">mulation in patients with pressure-overloaded heart and metabolic</text>
<text top="799" left="90" width="169" height="10" font="4">syndrome. J Lipid Res 2009;50:2314</text>
<text top="796" left="259" width="20" height="15" font="4">–23.</text>
<text top="813" left="64" width="350" height="10" font="4">126. Schulze PC. Myocardial lipid accumulation and lipotoxicity in heart</text>
<text top="827" left="90" width="154" height="10" font="4">failure. J Lipid Res 2009;50:2137</text>
<text top="824" left="244" width="14" height="15" font="4">–8.</text>
<text top="841" left="64" width="350" height="10" font="4">127. Aguilar D, Bozkurt B, Ramasubbu K, et al. Relationship of hemoglobin</text>
<text top="856" left="90" width="324" height="10" font="4">A1C and mortality in heart failure patients with diabetes. J Am Coll</text>
<text top="870" left="90" width="93" height="10" font="4">Cardiol 2009;54:422</text>
<text top="867" left="184" width="14" height="15" font="4">–8.</text>
<text top="884" left="64" width="272" height="10" font="4">128. Eurich DT, McAlister FA, Blackburn DF, et al. Bene</text>
<text top="881" left="336" width="78" height="15" font="4">ﬁts and harms of</text>
<text top="898" left="90" width="324" height="10" font="4">antidiabetic agents in patients with diabetes and heart failure: systematic</text>
<text top="912" left="90" width="127" height="10" font="4">review. BMJ 2007;335:497.</text>
<text top="927" left="64" width="350" height="10" font="4">129. Aguilar D, Bozkurt B, Pritchett A, et al. The impact of thiazolidinedione</text>
<text top="941" left="90" width="324" height="10" font="4">use on outcomes in ambulatory patients with diabetes mellitus and heart</text>
<text top="955" left="90" width="174" height="10" font="4">failure. J Am Coll Cardiol 2007;50:32</text>
<text top="952" left="264" width="14" height="15" font="4">–6.</text>
<text top="969" left="64" width="350" height="10" font="4">130. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metfor-</text>
<text top="983" left="90" width="324" height="10" font="4">min, and outcomes in older patients with diabetes and heart failure: an</text>
<text top="998" left="90" width="210" height="10" font="4">observational study. Circulation 2005;111:583</text>
<text top="995" left="300" width="20" height="15" font="4">–90.</text>
<text top="1012" left="64" width="350" height="10" font="4">131. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with</text>
<text top="1026" left="90" width="281" height="10" font="4">diabetes treated with metformin. N Engl J Med 1998;338:265</text>
<text top="1023" left="371" width="14" height="15" font="4">–6.</text>
<text top="1040" left="64" width="323" height="10" font="4">132. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use,</text>
<text top="1037" left="394" width="20" height="15" font="4">ﬂuid</text>
<text top="1054" left="90" width="324" height="10" font="4">retention, and congestive heart failure: a consensus statement from the</text>
<text top="1069" left="90" width="324" height="10" font="4">American Heart Association and American Diabetes Association.</text>
<text top="1083" left="90" width="121" height="10" font="4">Circulation 2003;108:2941</text>
<text top="1080" left="211" width="14" height="15" font="4">–8.</text>
<text top="103" left="450" width="350" height="10" font="4">133. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system.</text>
<text top="117" left="475" width="131" height="10" font="4">N Engl J Med 2001;344:501</text>
<text top="114" left="606" width="14" height="15" font="4">–9.</text>
<text top="132" left="450" width="350" height="10" font="4">134. Lee RT, Plappert M, Sutton MG. Depressed left ventricular systolic</text>
<text top="146" left="475" width="276" height="10" font="4">ejection force in hypothyroidism. Am J Cardiol 1990;65:526</text>
<text top="143" left="752" width="14" height="15" font="4">–7.</text>
<text top="160" left="450" width="350" height="10" font="4">135. Colao A, Marzullo P, Di Somma C, et al. Growth hormone and the heart.</text>
<text top="174" left="475" width="161" height="10" font="4">Clin Endocrinol (Oxf) 2001;54:137</text>
<text top="171" left="636" width="20" height="15" font="4">–54.</text>
<text top="188" left="450" width="350" height="10" font="4">136. Piano MR. Alcoholic cardiomyopathy: incidence, clinical characteristics,</text>
<text top="203" left="475" width="198" height="10" font="4">and pathophysiology. Chest 2002;121:1638</text>
<text top="200" left="673" width="20" height="15" font="4">–50.</text>
<text top="217" left="450" width="350" height="10" font="4">137. Cerqueira MD, Harp GD, Ritchie JL, et al. Rarity of preclinical alcoholic</text>
<text top="231" left="475" width="324" height="10" font="4">cardiomyopathy in chronic alcoholics less than 40 years of age. Am J</text>
<text top="245" left="475" width="93" height="10" font="4">Cardiol 1991;67:183</text>
<text top="242" left="569" width="14" height="15" font="4">–7.</text>
<text top="259" left="450" width="202" height="10" font="4">138. Faris RF, Henein MY, Coats AJ. In</text>
<text top="256" left="652" width="148" height="15" font="4">ﬂuence of gender and reported</text>
<text top="274" left="475" width="324" height="10" font="4">alcohol intake on mortality in nonischemic dilated cardiomyopathy.</text>
<text top="288" left="475" width="93" height="10" font="4">Heart Dis 2003;5:89</text>
<text top="285" left="568" width="20" height="15" font="4">–94.</text>
<text top="302" left="450" width="350" height="10" font="4">139. Abramson JL, Williams SA, Krumholz HM, et al. Moderate alcohol</text>
<text top="316" left="475" width="324" height="10" font="4">consumption and risk of heart failure among older persons. JAMA 2001;</text>
<text top="330" left="475" width="42" height="10" font="4">285:1971</text>
<text top="327" left="518" width="14" height="15" font="4">–7.</text>
<text top="345" left="450" width="350" height="10" font="4">140. Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk</text>
<text top="359" left="475" width="324" height="10" font="4">for congestive heart failure in the Framingham Heart Study. Ann Intern</text>
<text top="373" left="475" width="86" height="10" font="4">Med 2002;136:181</text>
<text top="370" left="562" width="20" height="15" font="4">–91.</text>
<text top="387" left="450" width="350" height="10" font="4">141. Pavan D, Nicolosi GL, Lestuzzi C, et al. Normalization of variables of</text>
<text top="401" left="475" width="324" height="10" font="4">left ventricular function in patients with alcoholic cardiomyopathy after</text>
<text top="416" left="475" width="324" height="10" font="4">cessation of excessive alcohol intake: an echocardiographic study. Eur</text>
<text top="430" left="475" width="87" height="10" font="4">Heart J 1987;8:535</text>
<text top="427" left="563" width="20" height="15" font="4">–40.</text>
<text top="444" left="450" width="350" height="10" font="4">142. Bertolet BD, Freund G, Martin CA, et al. Unrecognized left ventricular</text>
<text top="458" left="475" width="324" height="10" font="4">dysfunction in an apparently healthy cocaine abuse population. Clin</text>
<text top="472" left="475" width="93" height="10" font="4">Cardiol 1990;13:323</text>
<text top="469" left="569" width="14" height="15" font="4">–8.</text>
<text top="486" left="450" width="350" height="10" font="4">143. Chakko S, Myerburg RJ. Cardiac complications of cocaine abuse. Clin</text>
<text top="501" left="475" width="88" height="10" font="4">Cardiol 1995;18:67</text>
<text top="498" left="563" width="20" height="15" font="4">–72.</text>
<text top="515" left="450" width="350" height="10" font="4">144. Moliterno DJ, Willard JE, Lange RA, et al. Coronary-artery vasocon-</text>
<text top="529" left="475" width="324" height="10" font="4">striction induced by cocaine, cigarette smoking, or both. N Engl J Med</text>
<text top="543" left="475" width="62" height="10" font="4">1994;330:454</text>
<text top="540" left="538" width="14" height="15" font="4">–9.</text>
<text top="557" left="450" width="350" height="10" font="4">145. McCord J, Jneid H, Hollander JE, et al. Management of cocaine-</text>
<text top="572" left="475" width="266" height="10" font="4">associated chest pain and myocardial infarction: a scienti</text>
<text top="569" left="741" width="58" height="15" font="4">ﬁc statement</text>
<text top="586" left="475" width="324" height="10" font="4">from the American Heart Association Acute Cardiac Care Committee of</text>
<text top="600" left="475" width="288" height="10" font="4">the Council on Clinical Cardiology. Circulation 2008;117:1897</text>
<text top="597" left="763" width="25" height="15" font="4">–907.</text>
<text top="614" left="450" width="350" height="10" font="4">146. Marty M, Espie M, Llombart A, et al. Multicenter randomized phase III</text>
<text top="628" left="475" width="324" height="10" font="4">study of the cardioprotective effect of dexrazoxane (Cardioxane) in</text>
<text top="643" left="475" width="324" height="10" font="4">advanced/metastatic breast cancer patients treated with anthracycline-</text>
<text top="657" left="475" width="209" height="10" font="4">based chemotherapy. Ann Oncol 2006;17:614</text>
<text top="654" left="684" width="20" height="15" font="4">–22.</text>
<text top="671" left="450" width="350" height="10" font="4">147. van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective</text>
<text top="685" left="475" width="324" height="10" font="4">interventions for cancer patients receiving anthracyclines. Cochrane</text>
<text top="699" left="475" width="186" height="10" font="4">Database Syst Rev 2008; (2):CD003917.</text>
<text top="714" left="450" width="350" height="10" font="4">148. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic</text>
<text top="728" left="475" width="324" height="10" font="4">agents and radiotherapy-related heart disease: ESMO Clinical Practice</text>
<text top="742" left="475" width="210" height="10" font="4">Guidelines. Ann Oncol 2010;21 Suppl 5:v277</text>
<text top="739" left="685" width="20" height="15" font="4">–82.</text>
<text top="756" left="450" width="350" height="10" font="4">149. Martin M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while</text>
<text top="770" left="475" width="112" height="10" font="4">optimizing treatment ef</text>
<text top="767" left="588" width="212" height="15" font="4">ﬁcacy with trastuzumab: review and expert</text>
<text top="785" left="475" width="183" height="10" font="4">recommendations. Oncologist 2009;14:1</text>
<text top="782" left="659" width="20" height="15" font="4">–11.</text>
<text top="799" left="450" width="350" height="10" font="4">150. Figueredo VM. Chemical cardiomyopathies: the negative effects of medi-</text>
<text top="813" left="475" width="311" height="10" font="4">cations and nonprescribed drugs on the heart. Am J Med 2011;124:480</text>
<text top="810" left="786" width="14" height="15" font="4">–8.</text>
<text top="827" left="450" width="350" height="10" font="4">151. Dunnick JK, Kissling G, Gerken DK, et al. Cardiotoxicity of Ma Huang/</text>
<text top="841" left="475" width="324" height="10" font="4">caffeine or ephedrine/caffeine in a rodent model system. Toxicol Pathol</text>
<text top="856" left="475" width="56" height="10" font="4">2007;35:657</text>
<text top="853" left="532" width="20" height="15" font="4">–64.</text>
<text top="870" left="450" width="350" height="10" font="4">152. Djoenaidi W, Notermans SL, Dunda G. Beriberi cardiomyopathy. Eur J</text>
<text top="884" left="475" width="103" height="10" font="4">Clin Nutr 1992;46:227</text>
<text top="881" left="579" width="20" height="15" font="4">–34.</text>
<text top="898" left="450" width="350" height="10" font="4">153. Retter AS. Carnitine and its role in cardiovascular disease. Heart Dis</text>
<text top="912" left="475" width="51" height="10" font="4">1999;1:108</text>
<text top="909" left="526" width="20" height="15" font="4">–13.</text>
<text top="927" left="450" width="350" height="10" font="4">154. Khasnis A, Jongnarangsin K, Abela G, et al. Tachycardia-induced</text>
<text top="941" left="475" width="324" height="10" font="4">cardiomyopathy: a review of literature. Pacing Clin Electrophysiol 2005;</text>
<text top="955" left="475" width="31" height="10" font="4">28:710</text>
<text top="952" left="506" width="20" height="15" font="4">–21.</text>
<text top="969" left="450" width="350" height="10" font="4">155. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or</text>
<text top="983" left="475" width="279" height="10" font="4">ventricular backup pacing in patients with an implantable de</text>
<text top="980" left="755" width="45" height="15" font="4">ﬁbrillator:</text>
<text top="998" left="475" width="206" height="10" font="4">the Dual Chamber and VVI Implantable De</text>
<text top="995" left="681" width="118" height="15" font="4">ﬁbrillator (DAVID) Trial.</text>
<text top="1012" left="475" width="102" height="10" font="4">JAMA 2002;288:3115</text>
<text top="1009" left="577" width="20" height="15" font="4">–23.</text>
<text top="1026" left="450" width="350" height="10" font="4">156. Wilkoff BL, Kudenchuk PJ, Buxton AE, et al. The DAVID (Dual</text>
<text top="1040" left="475" width="157" height="10" font="4">Chamber and VVI Implantable De</text>
<text top="1037" left="632" width="167" height="15" font="4">ﬁbrillator) II trial. J Am Coll Cardiol</text>
<text top="1054" left="475" width="56" height="10" font="4">2009;53:872</text>
<text top="1051" left="532" width="20" height="15" font="4">–80.</text>
<text top="1069" left="450" width="350" height="10" font="4">157. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am</text>
<text top="1083" left="475" width="116" height="10" font="4">Coll Cardiol 2012;59:779</text>
<text top="1080" left="592" width="20" height="15" font="4">–92.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e213</text>
</page>
<page number="68" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">158. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome</text>
<text top="117" left="90" width="324" height="10" font="4">of fulminant myocarditis as compared with acute (nonfulminant)</text>
<text top="132" left="90" width="190" height="10" font="4">myocarditis. N Engl J Med 2000;342:690</text>
<text top="129" left="280" width="14" height="15" font="4">–5.</text>
<text top="146" left="64" width="250" height="10" font="4">159. Elliott P, Andersson B, Arbustini E, et al. Classi</text>
<text top="143" left="314" width="100" height="15" font="4">ﬁcation of the cardio-</text>
<text top="160" left="90" width="324" height="10" font="4">myopathies: a position statement from the European Society Of Cardi-</text>
<text top="174" left="90" width="324" height="10" font="4">ology Working Group on Myocardial and Pericardial Diseases. Eur</text>
<text top="188" left="90" width="93" height="10" font="4">Heart J 2008;29:270</text>
<text top="185" left="183" width="14" height="15" font="4">–6.</text>
<text top="203" left="64" width="323" height="10" font="4">160. Frustaci A, Russo MA, Chimenti C. Randomized study on the ef</text>
<text top="200" left="387" width="27" height="15" font="4">ﬁcacy</text>
<text top="217" left="90" width="287" height="10" font="4">of immunosuppressive therapy in patients with virus-negative in</text>
<text top="214" left="377" width="37" height="15" font="4">ﬂamma-</text>
<text top="231" left="90" width="293" height="10" font="4">tory cardiomyopathy: the TIMIC study. Eur Heart J 2009;30:1995</text>
<text top="228" left="383" width="31" height="15" font="4">–2002.</text>
<text top="245" left="64" width="350" height="10" font="4">161. Cooper LT Jr., Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis:</text>
<text top="259" left="90" width="324" height="10" font="4">natural history and treatment: Multicenter Giant Cell Myocarditis Study</text>
<text top="274" left="90" width="232" height="10" font="4">Group Investigators. N Engl J Med 1997;336:1860</text>
<text top="271" left="322" width="14" height="15" font="4">–6.</text>
<text top="288" left="64" width="350" height="10" font="4">162. Cooper LT Jr., Hare JM, Tazelaar HD, et al. Usefulness of immuno-</text>
<text top="302" left="90" width="310" height="10" font="4">suppression for giant cell myocarditis. Am J Cardiol 2008;102:1535</text>
<text top="299" left="400" width="14" height="15" font="4">–9.</text>
<text top="316" left="64" width="350" height="10" font="4">163. Kaul S, Fishbein MC, Siegel RJ. Cardiac manifestations of acquired</text>
<text top="330" left="90" width="52" height="10" font="4">immune de</text>
<text top="327" left="142" width="272" height="15" font="4">ﬁciency syndrome: a 1991 update. Am Heart J 1991;122:</text>
<text top="345" left="90" width="17" height="10" font="4">535</text>
<text top="342" left="107" width="20" height="15" font="4">–44.</text>
<text top="359" left="64" width="350" height="10" font="4">164. Grody WW, Cheng L, Lewis W. Infection of the heart by the human</text>
<text top="373" left="90" width="48" height="10" font="4">immunode</text>
<text top="370" left="138" width="204" height="15" font="4">ﬁciency virus. Am J Cardiol 1990;66:203–6.</text>
<text top="387" left="64" width="350" height="10" font="4">165. Raidel SM, Haase C, Jansen NR, et al. Targeted myocardial transgenic</text>
<text top="401" left="90" width="324" height="10" font="4">expression of HIV Tat causes cardiomyopathy and mitochondrial</text>
<text top="416" left="90" width="271" height="10" font="4">damage. Am J Physiol Heart Circ Physiol 2002;282:H1672</text>
<text top="413" left="361" width="14" height="15" font="4">–8.</text>
<text top="430" left="64" width="350" height="10" font="4">166. Barbaro G, Di Lorenzo G, Grisorio B, et al. Incidence of dilated</text>
<text top="444" left="90" width="324" height="10" font="4">cardiomyopathy and detection of HIV in myocardial cells of HIV-</text>
<text top="458" left="90" width="324" height="10" font="4">positive patients: Gruppo Italiano per lo Studio Cardiologico dei</text>
<text top="472" left="90" width="255" height="10" font="4">Pazienti Affetti da AIDS. N Engl J Med 1998;339:1093</text>
<text top="469" left="345" width="14" height="15" font="4">–9.</text>
<text top="486" left="64" width="350" height="10" font="4">167. Rossi MA, Bestetti RB. The challenge of chagasic cardiomyopathy: the</text>
<text top="501" left="90" width="324" height="10" font="4">pathologic roles of autonomic abnormalities, autoimmune mechanisms</text>
<text top="515" left="90" width="324" height="10" font="4">and microvascular changes, and therapeutic implications. Cardiology</text>
<text top="529" left="90" width="45" height="10" font="4">1995;86:1</text>
<text top="526" left="135" width="14" height="15" font="4">–7.</text>
<text top="543" left="64" width="350" height="10" font="4">168. Kounis GN, Soufras GD, Kouni SA, et al. Hypersensitivity myocarditis</text>
<text top="557" left="90" width="324" height="10" font="4">and hypersensitivity coronary syndrome (Kounis syndrome). Am J</text>
<text top="572" left="90" width="114" height="10" font="4">Emerg Med 2009;27:506</text>
<text top="569" left="204" width="14" height="15" font="4">–8.</text>
<text top="586" left="64" width="350" height="10" font="4">169. Leyngold I, Baughman K, Kasper E, et al. Comparison of survival</text>
<text top="600" left="90" width="324" height="10" font="4">among patients with connective tissue disease and cardiomyopathy</text>
<text top="614" left="90" width="324" height="10" font="4">(systemic sclerosis, systemic lupus erythematosus, and undifferentiated</text>
<text top="628" left="90" width="170" height="10" font="4">disease). Am J Cardiol 2007;100:513</text>
<text top="625" left="260" width="14" height="15" font="4">–7.</text>
<text top="643" left="64" width="350" height="10" font="4">170. Paradiso M, Gabrielli F, Masala C, et al. Evaluation of myocardial</text>
<text top="657" left="90" width="324" height="10" font="4">involvement in systemic lupus erythematosus by signal-averaged elec-</text>
<text top="671" left="90" width="299" height="10" font="4">trocardiography and echocardiography. Acta Cardiol 2001;56:381</text>
<text top="668" left="389" width="14" height="15" font="4">–6.</text>
<text top="685" left="64" width="350" height="10" font="4">171. Kazzam E, Caidahl K, Hallgren R, et al. Non-invasive assessment of</text>
<text top="699" left="90" width="324" height="10" font="4">systolic left ventricular function in systemic sclerosis. Eur Heart J 1991;</text>
<text top="714" left="90" width="31" height="10" font="4">12:151</text>
<text top="711" left="121" width="14" height="15" font="4">–6.</text>
<text top="728" left="64" width="350" height="10" font="4">172. Goldenberg J, Ferraz MB, Pessoa AP, et al. Symptomatic cardiac</text>
<text top="742" left="90" width="324" height="10" font="4">involvement in juvenile rheumatoid arthritis. Int J Cardiol 1992;34:</text>
<text top="756" left="90" width="11" height="10" font="4">57</text>
<text top="753" left="101" width="20" height="15" font="4">–62.</text>
<text top="770" left="64" width="182" height="10" font="4">173. Gasparyan AY, Cocco G, Pandol</text>
<text top="767" left="246" width="168" height="15" font="4">ﬁ S. Cardiac complications in rheu-</text>
<text top="785" left="90" width="324" height="10" font="4">matoid arthritis in the absence of occlusive coronary pathology. Rheu-</text>
<text top="799" left="90" width="101" height="10" font="4">matol Int 2012;32:461</text>
<text top="796" left="191" width="14" height="15" font="4">–4.</text>
<text top="813" left="64" width="350" height="10" font="4">174. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of</text>
<text top="827" left="90" width="324" height="10" font="4">subsequent pregnancies in women with peripartum cardiomyopathy.</text>
<text top="841" left="90" width="136" height="10" font="4">N Engl J Med 2001;344:1567</text>
<text top="838" left="226" width="20" height="15" font="4">–71.</text>
<text top="856" left="64" width="34" height="10" font="4">175. O</text>
<text top="853" left="98" width="316" height="15" font="4">’Connell JB, Costanzo-Nordin MR, Subramanian R, et al. Peripartum</text>
<text top="870" left="90" width="324" height="10" font="4">cardiomyopathy: clinical, hemodynamic, histologic and prognostic</text>
<text top="884" left="90" width="203" height="10" font="4">characteristics. J Am Coll Cardiol 1986;8:52</text>
<text top="881" left="293" width="14" height="15" font="4">–6.</text>
<text top="898" left="64" width="350" height="10" font="4">176. Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology,</text>
<text top="912" left="90" width="227" height="10" font="4">diagnosis, and treatment. J Card Fail 2010;16:888</text>
<text top="909" left="317" width="25" height="15" font="4">–900.</text>
<text top="927" left="64" width="350" height="10" font="4">177. Wojcik JP, Speechley MR, Kertesz AE, et al. Natural history of</text>
<text top="941" left="90" width="324" height="10" font="4">C282Y homozygotes for hemochromatosis. Can J Gastroenterol 2002;</text>
<text top="955" left="90" width="31" height="10" font="4">16:297</text>
<text top="952" left="121" width="25" height="15" font="4">–302.</text>
<text top="969" left="64" width="350" height="10" font="4">178. Gujja P, Rosing DR, Tripodi DJ, et al. Iron overload cardiomyopathy:</text>
<text top="983" left="90" width="324" height="10" font="4">better understanding of an increasing disorder. J Am Coll Cardiol 2010;</text>
<text top="998" left="90" width="37" height="10" font="4">56:1001</text>
<text top="995" left="127" width="20" height="15" font="4">–12.</text>
<text top="1012" left="64" width="350" height="10" font="4">179. Ronsyn M, Shivalkar B, Vrints CJ. Cardiac amyloidosis in full glory.</text>
<text top="1026" left="90" width="88" height="10" font="4">Heart 2011;97:720.</text>
<text top="1040" left="64" width="350" height="10" font="4">180. Dietrich S, Schonland SO, Benner A, et al. Treatment with intravenous</text>
<text top="1054" left="90" width="324" height="10" font="4">melphalan and dexamethasone is not able to overcome the poor prog-</text>
<text top="1069" left="90" width="324" height="10" font="4">nosis of patients with newly diagnosed systemic light chain amyloidosis</text>
<text top="1083" left="90" width="243" height="10" font="4">and severe cardiac involvement. Blood 2010;116:522</text>
<text top="1080" left="333" width="14" height="15" font="4">–8.</text>
<text top="103" left="450" width="350" height="10" font="4">181. Palladini G, Barassi A, Klersy C, et al. The combination of high-</text>
<text top="117" left="475" width="324" height="10" font="4">sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in</text>
<text top="132" left="475" width="324" height="10" font="4">N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy</text>
<text top="146" left="475" width="290" height="10" font="4">best predicts survival in AL amyloidosis. Blood 2010;116:3426</text>
<text top="143" left="765" width="20" height="15" font="4">–30.</text>
<text top="160" left="450" width="350" height="10" font="4">182. Jacobson D, Tagoe C, Schwartzbard A, et al. Relation of clinical,</text>
<text top="174" left="475" width="82" height="10" font="4">echocardiographic</text>
<text top="174" left="569" width="16" height="10" font="4">and</text>
<text top="174" left="597" width="91" height="10" font="4">electrocardiographic</text>
<text top="174" left="700" width="35" height="10" font="4">features</text>
<text top="174" left="747" width="9" height="10" font="4">of</text>
<text top="174" left="768" width="32" height="10" font="4">cardiac</text>
<text top="188" left="475" width="324" height="10" font="4">amyloidosis to the presence of the transthyretin V122I allele in older</text>
<text top="203" left="475" width="238" height="10" font="4">African-American men. Am J Cardiol 2011;108:440</text>
<text top="200" left="713" width="14" height="15" font="4">–4.</text>
<text top="217" left="450" width="350" height="10" font="4">183. Srichai MB, Addrizzo-Harris DJ, Friedman K. Cardiac sarcoidosis. J Am</text>
<text top="231" left="475" width="119" height="10" font="4">Coll Cardiol 2011;58:438.</text>
<text top="245" left="450" width="350" height="10" font="4">184. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoid-</text>
<text top="259" left="475" width="178" height="10" font="4">osis. Prog Cardiovasc Dis 2010;52:336</text>
<text top="256" left="653" width="20" height="15" font="4">–46.</text>
<text top="274" left="450" width="202" height="10" font="4">185. Kron J, Sauer W, Schuller J, et al. Ef</text>
<text top="271" left="652" width="148" height="15" font="4">ﬁcacy and safety of implantable</text>
<text top="288" left="475" width="46" height="10" font="4">cardiac de</text>
<text top="285" left="521" width="278" height="15" font="4">ﬁbrillators for treatment of ventricular arrhythmias in patients</text>
<text top="302" left="475" width="217" height="10" font="4">with cardiac sarcoidosis. Europace 2013;15:347</text>
<text top="299" left="692" width="20" height="15" font="4">–54.</text>
<text top="316" left="450" width="350" height="10" font="4">186. Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and</text>
<text top="330" left="475" width="100" height="10" font="4">expansive clinical pro</text>
<text top="327" left="576" width="224" height="15" font="4">ﬁle of stress (tako-tsubo) cardiomyopathy. J Am</text>
<text top="345" left="475" width="116" height="10" font="4">Coll Cardiol 2010;55:333</text>
<text top="342" left="592" width="20" height="15" font="4">–41.</text>
<text top="359" left="450" width="350" height="10" font="4">187. Butman SM, Ewy GA, Standen JR, et al. Bedside cardiovascular</text>
<text top="373" left="475" width="324" height="10" font="4">examination in patients with severe chronic heart failure: importance of</text>
<text top="387" left="475" width="324" height="10" font="4">rest or inducible jugular venous distension. J Am Coll Cardiol 1993;22:</text>
<text top="401" left="475" width="17" height="10" font="4">968</text>
<text top="398" left="492" width="20" height="15" font="4">–74.</text>
<text top="416" left="450" width="350" height="10" font="4">188. Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance of</text>
<text top="430" left="475" width="324" height="10" font="4">elevated jugular venous pressure and a third heart sound in patients with</text>
<text top="444" left="475" width="192" height="10" font="4">heart failure. N Engl J Med 2001;345:574</text>
<text top="441" left="667" width="20" height="15" font="4">–81.</text>
<text top="458" left="450" width="350" height="10" font="4">189. Drazner MH, Hellkamp AS, Leier CV, et al. Value of clinician assess-</text>
<text top="472" left="475" width="324" height="10" font="4">ment of hemodynamics in advanced heart failure: the ESCAPE trial. Circ</text>
<text top="486" left="475" width="100" height="10" font="4">Heart Fail 2008;1:170</text>
<text top="483" left="575" width="14" height="15" font="4">–7.</text>
<text top="501" left="450" width="350" height="10" font="4">190. Stevenson LW, Perloff JK. The limited reliability of physical signs</text>
<text top="515" left="475" width="324" height="10" font="4">for estimating hemodynamics in chronic heart failure. JAMA 1989;261:</text>
<text top="529" left="475" width="17" height="10" font="4">884</text>
<text top="526" left="492" width="14" height="15" font="4">–8.</text>
<text top="543" left="450" width="350" height="10" font="4">191. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk</text>
<text top="557" left="475" width="302" height="10" font="4">factor for mortality in chronic heart failure. Lancet 1997;349:1050</text>
<text top="554" left="778" width="14" height="15" font="4">–3.</text>
<text top="572" left="450" width="350" height="10" font="4">192. Mishkin JD, Saxonhouse SJ, Woo GW, et al. Appropriate evaluation and</text>
<text top="586" left="475" width="324" height="10" font="4">treatment of heart failure patients after implantable cardioverter-</text>
<text top="600" left="475" width="11" height="10" font="4">de</text>
<text top="597" left="486" width="314" height="15" font="4">ﬁbrillator discharge: time to go beyond the initial shock. J Am Coll</text>
<text top="614" left="475" width="99" height="10" font="4">Cardiol 2009;54:1993</text>
<text top="611" left="575" width="31" height="15" font="4">–2000.</text>
<text top="628" left="450" width="350" height="10" font="4">193. Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: patho-</text>
<text top="643" left="475" width="324" height="10" font="4">physiologic and therapeutic implications. J Am Coll Cardiol 2011;57:</text>
<text top="657" left="475" width="17" height="10" font="4">119</text>
<text top="654" left="492" width="20" height="15" font="4">–27.</text>
<text top="671" left="450" width="350" height="10" font="4">194. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations</text>
<text top="685" left="475" width="324" height="10" font="4">predict mortality in the community population with heart failure. Am</text>
<text top="699" left="475" width="98" height="10" font="4">Heart J 2007;154:260</text>
<text top="696" left="574" width="14" height="15" font="4">–6.</text>
<text top="714" left="450" width="247" height="10" font="4">195. Fonarow GC, Abraham WT, Albert NM, et al. In</text>
<text top="711" left="697" width="103" height="15" font="4">ﬂuence of beta-blocker</text>
<text top="728" left="475" width="324" height="10" font="4">continuation or withdrawal on outcomes in patients hospitalized with</text>
<text top="742" left="475" width="59" height="10" font="4">heart failure:</text>
<text top="739" left="540" width="259" height="15" font="4">ﬁndings from the OPTIMIZE-HF program. J Am Coll</text>
<text top="756" left="475" width="93" height="10" font="4">Cardiol 2008;52:190</text>
<text top="753" left="569" width="14" height="15" font="4">–9.</text>
<text top="770" left="450" width="350" height="10" font="4">196. Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-</text>
<text top="785" left="475" width="309" height="10" font="4">renal limitations to angiotensin-converting enzyme inhibitors identi</text>
<text top="782" left="784" width="15" height="15" font="4">ﬁes</text>
<text top="799" left="475" width="324" height="10" font="4">patients with severe heart failure and early mortality. J Am Coll Cardiol</text>
<text top="813" left="475" width="62" height="10" font="4">2003;41:2029</text>
<text top="810" left="538" width="20" height="15" font="4">–35.</text>
<text top="827" left="450" width="350" height="10" font="4">197. Felker GM, Cuculich PS, Gheorghiade M. The Valsalva maneuver:</text>
<text top="841" left="475" width="43" height="10" font="4">a bedside</text>
<text top="838" left="522" width="271" height="15" font="4">“biomarker” for heart failure. Am J Med 2006;119:117–22.</text>
<text top="856" left="450" width="350" height="10" font="4">198. Leier CV, Young JB, Levine TB, et al. Nuggets, pearls, and vignettes of</text>
<text top="870" left="475" width="324" height="10" font="4">master heart failure clinicians: part 2: the physical examination. Congest</text>
<text top="884" left="475" width="100" height="10" font="4">Heart Fail 2001;7:297</text>
<text top="881" left="575" width="25" height="15" font="4">–308.</text>
<text top="898" left="450" width="350" height="10" font="4">199. Aaronson KD, Schwartz JS, Chen TM, et al. Development and</text>
<text top="912" left="475" width="324" height="10" font="4">prospective validation of a clinical index to predict survival in ambu-</text>
<text top="927" left="475" width="324" height="10" font="4">latory patients referred for cardiac transplant evaluation. Circulation</text>
<text top="941" left="475" width="62" height="10" font="4">1997;95:2660</text>
<text top="938" left="538" width="14" height="15" font="4">–7.</text>
<text top="955" left="450" width="300" height="10" font="4">200. Fonarow GC, Adams KF Jr., Abraham WT, et al. Risk strati</text>
<text top="952" left="750" width="50" height="15" font="4">ﬁcation for</text>
<text top="969" left="475" width="304" height="10" font="4">in-hospital mortality in acutely decompensated heart failure: classi</text>
<text top="966" left="780" width="20" height="15" font="4">ﬁca-</text>
<text top="983" left="475" width="249" height="10" font="4">tion and regression tree analysis. JAMA 2005;293:572</text>
<text top="980" left="724" width="20" height="15" font="4">–80.</text>
<text top="998" left="450" width="350" height="10" font="4">201. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome</text>
<text top="1012" left="475" width="233" height="10" font="4">in heart failure with preserved ejection fraction:</text>
<text top="1009" left="716" width="84" height="15" font="4">ﬁndings from the</text>
<text top="1026" left="475" width="324" height="10" font="4">Irbesartan in Heart Failure with Preserved Ejection Fraction Study</text>
<text top="1040" left="475" width="194" height="10" font="4">(I-PRESERVE). Circ Heart Fail 2011;4:27</text>
<text top="1037" left="669" width="20" height="15" font="4">–35.</text>
<text top="1054" left="450" width="350" height="10" font="4">202. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among</text>
<text top="1069" left="475" width="324" height="10" font="4">patients hospitalized for heart failure: derivation and validation of</text>
<text top="1083" left="475" width="181" height="10" font="4">a clinical model. JAMA 2003;290:2581</text>
<text top="1080" left="656" width="14" height="15" font="4">–7.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e214</text>
</page>
<page number="69" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">203. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure</text>
<text top="117" left="90" width="324" height="10" font="4">Model: prediction of survival in heart failure. Circulation 2006;113:</text>
<text top="132" left="90" width="22" height="10" font="4">1424</text>
<text top="129" left="112" width="20" height="15" font="4">–33.</text>
<text top="146" left="64" width="34" height="10" font="4">204. O</text>
<text top="143" left="98" width="316" height="15" font="4">’Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality</text>
<text top="160" left="90" width="324" height="10" font="4">after discharge in patients hospitalized with heart failure: an analysis</text>
<text top="174" left="90" width="324" height="10" font="4">from the Organized Program to Initiate Lifesaving Treatment in</text>
<text top="188" left="90" width="324" height="10" font="4">Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J</text>
<text top="203" left="90" width="62" height="10" font="4">2008;156:662</text>
<text top="200" left="152" width="20" height="15" font="4">–73.</text>
<text top="217" left="64" width="350" height="10" font="4">205. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-</text>
<text top="231" left="90" width="324" height="10" font="4">hospital mortality in patients with heart failure from the American Heart</text>
<text top="245" left="90" width="324" height="10" font="4">Association Get With The Guidelines program. Circ Cardiovasc Qual</text>
<text top="259" left="90" width="94" height="10" font="4">Outcomes 2010;3:25</text>
<text top="256" left="184" width="20" height="15" font="4">–32.</text>
<text top="274" left="64" width="350" height="10" font="4">206. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality</text>
<text top="288" left="90" width="324" height="10" font="4">and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:</text>
<text top="302" left="90" width="11" height="10" font="4">65</text>
<text top="299" left="101" width="20" height="15" font="4">–75.</text>
<text top="316" left="64" width="350" height="10" font="4">207. Wedel H, McMurray JJ, Lindberg M, et al. Predictors of fatal and non-</text>
<text top="330" left="90" width="324" height="10" font="4">fatal outcomes in the Controlled Rosuvastatin Multinational Trial in</text>
<text top="345" left="90" width="324" height="10" font="4">Heart Failure (CORONA): incremental value of apolipoprotein A-1,</text>
<text top="359" left="90" width="324" height="10" font="4">high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic</text>
<text top="373" left="90" width="173" height="10" font="4">peptide. Eur J Heart Fail 2009;11:281</text>
<text top="370" left="263" width="20" height="15" font="4">–91.</text>
<text top="387" left="64" width="350" height="10" font="4">208. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion</text>
<text top="401" left="90" width="324" height="10" font="4">predicts good survival despite previous class IV symptoms of heart</text>
<text top="416" left="90" width="154" height="10" font="4">failure. Am Heart J 2000;140:840</text>
<text top="413" left="244" width="14" height="15" font="4">–7.</text>
<text top="430" left="64" width="350" height="10" font="4">209. Amarasingham R, Moore BJ, Tabak YP, et al. An automated model to</text>
<text top="444" left="90" width="324" height="10" font="4">identify heart failure patients at risk for 30-day readmission or death</text>
<text top="458" left="90" width="276" height="10" font="4">using electronic medical record data. Med Care 2010;48:981</text>
<text top="455" left="366" width="14" height="15" font="4">–8.</text>
<text top="472" left="64" width="350" height="10" font="4">210. The University of Washington. The Seattle Heart Failure Model.</text>
<text top="486" left="90" width="57" height="10" font="4">Available at:</text>
<text top="486" left="150" width="150" height="10" font="5"><a href="http://depts.washington.edu/shfm/">http://depts.washington.edu/shfm/</a></text>
<text top="486" left="299" width="115" height="10" font="4">. 2012. Accessed July 11,</text>
<text top="501" left="90" width="25" height="10" font="4">2013.</text>
<text top="515" left="64" width="350" height="10" font="4">211. Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al. Hospitaliza-</text>
<text top="529" left="90" width="324" height="10" font="4">tion epidemic in patients with heart failure: risk factors, risk prediction,</text>
<text top="543" left="90" width="285" height="10" font="4">knowledge gaps, and future directions. J Card Fail 2011;17:54</text>
<text top="540" left="375" width="20" height="15" font="4">–75.</text>
<text top="557" left="64" width="165" height="10" font="4">212. Januzzi JL Jr., Sakhuja R, O</text>
<text top="554" left="230" width="184" height="15" font="4">’Donoghue M, et al. Utility of amino-</text>
<text top="572" left="90" width="324" height="10" font="4">terminal pro-brain natriuretic peptide testing for prediction of 1-year</text>
<text top="586" left="90" width="324" height="10" font="4">mortality in patients with dyspnea treated in the emergency depart-</text>
<text top="600" left="90" width="171" height="10" font="4">ment. Arch Intern Med 2006;166:315</text>
<text top="597" left="261" width="20" height="15" font="4">–20.</text>
<text top="614" left="64" width="350" height="10" font="4">213. Januzzi JL Jr., Rehman S, Mueller T, et al. Importance of biomarkers for</text>
<text top="628" left="90" width="324" height="10" font="4">long-term mortality prediction in acutely dyspneic patients. Clin Chem</text>
<text top="643" left="90" width="62" height="10" font="4">2010;56:1814</text>
<text top="640" left="152" width="20" height="15" font="4">–21.</text>
<text top="657" left="64" width="34" height="10" font="4">214. O</text>
<text top="654" left="98" width="316" height="15" font="4">’Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitali-</text>
<text top="671" left="90" width="324" height="10" font="4">zation with advanced heart failure: the ESCAPE (Evaluation Study of</text>
<text top="685" left="90" width="324" height="10" font="4">Congestive Heart Failure and Pulmonary Artery Catheterization Effec-</text>
<text top="699" left="90" width="324" height="10" font="4">tiveness) risk model and discharge score. J Am Coll Cardiol 2010;55:</text>
<text top="714" left="90" width="17" height="10" font="4">872</text>
<text top="711" left="107" width="14" height="15" font="4">–8.</text>
<text top="728" left="64" width="350" height="10" font="4">215. Kociol RD, Horton JR, Fonarow GC, et al. Admission, discharge, or</text>
<text top="742" left="90" width="324" height="10" font="4">change in B-type natriuretic peptide and long-term outcomes: data from</text>
<text top="756" left="90" width="324" height="10" font="4">Organized Program to Initiate Lifesaving Treatment in Hospitalized</text>
<text top="770" left="90" width="324" height="10" font="4">Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.</text>
<text top="785" left="90" width="123" height="10" font="4">Circ Heart Fail 2011;4:628</text>
<text top="782" left="213" width="20" height="15" font="4">–36.</text>
<text top="799" left="64" width="350" height="10" font="4">216. Okonko DO, Mandal AK, Missouris CG, et al. Disordered iron</text>
<text top="813" left="90" width="324" height="10" font="4">homeostasis in chronic heart failure: prevalence, predictors, and relation</text>
<text top="827" left="90" width="324" height="10" font="4">to anemia, exercise capacity, and survival. J Am Coll Cardiol 2011;58:</text>
<text top="841" left="90" width="22" height="10" font="4">1241</text>
<text top="838" left="112" width="20" height="15" font="4">–51.</text>
<text top="856" left="64" width="229" height="10" font="4">217. Costello-Boerrigter LC, Boerrigter G, Red</text>
<text top="853" left="293" width="121" height="15" font="4">ﬁeld MM, et al. Amino-</text>
<text top="870" left="90" width="324" height="10" font="4">terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in</text>
<text top="884" left="90" width="324" height="10" font="4">the general community: determinants and detection of left ventricular</text>
<text top="898" left="90" width="204" height="10" font="4">dysfunction. J Am Coll Cardiol 2006;47:345</text>
<text top="895" left="294" width="20" height="15" font="4">–53.</text>
<text top="912" left="64" width="350" height="10" font="4">218. de Lemos JA, McGuire DK, Khera A, et al. Screening the population for</text>
<text top="927" left="90" width="324" height="10" font="4">left ventricular hypertrophy and left ventricular systolic dysfunction</text>
<text top="941" left="90" width="324" height="10" font="4">using natriuretic peptides: results from the Dallas Heart Study. Am Heart</text>
<text top="955" left="90" width="70" height="10" font="4">J 2009;157:746</text>
<text top="952" left="160" width="20" height="15" font="4">–53.</text>
<text top="969" left="64" width="350" height="10" font="4">219. Goetze JP, Mogelvang R, Maage L, et al. Plasma pro-B-type natriuretic</text>
<text top="983" left="90" width="324" height="10" font="4">peptide in the general population: screening for left ventricular hyper-</text>
<text top="998" left="90" width="267" height="10" font="4">trophy and systolic dysfunction. Eur Heart J 2006;27:3004</text>
<text top="995" left="357" width="20" height="15" font="4">–10.</text>
<text top="1012" left="64" width="350" height="10" font="4">220. Ng LL, Loke IW, Davies JE, et al. Community screening for left</text>
<text top="1026" left="90" width="324" height="10" font="4">ventricular systolic dysfunction using plasma and urinary natriuretic</text>
<text top="1040" left="90" width="194" height="10" font="4">peptides. J Am Coll Cardiol 2005;45:1043</text>
<text top="1037" left="284" width="20" height="15" font="4">–50.</text>
<text top="1054" left="64" width="350" height="10" font="4">221. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-</text>
<text top="1069" left="90" width="324" height="10" font="4">brain natriuretic peptide and adrenomedullin: prognostic utility and</text>
<text top="1083" left="90" width="82" height="10" font="4">prediction of bene</text>
<text top="1080" left="172" width="242" height="15" font="4">ﬁt from carvedilol in chronic ischemic left ventricular</text>
<text top="103" left="476" width="324" height="10" font="4">dysfunction: Australia-New Zealand Heart Failure Group. J Am Coll</text>
<text top="117" left="476" width="99" height="10" font="4">Cardiol 2001;37:1781</text>
<text top="114" left="575" width="14" height="15" font="4">–7.</text>
<text top="132" left="450" width="350" height="10" font="4">222. Tang WH, Girod JP, Lee MJ, et al. Plasma B-type natriuretic peptide</text>
<text top="146" left="476" width="324" height="10" font="4">levels in ambulatory patients with established chronic symptomatic</text>
<text top="160" left="476" width="220" height="10" font="4">systolic heart failure. Circulation 2003;108:2964</text>
<text top="157" left="695" width="14" height="15" font="4">–6.</text>
<text top="174" left="450" width="350" height="10" font="4">223. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides</text>
<text top="188" left="476" width="324" height="10" font="4">for community screening for left ventricular hypertrophy and systolic</text>
<text top="203" left="476" width="300" height="10" font="4">dysfunction: the Framingham Heart Study. JAMA 2002;288:1252</text>
<text top="200" left="775" width="14" height="15" font="4">–9.</text>
<text top="217" left="450" width="350" height="10" font="4">224. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide</text>
<text top="231" left="475" width="324" height="10" font="4">predicts sudden death in patients with chronic heart failure. Circulation</text>
<text top="245" left="475" width="68" height="10" font="4">2002;105:2392</text>
<text top="242" left="543" width="14" height="15" font="4">–7.</text>
<text top="259" left="450" width="350" height="10" font="4">225. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic</text>
<text top="274" left="475" width="324" height="10" font="4">peptide and norepinephrine over time and mortality and morbidity in</text>
<text top="288" left="475" width="324" height="10" font="4">the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:</text>
<text top="302" left="475" width="22" height="10" font="4">1278</text>
<text top="299" left="498" width="20" height="15" font="4">–83.</text>
<text top="316" left="450" width="41" height="10" font="4">226. For</text>
<text top="313" left="491" width="309" height="15" font="4">ﬁa PR, Watkins SP, Rame JE, et al. Relationship between B-type</text>
<text top="330" left="475" width="324" height="10" font="4">natriuretic peptides and pulmonary capillary wedge pressure in the</text>
<text top="345" left="475" width="240" height="10" font="4">intensive care unit. J Am Coll Cardiol 2005;45:1667</text>
<text top="342" left="716" width="20" height="15" font="4">–71.</text>
<text top="359" left="450" width="350" height="10" font="4">227. Taub PR, Daniels LB, Maisel AS. Usefulness of B-type natriuretic</text>
<text top="373" left="475" width="324" height="10" font="4">peptide levels in predicting hemodynamic and clinical decompensation.</text>
<text top="387" left="475" width="123" height="10" font="4">Heart Fail Clin 2009;5:169</text>
<text top="384" left="598" width="20" height="15" font="4">–75.</text>
<text top="401" left="450" width="350" height="10" font="4">228. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain</text>
<text top="416" left="475" width="324" height="10" font="4">natriuretic peptide and interleukin-6 after optimized treatment for heart</text>
<text top="430" left="475" width="324" height="10" font="4">failure are independent risk factors for morbidity and mortality</text>
<text top="444" left="475" width="324" height="10" font="4">in patients with congestive heart failure. J Am Coll Cardiol 2000;36:</text>
<text top="458" left="475" width="22" height="10" font="4">1587</text>
<text top="455" left="498" width="20" height="15" font="4">–93.</text>
<text top="472" left="450" width="350" height="10" font="4">229. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-</text>
<text top="486" left="475" width="324" height="10" font="4">type natriuretic peptide, and amino-terminal pro-B-type natriuretic</text>
<text top="501" left="475" width="324" height="10" font="4">peptide in patients with chronic heart failure: prediction of death at</text>
<text top="515" left="475" width="286" height="10" font="4">different stages of the disease. J Am Coll Cardiol 2008;52:266</text>
<text top="512" left="762" width="20" height="15" font="4">–72.</text>
<text top="529" left="450" width="350" height="10" font="4">230. Januzzi JL Jr., Rehman SU, Mohammed AA, et al. Use of amino-</text>
<text top="543" left="475" width="324" height="10" font="4">terminal pro-B-type natriuretic peptide to guide outpatient therapy of</text>
<text top="557" left="475" width="324" height="10" font="4">patients with chronic left ventricular systolic dysfunction. J Am Coll</text>
<text top="572" left="475" width="99" height="10" font="4">Cardiol 2011;58:1881</text>
<text top="569" left="575" width="14" height="15" font="4">–9.</text>
<text top="586" left="450" width="350" height="10" font="4">231. Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic</text>
<text top="600" left="475" width="324" height="10" font="4">peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med</text>
<text top="614" left="475" width="62" height="10" font="4">2010;170:507</text>
<text top="611" left="538" width="20" height="15" font="4">–14.</text>
<text top="628" left="450" width="350" height="10" font="4">232. Felker GM, Hasselblad V, Hernandez AF, et al. Biomarker-guided</text>
<text top="643" left="475" width="324" height="10" font="4">therapy in chronic heart failure: a meta-analysis of randomized</text>
<text top="657" left="475" width="196" height="10" font="4">controlled trials. Am Heart J 2009;158:422</text>
<text top="654" left="671" width="20" height="15" font="4">–30.</text>
<text top="671" left="450" width="350" height="10" font="4">233. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-</text>
<text top="685" left="475" width="324" height="10" font="4">guided therapy to improve outcome in heart failure: the STARS-BNP</text>
<text top="699" left="475" width="238" height="10" font="4">Multicenter Study. J Am Coll Cardiol 2007;49:1733</text>
<text top="697" left="714" width="14" height="15" font="4">–9.</text>
<text top="714" left="450" width="32" height="10" font="4">234. P</text>
<text top="711" left="482" width="318" height="15" font="4">ﬁsterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided</text>
<text top="728" left="475" width="201" height="10" font="4">heart failure therapy: the Trial of Intensi</text>
<text top="725" left="677" width="122" height="15" font="4">ﬁed vs Standard Medical</text>
<text top="742" left="475" width="324" height="10" font="4">Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF)</text>
<text top="756" left="475" width="176" height="10" font="4">randomized trial. JAMA 2009;301:383</text>
<text top="753" left="652" width="20" height="15" font="4">–92.</text>
<text top="770" left="450" width="350" height="10" font="4">235. Berger R, Moertl D, Peter S, et al. N-terminal pro-B-type natriuretic</text>
<text top="785" left="475" width="324" height="10" font="4">peptide-guided, intensive patient management in addition to multidis-</text>
<text top="799" left="475" width="324" height="10" font="4">ciplinary care in chronic heart failure: a 3-arm, prospective, randomized</text>
<text top="813" left="475" width="200" height="10" font="4">pilot study. J Am Coll Cardiol 2010;55:645</text>
<text top="810" left="675" width="20" height="15" font="4">–53.</text>
<text top="827" left="450" width="350" height="10" font="4">236. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart</text>
<text top="841" left="475" width="324" height="10" font="4">failure guided by plasma aminoterminal brain natriuretic peptide</text>
<text top="856" left="475" width="217" height="10" font="4">(N-BNP) concentrations. Lancet 2000;355:1126</text>
<text top="853" left="693" width="20" height="15" font="4">–30.</text>
<text top="870" left="450" width="350" height="10" font="4">237. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-</text>
<text top="884" left="475" width="324" height="10" font="4">B-type natriuretic peptide-guided treatment for chronic heart failure:</text>
<text top="898" left="475" width="324" height="10" font="4">results from the BATTLESCARRED (NT-proBNP-Assisted Treatment</text>
<text top="912" left="475" width="324" height="10" font="4">To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll</text>
<text top="927" left="475" width="88" height="10" font="4">Cardiol 2009;55:53</text>
<text top="924" left="563" width="20" height="15" font="4">–60.</text>
<text top="941" left="450" width="350" height="10" font="4">238. Horwich TB, Patel J, MacLellan WR, et al. Cardiac troponin I is asso-</text>
<text top="955" left="475" width="324" height="10" font="4">ciated with impaired hemodynamics, progressive left ventricular</text>
<text top="969" left="475" width="324" height="10" font="4">dysfunction, and increased mortality rates in advanced heart failure.</text>
<text top="983" left="475" width="116" height="10" font="4">Circulation 2003;108:833</text>
<text top="980" left="591" width="14" height="15" font="4">–8.</text>
<text top="998" left="450" width="350" height="10" font="4">239. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum</text>
<text top="1012" left="475" width="324" height="10" font="4">concentrations of cardiac troponin t in patients with idiopathic dilated</text>
<text top="1026" left="475" width="324" height="10" font="4">cardiomyopathy are predictive of adverse outcomes. Circulation 2001;</text>
<text top="1040" left="475" width="37" height="10" font="4">103:369</text>
<text top="1037" left="512" width="20" height="15" font="4">–74.</text>
<text top="1054" left="450" width="266" height="10" font="4">240. Setsuta K, Seino Y, Takahashi N, et al. Clinical signi</text>
<text top="1051" left="715" width="84" height="15" font="4">ﬁcance of elevated</text>
<text top="1069" left="475" width="324" height="10" font="4">levels of cardiac troponin T in patients with chronic heart failure. Am J</text>
<text top="1083" left="475" width="93" height="10" font="4">Cardiol 1999;84:608</text>
<text top="1080" left="569" width="40" height="15" font="4">–11, A9.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e215</text>
</page>
<page number="70" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="95" height="10" font="4">241. Hudson MP, O</text>
<text top="100" left="159" width="255" height="15" font="4">’Connor CM, Gattis WA, et al. Implications of elevated</text>
<text top="117" left="90" width="324" height="10" font="4">cardiac troponin T in ambulatory patients with heart failure: a prospec-</text>
<text top="132" left="90" width="181" height="10" font="4">tive analysis. Am Heart J 2004;147:546</text>
<text top="129" left="271" width="20" height="15" font="4">–52.</text>
<text top="146" left="64" width="350" height="10" font="4">242. Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3</text>
<text top="160" left="90" width="265" height="10" font="4">levels in systolic heart failure to predict renal insuf</text>
<text top="157" left="355" width="59" height="15" font="4">ﬁciency and</text>
<text top="174" left="90" width="170" height="10" font="4">survival. Am J Cardiol 2011;108:385</text>
<text top="171" left="260" width="20" height="15" font="4">–90.</text>
<text top="188" left="64" width="350" height="10" font="4">243. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma</text>
<text top="203" left="90" width="324" height="10" font="4">galectin-3 levels in heart failure with reduced and preserved ejection</text>
<text top="217" left="90" width="139" height="10" font="4">fraction. Ann Med 2011;43:60</text>
<text top="214" left="229" width="14" height="15" font="4">–8.</text>
<text top="231" left="64" width="350" height="10" font="4">244. Lok DJ, van der Meer P, de la Porte PW, et al. Prognostic value of</text>
<text top="245" left="90" width="138" height="10" font="4">galectin-3, a novel marker of</text>
<text top="242" left="234" width="180" height="15" font="4">ﬁbrosis, in patients with chronic heart</text>
<text top="259" left="90" width="310" height="10" font="4">failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323</text>
<text top="256" left="400" width="14" height="15" font="4">–8.</text>
<text top="274" left="64" width="350" height="10" font="4">245. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic</text>
<text top="288" left="90" width="324" height="10" font="4">peptide in the diagnosis of congestive heart failure in an urgent-care</text>
<text top="302" left="90" width="181" height="10" font="4">setting. J Am Coll Cardiol 2001;37:379</text>
<text top="299" left="271" width="20" height="15" font="4">–85.</text>
<text top="316" left="64" width="350" height="10" font="4">246. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in</text>
<text top="330" left="90" width="238" height="10" font="4">assessment of acute dyspnoea. Lancet 1994;343:440</text>
<text top="327" left="328" width="14" height="15" font="4">–4.</text>
<text top="345" left="64" width="350" height="10" font="4">247. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of</text>
<text top="359" left="90" width="324" height="10" font="4">B-type natriuretic peptide in the emergency diagnosis of heart failure.</text>
<text top="373" left="90" width="131" height="10" font="4">N Engl J Med 2002;347:161</text>
<text top="370" left="221" width="14" height="15" font="4">–7.</text>
<text top="387" left="64" width="350" height="10" font="4">248. van Kimmenade RR, Pinto YM, Bayes-Genis A, et al. Usefulness of</text>
<text top="401" left="90" width="324" height="10" font="4">intermediate amino-terminal pro-brain natriuretic peptide concentrations</text>
<text top="416" left="90" width="324" height="10" font="4">for diagnosis and prognosis of acute heart failure. Am J Cardiol 2006;98:</text>
<text top="430" left="90" width="17" height="10" font="4">386</text>
<text top="427" left="107" width="20" height="15" font="4">–90.</text>
<text top="444" left="64" width="350" height="10" font="4">249. Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro-B-type natriuretic</text>
<text top="458" left="90" width="324" height="10" font="4">peptide testing improves the management of patients with suspected</text>
<text top="472" left="90" width="324" height="10" font="4">acute heart failure: primary results of the Canadian prospective</text>
<text top="486" left="90" width="324" height="10" font="4">randomized multicenter IMPROVE-CHF study. Circulation 2007;115:</text>
<text top="501" left="90" width="22" height="10" font="4">3103</text>
<text top="498" left="112" width="20" height="15" font="4">–10.</text>
<text top="515" left="64" width="350" height="10" font="4">250. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic</text>
<text top="529" left="90" width="324" height="10" font="4">peptide in the evaluation and management of acute dyspnea. N Engl J</text>
<text top="543" left="90" width="86" height="10" font="4">Med 2004;350:647</text>
<text top="540" left="176" width="20" height="15" font="4">–54.</text>
<text top="557" left="64" width="350" height="10" font="4">251. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natri-</text>
<text top="572" left="90" width="324" height="10" font="4">uretic peptide predicts outcome after hospital discharge in heart failure</text>
<text top="586" left="90" width="162" height="10" font="4">patients. Circulation 2004;110:2168</text>
<text top="583" left="252" width="20" height="15" font="4">–74.</text>
<text top="600" left="64" width="350" height="10" font="4">252. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type</text>
<text top="614" left="90" width="324" height="10" font="4">peptide predicts treatment outcomes in patients admitted for decom-</text>
<text top="628" left="90" width="304" height="10" font="4">pensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386</text>
<text top="625" left="394" width="20" height="15" font="4">–91.</text>
<text top="643" left="64" width="350" height="10" font="4">253. Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-type</text>
<text top="657" left="90" width="324" height="10" font="4">natriuretic peptide and cardiac troponin levels to predict in-hospital</text>
<text top="671" left="90" width="249" height="10" font="4">mortality from ADHERE. Am J Cardiol 2008;101:231</text>
<text top="668" left="339" width="14" height="15" font="4">–7.</text>
<text top="685" left="64" width="350" height="10" font="4">254. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic</text>
<text top="699" left="90" width="324" height="10" font="4">peptide assay for identifying patients at high risk of re-admission after</text>
<text top="714" left="90" width="278" height="10" font="4">decompensated heart failure. J Am Coll Cardiol 2004;43:635</text>
<text top="711" left="368" width="20" height="15" font="4">–41.</text>
<text top="728" left="64" width="350" height="10" font="4">255. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid</text>
<text top="742" left="90" width="324" height="10" font="4">Emergency Department Heart Failure Outpatient Trial (REDHOT):</text>
<text top="756" left="90" width="324" height="10" font="4">a multicenter study of B-type natriuretic peptide levels, emergency</text>
<text top="770" left="90" width="324" height="10" font="4">department decision making, and outcomes in patients presenting with</text>
<text top="785" left="90" width="243" height="10" font="4">shortness of breath. J Am Coll Cardiol 2004;44:1328</text>
<text top="782" left="333" width="20" height="15" font="4">–33.</text>
<text top="799" left="64" width="350" height="10" font="4">256. Zairis MN, Tsiaousis GZ, Georgilas AT, et al. Multimarker strategy for</text>
<text top="813" left="90" width="324" height="10" font="4">the prediction of 31 days cardiac death in patients with acutely</text>
<text top="827" left="90" width="293" height="10" font="4">decompensated chronic heart failure. Int J Cardiol 2010;141:284</text>
<text top="824" left="383" width="20" height="15" font="4">–90.</text>
<text top="841" left="64" width="350" height="10" font="4">257. Peacock WFIV, De Marco T, Fonarow GC, et al. Cardiac troponin and</text>
<text top="856" left="90" width="279" height="10" font="4">outcome in acute heart failure. N Engl J Med 2008;358:2117</text>
<text top="853" left="369" width="20" height="15" font="4">–26.</text>
<text top="870" left="64" width="350" height="10" font="4">258. Lee DS, Stitt A, Austin PC, et al. Prediction of heart failure mortality in</text>
<text top="884" left="90" width="281" height="10" font="4">emergent care: a cohort study. Ann Intern Med 2012;156:767</text>
<text top="881" left="371" width="20" height="15" font="4">–75.</text>
<text top="898" left="64" width="350" height="10" font="4">259. Bayes-Genis A, Lopez L, Zapico E, et al. NT-ProBNP reduction</text>
<text top="912" left="90" width="324" height="10" font="4">percentage during admission for acutely decompensated heart failure</text>
<text top="927" left="90" width="307" height="10" font="4">predicts long-term cardiovascular mortality. J Card Fail 2005;11:S3</text>
<text top="924" left="397" width="14" height="15" font="4">–8.</text>
<text top="941" left="64" width="350" height="10" font="4">260. Dhaliwal AS, Deswal A, Pritchett A, et al. Reduction in BNP levels with</text>
<text top="955" left="90" width="324" height="10" font="4">treatment of decompensated heart failure and future clinical events.</text>
<text top="969" left="90" width="111" height="10" font="4">J Card Fail 2009;15:293</text>
<text top="966" left="201" width="14" height="15" font="4">–9.</text>
<text top="983" left="64" width="350" height="10" font="4">261. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-</text>
<text top="998" left="90" width="324" height="10" font="4">reactive protein as a predictor of improvement and readmission in heart</text>
<text top="1012" left="90" width="163" height="10" font="4">failure. Eur J Heart Fail 2002;4:331</text>
<text top="1009" left="253" width="14" height="15" font="4">–6.</text>
<text top="1026" left="64" width="350" height="10" font="4">262. Dieplinger B, Gegenhuber A, Kaar G, et al. Prognostic value of estab-</text>
<text top="1040" left="90" width="324" height="10" font="4">lished and novel biomarkers in patients with shortness of breath</text>
<text top="1054" left="90" width="291" height="10" font="4">attending an emergency department. Clin Biochem 2010;43:714</text>
<text top="1051" left="381" width="14" height="15" font="4">–9.</text>
<text top="1069" left="64" width="269" height="10" font="4">263. Ilva T, Lassus J, Siirila-Waris K, et al. Clinical signi</text>
<text top="1066" left="333" width="80" height="15" font="4">ﬁcance of cardiac</text>
<text top="1083" left="90" width="310" height="10" font="4">troponins I and T in acute heart failure. Eur J Heart Fail 2008;10:772</text>
<text top="1080" left="400" width="14" height="15" font="4">–9.</text>
<text top="103" left="450" width="350" height="10" font="4">264. Januzzi JL Jr., Peacock WF, Maisel AS, et al. Measurement of the</text>
<text top="117" left="475" width="324" height="10" font="4">interleukin family member ST2 in patients with acute dyspnea: results</text>
<text top="132" left="475" width="324" height="10" font="4">from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea</text>
<text top="146" left="475" width="304" height="10" font="4">in the Emergency Department) study. J Am Coll Cardiol 2007;50:607</text>
<text top="143" left="780" width="20" height="15" font="4">–13.</text>
<text top="160" left="450" width="350" height="10" font="4">265. Manzano-Fernandez S, Mueller T, Pascual-Figal D, et al. Usefulness of</text>
<text top="174" left="475" width="324" height="10" font="4">soluble concentrations of interleukin family member ST2 as predictor of</text>
<text top="188" left="475" width="324" height="10" font="4">mortality in patients with acutely decompensated heart failure relative to</text>
<text top="203" left="475" width="277" height="10" font="4">left ventricular ejection fraction. Am J Cardiol 2011;107:259</text>
<text top="200" left="753" width="20" height="15" font="4">–67.</text>
<text top="217" left="450" width="350" height="10" font="4">266. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel</text>
<text top="231" left="475" width="324" height="10" font="4">interleukin family biomarker ST2 in patients with acute heart failure.</text>
<text top="245" left="475" width="150" height="10" font="4">J Am Coll Cardiol 2008;52:1458</text>
<text top="242" left="626" width="20" height="15" font="4">–65.</text>
<text top="259" left="450" width="350" height="10" font="4">267. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac</text>
<text top="274" left="475" width="324" height="10" font="4">structure and function, and long-term mortality in patients with acutely</text>
<text top="288" left="475" width="267" height="10" font="4">decompensated heart failure. Eur J Heart Fail 2010;12:826</text>
<text top="285" left="742" width="20" height="15" font="4">–32.</text>
<text top="302" left="450" width="350" height="10" font="4">268. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function,</text>
<text top="316" left="475" width="324" height="10" font="4">congestive heart failure, and amino-terminal pro-brain natriuretic peptide</text>
<text top="330" left="475" width="324" height="10" font="4">measurement: results from the ProBNP Investigation of Dyspnea in</text>
<text top="345" left="475" width="324" height="10" font="4">the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47:</text>
<text top="359" left="475" width="11" height="10" font="4">91</text>
<text top="356" left="487" width="14" height="15" font="4">–7.</text>
<text top="373" left="450" width="44" height="10" font="4">269. Red</text>
<text top="370" left="493" width="306" height="15" font="4">ﬁeld MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic</text>
<text top="387" left="475" width="324" height="10" font="4">peptide concentration: impact of age and gender. J Am Coll Cardiol</text>
<text top="401" left="475" width="56" height="10" font="4">2002;40:976</text>
<text top="398" left="532" width="20" height="15" font="4">–82.</text>
<text top="416" left="450" width="350" height="10" font="4">270. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma</text>
<text top="430" left="475" width="310" height="10" font="4">natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254</text>
<text top="427" left="785" width="14" height="15" font="4">–8.</text>
<text top="444" left="450" width="350" height="10" font="4">271. Chang AY, Abdullah SM, Jain T, et al. Associations among androgens,</text>
<text top="458" left="475" width="324" height="10" font="4">estrogens, and natriuretic peptides in young women: observations from</text>
<text top="472" left="475" width="255" height="10" font="4">the Dallas Heart Study. J Am Coll Cardiol 2007;49:109</text>
<text top="469" left="730" width="20" height="15" font="4">–16.</text>
<text top="486" left="450" width="350" height="10" font="4">272. Frantz RP, Olson LJ, Grill D, et al. Carvedilol therapy is associated with</text>
<text top="501" left="475" width="324" height="10" font="4">a sustained decline in brain natriuretic peptide levels in patients with</text>
<text top="515" left="475" width="231" height="10" font="4">congestive heart failure. Am Heart J 2005;149:541</text>
<text top="512" left="707" width="14" height="15" font="4">–7.</text>
<text top="529" left="450" width="350" height="10" font="4">273. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma</text>
<text top="543" left="475" width="324" height="10" font="4">brain natriuretic peptide and left ventricular remodeling in patients with</text>
<text top="557" left="475" width="256" height="10" font="4">congestive heart failure. J Am Coll Cardiol 2001;37:1228</text>
<text top="554" left="732" width="20" height="15" font="4">–33.</text>
<text top="572" left="450" width="350" height="10" font="4">274. Fruhwald FM, Fahrleitner-Pammer A, Berger R, et al. Early and sus-</text>
<text top="586" left="475" width="324" height="10" font="4">tained effects of cardiac resynchronization therapy on N-terminal pro-</text>
<text top="600" left="475" width="324" height="10" font="4">B-type natriuretic peptide in patients with moderate to severe heart</text>
<text top="614" left="475" width="275" height="10" font="4">failure and cardiac dyssynchrony. Eur Heart J 2007;28:1592</text>
<text top="611" left="750" width="14" height="15" font="4">–7.</text>
<text top="628" left="450" width="183" height="10" font="4">275. Januzzi JL Jr. Use of biomarkers to</text>
<text top="625" left="636" width="163" height="15" font="4">“guide” care in chronic heart failure:</text>
<text top="643" left="475" width="255" height="10" font="4">what have we learned (so far)? J Card Fail 2011;17:622</text>
<text top="640" left="731" width="14" height="15" font="4">–5.</text>
<text top="657" left="450" width="350" height="10" font="4">276. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe</text>
<text top="671" left="475" width="228" height="10" font="4">congestive heart failure. Circulation 1997;96:2953</text>
<text top="668" left="703" width="14" height="15" font="4">–8.</text>
<text top="685" left="450" width="350" height="10" font="4">277. Ather S, Hira RS, Shenoy M, et al. Recurrent low-level troponin I</text>
<text top="699" left="475" width="324" height="10" font="4">elevation is a worse prognostic indicator than occasional injury pattern in</text>
<text top="714" left="475" width="304" height="10" font="4">patients hospitalized with heart failure. Int J Cardiol 2011;301:H2351</text>
<text top="711" left="780" width="20" height="15" font="4">–61.</text>
<text top="728" left="450" width="350" height="10" font="4">278. Januzzi JL Jr., Filippatos G, Nieminen M, et al. Troponin elevation in</text>
<text top="742" left="475" width="279" height="10" font="4">patients with heart failure: on behalf of the third Universal De</text>
<text top="739" left="755" width="45" height="15" font="4">ﬁnition of</text>
<text top="756" left="475" width="324" height="10" font="4">Myocardial Infarction Global Task Force: Heart Failure Section. Eur</text>
<text top="770" left="475" width="98" height="10" font="4">Heart J 2012;33:2265</text>
<text top="767" left="574" width="20" height="15" font="4">–71.</text>
<text top="785" left="450" width="350" height="10" font="4">279. Matsumura Y, Takata J, Kitaoka H, et al. Long-term prognosis of dilated</text>
<text top="799" left="475" width="324" height="10" font="4">cardiomyopathy revisited: an improvement in survival over the past 20</text>
<text top="813" left="475" width="117" height="10" font="4">years. Circ J 2006;70:376</text>
<text top="810" left="593" width="20" height="15" font="4">–83.</text>
<text top="827" left="450" width="102" height="10" font="4">280. Deleted in press.</text>
<text top="841" left="450" width="350" height="10" font="4">281. Rizzello V, Poldermans D, Biagini E, et al. Prognosis of patients with</text>
<text top="856" left="475" width="324" height="10" font="4">ischaemic cardiomyopathy after coronary revascularisation: relation to</text>
<text top="870" left="475" width="324" height="10" font="4">viability and improvement in left ventricular ejection fraction. Heart</text>
<text top="884" left="475" width="62" height="10" font="4">2009;95:1273</text>
<text top="881" left="538" width="14" height="15" font="4">–7.</text>
<text top="898" left="450" width="350" height="10" font="4">282. Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability</text>
<text top="912" left="475" width="324" height="10" font="4">testing and impact of revascularization on prognosis in patients with</text>
<text top="927" left="475" width="324" height="10" font="4">coronary artery disease and left ventricular dysfunction: a meta-analysis.</text>
<text top="941" left="475" width="150" height="10" font="4">J Am Coll Cardiol 2002;39:1151</text>
<text top="938" left="626" width="14" height="15" font="4">–8.</text>
<text top="955" left="450" width="350" height="10" font="4">283. Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomog-</text>
<text top="969" left="475" width="324" height="10" font="4">raphy and recovery following revascularization (PARR-1): the importance</text>
<text top="983" left="475" width="324" height="10" font="4">of scar and the development of a prediction rule for the degree of recovery</text>
<text top="998" left="475" width="270" height="10" font="4">of left ventricular function. J Am Coll Cardiol 2002;40:1735</text>
<text top="995" left="745" width="20" height="15" font="4">–43.</text>
<text top="1012" left="450" width="350" height="10" font="4">284. Pagley PR, Beller GA, Watson DD, et al. Improved outcome after</text>
<text top="1026" left="475" width="324" height="10" font="4">coronary bypass surgery in patients with ischemic cardiomyopathy and</text>
<text top="1040" left="475" width="246" height="10" font="4">residual myocardial viability. Circulation 1997;96:793</text>
<text top="1037" left="721" width="25" height="15" font="4">–800.</text>
<text top="1054" left="450" width="350" height="10" font="4">285. Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography</text>
<text top="1069" left="475" width="324" height="10" font="4">predicts long-term survival after revascularization in patients with</text>
<text top="1083" left="475" width="304" height="10" font="4">ischemic congestive heart failure. J Am Coll Cardiol 1999;33:1848</text>
<text top="1080" left="780" width="20" height="15" font="4">–54.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e216</text>
</page>
<page number="71" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">286. Kwon DH, Halley CM, Carrigan TP, et al. Extent of left ventricular scar</text>
<text top="117" left="90" width="314" height="10" font="4">predicts outcomes in ischemic cardiomyopathy patients with signi</text>
<text top="114" left="404" width="10" height="15" font="4">ﬁ-</text>
<text top="132" left="90" width="324" height="10" font="4">cantly reduced systolic function: a delayed hyperenhancement cardiac</text>
<text top="146" left="90" width="294" height="10" font="4">magnetic resonance study. JACC Cardiovasc Imaging 2009;2:34</text>
<text top="143" left="384" width="20" height="15" font="4">–44.</text>
<text top="160" left="64" width="350" height="10" font="4">287. Ordovas KG, Higgins CB. Delayed contrast enhancement on MR images</text>
<text top="174" left="90" width="284" height="10" font="4">of myocardium: past, present, future. Radiology 2011;261:358</text>
<text top="171" left="374" width="20" height="15" font="4">–74.</text>
<text top="188" left="64" width="350" height="10" font="4">288. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance</text>
<text top="203" left="90" width="324" height="10" font="4">imaging in the detection of cardiac amyloidosis. JACC Cardiovasc</text>
<text top="217" left="90" width="92" height="10" font="4">Imaging 2010;3:155</text>
<text top="214" left="182" width="20" height="15" font="4">–64.</text>
<text top="231" left="64" width="350" height="10" font="4">289. Beller GA. Tests that may be overused or misused in cardiology: the</text>
<text top="245" left="90" width="258" height="10" font="4">Choosing Wisely campaign. J Nucl Cardiol 2012;19:401</text>
<text top="242" left="348" width="14" height="15" font="4">–3.</text>
<text top="259" left="64" width="350" height="10" font="4">290. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/</text>
<text top="274" left="90" width="324" height="10" font="4">HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate use cri-</text>
<text top="288" left="90" width="324" height="10" font="4">teria for echocardiography: a report of the American College of</text>
<text top="302" left="90" width="324" height="10" font="4">Cardiology Foundation Appropriate Use Criteria Task Force, Amer-</text>
<text top="316" left="90" width="324" height="10" font="4">ican Society of Echocardiography, American Heart Association,</text>
<text top="330" left="90" width="324" height="10" font="4">American Society of Nuclear Cardiology, Heart Failure Society of</text>
<text top="345" left="90" width="324" height="10" font="4">America, Heart Rhythm Society, Society for Cardiovascular Angi-</text>
<text top="359" left="90" width="324" height="10" font="4">ography and Interventions, Society of Critical Care Medicine, Society</text>
<text top="373" left="90" width="324" height="10" font="4">of Cardiovascular Computed Tomography, and Society for Cardio-</text>
<text top="387" left="90" width="303" height="10" font="4">vascular Magnetic Resonance. J Am Coll Cardiol 2011;57:1126</text>
<text top="384" left="393" width="20" height="15" font="4">–66.</text>
<text top="401" left="64" width="350" height="10" font="4">291. Agha SA, Kalogeropoulos AP, Shih J, et al. Echocardiography and risk</text>
<text top="416" left="90" width="324" height="10" font="4">prediction in advanced heart failure: incremental value over clinical</text>
<text top="430" left="90" width="153" height="10" font="4">markers. J Card Fail 2009;15:586</text>
<text top="427" left="243" width="20" height="15" font="4">–92.</text>
<text top="444" left="64" width="350" height="10" font="4">292. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of</text>
<text top="458" left="90" width="324" height="10" font="4">systolic and diastolic function for incident congestive heart failure in the</text>
<text top="472" left="90" width="324" height="10" font="4">elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2001;37:</text>
<text top="486" left="90" width="22" height="10" font="4">1042</text>
<text top="483" left="112" width="14" height="15" font="4">–8.</text>
<text top="501" left="64" width="350" height="10" font="4">293. Chen AA, Wood MJ, Krauser DG, et al. NT-proBNP levels, echocar-</text>
<text top="515" left="90" width="47" height="10" font="4">diographic</text>
<text top="512" left="140" width="274" height="15" font="4">ﬁndings, and outcomes in breathless patients: results from the</text>
<text top="529" left="90" width="324" height="10" font="4">ProBNP Investigation of Dyspnoea in the Emergency Department</text>
<text top="543" left="90" width="288" height="10" font="4">(PRIDE) echocardiographic substudy. Eur Heart J 2006;27:839</text>
<text top="540" left="377" width="20" height="15" font="4">–45.</text>
<text top="557" left="64" width="350" height="10" font="4">294. Gardin JM, McClelland R, Kitzman D, et al. M-mode echocardiographic</text>
<text top="572" left="90" width="324" height="10" font="4">predictors of six- to seven-year incidence of coronary heart disease,</text>
<text top="586" left="90" width="324" height="10" font="4">stroke, congestive heart failure, and mortality in an elderly cohort (the</text>
<text top="600" left="90" width="268" height="10" font="4">Cardiovascular Health Study). Am J Cardiol 2001;87:1051</text>
<text top="597" left="358" width="14" height="15" font="4">–7.</text>
<text top="614" left="64" width="350" height="10" font="4">295. Grayburn PA, Appleton CP, DeMaria AN, et al. Echocardiographic</text>
<text top="628" left="90" width="324" height="10" font="4">predictors of morbidity and mortality in patients with advanced heart</text>
<text top="643" left="90" width="324" height="10" font="4">failure: the Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll</text>
<text top="657" left="90" width="99" height="10" font="4">Cardiol 2005;45:1064</text>
<text top="654" left="189" width="20" height="15" font="4">–71.</text>
<text top="671" left="64" width="350" height="10" font="4">296. Francis CM, Caruana L, Kearney P, et al. Open access echocardiography</text>
<text top="685" left="90" width="310" height="10" font="4">in management of heart failure in the community. BMJ 1995;310:634</text>
<text top="682" left="400" width="14" height="15" font="4">–6.</text>
<text top="699" left="64" width="350" height="10" font="4">297. Bonow RO, Bennett S, Casey DE Jr., et al. ACC/AHA clinical perfor-</text>
<text top="714" left="90" width="324" height="10" font="4">mance measures for adults with chronic heart failure: a report of the</text>
<text top="728" left="90" width="324" height="10" font="4">American College of Cardiology/American Heart Association Task</text>
<text top="742" left="90" width="324" height="10" font="4">Force on Performance Measures (Writing Committee to Develop Heart</text>
<text top="756" left="90" width="324" height="10" font="4">Failure Clinical Performance Measures). J Am Coll Cardiol 2005;46:</text>
<text top="770" left="90" width="22" height="10" font="4">1144</text>
<text top="767" left="112" width="20" height="15" font="4">–78.</text>
<text top="785" left="64" width="350" height="10" font="4">298. Valle-Munoz A, Estornell-Erill J, Soriano-Navarro CJ, et al. Late gado-</text>
<text top="799" left="90" width="281" height="10" font="4">linium enhancement-cardiovascular magnetic resonance identi</text>
<text top="796" left="371" width="43" height="15" font="4">ﬁes coro-</text>
<text top="813" left="90" width="324" height="10" font="4">nary artery disease as the aetiology of left ventricular dysfunction in acute</text>
<text top="827" left="90" width="304" height="10" font="4">new-onset congestive heart failure. Eur J Echocardiogr 2009;10:968</text>
<text top="824" left="394" width="20" height="15" font="4">–74.</text>
<text top="841" left="64" width="350" height="10" font="4">299. Butler J. The emerging role of multi-detector computed tomography in</text>
<text top="856" left="90" width="172" height="10" font="4">heart failure. J Card Fail 2007;13:215</text>
<text top="853" left="262" width="20" height="15" font="4">–26.</text>
<text top="870" left="64" width="350" height="10" font="4">300. van Royen N, Jaffe CC, Krumholz HM, et al. Comparison and repro-</text>
<text top="884" left="90" width="324" height="10" font="4">ducibility of visual echocardiographic and quantitative radionuclide left</text>
<text top="898" left="90" width="258" height="10" font="4">ventricular ejection fractions. Am J Cardiol 1996;77:843</text>
<text top="895" left="347" width="20" height="15" font="4">–50.</text>
<text top="912" left="64" width="350" height="10" font="4">301. Atchley AE, Kitzman DW, Whellan DJ, et al. Myocardial perfusion,</text>
<text top="927" left="90" width="324" height="10" font="4">function, and dyssynchrony in patients with heart failure: baseline results</text>
<text top="941" left="90" width="324" height="10" font="4">from the single-photon emission computed tomography imaging ancillary</text>
<text top="955" left="90" width="324" height="10" font="4">study of the Heart Failure and A Controlled Trial Investigating Outcomes</text>
<text top="969" left="90" width="304" height="10" font="4">of Exercise TraiNing (HF-ACTION) Trial. Am Heart J 2009;158:S53</text>
<text top="966" left="394" width="20" height="15" font="4">–63.</text>
<text top="983" left="64" width="350" height="10" font="4">302. Nichols KJ, Van TA, Wang Y, et al. Automated detection of left</text>
<text top="998" left="90" width="324" height="10" font="4">ventricular dyskinesis by gated blood pool SPECT. Nucl Med Commun</text>
<text top="1012" left="90" width="56" height="10" font="4">2010;31:881</text>
<text top="1009" left="146" width="14" height="15" font="4">–8.</text>
<text top="1026" left="64" width="350" height="10" font="4">303. Soman P, Lahiri A, Mieres JH, et al. Etiology and pathophysiology of</text>
<text top="1040" left="90" width="324" height="10" font="4">new-onset heart failure: evaluation by myocardial perfusion imaging.</text>
<text top="1054" left="90" width="121" height="10" font="4">J Nucl Cardiol 2009;16:82</text>
<text top="1051" left="211" width="20" height="15" font="4">–91.</text>
<text top="1069" left="64" width="350" height="10" font="4">304. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in</text>
<text top="1083" left="90" width="301" height="10" font="4">ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617</text>
<text top="1080" left="391" width="20" height="15" font="4">–25.</text>
<text top="103" left="450" width="350" height="10" font="4">305. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of</text>
<text top="117" left="475" width="324" height="10" font="4">congestive heart failure and pulmonary artery catheterization effective-</text>
<text top="132" left="475" width="214" height="10" font="4">ness: the ESCAPE trial. JAMA 2005;294:1625</text>
<text top="129" left="690" width="20" height="15" font="4">–33.</text>
<text top="146" left="450" width="350" height="10" font="4">306. Shah MR, Hasselblad V, Stevenson LW, et al. Impact of the pulmonary</text>
<text top="160" left="475" width="324" height="10" font="4">artery catheter in critically ill patients: meta-analysis of randomized</text>
<text top="174" left="475" width="166" height="10" font="4">clinical trials. JAMA 2005;294:1664</text>
<text top="171" left="642" width="20" height="15" font="4">–70.</text>
<text top="188" left="450" width="350" height="10" font="4">307. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery</text>
<text top="203" left="475" width="324" height="10" font="4">surgery in patients with poor left ventricular function (CASS). Circula-</text>
<text top="217" left="475" width="77" height="10" font="4">tion 1983;68:785</text>
<text top="214" left="553" width="20" height="15" font="4">–95.</text>
<text top="231" left="450" width="350" height="10" font="4">308. Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/</text>
<text top="245" left="475" width="324" height="10" font="4">AHA/ASNC 2009 appropriateness criteria for coronary revascularization:</text>
<text top="259" left="475" width="324" height="10" font="4">a report by the American College of Cardiology Foundation Appropri-</text>
<text top="274" left="475" width="324" height="10" font="4">ateness Criteria Task Force, Society for Cardiovascular Angiography and</text>
<text top="288" left="475" width="324" height="10" font="4">Interventions, Society of Thoracic Surgeons, American Association for</text>
<text top="302" left="475" width="324" height="10" font="4">Thoracic Surgery, American Heart Association, and the American</text>
<text top="316" left="475" width="287" height="10" font="4">Society of Nuclear Cardiology. J Am Coll Cardiol 2009;53:530</text>
<text top="313" left="762" width="20" height="15" font="4">–53.</text>
<text top="330" left="450" width="350" height="10" font="4">309. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery</text>
<text top="345" left="475" width="324" height="10" font="4">in patients with left ventricular dysfunction. N Engl J Med 2011;364:</text>
<text top="359" left="475" width="22" height="10" font="4">1607</text>
<text top="356" left="498" width="20" height="15" font="4">–16.</text>
<text top="373" left="450" width="350" height="10" font="4">310. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyo-</text>
<text top="387" left="475" width="313" height="10" font="4">cardial biopsy in the management of cardiovascular disease: a scienti</text>
<text top="384" left="788" width="11" height="15" font="4">ﬁc</text>
<text top="401" left="475" width="324" height="10" font="4">statement from the American Heart Association, the American College</text>
<text top="416" left="475" width="324" height="10" font="4">of Cardiology, and the European Society of Cardiology. Circulation</text>
<text top="430" left="475" width="68" height="10" font="4">2007;116:2216</text>
<text top="427" left="543" width="20" height="15" font="4">–33.</text>
<text top="444" left="450" width="350" height="10" font="4">311. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in</text>
<text top="458" left="475" width="291" height="10" font="4">patients 80 years of age or older. N Engl J Med 2008;358:1887</text>
<text top="455" left="766" width="20" height="15" font="4">–98.</text>
<text top="472" left="450" width="350" height="10" font="4">312. Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and</text>
<text top="486" left="475" width="324" height="10" font="4">development of heart failure in hypertension: a Bayesian network meta-</text>
<text top="501" left="475" width="324" height="10" font="4">analysis of studies in patients with hypertension and high cardiovascular</text>
<text top="515" left="475" width="165" height="10" font="4">risk. Arch Intern Med 2011;171:384</text>
<text top="512" left="641" width="20" height="15" font="4">–94.</text>
<text top="529" left="450" width="350" height="10" font="4">313. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood</text>
<text top="543" left="475" width="324" height="10" font="4">pressure reduction: a quantitative overview updated until 1 March 2003.</text>
<text top="557" left="475" width="119" height="10" font="4">J Hypertens 2003;21:1055</text>
<text top="554" left="595" width="20" height="15" font="4">–76.</text>
<text top="572" left="450" width="350" height="10" font="4">314. Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril,</text>
<text top="586" left="475" width="324" height="10" font="4">and their combination on left ventricular hypertrophy in individuals at</text>
<text top="600" left="475" width="324" height="10" font="4">high vascular risk in the Ongoing Telmisartan Alone and in Combination</text>
<text top="614" left="475" width="324" height="10" font="4">With Ramipril Global End Point Trial and the Telmisartan Randomized</text>
<text top="628" left="475" width="324" height="10" font="4">Assessment Study in ACE Intolerant Subjects With Cardiovascular</text>
<text top="643" left="475" width="162" height="10" font="4">Disease. Circulation 2009;120:1380</text>
<text top="640" left="638" width="14" height="15" font="4">–9.</text>
<text top="657" left="450" width="350" height="10" font="4">315. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular</text>
<text top="671" left="475" width="324" height="10" font="4">mortality and events with statin treatments: a network meta-analysis in-</text>
<text top="685" left="475" width="304" height="10" font="4">volving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769</text>
<text top="682" left="780" width="20" height="15" font="4">–81.</text>
<text top="699" left="450" width="350" height="10" font="4">316. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of</text>
<text top="714" left="475" width="324" height="10" font="4">cardiovascular disease. Cochrane Database Syst Rev 2011; (1)CD004816.</text>
<text top="728" left="450" width="350" height="10" font="4">317. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-</text>
<text top="742" left="475" width="324" height="10" font="4">enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;</text>
<text top="756" left="475" width="42" height="10" font="4">351:2058</text>
<text top="753" left="518" width="20" height="15" font="4">–68.</text>
<text top="770" left="450" width="350" height="10" font="4">318. Kenchaiah S, Sesso HD, Gaziano JM. Body mass index and vigorous</text>
<text top="785" left="475" width="324" height="10" font="4">physical activity and the risk of heart failure among men. Circulation</text>
<text top="799" left="475" width="56" height="10" font="4">2009;119:44</text>
<text top="796" left="532" width="20" height="15" font="4">–52.</text>
<text top="813" left="450" width="350" height="10" font="4">319. Lee DS, Massaro JM, Wang TJ, et al. Antecedent blood pressure, body</text>
<text top="827" left="475" width="324" height="10" font="4">mass index, and the risk of incident heart failure in later life. Hyper-</text>
<text top="841" left="475" width="92" height="10" font="4">tension 2007;50:869</text>
<text top="838" left="568" width="20" height="15" font="4">–76.</text>
<text top="856" left="450" width="350" height="10" font="4">320. Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Incident heart</text>
<text top="870" left="475" width="324" height="10" font="4">failure prediction in the elderly: the Health ABC heart failure score. Circ</text>
<text top="884" left="475" width="100" height="10" font="4">Heart Fail 2008;1:125</text>
<text top="881" left="575" width="20" height="15" font="4">–33.</text>
<text top="898" left="450" width="350" height="10" font="4">321. Kalogeropoulos A, Georgiopoulou V, Harris TB, et al. Glycemic status</text>
<text top="912" left="475" width="324" height="10" font="4">and incident heart failure in elderly without history of diabetes mellitus: the</text>
<text top="927" left="475" width="310" height="10" font="4">Health, Aging, and Body Composition study. J Card Fail 2009;15:593</text>
<text top="924" left="785" width="14" height="15" font="4">–9.</text>
<text top="941" left="450" width="350" height="10" font="4">322. Lind M, Bounias I, Olsson M, et al. Glycaemic control and incidence of</text>
<text top="955" left="475" width="324" height="10" font="4">heart failure in 20,985 patients with type 1 diabetes: an observational</text>
<text top="969" left="475" width="127" height="10" font="4">study. Lancet 2011;378:140</text>
<text top="966" left="602" width="14" height="15" font="4">–6.</text>
<text top="983" left="450" width="32" height="10" font="4">323. P</text>
<text top="980" left="482" width="318" height="15" font="4">ﬁster R, Cairns R, Erdmann E, et al. A clinical risk score for heart</text>
<text top="998" left="475" width="324" height="10" font="4">failure in patients with type 2 diabetes and macrovascular disease: an</text>
<text top="1012" left="475" width="275" height="10" font="4">analysis of the PROactive study. Int J Cardiol 2013;162:112</text>
<text top="1009" left="751" width="14" height="15" font="4">–6.</text>
<text top="1026" left="450" width="350" height="10" font="4">324. Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Predictors of heart failure</text>
<text top="1040" left="475" width="292" height="10" font="4">among women with coronary disease. Circulation 2004;110:1424</text>
<text top="1037" left="767" width="20" height="15" font="4">–30.</text>
<text top="1054" left="450" width="350" height="10" font="4">325. The EUCLID Study Group. Randomised placebo-controlled trial of</text>
<text top="1069" left="475" width="324" height="10" font="4">lisinopril in normotensive patients with insulin-dependent diabetes and</text>
<text top="1083" left="475" width="287" height="10" font="4">normoalbuminuria or microalbuminuria. Lancet 1997;349:1787</text>
<text top="1080" left="762" width="20" height="15" font="4">–92.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e217</text>
</page>
<page number="72" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">326. Coyle JD, Gardner SF, White CM. The renal protective effects of</text>
<text top="117" left="90" width="324" height="10" font="4">angiotensin II receptor blockers in type 2 diabetes mellitus. Ann Phar-</text>
<text top="132" left="90" width="107" height="10" font="4">macother 2004;38:1731</text>
<text top="129" left="197" width="14" height="15" font="4">–8.</text>
<text top="146" left="64" width="350" height="10" font="4">327. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the</text>
<text top="160" left="90" width="324" height="10" font="4">Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes</text>
<text top="174" left="90" width="248" height="10" font="4">and overt nephropathy. Ann Intern Med 2003;138:542</text>
<text top="171" left="338" width="14" height="15" font="4">–9.</text>
<text top="188" left="64" width="350" height="10" font="4">328. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal</text>
<text top="203" left="90" width="324" height="10" font="4">and cardiovascular outcomes in patients with type 2 diabetes and</text>
<text top="217" left="90" width="193" height="10" font="4">nephropathy. N Engl J Med 2001;345:861</text>
<text top="214" left="283" width="14" height="15" font="4">–9.</text>
<text top="231" left="64" width="350" height="10" font="4">329. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-</text>
<text top="245" left="90" width="324" height="10" font="4">enzyme inhibitor, ramipril, on cardiovascular events in high-risk</text>
<text top="259" left="90" width="324" height="10" font="4">patients: the Heart Outcomes Prevention Evaluation Study Investiga-</text>
<text top="274" left="90" width="154" height="10" font="4">tors. N Engl J Med 2000;342:145</text>
<text top="271" left="244" width="20" height="15" font="4">–53.</text>
<text top="288" left="64" width="350" height="10" font="4">330. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in</text>
<text top="302" left="90" width="324" height="10" font="4">patients with breast cancer treated with bevacizumab. J Clin Oncol 2011;</text>
<text top="316" left="90" width="31" height="10" font="4">29:632</text>
<text top="313" left="121" width="14" height="15" font="4">–8.</text>
<text top="330" left="64" width="350" height="10" font="4">331. Du XL, Xia R, Burau K, et al. Cardiac risk associated with the receipt of</text>
<text top="345" left="90" width="324" height="10" font="4">anthracycline and trastuzumab in a large nationwide cohort of older women</text>
<text top="359" left="90" width="108" height="10" font="4">with breast cancer, 1998</text>
<text top="356" left="198" width="199" height="15" font="4">–2005. Med Oncol 2011;28 Suppl 1:S80–90.</text>
<text top="373" left="64" width="350" height="10" font="4">332. Yusuf SW, Ilias-Khan NA, Durand JB. Chemotherapy-induced cardio-</text>
<text top="387" left="90" width="235" height="10" font="4">myopathy. Expert Rev Cardiovasc Ther 2011;9:231</text>
<text top="384" left="325" width="20" height="15" font="4">–43.</text>
<text top="401" left="64" width="350" height="10" font="4">333. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of</text>
<text top="416" left="90" width="324" height="10" font="4">cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:</text>
<text top="430" left="90" width="22" height="10" font="4">1375</text>
<text top="427" left="112" width="20" height="15" font="4">–80.</text>
<text top="444" left="64" width="350" height="10" font="4">334. Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, et al. Epidemi-</text>
<text top="458" left="90" width="324" height="10" font="4">ology of incident heart failure in a contemporary elderly cohort: the</text>
<text top="472" left="90" width="324" height="10" font="4">health, aging, and body composition study. Arch Intern Med 2009;169:</text>
<text top="486" left="90" width="17" height="10" font="4">708</text>
<text top="483" left="107" width="20" height="15" font="4">–15.</text>
<text top="501" left="64" width="350" height="10" font="4">335. McKie PM, Cataliotti A, Lahr BD, et al. The prognostic value of</text>
<text top="515" left="90" width="324" height="10" font="4">N-terminal pro-B-type natriuretic peptide for death and cardiovascular</text>
<text top="529" left="90" width="324" height="10" font="4">events in healthy normal and stage A/B heart failure subjects. J Am Coll</text>
<text top="543" left="90" width="99" height="10" font="4">Cardiol 2010;55:2140</text>
<text top="540" left="189" width="14" height="15" font="4">–7.</text>
<text top="557" left="64" width="350" height="10" font="4">336. Velagaleti RS, Gona P, Larson MG, et al. Multimarker approach for the</text>
<text top="572" left="90" width="324" height="10" font="4">prediction of heart failure incidence in the community. Circulation 2010;</text>
<text top="586" left="90" width="42" height="10" font="4">122:1700</text>
<text top="583" left="132" width="14" height="15" font="4">–6.</text>
<text top="600" left="64" width="350" height="10" font="4">337. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial</text>
<text top="614" left="90" width="324" height="10" font="4">measures of cardiac troponin T using a sensitive assay with incident</text>
<text top="628" left="90" width="324" height="10" font="4">heart failure and cardiovascular mortality in older adults. JAMA 2010;</text>
<text top="643" left="90" width="42" height="10" font="4">304:2494</text>
<text top="640" left="132" width="25" height="15" font="4">–502.</text>
<text top="657" left="64" width="350" height="10" font="4">338. Blecker S, Matsushita K, Kottgen A, et al. High-normal albuminuria</text>
<text top="671" left="90" width="324" height="10" font="4">and risk of heart failure in the community. Am J Kidney Dis 2011;58:</text>
<text top="685" left="90" width="11" height="10" font="4">47</text>
<text top="682" left="101" width="20" height="15" font="4">–55.</text>
<text top="699" left="64" width="350" height="10" font="4">339. Dhingra R, Gaziano JM, Djousse L. Chronic kidney disease and the risk</text>
<text top="714" left="90" width="232" height="10" font="4">of heart failure in men. Circ Heart Fail 2011;4:138</text>
<text top="711" left="322" width="20" height="15" font="4">–44.</text>
<text top="728" left="64" width="350" height="10" font="4">340. Dhingra R, Gona P, Benjamin EJ, et al. Relations of serum phosphorus</text>
<text top="742" left="90" width="324" height="10" font="4">levels to echocardiographic left ventricular mass and incidence of heart</text>
<text top="756" left="90" width="253" height="10" font="4">failure in the community. Eur J Heart Fail 2010;12:812</text>
<text top="753" left="343" width="14" height="15" font="4">–8.</text>
<text top="770" left="64" width="350" height="10" font="4">341. Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost-effectiveness of</text>
<text top="785" left="90" width="324" height="10" font="4">screening with B-type natriuretic peptide to identify patients with</text>
<text top="799" left="90" width="324" height="10" font="4">reduced left ventricular ejection fraction. J Am Coll Cardiol 2004;43:</text>
<text top="813" left="90" width="22" height="10" font="4">1019</text>
<text top="810" left="112" width="20" height="15" font="4">–26.</text>
<text top="827" left="64" width="350" height="10" font="4">342. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on</text>
<text top="841" left="90" width="324" height="10" font="4">mortality and morbidity in patients with left ventricular dysfunction after</text>
<text top="856" left="90" width="324" height="10" font="4">myocardial infarction: results of the survival and ventricular enlargement</text>
<text top="870" left="90" width="269" height="10" font="4">trial: the SAVE Investigators. N Engl J Med 1992;327:669</text>
<text top="867" left="359" width="20" height="15" font="4">–77.</text>
<text top="884" left="64" width="350" height="10" font="4">343. The CONSENSUS Trial Study Group. Effects of enalapril on mortality</text>
<text top="898" left="90" width="324" height="10" font="4">in severe congestive heart failure: results of the Cooperative North</text>
<text top="912" left="90" width="324" height="10" font="4">Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med</text>
<text top="927" left="90" width="68" height="10" font="4">1987;316:1429</text>
<text top="924" left="158" width="20" height="15" font="4">–35.</text>
<text top="941" left="64" width="350" height="10" font="4">344. The SOLVD Investigators. Effect of enalapril on mortality and the</text>
<text top="955" left="90" width="324" height="10" font="4">development of heart failure in asymptomatic patients with reduced left</text>
<text top="969" left="90" width="266" height="10" font="4">ventricular ejection fractions. N Engl J Med 1992;327:685</text>
<text top="966" left="356" width="20" height="15" font="4">–91.</text>
<text top="983" left="64" width="350" height="10" font="4">345. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or</text>
<text top="998" left="90" width="324" height="10" font="4">both in myocardial infarction complicated by heart failure, left ventric-</text>
<text top="1012" left="90" width="256" height="10" font="4">ular dysfunction, or both. N Engl J Med 2003;349:1893</text>
<text top="1009" left="346" width="25" height="15" font="4">–906.</text>
<text top="1026" left="64" width="350" height="10" font="4">346. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in</text>
<text top="1040" left="90" width="324" height="10" font="4">patients with left-ventricular dysfunction: the CAPRICORN randomised</text>
<text top="1054" left="90" width="126" height="10" font="4">trial. Lancet 2001;357:1385</text>
<text top="1051" left="216" width="20" height="15" font="4">–90.</text>
<text top="1069" left="64" width="294" height="10" font="4">347. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive bene</text>
<text top="1066" left="359" width="55" height="15" font="4">ﬁcial effects</text>
<text top="1083" left="90" width="324" height="10" font="4">of beta-blockers to angiotensin-converting enzyme inhibitors in the</text>
<text top="103" left="476" width="324" height="10" font="4">Survival and Ventricular Enlargement (SAVE) Study: SAVE Investi-</text>
<text top="117" left="476" width="178" height="10" font="4">gators. J Am Coll Cardiol 1997;29:229</text>
<text top="114" left="654" width="20" height="15" font="4">–36.</text>
<text top="132" left="450" width="350" height="10" font="4">348. Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking</text>
<text top="146" left="476" width="324" height="10" font="4">agent use and mortality in patients with asymptomatic and symptomatic</text>
<text top="160" left="476" width="324" height="10" font="4">left ventricular systolic dysfunction: a post hoc analysis of the Studies of</text>
<text top="174" left="476" width="282" height="10" font="4">Left Ventricular Dysfunction. J Am Coll Cardiol 1999;33:916</text>
<text top="171" left="758" width="20" height="15" font="4">–23.</text>
<text top="188" left="450" width="350" height="10" font="4">349. Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and</text>
<text top="203" left="475" width="324" height="10" font="4">the risk of hospitalization for heart failure after an acute coronary</text>
<text top="217" left="475" width="324" height="10" font="4">syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47:</text>
<text top="231" left="475" width="22" height="10" font="4">2326</text>
<text top="228" left="498" width="20" height="15" font="4">–31.</text>
<text top="245" left="450" width="34" height="10" font="4">350. A</text>
<text top="242" left="483" width="316" height="15" font="4">ﬁlalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute</text>
<text top="259" left="475" width="324" height="10" font="4">coronary syndromes and stable coronary heart disease: a comparative</text>
<text top="274" left="475" width="295" height="10" font="4">meta-analysis of randomised controlled trials. Heart 2007;93:914</text>
<text top="271" left="770" width="20" height="15" font="4">–21.</text>
<text top="288" left="450" width="350" height="10" font="4">351. Ho JE, Waters DD, Kean A, et al. Relation of improvement in estimated</text>
<text top="302" left="475" width="49" height="10" font="4">glomerular</text>
<text top="299" left="528" width="271" height="15" font="4">ﬁltration rate with atorvastatin to reductions in hospitaliza-</text>
<text top="316" left="475" width="324" height="10" font="4">tions for heart failure (from the Treating to New Targets [TNT] study).</text>
<text top="330" left="475" width="133" height="10" font="4">Am J Cardiol 2012;109:1761</text>
<text top="327" left="609" width="14" height="15" font="4">–6.</text>
<text top="345" left="450" width="350" height="10" font="4">352. Strandberg TE, Holme I, Faergeman O, et al. Comparative effect of</text>
<text top="359" left="475" width="324" height="10" font="4">atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing</text>
<text top="373" left="475" width="324" height="10" font="4">hospitalizations for heart failure in patients with previous myocardial</text>
<text top="387" left="475" width="183" height="10" font="4">infarction. Am J Cardiol 2009;103:1381</text>
<text top="384" left="658" width="14" height="15" font="4">–5.</text>
<text top="401" left="450" width="350" height="10" font="4">353. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on</text>
<text top="416" left="475" width="324" height="10" font="4">the incidence of heart failure in patients with coronary heart disease.</text>
<text top="430" left="475" width="105" height="10" font="4">J Card Fail 1997;3:249</text>
<text top="427" left="581" width="20" height="15" font="4">–54.</text>
<text top="444" left="450" width="350" height="10" font="4">354. Sacks FM, Pfeffer MA, Moye LA, et al.; Cholesterol and Recurrent</text>
<text top="458" left="475" width="324" height="10" font="4">Events Trial Investigators. The effect of pravastatin on coronary events</text>
<text top="472" left="475" width="324" height="10" font="4">after myocardial infarction in patients with average cholesterol levels.</text>
<text top="486" left="475" width="136" height="10" font="4">N Engl J Med 1996;335:1001</text>
<text top="483" left="612" width="14" height="15" font="4">–9.</text>
<text top="501" left="450" width="350" height="10" font="4">355. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of</text>
<text top="515" left="475" width="18" height="10" font="4">a de</text>
<text top="512" left="494" width="306" height="15" font="4">ﬁbrillator in patients with myocardial infarction and reduced ejection</text>
<text top="529" left="475" width="172" height="10" font="4">fraction. N Engl J Med 2002;346:877</text>
<text top="526" left="647" width="20" height="15" font="4">–83.</text>
<text top="543" left="450" width="350" height="10" font="4">356. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs</text>
<text top="557" left="475" width="324" height="10" font="4">a delayed conservative simvastatin strategy in patients with acute coro-</text>
<text top="572" left="475" width="304" height="10" font="4">nary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307</text>
<text top="569" left="780" width="20" height="15" font="4">–16.</text>
<text top="586" left="450" width="350" height="10" font="4">357. Dahlof B, Devereux R, de Faire U, et al. The Losartan Intervention For</text>
<text top="600" left="475" width="324" height="10" font="4">Endpoint reduction (LIFE) in Hypertension study: rationale, design, and</text>
<text top="614" left="475" width="288" height="10" font="4">methods: the LIFE Study Group. Am J Hypertens 1997;10:705</text>
<text top="611" left="763" width="20" height="15" font="4">–13.</text>
<text top="628" left="450" width="350" height="10" font="4">358. Mancia G. Effects of intensive blood pressure control in the management</text>
<text top="643" left="475" width="324" height="10" font="4">of patients with type 2 diabetes mellitus in the Action to Control Cardio-</text>
<text top="657" left="475" width="310" height="10" font="4">vascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:847</text>
<text top="654" left="785" width="14" height="15" font="4">–9.</text>
<text top="671" left="450" width="104" height="10" font="4">359. The ALLHAT Of</text>
<text top="668" left="554" width="245" height="15" font="4">ﬁcers and Coordinators for the ALLHAT Collaborative</text>
<text top="685" left="475" width="324" height="10" font="4">Research Group. Major outcomes in high-risk hypertensive patients</text>
<text top="699" left="475" width="324" height="10" font="4">randomized to angiotensin-converting enzyme inhibitor or calcium</text>
<text top="714" left="475" width="324" height="10" font="4">channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering</text>
<text top="728" left="475" width="324" height="10" font="4">Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:</text>
<text top="742" left="475" width="22" height="10" font="4">2981</text>
<text top="739" left="498" width="299" height="15" font="4">–97. Errata in: JAMA. 2004;291:2196 and JAMA. 2003;289:178.</text>
<text top="756" left="450" width="350" height="10" font="4">360. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood</text>
<text top="770" left="475" width="267" height="10" font="4">pressure reduction: a meta-analysis. Lancet 2001;358:1305</text>
<text top="767" left="742" width="20" height="15" font="4">–15.</text>
<text top="785" left="450" width="350" height="10" font="4">361. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril,</text>
<text top="799" left="475" width="324" height="10" font="4">and eplerenone/enalapril in patients with essential hypertension and left</text>
<text top="813" left="475" width="324" height="10" font="4">ventricular hypertrophy: the 4E-left ventricular hypertrophy study.</text>
<text top="827" left="475" width="121" height="10" font="4">Circulation 2003;108:1831</text>
<text top="824" left="597" width="14" height="15" font="4">–8.</text>
<text top="841" left="450" width="350" height="10" font="4">362. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an</text>
<text top="856" left="475" width="58" height="10" font="4">implanted de</text>
<text top="853" left="534" width="265" height="15" font="4">ﬁbrillator in patients with coronary disease at high risk for</text>
<text top="870" left="475" width="223" height="10" font="4">ventricular arrhythmia: Multicenter Automatic De</text>
<text top="867" left="698" width="101" height="15" font="4">ﬁbrillator Implantation</text>
<text top="884" left="475" width="225" height="10" font="4">Trial Investigators. N Engl J Med 1996;335:1933</text>
<text top="881" left="701" width="20" height="15" font="4">–40.</text>
<text top="898" left="450" width="111" height="10" font="4">363. Boren SA, Wake</text>
<text top="895" left="560" width="239" height="15" font="4">ﬁeld BJ, Gunlock TL, et al. Heart failure self-</text>
<text top="912" left="475" width="324" height="10" font="4">management education: a systematic review of the evidence. Int J</text>
<text top="927" left="475" width="145" height="10" font="4">Evid Based Healthc 2009;7:159</text>
<text top="924" left="620" width="20" height="15" font="4">–68.</text>
<text top="941" left="450" width="350" height="10" font="4">364. Gwadry-Sridhar FH, Arnold JM, Zhang Y, et al. Pilot study to determine</text>
<text top="955" left="475" width="324" height="10" font="4">the impact of a multidisciplinary educational intervention in patients</text>
<text top="969" left="475" width="263" height="10" font="4">hospitalized with heart failure. Am Heart J 2005;150:982.</text>
<text top="983" left="450" width="350" height="10" font="4">365. Koelling TM, Johnson ML, Cody RJ, et al. Discharge education</text>
<text top="998" left="475" width="324" height="10" font="4">improves clinical outcomes in patients with chronic heart failure.</text>
<text top="1012" left="475" width="116" height="10" font="4">Circulation 2005;111:179</text>
<text top="1009" left="591" width="20" height="15" font="4">–85.</text>
<text top="1026" left="450" width="350" height="10" font="4">366. VanSuch M, Naessens JM, Stroebel RJ, et al. Effect of discharge</text>
<text top="1040" left="475" width="324" height="10" font="4">instructions on readmission of hospitalised patients with heart failure: do</text>
<text top="1054" left="475" width="324" height="10" font="4">all of the Joint Commission on Accreditation of Healthcare Organiza-</text>
<text top="1069" left="475" width="154" height="10" font="4">tions heart failure core measures re</text>
<text top="1066" left="630" width="170" height="15" font="4">ﬂect better care? Qual Saf Health Care</text>
<text top="1083" left="475" width="56" height="10" font="4">2006;15:414</text>
<text top="1080" left="532" width="14" height="15" font="4">–7.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e218</text>
</page>
<page number="73" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">367. Aguado O, Morcillo C, Delas J, et al. Long-term implications of a single</text>
<text top="117" left="90" width="324" height="10" font="4">home-based educational intervention in patients with heart failure. Heart</text>
<text top="132" left="90" width="84" height="10" font="4">Lung 2010;39:S14</text>
<text top="129" left="174" width="20" height="15" font="4">–22.</text>
<text top="146" left="64" width="350" height="10" font="4">368. Riegel B, Moser DK, Anker SD, et al. State of the science: promoting</text>
<text top="160" left="90" width="221" height="10" font="4">self-care in persons with heart failure: a scienti</text>
<text top="157" left="311" width="103" height="15" font="4">ﬁc statement from the</text>
<text top="174" left="90" width="256" height="10" font="4">American Heart Association. Circulation 2009;120:1141</text>
<text top="171" left="346" width="20" height="15" font="4">–63.</text>
<text top="188" left="64" width="350" height="10" font="4">369. Powell LH, Calvin JE Jr., Richardson D, et al. Self-management coun-</text>
<text top="203" left="90" width="324" height="10" font="4">seling in patients with heart failure: the Heart Failure Adherence and</text>
<text top="217" left="90" width="289" height="10" font="4">Retention Randomized Behavioral Trial. JAMA 2010;304:1331</text>
<text top="214" left="379" width="14" height="15" font="4">–8.</text>
<text top="231" left="64" width="350" height="10" font="4">370. Jha AK, Orav EJ, Epstein AM. Public reporting of discharge planning</text>
<text top="245" left="90" width="258" height="10" font="4">and rates of readmissions. N Engl J Med 2009;361:2637</text>
<text top="242" left="348" width="20" height="15" font="4">–45.</text>
<text top="259" left="64" width="350" height="10" font="4">371. Gallager R, Luttik ML, Jaarsma T. Social support and self-care in heart</text>
<text top="274" left="90" width="179" height="10" font="4">failure. J Cardiovasc Nurs 2011;26:439</text>
<text top="271" left="269" width="20" height="15" font="4">–45.</text>
<text top="288" left="64" width="350" height="10" font="4">372. Luttik ML, Jaarsma T, Moser D, et al. The importance and impact of</text>
<text top="302" left="90" width="324" height="10" font="4">social support on outcomes in patients with heart failure: an overview of</text>
<text top="316" left="90" width="207" height="10" font="4">the literature. J Cardiovasc Nurs 2005;20:162</text>
<text top="313" left="297" width="14" height="15" font="4">–9.</text>
<text top="330" left="64" width="350" height="10" font="4">373. Struthers AD, Anderson G, Donnan PT, et al. Social deprivation</text>
<text top="345" left="90" width="324" height="10" font="4">increases cardiac hospitalisations in chronic heart failure independent of</text>
<text top="359" left="90" width="283" height="10" font="4">disease severity and diuretic non-adherence. Heart 2000;83:12</text>
<text top="356" left="373" width="14" height="15" font="4">–6.</text>
<text top="373" left="64" width="350" height="10" font="4">374. Murberg TA, Bru E. Social relationships and mortality in patients with</text>
<text top="387" left="90" width="252" height="10" font="4">congestive heart failure. J Psychosom Res 2001;51:521</text>
<text top="384" left="342" width="14" height="15" font="4">–7.</text>
<text top="401" left="64" width="350" height="10" font="4">375. Murberg TA. Long-term effect of social relationships on mortality in</text>
<text top="416" left="90" width="305" height="10" font="4">patients with congestive heart failure. Int J Psychiatry Med 2004;34:207</text>
<text top="413" left="395" width="19" height="15" font="4">–17.</text>
<text top="430" left="64" width="350" height="10" font="4">376. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the</text>
<text top="444" left="90" width="324" height="10" font="4">diagnosis and treatment of acute and chronic heart failure 2008: the Task</text>
<text top="458" left="90" width="324" height="10" font="4">Force for the Diagnosis and Treatment of Acute and Chronic Heart</text>
<text top="472" left="90" width="324" height="10" font="4">Failure 2008 of the European Society of Cardiology: developed in</text>
<text top="486" left="90" width="324" height="10" font="4">collaboration with the Heart Failure Association of the ESC (HFA) and</text>
<text top="501" left="90" width="324" height="10" font="4">endorsed by the European Society of Intensive Care Medicine (ESICM).</text>
<text top="515" left="90" width="118" height="10" font="4">Eur Heart J 2008;29:2388</text>
<text top="512" left="208" width="25" height="15" font="4">–442.</text>
<text top="529" left="64" width="350" height="10" font="4">377. Malcom J, Arnold O, Howlett JG, et al. Canadian Cardiovascular</text>
<text top="543" left="90" width="260" height="10" font="4">Society Consensus Conference guidelines on heart failure</text>
<text top="540" left="350" width="64" height="15" font="4">–2008 update:</text>
<text top="557" left="90" width="324" height="10" font="4">best practices for the transition of care of heart failure patients, and the</text>
<text top="572" left="90" width="324" height="10" font="4">recognition, investigation and treatment of cardiomyopathies. Can J</text>
<text top="586" left="90" width="88" height="10" font="4">Cardiol 2008;24:21</text>
<text top="583" left="178" width="20" height="15" font="4">–40.</text>
<text top="600" left="64" width="350" height="10" font="4">378. Lennie TA, Song EK, Wu JR, et al. Three gram sodium intake is</text>
<text top="614" left="90" width="324" height="10" font="4">associated with longer event-free survival only in patients with advanced</text>
<text top="628" left="90" width="172" height="10" font="4">heart failure. J Card Fail 2011;17:325</text>
<text top="625" left="262" width="20" height="15" font="4">–30.</text>
<text top="643" left="64" width="350" height="10" font="4">379. Arcand J, Ivanov J, Sasson A, et al. A high-sodium diet is associated</text>
<text top="657" left="90" width="324" height="10" font="4">with acute decompensated heart failure in ambulatory heart failure</text>
<text top="671" left="90" width="307" height="10" font="4">patients: a prospective follow-up study. Am J Clin Nutr 2011;93:332</text>
<text top="668" left="397" width="14" height="15" font="4">–7.</text>
<text top="685" left="64" width="350" height="10" font="4">380. Cody RJ, Covit AB, Schaer GL, et al. Sodium and water balance in</text>
<text top="699" left="90" width="273" height="10" font="4">chronic congestive heart failure. J Clin Invest 1986;77:1441</text>
<text top="696" left="363" width="20" height="15" font="4">–52.</text>
<text top="714" left="64" width="350" height="10" font="4">381. Damgaard M, Norsk P, Gustafsson F, et al. Hemodynamic and neuro-</text>
<text top="728" left="90" width="324" height="10" font="4">endocrine responses to changes in sodium intake in compensated heart</text>
<text top="742" left="90" width="299" height="10" font="4">failure. Am J Physiol Regul Integr Comp Physiol 2006;290:R1294</text>
<text top="739" left="389" width="25" height="15" font="4">–301.</text>
<text top="756" left="64" width="350" height="10" font="4">382. Volpe M, Magri P, Rao MA, et al. Intrarenal determinants of sodium</text>
<text top="770" left="90" width="324" height="10" font="4">retention in mild heart failure: effects of angiotensin-converting enzyme</text>
<text top="785" left="90" width="170" height="10" font="4">inhibition. Hypertension 1997;30:168</text>
<text top="782" left="260" width="20" height="15" font="4">–76.</text>
<text top="799" left="64" width="350" height="10" font="4">383. Volpe M, Tritto C, DeLuca N, et al. Abnormalities of sodium handling</text>
<text top="813" left="90" width="324" height="10" font="4">and of cardiovascular adaptations during high salt diet in patients with</text>
<text top="827" left="90" width="201" height="10" font="4">mild heart failure. Circulation 1993;88:1620</text>
<text top="824" left="291" width="14" height="15" font="4">–7.</text>
<text top="841" left="64" width="350" height="10" font="4">384. Paterna S, Parrinello G, Cannizzaro S, et al. Medium term effects of</text>
<text top="856" left="90" width="205" height="10" font="4">different dosage of diuretic, sodium, and</text>
<text top="853" left="303" width="111" height="15" font="4">ﬂuid administration on</text>
<text top="870" left="90" width="324" height="10" font="4">neurohormonal and clinical outcome in patients with recently compen-</text>
<text top="884" left="90" width="209" height="10" font="4">sated heart failure. Am J Cardiol 2009;103:93</text>
<text top="881" left="300" width="25" height="15" font="4">–102.</text>
<text top="898" left="64" width="350" height="10" font="4">385. Paterna S, Gaspare P, Fasullo S, et al. Normal-sodium diet compared</text>
<text top="912" left="90" width="324" height="10" font="4">with low-sodium diet in compensated congestive heart failure: is sodium</text>
<text top="927" left="90" width="282" height="10" font="4">an old enemy or a new friend? Clin Sci (Lond) 2008;114:221</text>
<text top="924" left="372" width="20" height="15" font="4">–30.</text>
<text top="941" left="64" width="350" height="10" font="4">386. Parrinello G, Di Pasquale P, Licata G, et al. Long-term effects of dietary</text>
<text top="955" left="90" width="324" height="10" font="4">sodium intake on cytokines and neurohormonal activation in patients</text>
<text top="969" left="90" width="324" height="10" font="4">with recently compensated congestive heart failure. J Card Fail 2009;15:</text>
<text top="983" left="90" width="17" height="10" font="4">864</text>
<text top="980" left="107" width="20" height="15" font="4">–73.</text>
<text top="998" left="64" width="350" height="10" font="4">387. He FJ, MacGregor GA. Effect of longer-term modest salt reduction on</text>
<text top="1012" left="90" width="302" height="10" font="4">blood pressure. Cochrane Database Syst Rev 2004; (3)CD004937.</text>
<text top="1026" left="64" width="350" height="10" font="4">388. The Trials of Hypertension Prevention Collaborative Research Group.</text>
<text top="1040" left="90" width="324" height="10" font="4">Effects of weight loss and sodium reduction intervention on blood</text>
<text top="1054" left="90" width="324" height="10" font="4">pressure and hypertension incidence in overweight people with high-</text>
<text top="1069" left="90" width="324" height="10" font="4">normal blood pressure: the Trials of Hypertension Prevention, phase</text>
<text top="1083" left="90" width="156" height="10" font="4">II. Arch Intern Med 1997;157:657</text>
<text top="1080" left="246" width="20" height="15" font="4">–67.</text>
<text top="103" left="450" width="350" height="10" font="4">389. Jula AM, Karanko HM. Effects on left ventricular hypertrophy of long-</text>
<text top="117" left="476" width="324" height="10" font="4">term nonpharmacological treatment with sodium restriction in mild-to-</text>
<text top="132" left="476" width="266" height="10" font="4">moderate essential hypertension. Circulation 1994;89:1023</text>
<text top="129" left="742" width="20" height="15" font="4">–31.</text>
<text top="146" left="450" width="350" height="10" font="4">390. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary</text>
<text top="160" left="475" width="324" height="10" font="4">sodium reduction on cardiovascular disease outcomes: observational</text>
<text top="174" left="475" width="324" height="10" font="4">follow-up of the Trials of Hypertension Prevention (TOHP). BMJ 2007;</text>
<text top="188" left="475" width="37" height="10" font="4">334:885</text>
<text top="185" left="512" width="14" height="15" font="4">–8.</text>
<text top="203" left="450" width="99" height="10" font="4">391. Strazzullo P, D</text>
<text top="200" left="549" width="250" height="15" font="4">’Elia L, Kandala NB, et al. Salt intake, stroke, and</text>
<text top="217" left="475" width="324" height="10" font="4">cardiovascular disease: meta-analysis of prospective studies. BMJ 2009;</text>
<text top="231" left="475" width="51" height="10" font="4">339:b4567.</text>
<text top="245" left="450" width="350" height="10" font="4">392. Gupta D, Georgiopoulou VV, Kalogeropoulos AP, et al. Dietary sodium</text>
<text top="259" left="475" width="220" height="10" font="4">intake in heart failure. Circulation 2012;126:479</text>
<text top="256" left="695" width="20" height="15" font="4">–85.</text>
<text top="274" left="450" width="350" height="10" font="4">393. Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea</text>
<text top="288" left="475" width="324" height="10" font="4">by continuous positive airway pressure and transplant-free survival in</text>
<text top="302" left="475" width="324" height="10" font="4">heart failure: a post hoc analysis of the Canadian Continuous Positive</text>
<text top="316" left="475" width="324" height="10" font="4">Airway Pressure for Patients with Central Sleep Apnea and Heart Failure</text>
<text top="330" left="475" width="204" height="10" font="4">Trial (CANPAP). Circulation 2007;115:3173</text>
<text top="327" left="680" width="20" height="15" font="4">–80.</text>
<text top="345" left="450" width="350" height="10" font="4">394. Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway</text>
<text top="359" left="475" width="324" height="10" font="4">pressure for central sleep apnea and heart failure. N Engl J Med 2005;</text>
<text top="373" left="475" width="42" height="10" font="4">353:2025</text>
<text top="370" left="518" width="20" height="15" font="4">–33.</text>
<text top="387" left="450" width="350" height="10" font="4">395. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous</text>
<text top="401" left="475" width="324" height="10" font="4">positive airway pressure in patients with heart failure and obstructive</text>
<text top="416" left="475" width="195" height="10" font="4">sleep apnea. N Engl J Med 2003;348:1233</text>
<text top="413" left="671" width="20" height="15" font="4">–41.</text>
<text top="430" left="450" width="50" height="10" font="4">396. Mans</text>
<text top="427" left="500" width="299" height="15" font="4">ﬁeld DR, Gollogly NC, Kaye DM, et al. Controlled trial of</text>
<text top="444" left="475" width="324" height="10" font="4">continuous positive airway pressure in obstructive sleep apnea and heart</text>
<text top="458" left="475" width="228" height="10" font="4">failure. Am J Respir Crit Care Med 2004;169:361</text>
<text top="455" left="704" width="14" height="15" font="4">–6.</text>
<text top="472" left="450" width="350" height="10" font="4">397. MacDonald M, Fang J, Pittman SD, et al. The current prevalence of</text>
<text top="486" left="475" width="324" height="10" font="4">sleep disordered breathing in congestive heart failure patients treated</text>
<text top="501" left="475" width="218" height="10" font="4">with beta-blockers. J Clin Sleep Med 2008;4:38</text>
<text top="498" left="694" width="20" height="15" font="4">–42.</text>
<text top="515" left="450" width="350" height="10" font="4">398. Arzt M, Young T, Finn L, et al. Sleepiness and sleep in patients with</text>
<text top="529" left="475" width="324" height="10" font="4">both systolic heart failure and obstructive sleep apnea. Arch Intern Med</text>
<text top="543" left="475" width="68" height="10" font="4">2006;166:1716</text>
<text top="540" left="543" width="20" height="15" font="4">–22.</text>
<text top="557" left="450" width="350" height="10" font="4">399. Pasini E, Opasich C, Pastoris O, et al. Inadequate nutritional intake for</text>
<text top="572" left="475" width="324" height="10" font="4">daily life activity of clinically stable patients with chronic heart failure.</text>
<text top="586" left="475" width="124" height="10" font="4">Am J Cardiol 2004;93:41A</text>
<text top="583" left="600" width="22" height="15" font="4">–3A.</text>
<text top="600" left="450" width="350" height="10" font="4">400. Habbu A, Lakkis NM, Dokainish H. The obesity paradox: fact or</text>
<text top="611" left="475" width="173" height="15" font="4">ﬁction? Am J Cardiol 2006;98:944–8.</text>
<text top="628" left="450" width="350" height="10" font="4">401. Alpert MA, Lambert CR, Panayiotou H, et al. Relation of duration of</text>
<text top="643" left="475" width="324" height="10" font="4">morbid obesity to left ventricular mass, systolic function, and diastolic</text>
<text top="654" left="475" width="294" height="15" font="4">ﬁlling, and effect of weight loss. Am J Cardiol 1995;76:1194–7.</text>
<text top="671" left="450" width="350" height="10" font="4">402. Ristow B, Rabkin J, Haeusslein E. Improvement in dilated cardiomy-</text>
<text top="685" left="475" width="249" height="10" font="4">opathy after bariatric surgery. J Card Fail 2008;14:198</text>
<text top="682" left="724" width="25" height="15" font="4">–202.</text>
<text top="699" left="450" width="350" height="10" font="4">403. Sayin T, Guldal M. Sibutramine: possible cause of a reversible cardio-</text>
<text top="714" left="475" width="169" height="10" font="4">myopathy. Int J Cardiol 2005;99:481</text>
<text top="711" left="644" width="14" height="15" font="4">–2.</text>
<text top="728" left="450" width="350" height="10" font="4">404. Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart</text>
<text top="742" left="475" width="324" height="10" font="4">failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail</text>
<text top="756" left="475" width="56" height="10" font="4">2010;12:706</text>
<text top="753" left="532" width="20" height="15" font="4">–15.</text>
<text top="770" left="450" width="350" height="10" font="4">405. McKelvie RS. Exercise training in patients with heart failure: clinical</text>
<text top="785" left="475" width="273" height="10" font="4">outcomes, safety, and indications. Heart Fail Rev 2008;13:3</text>
<text top="782" left="749" width="20" height="15" font="4">–11.</text>
<text top="799" left="450" width="34" height="10" font="4">406. O</text>
<text top="796" left="483" width="316" height="15" font="4">’Connor CM, Whellan DJ, Lee KL, et al. Efﬁcacy and safety of</text>
<text top="813" left="475" width="324" height="10" font="4">exercise training in patients with chronic heart failure: HF-ACTION</text>
<text top="827" left="475" width="231" height="10" font="4">randomized controlled trial. JAMA 2009;301:1439</text>
<text top="824" left="706" width="20" height="15" font="4">–50.</text>
<text top="841" left="450" width="350" height="10" font="4">407. Pina IL, Apstein CS, Balady GJ, et al. Exercise and heart failure:</text>
<text top="856" left="475" width="324" height="10" font="4">a statement from the American Heart Association Committee on Exer-</text>
<text top="870" left="475" width="289" height="10" font="4">cise, Rehabilitation, and Prevention. Circulation 2003;107:1210</text>
<text top="867" left="764" width="20" height="15" font="4">–25.</text>
<text top="884" left="450" width="350" height="10" font="4">408. Smart N, Marwick TH. Exercise training for patients with heart failure:</text>
<text top="898" left="475" width="324" height="10" font="4">a systematic review of factors that improve mortality and morbidity. Am</text>
<text top="912" left="475" width="94" height="10" font="4">J Med 2004;116:693</text>
<text top="909" left="570" width="25" height="15" font="4">–706.</text>
<text top="927" left="450" width="350" height="10" font="4">409. Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis</text>
<text top="941" left="475" width="324" height="10" font="4">of trials in patients with chronic heart failure (ExTraMATCH). BMJ</text>
<text top="955" left="475" width="65" height="10" font="4">2004;328:189.</text>
<text top="969" left="450" width="350" height="10" font="4">410. Austin J, Williams R, Ross L, et al. Randomised controlled trial of</text>
<text top="983" left="475" width="324" height="10" font="4">cardiac rehabilitation in elderly patients with heart failure. Eur J Heart</text>
<text top="998" left="475" width="72" height="10" font="4">Fail 2005;7:411</text>
<text top="995" left="547" width="14" height="15" font="4">–7.</text>
<text top="1012" left="450" width="286" height="10" font="4">411. Austin J, Williams WR, Ross L, et al. Five-year follow-up</text>
<text top="1009" left="739" width="60" height="15" font="4">ﬁndings from</text>
<text top="1026" left="475" width="324" height="10" font="4">a randomized controlled trial of cardiac rehabilitation for heart failure.</text>
<text top="1040" left="475" width="200" height="10" font="4">Eur J Cardiovasc Prev Rehabil 2008;15:162</text>
<text top="1037" left="676" width="14" height="15" font="4">–7.</text>
<text top="1054" left="450" width="350" height="10" font="4">412. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with</text>
<text top="1069" left="475" width="324" height="10" font="4">hydralazine-isosorbide dinitrate in the treatment of chronic congestive</text>
<text top="1083" left="475" width="192" height="10" font="4">heart failure. N Engl J Med 1991;325:303</text>
<text top="1080" left="667" width="20" height="15" font="4">–10.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e219</text>
</page>
<page number="74" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">413. The SOLVD Investigators.. Effect of enalapril on survival in patients</text>
<text top="117" left="90" width="324" height="10" font="4">with reduced left ventricular ejection fractions and congestive heart</text>
<text top="132" left="90" width="166" height="10" font="4">failure. N Engl J Med 1991;325:293</text>
<text top="129" left="256" width="25" height="15" font="4">–302.</text>
<text top="146" left="64" width="350" height="10" font="4">414. Garg R, Yusuf S. Overview of randomized trials of angiotensin-</text>
<text top="160" left="90" width="324" height="10" font="4">converting enzyme inhibitors on mortality and morbidity in patients</text>
<text top="174" left="90" width="324" height="10" font="4">with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA</text>
<text top="188" left="90" width="68" height="10" font="4">1995;273:1450</text>
<text top="185" left="158" width="14" height="15" font="4">–6.</text>
<text top="203" left="64" width="350" height="10" font="4">415. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on</text>
<text top="217" left="90" width="324" height="10" font="4">morbidity and mortality in patients with heart failure not receiving</text>
<text top="231" left="90" width="324" height="10" font="4">angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:</text>
<text top="245" left="90" width="22" height="10" font="4">1414</text>
<text top="242" left="112" width="20" height="15" font="4">–21.</text>
<text top="259" left="64" width="350" height="10" font="4">416. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in</text>
<text top="274" left="90" width="178" height="10" font="4">severe heart failure. Lancet 1990;336:1</text>
<text top="271" left="268" width="14" height="15" font="4">–6.</text>
<text top="288" left="64" width="350" height="10" font="4">417. Australia-New Zealand Heart Failure Research Collaborative Group.</text>
<text top="302" left="90" width="324" height="10" font="4">Effects of carvedilol, a vasodilator-beta-blocker, in patients with</text>
<text top="316" left="90" width="324" height="10" font="4">congestive heart failure due to ischemic heart disease. Circulation 1995;</text>
<text top="330" left="90" width="31" height="10" font="4">92:212</text>
<text top="327" left="121" width="14" height="15" font="4">–8.</text>
<text top="345" left="64" width="350" height="10" font="4">418. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of</text>
<text top="359" left="90" width="324" height="10" font="4">the beta-blocker bucindolol in patients with advanced chronic heart</text>
<text top="373" left="90" width="172" height="10" font="4">failure. N Engl J Med 2001;344:1659</text>
<text top="370" left="262" width="20" height="15" font="4">–67.</text>
<text top="387" left="64" width="350" height="10" font="4">419. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of car-</text>
<text top="401" left="90" width="324" height="10" font="4">vedilol and metoprolol on clinical outcomes in patients with chronic</text>
<text top="416" left="90" width="324" height="10" font="4">heart failure in the Carvedilol Or Metoprolol European Trial (COMET):</text>
<text top="430" left="90" width="213" height="10" font="4">randomised controlled trial. Lancet 2003;362:7</text>
<text top="427" left="303" width="20" height="15" font="4">–13.</text>
<text top="444" left="64" width="350" height="10" font="4">420. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on</text>
<text top="458" left="90" width="324" height="10" font="4">mortality and morbidity in patients with chronic heart failure: the</text>
<text top="472" left="90" width="235" height="10" font="4">CHARM-Overall programme. Lancet 2003;362:759</text>
<text top="469" left="325" width="20" height="15" font="4">–66.</text>
<text top="486" left="64" width="350" height="10" font="4">421. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus</text>
<text top="501" left="90" width="324" height="10" font="4">low-dose losartan on clinical outcomes in patients with heart failure</text>
<text top="515" left="90" width="324" height="10" font="4">(HEAAL study): a randomised, double-blind trial. Lancet 2009;374:</text>
<text top="529" left="90" width="22" height="10" font="4">1840</text>
<text top="526" left="112" width="14" height="15" font="4">–8.</text>
<text top="543" left="64" width="350" height="10" font="4">422. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus</text>
<text top="557" left="90" width="324" height="10" font="4">captopril in patients over 65 with heart failure (Evaluation of Losartan in</text>
<text top="572" left="90" width="223" height="10" font="4">the Elderly Study, ELITE). Lancet 1997;349:747</text>
<text top="569" left="313" width="20" height="15" font="4">–52.</text>
<text top="586" left="64" width="350" height="10" font="4">423. Carson P, Ziesche S, Johnson G, et al., Vasodilator-Heart Failure Trial</text>
<text top="600" left="90" width="324" height="10" font="4">Study Group. Racial differences in response to therapy for heart failure:</text>
<text top="614" left="90" width="304" height="10" font="4">analysis of the vasodilator-heart failure trials. J Card Fail 1999;5:178</text>
<text top="611" left="394" width="20" height="15" font="4">–87.</text>
<text top="628" left="64" width="350" height="10" font="4">424. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dini-</text>
<text top="643" left="90" width="324" height="10" font="4">trate and hydralazine in blacks with heart failure. N Engl J Med 2004;</text>
<text top="657" left="90" width="42" height="10" font="4">351:2049</text>
<text top="654" left="132" width="20" height="15" font="4">–57.</text>
<text top="671" left="64" width="350" height="10" font="4">425. Pitt B, Zannad F, Remme WJ, et al., Randomized Aldactone Evaluation</text>
<text top="685" left="90" width="324" height="10" font="4">Study Investigators. The effect of spironolactone on morbidity and</text>
<text top="699" left="90" width="324" height="10" font="4">mortality in patients with severe heart failure. N Engl J Med 1999;341:</text>
<text top="714" left="90" width="17" height="10" font="4">709</text>
<text top="711" left="107" width="20" height="15" font="4">–17.</text>
<text top="728" left="64" width="350" height="10" font="4">426. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with</text>
<text top="742" left="90" width="304" height="10" font="4">systolic heart failure and mild symptoms. N Engl J Med 2011;364:11</text>
<text top="739" left="394" width="20" height="15" font="4">–21.</text>
<text top="756" left="64" width="290" height="10" font="4">427. Brater DC. Diuretic therapy. N Engl J Med 1998;339:387</text>
<text top="753" left="354" width="20" height="15" font="4">–95.</text>
<text top="770" left="64" width="350" height="10" font="4">428. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium</text>
<text top="785" left="90" width="304" height="10" font="4">retention of congestive heart failure. Arch Intern Med 1994;154:1905</text>
<text top="782" left="394" width="20" height="15" font="4">–14.</text>
<text top="799" left="64" width="350" height="10" font="4">429. Patterson JH, Adams KF Jr., Applefeld MM, et al. Oral torsemide in</text>
<text top="813" left="90" width="324" height="10" font="4">patients with chronic congestive heart failure: effects on body weight,</text>
<text top="827" left="90" width="324" height="10" font="4">edema, and electrolyte excretion: Torsemide Investigators Group.</text>
<text top="841" left="90" width="138" height="10" font="4">Pharmacotherapy 1994;14:514</text>
<text top="838" left="228" width="20" height="15" font="4">–21.</text>
<text top="856" left="64" width="350" height="10" font="4">430. Sherman LG, Liang CS, Baumgardner S, et al. Piretanide, a potent</text>
<text top="870" left="90" width="324" height="10" font="4">diuretic with potassium-sparing properties, for the treatment of conges-</text>
<text top="884" left="90" width="236" height="10" font="4">tive heart failure. Clin Pharmacol Ther 1986;40:587</text>
<text top="881" left="326" width="20" height="15" font="4">–94.</text>
<text top="898" left="64" width="350" height="10" font="4">431. Wilson JR, Reichek N, Dunkman WB, et al. Effect of diuresis on the</text>
<text top="912" left="90" width="310" height="10" font="4">performance of the failing left ventricle in man. Am J Med 1981;70:234</text>
<text top="909" left="400" width="14" height="15" font="4">–9.</text>
<text top="927" left="64" width="350" height="10" font="4">432. Parker JO. The effects of oral ibopamine in patients with mild heart</text>
<text top="941" left="90" width="324" height="10" font="4">failure: a double blind placebo controlled comparison to furosemide: the</text>
<text top="955" left="90" width="234" height="10" font="4">Ibopamine Study Group. Int J Cardiol 1993;40:221</text>
<text top="952" left="324" width="14" height="15" font="4">–7.</text>
<text top="969" left="64" width="350" height="10" font="4">433. Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison of</text>
<text top="983" left="90" width="324" height="10" font="4">captopril alone against frusemide plus amiloride in mild heart failure.</text>
<text top="998" left="90" width="85" height="10" font="4">Lancet 1987;2:709</text>
<text top="995" left="175" width="20" height="15" font="4">–11.</text>
<text top="1012" left="64" width="350" height="10" font="4">434. Risler T, Schwab A, Kramer B, et al. Comparative pharmacokinetics and</text>
<text top="1026" left="90" width="324" height="10" font="4">pharmacodynamics of loop diuretics in renal failure. Cardiology 1994;84</text>
<text top="1040" left="90" width="55" height="10" font="4">Suppl 2:155</text>
<text top="1037" left="145" width="20" height="15" font="4">–61.</text>
<text top="1054" left="64" width="350" height="10" font="4">435. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacoki-</text>
<text top="1069" left="90" width="324" height="10" font="4">netics, and pharmacodynamics of torsemide and furosemide in patients</text>
<text top="1083" left="90" width="291" height="10" font="4">with congestive heart failure. Clin Pharmacol Ther 1995;57:601</text>
<text top="1080" left="381" width="14" height="15" font="4">–9.</text>
<text top="103" left="450" width="350" height="10" font="4">436. Herchuelz A, Derenne F, Deger F, et al. Interaction between nonsteroidal</text>
<text top="117" left="476" width="29" height="10" font="4">anti-in</text>
<text top="114" left="504" width="295" height="15" font="4">ﬂammatory drugs and loop diuretics: modulation by sodium</text>
<text top="132" left="476" width="214" height="10" font="4">balance. J Pharmacol Exp Ther 1989;248:1175</text>
<text top="129" left="689" width="20" height="15" font="4">–81.</text>
<text top="146" left="450" width="350" height="10" font="4">437. Gottlieb SS, Robinson S, Krichten CM, et al. Renal response to indo-</text>
<text top="160" left="476" width="324" height="10" font="4">methacin in congestive heart failure secondary to ischemic or idiopathic</text>
<text top="174" left="475" width="235" height="10" font="4">dilated cardiomyopathy. Am J Cardiol 1992;70:890</text>
<text top="171" left="710" width="14" height="15" font="4">–3.</text>
<text top="188" left="450" width="350" height="10" font="4">438. Brater DC, Harris C, Redfern JS, et al. Renal effects of COX-2-selective</text>
<text top="203" left="475" width="163" height="10" font="4">inhibitors. Am J Nephrol 2001;21:1</text>
<text top="200" left="638" width="20" height="15" font="4">–15.</text>
<text top="217" left="450" width="286" height="10" font="4">439. Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic ef</text>
<text top="214" left="736" width="63" height="15" font="4">ﬁcacy of high</text>
<text top="231" left="475" width="324" height="10" font="4">dose furosemide in severe heart failure: bolus injection versus contin-</text>
<text top="245" left="475" width="213" height="10" font="4">uous infusion. J Am Coll Cardiol 1996;28:376</text>
<text top="242" left="688" width="20" height="15" font="4">–82.</text>
<text top="259" left="450" width="350" height="10" font="4">440. Oster JR, Epstein M, Smoller S. Combined therapy with thiazide-type</text>
<text top="274" left="475" width="324" height="10" font="4">and loop diuretic agents for resistant sodium retention. Ann Intern</text>
<text top="288" left="475" width="81" height="10" font="4">Med 1983;99:405</text>
<text top="285" left="556" width="14" height="15" font="4">–6.</text>
<text top="302" left="450" width="350" height="10" font="4">441. Ellison DH. The physiologic basis of diuretic synergism: its role in</text>
<text top="316" left="475" width="264" height="10" font="4">treating diuretic resistance. Ann Intern Med 1991;114:886</text>
<text top="313" left="740" width="20" height="15" font="4">–94.</text>
<text top="330" left="450" width="350" height="10" font="4">442. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states:</text>
<text top="345" left="475" width="324" height="10" font="4">pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet</text>
<text top="359" left="475" width="56" height="10" font="4">1996;30:229</text>
<text top="356" left="532" width="20" height="15" font="4">–49.</text>
<text top="373" left="450" width="350" height="10" font="4">443. Epstein M, Lepp B, Hoffman D. Potentiation of furosemide by meto-</text>
<text top="387" left="475" width="239" height="10" font="4">lazone in refractory edema. Curr Ther Res 1977:656</text>
<text top="384" left="714" width="20" height="15" font="4">–67.</text>
<text top="401" left="450" width="350" height="10" font="4">444. Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalaemia</text>
<text top="416" left="475" width="324" height="10" font="4">and potassium loss during maintenance digoxin therapy. Br Heart J</text>
<text top="430" left="475" width="56" height="10" font="4">1976;38:167</text>
<text top="427" left="532" width="20" height="15" font="4">–72.</text>
<text top="444" left="450" width="350" height="10" font="4">445. Packer M, Poole-Wilson PA, Armstrong PW, et al., ATLAS Study</text>
<text top="458" left="475" width="324" height="10" font="4">Group. Comparative effects of low and high doses of the angiotensin-</text>
<text top="472" left="475" width="324" height="10" font="4">converting enzyme inhibitor, lisinopril, on morbidity and mortality in</text>
<text top="486" left="475" width="219" height="10" font="4">chronic heart failure. Circulation 1999;100:2312</text>
<text top="483" left="695" width="14" height="15" font="4">–8.</text>
<text top="501" left="450" width="350" height="10" font="4">446. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone</text>
<text top="515" left="475" width="324" height="10" font="4">blocker, in patients with left ventricular dysfunction after myocardial</text>
<text top="529" left="475" width="186" height="10" font="4">infarction. N Engl J Med 2003;348:1309</text>
<text top="526" left="661" width="20" height="15" font="4">–21.</text>
<text top="543" left="450" width="350" height="10" font="4">447. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in</text>
<text top="557" left="475" width="266" height="10" font="4">severe chronic heart failure. N Engl J Med 2001;344:1651</text>
<text top="554" left="742" width="14" height="15" font="4">–8.</text>
<text top="572" left="450" width="350" height="10" font="4">448. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL</text>
<text top="586" left="475" width="324" height="10" font="4">Randomised Intervention Trial in Congestive Heart Failure (MERIT-</text>
<text top="600" left="475" width="126" height="10" font="4">HF). Lancet 1999;353:2001</text>
<text top="597" left="601" width="14" height="15" font="4">–7.</text>
<text top="614" left="450" width="350" height="10" font="4">449. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator</text>
<text top="628" left="475" width="324" height="10" font="4">therapy on mortality in chronic congestive heart failure: results of</text>
<text top="643" left="475" width="324" height="10" font="4">a Veterans Administration Cooperative Study. N Engl J Med 1986;</text>
<text top="657" left="475" width="42" height="10" font="4">314:1547</text>
<text top="654" left="518" width="20" height="15" font="4">–52.</text>
<text top="671" left="450" width="350" height="10" font="4">450. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in</text>
<text top="685" left="475" width="324" height="10" font="4">patients with chronic heart failure and reduced left-ventricular systolic</text>
<text top="699" left="475" width="324" height="10" font="4">function intolerant to angiotensin-converting-enzyme inhibitors: the</text>
<text top="714" left="475" width="218" height="10" font="4">CHARM-Alternative trial. Lancet 2003;362:772</text>
<text top="711" left="694" width="14" height="15" font="4">–6.</text>
<text top="728" left="450" width="350" height="10" font="4">451. Crozier I, Ikram H, Awan N, et al., Losartan Hemodynamic Study</text>
<text top="742" left="475" width="324" height="10" font="4">Group. Losartan in heart failure: hemodynamic effects and tolerability.</text>
<text top="756" left="475" width="110" height="10" font="4">Circulation 1995;91:691</text>
<text top="753" left="586" width="14" height="15" font="4">–7.</text>
<text top="770" left="450" width="350" height="10" font="4">452. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohor-</text>
<text top="785" left="475" width="324" height="10" font="4">monal effects of the angiotensin II antagonist losartan in patients with</text>
<text top="799" left="475" width="228" height="10" font="4">congestive heart failure. Circulation 1993;88:1602</text>
<text top="796" left="704" width="14" height="15" font="4">–9.</text>
<text top="813" left="450" width="350" height="10" font="4">453. Mazayev VP, Fomina IG, Kazakov EN, et al. Valsartan in heart failure</text>
<text top="827" left="475" width="324" height="10" font="4">patients previously untreated with an ACE inhibitor. Int J Cardiol 1998;</text>
<text top="841" left="475" width="31" height="10" font="4">65:239</text>
<text top="838" left="506" width="20" height="15" font="4">–46.</text>
<text top="856" left="450" width="350" height="10" font="4">454. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan,</text>
<text top="870" left="475" width="324" height="10" font="4">enalapril, and their combination in congestive heart failure: randomized</text>
<text top="884" left="475" width="324" height="10" font="4">evaluation of strategies for left ventricular dysfunction (RESOLVD)</text>
<text top="898" left="475" width="324" height="10" font="4">pilot study: the RESOLVD Pilot Study Investigators. Circulation 1999;</text>
<text top="912" left="475" width="42" height="10" font="4">100:1056</text>
<text top="909" left="518" width="20" height="15" font="4">–64.</text>
<text top="927" left="450" width="350" height="10" font="4">455. Riegger GA, Bouzo H, Petr P, et al., Symptom, Tolerability, Response to</text>
<text top="941" left="475" width="324" height="10" font="4">Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH)</text>
<text top="955" left="475" width="324" height="10" font="4">Investigators. Improvement in exercise tolerance and symptoms of</text>
<text top="969" left="475" width="324" height="10" font="4">congestive heart failure during treatment with candesartan cilexetil.</text>
<text top="983" left="475" width="121" height="10" font="4">Circulation 1999;100:2224</text>
<text top="980" left="597" width="20" height="15" font="4">–30.</text>
<text top="998" left="450" width="350" height="10" font="4">456. Sharma D, Buyse M, Pitt B, et al. Meta-analysis of observed mortality</text>
<text top="1012" left="475" width="324" height="10" font="4">data from all-controlled, double-blind, multiple-dose studies of losartan</text>
<text top="1026" left="475" width="324" height="10" font="4">in heart failure: Losartan Heart Failure Mortality Meta-analysis Study</text>
<text top="1040" left="475" width="157" height="10" font="4">Group. Am J Cardiol 2000;85:187</text>
<text top="1037" left="632" width="20" height="15" font="4">–92.</text>
<text top="1054" left="450" width="350" height="10" font="4">457. Velazquez EJ, Pfeffer MA, McMurray JV, et al. VALsartan In Acute</text>
<text top="1069" left="475" width="324" height="10" font="4">myocardial iNfarcTion (VALIANT) trial: baseline characteristics in</text>
<text top="1083" left="475" width="167" height="10" font="4">context. Eur J Heart Fail 2003;5:537</text>
<text top="1080" left="642" width="20" height="15" font="4">–44.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e220</text>
</page>
<page number="75" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">458. Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema associated</text>
<text top="117" left="90" width="324" height="10" font="4">with angiotensin-converting enzyme inhibitor use: outcome after</text>
<text top="132" left="90" width="300" height="10" font="4">switching to a different treatment. Arch Intern Med 2004;164:910</text>
<text top="129" left="390" width="14" height="15" font="4">–3.</text>
<text top="146" left="64" width="350" height="10" font="4">459. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized</text>
<text top="160" left="90" width="324" height="10" font="4">trials of angioedema as an adverse event of renin-angiotensin system</text>
<text top="174" left="90" width="177" height="10" font="4">inhibitors. Am J Cardiol 2012;110:383</text>
<text top="171" left="267" width="20" height="15" font="4">–91.</text>
<text top="188" left="64" width="350" height="10" font="4">460. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for</text>
<text top="203" left="90" width="324" height="10" font="4">angioedema associated with the use of drugs that target the renin-</text>
<text top="217" left="90" width="295" height="10" font="4">angiotensin-aldosterone system. Arch Intern Med 2012;172:1582</text>
<text top="214" left="385" width="14" height="15" font="4">–9.</text>
<text top="231" left="64" width="350" height="10" font="4">461. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor</text>
<text top="245" left="90" width="324" height="10" font="4">blockers in patients with ACE inhibitor-induced angioedema. Ann</text>
<text top="259" left="90" width="122" height="10" font="4">Pharmacother 2000;34:526</text>
<text top="256" left="212" width="14" height="15" font="4">–8.</text>
<text top="274" left="64" width="252" height="10" font="4">462. Fisher ML, Gottlieb SS, Plotnick GD, et al. Bene</text>
<text top="271" left="316" width="98" height="15" font="4">ﬁcial effects of meto-</text>
<text top="288" left="90" width="324" height="10" font="4">prolol in heart failure associated with coronary artery disease:</text>
<text top="302" left="90" width="234" height="10" font="4">a randomized trial. J Am Coll Cardiol 1994;23:943</text>
<text top="299" left="324" width="20" height="15" font="4">–50.</text>
<text top="316" left="64" width="350" height="10" font="4">463. Metra M, Nardi M, Giubbini R, et al. Effects of short- and long-term</text>
<text top="330" left="90" width="324" height="10" font="4">carvedilol administration on rest and exercise hemodynamic variables,</text>
<text top="345" left="90" width="324" height="10" font="4">exercise capacity and clinical conditions in patients with idiopathic</text>
<text top="359" left="90" width="263" height="10" font="4">dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678</text>
<text top="356" left="353" width="20" height="15" font="4">–87.</text>
<text top="373" left="64" width="350" height="10" font="4">464. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left</text>
<text top="387" left="90" width="324" height="10" font="4">ventricular function and symptoms in chronic heart failure: a double-</text>
<text top="401" left="90" width="264" height="10" font="4">blind randomized study. J Am Coll Cardiol 1995;25:1225</text>
<text top="398" left="354" width="20" height="15" font="4">–31.</text>
<text top="416" left="64" width="350" height="10" font="4">465. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind,</text>
<text top="430" left="90" width="215" height="10" font="4">placebo-controlled study of the long-term ef</text>
<text top="427" left="305" width="109" height="15" font="4">ﬁcacy of carvedilol in</text>
<text top="444" left="90" width="299" height="10" font="4">patients with severe chronic heart failure. Circulation 1995;92:1499</text>
<text top="441" left="389" width="25" height="15" font="4">–506.</text>
<text top="458" left="64" width="278" height="10" font="4">466. Waagstein F, Bristow MR, Swedberg K, et al. Bene</text>
<text top="455" left="342" width="72" height="15" font="4">ﬁcial effects of</text>
<text top="472" left="90" width="324" height="10" font="4">metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated</text>
<text top="486" left="90" width="306" height="10" font="4">Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441</text>
<text top="483" left="396" width="14" height="15" font="4">–6.</text>
<text top="501" left="64" width="109" height="10" font="4">467. The Cardiac Insuf</text>
<text top="498" left="173" width="241" height="15" font="4">ﬁciency Bisoprolol Study (CIBIS). CIBIS Investiga-</text>
<text top="515" left="90" width="324" height="10" font="4">tors and Committees. A randomized trial of beta-blockade in heart</text>
<text top="529" left="90" width="151" height="10" font="4">failure. Circulation 1994;90:1765</text>
<text top="526" left="241" width="20" height="15" font="4">–73.</text>
<text top="543" left="64" width="350" height="10" font="4">468. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind,</text>
<text top="557" left="90" width="324" height="10" font="4">placebo-controlled study of the effects of carvedilol in patients with</text>
<text top="572" left="90" width="324" height="10" font="4">moderate to severe heart failure: the PRECISE Trial: Prospective</text>
<text top="586" left="90" width="324" height="10" font="4">Randomized Evaluation of Carvedilol on Symptoms and Exercise.</text>
<text top="600" left="90" width="116" height="10" font="4">Circulation 1996;94:2793</text>
<text top="597" left="206" width="14" height="15" font="4">–9.</text>
<text top="614" left="64" width="350" height="10" font="4">469. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical</text>
<text top="628" left="90" width="324" height="10" font="4">progression in patients with mild symptoms of heart failure: US Car-</text>
<text top="643" left="90" width="278" height="10" font="4">vedilol Heart Failure Study Group. Circulation 1996;94:2800</text>
<text top="640" left="368" width="14" height="15" font="4">–6.</text>
<text top="657" left="64" width="350" height="10" font="4">470. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on</text>
<text top="671" left="90" width="324" height="10" font="4">morbidity and mortality in patients with chronic heart failure: U.S.</text>
<text top="685" left="90" width="324" height="10" font="4">Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:</text>
<text top="699" left="90" width="23" height="10" font="4">1349</text>
<text top="696" left="114" width="20" height="15" font="4">–55.</text>
<text top="714" left="64" width="350" height="10" font="4">471. Australia/New Zealand Heart Failure Research Collaborative Group.</text>
<text top="728" left="90" width="324" height="10" font="4">Randomised, placebo-controlled trial of carvedilol in patients with</text>
<text top="742" left="90" width="324" height="10" font="4">congestive heart failure due to ischaemic heart disease. Lancet 1997;349:</text>
<text top="756" left="90" width="17" height="10" font="4">375</text>
<text top="753" left="107" width="20" height="15" font="4">–80.</text>
<text top="770" left="64" width="350" height="10" font="4">472. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with</text>
<text top="785" left="90" width="324" height="10" font="4">nebivolol in elderly heart failure patients with impaired and preserved</text>
<text top="799" left="90" width="324" height="10" font="4">left ventricular ejection fraction: data from SENIORS (Study of Effects</text>
<text top="813" left="90" width="324" height="10" font="4">of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors</text>
<text top="827" left="90" width="246" height="10" font="4">With Heart Failure). J Am Coll Cardiol 2009;53:2150</text>
<text top="824" left="336" width="14" height="15" font="4">–8.</text>
<text top="841" left="64" width="350" height="10" font="4">473. The NETWORK Investigators. Clinical outcome with enalapril in</text>
<text top="856" left="90" width="324" height="10" font="4">symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998;</text>
<text top="870" left="90" width="31" height="10" font="4">19:481</text>
<text top="867" left="121" width="14" height="15" font="4">–9.</text>
<text top="884" left="64" width="350" height="10" font="4">474. Epstein SE, Braunwald E. The effect of beta adrenergic blockade on</text>
<text top="898" left="90" width="324" height="10" font="4">patterns of urinary sodium excretion: studies in normal subjects and in</text>
<text top="912" left="90" width="254" height="10" font="4">patients with heart disease. Ann Intern Med 1966;65:20</text>
<text top="909" left="344" width="14" height="15" font="4">–7.</text>
<text top="927" left="64" width="350" height="10" font="4">475. Weil JV, Chidsey CA. Plasma volume expansion resulting from inter-</text>
<text top="941" left="90" width="324" height="10" font="4">ference with adrenergic function in normal man. Circulation 1968;37:</text>
<text top="955" left="90" width="11" height="10" font="4">54</text>
<text top="952" left="101" width="20" height="15" font="4">–61.</text>
<text top="969" left="64" width="89" height="10" font="4">476. Gattis WA, O</text>
<text top="966" left="154" width="261" height="15" font="4">’Connor CM, Gallup DS, et al. Predischarge initiation of</text>
<text top="983" left="90" width="324" height="10" font="4">carvedilol in patients hospitalized for decompensated heart failure:</text>
<text top="998" left="90" width="324" height="10" font="4">results of the Initiation Management Predischarge: Process for Assess-</text>
<text top="1012" left="90" width="324" height="10" font="4">ment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am</text>
<text top="1026" left="90" width="122" height="10" font="4">Coll Cardiol 2004;43:1534</text>
<text top="1023" left="212" width="20" height="15" font="4">–41.</text>
<text top="1040" left="64" width="350" height="10" font="4">477. Waagstein F, Caidahl K, Wallentin I, et al. Long-term beta-blockade in</text>
<text top="1054" left="90" width="324" height="10" font="4">dilated cardiomyopathy: effects of short- and long-term metoprolol</text>
<text top="1069" left="90" width="324" height="10" font="4">treatment followed by withdrawal and readministration of metoprolol.</text>
<text top="1083" left="90" width="110" height="10" font="4">Circulation 1989;80:551</text>
<text top="1080" left="200" width="20" height="15" font="4">–63.</text>
<text top="103" left="450" width="87" height="10" font="4">478. Vizzardi E, D</text>
<text top="100" left="537" width="263" height="15" font="4">’Aloia A, Giubbini R, et al. Effect of spironolactone on left</text>
<text top="117" left="476" width="324" height="10" font="4">ventricular ejection fraction and volumes in patients with class I or II</text>
<text top="132" left="476" width="194" height="10" font="4">heart failure. Am J Cardiol 2010;106:1292</text>
<text top="129" left="670" width="14" height="15" font="4">–6.</text>
<text top="146" left="450" width="349" height="10" font="4">479. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after</text>
<text top="160" left="475" width="324" height="10" font="4">publication of the Randomized Aldactone Evaluation Study. N Engl J</text>
<text top="174" left="475" width="86" height="10" font="4">Med 2004;351:543</text>
<text top="171" left="562" width="20" height="15" font="4">–51.</text>
<text top="188" left="450" width="350" height="10" font="4">480. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate</text>
<text top="203" left="475" width="324" height="10" font="4">use of spironolactone in heart failure: when an old medicine spirals out</text>
<text top="217" left="475" width="232" height="10" font="4">of new guidelines. J Am Coll Cardiol 2003;41:211</text>
<text top="214" left="708" width="14" height="15" font="4">–4.</text>
<text top="231" left="450" width="350" height="10" font="4">481. Butler J, Ezekowitz JA, Collins SP, et al. Update on aldosterone</text>
<text top="245" left="475" width="324" height="10" font="4">antagonists use in heart failure with reduced left ventricular ejection</text>
<text top="259" left="475" width="324" height="10" font="4">fraction: Heart Failure Society of America Guidelines Committee. J Card</text>
<text top="274" left="475" width="77" height="10" font="4">Fail 2012;18:265</text>
<text top="271" left="553" width="20" height="15" font="4">–81.</text>
<text top="288" left="450" width="350" height="10" font="4">482. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al. Effect of direct</text>
<text top="302" left="475" width="324" height="10" font="4">vasodilation with hydralazine versus angiotensin-converting enzyme</text>
<text top="316" left="475" width="324" height="10" font="4">inhibition with captopril on mortality in advanced heart failure: the Hy-C</text>
<text top="330" left="475" width="169" height="10" font="4">trial. J Am Coll Cardiol 1992;19:842</text>
<text top="327" left="644" width="20" height="15" font="4">–50.</text>
<text top="345" left="450" width="350" height="10" font="4">483. Fonarow GC, Yancy CW, Hernandez AF, et al. Potential impact of</text>
<text top="359" left="475" width="324" height="10" font="4">optimal implementation of evidence-based heart failure therapies on</text>
<text top="373" left="475" width="171" height="10" font="4">mortality. Am Heart J 2011;161:1024</text>
<text top="370" left="647" width="20" height="15" font="4">–30.</text>
<text top="387" left="450" width="350" height="10" font="4">484. The Digitalis Investigation Group. The effect of digoxin on mortality</text>
<text top="401" left="475" width="324" height="10" font="4">and morbidity in patients with heart failure. N Engl J Med 1997;336:</text>
<text top="416" left="475" width="17" height="10" font="4">525</text>
<text top="413" left="492" width="20" height="15" font="4">–33.</text>
<text top="430" left="450" width="350" height="10" font="4">485. The Captopril-Digoxin Multicenter Research Group. Comparative</text>
<text top="444" left="475" width="324" height="10" font="4">effects of therapy with captopril and digoxin in patients with mild to</text>
<text top="458" left="475" width="202" height="10" font="4">moderate heart failure. JAMA 1988;259:539</text>
<text top="455" left="678" width="20" height="15" font="4">–44.</text>
<text top="472" left="450" width="350" height="10" font="4">486. Dobbs SM, Kenyon WI, Dobbs RJ. Maintenance digoxin after an</text>
<text top="486" left="475" width="324" height="10" font="4">episode of heart failure: placebo-controlled trial in outpatients. Br Med J</text>
<text top="501" left="475" width="51" height="10" font="4">1977;1:749</text>
<text top="498" left="526" width="20" height="15" font="4">–52.</text>
<text top="515" left="450" width="350" height="10" font="4">487. Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpatients:</text>
<text top="529" left="475" width="324" height="10" font="4">a randomized trial of digoxin versus placebo. N Engl J Med 1982;306:</text>
<text top="543" left="475" width="17" height="10" font="4">699</text>
<text top="540" left="492" width="25" height="15" font="4">–705.</text>
<text top="557" left="450" width="350" height="10" font="4">488. Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in</text>
<text top="572" left="475" width="234" height="10" font="4">congestive heart failure. Am J Cardiol 1988;61:371</text>
<text top="569" left="710" width="14" height="15" font="4">–5.</text>
<text top="586" left="450" width="350" height="10" font="4">489. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milri-</text>
<text top="600" left="475" width="324" height="10" font="4">none, digoxin, and their combination in the treatment of patients with</text>
<text top="614" left="475" width="229" height="10" font="4">chronic heart failure. N Engl J Med 1989;320:677</text>
<text top="611" left="704" width="20" height="15" font="4">–83.</text>
<text top="628" left="450" width="350" height="10" font="4">490. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing</text>
<text top="643" left="475" width="324" height="10" font="4">the effect of digoxin withdrawal in patients with mild to moderate</text>
<text top="657" left="475" width="324" height="10" font="4">chronic congestive heart failure: results of the PROVED trial: PROVED</text>
<text top="671" left="475" width="241" height="10" font="4">Investigative Group. J Am Coll Cardiol 1993;22:955</text>
<text top="668" left="716" width="20" height="15" font="4">–62.</text>
<text top="685" left="450" width="350" height="10" font="4">491. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin</text>
<text top="699" left="475" width="324" height="10" font="4">from patients with chronic heart failure treated with angiotensin-</text>
<text top="714" left="475" width="324" height="10" font="4">converting-enzyme inhibitors: RADIANCE Study. N Engl J Med 1993;</text>
<text top="728" left="475" width="25" height="10" font="4">329:1</text>
<text top="725" left="501" width="14" height="15" font="4">–7.</text>
<text top="742" left="450" width="350" height="10" font="4">492. Matsuda M, Matsuda Y, Yamagishi T, et al. Effects of digoxin,</text>
<text top="756" left="475" width="324" height="10" font="4">propranolol, and verapamil on exercise in patients with chronic isolated</text>
<text top="770" left="475" width="22" height="10" font="4">atrial</text>
<text top="767" left="502" width="198" height="15" font="4">ﬁbrillation. Cardiovasc Res 1991;25:453–7.</text>
<text top="785" left="450" width="210" height="10" font="4">493. David D, Segni ED, Klein HO, et al. Inef</text>
<text top="782" left="660" width="140" height="15" font="4">ﬁcacy of digitalis in the control</text>
<text top="799" left="475" width="194" height="10" font="4">of heart rate in patients with chronic atrial</text>
<text top="796" left="674" width="126" height="15" font="4">ﬁbrillation: beneﬁcial effect</text>
<text top="813" left="475" width="324" height="10" font="4">of an added beta adrenergic blocking agent. Am J Cardiol 1979;44:</text>
<text top="827" left="475" width="22" height="10" font="4">1378</text>
<text top="824" left="498" width="20" height="15" font="4">–82.</text>
<text top="841" left="450" width="350" height="10" font="4">494. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic</text>
<text top="856" left="475" width="22" height="10" font="4">atrial</text>
<text top="853" left="506" width="293" height="15" font="4">ﬁbrillation during daily activity and programmed exercise:</text>
<text top="870" left="475" width="143" height="10" font="4">a crossover open-label study of</text>
<text top="867" left="622" width="177" height="15" font="4">ﬁve drug regimens. J Am Coll Cardiol</text>
<text top="884" left="475" width="56" height="10" font="4">1999;33:304</text>
<text top="881" left="532" width="20" height="15" font="4">–10.</text>
<text top="898" left="450" width="350" height="10" font="4">495. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in</text>
<text top="912" left="475" width="259" height="10" font="4">combination with digoxin for the management of atrial</text>
<text top="909" left="739" width="60" height="15" font="4">ﬁbrillation in</text>
<text top="927" left="475" width="275" height="10" font="4">patients with heart failure? J Am Coll Cardiol 2003;42:1944</text>
<text top="924" left="751" width="20" height="15" font="4">–51.</text>
<text top="941" left="450" width="350" height="10" font="4">496. Jelliffe RW, Brooker G. A nomogram for digoxin therapy. Am J Med</text>
<text top="955" left="475" width="51" height="10" font="4">1974;57:63</text>
<text top="952" left="526" width="14" height="15" font="4">–8.</text>
<text top="969" left="450" width="350" height="10" font="4">497. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin</text>
<text top="983" left="475" width="324" height="10" font="4">concentration and outcomes in patients with heart failure. JAMA 2003;</text>
<text top="998" left="475" width="37" height="10" font="4">289:871</text>
<text top="995" left="512" width="14" height="15" font="4">–8.</text>
<text top="1012" left="450" width="350" height="10" font="4">498. Adams KF Jr., Patterson JH, Gattis WA, et al. Relationship of serum</text>
<text top="1026" left="475" width="324" height="10" font="4">digoxin concentration to mortality and morbidity in women in the</text>
<text top="1040" left="475" width="324" height="10" font="4">Digitalis Investigation Group trial: a retrospective analysis. J Am Coll</text>
<text top="1054" left="475" width="93" height="10" font="4">Cardiol 2005;46:497</text>
<text top="1051" left="569" width="25" height="15" font="4">–504.</text>
<text top="1069" left="450" width="350" height="10" font="4">499. Steiner JF, Robbins LJ, Hammermeister KE, et al. Incidence of digoxin</text>
<text top="1083" left="475" width="226" height="10" font="4">toxicity in outpatients. West J Med 1994;161:474</text>
<text top="1080" left="701" width="14" height="15" font="4">–8.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e221</text>
</page>
<page number="76" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">500. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy</text>
<text top="117" left="90" width="324" height="10" font="4">improves left ventricular function in heart failure. N Engl J Med 1980;</text>
<text top="132" left="90" width="42" height="10" font="4">303:1443</text>
<text top="129" left="132" width="14" height="15" font="4">–8.</text>
<text top="146" left="64" width="350" height="10" font="4">501. Gheorghiade M, Hall VB, Jacobsen G, et al. Effects of increasing</text>
<text top="160" left="90" width="324" height="10" font="4">maintenance dose of digoxin on left ventricular function and neurohor-</text>
<text top="174" left="90" width="324" height="10" font="4">mones in patients with chronic heart failure treated with diuretics</text>
<text top="188" left="90" width="324" height="10" font="4">and angiotensin-converting enzyme inhibitors. Circulation 1995;92:</text>
<text top="203" left="90" width="22" height="10" font="4">1801</text>
<text top="200" left="112" width="14" height="15" font="4">–7.</text>
<text top="217" left="64" width="350" height="10" font="4">502. Slatton ML, Irani WN, Hall SA, et al. Does digoxin provide additional</text>
<text top="231" left="90" width="162" height="10" font="4">hemodynamic and autonomic bene</text>
<text top="228" left="252" width="162" height="15" font="4">ﬁt at higher doses in patients with</text>
<text top="245" left="90" width="324" height="10" font="4">mild to moderate heart failure and normal sinus rhythm? J Am Coll</text>
<text top="259" left="90" width="99" height="10" font="4">Cardiol 1997;29:1206</text>
<text top="256" left="189" width="20" height="15" font="4">–13.</text>
<text top="274" left="64" width="350" height="10" font="4">503. Fogelman AM, La Mont JT, Finkelstein S, et al. Fallibility of plasma-</text>
<text top="288" left="90" width="324" height="10" font="4">digoxin in differentiating toxic from non-toxic patients. Lancet 1971;2:</text>
<text top="302" left="90" width="17" height="10" font="4">727</text>
<text top="299" left="107" width="14" height="15" font="4">–9.</text>
<text top="316" left="64" width="48" height="10" font="4">504. Ingel</text>
<text top="313" left="113" width="301" height="15" font="4">ﬁnger JA, Goldman P. The serum digitalis concentration: does it</text>
<text top="330" left="90" width="256" height="10" font="4">diagnose digitalis toxicity? N Engl J Med 1976;294:867</text>
<text top="327" left="346" width="20" height="15" font="4">–70.</text>
<text top="345" left="64" width="350" height="10" font="4">505. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions</text>
<text top="359" left="90" width="324" height="10" font="4">among elderly patients hospitalized for drug toxicity. JAMA 2003;289:</text>
<text top="373" left="90" width="22" height="10" font="4">1652</text>
<text top="370" left="112" width="14" height="15" font="4">–8.</text>
<text top="387" left="64" width="350" height="10" font="4">506. Hager WD, Fenster P, Mayersohn M, et al. Digoxin-quinidine interac-</text>
<text top="401" left="90" width="291" height="10" font="4">tion: pharmacokinetic evaluation. N Engl J Med 1979;300:1238</text>
<text top="398" left="381" width="20" height="15" font="4">–41.</text>
<text top="416" left="64" width="350" height="10" font="4">507. Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann Phar-</text>
<text top="430" left="90" width="107" height="10" font="4">macother 1997;31:1077</text>
<text top="427" left="197" width="14" height="15" font="4">–9.</text>
<text top="444" left="64" width="350" height="10" font="4">508. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin</text>
<text top="458" left="90" width="94" height="10" font="4">in patients with atrial</text>
<text top="455" left="186" width="199" height="15" font="4">ﬁbrillation. N Engl J Med 2011;365:981–92.</text>
<text top="472" left="64" width="350" height="10" font="4">509. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular</text>
<text top="486" left="90" width="62" height="10" font="4">Society atrial</text>
<text top="483" left="158" width="256" height="15" font="4">ﬁbrillation guidelines 2010: prevention of stroke and</text>
<text top="501" left="90" width="160" height="10" font="4">systemic thromboembolism in atrial</text>
<text top="498" left="252" width="161" height="15" font="4">ﬁbrillation and ﬂutter. Can J Cardiol</text>
<text top="515" left="90" width="51" height="10" font="4">2011;27:74</text>
<text top="512" left="141" width="20" height="15" font="4">–90.</text>
<text top="529" left="64" width="162" height="10" font="4">510. Risk factors for stroke and ef</text>
<text top="526" left="227" width="187" height="15" font="4">ﬁcacy of antithrombotic therapy in atrial</text>
<text top="540" left="90" width="324" height="15" font="4">ﬁbrillation: analysis of pooled data from ﬁve randomized controlled</text>
<text top="557" left="90" width="173" height="10" font="4">trials. Arch Intern Med 1994;154:1449</text>
<text top="554" left="263" width="151" height="15" font="4">–57. Erratum in: Arch Intern Med</text>
<text top="572" left="90" width="70" height="10" font="4">1994;154:2254.</text>
<text top="586" left="64" width="296" height="10" font="4">511. Hughes M, Lip GY. Stroke and thromboembolism in atrial</text>
<text top="583" left="364" width="50" height="15" font="4">ﬁbrillation:</text>
<text top="600" left="90" width="234" height="10" font="4">a systematic review of stroke risk factors, risk strati</text>
<text top="597" left="324" width="90" height="15" font="4">ﬁcation schema and</text>
<text top="614" left="90" width="247" height="10" font="4">cost effectiveness data. Thromb Haemost 2008;99:295</text>
<text top="611" left="337" width="25" height="15" font="4">–304.</text>
<text top="628" left="64" width="350" height="10" font="4">512. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin</text>
<text top="643" left="90" width="96" height="10" font="4">in patients with atrial</text>
<text top="640" left="190" width="209" height="15" font="4">ﬁbrillation. N Engl J Med 2009;361:1139–51.</text>
<text top="657" left="64" width="289" height="10" font="4">513. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identi</text>
<text top="654" left="353" width="61" height="15" font="4">ﬁed events in</text>
<text top="671" left="90" width="214" height="10" font="4">the RE-LY trial. N Engl J Med 2010;363:1875</text>
<text top="668" left="304" width="14" height="15" font="4">–6.</text>
<text top="685" left="64" width="350" height="10" font="4">514. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in</text>
<text top="699" left="90" width="79" height="10" font="4">nonvalvular atrial</text>
<text top="696" left="173" width="204" height="15" font="4">ﬁbrillation. N Engl J Med 2011;365:883–91.</text>
<text top="714" left="64" width="350" height="10" font="4">515. Dries DL, Rosenberg YD, Waclawiw MA, et al. Ejection fraction and</text>
<text top="728" left="90" width="324" height="10" font="4">risk of thromboembolic events in patients with systolic dysfunction and</text>
<text top="742" left="90" width="324" height="10" font="4">sinus rhythm: evidence for gender differences in the studies of left</text>
<text top="756" left="90" width="287" height="10" font="4">ventricular dysfunction trials. J Am Coll Cardiol 1997;29:1074</text>
<text top="753" left="377" width="20" height="15" font="4">–80.</text>
<text top="770" left="64" width="350" height="10" font="4">516. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of</text>
<text top="785" left="90" width="22" height="10" font="4">atrial</text>
<text top="782" left="117" width="297" height="15" font="4">ﬁbrillation: the Task Force for the Management of Atrial Fibril-</text>
<text top="799" left="90" width="324" height="10" font="4">lation of the European Society of Cardiology (ESC). Eur Heart J 2010;</text>
<text top="813" left="90" width="37" height="10" font="4">31:2369</text>
<text top="810" left="127" width="25" height="15" font="4">–429.</text>
<text top="827" left="64" width="350" height="10" font="4">517. Freudenberger RS, Hellkamp AS, Halperin JL, et al. Risk of thrombo-</text>
<text top="841" left="90" width="324" height="10" font="4">embolism in heart failure: an analysis from the Sudden Cardiac Death in</text>
<text top="856" left="90" width="275" height="10" font="4">Heart Failure Trial (SCD-HeFT). Circulation 2007;115:2637</text>
<text top="853" left="365" width="20" height="15" font="4">–41.</text>
<text top="870" left="64" width="350" height="10" font="4">518. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk</text>
<text top="884" left="90" width="301" height="10" font="4">of stroke after myocardial infarction. N Engl J Med 1997;336:251</text>
<text top="881" left="391" width="14" height="15" font="4">–7.</text>
<text top="898" left="64" width="350" height="10" font="4">519. Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin,</text>
<text top="912" left="90" width="324" height="10" font="4">aspirin, and clopidogrel in patients with chronic heart failure: the</text>
<text top="927" left="90" width="324" height="10" font="4">Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH)</text>
<text top="941" left="90" width="146" height="10" font="4">trial. Circulation 2009;119:1616</text>
<text top="938" left="235" width="20" height="15" font="4">–24.</text>
<text top="955" left="64" width="350" height="10" font="4">520. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in</text>
<text top="969" left="90" width="324" height="10" font="4">patients with heart failure and sinus rhythm. N Engl J Med 2012;366:</text>
<text top="983" left="90" width="22" height="10" font="4">1859</text>
<text top="980" left="112" width="20" height="15" font="4">–69.</text>
<text top="998" left="64" width="350" height="10" font="4">521. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic</text>
<text top="1012" left="90" width="235" height="10" font="4">dilated cardiomyopathy. Am J Cardiol 1981;47:525</text>
<text top="1009" left="325" width="20" height="15" font="4">–31.</text>
<text top="1026" left="64" width="350" height="10" font="4">522. Stratton JR, Nemanich JW, Johannessen KA, et al. Fate of left</text>
<text top="1040" left="90" width="324" height="10" font="4">ventricular thrombi in patients with remote myocardial infarction or</text>
<text top="1054" left="90" width="243" height="10" font="4">idiopathic cardiomyopathy. Circulation 1988;78:1388</text>
<text top="1051" left="333" width="20" height="15" font="4">–93.</text>
<text top="1069" left="64" width="350" height="10" font="4">523. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Hemost</text>
<text top="1083" left="90" width="56" height="10" font="4">1997;23:543</text>
<text top="1080" left="146" width="14" height="15" font="4">–5.</text>
<text top="103" left="450" width="350" height="10" font="4">524. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thrombo-</text>
<text top="117" left="475" width="324" height="10" font="4">embolic events in congestive heart failure: the V-HeFT VA Cooperative</text>
<text top="132" left="475" width="227" height="10" font="4">Studies Group. Circulation 1993;87 6 Suppl:VI94</text>
<text top="129" left="702" width="25" height="15" font="4">–101.</text>
<text top="146" left="450" width="350" height="10" font="4">525. Dunkman WB. Thromboembolism and antithrombotic therapy in</text>
<text top="160" left="475" width="249" height="10" font="4">congestive heart failure. J Cardiovasc Risk 1995;2:107</text>
<text top="157" left="725" width="20" height="15" font="4">–17.</text>
<text top="174" left="450" width="45" height="10" font="4">526. Ciof</text>
<text top="171" left="495" width="304" height="15" font="4">ﬁ G, Pozzoli M, Forni G, et al. Systemic thromboembolism in</text>
<text top="188" left="475" width="324" height="10" font="4">chronic heart failure: a prospective study in 406 patients. Eur Heart J</text>
<text top="203" left="475" width="62" height="10" font="4">1996;17:1381</text>
<text top="200" left="538" width="14" height="15" font="4">–9.</text>
<text top="217" left="450" width="350" height="10" font="4">527. Baker DW, Wright RF. Management of heart failure, IV: anticoagulation</text>
<text top="231" left="475" width="324" height="10" font="4">for patients with heart failure due to left ventricular systolic dysfunction.</text>
<text top="245" left="475" width="102" height="10" font="4">JAMA 1994;272:1614</text>
<text top="242" left="577" width="14" height="15" font="4">–8.</text>
<text top="259" left="450" width="350" height="10" font="4">528. Katz SD. Left ventricular thrombus and the incidence of thromboem-</text>
<text top="274" left="475" width="324" height="10" font="4">bolism in patients with congestive heart failure: can clinical factors</text>
<text top="288" left="475" width="290" height="10" font="4">identify patients at increased risk? J Cardiovasc Risk 1995;2:97</text>
<text top="285" left="765" width="25" height="15" font="4">–102.</text>
<text top="302" left="450" width="350" height="10" font="4">529. Al-Khadra AS, Salem DN, Rand WM, et al. Warfarin anticoagulation</text>
<text top="316" left="475" width="324" height="10" font="4">and survival: a cohort analysis from the Studies of Left Ventricular</text>
<text top="330" left="475" width="206" height="10" font="4">Dysfunction. J Am Coll Cardiol 1998;31:749</text>
<text top="327" left="682" width="20" height="15" font="4">–53.</text>
<text top="345" left="450" width="350" height="10" font="4">530. Dries DL, Domanski MJ, Waclawiw MA, et al. Effect of antithrombotic</text>
<text top="359" left="475" width="324" height="10" font="4">therapy on risk of sudden coronary death in patients with congestive</text>
<text top="373" left="475" width="183" height="10" font="4">heart failure. Am J Cardiol 1997;79:909</text>
<text top="370" left="658" width="20" height="15" font="4">–13.</text>
<text top="387" left="450" width="210" height="10" font="4">531. Lip GY, Nieuwlaat R, Pisters R, et al. Re</text>
<text top="384" left="660" width="139" height="15" font="4">ﬁning clinical risk stratiﬁcation</text>
<text top="401" left="475" width="243" height="10" font="4">for predicting stroke and thromboembolism in atrial</text>
<text top="398" left="724" width="76" height="15" font="4">ﬁbrillation using</text>
<text top="416" left="475" width="324" height="10" font="4">a novel risk factor-based approach: the Euro Heart Survey on atrial</text>
<text top="427" left="475" width="164" height="15" font="4">ﬁbrillation. Chest 2010;137:263–72.</text>
<text top="444" left="450" width="350" height="10" font="4">532. Lip GY, Gibbs CR. Antiplatelet agents versus control or anticoagulation</text>
<text top="458" left="475" width="324" height="10" font="4">for heart failure in sinus rhythm. Cochrane Database Syst Rev 2001;(4):</text>
<text top="472" left="475" width="52" height="10" font="4">CD003333.</text>
<text top="472" left="531" width="163" height="10" font="5"><a href="http://dx.doi.org/10.1002/14651858.CD003333">DOI: 10.1002/14651858.CD003333</a></text>
<text top="472" left="694" width="3" height="10" font="4">.</text>
<text top="486" left="450" width="350" height="10" font="4">533. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated</text>
<text top="501" left="475" width="324" height="10" font="4">with improved survival in ischemic and non-ischemic heart failure. J Am</text>
<text top="515" left="475" width="116" height="10" font="4">Coll Cardiol 2004;43:642</text>
<text top="512" left="592" width="14" height="15" font="4">–8.</text>
<text top="529" left="450" width="350" height="10" font="4">534. Anker SD, Clark AL, Winkler R, et al. Statin use and survival in patients</text>
<text top="543" left="475" width="324" height="10" font="4">with chronic heart failure: results from two observational studies with</text>
<text top="557" left="475" width="190" height="10" font="4">5200 patients. Int J Cardiol 2006;112:234</text>
<text top="554" left="666" width="20" height="15" font="4">–42.</text>
<text top="572" left="450" width="350" height="10" font="4">535. Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and</text>
<text top="586" left="475" width="281" height="10" font="4">hospitalization in chronic heart failure. JAMA 2006;296:2105</text>
<text top="583" left="757" width="20" height="15" font="4">–11.</text>
<text top="600" left="450" width="350" height="10" font="4">536. Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly</text>
<text top="614" left="475" width="301" height="10" font="4">patients hospitalized with heart failure. Circulation 2006;113:1086</text>
<text top="611" left="777" width="20" height="15" font="4">–92.</text>
<text top="628" left="450" width="350" height="10" font="4">537. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients</text>
<text top="643" left="475" width="258" height="10" font="4">with systolic heart failure. N Engl J Med 2007;357:2248</text>
<text top="640" left="734" width="20" height="15" font="4">–61.</text>
<text top="657" left="450" width="350" height="10" font="4">538. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in</text>
<text top="671" left="475" width="324" height="10" font="4">patients with chronic heart failure (the GISSI-HF trial): a randomised,</text>
<text top="685" left="475" width="276" height="10" font="4">double-blind, placebo-controlled trial. Lancet 2008;372:1231</text>
<text top="682" left="752" width="14" height="15" font="4">–9.</text>
<text top="699" left="450" width="350" height="10" font="4">539. Macchia A, Levantesi G, Franzosi MG, et al. Left ventricular systolic</text>
<text top="714" left="475" width="324" height="10" font="4">dysfunction, total mortality, and sudden death in patients with myocar-</text>
<text top="728" left="475" width="324" height="10" font="4">dial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart</text>
<text top="742" left="475" width="72" height="10" font="4">Fail 2005;7:904</text>
<text top="739" left="547" width="14" height="15" font="4">–9.</text>
<text top="756" left="450" width="350" height="10" font="4">540. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 poly-</text>
<text top="770" left="475" width="324" height="10" font="4">unsaturated fatty acids in patients with chronic heart failure (the GISSI-</text>
<text top="785" left="475" width="324" height="10" font="4">HF trial): a randomised, double-blind, placebo-controlled trial. Lancet</text>
<text top="799" left="475" width="68" height="10" font="4">2008;372:1223</text>
<text top="796" left="543" width="20" height="15" font="4">–30.</text>
<text top="813" left="450" width="350" height="10" font="4">541. Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty</text>
<text top="827" left="475" width="302" height="10" font="4">acids and cardiovascular diseases. J Am Coll Cardiol 2009;54:585</text>
<text top="824" left="778" width="20" height="15" font="4">–94.</text>
<text top="841" left="450" width="289" height="10" font="4">542. Gruppo Italiano per lo Studio della Sopravvivenza nell</text>
<text top="838" left="739" width="60" height="15" font="4">’Infarto mio-</text>
<text top="856" left="475" width="324" height="10" font="4">cardico. Dietary supplementation with n-3 polyunsaturated fatty acids</text>
<text top="870" left="475" width="324" height="10" font="4">and vitamin E after myocardial infarction: results of the GISSI-</text>
<text top="884" left="475" width="179" height="10" font="4">Prevenzione trial. Lancet 1999;354:447</text>
<text top="881" left="654" width="20" height="15" font="4">–55.</text>
<text top="898" left="450" width="350" height="10" font="4">543. Nodari S, Triggiani M, Campia U, et al. Effects of n-3 polyunsaturated</text>
<text top="912" left="475" width="324" height="10" font="4">fatty acids on left ventricular function and functional capacity in patients</text>
<text top="927" left="475" width="281" height="10" font="4">with dilated cardiomyopathy. J Am Coll Cardiol 2011;57:870</text>
<text top="924" left="756" width="14" height="15" font="4">–9.</text>
<text top="941" left="450" width="350" height="10" font="4">544. McMurray JJ, Dunselman P, Wedel H, et al. Coenzyme Q10, rosuvas-</text>
<text top="955" left="475" width="251" height="10" font="4">tatin, and clinical outcomes in heart failure: a pre-speci</text>
<text top="952" left="726" width="73" height="15" font="4">ﬁed substudy of</text>
<text top="969" left="475" width="324" height="10" font="4">CORONA (Controlled Rosuvastatin Multinational Study in Heart</text>
<text top="983" left="475" width="192" height="10" font="4">Failure). J Am Coll Cardiol 2010;56:1196</text>
<text top="980" left="667" width="25" height="15" font="4">–204.</text>
<text top="998" left="450" width="292" height="10" font="4">545. Soukoulis V, Dihu JB, Sole M, et al. Micronutrient de</text>
<text top="995" left="742" width="58" height="15" font="4">ﬁciencies an</text>
<text top="1012" left="475" width="280" height="10" font="4">unmet need in heart failure. J Am Coll Cardiol 2009;54:1660</text>
<text top="1009" left="756" width="20" height="15" font="4">–73.</text>
<text top="1026" left="450" width="350" height="10" font="4">546. Effect of verapamil on mortality and major events after acute myocardial</text>
<text top="1040" left="475" width="236" height="10" font="4">infarction (the Danish Verapamil Infarction Trial II</text>
<text top="1037" left="712" width="88" height="15" font="4">–DAVIT II). Am J</text>
<text top="1054" left="475" width="93" height="10" font="4">Cardiol 1990;66:779</text>
<text top="1051" left="569" width="20" height="15" font="4">–85.</text>
<text top="1069" left="450" width="350" height="10" font="4">547. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-</text>
<text top="1083" left="475" width="324" height="10" font="4">onset congestive heart failure in postinfarction patients with early</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e222</text>
</page>
<page number="77" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="90" width="324" height="10" font="4">reduction in ejection fraction: the Adverse Experience Committee; and</text>
<text top="117" left="90" width="324" height="10" font="4">the Multicenter Diltiazem Postinfarction Research Group. Circulation</text>
<text top="132" left="90" width="51" height="10" font="4">1991;83:52</text>
<text top="129" left="141" width="20" height="15" font="4">–60.</text>
<text top="146" left="64" width="350" height="10" font="4">548. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality</text>
<text top="160" left="90" width="324" height="10" font="4">in patients with left ventricular dysfunction after recent and remote</text>
<text top="174" left="90" width="324" height="10" font="4">myocardial infarction: the SWORD Investigators: Survival With Oral</text>
<text top="188" left="90" width="132" height="10" font="4">d-Sotalol. Lancet 1996;348:7</text>
<text top="185" left="222" width="20" height="15" font="4">–12.</text>
<text top="203" left="64" width="350" height="10" font="4">549. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after</text>
<text top="217" left="90" width="324" height="10" font="4">dronedarone therapy for severe heart failure. N Engl J Med 2008;358:</text>
<text top="231" left="90" width="22" height="10" font="4">2678</text>
<text top="228" left="112" width="20" height="15" font="4">–87.</text>
<text top="245" left="64" width="350" height="10" font="4">550. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators.</text>
<text top="259" left="90" width="200" height="10" font="4">Preliminary report: effect of encainide and</text>
<text top="256" left="295" width="119" height="15" font="4">ﬂecainide on mortality in</text>
<text top="274" left="90" width="324" height="10" font="4">a randomized trial of arrhythmia suppression after myocardial infarction.</text>
<text top="288" left="90" width="131" height="10" font="4">N Engl J Med 1989;321:406</text>
<text top="285" left="221" width="20" height="15" font="4">–12.</text>
<text top="302" left="64" width="350" height="10" font="4">551. The Multicenter Diltiazem Postinfarction Trial Research Group. The</text>
<text top="316" left="90" width="324" height="10" font="4">effect of diltiazem on mortality and reinfarction after myocardial</text>
<text top="330" left="90" width="180" height="10" font="4">infarction. N Engl J Med 1988;319:385</text>
<text top="327" left="270" width="20" height="15" font="4">–92.</text>
<text top="345" left="64" width="350" height="10" font="4">552. Figulla HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac</text>
<text top="359" left="90" width="324" height="10" font="4">function and exercise capacity in patients with idiopathic dilated</text>
<text top="373" left="90" width="324" height="10" font="4">cardiomyopathy: results of the Diltiazem in Dilated Cardiomyopathy</text>
<text top="387" left="90" width="138" height="10" font="4">Trial. Circulation 1996;94:346</text>
<text top="384" left="228" width="20" height="15" font="4">–52.</text>
<text top="401" left="64" width="350" height="10" font="4">553. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-</text>
<text top="416" left="90" width="192" height="10" font="4">blind, crossover study to compare the ef</text>
<text top="413" left="282" width="132" height="15" font="4">ﬁcacy and safety of chronic</text>
<text top="430" left="90" width="324" height="10" font="4">nifedipine therapy with that of isosorbide dinitrate and their combination</text>
<text top="444" left="90" width="324" height="10" font="4">in the treatment of chronic congestive heart failure. Circulation 1990;82:</text>
<text top="458" left="90" width="22" height="10" font="4">1954</text>
<text top="455" left="112" width="20" height="15" font="4">–61.</text>
<text top="472" left="64" width="350" height="10" font="4">554. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality</text>
<text top="486" left="90" width="324" height="10" font="4">and cardiovascular morbidity associated with use of nonsteroidal anti-</text>
<text top="501" left="90" width="9" height="10" font="4">in</text>
<text top="498" left="99" width="315" height="15" font="4">ﬂammatory drugs in chronic heart failure. Arch Intern Med 2009;</text>
<text top="515" left="90" width="37" height="10" font="4">169:141</text>
<text top="512" left="127" width="14" height="15" font="4">–9.</text>
<text top="529" left="64" width="350" height="10" font="4">555. Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDs associated with</text>
<text top="543" left="90" width="324" height="10" font="4">increased risk of congestive heart failure in elderly patients taking</text>
<text top="557" left="90" width="192" height="10" font="4">diuretics. Arch Intern Med 1998;158:1108</text>
<text top="554" left="282" width="20" height="15" font="4">–12.</text>
<text top="572" left="64" width="350" height="10" font="4">556. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with</text>
<text top="586" left="90" width="324" height="10" font="4">congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal</text>
<text top="600" left="90" width="29" height="10" font="4">anti-in</text>
<text top="597" left="119" width="294" height="15" font="4">ﬂammatory drugs: population based study. BMJ 2005;330:1370.</text>
<text top="614" left="64" width="350" height="10" font="4">557. Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and</text>
<text top="628" left="90" width="324" height="10" font="4">cardiovascular outcomes in older patients with diabetes. JAMA 2007;</text>
<text top="643" left="90" width="42" height="10" font="4">298:2634</text>
<text top="640" left="132" width="20" height="15" font="4">–43.</text>
<text top="657" left="64" width="350" height="10" font="4">558. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic</text>
<text top="671" left="90" width="324" height="10" font="4">congestive heart failure and its prospective application. Jpn Circ J 1992;</text>
<text top="685" left="90" width="25" height="10" font="4">56:95</text>
<text top="682" left="115" width="14" height="15" font="4">–9.</text>
<text top="699" left="64" width="350" height="10" font="4">559. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth</text>
<text top="714" left="90" width="324" height="10" font="4">hormone in the treatment of dilated cardiomyopathy. N Engl J Med</text>
<text top="728" left="90" width="62" height="10" font="4">1996;334:809</text>
<text top="725" left="152" width="20" height="15" font="4">–14.</text>
<text top="742" left="64" width="350" height="10" font="4">560. Ferrari R, De Giuli F. The propionyl-L-carnitine hypothesis: an alter-</text>
<text top="756" left="90" width="291" height="10" font="4">native approach to treating heart failure. J Card Fail 1997;3:217</text>
<text top="753" left="381" width="20" height="15" font="4">–24.</text>
<text top="770" left="64" width="350" height="10" font="4">561. Ghatak A, Brar MJ, Agarwal A, et al. Oxy free radical system in</text>
<text top="785" left="90" width="324" height="10" font="4">heart failure and therapeutic role of oral vitamin E. Int J Cardiol 1996;57:</text>
<text top="799" left="90" width="17" height="10" font="4">119</text>
<text top="796" left="107" width="20" height="15" font="4">–27.</text>
<text top="813" left="64" width="350" height="10" font="4">562. Hamilton MA, Stevenson LW. Thyroid hormone abnormalities in heart</text>
<text top="827" left="90" width="239" height="10" font="4">failure: possibilities for therapy. Thyroid 1996;6:527</text>
<text top="824" left="329" width="14" height="15" font="4">–9.</text>
<text top="841" left="64" width="350" height="10" font="4">563. Soja AM, Mortensen SA. Treatment of congestive heart failure with</text>
<text top="856" left="90" width="324" height="10" font="4">coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol</text>
<text top="870" left="90" width="156" height="10" font="4">Aspects Med 1997;18 Suppl:S159</text>
<text top="867" left="246" width="20" height="15" font="4">–68.</text>
<text top="884" left="64" width="350" height="10" font="4">564. Toma M, McAlister FA, Coglianese EE, et al. Testosterone supplemen-</text>
<text top="898" left="90" width="293" height="10" font="4">tation in heart failure: a meta-analysis. Circ Heart Fail 2012;5:315</text>
<text top="895" left="383" width="20" height="15" font="4">–21.</text>
<text top="912" left="64" width="350" height="10" font="4">565. Morris CD, Carson S. Routine vitamin supplementation to prevent</text>
<text top="927" left="90" width="324" height="10" font="4">cardiovascular disease: a summary of the evidence for the U.S.</text>
<text top="941" left="90" width="283" height="10" font="4">Preventive Services Task Force. Ann Intern Med 2003;139:56</text>
<text top="938" left="373" width="20" height="15" font="4">–70.</text>
<text top="955" left="64" width="350" height="10" font="4">566. Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an</text>
<text top="969" left="90" width="324" height="10" font="4">adjunctive in the treatment of chronic congestive heart failure: the Q10</text>
<text top="983" left="90" width="170" height="10" font="4">Study Group. J Card Fail 1995;1:101</text>
<text top="980" left="260" width="14" height="15" font="4">–7.</text>
<text top="998" left="64" width="350" height="10" font="4">567. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q</text>
<text top="1012" left="90" width="324" height="10" font="4">on left ventricular function in patients with congestive heart failure.</text>
<text top="1026" left="90" width="150" height="10" font="4">J Am Coll Cardiol 1999;33:1549</text>
<text top="1023" left="240" width="20" height="15" font="4">–52.</text>
<text top="1040" left="64" width="350" height="10" font="4">568. Baggio E, Gandini R, Plancher AC, et al. Italian multicenter study on the</text>
<text top="1054" left="90" width="62" height="10" font="4">safety and ef</text>
<text top="1051" left="152" width="262" height="15" font="4">ﬁcacy of coenzyme Q10 as adjunctive therapy in heart</text>
<text top="1069" left="90" width="324" height="10" font="4">failure: CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994;</text>
<text top="1083" left="90" width="65" height="10" font="4">15 Suppl:s287</text>
<text top="1080" left="155" width="20" height="15" font="4">–94.</text>
<text top="103" left="450" width="350" height="10" font="4">569. Miller KL, Liebowitz RS, Newby LK. Complementary and alternative</text>
<text top="117" left="475" width="324" height="10" font="4">medicine in cardiovascular disease: a review of biologically based</text>
<text top="132" left="475" width="175" height="10" font="4">approaches. Am Heart J 2004;147:401</text>
<text top="129" left="651" width="20" height="15" font="4">–11.</text>
<text top="146" left="450" width="350" height="10" font="4">570. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose</text>
<text top="160" left="475" width="324" height="10" font="4">amiodarone in severe congestive heart failure: Grupo de Estudio de la</text>
<text top="174" left="475" width="94" height="10" font="4">Sobrevida en la Insu</text>
<text top="171" left="569" width="230" height="15" font="4">ﬁciencia Cardiaca en Argentina (GESICA). Lancet</text>
<text top="188" left="475" width="62" height="10" font="4">1994;344:493</text>
<text top="185" left="538" width="14" height="15" font="4">–8.</text>
<text top="203" left="450" width="350" height="10" font="4">571. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with</text>
<text top="217" left="475" width="324" height="10" font="4">congestive heart failure and asymptomatic ventricular arrhythmia:</text>
<text top="231" left="475" width="324" height="10" font="4">Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.</text>
<text top="245" left="475" width="125" height="10" font="4">N Engl J Med 1995;333:77</text>
<text top="242" left="601" width="20" height="15" font="4">–82.</text>
<text top="259" left="450" width="350" height="10" font="4">572. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in</text>
<text top="274" left="475" width="324" height="10" font="4">patients with congestive heart failure and left ventricular dysfunction:</text>
<text top="288" left="475" width="324" height="10" font="4">Danish Investigations of Arrhythmia and Mortality on Dofetilide Study</text>
<text top="302" left="475" width="166" height="10" font="4">Group. N Engl J Med 1999;341:857</text>
<text top="299" left="641" width="20" height="15" font="4">–65.</text>
<text top="316" left="450" width="350" height="10" font="4">573. Kober L, Bloch Thomsen PE, Moller M, et al. Effect of dofetilide in</text>
<text top="330" left="475" width="324" height="10" font="4">patients with recent myocardial infarction and left-ventricular dysfunc-</text>
<text top="345" left="475" width="214" height="10" font="4">tion: a randomised trial. Lancet 2000;356:2052</text>
<text top="342" left="689" width="14" height="15" font="4">–8.</text>
<text top="359" left="450" width="350" height="10" font="4">574. Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for</text>
<text top="373" left="475" width="324" height="10" font="4">congestive heart failure associated with abnormal left ventricular dia-</text>
<text top="387" left="475" width="24" height="10" font="4">stolic</text>
<text top="384" left="505" width="295" height="15" font="4">ﬁlling and normal left ventricular systolic performance. Am J</text>
<text top="401" left="475" width="93" height="10" font="4">Cardiol 1990;66:981</text>
<text top="398" left="569" width="14" height="15" font="4">–6.</text>
<text top="416" left="450" width="87" height="10" font="4">575. Packer M, O</text>
<text top="413" left="537" width="262" height="15" font="4">’Connor CM, Ghali JK, et al. Effect of amlodipine on</text>
<text top="430" left="475" width="324" height="10" font="4">morbidity and mortality in severe chronic heart failure: Prospective</text>
<text top="444" left="475" width="324" height="10" font="4">Randomized Amlodipine Survival Evaluation Study Group. N Engl J</text>
<text top="458" left="475" width="92" height="10" font="4">Med 1996;335:1107</text>
<text top="455" left="567" width="20" height="15" font="4">–14.</text>
<text top="472" left="450" width="350" height="10" font="4">576. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist</text>
<text top="486" left="475" width="324" height="10" font="4">felodipine as supplementary vasodilator therapy in patients with chronic</text>
<text top="501" left="475" width="324" height="10" font="4">heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart</text>
<text top="515" left="475" width="284" height="10" font="4">Failure Trial (V-HeFT) Study Group. Circulation 1997;96:856</text>
<text top="512" left="759" width="20" height="15" font="4">–63.</text>
<text top="529" left="450" width="350" height="10" font="4">577. Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in</text>
<text top="543" left="475" width="324" height="10" font="4">patients with mild to moderate heart failure: UK Study Group. Br Heart J</text>
<text top="557" left="475" width="56" height="10" font="4">1995;73:428</text>
<text top="554" left="532" width="20" height="15" font="4">–33.</text>
<text top="572" left="450" width="350" height="10" font="4">578. Udelson JE, DeAbate CA, Berk M, et al. Effects of amlodipine on</text>
<text top="586" left="475" width="324" height="10" font="4">exercise tolerance, quality of life, and left ventricular function in patients</text>
<text top="600" left="475" width="324" height="10" font="4">with heart failure from left ventricular systolic dysfunction. Am Heart J</text>
<text top="614" left="475" width="62" height="10" font="4">2000;139:503</text>
<text top="611" left="538" width="20" height="15" font="4">–10.</text>
<text top="628" left="450" width="350" height="10" font="4">579. Thackray S, Witte K, Clark AL, et al. Clinical trials update: OPTIME-</text>
<text top="643" left="475" width="265" height="10" font="4">CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2000;2:209</text>
<text top="640" left="740" width="20" height="15" font="4">–12.</text>
<text top="657" left="450" width="350" height="10" font="4">580. Page J, Henry D. Consumption of NSAIDs and the development of</text>
<text top="671" left="475" width="324" height="10" font="4">congestive heart failure in elderly patients: an underrecognized public</text>
<text top="685" left="475" width="217" height="10" font="4">health problem. Arch Intern Med 2000;160:777</text>
<text top="682" left="692" width="20" height="15" font="4">–84.</text>
<text top="699" left="450" width="350" height="10" font="4">581. Feenstra J, Heerdink ER, Grobbee DE, et al. Association of nonsteroidal</text>
<text top="714" left="475" width="29" height="10" font="4">anti-in</text>
<text top="711" left="504" width="295" height="15" font="4">ﬂammatory drugs with ﬁrst occurrence of heart failure and with</text>
<text top="728" left="475" width="324" height="10" font="4">relapsing heart failure: the Rotterdam Study. Arch Intern Med 2002;162:</text>
<text top="742" left="475" width="17" height="10" font="4">265</text>
<text top="739" left="492" width="20" height="15" font="4">–70.</text>
<text top="756" left="450" width="350" height="10" font="4">582. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors</text>
<text top="770" left="475" width="186" height="10" font="4">versus non-selective non-steroidal anti-in</text>
<text top="767" left="662" width="138" height="15" font="4">ﬂammatory drugs and conges-</text>
<text top="785" left="475" width="324" height="10" font="4">tive heart failure outcomes in elderly patients: a population-based cohort</text>
<text top="799" left="475" width="132" height="10" font="4">study. Lancet 2004;363:1751</text>
<text top="796" left="608" width="14" height="15" font="4">–6.</text>
<text top="813" left="450" width="350" height="10" font="4">583. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones</text>
<text top="827" left="475" width="324" height="10" font="4">and risk of heart failure in people with type 2 diabetes: a retrospective</text>
<text top="841" left="475" width="192" height="10" font="4">cohort study. Diabetes Care 2003;26:2983</text>
<text top="838" left="667" width="14" height="15" font="4">–9.</text>
<text top="856" left="450" width="350" height="10" font="4">584. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-</text>
<text top="870" left="475" width="324" height="10" font="4">controlled trial assessing the effects of rosiglitazone on echocardio-</text>
<text top="884" left="475" width="324" height="10" font="4">graphic function and cardiac status in type 2 diabetic patients with New</text>
<text top="898" left="475" width="324" height="10" font="4">York Heart Association functional class I or II heart failure. J Am Coll</text>
<text top="912" left="475" width="99" height="10" font="4">Cardiol 2007;49:1696</text>
<text top="909" left="575" width="25" height="15" font="4">–704.</text>
<text top="927" left="450" width="350" height="10" font="4">585. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardio-</text>
<text top="941" left="475" width="324" height="10" font="4">vascular death in patients with prediabetes and type 2 diabetes given</text>
<text top="955" left="475" width="324" height="10" font="4">thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet</text>
<text top="969" left="475" width="68" height="10" font="4">2007;370:1129</text>
<text top="966" left="543" width="20" height="15" font="4">–36.</text>
<text top="983" left="450" width="350" height="10" font="4">586. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for</text>
<text top="998" left="475" width="324" height="10" font="4">cardiovascular outcomes in oral agent combination therapy for type 2</text>
<text top="1012" left="475" width="324" height="10" font="4">diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet</text>
<text top="1026" left="475" width="68" height="10" font="4">2009;373:2125</text>
<text top="1023" left="543" width="20" height="15" font="4">–35.</text>
<text top="1040" left="450" width="350" height="10" font="4">587. Giles TD, Elkayam U, Bhattacharya M, et al. Comparison of pioglita-</text>
<text top="1054" left="475" width="324" height="10" font="4">zone vs glyburide in early heart failure: insights from a randomized</text>
<text top="1069" left="475" width="324" height="10" font="4">controlled study of patients with type 2 diabetes and mild cardiac</text>
<text top="1083" left="475" width="184" height="10" font="4">disease. Congest Heart Fail 2010;16:111</text>
<text top="1080" left="660" width="14" height="15" font="4">–7.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e223</text>
</page>
<page number="78" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">588. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events</text>
<text top="117" left="90" width="324" height="10" font="4">with rosiglitazone in type 2 diabetes: data from the RECORD clinical</text>
<text top="132" left="90" width="137" height="10" font="4">trial. Eur Heart J 2010;31:824</text>
<text top="129" left="227" width="20" height="15" font="4">–31.</text>
<text top="146" left="64" width="350" height="10" font="4">589. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in</text>
<text top="160" left="90" width="324" height="10" font="4">patients with chronic heart failure and preserved left-ventricular ejection</text>
<text top="174" left="90" width="280" height="10" font="4">fraction: the CHARM-Preserved Trial. Lancet 2003;362:777</text>
<text top="171" left="370" width="20" height="15" font="4">–81.</text>
<text top="188" left="64" width="350" height="10" font="4">590. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on</text>
<text top="203" left="90" width="324" height="10" font="4">diastolic function and exercise capacity in patients with heart failure with</text>
<text top="217" left="90" width="324" height="10" font="4">preserved ejection fraction: the Aldo-DHF randomized controlled trial.</text>
<text top="231" left="90" width="96" height="10" font="4">JAMA 2013;309:781</text>
<text top="228" left="186" width="20" height="15" font="4">–91.</text>
<text top="245" left="64" width="350" height="10" font="4">591. Piller LB, Baraniuk S, Simpson LM, et al. Long-term follow-up of</text>
<text top="259" left="90" width="324" height="10" font="4">participants with heart failure in the Antihypertensive and Lipid-</text>
<text top="274" left="90" width="324" height="10" font="4">Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circu-</text>
<text top="288" left="90" width="97" height="10" font="4">lation 2011;124:1811</text>
<text top="285" left="187" width="14" height="15" font="4">–8.</text>
<text top="302" left="64" width="350" height="10" font="4">592. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in</text>
<text top="316" left="90" width="324" height="10" font="4">patients with acute decompensated heart failure requiring intravenous</text>
<text top="330" left="90" width="324" height="10" font="4">vasoactive medications: an analysis from the Acute Decompensated Heart</text>
<text top="345" left="90" width="304" height="10" font="4">Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46:57</text>
<text top="342" left="394" width="20" height="15" font="4">–64.</text>
<text top="359" left="64" width="350" height="10" font="4">593. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable</text>
<text top="373" left="90" width="67" height="10" font="4">cardioverter-de</text>
<text top="370" left="157" width="256" height="15" font="4">ﬁbrillator for congestive heart failure. N Engl J Med</text>
<text top="387" left="90" width="62" height="10" font="4">2005;352:225</text>
<text top="384" left="152" width="20" height="15" font="4">–37.</text>
<text top="401" left="64" width="350" height="10" font="4">594. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in</text>
<text top="416" left="90" width="234" height="10" font="4">chronic heart failure. N Engl J Med 2002;346:1845</text>
<text top="413" left="324" width="20" height="15" font="4">–53.</text>
<text top="430" left="64" width="350" height="10" font="4">595. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy</text>
<text top="444" left="90" width="324" height="10" font="4">for the prevention of heart-failure events. N Engl J Med 2009;361:</text>
<text top="458" left="90" width="22" height="10" font="4">1329</text>
<text top="455" left="112" width="20" height="15" font="4">–38.</text>
<text top="472" left="64" width="350" height="10" font="4">596. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization ther-</text>
<text top="486" left="90" width="304" height="10" font="4">apy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385</text>
<text top="483" left="394" width="20" height="15" font="4">–95.</text>
<text top="501" left="64" width="350" height="10" font="4">597. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the</text>
<text top="515" left="90" width="324" height="10" font="4">prevention of sudden death in patients with coronary artery disease:</text>
<text top="529" left="90" width="324" height="10" font="4">Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med</text>
<text top="543" left="90" width="68" height="10" font="4">1999;341:1882</text>
<text top="540" left="158" width="20" height="15" font="4">–90.</text>
<text top="557" left="64" width="350" height="10" font="4">598. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an</text>
<text top="572" left="90" width="124" height="10" font="4">implantable cardioverter-de</text>
<text top="569" left="214" width="199" height="15" font="4">ﬁbrillator after acute myocardial infarction.</text>
<text top="586" left="90" width="136" height="10" font="4">N Engl J Med 2004;351:2481</text>
<text top="583" left="226" width="14" height="15" font="4">–8.</text>
<text top="600" left="64" width="350" height="10" font="4">599. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac</text>
<text top="614" left="90" width="324" height="10" font="4">resynchronization in mildly symptomatic heart failure patients and in</text>
<text top="628" left="90" width="324" height="10" font="4">asymptomatic patients with left ventricular dysfunction and previous</text>
<text top="643" left="90" width="261" height="10" font="4">heart failure symptoms. J Am Coll Cardiol 2008;52:1834</text>
<text top="640" left="351" width="20" height="15" font="4">–43.</text>
<text top="657" left="64" width="350" height="10" font="4">600. Brignole M, Gammage M, Puggioni E, et al. Comparative assessment of</text>
<text top="671" left="90" width="324" height="10" font="4">right, left, and biventricular pacing in patients with permanent atrial</text>
<text top="682" left="90" width="185" height="15" font="4">ﬁbrillation. Eur Heart J 2005;26:712–22.</text>
<text top="699" left="64" width="350" height="10" font="4">601. Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy</text>
<text top="714" left="90" width="324" height="10" font="4">in patients undergoing atrioventricular junction ablation for permanent</text>
<text top="728" left="90" width="22" height="10" font="4">atrial</text>
<text top="725" left="116" width="274" height="15" font="4">ﬁbrillation: a randomized trial. Eur Heart J 2011;32:2420–9.</text>
<text top="742" left="64" width="350" height="10" font="4">602. Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac</text>
<text top="756" left="90" width="324" height="10" font="4">stimulation post AV nodal ablation evaluation (the PAVE study).</text>
<text top="770" left="90" width="192" height="10" font="4">J Cardiovasc Electrophysiol 2005;16:1160</text>
<text top="767" left="282" width="14" height="15" font="4">–5.</text>
<text top="785" left="64" width="276" height="10" font="4">603. Gasparini M, Auricchio A, Regoli F, et al. Four-year ef</text>
<text top="782" left="340" width="74" height="15" font="4">ﬁcacy of cardiac</text>
<text top="799" left="90" width="324" height="10" font="4">resynchronization therapy on exercise tolerance and disease progression:</text>
<text top="813" left="90" width="324" height="10" font="4">the importance of performing atrioventricular junction ablation in</text>
<text top="827" left="90" width="84" height="10" font="4">patients with atrial</text>
<text top="824" left="178" width="218" height="15" font="4">ﬁbrillation. J Am Coll Cardiol 2006;48:734–43.</text>
<text top="841" left="64" width="350" height="10" font="4">604. Wilton SB, Leung AA, Ghali WA, et al. Outcomes of cardiac</text>
<text top="856" left="90" width="324" height="10" font="4">resynchronization therapy in patients with versus those without atrial</text>
<text top="867" left="90" width="324" height="15" font="4">ﬁbrillation: a systematic review and meta-analysis. Heart Rhythm 2011;</text>
<text top="884" left="90" width="31" height="10" font="4">8:1088</text>
<text top="881" left="121" width="20" height="15" font="4">–94.</text>
<text top="898" left="64" width="350" height="10" font="4">605. Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchro-</text>
<text top="912" left="90" width="133" height="10" font="4">nization in patients with atrial</text>
<text top="909" left="226" width="188" height="15" font="4">ﬁbrillation: a meta-analysis of prospective</text>
<text top="927" left="90" width="220" height="10" font="4">cohort studies. J Am Coll Cardiol 2008;52:1239</text>
<text top="924" left="310" width="20" height="15" font="4">–46.</text>
<text top="941" left="64" width="350" height="10" font="4">606. Adelstein E, Schwartzman D, Gorcsan J 3rd, et al. Predicting hyper-</text>
<text top="955" left="90" width="324" height="10" font="4">response among pacemaker-dependent nonischemic cardiomyopathy</text>
<text top="969" left="90" width="324" height="10" font="4">patients upgraded to cardiac resynchronization. J Cardiovasc Electro-</text>
<text top="983" left="90" width="93" height="10" font="4">physiol 2011;22:905</text>
<text top="980" left="183" width="20" height="15" font="4">–11.</text>
<text top="998" left="64" width="350" height="10" font="4">607. Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term</text>
<text top="1012" left="90" width="324" height="10" font="4">resynchronization therapy on left ventricular remodeling in pacemaker</text>
<text top="1026" left="90" width="324" height="10" font="4">patients upgraded to biventricular devices. Am J Cardiol 2009;103:</text>
<text top="1040" left="90" width="22" height="10" font="4">1280</text>
<text top="1037" left="112" width="14" height="15" font="4">–4.</text>
<text top="1054" left="64" width="328" height="10" font="4">608. Setoguchi S, Nohria A, Rassen JA, et al. Maximum potential bene</text>
<text top="1051" left="392" width="22" height="15" font="4">ﬁt of</text>
<text top="1069" left="90" width="70" height="10" font="4">implantable de</text>
<text top="1066" left="160" width="254" height="15" font="4">ﬁbrillators in preventing sudden death after hospital</text>
<text top="1083" left="90" width="257" height="10" font="4">admission because of heart failure. CMAJ 2009;180:611</text>
<text top="1080" left="347" width="14" height="15" font="4">–6.</text>
<text top="103" left="450" width="123" height="10" font="4">609. Carson P, Anand I, O</text>
<text top="100" left="573" width="227" height="15" font="4">’Connor C, et al. Mode of death in advanced heart</text>
<text top="117" left="475" width="231" height="10" font="4">failure: the Comparison of Medical, Pacing, and De</text>
<text top="114" left="706" width="93" height="15" font="4">ﬁbrillation Therapies</text>
<text top="132" left="475" width="324" height="10" font="4">in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005;46:</text>
<text top="146" left="475" width="22" height="10" font="4">2329</text>
<text top="143" left="498" width="20" height="15" font="4">–34.</text>
<text top="160" left="450" width="350" height="10" font="4">610. Zareba W, Piotrowicz K, McNitt S, et al. Implantable cardioverter-</text>
<text top="174" left="475" width="11" height="10" font="4">de</text>
<text top="171" left="486" width="313" height="15" font="4">ﬁbrillator efﬁcacy in patients with heart failure and left ventricular</text>
<text top="188" left="475" width="324" height="10" font="4">dysfunction (from the MADIT II population). Am J Cardiol 2005;95:</text>
<text top="203" left="475" width="22" height="10" font="4">1487</text>
<text top="200" left="498" width="20" height="15" font="4">–91.</text>
<text top="217" left="450" width="350" height="10" font="4">611. Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death</text>
<text top="231" left="475" width="324" height="10" font="4">in heart failure: the Seattle Heart Failure Model. Circulation 2007;116:</text>
<text top="245" left="475" width="17" height="10" font="4">392</text>
<text top="242" left="492" width="14" height="15" font="4">–8.</text>
<text top="259" left="450" width="350" height="10" font="4">612. Rickard J, Bassiouny M, Cronin EM, et al. Predictors of response to</text>
<text top="274" left="475" width="324" height="10" font="4">cardiac resynchronization therapy in patients with a non-left bundle</text>
<text top="288" left="475" width="257" height="10" font="4">branch block morphology. Am J Cardiol 2011;108:1576</text>
<text top="285" left="732" width="20" height="15" font="4">–80.</text>
<text top="302" left="450" width="102" height="10" font="4">613. Deleted in press.</text>
<text top="316" left="450" width="224" height="10" font="4">614. Steinbeck G, Andresen D, Seidl K, et al. De</text>
<text top="313" left="673" width="126" height="15" font="4">ﬁbrillator implantation early</text>
<text top="330" left="475" width="263" height="10" font="4">after myocardial infarction. N Engl J Med 2009;361:1427</text>
<text top="327" left="739" width="20" height="15" font="4">–36.</text>
<text top="345" left="450" width="350" height="10" font="4">615. Sears SF, Hauf JD, Kirian K, et al. Posttraumatic stress and the</text>
<text top="359" left="475" width="124" height="10" font="4">implantable cardioverter-de</text>
<text top="356" left="600" width="200" height="15" font="4">ﬁbrillator patient: what the electrophysiolo-</text>
<text top="373" left="475" width="282" height="10" font="4">gist needs to know. Circ Arrhythm Electrophysiol 2011;4:242</text>
<text top="370" left="758" width="20" height="15" font="4">–50.</text>
<text top="387" left="450" width="350" height="10" font="4">616. Al-Khatib SM, Greiner MA, Peterson ED, et al. Patient and implanting</text>
<text top="401" left="475" width="324" height="10" font="4">physician factors associated with mortality and complications after</text>
<text top="416" left="475" width="128" height="10" font="4">implantable cardioverter-de</text>
<text top="413" left="603" width="196" height="15" font="4">ﬁbrillator implantation, 2002–2005. Circ</text>
<text top="430" left="475" width="167" height="10" font="4">Arrhythm Electrophysiol 2008;1:240</text>
<text top="427" left="642" width="14" height="15" font="4">–9.</text>
<text top="444" left="450" width="350" height="10" font="4">617. Epstein AE, Kay GN, Plumb VJ, et al. Implantable cardioverter-</text>
<text top="458" left="475" width="11" height="10" font="4">de</text>
<text top="455" left="486" width="313" height="15" font="4">ﬁbrillator prescription in the elderly. Heart Rhythm 2009;6:1136–43.</text>
<text top="472" left="450" width="350" height="10" font="4">618. Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable</text>
<text top="486" left="475" width="11" height="10" font="4">de</text>
<text top="483" left="486" width="314" height="15" font="4">ﬁbrillator among elderly patients with a history of life-threatening</text>
<text top="501" left="475" width="229" height="10" font="4">ventricular arrhythmias. Eur Heart J 2007;28:1746</text>
<text top="498" left="705" width="14" height="15" font="4">–9.</text>
<text top="515" left="450" width="350" height="10" font="4">619. Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis: age</text>
<text top="529" left="475" width="275" height="10" font="4">and effectiveness of prophylactic implantable cardioverter-de</text>
<text top="526" left="751" width="49" height="15" font="4">ﬁbrillators.</text>
<text top="543" left="475" width="139" height="10" font="4">Ann Intern Med 2010;153:592</text>
<text top="540" left="615" width="14" height="15" font="4">–9.</text>
<text top="557" left="450" width="350" height="10" font="4">620. Stevenson LW, Desai AS. Selecting patients for discussion of the ICD as</text>
<text top="572" left="475" width="324" height="10" font="4">primary prevention for sudden death in heart failure. J Card Fail 2006;</text>
<text top="586" left="475" width="31" height="10" font="4">12:407</text>
<text top="583" left="506" width="20" height="15" font="4">–12.</text>
<text top="600" left="450" width="350" height="10" font="4">621. Lampert R, Hayes DL, Annas GJ, et al. HRS expert consensus statement</text>
<text top="614" left="475" width="324" height="10" font="4">on the management of cardiovascular implantable electronic devices</text>
<text top="628" left="475" width="324" height="10" font="4">(CIEDs) in patients nearing end of life or requesting withdrawal of</text>
<text top="643" left="475" width="164" height="10" font="4">therapy. Heart Rhythm 2010;7:1008</text>
<text top="640" left="640" width="20" height="15" font="4">–26.</text>
<text top="657" left="450" width="350" height="10" font="4">622. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynch-</text>
<text top="671" left="475" width="212" height="10" font="4">ronization and implantable cardioversion de</text>
<text top="668" left="688" width="111" height="15" font="4">ﬁbrillation in advanced</text>
<text top="685" left="475" width="324" height="10" font="4">chronic heart failure: the MIRACLE ICD Trial. JAMA 2003;289:</text>
<text top="699" left="475" width="22" height="10" font="4">2685</text>
<text top="696" left="498" width="20" height="15" font="4">–94.</text>
<text top="714" left="450" width="350" height="10" font="4">623. Saxon LA, Ellenbogen KA. Resynchronization therapy for the treatment</text>
<text top="728" left="475" width="195" height="10" font="4">of heart failure. Circulation 2003;108:1044</text>
<text top="725" left="671" width="14" height="15" font="4">–8.</text>
<text top="742" left="450" width="350" height="10" font="4">624. Sipahi I, Carrigan TP, Rowland DY, et al. Impact of QRS duration on</text>
<text top="756" left="475" width="324" height="10" font="4">clinical event reduction with cardiac resynchronization therapy: meta-</text>
<text top="770" left="475" width="324" height="10" font="4">analysis of randomized controlled trials. Arch Intern Med 2011;171:</text>
<text top="785" left="475" width="22" height="10" font="4">1454</text>
<text top="782" left="498" width="20" height="15" font="4">–62.</text>
<text top="799" left="450" width="238" height="10" font="4">625. Stavrakis S, Lazzara R, Thadani U. The bene</text>
<text top="796" left="688" width="111" height="15" font="4">ﬁt of cardiac resynchro-</text>
<text top="813" left="475" width="324" height="10" font="4">nization therapy and QRS duration: a meta-analysis. J Cardiovasc</text>
<text top="827" left="475" width="125" height="10" font="4">Electrophysiol 2012;23:163</text>
<text top="824" left="600" width="14" height="15" font="4">–8.</text>
<text top="841" left="450" width="350" height="10" font="4">626. Bilchick KC, Kamath S, DiMarco JP, et al. Bundle-branch block</text>
<text top="856" left="475" width="324" height="10" font="4">morphology and other predictors of outcome after cardiac resynchroni-</text>
<text top="870" left="475" width="288" height="10" font="4">zation therapy in Medicare patients. Circulation 2010;122:2022</text>
<text top="867" left="763" width="20" height="15" font="4">–30.</text>
<text top="884" left="450" width="350" height="10" font="4">627. Adelstein EC, Saba S. Usefulness of baseline electrocardiographic QRS</text>
<text top="898" left="475" width="324" height="10" font="4">complex pattern to predict response to cardiac resynchronization. Am J</text>
<text top="912" left="475" width="99" height="10" font="4">Cardiol 2009;103:238</text>
<text top="909" left="575" width="20" height="15" font="4">–42.</text>
<text top="927" left="450" width="350" height="10" font="4">628. Rickard J, Kumbhani DJ, Gorodeski EZ, et al. Cardiac resynchronization</text>
<text top="941" left="475" width="324" height="10" font="4">therapy in non-left bundle branch block morphologies. Pacing Clin</text>
<text top="955" left="475" width="125" height="10" font="4">Electrophysiol 2010;33:590</text>
<text top="952" left="600" width="14" height="15" font="4">–5.</text>
<text top="969" left="450" width="350" height="10" font="4">629. Sharma A, Heist EK. The utility of cardiac resynchronization therapy in</text>
<text top="983" left="475" width="85" height="10" font="4">patients with atrial</text>
<text top="980" left="565" width="234" height="15" font="4">ﬁbrillation. J Innovations Cardiac Rhythm Manage</text>
<text top="998" left="475" width="42" height="10" font="4">2012:621</text>
<text top="995" left="518" width="14" height="15" font="4">–6.</text>
<text top="1012" left="450" width="350" height="10" font="4">630. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease</text>
<text top="1026" left="475" width="324" height="10" font="4">progression by cardiac resynchronization therapy in patients with</text>
<text top="1040" left="475" width="324" height="10" font="4">asymptomatic or mildly symptomatic left ventricular dysfunction:</text>
<text top="1054" left="475" width="324" height="10" font="4">insights from the European cohort of the REVERSE (Resynchronization</text>
<text top="1069" left="475" width="324" height="10" font="4">Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.</text>
<text top="1083" left="475" width="150" height="10" font="4">J Am Coll Cardiol 2009;54:1837</text>
<text top="1080" left="626" width="20" height="15" font="4">–46.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e224</text>
</page>
<page number="79" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">631. Santangeli P, Di Biase L, Pelargonio G, et al. Cardiac resynchronization</text>
<text top="117" left="90" width="324" height="10" font="4">therapy in patients with mild heart failure: a systematic review and meta-</text>
<text top="132" left="90" width="231" height="10" font="4">analysis. J Interv Card Electrophysiol 2011;32:125</text>
<text top="129" left="321" width="20" height="15" font="4">–35.</text>
<text top="146" left="64" width="350" height="10" font="4">632. Barsheshet A, Wang PJ, Moss AJ, et al. Reverse remodeling and the risk</text>
<text top="160" left="90" width="324" height="10" font="4">of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter</text>
<text top="174" left="90" width="65" height="10" font="4">Automatic De</text>
<text top="171" left="155" width="258" height="15" font="4">ﬁbrillator Implantation Trial-Cardiac Resynchronization</text>
<text top="188" left="90" width="198" height="10" font="4">Therapy). J Am Coll Cardiol 2011;57:2416</text>
<text top="185" left="288" width="20" height="15" font="4">–23.</text>
<text top="203" left="64" width="303" height="10" font="4">633. Tang AS, Wells GA, Arnold M, et al. Resynchronization/de</text>
<text top="200" left="367" width="47" height="15" font="4">ﬁbrillation</text>
<text top="217" left="90" width="324" height="10" font="4">for ambulatory heart failure trial: rationale and trial design. Curr Opin</text>
<text top="231" left="90" width="82" height="10" font="4">Cardiol 2009;24:1</text>
<text top="228" left="172" width="14" height="15" font="4">–8.</text>
<text top="245" left="64" width="102" height="10" font="4">634. Deleted in press.</text>
<text top="259" left="64" width="350" height="10" font="4">635. University of Alabama Birmingham. INTERMACS manual of opera-</text>
<text top="274" left="90" width="105" height="10" font="4">tions version 2.3: user</text>
<text top="271" left="195" width="219" height="15" font="4">’s guide. Birmingham, Ala: University of Ala-</text>
<text top="288" left="90" width="56" height="10" font="4">bama; 2008.</text>
<text top="302" left="64" width="350" height="10" font="4">636. Ambardekar AV, Fonarow GC, Hernandez AF, et al. Characteristics and</text>
<text top="316" left="90" width="285" height="10" font="4">in-hospital outcomes for nonadherent patients with heart failure:</text>
<text top="313" left="378" width="36" height="15" font="4">ﬁndings</text>
<text top="330" left="90" width="324" height="10" font="4">from Get With The Guidelines-Heart Failure (GWTG-HF). Am Heart J</text>
<text top="345" left="90" width="62" height="10" font="4">2009;158:644</text>
<text top="342" left="152" width="20" height="15" font="4">–52.</text>
<text top="359" left="64" width="350" height="10" font="4">637. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication</text>
<text top="373" left="90" width="324" height="10" font="4">adherence in chronic medical conditions: a systematic review. Arch</text>
<text top="387" left="90" width="116" height="10" font="4">Intern Med 2007;167:540</text>
<text top="384" left="206" width="20" height="15" font="4">–50.</text>
<text top="401" left="64" width="350" height="10" font="4">638. Wu JR, Moser DK, Lennie TA, et al. Medication adherence in patients</text>
<text top="416" left="90" width="324" height="10" font="4">who have heart failure: a review of the literature. Nurs Clin North Am</text>
<text top="430" left="90" width="56" height="10" font="4">2008;43:133</text>
<text top="427" left="146" width="20" height="15" font="4">–53.</text>
<text top="444" left="64" width="350" height="10" font="4">639. Bagchi AD, Esposito D, Kim M, et al. Utilization of, and adherence to,</text>
<text top="458" left="90" width="158" height="10" font="4">drug therapy among Medicaid bene</text>
<text top="455" left="248" width="166" height="15" font="4">ﬁciaries with congestive heart failure.</text>
<text top="472" left="90" width="110" height="10" font="4">Clin Ther 2007;29:1771</text>
<text top="469" left="200" width="20" height="15" font="4">–83.</text>
<text top="486" left="64" width="350" height="10" font="4">640. Neily JB, Toto KH, Gardner EB, et al. Potential contributing factors to</text>
<text top="501" left="90" width="324" height="10" font="4">noncompliance with dietary sodium restriction in patients with heart</text>
<text top="515" left="90" width="148" height="10" font="4">failure. Am Heart J 2002;143:29</text>
<text top="512" left="238" width="20" height="15" font="4">–33.</text>
<text top="529" left="64" width="350" height="10" font="4">641. van der Wal MH, van Veldhuisen DJ, Veeger NJ, et al. Compliance with</text>
<text top="543" left="90" width="324" height="10" font="4">non-pharmacological recommendations and outcome in heart failure</text>
<text top="557" left="90" width="159" height="10" font="4">patients. Eur Heart J 2010;31:1486</text>
<text top="554" left="249" width="20" height="15" font="4">–93.</text>
<text top="572" left="64" width="350" height="10" font="4">642. Russell SD, Miller LW, Pagani FD. Advanced heart failure: a call to</text>
<text top="586" left="90" width="180" height="10" font="4">action. Congest Heart Fail 2008;14:316</text>
<text top="583" left="269" width="20" height="15" font="4">–21.</text>
<text top="600" left="64" width="318" height="10" font="4">643. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS pro</text>
<text top="597" left="382" width="32" height="15" font="4">ﬁles of</text>
<text top="614" left="90" width="324" height="10" font="4">advanced heart failure: the current picture. J Heart Lung Transplant</text>
<text top="628" left="90" width="56" height="10" font="4">2009;28:535</text>
<text top="625" left="146" width="20" height="15" font="4">–41.</text>
<text top="643" left="64" width="88" height="10" font="4">644. Travers B, O</text>
<text top="640" left="152" width="262" height="15" font="4">’Loughlin C, Murphy NF, et al. Fluid restriction in the</text>
<text top="657" left="90" width="324" height="10" font="4">management of decompensated heart failure: no impact on time to</text>
<text top="671" left="90" width="189" height="10" font="4">clinical stability. J Card Fail 2007;13:128</text>
<text top="668" left="279" width="20" height="15" font="4">–32.</text>
<text top="685" left="64" width="350" height="10" font="4">645. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between</text>
<text top="699" left="90" width="324" height="10" font="4">admission serum sodium concentration and clinical outcomes in patients</text>
<text top="714" left="90" width="324" height="10" font="4">hospitalized for heart failure: an analysis from the OPTIMIZE-HF</text>
<text top="728" left="90" width="153" height="10" font="4">registry. Eur Heart J 2007;28:980</text>
<text top="725" left="243" width="14" height="15" font="4">–8.</text>
<text top="742" left="64" width="76" height="10" font="4">646. Klein L, O</text>
<text top="739" left="140" width="274" height="15" font="4">’Connor CM, Leimberger JD, et al. Lower serum sodium is</text>
<text top="756" left="90" width="324" height="10" font="4">associated with increased short-term mortality in hospitalized patients</text>
<text top="770" left="90" width="324" height="10" font="4">with worsening heart failure: results from the Outcomes of a Prospective</text>
<text top="785" left="90" width="324" height="10" font="4">Trial of Intravenous Milrinone for Exacerbations of Chronic Heart</text>
<text top="799" left="90" width="265" height="10" font="4">Failure (OPTIME-CHF) study. Circulation 2005;111:2454</text>
<text top="796" left="355" width="20" height="15" font="4">–60.</text>
<text top="813" left="64" width="116" height="10" font="4">647. Aranda JM Jr., Scho</text>
<text top="810" left="180" width="234" height="15" font="4">ﬁeld RS, Pauly DF, et al. Comparison of dobutamine</text>
<text top="827" left="90" width="324" height="10" font="4">versus milrinone therapy in hospitalized patients awaiting cardiac trans-</text>
<text top="841" left="90" width="310" height="10" font="4">plantation: a prospective, randomized trial. Am Heart J 2003;145:324</text>
<text top="838" left="400" width="14" height="15" font="4">–9.</text>
<text top="856" left="64" width="350" height="10" font="4">648. Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of</text>
<text top="870" left="90" width="324" height="10" font="4">continuous intravenous milrinone therapy for status IB patients awaiting</text>
<text top="884" left="90" width="293" height="10" font="4">heart transplant at home. J Heart Lung Transplant 2004;23:1082</text>
<text top="881" left="383" width="14" height="15" font="4">–6.</text>
<text top="898" left="64" width="350" height="10" font="4">649. Cuffe MS, Califf RM, Adams KF Jr., et al. Short-term intravenous</text>
<text top="912" left="90" width="324" height="10" font="4">milrinone for acute exacerbation of chronic heart failure: a randomized</text>
<text top="927" left="90" width="175" height="10" font="4">controlled trial. JAMA 2002;287:1541</text>
<text top="924" left="265" width="14" height="15" font="4">–7.</text>
<text top="941" left="64" width="350" height="10" font="4">650. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and</text>
<text top="955" left="90" width="324" height="10" font="4">vasodilator therapy in hospitalized patients with severe heart failure. Am</text>
<text top="969" left="90" width="93" height="10" font="4">Heart J 2007;153:98</text>
<text top="966" left="183" width="25" height="15" font="4">–104.</text>
<text top="983" left="64" width="34" height="10" font="4">651. O</text>
<text top="980" left="98" width="316" height="15" font="4">’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous</text>
<text top="998" left="90" width="324" height="10" font="4">dobutamine is associated with an increased risk of death in patients with</text>
<text top="1012" left="90" width="324" height="10" font="4">advanced heart failure: insights from the Flolan International Random-</text>
<text top="1026" left="90" width="246" height="10" font="4">ized Survival Trial (FIRST). Am Heart J 1999;138:78</text>
<text top="1023" left="336" width="20" height="15" font="4">–86.</text>
<text top="1040" left="64" width="350" height="10" font="4">652. Hershberger RE, Nauman D, Walker TL, et al. Care processes and</text>
<text top="1054" left="90" width="324" height="10" font="4">clinical outcomes of continuous outpatient support with inotropes</text>
<text top="1069" left="90" width="324" height="10" font="4">(COSI) in patients with refractory endstage heart failure. J Card Fail</text>
<text top="1083" left="90" width="51" height="10" font="4">2003;9:180</text>
<text top="1080" left="141" width="14" height="15" font="4">–7.</text>
<text top="103" left="450" width="350" height="10" font="4">653. Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis on chronic dobut-</text>
<text top="117" left="475" width="324" height="10" font="4">amine or milrinone infusions for stage D heart failure. Circ Heart Fail</text>
<text top="132" left="475" width="51" height="10" font="4">2009;2:320</text>
<text top="129" left="526" width="14" height="15" font="4">–4.</text>
<text top="146" left="450" width="350" height="10" font="4">654. Cohn JN, Goldstein SO, Greenberg BH, et al., Vesnarinone Trial</text>
<text top="160" left="475" width="324" height="10" font="4">Investigators. A dose-dependent increase in mortality with vesnarinone</text>
<text top="174" left="475" width="324" height="10" font="4">among patients with severe heart failure. N Engl J Med 1998;339:</text>
<text top="188" left="475" width="23" height="10" font="4">1810</text>
<text top="185" left="498" width="14" height="15" font="4">–6.</text>
<text top="203" left="450" width="350" height="10" font="4">655. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of</text>
<text top="217" left="475" width="324" height="10" font="4">effect of ibopamine on survival in patients with advanced severe heart</text>
<text top="231" left="475" width="324" height="10" font="4">failure: Second Prospective Randomised Study of Ibopamine on Mortality</text>
<text top="245" left="475" width="29" height="10" font="4">and Ef</text>
<text top="242" left="505" width="255" height="15" font="4">ﬁcacy (PRIME II) Investigators. Lancet 1997;349:971–7.</text>
<text top="259" left="450" width="350" height="10" font="4">656. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on</text>
<text top="274" left="475" width="324" height="10" font="4">exercise capacity in patients with heart failure: main results from the</text>
<text top="288" left="475" width="324" height="10" font="4">Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996;76:</text>
<text top="302" left="475" width="17" height="10" font="4">223</text>
<text top="299" left="492" width="20" height="15" font="4">–31.</text>
<text top="316" left="450" width="350" height="10" font="4">657. Packer M, Carver JR, Rodeheffer RJ, et al., the PROMISE Study</text>
<text top="330" left="475" width="324" height="10" font="4">Research Group. Effect of oral milrinone on mortality in severe chronic</text>
<text top="345" left="475" width="197" height="10" font="4">heart failure. N Engl J Med 1991;325:1468</text>
<text top="342" left="673" width="20" height="15" font="4">–75.</text>
<text top="359" left="450" width="350" height="10" font="4">658. Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral</text>
<text top="373" left="475" width="324" height="10" font="4">enoximone administration on mortality, morbidity, and exercise capacity</text>
<text top="387" left="475" width="324" height="10" font="4">in patients with advanced heart failure: the randomized, double-blind,</text>
<text top="401" left="475" width="324" height="10" font="4">placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J</text>
<text top="416" left="475" width="62" height="10" font="4">2009;30:3015</text>
<text top="413" left="538" width="20" height="15" font="4">–26.</text>
<text top="430" left="450" width="350" height="10" font="4">659. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose</text>
<text top="444" left="475" width="324" height="10" font="4">dobutamine infusion in severe heart failure: DICE multicenter trial.</text>
<text top="458" left="475" width="119" height="10" font="4">Am Heart J 1999;138:247</text>
<text top="455" left="594" width="20" height="15" font="4">–53.</text>
<text top="472" left="450" width="350" height="10" font="4">660. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circu-</text>
<text top="486" left="475" width="164" height="10" font="4">latory support with a continuous-</text>
<text top="483" left="639" width="160" height="15" font="4">ﬂow rotary left ventricular assist</text>
<text top="501" left="475" width="180" height="10" font="4">device. J Am Coll Cardiol 2009;54:312</text>
<text top="498" left="656" width="20" height="15" font="4">–21.</text>
<text top="515" left="450" width="214" height="10" font="4">661. Alba AC, Rao V, Ross HJ, et al. Impact of</text>
<text top="512" left="666" width="133" height="15" font="4">ﬁxed pulmonary hypertension</text>
<text top="529" left="475" width="324" height="10" font="4">on post-heart transplant outcomes in bridge-to-transplant patients.</text>
<text top="543" left="475" width="177" height="10" font="4">J Heart Lung Transplant 2010;29:1253</text>
<text top="540" left="652" width="14" height="15" font="4">–8.</text>
<text top="557" left="450" width="350" height="10" font="4">662. Elhenawy AM, Algarni KD, Rodger M, et al. Mechanical circulatory</text>
<text top="572" left="475" width="310" height="10" font="4">support as a bridge to transplant candidacy. J Card Surg 2011;26:542</text>
<text top="569" left="786" width="14" height="15" font="4">–7.</text>
<text top="586" left="450" width="350" height="10" font="4">663. Nair PK, Kormos RL, Teuteberg JJ, et al. Pulsatile left ventricular assist</text>
<text top="600" left="475" width="324" height="10" font="4">device support as a bridge to decision in patients with end-stage heart</text>
<text top="614" left="475" width="324" height="10" font="4">failure complicated by pulmonary hypertension. J Heart Lung Transplant</text>
<text top="628" left="475" width="56" height="10" font="4">2010;29:201</text>
<text top="625" left="532" width="14" height="15" font="4">–8.</text>
<text top="643" left="450" width="330" height="10" font="4">664. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-</text>
<text top="640" left="780" width="20" height="15" font="4">ﬂow</text>
<text top="657" left="475" width="324" height="10" font="4">device in patients awaiting heart transplantation. N Engl J Med 2007;</text>
<text top="671" left="475" width="37" height="10" font="4">357:885</text>
<text top="668" left="512" width="20" height="15" font="4">–96.</text>
<text top="685" left="450" width="350" height="10" font="4">665. Lahpor J, Khaghani A, Hetzer R, et al. European results with a</text>
<text top="699" left="475" width="52" height="10" font="4">continuous-</text>
<text top="696" left="528" width="271" height="15" font="4">ﬂow ventricular assist device for advanced heart-failure</text>
<text top="714" left="475" width="212" height="10" font="4">patients. Eur J Cardiothorac Surg 2010;37:357</text>
<text top="711" left="687" width="20" height="15" font="4">–61.</text>
<text top="728" left="450" width="350" height="10" font="4">666. Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and</text>
<text top="742" left="475" width="246" height="10" font="4">Drug Administration-approval study with a continuous</text>
<text top="739" left="724" width="75" height="15" font="4">ﬂow left ventric-</text>
<text top="756" left="475" width="324" height="10" font="4">ular assist device as a bridge to heart transplantation: a prospective study</text>
<text top="770" left="475" width="324" height="10" font="4">using the INTERMACS (Interagency Registry for Mechanically Assisted</text>
<text top="785" left="475" width="245" height="10" font="4">Circulatory Support). J Am Coll Cardiol 2011;57:1890</text>
<text top="782" left="720" width="14" height="15" font="4">–8.</text>
<text top="799" left="450" width="350" height="10" font="4">667. Grady KL, Meyer PM, Dressler D, et al. Longitudinal change in quality</text>
<text top="813" left="475" width="324" height="10" font="4">of life and impact on survival after left ventricular assist device</text>
<text top="827" left="475" width="208" height="10" font="4">implantation. Ann Thorac Surg 2004;77:1321</text>
<text top="824" left="683" width="14" height="15" font="4">–7.</text>
<text top="841" left="450" width="350" height="10" font="4">668. Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter</text>
<text top="856" left="475" width="200" height="10" font="4">clinical study to evaluate the safety and ef</text>
<text top="853" left="675" width="124" height="15" font="4">ﬁcacy of the TandemHeart</text>
<text top="870" left="475" width="324" height="10" font="4">percutaneous ventricular assist device versus conventional therapy with</text>
<text top="884" left="475" width="324" height="10" font="4">intraaortic balloon pumping for treatment of cardiogenic shock. Am</text>
<text top="898" left="475" width="112" height="10" font="4">Heart J 2006;152:469.e1</text>
<text top="895" left="587" width="14" height="15" font="4">–8.</text>
<text top="912" left="450" width="350" height="10" font="4">669. Greenberg B, Czerska B, Delgado RM, et al. Effects of continuous aortic</text>
<text top="924" left="475" width="324" height="15" font="4">ﬂow augmentation in patients with exacerbation of heart failure inade-</text>
<text top="941" left="475" width="324" height="10" font="4">quately responsive to medical therapy: results of the Multicenter Trial of</text>
<text top="955" left="475" width="324" height="10" font="4">the Orqis Medical Cancion System for the Enhanced Treatment of Heart</text>
<text top="969" left="475" width="324" height="10" font="4">Failure Unresponsive to Medical Therapy (MOMENTUM). Circulation</text>
<text top="983" left="475" width="68" height="10" font="4">2008;118:1241</text>
<text top="980" left="543" width="14" height="15" font="4">–9.</text>
<text top="998" left="450" width="350" height="10" font="4">670. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to</text>
<text top="1012" left="475" width="116" height="10" font="4">evaluate the safety and ef</text>
<text top="1009" left="592" width="208" height="15" font="4">ﬁcacy of a percutaneous left ventricular assist</text>
<text top="1026" left="475" width="324" height="10" font="4">device versus intra-aortic balloon pumping for treatment of cardiogenic</text>
<text top="1040" left="475" width="324" height="10" font="4">shock caused by myocardial infarction. J Am Coll Cardiol 2008;52:</text>
<text top="1054" left="475" width="22" height="10" font="4">1584</text>
<text top="1051" left="498" width="14" height="15" font="4">–8.</text>
<text top="1069" left="450" width="350" height="10" font="4">671. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-</text>
<text top="1083" left="475" width="324" height="10" font="4">aortic balloon support with a percutaneous left ventricular assist device</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e225</text>
</page>
<page number="80" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="90" width="324" height="10" font="4">in patients with revascularized acute myocardial infarction complicated</text>
<text top="117" left="90" width="221" height="10" font="4">by cardiogenic shock. Eur Heart J 2005;26:1276</text>
<text top="114" left="311" width="20" height="15" font="4">–83.</text>
<text top="132" left="64" width="350" height="10" font="4">672. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left</text>
<text top="146" left="90" width="324" height="10" font="4">ventricular assist device for end-stage heart failure. N Engl J Med 2001;</text>
<text top="160" left="90" width="42" height="10" font="4">345:1435</text>
<text top="157" left="132" width="20" height="15" font="4">–43.</text>
<text top="174" left="64" width="350" height="10" font="4">673. Stevenson LW, Miller LW, Desvigne-Nickens P, et al. Left ventricular</text>
<text top="188" left="90" width="324" height="10" font="4">assist device as destination for patients undergoing intravenous inotropic</text>
<text top="203" left="90" width="324" height="10" font="4">therapy: a subset analysis from REMATCH (Randomized Evaluation of</text>
<text top="217" left="90" width="324" height="10" font="4">Mechanical Assistance in Treatment of Chronic Heart Failure). Circu-</text>
<text top="231" left="90" width="91" height="10" font="4">lation 2004;110:975</text>
<text top="228" left="181" width="20" height="15" font="4">–81.</text>
<text top="245" left="64" width="350" height="10" font="4">674. Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory</text>
<text top="259" left="90" width="324" height="10" font="4">support for inotrope-dependent heart failure patients who are not trans-</text>
<text top="274" left="90" width="324" height="10" font="4">plant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 2007;</text>
<text top="288" left="90" width="31" height="10" font="4">50:741</text>
<text top="285" left="121" width="14" height="15" font="4">–7.</text>
<text top="302" left="64" width="350" height="10" font="4">675. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure</text>
<text top="316" left="90" width="108" height="10" font="4">treated with continuous-</text>
<text top="313" left="198" width="216" height="15" font="4">ﬂow left ventricular assist device. N Engl J Med</text>
<text top="330" left="90" width="68" height="10" font="4">2009;361:2241</text>
<text top="327" left="158" width="20" height="15" font="4">–51.</text>
<text top="345" left="64" width="350" height="10" font="4">676. Liotta D, Crawford ES, Cooley DA, et al. Prolonged partial left</text>
<text top="359" left="90" width="324" height="10" font="4">ventricular bypass by means of an intrathoracic pump implanted in the</text>
<text top="373" left="90" width="254" height="10" font="4">left chest. Trans Am Soc Artif Intern Organs 1962;8:90</text>
<text top="370" left="344" width="14" height="15" font="4">–9.</text>
<text top="387" left="64" width="350" height="10" font="4">677. Holman WL, Kormos RL, Naftel DC, et al. Predictors of death and</text>
<text top="401" left="90" width="324" height="10" font="4">transplant in patients with a mechanical circulatory support device:</text>
<text top="416" left="90" width="289" height="10" font="4">a multi-institutional study. J Heart Lung Transplant 2009;28:44</text>
<text top="413" left="379" width="20" height="15" font="4">–50.</text>
<text top="430" left="64" width="350" height="10" font="4">678. Hall JL, Fermin DR, Birks EJ, et al. Clinical, molecular, and genomic</text>
<text top="444" left="90" width="324" height="10" font="4">changes in response to a left ventricular assist device. J Am Coll Cardiol</text>
<text top="458" left="90" width="56" height="10" font="4">2011;57:641</text>
<text top="455" left="146" width="20" height="15" font="4">–52.</text>
<text top="472" left="64" width="297" height="10" font="4">679. Kato TS, Chokshi A, Singh P, et al. Effects of continuous-</text>
<text top="469" left="362" width="52" height="15" font="4">ﬂow versus</text>
<text top="486" left="90" width="41" height="10" font="4">pulsatile-</text>
<text top="483" left="131" width="283" height="15" font="4">ﬂow left ventricular assist devices on myocardial unloading and</text>
<text top="501" left="90" width="180" height="10" font="4">remodeling. Circ Heart Fail 2011;4:546</text>
<text top="498" left="270" width="20" height="15" font="4">–53.</text>
<text top="515" left="64" width="350" height="10" font="4">680. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart</text>
<text top="529" left="90" width="324" height="10" font="4">transplantation: International Society for Heart and Lung Transplantation</text>
<text top="543" left="90" width="255" height="10" font="4">guidelines for the care of cardiac transplant candidates</text>
<text top="540" left="345" width="69" height="15" font="4">–2006. J Heart</text>
<text top="557" left="90" width="141" height="10" font="4">Lung Transplant 2006;25:1024</text>
<text top="554" left="230" width="20" height="15" font="4">–42.</text>
<text top="572" left="64" width="350" height="10" font="4">681. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the</text>
<text top="586" left="90" width="324" height="10" font="4">International Society for Heart and Lung Transplantation: Twenty-eighth</text>
<text top="600" left="90" width="137" height="10" font="4">Adult Heart Transplant Report</text>
<text top="597" left="227" width="187" height="15" font="4">–2011. J Heart Lung Transplant 2011;30:</text>
<text top="614" left="90" width="22" height="10" font="4">1078</text>
<text top="611" left="112" width="20" height="15" font="4">–94.</text>
<text top="628" left="64" width="350" height="10" font="4">682. Grady KL, Jalowiec A, White-Williams C. Improvement in quality of</text>
<text top="643" left="90" width="324" height="10" font="4">life in patients with heart failure who undergo transplantation. J Heart</text>
<text top="657" left="90" width="135" height="10" font="4">Lung Transplant 1996;15:749</text>
<text top="654" left="225" width="20" height="15" font="4">–57.</text>
<text top="671" left="64" width="350" height="10" font="4">683. Grady KL, Jalowiec A, White-Williams C. Predictors of quality of life in</text>
<text top="685" left="90" width="324" height="10" font="4">patients at one year after heart transplantation. J Heart Lung Transplant</text>
<text top="699" left="90" width="56" height="10" font="4">1999;18:202</text>
<text top="696" left="146" width="20" height="15" font="4">–10.</text>
<text top="714" left="64" width="350" height="10" font="4">684. Grady KL, Naftel DC, Young JB, et al. Patterns and predictors of</text>
<text top="728" left="90" width="324" height="10" font="4">physical functional disability at 5 to 10 years after heart transplantation.</text>
<text top="742" left="90" width="177" height="10" font="4">J Heart Lung Transplant 2007;26:1182</text>
<text top="739" left="267" width="20" height="15" font="4">–91.</text>
<text top="756" left="64" width="350" height="10" font="4">685. Habedank D, Ewert R, Hummel M, et al. Changes in exercise capacity,</text>
<text top="770" left="90" width="324" height="10" font="4">ventilation, and body weight following heart transplantation. Eur J Heart</text>
<text top="785" left="90" width="72" height="10" font="4">Fail 2007;9:310</text>
<text top="782" left="162" width="14" height="15" font="4">–6.</text>
<text top="799" left="64" width="350" height="10" font="4">686. Kobashigawa JA, Leaf DA, Lee N, et al. A controlled trial of exercise</text>
<text top="813" left="90" width="310" height="10" font="4">rehabilitation after heart transplantation. N Engl J Med 1999;340:272</text>
<text top="810" left="400" width="14" height="15" font="4">–7.</text>
<text top="827" left="64" width="350" height="10" font="4">687. Salyer J, Flattery MP, Joyner PL, et al. Lifestyle and quality of life in</text>
<text top="841" left="90" width="324" height="10" font="4">long-term cardiac transplant recipients. J Heart Lung Transplant 2003;</text>
<text top="856" left="90" width="31" height="10" font="4">22:309</text>
<text top="853" left="121" width="20" height="15" font="4">–21.</text>
<text top="870" left="64" width="350" height="10" font="4">688. Grady KL, Naftel DC, Kobashigawa J, et al. Patterns and predictors of</text>
<text top="884" left="90" width="324" height="10" font="4">quality of life at 5 to 10 years after heart transplantation. J Heart Lung</text>
<text top="898" left="90" width="108" height="10" font="4">Transplant 2007;26:535</text>
<text top="895" left="198" width="20" height="15" font="4">–43.</text>
<text top="912" left="64" width="350" height="10" font="4">689. Deng MC, De Meester JM, Smits JM, et al. Effect of receiving a heart</text>
<text top="927" left="90" width="308" height="10" font="4">transplant: analysis of a national cohort entered on to a waiting list, strati</text>
<text top="924" left="398" width="17" height="15" font="4">ﬁed</text>
<text top="941" left="90" width="293" height="10" font="4">by heart failure severity: Comparative Outcome and Clinical Pro</text>
<text top="938" left="383" width="31" height="15" font="4">ﬁles in</text>
<text top="955" left="90" width="267" height="10" font="4">Transplantation (COCPIT) Study Group. BMJ 2000;321:540</text>
<text top="952" left="357" width="14" height="15" font="4">–5.</text>
<text top="969" left="64" width="350" height="10" font="4">690. Arena R, Myers J, Aslam SS, et al. Peak VO2 and VE/VCO2 slope in</text>
<text top="983" left="90" width="324" height="10" font="4">patients with heart failure: a prognostic comparison. Am Heart J 2004;</text>
<text top="998" left="90" width="37" height="10" font="4">147:354</text>
<text top="995" left="127" width="20" height="15" font="4">–60.</text>
<text top="1012" left="64" width="350" height="10" font="4">691. Butler J, Khadim G, Paul KM, et al. Selection of patients for heart</text>
<text top="1026" left="90" width="324" height="10" font="4">transplantation in the current era of heart failure therapy. J Am Coll</text>
<text top="1040" left="90" width="93" height="10" font="4">Cardiol 2004;43:787</text>
<text top="1037" left="183" width="20" height="15" font="4">–93.</text>
<text top="1054" left="64" width="350" height="10" font="4">692. Chase P, Arena R, Guazzi M, et al. Prognostic usefulness of the func-</text>
<text top="1069" left="90" width="324" height="10" font="4">tional aerobic reserve in patients with heart failure. Am Heart J 2010;</text>
<text top="1083" left="90" width="37" height="10" font="4">160:922</text>
<text top="1080" left="127" width="14" height="15" font="4">–7.</text>
<text top="103" left="450" width="295" height="10" font="4">693. Ferreira AM, Tabet JY, Frankenstein L, et al. Ventilatory ef</text>
<text top="100" left="745" width="54" height="15" font="4">ﬁciency and</text>
<text top="117" left="475" width="324" height="10" font="4">the selection of patients for heart transplantation. Circ Heart Fail 2010;3:</text>
<text top="132" left="475" width="17" height="10" font="4">378</text>
<text top="129" left="492" width="20" height="15" font="4">–86.</text>
<text top="146" left="450" width="350" height="10" font="4">694. Goda A, Lund LH, Mancini D. The Heart Failure Survival Score</text>
<text top="160" left="475" width="324" height="10" font="4">outperforms the peak oxygen consumption for heart transplantation</text>
<text top="174" left="475" width="324" height="10" font="4">selection in the era of device therapy. J Heart Lung Transplant 2011;30:</text>
<text top="188" left="475" width="17" height="10" font="4">315</text>
<text top="185" left="492" width="20" height="15" font="4">–25.</text>
<text top="203" left="450" width="350" height="10" font="4">695. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambula-</text>
<text top="217" left="475" width="324" height="10" font="4">tory patients with severe heart failure on beta-blocker therapy. Am J</text>
<text top="231" left="475" width="99" height="10" font="4">Cardiol 2003;92:1350</text>
<text top="228" left="575" width="14" height="15" font="4">–4.</text>
<text top="245" left="450" width="350" height="10" font="4">696. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise</text>
<text top="259" left="475" width="324" height="10" font="4">oxygen consumption for optimal timing of cardiac transplantation in</text>
<text top="274" left="475" width="287" height="10" font="4">ambulatory patients with heart failure. Circulation 1991;83:778</text>
<text top="271" left="763" width="20" height="15" font="4">–86.</text>
<text top="288" left="450" width="350" height="10" font="4">697. Klotz S, Deng MC, Hanafy D, et al. Reversible pulmonary hypertension</text>
<text top="302" left="475" width="324" height="10" font="4">in heart transplant candidates: pretransplant evaluation and outcome after</text>
<text top="316" left="475" width="275" height="10" font="4">orthotopic heart transplantation. Eur J Heart Fail 2003;5:645</text>
<text top="313" left="751" width="20" height="15" font="4">–53.</text>
<text top="330" left="450" width="350" height="10" font="4">698. Maron MS, Kalsmith BM, Udelson JE, et al. Survival after cardiac</text>
<text top="345" left="475" width="324" height="10" font="4">transplantation in patients with hypertrophic cardiomyopathy. Circ Heart</text>
<text top="359" left="475" width="72" height="10" font="4">Fail 2010;3:574</text>
<text top="356" left="547" width="14" height="15" font="4">–9.</text>
<text top="373" left="450" width="350" height="10" font="4">699. Rasmusson KD, Stehlik J, Brown RN, et al. Long-term outcomes of</text>
<text top="387" left="475" width="324" height="10" font="4">cardiac transplantation for peri-partum cardiomyopathy: a multiinstitu-</text>
<text top="401" left="475" width="248" height="10" font="4">tional analysis. J Heart Lung Transplant 2007;26:1097</text>
<text top="398" left="723" width="25" height="15" font="4">–104.</text>
<text top="416" left="450" width="145" height="10" font="4">700. Zangwill SD, Naftel D, L</text>
<text top="413" left="595" width="204" height="15" font="4">’Ecuyer T, et al. Outcomes of children with</text>
<text top="430" left="475" width="44" height="10" font="4">restrictive</text>
<text top="430" left="530" width="72" height="10" font="4">cardiomyopathy</text>
<text top="430" left="612" width="79" height="10" font="4">listed for heart</text>
<text top="430" left="701" width="99" height="10" font="4">transplant: a multi-</text>
<text top="444" left="475" width="264" height="10" font="4">institutional study. J Heart Lung Transplant 2009;28:1335</text>
<text top="441" left="740" width="20" height="15" font="4">–40.</text>
<text top="458" left="450" width="350" height="10" font="4">701. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in</text>
<text top="472" left="475" width="324" height="10" font="4">patients with sarcoid cardiomyopathy. J Heart Lung Transplant 2007;26:</text>
<text top="486" left="475" width="17" height="10" font="4">714</text>
<text top="483" left="492" width="14" height="15" font="4">–7.</text>
<text top="501" left="450" width="350" height="10" font="4">702. Wu RS, Gupta S, Brown RN, et al. Clinical outcomes after cardiac</text>
<text top="515" left="475" width="324" height="10" font="4">transplantation in muscular dystrophy patients. J Heart Lung Transplant</text>
<text top="529" left="475" width="56" height="10" font="4">2010;29:432</text>
<text top="526" left="532" width="14" height="15" font="4">–8.</text>
<text top="543" left="450" width="350" height="10" font="4">703. Fang J, Mensah GA, Croft JB, et al. Heart failure-related hospitalization</text>
<text top="557" left="475" width="268" height="10" font="4">in the U.S., 1979 to 2004. J Am Coll Cardiol 2008;52:428</text>
<text top="554" left="744" width="20" height="15" font="4">–34.</text>
<text top="572" left="450" width="350" height="10" font="4">704. Kociol RD, Hammill BG, Fonarow GC, et al. Generalizability and</text>
<text top="586" left="475" width="324" height="10" font="4">longitudinal outcomes of a national heart failure clinical registry:</text>
<text top="600" left="475" width="324" height="10" font="4">Comparison of Acute Decompensated Heart Failure National Registry</text>
<text top="614" left="475" width="222" height="10" font="4">(ADHERE) and non-ADHERE Medicare bene</text>
<text top="611" left="697" width="102" height="15" font="4">ﬁciaries. Am Heart J</text>
<text top="628" left="475" width="62" height="10" font="4">2010;160:885</text>
<text top="625" left="538" width="20" height="15" font="4">–92.</text>
<text top="643" left="450" width="350" height="10" font="4">705. Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure</text>
<text top="657" left="475" width="324" height="10" font="4">syndromes: emergency department presentation, treatment, and dispo-</text>
<text top="671" left="475" width="240" height="10" font="4">sition: current approaches and future aims: a scienti</text>
<text top="668" left="716" width="84" height="15" font="4">ﬁc statement from</text>
<text top="685" left="475" width="274" height="10" font="4">the American Heart Association. Circulation 2010;122:1975</text>
<text top="682" left="750" width="20" height="15" font="4">–96.</text>
<text top="699" left="450" width="350" height="10" font="4">706. Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in</text>
<text top="714" left="475" width="324" height="10" font="4">clinical characteristics, treatments, and outcomes for heart failure hospi-</text>
<text top="728" left="475" width="120" height="10" font="4">talizations, 2002 to 2004:</text>
<text top="725" left="600" width="199" height="15" font="4">ﬁndings from Acute Decompensated Heart</text>
<text top="742" left="475" width="295" height="10" font="4">Failure National Registry (ADHERE). Am Heart J 2007;153:1021</text>
<text top="739" left="771" width="14" height="15" font="4">–8.</text>
<text top="756" left="450" width="350" height="10" font="4">707. West R, Liang L, Fonarow GC, et al. Characterization of heart failure</text>
<text top="770" left="475" width="324" height="10" font="4">patients with preserved ejection fraction: a comparison between</text>
<text top="785" left="475" width="324" height="10" font="4">ADHERE-US registry and ADHERE-International registry. Eur J Heart</text>
<text top="799" left="475" width="77" height="10" font="4">Fail 2011;13:945</text>
<text top="796" left="553" width="20" height="15" font="4">–52.</text>
<text top="813" left="450" width="350" height="10" font="4">708. Baggish AL, van KR, Bayes-Genis A, et al. Hemoglobin and N-terminal</text>
<text top="827" left="475" width="324" height="10" font="4">pro-brain natriuretic peptide: independent and synergistic predictors of</text>
<text top="841" left="475" width="324" height="10" font="4">mortality in patients with acute heart failure: results from the Interna-</text>
<text top="856" left="475" width="324" height="10" font="4">tional Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta</text>
<text top="870" left="475" width="62" height="10" font="4">2007;381:145</text>
<text top="867" left="538" width="20" height="15" font="4">–50.</text>
<text top="884" left="450" width="350" height="10" font="4">709. Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prog-</text>
<text top="898" left="475" width="324" height="10" font="4">nostic value of persistent hyponatremia in patients with severe heart</text>
<text top="912" left="475" width="283" height="10" font="4">failure in the ESCAPE Trial. Arch Intern Med 2007;167:1998</text>
<text top="909" left="758" width="31" height="15" font="4">–2005.</text>
<text top="927" left="450" width="350" height="10" font="4">710. Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of</text>
<text top="941" left="475" width="324" height="10" font="4">renal dysfunction and its impact on outcome in 118,465 patients</text>
<text top="955" left="475" width="324" height="10" font="4">hospitalized with acute decompensated heart failure: a report from the</text>
<text top="969" left="475" width="204" height="10" font="4">ADHERE database. J Card Fail 2007;13:422</text>
<text top="966" left="680" width="20" height="15" font="4">–30.</text>
<text top="983" left="450" width="350" height="10" font="4">711. Mohammed AA, van Kimmenade RR, Richards M, et al. Hyponatremia,</text>
<text top="998" left="475" width="324" height="10" font="4">natriuretic peptides, and outcomes in acutely decompensated heart</text>
<text top="1012" left="475" width="324" height="10" font="4">failure: results from the International Collaborative of NT-proBNP</text>
<text top="1026" left="475" width="155" height="10" font="4">Study. Circ Heart Fail 2010;3:354</text>
<text top="1023" left="631" width="20" height="15" font="4">–61.</text>
<text top="1040" left="450" width="350" height="10" font="4">712. van Kimmenade RR, Januzzi JL Jr., Baggish AL, et al. Amino-terminal</text>
<text top="1054" left="475" width="324" height="10" font="4">pro-brain natriuretic Peptide, renal function, and outcomes in acute heart</text>
<text top="1069" left="475" width="54" height="10" font="4">failure: rede</text>
<text top="1066" left="530" width="270" height="15" font="4">ﬁning the cardiorenal interaction? J Am Coll Cardiol 2006;</text>
<text top="1083" left="475" width="37" height="10" font="4">48:1621</text>
<text top="1080" left="512" width="14" height="15" font="4">–7.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e226</text>
</page>
<page number="81" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="350" height="10" font="4">713. van Kimmenade RR, Mohammed AA, Uthamalingam S, et al. Red blood</text>
<text top="117" left="90" width="324" height="10" font="4">cell distribution width and 1-year mortality in acute heart failure. Eur J</text>
<text top="132" left="90" width="106" height="10" font="4">Heart Fail 2010;12:129</text>
<text top="129" left="196" width="20" height="15" font="4">–36.</text>
<text top="146" left="64" width="350" height="10" font="4">714. Sweitzer NK, Lopatin M, Yancy CW, et al. Comparison of clinical</text>
<text top="160" left="90" width="324" height="10" font="4">features and outcomes of patients hospitalized with heart failure and</text>
<text top="174" left="90" width="114" height="10" font="4">normal ejection fraction (</text>
<text top="171" left="204" width="210" height="15" font="4">&gt; or ¼55%) versus those with mildly reduced</text>
<text top="188" left="90" width="228" height="10" font="4">(40% to 55%) and moderately to severely reduced (</text>
<text top="185" left="318" width="96" height="15" font="4">&lt;40%) fractions. Am</text>
<text top="203" left="90" width="113" height="10" font="4">J Cardiol 2008;101:1151</text>
<text top="200" left="203" width="14" height="15" font="4">–6.</text>
<text top="217" left="64" width="350" height="10" font="4">715. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation,</text>
<text top="231" left="90" width="324" height="10" font="4">management, and in-hospital outcomes of patients admitted with acute</text>
<text top="245" left="90" width="324" height="10" font="4">decompensated heart failure with preserved systolic function: a report</text>
<text top="259" left="90" width="324" height="10" font="4">from the Acute Decompensated Heart Failure National Registry</text>
<text top="274" left="90" width="243" height="10" font="4">(ADHERE) Database. J Am Coll Cardiol 2006;47:76</text>
<text top="271" left="333" width="20" height="15" font="4">–84.</text>
<text top="288" left="64" width="350" height="10" font="4">716. Nohria A, Lewis E, Stevenson LW. Medical management of advanced</text>
<text top="302" left="90" width="157" height="10" font="4">heart failure. JAMA 2002;287:628</text>
<text top="299" left="247" width="20" height="15" font="4">–40.</text>
<text top="316" left="64" width="350" height="10" font="4">717. Martinez-Rumayor AA, Vazquez J, Rehman SU, et al. Relative value of</text>
<text top="330" left="90" width="324" height="10" font="4">amino-terminal pro-B-type natriuretic peptide testing and radiographic</text>
<text top="345" left="90" width="324" height="10" font="4">standards for the diagnostic evaluation of heart failure in acutely</text>
<text top="359" left="90" width="198" height="10" font="4">dyspneic subjects. Biomarkers 2010;15:175</text>
<text top="356" left="288" width="20" height="15" font="4">–82.</text>
<text top="373" left="64" width="350" height="10" font="4">718. Januzzi JL Jr., Camargo CA, Anwaruddin S, et al. The N-terminal Pro-</text>
<text top="387" left="90" width="324" height="10" font="4">BNP investigation of dyspnea in the emergency department (PRIDE)</text>
<text top="401" left="90" width="153" height="10" font="4">study. Am J Cardiol 2005;95:948</text>
<text top="398" left="243" width="20" height="15" font="4">–54.</text>
<text top="416" left="64" width="350" height="10" font="4">719. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing</text>
<text top="430" left="90" width="324" height="10" font="4">for diagnosis and short-term prognosis in acute destabilized heart failure:</text>
<text top="444" left="90" width="324" height="10" font="4">an international pooled analysis of 1256 patients: the International</text>
<text top="458" left="90" width="281" height="10" font="4">Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330</text>
<text top="455" left="371" width="14" height="15" font="4">–7.</text>
<text top="472" left="64" width="350" height="10" font="4">720. Green SM, Martinez-Rumayor A, Gregory SA, et al. Clinical uncer-</text>
<text top="486" left="90" width="324" height="10" font="4">tainty, diagnostic accuracy, and outcomes in emergency department</text>
<text top="501" left="90" width="297" height="10" font="4">patients presenting with dyspnea. Arch Intern Med 2008;168:741</text>
<text top="498" left="387" width="14" height="15" font="4">–8.</text>
<text top="515" left="64" width="350" height="10" font="4">721. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide</text>
<text top="529" left="90" width="324" height="10" font="4">and clinical judgment in emergency diagnosis of heart failure: analysis</text>
<text top="543" left="90" width="324" height="10" font="4">from Breathing Not Properly (BNP) Multinational Study. Circulation</text>
<text top="557" left="90" width="62" height="10" font="4">2002;106:416</text>
<text top="554" left="152" width="20" height="15" font="4">–22.</text>
<text top="572" left="64" width="350" height="10" font="4">722. Steinhart B, Thorpe KE, Bayoumi AM, et al. Improving the diagnosis of</text>
<text top="586" left="90" width="324" height="10" font="4">acute heart failure using a validated prediction model. J Am Coll Cardiol</text>
<text top="600" left="90" width="62" height="10" font="4">2009;54:1515</text>
<text top="597" left="152" width="20" height="15" font="4">–21.</text>
<text top="614" left="64" width="350" height="10" font="4">723. Collins SP, Peacock WF, Lindsell CJ, et al. S3 detection as a diagnostic</text>
<text top="628" left="90" width="324" height="10" font="4">and prognostic aid in emergency department patients with acute dysp-</text>
<text top="643" left="90" width="159" height="10" font="4">nea. Ann Emerg Med 2009;53:748</text>
<text top="640" left="249" width="20" height="15" font="4">–57.</text>
<text top="657" left="64" width="350" height="10" font="4">724. Di Somma S, De Berardinis B, Bongiovanni C, et al. Use of BNP and</text>
<text top="671" left="90" width="324" height="10" font="4">bioimpedance to drive therapy in heart failure patients. Congest Heart</text>
<text top="685" left="90" width="117" height="10" font="4">Fail 2010;16 Suppl 1:S56</text>
<text top="682" left="207" width="20" height="15" font="4">–61.</text>
<text top="699" left="64" width="350" height="10" font="4">725. Cotter G, Moshkovitz Y, Kaluski E, et al. Accurate, noninvasive</text>
<text top="714" left="90" width="324" height="10" font="4">continuous monitoring of cardiac output by whole-body electrical bio-</text>
<text top="728" left="90" width="151" height="10" font="4">impedance. Chest 2004;125:1431</text>
<text top="725" left="241" width="20" height="15" font="4">–40.</text>
<text top="742" left="64" width="350" height="10" font="4">726. Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in</text>
<text top="756" left="90" width="324" height="10" font="4">patients with coronary artery disease early assessment and treatment.</text>
<text top="770" left="90" width="145" height="10" font="4">J Am Coll Cardiol 2009;53:254</text>
<text top="767" left="235" width="20" height="15" font="4">–63.</text>
<text top="785" left="64" width="350" height="10" font="4">727. Kociol RD, Pang PS, Gheorghiade M, et al. Troponin elevation in heart</text>
<text top="799" left="90" width="324" height="10" font="4">failure prevalence, mechanisms, and clinical implications. J Am Coll</text>
<text top="813" left="90" width="99" height="10" font="4">Cardiol 2010;56:1071</text>
<text top="810" left="189" width="14" height="15" font="4">–8.</text>
<text top="827" left="64" width="350" height="10" font="4">728. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma</text>
<text top="841" left="90" width="324" height="10" font="4">concentrations of troponin T in patients with stable chronic heart failure.</text>
<text top="856" left="90" width="121" height="10" font="4">Circulation 2007;116:1242</text>
<text top="853" left="211" width="14" height="15" font="4">–9.</text>
<text top="870" left="64" width="350" height="10" font="4">729. Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes</text>
<text top="884" left="90" width="324" height="10" font="4">in acute decompensated heart failure: an ADHERE analysis. Emerg Med</text>
<text top="898" left="90" width="64" height="10" font="4">J 2008;25:205</text>
<text top="895" left="154" width="14" height="15" font="4">–9.</text>
<text top="912" left="64" width="318" height="10" font="4">730. Fonarow GC, Abraham WT, Albert NM, et al. Factors identi</text>
<text top="909" left="383" width="31" height="15" font="4">ﬁed as</text>
<text top="927" left="90" width="56" height="10" font="4">precipitating</text>
<text top="927" left="156" width="35" height="10" font="4">hospital</text>
<text top="927" left="201" width="49" height="10" font="4">admissions</text>
<text top="927" left="261" width="13" height="10" font="4">for</text>
<text top="927" left="284" width="22" height="10" font="4">heart</text>
<text top="927" left="316" width="29" height="10" font="4">failure</text>
<text top="927" left="355" width="16" height="10" font="4">and</text>
<text top="927" left="382" width="32" height="10" font="4">clinical</text>
<text top="941" left="90" width="46" height="10" font="4">outcomes:</text>
<text top="938" left="140" width="274" height="15" font="4">ﬁndings from OPTIMIZE-HF. Arch Intern Med 2008;168:</text>
<text top="955" left="90" width="17" height="10" font="4">847</text>
<text top="952" left="107" width="20" height="15" font="4">–54.</text>
<text top="969" left="64" width="350" height="10" font="4">731. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure</text>
<text top="983" left="90" width="324" height="10" font="4">at admission, clinical characteristics, and outcomes in patients hospi-</text>
<text top="998" left="90" width="247" height="10" font="4">talized with acute heart failure. JAMA 2006;296:2217</text>
<text top="995" left="336" width="20" height="15" font="4">–26.</text>
<text top="1012" left="64" width="350" height="10" font="4">732. Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe</text>
<text top="1026" left="90" width="264" height="10" font="4">sepsis and septic shock. Curr Opin Crit Care 2009;15:392</text>
<text top="1023" left="354" width="14" height="15" font="4">–7.</text>
<text top="1040" left="64" width="350" height="10" font="4">733. Klemperer JD, Ojamaa K, Klein I. Thyroid hormone therapy in</text>
<text top="1054" left="90" width="261" height="10" font="4">cardiovascular disease. Prog Cardiovasc Dis 1996;38:329</text>
<text top="1051" left="351" width="20" height="15" font="4">–36.</text>
<text top="1069" left="64" width="350" height="10" font="4">734. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan</text>
<text top="1083" left="90" width="324" height="10" font="4">and placebo and outcomes in chronic heart failure in the CHARM</text>
<text top="103" left="476" width="324" height="10" font="4">programme: double-blind, randomised, controlled clinical trial. Lancet</text>
<text top="117" left="476" width="68" height="10" font="4">2005;366:2005</text>
<text top="114" left="543" width="20" height="15" font="4">–11.</text>
<text top="132" left="450" width="350" height="10" font="4">735. Metra M, Torp-Pedersen C, Cleland JG, et al. Should beta-blocker</text>
<text top="146" left="475" width="324" height="10" font="4">therapy be reduced or withdrawn after an episode of decompensated</text>
<text top="160" left="475" width="298" height="10" font="4">heart failure? Results from COMET. Eur J Heart Fail 2007;9:901</text>
<text top="157" left="774" width="14" height="15" font="4">–9.</text>
<text top="174" left="450" width="350" height="10" font="4">736. Butler J, Young JB, Abraham WT, et al. Beta-blocker use and outcomes</text>
<text top="188" left="475" width="324" height="10" font="4">among hospitalized heart failure patients. J Am Coll Cardiol 2006;47:</text>
<text top="203" left="475" width="22" height="10" font="4">2462</text>
<text top="200" left="498" width="14" height="15" font="4">–9.</text>
<text top="217" left="450" width="350" height="10" font="4">737. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive</text>
<text top="231" left="475" width="324" height="10" font="4">B-type natriuretic peptide levels and treatment delay in acute decom-</text>
<text top="245" left="475" width="324" height="10" font="4">pensated heart failure: an ADHERE (Acute Decompensated Heart</text>
<text top="259" left="475" width="304" height="10" font="4">Failure National Registry) analysis. J Am Coll Cardiol 2008;52:534</text>
<text top="256" left="780" width="20" height="15" font="4">–40.</text>
<text top="274" left="450" width="350" height="10" font="4">738. Peacock WF, Fonarow GC, Emerman CL, et al. Impact of early initiation</text>
<text top="288" left="475" width="324" height="10" font="4">of intravenous therapy for acute decompensated heart failure on</text>
<text top="302" left="475" width="221" height="10" font="4">outcomes in ADHERE. Cardiology 2007;107:44</text>
<text top="299" left="696" width="20" height="15" font="4">–51.</text>
<text top="316" left="450" width="350" height="10" font="4">739. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients</text>
<text top="330" left="475" width="324" height="10" font="4">with acute decompensated heart failure. N Engl J Med 2011;364:</text>
<text top="345" left="475" width="17" height="10" font="4">797</text>
<text top="342" left="492" width="25" height="15" font="4">–805.</text>
<text top="359" left="450" width="350" height="10" font="4">740. Grosskopf I, Rabinovitz M, Rosenfeld JB. Combination of furosemide</text>
<text top="373" left="475" width="324" height="10" font="4">and metolazone in the treatment of severe congestive heart failure. Isr J</text>
<text top="387" left="475" width="99" height="10" font="4">Med Sci 1986;22:787</text>
<text top="384" left="574" width="20" height="15" font="4">–90.</text>
<text top="401" left="450" width="350" height="10" font="4">741. Channer KS, McLean KA, Lawson-Matthew P, et al. Combination</text>
<text top="416" left="475" width="324" height="10" font="4">diuretic treatment in severe heart failure: a randomised controlled trial.</text>
<text top="430" left="475" width="108" height="10" font="4">Br Heart J 1994;71:146</text>
<text top="427" left="583" width="20" height="15" font="4">–50.</text>
<text top="444" left="450" width="350" height="10" font="4">742. Sigurd B, Olesen KH, Wennevold A. The supra-additive natriuretic</text>
<text top="458" left="475" width="118" height="10" font="4">effect addition of bendro</text>
<text top="455" left="593" width="206" height="15" font="4">ﬂumethiazide and bumetanide in congestive</text>
<text top="472" left="475" width="324" height="10" font="4">heart failure: permutation trial tests in patients in long-term treatment</text>
<text top="486" left="475" width="195" height="10" font="4">with bumetanide. Am Heart J 1975;89:163</text>
<text top="483" left="670" width="20" height="15" font="4">–70.</text>
<text top="501" left="450" width="350" height="10" font="4">743. Rosenberg J, Gustafsson F, Galatius S, et al. Combination therapy with</text>
<text top="515" left="475" width="324" height="10" font="4">metolazone and loop diuretics in outpatients with refractory heart failure:</text>
<text top="529" left="475" width="324" height="10" font="4">an observational study and review of the literature. Cardiovasc Drugs</text>
<text top="543" left="475" width="81" height="10" font="4">Ther 2005;19:301</text>
<text top="540" left="557" width="14" height="15" font="4">–6.</text>
<text top="557" left="450" width="350" height="10" font="4">744. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion</text>
<text top="572" left="475" width="324" height="10" font="4">on renal function in hospitalized heart failure patients: results of the</text>
<text top="586" left="475" width="324" height="10" font="4">Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial.</text>
<text top="600" left="475" width="111" height="10" font="4">J Card Fail 2010;16:922</text>
<text top="597" left="586" width="20" height="15" font="4">–30.</text>
<text top="614" left="450" width="350" height="10" font="4">745. Elkayam U, Ng TM, Hatamizadeh P, et al. Renal vasodilatory action of</text>
<text top="628" left="475" width="324" height="10" font="4">dopamine in patients with heart failure: magnitude of effect and site of</text>
<text top="643" left="475" width="149" height="10" font="4">action. Circulation 2008;117:200</text>
<text top="640" left="625" width="14" height="15" font="4">–5.</text>
<text top="657" left="450" width="350" height="10" font="4">746. Cleland JG, Coletta A, Witte K. Practical applications of intravenous</text>
<text top="671" left="475" width="324" height="10" font="4">diuretic therapy in decompensated heart failure. Am J Med 2006;119:</text>
<text top="685" left="475" width="17" height="10" font="4">S26</text>
<text top="682" left="493" width="20" height="15" font="4">–36.</text>
<text top="699" left="450" width="350" height="10" font="4">747. Vasko MR, Cartwright DB, Knochel JP, et al. Furosemide absorption</text>
<text top="714" left="475" width="324" height="10" font="4">altered in decompensated congestive heart failure. Ann Intern Med 1985;</text>
<text top="728" left="475" width="37" height="10" font="4">102:314</text>
<text top="725" left="512" width="14" height="15" font="4">–8.</text>
<text top="742" left="450" width="350" height="10" font="4">748. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to</text>
<text top="756" left="475" width="324" height="10" font="4">furosemide, I: effects of salt intake and renal compensation. J Lab Clin</text>
<text top="770" left="475" width="86" height="10" font="4">Med 1983;102:450</text>
<text top="767" left="562" width="14" height="15" font="4">–8.</text>
<text top="785" left="450" width="350" height="10" font="4">749. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct</text>
<text top="799" left="475" width="293" height="10" font="4">cause of renal sodium retention in oedema? Lancet 1988;1:1033</text>
<text top="796" left="768" width="14" height="15" font="4">–5.</text>
<text top="813" left="450" width="350" height="10" font="4">750. Pivac N, Rumboldt Z, Sardelic S, et al. Diuretic effects of furosemide</text>
<text top="827" left="475" width="324" height="10" font="4">infusion versus bolus injection in congestive heart failure. Int J Clin</text>
<text top="841" left="475" width="128" height="10" font="4">Pharmacol Res 1998;18:121</text>
<text top="838" left="603" width="14" height="15" font="4">–8.</text>
<text top="856" left="450" width="350" height="10" font="4">751. Salvador DR, Rey NR, Ramos GC, et al. Continuous infusion versus</text>
<text top="870" left="475" width="324" height="10" font="4">bolus injection of loop diuretics in congestive heart failure. Cochrane</text>
<text top="884" left="475" width="183" height="10" font="4">Database Syst Rev 2005;(3):CD003178.</text>
<text top="898" left="450" width="278" height="10" font="4">752. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultra</text>
<text top="895" left="728" width="71" height="15" font="4">ﬁltration versus</text>
<text top="912" left="475" width="324" height="10" font="4">intravenous diuretics for patients hospitalized for acute decompensated</text>
<text top="927" left="475" width="206" height="10" font="4">heart failure. J Am Coll Cardiol 2007;49:675</text>
<text top="924" left="681" width="20" height="15" font="4">–83.</text>
<text top="941" left="450" width="213" height="10" font="4">753. Bart BA, Boyle A, Bank AJ, et al. Ultra</text>
<text top="938" left="662" width="137" height="15" font="4">ﬁltration versus usual care for</text>
<text top="955" left="475" width="324" height="10" font="4">hospitalized patients with heart failure: the Relief for Acutely Fluid-</text>
<text top="969" left="475" width="324" height="10" font="4">Overloaded Patients With Decompensated Congestive Heart Failure</text>
<text top="983" left="475" width="244" height="10" font="4">(RAPID-CHF) trial. J Am Coll Cardiol 2005;46:2043</text>
<text top="980" left="720" width="14" height="15" font="4">–6.</text>
<text top="998" left="450" width="156" height="10" font="4">754. Bourge RC, Tallaj JA. Ultra</text>
<text top="995" left="605" width="194" height="15" font="4">ﬁltration: a new approach toward mechan-</text>
<text top="1012" left="475" width="282" height="10" font="4">ical diuresis in heart failure. J Am Coll Cardiol 2005;46:2052</text>
<text top="1009" left="757" width="14" height="15" font="4">–3.</text>
<text top="1026" left="450" width="350" height="10" font="4">755. Jaski BE, Ha J, Denys BG, et al. Peripherally inserted veno-venous</text>
<text top="1040" left="475" width="20" height="10" font="4">ultra</text>
<text top="1037" left="496" width="304" height="15" font="4">ﬁltration for rapid treatment of volume overloaded patients.</text>
<text top="1054" left="475" width="105" height="10" font="4">J Card Fail 2003;9:227</text>
<text top="1051" left="580" width="20" height="15" font="4">–31.</text>
<text top="1069" left="450" width="160" height="10" font="4">756. Costanzo M, Saltzburg M, O</text>
<text top="1066" left="609" width="190" height="15" font="4">’Sullivan J, et al. EUPHORIA trial: early</text>
<text top="1083" left="475" width="20" height="10" font="4">ultra</text>
<text top="1080" left="496" width="304" height="15" font="4">ﬁltration therapy in patients with decompensated heart failure and</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e227</text>
</page>
<page number="82" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="90" width="324" height="10" font="4">observed resistance to intervention with diuretic agents. J Card Fail</text>
<text top="117" left="90" width="90" height="10" font="4">2004;10 Suppl:S78.</text>
<text top="132" left="64" width="350" height="10" font="4">757. Bart B, Boyle A, Bank A, et al. Randomized controlled trial of ultra-</text>
<text top="143" left="90" width="324" height="15" font="4">ﬁltration versus usual care for hospitalized patients with heart failure:</text>
<text top="160" left="90" width="318" height="10" font="4">preliminary report of the Rapid Trial. J Card Fail 2004;10 Suppl:S23.</text>
<text top="174" left="64" width="350" height="10" font="4">758. Bart BA, Goldsmith SR, Lee KL, et al. Cardiorenal rescue study in</text>
<text top="188" left="90" width="324" height="10" font="4">acute decompensated heart failure: rationale and design of CARRESS-HF,</text>
<text top="203" left="90" width="324" height="10" font="4">for the Heart Failure Clinical Research Network. J Card Fail 2012;18:</text>
<text top="217" left="90" width="17" height="10" font="4">176</text>
<text top="214" left="107" width="20" height="15" font="4">–82.</text>
<text top="231" left="64" width="228" height="10" font="4">759. Bart BA, Goldsmith SR, Lee KL, et al. Ultra</text>
<text top="228" left="292" width="122" height="15" font="4">ﬁltration in decompensated</text>
<text top="245" left="90" width="324" height="10" font="4">heart failure with cardiorenal syndrome. N Engl J Med 2012;367:</text>
<text top="259" left="90" width="22" height="10" font="4">2296</text>
<text top="256" left="112" width="25" height="15" font="4">–304.</text>
<text top="274" left="64" width="350" height="10" font="4">760. Colucci WS, Elkayam U, Horton DP, et al., Nesiritide Study Group.</text>
<text top="288" left="90" width="324" height="10" font="4">Intravenous nesiritide, a natriuretic peptide, in the treatment of decom-</text>
<text top="302" left="90" width="275" height="10" font="4">pensated congestive heart failure. N Engl J Med 2000;343:246</text>
<text top="299" left="365" width="49" height="15" font="4">–53. Errata</text>
<text top="316" left="90" width="299" height="10" font="4">in: N Engl J Med 2000;343:1504 and N Engl J Med 2000;343:896.</text>
<text top="330" left="64" width="45" height="10" font="4">761. Ciof</text>
<text top="327" left="110" width="304" height="15" font="4">ﬁ G, Stefenelli C, Tarantini L, et al. Hemodynamic response to</text>
<text top="345" left="90" width="324" height="10" font="4">intensive unloading therapy (furosemide and nitroprusside) in patients</text>
<text top="356" left="90" width="324" height="15" font="4">&gt;70 years of age with left ventricular systolic dysfunction and decom-</text>
<text top="373" left="90" width="268" height="10" font="4">pensated chronic heart failure. Am J Cardiol 2003;92:1050</text>
<text top="370" left="358" width="14" height="15" font="4">–6.</text>
<text top="387" left="64" width="34" height="10" font="4">762. O</text>
<text top="384" left="98" width="316" height="15" font="4">’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in</text>
<text top="401" left="90" width="324" height="10" font="4">patients with acute decompensated heart failure. N Engl J Med 2011;</text>
<text top="416" left="90" width="31" height="10" font="4">365:32</text>
<text top="413" left="121" width="20" height="15" font="4">–43.</text>
<text top="430" left="64" width="350" height="10" font="4">763. Publication Committee for the VMAC Investigators. Intravenous</text>
<text top="444" left="90" width="324" height="10" font="4">nesiritide vs nitroglycerin for treatment of decompensated congestive</text>
<text top="458" left="90" width="304" height="10" font="4">heart failure: a randomized controlled trial. JAMA 2002;287:1531</text>
<text top="455" left="394" width="20" height="15" font="4">–40.</text>
<text top="472" left="90" width="154" height="10" font="4">Erratum in: JAMA 2002;288:577.</text>
<text top="486" left="64" width="350" height="10" font="4">764. Elkayam U, Akhter MW, Singh H, et al. Comparison of effects on left</text>
<text top="501" left="90" width="48" height="10" font="4">ventricular</text>
<text top="498" left="145" width="269" height="15" font="4">ﬁlling pressure of intravenous nesiritide and high-dose</text>
<text top="515" left="90" width="324" height="10" font="4">nitroglycerin in patients with decompensated heart failure. Am J Car-</text>
<text top="529" left="90" width="77" height="10" font="4">diol 2004;93:237</text>
<text top="526" left="167" width="20" height="15" font="4">–40.</text>
<text top="543" left="64" width="350" height="10" font="4">765. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose</text>
<text top="557" left="90" width="324" height="10" font="4">isosorbide dinitrate plus low-dose furosemide versus high-dose furose-</text>
<text top="572" left="90" width="324" height="10" font="4">mide plus low-dose isosorbide dinitrate in severe pulmonary oedema.</text>
<text top="586" left="90" width="96" height="10" font="4">Lancet 1998;351:389</text>
<text top="583" left="186" width="20" height="15" font="4">–93.</text>
<text top="600" left="64" width="350" height="10" font="4">766. Elkayam U, Kulick D, McIntosh N, et al. Incidence of early tolerance to</text>
<text top="614" left="90" width="324" height="10" font="4">hemodynamic effects of continuous infusion of nitroglycerin in patients</text>
<text top="628" left="90" width="324" height="10" font="4">with coronary artery disease and heart failure. Circulation 1987;76:</text>
<text top="643" left="90" width="17" height="10" font="4">577</text>
<text top="640" left="107" width="20" height="15" font="4">–84.</text>
<text top="657" left="64" width="350" height="10" font="4">767. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous</text>
<text top="671" left="90" width="324" height="10" font="4">nitroglycerin in patients with congestive heart failure: role of increased</text>
<text top="685" left="90" width="324" height="10" font="4">intravascular volume, neurohumoral activation and lack of prevention</text>
<text top="699" left="90" width="249" height="10" font="4">with N-acetylcysteine. J Am Coll Cardiol 1990;16:923</text>
<text top="696" left="339" width="20" height="15" font="4">–31.</text>
<text top="714" left="64" width="350" height="10" font="4">768. Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs</text>
<text top="728" left="90" width="76" height="10" font="4">Ther 1994;8:489</text>
<text top="725" left="165" width="20" height="15" font="4">–99.</text>
<text top="742" left="64" width="350" height="10" font="4">769. Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for</text>
<text top="756" left="90" width="304" height="10" font="4">advanced low-output heart failure. J Am Coll Cardiol 2008;52:200</text>
<text top="753" left="394" width="14" height="15" font="4">–7.</text>
<text top="770" left="64" width="350" height="10" font="4">770. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous throm-</text>
<text top="785" left="90" width="324" height="10" font="4">boembolism in medical patients with enoxaparin: a subgroup analysis of</text>
<text top="799" left="90" width="288" height="10" font="4">the MEDENOX study. Blood Coagul Fibrinolysis 2003;14:341</text>
<text top="796" left="378" width="14" height="15" font="4">–6.</text>
<text top="813" left="64" width="350" height="10" font="4">771. Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis</text>
<text top="827" left="90" width="304" height="10" font="4">in medical patients by low-dose heparin. Scott Med J 1981;26:115</text>
<text top="824" left="394" width="14" height="15" font="4">–7.</text>
<text top="841" left="64" width="350" height="10" font="4">772. Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enox-</text>
<text top="856" left="90" width="324" height="10" font="4">aparin with unfractionated heparin for the prevention of venous throm-</text>
<text top="870" left="90" width="324" height="10" font="4">boembolism in medical patients with heart failure or severe respiratory</text>
<text top="884" left="90" width="157" height="10" font="4">disease. Am Heart J 2003;145:614</text>
<text top="881" left="247" width="20" height="15" font="4">–21.</text>
<text top="898" left="64" width="350" height="10" font="4">773. Samama MM, Cohen AT, Darmon JY, et al., Prophylaxis in Medical</text>
<text top="912" left="90" width="324" height="10" font="4">Patients with Enoxaparin Study Group. A comparison of enoxaparin</text>
<text top="927" left="90" width="324" height="10" font="4">with placebo for the prevention of venous thromboembolism in acutely</text>
<text top="941" left="90" width="223" height="10" font="4">ill medical patients. N Engl J Med 1999;341:793</text>
<text top="938" left="313" width="25" height="15" font="4">–800.</text>
<text top="955" left="64" width="350" height="10" font="4">774. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient:</text>
<text top="969" left="90" width="324" height="10" font="4">insights from the prophylaxis in MEDical patients with ENOXaparin</text>
<text top="983" left="90" width="217" height="10" font="4">(MEDENOX) trial. Am J Cardiol 2000;86:48M</text>
<text top="980" left="307" width="29" height="15" font="4">–52M.</text>
<text top="998" left="64" width="102" height="10" font="4">775. Deleted in press.</text>
<text top="1012" left="64" width="350" height="10" font="4">776. Cohen AT, Turpie AG, Leizorovicz A, et al. Thromboprophylaxis with</text>
<text top="1026" left="90" width="231" height="10" font="4">dalteparin in medical patients: which patients bene</text>
<text top="1023" left="321" width="93" height="15" font="4">ﬁt? Vasc Med 2007;</text>
<text top="1040" left="90" width="31" height="10" font="4">12:123</text>
<text top="1037" left="121" width="14" height="15" font="4">–7.</text>
<text top="1054" left="64" width="350" height="10" font="4">777. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-</text>
<text top="1069" left="90" width="324" height="10" font="4">controlled trial of dalteparin for the prevention of venous thromboem-</text>
<text top="1083" left="90" width="290" height="10" font="4">bolism in acutely ill medical patients. Circulation 2004;110:874</text>
<text top="1080" left="380" width="14" height="15" font="4">–9.</text>
<text top="103" left="450" width="350" height="10" font="4">778. Anderson GM, Hull E. The effect of dicumarol upon the mortality and</text>
<text top="117" left="476" width="324" height="10" font="4">incidence of thromboembolic complications in congestive heart failure.</text>
<text top="132" left="476" width="113" height="10" font="4">Am Heart J 1950;39:697</text>
<text top="129" left="589" width="25" height="15" font="4">–702.</text>
<text top="146" left="450" width="44" height="10" font="4">779. Grif</text>
<text top="143" left="494" width="306" height="15" font="4">ﬁth GC, Stragnell R, Levinson DC, et al. A study of the beneﬁcial</text>
<text top="160" left="475" width="324" height="10" font="4">effects of anticoagulant therapy in congestive heart failure. Ann Intern</text>
<text top="174" left="475" width="81" height="10" font="4">Med 1952;37:867</text>
<text top="171" left="556" width="20" height="15" font="4">–87.</text>
<text top="188" left="450" width="350" height="10" font="4">780. Harvey WP, Finch CA. Dicumarol prophylaxis of thromboembolic</text>
<text top="203" left="475" width="291" height="10" font="4">disease in congestive heart failure. N Engl J Med 1950;242:208</text>
<text top="200" left="767" width="20" height="15" font="4">–11.</text>
<text top="217" left="450" width="238" height="10" font="4">781. Cohen AT, Davidson BL, Gallus AS, et al. Ef</text>
<text top="214" left="688" width="112" height="15" font="4">ﬁcacy and safety of fon-</text>
<text top="231" left="475" width="324" height="10" font="4">daparinux for the prevention of venous thromboembolism in older acute</text>
<text top="245" left="475" width="324" height="10" font="4">medical patients: randomised placebo controlled trial. BMJ 2006;332:</text>
<text top="259" left="475" width="17" height="10" font="4">325</text>
<text top="256" left="492" width="14" height="15" font="4">–9.</text>
<text top="274" left="450" width="350" height="10" font="4">782. Wojnicz R, Nowak J, Szygula-Jurkiewicz B, et al. Adjunctive therapy</text>
<text top="288" left="475" width="324" height="10" font="4">with low-molecular-weight heparin in patients with chronic heart failure</text>
<text top="302" left="475" width="324" height="10" font="4">secondary to dilated cardiomyopathy: one-year follow-up results of the</text>
<text top="316" left="475" width="212" height="10" font="4">randomized trial. Am Heart J 2006;152:713.e1</text>
<text top="313" left="688" width="14" height="15" font="4">–7.</text>
<text top="330" left="450" width="350" height="10" font="4">783. Tebbe U, Schellong SM, Haas S, et al. Certoparin versus unfractionated</text>
<text top="345" left="475" width="324" height="10" font="4">heparin to prevent venous thromboembolic events in patients hospital-</text>
<text top="359" left="475" width="324" height="10" font="4">ized because of heart failure: a subgroup analysis of the randomized,</text>
<text top="373" left="475" width="248" height="10" font="4">controlled CERTIFY study. Am Heart J 2011;161:322</text>
<text top="370" left="724" width="14" height="15" font="4">–8.</text>
<text top="387" left="450" width="350" height="10" font="4">784. Lederle FA, Zylla D, MacDonald R, et al. Venous thromboembolism</text>
<text top="401" left="475" width="324" height="10" font="4">prophylaxis in hospitalized medical patients and those with stroke:</text>
<text top="416" left="475" width="324" height="10" font="4">a background review for an American College of Physicians Clinical</text>
<text top="430" left="475" width="229" height="10" font="4">Practice Guideline. Ann Intern Med 2011;155:602</text>
<text top="427" left="704" width="20" height="15" font="4">–15.</text>
<text top="444" left="450" width="350" height="10" font="4">785. Dennis M, Sandercock PA, Reid J, et al. Effectiveness of thigh-length</text>
<text top="458" left="475" width="324" height="10" font="4">graduated compression stockings to reduce the risk of deep vein</text>
<text top="472" left="475" width="324" height="10" font="4">thrombosis after stroke (CLOTS trial 1): a multicentre, randomised</text>
<text top="486" left="475" width="174" height="10" font="4">controlled trial. Lancet 2009;373:1958</text>
<text top="483" left="650" width="20" height="15" font="4">–65.</text>
<text top="501" left="450" width="350" height="10" font="4">786. Muir KW, Watt A, Baxter G, et al. Randomized trial of graded</text>
<text top="515" left="475" width="324" height="10" font="4">compression stockings for prevention of deep-vein thrombosis after</text>
<text top="529" left="475" width="143" height="10" font="4">acute stroke. QJM 2000;93:359</text>
<text top="526" left="619" width="20" height="15" font="4">–64.</text>
<text top="543" left="450" width="215" height="10" font="4">787. Ghali JK, Koren MJ, Taylor JR, et al. Ef</text>
<text top="540" left="665" width="135" height="15" font="4">ﬁcacy and safety of oral con-</text>
<text top="557" left="475" width="324" height="10" font="4">ivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in</text>
<text top="572" left="475" width="324" height="10" font="4">a randomized, placebo-controlled trial in patients with euvolemic or</text>
<text top="586" left="475" width="304" height="10" font="4">hypervolemic hyponatremia. J Clin Endocrinol Metab 2006;91:2145</text>
<text top="583" left="780" width="20" height="15" font="4">–52.</text>
<text top="600" left="450" width="350" height="10" font="4">788. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral</text>
<text top="614" left="475" width="324" height="10" font="4">vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med</text>
<text top="628" left="475" width="68" height="10" font="4">2006;355:2099</text>
<text top="625" left="543" width="25" height="15" font="4">–112.</text>
<text top="643" left="450" width="350" height="10" font="4">789. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hypona-</text>
<text top="657" left="475" width="272" height="10" font="4">tremia is associated with falls, unsteadiness, and attention de</text>
<text top="654" left="748" width="52" height="15" font="4">ﬁcits. Am J</text>
<text top="671" left="475" width="81" height="10" font="4">Med 2006;119:71</text>
<text top="668" left="556" width="14" height="15" font="4">–8.</text>
<text top="685" left="450" width="350" height="10" font="4">790. Gheorghiade M, Konstam MA, Burnett JC Jr., et al. Short-term clinical</text>
<text top="699" left="475" width="324" height="10" font="4">effects of tolvaptan, an oral vasopressin antagonist, in patients hospi-</text>
<text top="714" left="475" width="324" height="10" font="4">talized for heart failure: the EVEREST Clinical Status Trials. JAMA</text>
<text top="728" left="475" width="68" height="10" font="4">2007;297:1332</text>
<text top="725" left="543" width="20" height="15" font="4">–43.</text>
<text top="742" left="450" width="350" height="10" font="4">791. Konstam MA, Gheorghiade M, Burnett JC Jr., et al. Effects of oral</text>
<text top="756" left="475" width="324" height="10" font="4">tolvaptan in patients hospitalized for worsening heart failure: the</text>
<text top="770" left="475" width="227" height="10" font="4">EVEREST Outcome Trial. JAMA 2007;297:1319</text>
<text top="767" left="702" width="20" height="15" font="4">–31.</text>
<text top="785" left="450" width="350" height="10" font="4">792. Naylor M, Brooten D, Jones R, et al. Comprehensive discharge planning</text>
<text top="799" left="475" width="324" height="10" font="4">for the hospitalized elderly: a randomized clinical trial. Ann Intern Med</text>
<text top="813" left="475" width="62" height="10" font="4">1994;120:999</text>
<text top="810" left="538" width="31" height="15" font="4">–1006.</text>
<text top="827" left="450" width="350" height="10" font="4">793. Naylor MD, Brooten DA, Campbell RL, et al. Transitional care of older</text>
<text top="841" left="475" width="324" height="10" font="4">adults hospitalized with heart failure: a randomized, controlled trial.</text>
<text top="856" left="475" width="140" height="10" font="4">J Am Geriatr Soc 2004;52:675</text>
<text top="853" left="616" width="20" height="15" font="4">–84.</text>
<text top="870" left="450" width="259" height="10" font="4">794. Fonarow GC, Abraham WT, Albert NM, et al. In</text>
<text top="867" left="709" width="91" height="15" font="4">ﬂuence of a perfor-</text>
<text top="884" left="475" width="324" height="10" font="4">mance-improvement initiative on quality of care for patients hospital-</text>
<text top="898" left="475" width="324" height="10" font="4">ized with heart failure: results of the Organized Program to Initiate</text>
<text top="912" left="475" width="324" height="10" font="4">Lifesaving Treatment in Hospitalized Patients With Heart Failure</text>
<text top="927" left="475" width="231" height="10" font="4">(OPTIMIZE-HF). Arch Intern Med 2007;167:1493</text>
<text top="924" left="707" width="25" height="15" font="4">–502.</text>
<text top="941" left="450" width="350" height="10" font="4">795. Lappe JM, Muhlestein JB, Lappe DL, et al. Improvements in 1-year</text>
<text top="955" left="475" width="324" height="10" font="4">cardiovascular clinical outcomes associated with a hospital-based</text>
<text top="969" left="475" width="283" height="10" font="4">discharge medication program. Ann Intern Med 2004;141:446</text>
<text top="966" left="758" width="20" height="15" font="4">–53.</text>
<text top="983" left="450" width="350" height="10" font="4">796. Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge</text>
<text top="998" left="475" width="324" height="10" font="4">planning with postdischarge support for older patients with congestive</text>
<text top="1012" left="475" width="239" height="10" font="4">heart failure: a meta-analysis. JAMA 2004;291:1358</text>
<text top="1009" left="715" width="20" height="15" font="4">–67.</text>
<text top="1026" left="450" width="350" height="10" font="4">797. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of</text>
<text top="1040" left="475" width="324" height="10" font="4">evidence-based pharmacotherapy in heart failure is associated with</text>
<text top="1054" left="475" width="211" height="10" font="4">improved outcomes. Circulation 2007;116:737</text>
<text top="1051" left="687" width="20" height="15" font="4">–44.</text>
<text top="1069" left="450" width="350" height="10" font="4">798. Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and</text>
<text top="1083" left="475" width="324" height="10" font="4">effectiveness of angiotensin-converting enzyme inhibitors in older</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e228</text>
</page>
<page number="83" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="90" width="324" height="10" font="4">patients with heart failure and left ventricular systolic dysfunction.</text>
<text top="117" left="90" width="116" height="10" font="4">Circulation 2004;110:724</text>
<text top="114" left="206" width="20" height="15" font="4">–31.</text>
<text top="132" left="64" width="350" height="10" font="4">799. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comor-</text>
<text top="146" left="90" width="324" height="10" font="4">bidity increases preventable hospitalizations and mortality among</text>
<text top="160" left="90" width="68" height="10" font="4">Medicare bene</text>
<text top="157" left="158" width="256" height="15" font="4">ﬁciaries with chronic heart failure. J Am Coll Cardiol</text>
<text top="174" left="90" width="62" height="10" font="4">2003;42:1226</text>
<text top="171" left="152" width="20" height="15" font="4">–33.</text>
<text top="188" left="64" width="350" height="10" font="4">800. Windham BG, Bennett RG, Gottlieb S. Care management interventions</text>
<text top="203" left="90" width="324" height="10" font="4">for older patients with congestive heart failure. Am J Manag Care 2003;</text>
<text top="217" left="90" width="25" height="10" font="4">9:447</text>
<text top="214" left="115" width="20" height="15" font="4">–59.</text>
<text top="231" left="64" width="350" height="10" font="4">801. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based</text>
<text top="245" left="90" width="324" height="10" font="4">care for heart failure in outpatient cardiology practices: primary results</text>
<text top="259" left="90" width="324" height="10" font="4">of the Registry to Improve the Use of Evidence-Based Heart Failure</text>
<text top="274" left="90" width="324" height="10" font="4">Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010;</text>
<text top="288" left="90" width="37" height="10" font="4">122:585</text>
<text top="285" left="127" width="20" height="15" font="4">–96.</text>
<text top="302" left="64" width="350" height="10" font="4">802. Fonarow GC, Abraham WT, Albert NM, et al. Association between</text>
<text top="316" left="90" width="324" height="10" font="4">performance measures and clinical outcomes for patients hospitalized</text>
<text top="330" left="90" width="175" height="10" font="4">with heart failure. JAMA 2007;297:61</text>
<text top="327" left="265" width="20" height="15" font="4">–70.</text>
<text top="345" left="64" width="350" height="10" font="4">803. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between</text>
<text top="359" left="90" width="324" height="10" font="4">early physician follow-up and 30-day readmission among Medicare</text>
<text top="373" left="90" width="21" height="10" font="4">bene</text>
<text top="370" left="111" width="295" height="15" font="4">ﬁciaries hospitalized for heart failure. JAMA 2010;303:1716–22.</text>
<text top="387" left="64" width="350" height="10" font="4">804. Agency for Healthcare Research and Quality. 30 Safe practices for</text>
<text top="401" left="90" width="265" height="10" font="4">better health care: fact sheet. March 2005. Available at:</text>
<text top="401" left="359" width="55" height="10" font="5"><a href="http://www.ahrq.gov/research/findings/factsheets/errors-safety/30safe/index.html">http://www.</a></text>
<text top="416" left="90" width="86" height="10" font="5"><a href="http://www.ahrq.gov/research/findings/factsheets/errors-safety/30safe/index.html">ahrq.gov/research/</a></text>
<text top="413" left="176" width="234" height="15" font="5"><a href="http://www.ahrq.gov/research/findings/factsheets/errors-safety/30safe/index.html">ﬁndings/factsheets/errors-safety/30safe/index.html</a></text>
<text top="416" left="410" width="3" height="10" font="4">.</text>
<text top="430" left="90" width="116" height="10" font="4">Accessed July 11, 2013..</text>
<text top="444" left="64" width="350" height="10" font="4">805. The Joint Commission. 2011 National patient safety goals. 2012.</text>
<text top="458" left="90" width="62" height="10" font="4">Available at:</text>
<text top="458" left="160" width="254" height="10" font="5"><a href="http://www.jointcommission.org/assets/1/18/2011-2012_npsg_presentation_final_8-4-11.pdf">http://www.jointcommission.org/assets/1/18/2011-2012_</a></text>
<text top="472" left="90" width="87" height="10" font="5"><a href="http://www.jointcommission.org/assets/1/18/2011-2012_npsg_presentation_final_8-4-11.pdf">npsg_presentation_</a></text>
<text top="469" left="176" width="73" height="15" font="5"><a href="http://www.jointcommission.org/assets/1/18/2011-2012_npsg_presentation_final_8-4-11.pdf">ﬁnal_8-4-11.pdf</a></text>
<text top="472" left="253" width="117" height="10" font="4">. Accessed July 11, 2013.</text>
<text top="486" left="64" width="350" height="10" font="4">806. Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life</text>
<text top="501" left="90" width="324" height="10" font="4">for patients with congestive heart failure. J Am Geriatr Soc 2000;48:</text>
<text top="515" left="90" width="23" height="10" font="4">S101</text>
<text top="512" left="113" width="14" height="15" font="4">–9.</text>
<text top="529" left="64" width="350" height="10" font="4">807. Krumholz HM, Baker DW, Ashton CM, et al. Evaluating quality of care</text>
<text top="543" left="90" width="262" height="10" font="4">for patients with heart failure. Circulation 2000;101:E122</text>
<text top="540" left="352" width="20" height="15" font="4">–40.</text>
<text top="557" left="64" width="350" height="10" font="4">808. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial</text>
<text top="569" left="90" width="324" height="15" font="4">ﬁbrillation and congestive heart failure and their joint inﬂuence on</text>
<text top="586" left="90" width="307" height="10" font="4">mortality: the Framingham Heart Study. Circulation 2003;107:2920</text>
<text top="583" left="397" width="14" height="15" font="4">–5.</text>
<text top="600" left="64" width="188" height="10" font="4">809. Maisel WH, Stevenson LW. Atrial</text>
<text top="597" left="257" width="156" height="15" font="4">ﬁbrillation in heart failure: epide-</text>
<text top="614" left="90" width="324" height="10" font="4">miology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;</text>
<text top="628" left="90" width="28" height="10" font="4">91:2D</text>
<text top="625" left="118" width="22" height="15" font="4">–8D.</text>
<text top="643" left="64" width="102" height="10" font="4">810. Deleted in press.</text>
<text top="657" left="64" width="350" height="10" font="4">811. Tsang TS, Gersh BJ, Appleton CP, et al. Left ventricular diastolic</text>
<text top="671" left="90" width="161" height="10" font="4">dysfunction as a predictor of the</text>
<text top="668" left="257" width="157" height="15" font="4">ﬁrst diagnosed nonvalvular atrial</text>
<text top="682" left="90" width="324" height="15" font="4">ﬁbrillation in 840 elderly men and women. J Am Coll Cardiol 2002;40:</text>
<text top="699" left="90" width="22" height="10" font="4">1636</text>
<text top="696" left="112" width="20" height="15" font="4">–44.</text>
<text top="714" left="64" width="350" height="10" font="4">812. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for</text>
<text top="728" left="90" width="22" height="10" font="4">atrial</text>
<text top="725" left="116" width="287" height="15" font="4">ﬁbrillation and heart failure. N Engl J Med 2008;358:2667–77.</text>
<text top="742" left="64" width="288" height="10" font="4">813. Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial</text>
<text top="739" left="356" width="58" height="15" font="4">ﬁbrillation in</text>
<text top="756" left="90" width="249" height="10" font="4">congestive heart failure. N Engl J Med 2004;351:2373</text>
<text top="753" left="339" width="20" height="15" font="4">–83.</text>
<text top="770" left="64" width="350" height="10" font="4">814. Khan MN, Jais P, Cummings J, et al. Pulmonary-vein isolation for</text>
<text top="785" left="90" width="22" height="10" font="4">atrial</text>
<text top="782" left="116" width="298" height="15" font="4">ﬁbrillation in patients with heart failure. N Engl J Med 2008;359:</text>
<text top="799" left="90" width="22" height="10" font="4">1778</text>
<text top="796" left="112" width="20" height="15" font="4">–85.</text>
<text top="813" left="64" width="102" height="10" font="4">815. Deleted in press.</text>
<text top="827" left="64" width="102" height="10" font="4">816. Deleted in press.</text>
<text top="841" left="64" width="102" height="10" font="4">817. Deleted in press.</text>
<text top="856" left="64" width="350" height="10" font="4">818. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in</text>
<text top="870" left="90" width="324" height="10" font="4">heart failure patients a systematic review and meta-analysis. J Am Coll</text>
<text top="884" left="90" width="93" height="10" font="4">Cardiol 2008;52:818</text>
<text top="881" left="183" width="20" height="15" font="4">–27.</text>
<text top="898" left="64" width="350" height="10" font="4">819. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence,</text>
<text top="912" left="90" width="324" height="10" font="4">etiology, clinical correlates, and treatment options. Circulation 2006;</text>
<text top="927" left="90" width="42" height="10" font="4">113:2454</text>
<text top="924" left="132" width="20" height="15" font="4">–61.</text>
<text top="941" left="64" width="350" height="10" font="4">820. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney</text>
<text top="955" left="90" width="324" height="10" font="4">disease, and the risks of death and hospitalization in adults with chronic</text>
<text top="969" left="90" width="324" height="10" font="4">heart failure: the Anemia in Chronic Heart Failure: Outcomes and</text>
<text top="983" left="90" width="304" height="10" font="4">Resource Utilization (ANCHOR) Study. Circulation 2006;113:2713</text>
<text top="980" left="394" width="20" height="15" font="4">–23.</text>
<text top="998" left="64" width="350" height="10" font="4">821. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in</text>
<text top="1012" left="90" width="324" height="10" font="4">heart failure and is associated with poor outcomes: insights from a cohort</text>
<text top="1026" left="90" width="324" height="10" font="4">of 12 065 patients with new-onset heart failure. Circulation 2003;107:</text>
<text top="1040" left="90" width="17" height="10" font="4">223</text>
<text top="1037" left="107" width="14" height="15" font="4">–5.</text>
<text top="1054" left="64" width="350" height="10" font="4">822. Sharma R, Francis DP, Pitt B, et al. Haemoglobin predicts survival in</text>
<text top="1069" left="90" width="324" height="10" font="4">patients with chronic heart failure: a substudy of the ELITE II trial. Eur</text>
<text top="1083" left="90" width="98" height="10" font="4">Heart J 2004;25:1021</text>
<text top="1080" left="188" width="14" height="15" font="4">–8.</text>
<text top="103" left="450" width="350" height="10" font="4">823. von Haehling S, van Veldhuisen DJ, Roughton M, et al. Anaemia among</text>
<text top="117" left="475" width="324" height="10" font="4">patients with heart failure and preserved or reduced ejection fraction:</text>
<text top="132" left="475" width="289" height="10" font="4">results from the SENIORS study. Eur J Heart Fail 2011;13:656</text>
<text top="129" left="765" width="20" height="15" font="4">–63.</text>
<text top="146" left="450" width="350" height="10" font="4">824. Kalra PR, Bolger AP, Francis DP, et al. Effect of anemia on exercise</text>
<text top="160" left="475" width="304" height="10" font="4">tolerance in chronic heart failure in men. Am J Cardiol 2003;91:888</text>
<text top="157" left="780" width="20" height="15" font="4">–91.</text>
<text top="174" left="450" width="34" height="10" font="4">825. O</text>
<text top="171" left="483" width="316" height="15" font="4">’Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and</text>
<text top="188" left="475" width="324" height="10" font="4">consequences of anemia in a broad spectrum of patients with heart</text>
<text top="203" left="475" width="324" height="10" font="4">failure: results of the Candesartan in Heart Failure: Assessment of</text>
<text top="217" left="475" width="324" height="10" font="4">Reduction in Mortality and Morbidity (CHARM) Program. Circulation</text>
<text top="231" left="475" width="62" height="10" font="4">2006;113:986</text>
<text top="228" left="538" width="20" height="15" font="4">–94.</text>
<text top="245" left="450" width="350" height="10" font="4">826. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe</text>
<text top="259" left="475" width="324" height="10" font="4">heart failure: the prospective randomized amlodipine survival evaluation</text>
<text top="274" left="475" width="203" height="10" font="4">(PRAISE). J Am Coll Cardiol 2003;41:1933</text>
<text top="271" left="678" width="14" height="15" font="4">–9.</text>
<text top="288" left="450" width="350" height="10" font="4">827. Westenbrink BD, Voors AA, de Boer RA, et al. Bone marrow dysfunction</text>
<text top="302" left="475" width="274" height="10" font="4">in chronic heart failure patients. Eur J Heart Fail 2010;12:676</text>
<text top="299" left="749" width="20" height="15" font="4">–84.</text>
<text top="316" left="450" width="350" height="10" font="4">828. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous</text>
<text top="330" left="475" width="324" height="10" font="4">erythropoietin and intravenous iron for the treatment of the anemia of</text>
<text top="345" left="475" width="324" height="10" font="4">severe, resistant congestive heart failure improves cardiac and renal</text>
<text top="359" left="475" width="324" height="10" font="4">function and functional cardiac class, and markedly reduces hospitali-</text>
<text top="373" left="475" width="188" height="10" font="4">zations. J Am Coll Cardiol 2000;35:1737</text>
<text top="370" left="664" width="20" height="15" font="4">–44.</text>
<text top="387" left="450" width="350" height="10" font="4">829. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild</text>
<text top="401" left="475" width="324" height="10" font="4">anemia in severe, resistant congestive heart failure using subcutaneous</text>
<text top="416" left="475" width="324" height="10" font="4">erythropoietin and intravenous iron: a randomized controlled study.</text>
<text top="430" left="475" width="150" height="10" font="4">J Am Coll Cardiol 2001;37:1775</text>
<text top="427" left="626" width="20" height="15" font="4">–80.</text>
<text top="444" left="450" width="350" height="10" font="4">830. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on</text>
<text top="458" left="475" width="324" height="10" font="4">exercise capacity in patients with moderate to severe chronic heart</text>
<text top="472" left="475" width="151" height="10" font="4">failure. Circulation 2003;107:294</text>
<text top="469" left="626" width="14" height="15" font="4">–9.</text>
<text top="486" left="450" width="350" height="10" font="4">831. Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves</text>
<text top="501" left="475" width="324" height="10" font="4">anemia exercise tolerance and renal function and reduces B-type natri-</text>
<text top="515" left="475" width="324" height="10" font="4">uretic peptide and hospitalization in patients with heart failure and</text>
<text top="529" left="475" width="176" height="10" font="4">anemia. Am Heart J 2006;152:1096.e9</text>
<text top="526" left="652" width="20" height="15" font="4">–15.</text>
<text top="543" left="450" width="350" height="10" font="4">832. Parissis JT, Kourea K, Panou F, et al. Effects of darbepoetin alpha on</text>
<text top="557" left="475" width="324" height="10" font="4">right and left ventricular systolic and diastolic function in anemic</text>
<text top="572" left="475" width="324" height="10" font="4">patients with chronic heart failure secondary to ischemic or idiopathic</text>
<text top="586" left="475" width="232" height="10" font="4">dilated cardiomyopathy. Am Heart J 2008;155:751</text>
<text top="583" left="707" width="14" height="15" font="4">–7.</text>
<text top="600" left="450" width="350" height="10" font="4">833. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized,</text>
<text top="614" left="475" width="324" height="10" font="4">double-blind, placebo-controlled study to evaluate the effect of two</text>
<text top="628" left="475" width="324" height="10" font="4">dosing regimens of darbepoetin alfa in patients with heart failure and</text>
<text top="643" left="475" width="162" height="10" font="4">anaemia. Eur Heart J 2007;28:2208</text>
<text top="640" left="637" width="20" height="15" font="4">–16.</text>
<text top="657" left="450" width="350" height="10" font="4">834. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial</text>
<text top="671" left="475" width="324" height="10" font="4">of darbepoetin alfa in patients with symptomatic heart failure and</text>
<text top="685" left="475" width="154" height="10" font="4">anemia. Circulation 2008;117:526</text>
<text top="682" left="630" width="20" height="15" font="4">–35.</text>
<text top="699" left="450" width="350" height="10" font="4">835. McMurray JJ, Anand IS, Diaz R, et al. Design of the Reduction of</text>
<text top="714" left="475" width="324" height="10" font="4">Events with Darbepoetin alfa in Heart Failure (RED-HF): a phase III,</text>
<text top="728" left="475" width="324" height="10" font="4">anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009;11:</text>
<text top="742" left="475" width="17" height="10" font="4">795</text>
<text top="739" left="492" width="25" height="15" font="4">–801.</text>
<text top="756" left="450" width="350" height="10" font="4">836. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin</text>
<text top="770" left="475" width="279" height="10" font="4">alfa in chronic kidney disease. N Engl J Med 2006;355:2085</text>
<text top="767" left="754" width="20" height="15" font="4">–98.</text>
<text top="785" left="450" width="350" height="10" font="4">837. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin</text>
<text top="799" left="475" width="324" height="10" font="4">level in patients with chronic kidney disease and anemia. N Engl J Med</text>
<text top="813" left="475" width="68" height="10" font="4">2006;355:2071</text>
<text top="810" left="543" width="20" height="15" font="4">–84.</text>
<text top="827" left="450" width="350" height="10" font="4">838. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with</text>
<text top="841" left="475" width="310" height="10" font="4">darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210</text>
<text top="838" left="785" width="14" height="15" font="4">–9.</text>
<text top="856" left="450" width="102" height="10" font="4">839. Deleted in press.</text>
<text top="870" left="450" width="350" height="10" font="4">840. Anker SD, Comin C J, Filippatos G, et al. Ferric carboxymaltose in</text>
<text top="884" left="475" width="170" height="10" font="4">patients with heart failure and iron de</text>
<text top="881" left="645" width="154" height="15" font="4">ﬁciency. N Engl J Med 2009;361:</text>
<text top="898" left="475" width="22" height="10" font="4">2436</text>
<text top="895" left="498" width="20" height="15" font="4">–48.</text>
<text top="912" left="450" width="350" height="10" font="4">841. Holzapfel N, Lowe B, Wild B, et al. Self-care and depression in patients</text>
<text top="927" left="475" width="234" height="10" font="4">with chronic heart failure. Heart Lung 2009;38:392</text>
<text top="924" left="709" width="14" height="15" font="4">–7.</text>
<text top="941" left="450" width="350" height="10" font="4">842. Jiang W, Krishnan R, Kuchibhatla M, et al. Characteristics of depression</text>
<text top="955" left="475" width="324" height="10" font="4">remission and its relation with cardiovascular outcome among patients</text>
<text top="969" left="475" width="324" height="10" font="4">with chronic heart failure (from the SADHART-CHF Study). Am J</text>
<text top="983" left="475" width="99" height="10" font="4">Cardiol 2011;107:545</text>
<text top="980" left="575" width="20" height="15" font="4">–51.</text>
<text top="998" left="450" width="350" height="10" font="4">843. Bekelman DB, Havranek EP, Becker DM, et al. Symptoms, depression,</text>
<text top="1012" left="475" width="310" height="10" font="4">and quality of life in patients with heart failure. J Card Fail 2007;13:643</text>
<text top="1009" left="786" width="14" height="15" font="4">–8.</text>
<text top="1026" left="450" width="350" height="10" font="4">844. Freedland KE, Rich MW, Skala JA, et al. Prevalence of depression in</text>
<text top="1040" left="475" width="324" height="10" font="4">hospitalized patients with congestive heart failure. Psychosom Med</text>
<text top="1054" left="475" width="56" height="10" font="4">2003;65:119</text>
<text top="1051" left="532" width="20" height="15" font="4">–28.</text>
<text top="1069" left="450" width="350" height="10" font="4">845. Moser DK, Dracup K, Evangelista LS, et al. Comparison of prevalence</text>
<text top="1083" left="475" width="324" height="10" font="4">of symptoms of depression, anxiety, and hostility in elderly patients with</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e229</text>
</page>
<page number="84" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="90" width="324" height="10" font="4">heart failure, myocardial infarction, and a coronary artery bypass graft.</text>
<text top="117" left="90" width="112" height="10" font="4">Heart Lung 2010;39:378</text>
<text top="114" left="202" width="20" height="15" font="4">–85.</text>
<text top="132" left="64" width="350" height="10" font="4">846. York KM, Hassan M, Sheps DS. Psychobiology of depression/distress in</text>
<text top="146" left="90" width="234" height="10" font="4">congestive heart failure. Heart Fail Rev 2009;14:35</text>
<text top="143" left="324" width="20" height="15" font="4">–50.</text>
<text top="160" left="64" width="199" height="10" font="4">847. Unpublished data provided by the Of</text>
<text top="157" left="263" width="151" height="15" font="4">ﬁce of Information Products and</text>
<text top="174" left="90" width="324" height="10" font="4">Data Analytics-CMS. CMS Administrative Claims Data, Jan 2011 - Dec</text>
<text top="188" left="90" width="241" height="10" font="4">2011, from the Chronic Condition Warehouse. 2012.</text>
<text top="203" left="64" width="350" height="10" font="4">848. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and</text>
<text top="217" left="90" width="324" height="10" font="4">medical group survival in patients with left main coronary artery disease:</text>
<text top="231" left="90" width="249" height="10" font="4">long-term CASS experience. Circulation 1995;91:2325</text>
<text top="228" left="339" width="20" height="15" font="4">–34.</text>
<text top="245" left="64" width="350" height="10" font="4">849. The VA Coronary Artery Bypass Surgery Cooperative Study Group.</text>
<text top="259" left="90" width="324" height="10" font="4">Eighteen-year follow-up in the Veterans Affairs Cooperative Study of</text>
<text top="274" left="90" width="324" height="10" font="4">Coronary Artery Bypass Surgery for stable angina. Circulation 1992;86:</text>
<text top="288" left="90" width="17" height="10" font="4">121</text>
<text top="285" left="107" width="20" height="15" font="4">–30.</text>
<text top="302" left="64" width="350" height="10" font="4">850. The Veterans Administration Coronary Artery Bypass Surgery Coop-</text>
<text top="316" left="90" width="324" height="10" font="4">erative Study Group. Eleven-year survival in the Veterans Administra-</text>
<text top="330" left="90" width="324" height="10" font="4">tion randomized trial of coronary bypass surgery for stable angina.</text>
<text top="345" left="90" width="136" height="10" font="4">N Engl J Med 1984;311:1333</text>
<text top="342" left="226" width="14" height="15" font="4">–9.</text>
<text top="359" left="64" width="350" height="10" font="4">851. Cleland JG, Calvert M, Freemantle N, et al. The Heart Failure Revas-</text>
<text top="373" left="90" width="265" height="10" font="4">cularisation Trial (HEART). Eur J Heart Fail 2011;13:227</text>
<text top="370" left="355" width="20" height="15" font="4">–33.</text>
<text top="387" left="64" width="350" height="10" font="4">852. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical</text>
<text top="401" left="90" width="324" height="10" font="4">aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:</text>
<text top="416" left="90" width="22" height="10" font="4">2187</text>
<text top="413" left="112" width="20" height="15" font="4">–98.</text>
<text top="430" left="64" width="350" height="10" font="4">853. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve</text>
<text top="444" left="90" width="324" height="10" font="4">implantation for aortic stenosis in patients who cannot undergo</text>
<text top="458" left="90" width="176" height="10" font="4">surgery. N Engl J Med 2010;363:1597</text>
<text top="455" left="266" width="25" height="15" font="4">–607.</text>
<text top="472" left="64" width="350" height="10" font="4">854. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery</text>
<text top="486" left="90" width="247" height="10" font="4">for mitral regurgitation. N Engl J Med 2011;364:1395</text>
<text top="483" left="337" width="25" height="15" font="4">–406.</text>
<text top="501" left="64" width="350" height="10" font="4">855. Chan KM, Punjabi PP, Flather M, et al. Coronary artery bypass surgery</text>
<text top="515" left="90" width="324" height="10" font="4">with or without mitral valve annuloplasty in moderate functional</text>
<text top="529" left="90" width="134" height="10" font="4">ischemic mitral regurgitation:</text>
<text top="526" left="227" width="187" height="15" font="4">ﬁnal results of the Randomized Ischemic</text>
<text top="543" left="90" width="267" height="10" font="4">Mitral Evaluation (RIME) trial. Circulation 2012;126:2502</text>
<text top="540" left="357" width="20" height="15" font="4">–10.</text>
<text top="557" left="64" width="308" height="10" font="4">856. Fattouch K, Guccione F, Sampognaro R, et al. POINT: ef</text>
<text top="554" left="372" width="41" height="15" font="4">ﬁcacy of</text>
<text top="572" left="90" width="324" height="10" font="4">adding mitral valve restrictive annuloplasty to coronary artery bypass</text>
<text top="586" left="90" width="324" height="10" font="4">grafting in patients with moderate ischemic mitral valve regurgitation:</text>
<text top="600" left="90" width="273" height="10" font="4">a randomized trial. J Thorac Cardiovasc Surg 2009;138:278</text>
<text top="597" left="363" width="20" height="15" font="4">–85.</text>
<text top="614" left="64" width="290" height="10" font="4">857. Franzen O, van der Heyden J, Baldus S, et al. MitraClip</text>
<text top="611" left="354" width="59" height="15" font="4">Ò therapy in</text>
<text top="628" left="90" width="324" height="10" font="4">patients with end-stage systolic heart failure. Eur J Heart Fail 2011;13:</text>
<text top="643" left="90" width="17" height="10" font="4">569</text>
<text top="640" left="107" width="20" height="15" font="4">–76.</text>
<text top="657" left="64" width="350" height="10" font="4">858. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery</text>
<text top="671" left="90" width="324" height="10" font="4">with or without surgical ventricular reconstruction. N Engl J Med 2009;</text>
<text top="685" left="90" width="42" height="10" font="4">360:1705</text>
<text top="682" left="132" width="20" height="15" font="4">–17.</text>
<text top="699" left="64" width="350" height="10" font="4">859. Cleveland JC Jr., Naftel DC, Reece TB, et al. Survival after biventricular</text>
<text top="714" left="90" width="324" height="10" font="4">assist device implantation: an analysis of the Interagency Registry for</text>
<text top="728" left="90" width="324" height="10" font="4">Mechanically Assisted Circulatory Support database. J Heart Lung</text>
<text top="742" left="90" width="108" height="10" font="4">Transplant 2011;30:862</text>
<text top="739" left="198" width="14" height="15" font="4">–9.</text>
<text top="756" left="64" width="350" height="10" font="4">860. Klotz S, Meyns B, Simon A, et al. Partial mechanical long-term support</text>
<text top="770" left="90" width="324" height="10" font="4">with the CircuLite Synergy pump as bridge-to-transplant in congestive</text>
<text top="785" left="90" width="276" height="10" font="4">heart failure. Thorac Cardiovasc Surg 2010;58 Suppl 2:S173</text>
<text top="782" left="366" width="14" height="15" font="4">–8.</text>
<text top="799" left="64" width="350" height="10" font="4">861. Coronary artery surgery study (CASS): a randomized trial of coronary</text>
<text top="813" left="90" width="278" height="10" font="4">artery bypass surgery: survival data. Circulation 1983;68:939</text>
<text top="810" left="368" width="20" height="15" font="4">–50.</text>
<text top="827" left="64" width="350" height="10" font="4">862. Takaro T, Peduzzi P, Detre KM, et al. Survival in subgroups of patients</text>
<text top="841" left="90" width="324" height="10" font="4">with left main coronary artery disease: Veterans Administration Coop-</text>
<text top="856" left="90" width="324" height="10" font="4">erative Study of Surgery for Coronary Arterial Occlusive Disease.</text>
<text top="870" left="90" width="104" height="10" font="4">Circulation 1982;66:14</text>
<text top="867" left="194" width="20" height="15" font="4">–22.</text>
<text top="884" left="64" width="350" height="10" font="4">863. Hu S, Liu S, Zheng Z, et al. Isolated coronary artery bypass graft</text>
<text top="898" left="90" width="324" height="10" font="4">combined with bone marrow mononuclear cells delivered through a graft</text>
<text top="912" left="90" width="324" height="10" font="4">vessel for patients with previous myocardial infarction and chronic heart</text>
<text top="927" left="90" width="324" height="10" font="4">failure: a single-center, randomized, double-blind, placebo-controlled</text>
<text top="941" left="90" width="211" height="10" font="4">clinical trial. J Am Coll Cardiol 2011;57:2409</text>
<text top="938" left="301" width="20" height="15" font="4">–15.</text>
<text top="955" left="64" width="350" height="10" font="4">864. Perin EC, Silva GV, Henry TD, et al. A randomized study of trans-</text>
<text top="969" left="90" width="324" height="10" font="4">endocardial injection of autologous bone marrow mononuclear cells and</text>
<text top="983" left="90" width="324" height="10" font="4">cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J</text>
<text top="998" left="90" width="68" height="10" font="4">2011;161:1078</text>
<text top="995" left="158" width="20" height="15" font="4">–87.</text>
<text top="1012" left="64" width="350" height="10" font="4">865. Strauer BE, Yousef M, Schannwell CM. The acute and long-term</text>
<text top="1026" left="90" width="324" height="10" font="4">effects of intracoronary Stem cell Transplantation in 191 patients</text>
<text top="1040" left="90" width="324" height="10" font="4">with chronic heARt failure: the STAR-heart study. Eur J Heart Fail</text>
<text top="1054" left="90" width="56" height="10" font="4">2010;12:721</text>
<text top="1051" left="146" width="14" height="15" font="4">–9.</text>
<text top="1069" left="64" width="350" height="10" font="4">866. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006</text>
<text top="1083" left="90" width="324" height="10" font="4">guidelines for management of patients with ventricular arrhythmias and</text>
<text top="103" left="475" width="324" height="10" font="4">the prevention of sudden cardiac death: a report of the American College</text>
<text top="117" left="475" width="324" height="10" font="4">of Cardiology/American Heart Association Task Force and the European</text>
<text top="132" left="475" width="324" height="10" font="4">Society of Cardiology Committee for Practice Guidelines (Writing</text>
<text top="146" left="475" width="324" height="10" font="4">Committee to Develop Guidelines for Management of Patients With</text>
<text top="160" left="475" width="324" height="10" font="4">Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death).</text>
<text top="174" left="475" width="150" height="10" font="4">J Am Coll Cardiol 2006;48:e247</text>
<text top="171" left="625" width="25" height="15" font="4">–346.</text>
<text top="188" left="450" width="321" height="10" font="4">867. Gelsomino S, La Meir M, Luca F, et al. Treatment of lone atrial</text>
<text top="185" left="774" width="25" height="15" font="4">ﬁbril-</text>
<text top="203" left="475" width="324" height="10" font="4">lation: a look at the past, a view of the present and a glance at the future.</text>
<text top="217" left="475" width="176" height="10" font="4">Eur J Cardiothorac Surg 2012;41:1284</text>
<text top="214" left="652" width="20" height="15" font="4">–94.</text>
<text top="231" left="450" width="350" height="10" font="4">868. Maybaum S, Kamalakannan G, Murthy S. Cardiac recovery during</text>
<text top="245" left="475" width="324" height="10" font="4">mechanical assist device support. Semin Thorac Cardiovasc Surg 2008;</text>
<text top="259" left="475" width="31" height="10" font="4">20:234</text>
<text top="256" left="506" width="20" height="15" font="4">–46.</text>
<text top="274" left="450" width="350" height="10" font="4">869. Burkhoff D, Klotz S, Mancini DM. LVAD-induced reverse remodeling:</text>
<text top="288" left="475" width="324" height="10" font="4">basic and clinical implications for myocardial recovery. J Card Fail</text>
<text top="302" left="475" width="56" height="10" font="4">2006;12:227</text>
<text top="299" left="532" width="20" height="15" font="4">–39.</text>
<text top="316" left="450" width="350" height="10" font="4">870. Coleman EA, Boult. Improving the quality of transitional care for</text>
<text top="330" left="475" width="297" height="10" font="4">persons with complex care needs. J Am Geriatr Soc 2003;51:556</text>
<text top="327" left="773" width="14" height="15" font="4">–7.</text>
<text top="345" left="450" width="350" height="10" font="4">871. Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention</text>
<text top="359" left="475" width="324" height="10" font="4">among patients with congestive heart failure discharged from acute</text>
<text top="373" left="475" width="212" height="10" font="4">hospital care. Arch Intern Med 1998;158:1067</text>
<text top="370" left="687" width="20" height="15" font="4">–72.</text>
<text top="387" left="450" width="350" height="10" font="4">872. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-</text>
<text top="401" left="475" width="324" height="10" font="4">based intervention on unplanned readmissions and survival among</text>
<text top="416" left="475" width="324" height="10" font="4">patients with chronic congestive heart failure: a randomised controlled</text>
<text top="430" left="475" width="132" height="10" font="4">study. Lancet 1999;354:1077</text>
<text top="427" left="608" width="20" height="15" font="4">–83.</text>
<text top="444" left="450" width="350" height="10" font="4">873. Sochalski J, Jaarsma T, Krumholz HM, et al. What works in chronic care</text>
<text top="458" left="475" width="324" height="10" font="4">management: the case of heart failure. Health Aff (Millwood) 2009;28:</text>
<text top="472" left="475" width="17" height="10" font="4">179</text>
<text top="469" left="492" width="20" height="15" font="4">–89.</text>
<text top="486" left="450" width="350" height="10" font="4">874. Laramee AS, Levinsky SK, Sargent J, et al. Case management in</text>
<text top="501" left="475" width="324" height="10" font="4">a heterogeneous congestive heart failure population: a randomized</text>
<text top="515" left="475" width="215" height="10" font="4">controlled trial. Arch Intern Med 2003;163:809</text>
<text top="512" left="691" width="20" height="15" font="4">–17.</text>
<text top="529" left="450" width="350" height="10" font="4">875. Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or structured</text>
<text top="543" left="475" width="324" height="10" font="4">telephone support programmes for patients with chronic heart failure:</text>
<text top="557" left="475" width="262" height="10" font="4">systematic review and meta-analysis. BMJ 2007;334:942.</text>
<text top="572" left="450" width="350" height="10" font="4">876. Chaudhry SI, Phillips CO, Stewart SS, et al. Telemonitoring for patients</text>
<text top="586" left="475" width="304" height="10" font="4">with chronic heart failure: a systematic review. J Card Fail 2007;13:56</text>
<text top="583" left="780" width="20" height="15" font="4">–62.</text>
<text top="600" left="450" width="350" height="10" font="4">877. Riegel B, Carlson B, Kopp Z, et al. Effect of a standardized nurse case-</text>
<text top="614" left="475" width="324" height="10" font="4">management telephone intervention on resource use in patients with</text>
<text top="628" left="475" width="240" height="10" font="4">chronic heart failure. Arch Intern Med 2002;162:705</text>
<text top="626" left="716" width="20" height="15" font="4">–12.</text>
<text top="643" left="450" width="350" height="10" font="4">878. Riegel B, Carlson B, Glaser D, et al. Randomized controlled trial of</text>
<text top="657" left="475" width="324" height="10" font="4">telephone case management in Hispanics of Mexican origin with heart</text>
<text top="671" left="475" width="146" height="10" font="4">failure. J Card Fail 2006;12:211</text>
<text top="668" left="621" width="14" height="15" font="4">–9.</text>
<text top="685" left="450" width="350" height="10" font="4">879. Krumholz HM, Currie PM, Riegel B, et al. A taxonomy for disease</text>
<text top="699" left="475" width="99" height="10" font="4">management: a scienti</text>
<text top="697" left="574" width="225" height="15" font="4">ﬁc statement from the American Heart Association</text>
<text top="714" left="475" width="324" height="10" font="4">Disease Management Taxonomy Writing Group. Circulation 2006;114:</text>
<text top="728" left="475" width="22" height="10" font="4">1432</text>
<text top="725" left="498" width="20" height="15" font="4">–45.</text>
<text top="742" left="450" width="350" height="10" font="4">880. Faxon DP, Schwamm LH, Pasternak RC, et al. Improving quality of care</text>
<text top="756" left="475" width="324" height="10" font="4">through disease management: principles and recommendations from the</text>
<text top="770" left="475" width="131" height="10" font="4">American Heart Association</text>
<text top="767" left="606" width="193" height="15" font="4">’s Expert Panel on Disease Management.</text>
<text top="785" left="475" width="121" height="10" font="4">Circulation 2004;109:2651</text>
<text top="782" left="597" width="14" height="15" font="4">–4.</text>
<text top="799" left="450" width="350" height="10" font="4">881. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary inter-</text>
<text top="813" left="475" width="324" height="10" font="4">vention to prevent the readmission of elderly patients with congestive</text>
<text top="827" left="475" width="197" height="10" font="4">heart failure. N Engl J Med 1995;333:1190</text>
<text top="824" left="673" width="14" height="15" font="4">–5.</text>
<text top="841" left="450" width="350" height="10" font="4">882. McAlister FA, Lawson FM, Teo KK, et al. A systematic review of</text>
<text top="856" left="475" width="324" height="10" font="4">randomized trials of disease management programs in heart failure. Am J</text>
<text top="870" left="475" width="86" height="10" font="4">Med 2001;110:378</text>
<text top="867" left="562" width="20" height="15" font="4">–84.</text>
<text top="884" left="450" width="350" height="10" font="4">883. Riegel B, LePetri B. Heart failure disease management models. In:</text>
<text top="898" left="475" width="324" height="10" font="4">Moser D, Riegel B, editors. Improving outcomes in heart failure: an</text>
<text top="912" left="475" width="324" height="10" font="4">interdisciplinary approach. Gaithersburg, Md: Aspen Publishers; 2001:</text>
<text top="927" left="475" width="17" height="10" font="4">267</text>
<text top="924" left="492" width="20" height="15" font="4">–81.</text>
<text top="941" left="450" width="350" height="10" font="4">884. Coleman EA, Mahoney E, Parry C. Assessing the quality of preparation</text>
<text top="955" left="475" width="169" height="10" font="4">for posthospital care from the patient</text>
<text top="952" left="645" width="155" height="15" font="4">’s perspective: the care transitions</text>
<text top="969" left="475" width="149" height="10" font="4">measure. Med Care 2005;43:246</text>
<text top="966" left="624" width="20" height="15" font="4">–55.</text>
<text top="983" left="450" width="350" height="10" font="4">885. Lorenz KA, Lynn J, Dy SM, et al. Evidence for improving palliative care at</text>
<text top="998" left="475" width="299" height="10" font="4">the end of life: a systematic review. Ann Intern Med 2008;148:147</text>
<text top="995" left="774" width="20" height="15" font="4">–59.</text>
<text top="1012" left="450" width="350" height="10" font="4">886. Hauptman PJ, Havranek EP. Integrating palliative care into heart failure</text>
<text top="1026" left="475" width="167" height="10" font="4">care. Arch Intern Med 2005;165:374</text>
<text top="1023" left="643" width="14" height="15" font="4">–8.</text>
<text top="1040" left="450" width="97" height="10" font="4">887. Adler ED, Gold</text>
<text top="1037" left="546" width="253" height="15" font="4">ﬁnger JZ, Kalman J, et al. Palliative care in the treatment</text>
<text top="1054" left="475" width="241" height="10" font="4">of advanced heart failure. Circulation 2009;120:2597</text>
<text top="1051" left="716" width="25" height="15" font="4">–606.</text>
<text top="1069" left="450" width="350" height="10" font="4">888. Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to</text>
<text top="1083" left="475" width="324" height="10" font="4">improve the palliative care of pain, dyspnea, and depression at the end of</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e230</text>
</page>
<page number="85" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="90" width="324" height="10" font="4">life: a clinical practice guideline from the American College of Physi-</text>
<text top="117" left="90" width="169" height="10" font="4">cians. Ann Intern Med 2008;148:141</text>
<text top="114" left="259" width="14" height="15" font="4">–6.</text>
<text top="132" left="64" width="350" height="10" font="4">889. Bernheim SM, Grady JN, Lin Z, et al. National patterns of risk-</text>
<text top="146" left="90" width="324" height="10" font="4">standardized mortality and readmission for acute myocardial infarction</text>
<text top="160" left="90" width="324" height="10" font="4">and heart failure: update on publicly reported outcomes measures based</text>
<text top="174" left="90" width="297" height="10" font="4">on the 2010 release. Circ Cardiovasc Qual Outcomes 2010;3:459</text>
<text top="171" left="387" width="20" height="15" font="4">–67.</text>
<text top="188" left="64" width="350" height="10" font="4">890. Coleman EA. Falling through the cracks: challenges and opportunities</text>
<text top="203" left="90" width="324" height="10" font="4">for improving transitional care for persons with continuous complex care</text>
<text top="217" left="90" width="172" height="10" font="4">needs. J Am Geriatr Soc 2003;51:549</text>
<text top="214" left="262" width="20" height="15" font="4">–55.</text>
<text top="231" left="64" width="350" height="10" font="4">891. Bernheim SM, Spertus JA, Reid KJ, et al. Socioeconomic disparities</text>
<text top="245" left="90" width="324" height="10" font="4">in outcomes after acute myocardial infarction. Am Heart J 2007;153:</text>
<text top="259" left="90" width="17" height="10" font="4">313</text>
<text top="256" left="107" width="14" height="15" font="4">–9.</text>
<text top="274" left="64" width="350" height="10" font="4">892. Rahimi AR, Spertus JA, Reid KJ, et al. Financial barriers to health</text>
<text top="288" left="90" width="324" height="10" font="4">care and outcomes after acute myocardial infarction. JAMA 2007;297:</text>
<text top="302" left="90" width="22" height="10" font="4">1063</text>
<text top="299" left="112" width="20" height="15" font="4">–72.</text>
<text top="316" left="64" width="350" height="10" font="4">893. Smolderen KG, Spertus JA, Reid KJ, et al. The association of cognitive</text>
<text top="330" left="90" width="324" height="10" font="4">and somatic depressive symptoms with depression recognition and</text>
<text top="345" left="90" width="324" height="10" font="4">outcomes after myocardial infarction. Circ Cardiovasc Qual Outcomes</text>
<text top="359" left="90" width="51" height="10" font="4">2009;2:328</text>
<text top="356" left="141" width="20" height="15" font="4">–37.</text>
<text top="373" left="64" width="350" height="10" font="4">894. Subramanian D, Subramanian V, Deswal A, et al. New predictive</text>
<text top="387" left="90" width="324" height="10" font="4">models of heart failure mortality using time-series measurements and</text>
<text top="401" left="90" width="207" height="10" font="4">ensemble models. Circ Heart Fail 2011;4:456</text>
<text top="398" left="297" width="20" height="15" font="4">–62.</text>
<text top="416" left="64" width="350" height="10" font="4">895. Foraker RE, Rose KM, Suchindran CM, et al. Socioeconomic status,</text>
<text top="430" left="90" width="324" height="10" font="4">Medicaid coverage, clinical comorbidity, and rehospitalization or death</text>
<text top="444" left="90" width="324" height="10" font="4">after an incident heart failure hospitalization: Atherosclerosis Risk in</text>
<text top="458" left="90" width="293" height="10" font="4">Communities cohort (1987 to 2004). Circ Heart Fail 2011;4:308</text>
<text top="455" left="383" width="20" height="15" font="4">–16.</text>
<text top="472" left="64" width="350" height="10" font="4">896. Allen LA, Hernandez AF, Peterson ED, et al. Discharge to a skilled</text>
<text top="486" left="90" width="324" height="10" font="4">nursing facility and subsequent clinical outcomes among older patients</text>
<text top="501" left="90" width="258" height="10" font="4">hospitalized for heart failure. Circ Heart Fail 2011;4:293</text>
<text top="498" left="348" width="25" height="15" font="4">–300.</text>
<text top="515" left="64" width="350" height="10" font="4">897. Dunlay SM, Eveleth JM, Shah ND, et al. Medication adherence among</text>
<text top="529" left="90" width="324" height="10" font="4">community-dwelling patients with heart failure. Mayo Clin Proc 2011;</text>
<text top="543" left="90" width="31" height="10" font="4">86:273</text>
<text top="540" left="121" width="20" height="15" font="4">–81.</text>
<text top="557" left="64" width="350" height="10" font="4">898. National Quality Forum (NQF). Preferred practices and performance</text>
<text top="572" left="90" width="324" height="10" font="4">measures for measuring and reporting care coordination: a consensus</text>
<text top="586" left="90" width="170" height="10" font="4">report. Washington, DC: NQF; 2010.</text>
<text top="600" left="64" width="350" height="10" font="4">899. Department of Health and Human Services; Centers for Medicare &amp;</text>
<text top="614" left="90" width="324" height="10" font="4">Medicaid Services. Federal Register, Rules and Regulations. 2011.</text>
<text top="628" left="90" width="61" height="10" font="4">Available at:</text>
<text top="628" left="158" width="256" height="10" font="5"><a href="http://www.gpo.gov/fdsys/pkg/FR-2011-08-18/pdf/2011-19719.pdf">http://www.gpo.gov/fdsys/pkg/FR-2011-08-18/pdf/2011-</a></text>
<text top="643" left="90" width="46" height="10" font="5"><a href="http://www.gpo.gov/fdsys/pkg/FR-2011-08-18/pdf/2011-19719.pdf">19719.pdf</a></text>
<text top="643" left="139" width="111" height="10" font="4">Accessed July 11, 2013.</text>
<text top="657" left="64" width="350" height="10" font="4">900. Grady KL, Dracup K, Kennedy G, et al. Team management of patients</text>
<text top="671" left="90" width="324" height="10" font="4">with heart failure: a statement for healthcare professionals from the</text>
<text top="685" left="90" width="324" height="10" font="4">Cardiovascular Nursing Council of the American Heart Association.</text>
<text top="699" left="90" width="121" height="10" font="4">Circulation 2000;102:2443</text>
<text top="696" left="211" width="20" height="15" font="4">–56.</text>
<text top="714" left="64" width="350" height="10" font="4">901. Desai MM, Stauffer BD, Feringa HH, et al. Statistical models and patient</text>
<text top="728" left="90" width="324" height="10" font="4">predictors of readmission for acute myocardial infarction: a systematic</text>
<text top="742" left="90" width="238" height="10" font="4">review. Circ Cardiovasc Qual Outcomes 2009;2:500</text>
<text top="739" left="328" width="14" height="15" font="4">–7.</text>
<text top="756" left="64" width="350" height="10" font="4">902. Verouden NJ, Haeck JD, Kuijt WJ, et al. Prediction of 1-year mortality</text>
<text top="770" left="90" width="324" height="10" font="4">with different measures of ST-segment recovery in all-comers after</text>
<text top="785" left="90" width="324" height="10" font="4">primary percutaneous coronary intervention for acute myocardial</text>
<text top="799" left="90" width="251" height="10" font="4">infarction. Circ Cardiovasc Qual Outcomes 2010;3:522</text>
<text top="796" left="341" width="14" height="15" font="4">–9.</text>
<text top="813" left="64" width="350" height="10" font="4">903. Allen LA, Yager JE, Funk MJ, et al. Discordance between patient-</text>
<text top="827" left="90" width="324" height="10" font="4">predicted and model-predicted life expectancy among ambulatory</text>
<text top="841" left="90" width="225" height="10" font="4">patients with heart failure. JAMA 2008;299:2533</text>
<text top="838" left="314" width="20" height="15" font="4">–42.</text>
<text top="856" left="64" width="350" height="10" font="4">904. Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol</text>
<text top="870" left="90" width="56" height="10" font="4">2009;54:386</text>
<text top="867" left="147" width="20" height="15" font="4">–96.</text>
<text top="884" left="64" width="350" height="10" font="4">905. Nicholas LH, Langa KM, Iwashyna TJ, et al. Regional variation in the</text>
<text top="898" left="90" width="324" height="10" font="4">association between advance directives and end-of-life Medicare</text>
<text top="912" left="90" width="165" height="10" font="4">expenditures. JAMA 2011;306:1447</text>
<text top="909" left="255" width="20" height="15" font="4">–53.</text>
<text top="927" left="64" width="350" height="10" font="4">906. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for</text>
<text top="941" left="90" width="324" height="10" font="4">patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;</text>
<text top="955" left="90" width="37" height="10" font="4">363:733</text>
<text top="952" left="127" width="20" height="15" font="4">–42.</text>
<text top="969" left="64" width="350" height="10" font="4">907. Swetz KM, Freeman MR, AbouEzzeddine OF, et al. Palliative medicine</text>
<text top="983" left="90" width="324" height="10" font="4">consultation for preparedness planning in patients receiving left</text>
<text top="998" left="90" width="324" height="10" font="4">ventricular assist devices as destination therapy. Mayo Clin Proc 2011;</text>
<text top="1012" left="90" width="31" height="10" font="4">86:493</text>
<text top="1009" left="121" width="25" height="15" font="4">–500.</text>
<text top="1026" left="64" width="350" height="10" font="4">908. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of</text>
<text top="1040" left="90" width="324" height="10" font="4">stable chronic obstructive pulmonary disease: a clinical practice guide-</text>
<text top="1054" left="90" width="324" height="10" font="4">line update from the American College of Physicians, American College</text>
<text top="103" left="476" width="324" height="10" font="4">of Chest Physicians, American Thoracic Society, and European Respi-</text>
<text top="117" left="476" width="209" height="10" font="4">ratory Society. Ann Intern Med 2011;155:179</text>
<text top="114" left="685" width="20" height="15" font="4">–91.</text>
<text top="132" left="450" width="275" height="10" font="4">909. Harper SA, Bradley JS, Englund JA, et al. Seasonal in</text>
<text top="129" left="725" width="75" height="15" font="4">ﬂuenza in adults</text>
<text top="146" left="476" width="324" height="10" font="4">and children: diagnosis, treatment, chemoprophylaxis, and institutional</text>
<text top="160" left="476" width="324" height="10" font="4">outbreak management: clinical practice guidelines of the Infectious</text>
<text top="174" left="476" width="271" height="10" font="4">Diseases Society of America. Clin Infect Dis 2009;48:1003</text>
<text top="171" left="746" width="20" height="15" font="4">–32.</text>
<text top="188" left="450" width="350" height="10" font="4">910. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases</text>
<text top="203" left="476" width="324" height="10" font="4">Society of America/American Thoracic Society consensus guidelines on</text>
<text top="217" left="476" width="324" height="10" font="4">the management of community-acquired pneumonia in adults. Clin</text>
<text top="231" left="476" width="145" height="10" font="4">Infect Dis 2007;44 Suppl 2:S27</text>
<text top="228" left="620" width="20" height="15" font="4">–72.</text>
<text top="245" left="450" width="350" height="10" font="4">911. American Heart Association. AHA Family &amp; Friends CPR. Available at:</text>
<text top="259" left="476" width="323" height="10" font="5"><a href="http://www.heart.org/HEARTORG/CPRAndECC/CommunityTraining/CommunityProducts/Family-Friendsreg-CPR_UCM_303576_Article.jsp.">http://www.heart.org/HEARTORG/CPRAndECC/CommunityTraining/</a></text>
<text top="274" left="475" width="324" height="10" font="5"><a href="http://www.heart.org/HEARTORG/CPRAndECC/CommunityTraining/CommunityProducts/Family-Friendsreg-CPR_UCM_303576_Article.jsp.">CommunityProducts/Family-Friendsreg-CPR_UCM_303576_Article. jsp.</a></text>
<text top="288" left="475" width="113" height="10" font="4">Accessed May 28, 2013.</text>
<text top="302" left="450" width="350" height="10" font="4">912. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for</text>
<text top="316" left="475" width="255" height="10" font="4">the prevention of cardiovascular disease in women</text>
<text top="313" left="731" width="69" height="15" font="4">–2011 update:</text>
<text top="330" left="475" width="324" height="10" font="4">a guideline from the American Heart Association. Circulation 2011;123:</text>
<text top="345" left="475" width="22" height="10" font="4">1243</text>
<text top="342" left="498" width="20" height="15" font="4">–62.</text>
<text top="359" left="450" width="350" height="10" font="4">913. Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and</text>
<text top="373" left="475" width="146" height="10" font="4">cardiovascular disease: a scienti</text>
<text top="370" left="622" width="178" height="15" font="4">ﬁc statement from the American Heart</text>
<text top="387" left="475" width="180" height="10" font="4">Association. Circulation 2012;125:1058</text>
<text top="384" left="656" width="20" height="15" font="4">–72.</text>
<text top="401" left="450" width="350" height="10" font="4">914. US Preventive Services Task Force. Screening for depression in adults:</text>
<text top="416" left="475" width="324" height="10" font="4">U.S. Preventive Services Task Force recommendation statement. Ann</text>
<text top="430" left="475" width="116" height="10" font="4">Intern Med 2009;151:784</text>
<text top="427" left="592" width="20" height="15" font="4">–92.</text>
<text top="444" left="450" width="350" height="10" font="4">915. The Joint Commission. 2013 National patient safety goals 2012.</text>
<text top="458" left="475" width="63" height="10" font="4">Available at:</text>
<text top="458" left="548" width="251" height="10" font="5"><a href="http://www.jointcommission.org/standards_information/npsgs.aspx">http://www.jointcommission.org/standards_information/</a></text>
<text top="472" left="475" width="49" height="10" font="5"><a href="http://www.jointcommission.org/standards_information/npsgs.aspx">npsgs.aspx</a></text>
<text top="472" left="524" width="3" height="10" font="4">.</text>
<text top="486" left="450" width="350" height="10" font="4">916. National Quality Forum (NQF). A comprehensive framework and</text>
<text top="501" left="475" width="324" height="10" font="4">preferred practices for measuring and reporting cultural competency:</text>
<text top="515" left="475" width="227" height="10" font="4">a consensus report. Washington, DC: NQF; 2009.</text>
<text top="529" left="450" width="350" height="10" font="4">917. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to</text>
<text top="543" left="475" width="63" height="10" font="4">Medicare bene</text>
<text top="540" left="538" width="262" height="15" font="4">ﬁciaries, 1998–1999 to 2000–2001.JAMA 2003;289:305–12.</text>
<text top="557" left="450" width="350" height="10" font="4">918. US Department of Health and Human Services. Hospital Compare.</text>
<text top="572" left="475" width="196" height="10" font="5"><a href="http://www.medicare.gov/hospitalcompare/.">http://www.medicare.gov/hospitalcompare/.</a></text>
<text top="572" left="675" width="111" height="10" font="4">Accessed July 11, 2013.</text>
<text top="586" left="450" width="350" height="10" font="4">919. Spertus JA, Eagle KA, Krumholz HM, et al. American College of</text>
<text top="600" left="475" width="324" height="10" font="4">Cardiology and American Heart Association methodology for the</text>
<text top="614" left="475" width="324" height="10" font="4">selection and creation of performance measures for quantifying the</text>
<text top="628" left="475" width="262" height="10" font="4">quality of cardiovascular care. Circulation 2005;111:1703</text>
<text top="626" left="737" width="20" height="15" font="4">–12.</text>
<text top="643" left="450" width="350" height="10" font="4">920. Spertus JA, Bonow RO, Chan P, et al. ACCF/AHA new insights into the</text>
<text top="657" left="475" width="324" height="10" font="4">methodology of performance measurement: a report of the American</text>
<text top="671" left="475" width="324" height="10" font="4">College of Cardiology Foundation/American Heart Association Task</text>
<text top="685" left="475" width="302" height="10" font="4">Force on performance measures. J Am Coll Cardiol 2010;56:1767</text>
<text top="682" left="777" width="20" height="15" font="4">–82.</text>
<text top="699" left="450" width="350" height="10" font="4">921. Bonow RO, Ganiats TG, Beam CT, et al. ACCF/AHA/AMA-PCPI 2011</text>
<text top="714" left="475" width="324" height="10" font="4">performance measures for adults with heart failure: a report of the</text>
<text top="728" left="475" width="324" height="10" font="4">American College of Cardiology Foundation/American Heart Associa-</text>
<text top="742" left="475" width="324" height="10" font="4">tion Task Force on Performance Measures and the American Medical</text>
<text top="756" left="475" width="324" height="10" font="4">Association-Physician Consortium for Performance Improvement. J Am</text>
<text top="770" left="475" width="122" height="10" font="4">Coll Cardiol 2012;59:1812</text>
<text top="767" left="597" width="20" height="15" font="4">–32.</text>
<text top="785" left="450" width="316" height="10" font="4">922. Bonow RO, Masoudi FA, Rumsfeld JS, et al. ACC/AHA classi</text>
<text top="782" left="766" width="33" height="15" font="4">ﬁcation</text>
<text top="799" left="475" width="324" height="10" font="4">of care metrics: performance measures and quality metrics: a report of</text>
<text top="813" left="475" width="324" height="10" font="4">the American College of Cardiology/American Heart Association Task</text>
<text top="827" left="475" width="304" height="10" font="4">Force on Performance Measures. J Am Coll Cardiol 2008;52:2113</text>
<text top="824" left="779" width="14" height="15" font="4">–7.</text>
<text top="841" left="450" width="350" height="10" font="4">923. Krumholz HM, Normand SL, Spertus JA, et al. Measuring performance</text>
<text top="856" left="475" width="324" height="10" font="4">for treating heart attacks and heart failure: the case for outcomes</text>
<text top="870" left="475" width="224" height="10" font="4">measurement. Health Aff (Millwood) 2007;26:75</text>
<text top="867" left="699" width="20" height="15" font="4">–85.</text>
<text top="884" left="450" width="350" height="10" font="4">924. Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical</text>
<text top="898" left="475" width="324" height="10" font="4">models used for public reporting of health outcomes: an American Heart</text>
<text top="912" left="475" width="86" height="10" font="4">Association Scienti</text>
<text top="909" left="561" width="238" height="15" font="4">ﬁc Statement from the Quality of Care and Outcomes</text>
<text top="927" left="475" width="324" height="10" font="4">Research Interdisciplinary Writing Group: cosponsored by the Council</text>
<text top="941" left="475" width="324" height="10" font="4">on Epidemiology and Prevention and the Stroke Council. Circulation</text>
<text top="955" left="475" width="62" height="10" font="4">2006;113:456</text>
<text top="952" left="538" width="20" height="15" font="4">–62.</text>
<text top="1000" left="450" width="227" height="12" font="4">Key Words: ACCF/AHA Practice Guidelines</text>
<text top="1000" left="681" width="8" height="10" font="19">-</text>
<text top="1000" left="694" width="57" height="12" font="4">cardio-renal</text>
<text top="1013" left="450" width="132" height="12" font="4">physiology/pathophysiology</text>
<text top="1014" left="586" width="8" height="10" font="19">-</text>
<text top="1013" left="599" width="110" height="12" font="4">congestive heart failure</text>
<text top="1014" left="713" width="8" height="10" font="19">-</text>
<text top="1013" left="726" width="58" height="12" font="4">CV surgery:</text>
<text top="1027" left="450" width="71" height="12" font="4">transplantation</text>
<text top="1027" left="526" width="8" height="10" font="19">-</text>
<text top="1027" left="538" width="182" height="12" font="4">ventricular assistance, cardiomyopathy</text>
<text top="1027" left="725" width="8" height="10" font="19">-</text>
<text top="1040" left="450" width="64" height="12" font="4">epidemiology</text>
<text top="1041" left="518" width="8" height="10" font="19">-</text>
<text top="1040" left="530" width="170" height="12" font="4">health policy and outcome research</text>
<text top="1041" left="705" width="8" height="10" font="19">-</text>
<text top="1040" left="717" width="58" height="12" font="4">heart failure</text>
<text top="1041" left="779" width="8" height="10" font="19">-</text>
<text top="1053" left="450" width="89" height="12" font="4">other heart failure.</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e231</text>
</page>
<page number="86" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="64" height="12" font="9">Appendix 1.</text>
<text top="103" left="141" width="631" height="14" font="9">Author Relationships With Industry and Other Entities (Relevant)d2013 ACCF/AHA Guideline for the Management of</text>
<text top="119" left="64" width="69" height="12" font="9">Heart Failure</text>
<text top="181" left="64" width="48" height="11" font="4">Committee</text>
<text top="196" left="64" width="37" height="11" font="4">Member</text>
<text top="196" left="152" width="55" height="11" font="4">Employment</text>
<text top="196" left="265" width="47" height="11" font="4">Consultant</text>
<text top="181" left="364" width="44" height="11" font="4">Speaker’s</text>
<text top="196" left="370" width="31" height="11" font="4">Bureau</text>
<text top="166" left="436" width="50" height="11" font="4">Ownership/</text>
<text top="181" left="434" width="54" height="11" font="4">Partnership/</text>
<text top="196" left="442" width="38" height="11" font="4">Principal</text>
<text top="181" left="522" width="38" height="11" font="4">Personal</text>
<text top="196" left="521" width="41" height="11" font="4">Research</text>
<text top="151" left="618" width="54" height="11" font="4">Institutional,</text>
<text top="166" left="605" width="79" height="11" font="4">Organizational, or</text>
<text top="181" left="611" width="67" height="11" font="4">Other Financial</text>
<text top="196" left="629" width="31" height="11" font="4">Benefit</text>
<text top="181" left="706" width="28" height="11" font="4">Expert</text>
<text top="196" left="703" width="35" height="11" font="4">Witness</text>
<text top="166" left="759" width="27" height="11" font="4">Voting</text>
<text top="181" left="746" width="54" height="11" font="4">Recusals by</text>
<text top="196" left="754" width="33" height="11" font="4">Section</text>
<text top="196" left="787" width="4" height="11" font="5"><a href="e147.full.html#88">*</a></text>
<text top="216" left="64" width="40" height="11" font="4">Clyde W.</text>
<text top="231" left="64" width="29" height="11" font="4">Yancy,</text>
<text top="245" left="64" width="23" height="11" font="4">Chair</text>
<text top="216" left="121" width="59" height="11" font="4">Northwestern</text>
<text top="231" left="121" width="81" height="13" font="4">UniversitydChief,</text>
<text top="245" left="121" width="97" height="11" font="4">Division of Cardiology</text>
<text top="260" left="121" width="70" height="11" font="4">and Magerstadt</text>
<text top="275" left="121" width="98" height="11" font="4">Professor of Medicine</text>
<text top="216" left="277" width="23" height="11" font="4">None</text>
<text top="216" left="374" width="23" height="11" font="4">None</text>
<text top="216" left="450" width="23" height="11" font="4">None</text>
<text top="216" left="530" width="23" height="11" font="4">None</text>
<text top="216" left="633" width="23" height="11" font="4">None</text>
<text top="216" left="709" width="23" height="11" font="4">None</text>
<text top="216" left="761" width="23" height="11" font="4">None</text>
<text top="293" left="64" width="30" height="11" font="4">Mariell</text>
<text top="308" left="64" width="34" height="11" font="4">Jessup,</text>
<text top="323" left="64" width="45" height="11" font="4">Vice Chair</text>
<text top="293" left="121" width="55" height="11" font="4">University of</text>
<text top="308" left="121" width="70" height="13" font="4">Pennsylvaniad</text>
<text top="323" left="121" width="98" height="11" font="4">Professor of Medicine</text>
<text top="293" left="277" width="23" height="11" font="4">None</text>
<text top="293" left="374" width="23" height="11" font="4">None</text>
<text top="293" left="450" width="23" height="11" font="4">None</text>
<text top="290" left="491" width="43" height="16" font="4"> Amgen</text>
<text top="305" left="491" width="51" height="16" font="4"> Celladon</text>
<text top="320" left="491" width="59" height="16" font="4"> HeartWare</text>
<text top="293" left="633" width="23" height="11" font="4">None</text>
<text top="293" left="709" width="23" height="11" font="4">None</text>
<text top="293" left="761" width="23" height="11" font="4">7.4.4</text>
<text top="308" left="761" width="23" height="11" font="4">7.4.5</text>
<text top="323" left="761" width="23" height="11" font="4">7.4.6</text>
<text top="338" left="767" width="11" height="11" font="4">10</text>
<text top="356" left="64" width="33" height="11" font="4">Biykem</text>
<text top="371" left="64" width="34" height="11" font="4">Bozkurt</text>
<text top="356" left="121" width="105" height="11" font="4">Michael E. DeBakey VA</text>
<text top="371" left="121" width="96" height="13" font="4">Medical CenterdThe</text>
<text top="386" left="121" width="101" height="11" font="4">Mary and Gordon Cain</text>
<text top="401" left="121" width="101" height="11" font="4">Chair and Professor of</text>
<text top="416" left="121" width="40" height="11" font="4">Medicine</text>
<text top="356" left="277" width="23" height="11" font="4">None</text>
<text top="356" left="374" width="23" height="11" font="4">None</text>
<text top="356" left="450" width="23" height="11" font="4">None</text>
<text top="356" left="530" width="23" height="11" font="4">None</text>
<text top="356" left="633" width="23" height="11" font="4">None</text>
<text top="356" left="709" width="23" height="11" font="4">None</text>
<text top="356" left="761" width="23" height="11" font="4">None</text>
<text top="434" left="64" width="26" height="11" font="4">Javed</text>
<text top="449" left="64" width="26" height="11" font="4">Butler</text>
<text top="434" left="121" width="91" height="13" font="4">Emory Healthcared</text>
<text top="449" left="121" width="75" height="11" font="4">Director of Heart</text>
<text top="464" left="121" width="78" height="11" font="4">Failure Research;</text>
<text top="479" left="121" width="75" height="11" font="4">Emory University</text>
<text top="494" left="121" width="98" height="13" font="4">School of Medicined</text>
<text top="509" left="121" width="98" height="11" font="4">Professor of Medicine</text>
<text top="431" left="241" width="43" height="16" font="4"> Amgen</text>
<text top="446" left="241" width="69" height="16" font="4"> CardioMEMS</text>
<text top="461" left="241" width="47" height="16" font="4"> Gambro</text>
<text top="476" left="241" width="45" height="16" font="4"> Takeda</text>
<text top="434" left="374" width="23" height="11" font="4">None</text>
<text top="434" left="450" width="23" height="11" font="4">None</text>
<text top="434" left="530" width="23" height="11" font="4">None</text>
<text top="431" left="595" width="43" height="16" font="4"> Amgen</text>
<text top="446" left="595" width="51" height="16" font="4"> Biotronic</text>
<text top="461" left="595" width="87" height="16" font="4"> Boston Scientific</text>
<text top="476" left="595" width="69" height="16" font="4"> CardioMEMS</text>
<text top="491" left="595" width="50" height="16" font="4"> <a href="e147.full.html#88">Corthera</a></text>
<text top="491" left="645" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="506" left="595" width="42" height="16" font="4"> FoldRx</text>
<text top="521" left="595" width="52" height="16" font="4"> iOcopsys</text>
<text top="536" left="595" width="60" height="16" font="4"> Johnson &amp;</text>
<text top="554" left="619" width="37" height="11" font="4">Johnson</text>
<text top="566" left="595" width="57" height="16" font="4"> Medtronic</text>
<text top="581" left="595" width="51" height="16" font="4"> Thoratec</text>
<text top="596" left="595" width="65" height="16" font="4"> World Heart</text>
<text top="434" left="709" width="23" height="11" font="4">None</text>
<text top="434" left="765" width="14" height="11" font="4">6.4</text>
<text top="449" left="765" width="14" height="11" font="4">7.1</text>
<text top="464" left="765" width="14" height="11" font="4">7.2</text>
<text top="479" left="761" width="23" height="11" font="4">7.3.2</text>
<text top="494" left="761" width="23" height="11" font="4">7.3.3</text>
<text top="509" left="761" width="23" height="11" font="4">7.3.4</text>
<text top="524" left="761" width="23" height="11" font="4">7.4.4</text>
<text top="539" left="761" width="23" height="11" font="4">7.4.5</text>
<text top="554" left="761" width="23" height="11" font="4">7.4.6</text>
<text top="569" left="765" width="14" height="11" font="4">8.6</text>
<text top="583" left="765" width="14" height="11" font="4">8.7</text>
<text top="598" left="767" width="11" height="11" font="4">10</text>
<text top="617" left="64" width="43" height="11" font="4">Donald E.</text>
<text top="631" left="64" width="42" height="11" font="4">Casey, Jr</text>
<text top="617" left="121" width="88" height="11" font="4">Clinically Integrated</text>
<text top="631" left="121" width="85" height="11" font="4">Physician Network,</text>
<text top="646" left="121" width="99" height="11" font="4">NYU Langone Medical</text>
<text top="661" left="121" width="59" height="13" font="4">CenterdVice</text>
<text top="676" left="121" width="100" height="11" font="4">President and Medical</text>
<text top="691" left="121" width="35" height="11" font="4">Director</text>
<text top="617" left="277" width="23" height="11" font="4">None</text>
<text top="617" left="374" width="23" height="11" font="4">None</text>
<text top="617" left="450" width="23" height="11" font="4">None</text>
<text top="617" left="530" width="23" height="11" font="4">None</text>
<text top="617" left="633" width="23" height="11" font="4">None</text>
<text top="617" left="709" width="23" height="11" font="4">None</text>
<text top="617" left="761" width="23" height="11" font="4">None</text>
<text top="709" left="64" width="36" height="11" font="4">Mark H.</text>
<text top="724" left="64" width="34" height="11" font="4">Drazner</text>
<text top="709" left="121" width="85" height="11" font="4">University of Texas</text>
<text top="724" left="121" width="99" height="11" font="4">Southwestern Medical</text>
<text top="739" left="121" width="85" height="13" font="4">CenterdProfessor,</text>
<text top="754" left="121" width="77" height="11" font="4">Internal Medicine</text>
<text top="709" left="277" width="23" height="11" font="4">None</text>
<text top="709" left="374" width="23" height="11" font="4">None</text>
<text top="709" left="450" width="23" height="11" font="4">None</text>
<text top="706" left="491" width="59" height="16" font="4"> HeartWare</text>
<text top="721" left="491" width="87" height="16" font="4"> Scios/Johnson &amp;</text>
<text top="739" left="515" width="37" height="11" font="4"><a href="e147.full.html#88">Johnson</a></text>
<text top="736" left="552" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="706" left="595" width="57" height="16" font="4"> Medtronic</text>
<text top="721" left="595" width="51" height="16" font="4"> <a href="e147.full.html#88">Thoratec</a></text>
<text top="721" left="646" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="709" left="709" width="23" height="11" font="4">None</text>
<text top="709" left="765" width="14" height="11" font="4">7.1</text>
<text top="724" left="765" width="14" height="11" font="4">7.2</text>
<text top="739" left="761" width="23" height="11" font="4">7.3.2</text>
<text top="754" left="761" width="23" height="11" font="4">7.3.4</text>
<text top="769" left="761" width="23" height="11" font="4">7.4.4</text>
<text top="784" left="761" width="23" height="11" font="4">7.4.5</text>
<text top="799" left="761" width="23" height="11" font="4">7.4.6</text>
<text top="814" left="765" width="14" height="11" font="4">8.6</text>
<text top="829" left="765" width="14" height="11" font="4">8.7</text>
<text top="844" left="767" width="11" height="11" font="4">10</text>
<text top="862" left="64" width="39" height="11" font="4">Gregg C.</text>
<text top="877" left="64" width="38" height="11" font="4">Fonarow</text>
<text top="862" left="121" width="97" height="13" font="4">Director Ahmansond</text>
<text top="877" left="121" width="99" height="11" font="4">UCLA Cardiomyopathy</text>
<text top="892" left="121" width="86" height="13" font="4">Center; Co-Chiefd</text>
<text top="907" left="121" width="75" height="11" font="4">UCLA Division of</text>
<text top="922" left="121" width="47" height="11" font="4">Cardiology</text>
<text top="859" left="241" width="47" height="16" font="4"> Gambro</text>
<text top="877" left="265" width="61" height="11" font="4">(formerly CHF</text>
<text top="892" left="265" width="43" height="11" font="4">Solutions)</text>
<text top="904" left="241" width="57" height="16" font="4"> Medtronic</text>
<text top="919" left="241" width="48" height="16" font="4"> <a href="e147.full.html#88">Novartis</a></text>
<text top="919" left="289" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="934" left="241" width="45" height="16" font="4"> Takeda</text>
<text top="862" left="374" width="23" height="11" font="4">None</text>
<text top="862" left="450" width="23" height="11" font="4">None</text>
<text top="859" left="491" width="47" height="16" font="4"> Gambro</text>
<text top="877" left="515" width="61" height="11" font="4">(formerly CHF</text>
<text top="892" left="515" width="43" height="11" font="4">Solutions)</text>
<text top="904" left="491" width="48" height="16" font="4"> <a href="e147.full.html#88">Novartis</a></text>
<text top="904" left="539" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="859" left="595" width="57" height="16" font="4"> Medtronic</text>
<text top="862" left="709" width="23" height="11" font="4">None</text>
<text top="862" left="765" width="14" height="11" font="4">7.1</text>
<text top="877" left="765" width="14" height="11" font="4">7.2</text>
<text top="892" left="751" width="44" height="11" font="4">(Class IIa)</text>
<text top="907" left="761" width="23" height="11" font="4">7.3.2</text>
<text top="922" left="761" width="23" height="11" font="4">7.3.4</text>
<text top="937" left="765" width="14" height="11" font="4">8.3</text>
<text top="952" left="765" width="14" height="11" font="4">8.4</text>
<text top="966" left="765" width="14" height="11" font="4">8.7</text>
<text top="981" left="767" width="11" height="11" font="4">10</text>
<text top="999" left="64" width="49" height="11" font="4">Stephen A.</text>
<text top="1014" left="64" width="28" height="11" font="4">Geraci</text>
<text top="999" left="121" width="67" height="11" font="4">Quillen College</text>
<text top="1014" left="121" width="75" height="11" font="4">of Medicine/East</text>
<text top="1029" left="121" width="74" height="11" font="4">Tennessee State</text>
<text top="1044" left="121" width="97" height="13" font="4">UniversitydChairman</text>
<text top="1059" left="121" width="90" height="11" font="4">of Internal Medicine</text>
<text top="999" left="277" width="23" height="11" font="4">None</text>
<text top="999" left="374" width="23" height="11" font="4">None</text>
<text top="999" left="450" width="23" height="11" font="4">None</text>
<text top="999" left="530" width="23" height="11" font="4">None</text>
<text top="999" left="633" width="23" height="11" font="4">None</text>
<text top="999" left="709" width="23" height="11" font="4">None</text>
<text top="999" left="761" width="23" height="11" font="4">None</text>
<text top="1084" left="669" width="131" height="11" font="4">(Continued on the next page)</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e232</text>
</page>
<page number="87" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="125" height="12" font="9">Appendix 1. Continued</text>
<text top="164" left="64" width="48" height="11" font="4">Committee</text>
<text top="179" left="64" width="37" height="11" font="4">Member</text>
<text top="179" left="152" width="55" height="11" font="4">Employment</text>
<text top="179" left="265" width="47" height="11" font="4">Consultant</text>
<text top="164" left="364" width="44" height="11" font="4">Speaker’s</text>
<text top="179" left="370" width="31" height="11" font="4">Bureau</text>
<text top="149" left="436" width="50" height="11" font="4">Ownership/</text>
<text top="164" left="434" width="54" height="11" font="4">Partnership/</text>
<text top="179" left="442" width="38" height="11" font="4">Principal</text>
<text top="164" left="522" width="38" height="11" font="4">Personal</text>
<text top="179" left="521" width="41" height="11" font="4">Research</text>
<text top="134" left="618" width="54" height="11" font="4">Institutional,</text>
<text top="149" left="605" width="79" height="11" font="4">Organizational, or</text>
<text top="164" left="611" width="67" height="11" font="4">Other Financial</text>
<text top="179" left="629" width="31" height="11" font="4">Benefit</text>
<text top="164" left="706" width="28" height="11" font="4">Expert</text>
<text top="179" left="703" width="35" height="11" font="4">Witness</text>
<text top="149" left="759" width="27" height="11" font="4">Voting</text>
<text top="164" left="746" width="54" height="11" font="4">Recusals by</text>
<text top="179" left="754" width="33" height="11" font="4">Section</text>
<text top="179" left="787" width="4" height="11" font="5"><a href="e147.full.html#88">*</a></text>
<text top="199" left="64" width="34" height="11" font="4">Tamara</text>
<text top="214" left="64" width="36" height="11" font="4">Horwich</text>
<text top="199" left="121" width="82" height="13" font="4">AhmansondUCLA</text>
<text top="214" left="121" width="71" height="11" font="4">Cardiomyopathy</text>
<text top="229" left="121" width="81" height="13" font="4">CenterdAssistant</text>
<text top="244" left="121" width="101" height="11" font="4">Professor of Medicine,</text>
<text top="259" left="121" width="47" height="11" font="4">Cardiology</text>
<text top="199" left="277" width="23" height="11" font="4">None</text>
<text top="199" left="374" width="23" height="11" font="4">None</text>
<text top="199" left="450" width="23" height="11" font="4">None</text>
<text top="199" left="530" width="23" height="11" font="4">None</text>
<text top="199" left="633" width="23" height="11" font="4">None</text>
<text top="199" left="709" width="23" height="11" font="4">None</text>
<text top="199" left="761" width="23" height="11" font="4">None</text>
<text top="277" left="64" width="41" height="11" font="4">James L.</text>
<text top="292" left="64" width="33" height="11" font="4">Januzzi</text>
<text top="277" left="121" width="73" height="11" font="4">Harvard Medical</text>
<text top="292" left="121" width="84" height="13" font="4">SchooldAssociate</text>
<text top="307" left="121" width="101" height="11" font="4">Professor of Medicine;</text>
<text top="322" left="121" width="104" height="11" font="4">Massachusetts General</text>
<text top="337" left="121" width="85" height="13" font="4">HospitaldDirector,</text>
<text top="351" left="121" width="101" height="11" font="4">Cardiac Intensive Care</text>
<text top="366" left="121" width="17" height="11" font="4">Unit</text>
<text top="274" left="241" width="43" height="16" font="4"> Critical</text>
<text top="292" left="265" width="51" height="11" font="4"><a href="e147.full.html#88">Diagnostics</a></text>
<text top="289" left="316" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="304" left="241" width="40" height="16" font="4"> Roche</text>
<text top="322" left="265" width="51" height="11" font="4"><a href="e147.full.html#88">Diagnostics</a></text>
<text top="319" left="316" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="277" left="374" width="23" height="11" font="4">None</text>
<text top="277" left="450" width="23" height="11" font="4">None</text>
<text top="274" left="491" width="43" height="16" font="4"> Critical</text>
<text top="292" left="515" width="51" height="11" font="4"><a href="e147.full.html#88">Diagnostics</a></text>
<text top="289" left="566" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="304" left="491" width="40" height="16" font="4"> Roche</text>
<text top="322" left="515" width="51" height="11" font="4"><a href="e147.full.html#88">Diagnostics</a></text>
<text top="319" left="566" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="277" left="633" width="23" height="11" font="4">None</text>
<text top="277" left="709" width="23" height="11" font="4">None</text>
<text top="277" left="765" width="14" height="11" font="4">6.2</text>
<text top="292" left="765" width="14" height="11" font="4">6.3</text>
<text top="385" left="64" width="38" height="11" font="4">Maryl R.</text>
<text top="400" left="64" width="37" height="11" font="4">Johnson</text>
<text top="385" left="121" width="55" height="11" font="4">University of</text>
<text top="400" left="121" width="101" height="13" font="4">Wisconsin, Madisond</text>
<text top="414" left="121" width="101" height="11" font="4">Professor of Medicine,</text>
<text top="429" left="121" width="96" height="11" font="4">Director Heart Failure</text>
<text top="444" left="121" width="88" height="11" font="4">and Transplantation</text>
<text top="385" left="277" width="23" height="11" font="4">None</text>
<text top="385" left="374" width="23" height="11" font="4">None</text>
<text top="385" left="450" width="23" height="11" font="4">None</text>
<text top="385" left="530" width="23" height="11" font="4">None</text>
<text top="385" left="633" width="23" height="11" font="4">None</text>
<text top="385" left="709" width="23" height="11" font="4">None</text>
<text top="385" left="761" width="23" height="11" font="4">None</text>
<text top="462" left="64" width="46" height="11" font="4">Edward K.</text>
<text top="477" left="64" width="30" height="11" font="4">Kasper</text>
<text top="462" left="121" width="66" height="11" font="4">Johns Hopkins</text>
<text top="477" left="121" width="92" height="13" font="4">HospitaldE. Cowles</text>
<text top="492" left="121" width="88" height="11" font="4">Andrus Professor in</text>
<text top="507" left="121" width="47" height="11" font="4">Cardiology</text>
<text top="522" left="121" width="74" height="11" font="4">Director, Clinical</text>
<text top="537" left="121" width="47" height="11" font="4">Cardiology</text>
<text top="462" left="277" width="23" height="11" font="4">None</text>
<text top="462" left="374" width="23" height="11" font="4">None</text>
<text top="462" left="450" width="23" height="11" font="4">None</text>
<text top="462" left="530" width="23" height="11" font="4">None</text>
<text top="462" left="633" width="23" height="11" font="4">None</text>
<text top="462" left="709" width="23" height="11" font="4">None</text>
<text top="462" left="761" width="23" height="11" font="4">None</text>
<text top="555" left="64" width="43" height="11" font="4">Wayne C.</text>
<text top="570" left="64" width="20" height="11" font="4">Levy</text>
<text top="555" left="121" width="55" height="11" font="4">University of</text>
<text top="570" left="121" width="63" height="13" font="4">Washingtond</text>
<text top="585" left="121" width="101" height="11" font="4">Professor of Medicine,</text>
<text top="600" left="121" width="97" height="11" font="4">Division of Cardiology</text>
<text top="552" left="241" width="46" height="16" font="4"> Cardiac</text>
<text top="570" left="265" width="52" height="11" font="4">Dimensions</text>
<text top="567" left="317" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="582" left="241" width="69" height="16" font="4"> CardioMEMS</text>
<text top="597" left="241" width="55" height="16" font="4"> GE/Scios/</text>
<text top="615" left="265" width="48" height="11" font="4">Johnson &amp;</text>
<text top="630" left="265" width="37" height="11" font="4">Johnson</text>
<text top="552" left="340" width="44" height="16" font="4"> Amarin</text>
<text top="567" left="340" width="60" height="16" font="4"> Boehringer</text>
<text top="585" left="364" width="43" height="11" font="4">Ingelheim</text>
<text top="597" left="340" width="84" height="16" font="4"> GlaxoSmithKline</text>
<text top="555" left="450" width="23" height="11" font="4">None</text>
<text top="552" left="491" width="43" height="16" font="4"> <a href="e147.full.html#88">Amgen</a></text>
<text top="552" left="534" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="567" left="491" width="59" height="16" font="4"> HeartWare</text>
<text top="567" left="550" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="552" left="595" width="43" height="16" font="4"> Amgen</text>
<text top="567" left="595" width="56" height="16" font="4"> Epocrates</text>
<text top="582" left="595" width="76" height="16" font="4"> GE Healthcare</text>
<text top="597" left="595" width="59" height="16" font="4"> HeartWare</text>
<text top="612" left="595" width="51" height="16" font="4"> Thoratec</text>
<text top="555" left="709" width="23" height="11" font="4">None</text>
<text top="555" left="765" width="14" height="11" font="4">6.4</text>
<text top="570" left="765" width="14" height="11" font="4">6.5</text>
<text top="585" left="765" width="14" height="11" font="4">7.1</text>
<text top="600" left="765" width="14" height="11" font="4">7.2</text>
<text top="615" left="761" width="23" height="11" font="4">7.3.1</text>
<text top="630" left="761" width="23" height="11" font="4">7.3.2</text>
<text top="645" left="761" width="23" height="11" font="4">7.3.4</text>
<text top="660" left="761" width="23" height="11" font="4">7.4.5</text>
<text top="675" left="765" width="14" height="11" font="4">8.3</text>
<text top="690" left="765" width="14" height="11" font="4">8.6</text>
<text top="705" left="765" width="14" height="11" font="4">8.7</text>
<text top="720" left="767" width="11" height="11" font="4">10</text>
<text top="737" left="64" width="54" height="11" font="4">Frederick A.</text>
<text top="752" left="64" width="37" height="11" font="4">Masoudi</text>
<text top="737" left="121" width="101" height="11" font="4">University of Colorado,</text>
<text top="752" left="121" width="85" height="13" font="4">DenverdAssociate</text>
<text top="767" left="121" width="101" height="11" font="4">Professor of Medicine,</text>
<text top="782" left="121" width="97" height="11" font="4">Division of Cardiology</text>
<text top="737" left="277" width="23" height="11" font="4">None</text>
<text top="737" left="374" width="23" height="11" font="4">None</text>
<text top="737" left="450" width="23" height="11" font="4">None</text>
<text top="737" left="530" width="23" height="11" font="4">None</text>
<text top="737" left="633" width="23" height="11" font="4">None</text>
<text top="737" left="709" width="23" height="11" font="4">None</text>
<text top="737" left="761" width="23" height="11" font="4">None</text>
<text top="800" left="64" width="43" height="11" font="4">Patrick E.</text>
<text top="815" left="64" width="37" height="11" font="4">McBride</text>
<text top="800" left="121" width="104" height="11" font="4">University of Wisconsin</text>
<text top="815" left="121" width="86" height="11" font="4">School of Medicine</text>
<text top="830" left="121" width="91" height="13" font="4">and Public Healthd</text>
<text top="845" left="121" width="98" height="11" font="4">Professor of Medicine</text>
<text top="860" left="121" width="96" height="11" font="4">and Family Medicine,</text>
<text top="875" left="121" width="85" height="11" font="4">Associate Dean for</text>
<text top="890" left="121" width="88" height="11" font="4">Students, Associate</text>
<text top="905" left="121" width="88" height="11" font="4">Director, Preventive</text>
<text top="920" left="121" width="47" height="11" font="4">Cardiology</text>
<text top="800" left="277" width="23" height="11" font="4">None</text>
<text top="800" left="374" width="23" height="11" font="4">None</text>
<text top="800" left="450" width="23" height="11" font="4">None</text>
<text top="800" left="530" width="23" height="11" font="4">None</text>
<text top="800" left="633" width="23" height="11" font="4">None</text>
<text top="800" left="709" width="23" height="11" font="4">None</text>
<text top="800" left="761" width="23" height="11" font="4">None</text>
<text top="938" left="64" width="42" height="11" font="4">John J.V.</text>
<text top="953" left="64" width="45" height="11" font="4">McMurray</text>
<text top="938" left="121" width="100" height="11" font="4">University of Glasgow,</text>
<text top="953" left="121" width="105" height="11" font="4">Scotland, BHF Glasgow</text>
<text top="968" left="121" width="65" height="11" font="4">Cardiovascular</text>
<text top="983" left="121" width="86" height="13" font="4">Research Centerd</text>
<text top="998" left="121" width="93" height="11" font="4">Professor of Medical</text>
<text top="1013" left="121" width="47" height="11" font="4">Cardiology</text>
<text top="938" left="277" width="23" height="11" font="4">None</text>
<text top="938" left="374" width="23" height="11" font="4">None</text>
<text top="938" left="450" width="23" height="11" font="4">None</text>
<text top="935" left="491" width="84" height="16" font="4"> GlaxoSmi<a href="e147.full.html#88">thKline</a></text>
<text top="935" left="575" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="950" left="491" width="48" height="16" font="4"> Novartis</text>
<text top="965" left="491" width="77" height="16" font="4"> Roche (DSMB)</text>
<text top="935" left="595" width="48" height="16" font="4"> Novartis</text>
<text top="953" left="619" width="68" height="11" font="4">(PARADIGM–PI)</text>
<text top="938" left="709" width="23" height="11" font="4">None</text>
<text top="938" left="765" width="14" height="11" font="4">6.2</text>
<text top="953" left="765" width="14" height="11" font="4">6.3</text>
<text top="968" left="765" width="14" height="11" font="4">7.1</text>
<text top="983" left="765" width="14" height="11" font="4">7.2</text>
<text top="998" left="746" width="53" height="11" font="4">(Class I and</text>
<text top="1013" left="754" width="38" height="11" font="4">Class III)</text>
<text top="1028" left="761" width="23" height="11" font="4">7.3.2</text>
<text top="1043" left="765" width="14" height="11" font="4">8.3</text>
<text top="1058" left="765" width="14" height="11" font="4">8.7</text>
<text top="1082" left="669" width="131" height="11" font="4">(Continued on the next page)</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e233</text>
</page>
<page number="88" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="125" height="12" font="9">Appendix 1. Continued</text>
<text top="164" left="64" width="48" height="11" font="4">Committee</text>
<text top="179" left="64" width="37" height="11" font="4">Member</text>
<text top="179" left="152" width="55" height="11" font="4">Employment</text>
<text top="179" left="265" width="47" height="11" font="4">Consultant</text>
<text top="164" left="364" width="44" height="11" font="4">Speaker’s</text>
<text top="179" left="370" width="31" height="11" font="4">Bureau</text>
<text top="149" left="436" width="50" height="11" font="4">Ownership/</text>
<text top="164" left="434" width="54" height="11" font="4">Partnership/</text>
<text top="179" left="442" width="38" height="11" font="4">Principal</text>
<text top="164" left="522" width="38" height="11" font="4">Personal</text>
<text top="179" left="521" width="41" height="11" font="4">Research</text>
<text top="134" left="618" width="54" height="11" font="4">Institutional,</text>
<text top="149" left="605" width="79" height="11" font="4">Organizational, or</text>
<text top="164" left="611" width="67" height="11" font="4">Other Financial</text>
<text top="179" left="629" width="31" height="11" font="4">Benefit</text>
<text top="164" left="706" width="28" height="11" font="4">Expert</text>
<text top="179" left="703" width="35" height="11" font="4">Witness</text>
<text top="149" left="759" width="27" height="11" font="4">Voting</text>
<text top="164" left="746" width="54" height="11" font="4">Recusals by</text>
<text top="179" left="754" width="33" height="11" font="4">Section</text>
<text top="179" left="787" width="4" height="11" font="5"><a href="e147.full.html#88">*</a></text>
<text top="199" left="64" width="39" height="11" font="4">Judith E.</text>
<text top="214" left="64" width="35" height="11" font="4">Mitchell</text>
<text top="199" left="121" width="114" height="11" font="4">SUNY Downstate Medical</text>
<text top="214" left="121" width="106" height="13" font="4">CenterdDirector, Heart</text>
<text top="229" left="121" width="112" height="11" font="4">Failure Center; Associate</text>
<text top="244" left="121" width="98" height="11" font="4">Professor of Medicine</text>
<text top="199" left="277" width="23" height="11" font="4">None</text>
<text top="199" left="374" width="23" height="11" font="4">None</text>
<text top="199" left="450" width="23" height="11" font="4">None</text>
<text top="199" left="530" width="23" height="11" font="4">None</text>
<text top="199" left="633" width="23" height="11" font="4">None</text>
<text top="199" left="709" width="23" height="11" font="4">None</text>
<text top="199" left="761" width="23" height="11" font="4">None</text>
<text top="262" left="64" width="46" height="11" font="4">Pamela N.</text>
<text top="277" left="64" width="39" height="11" font="4">Peterson</text>
<text top="262" left="121" width="101" height="11" font="4">University of Colorado,</text>
<text top="277" left="121" width="102" height="11" font="4">Denver Health Medical</text>
<text top="292" left="121" width="83" height="13" font="4">CenterdAssociate</text>
<text top="307" left="121" width="101" height="11" font="4">Professor of Medicine,</text>
<text top="322" left="121" width="97" height="11" font="4">Division of Cardiology</text>
<text top="262" left="277" width="23" height="11" font="4">None</text>
<text top="262" left="374" width="23" height="11" font="4">None</text>
<text top="262" left="450" width="23" height="11" font="4">None</text>
<text top="262" left="530" width="23" height="11" font="4">None</text>
<text top="262" left="633" width="23" height="11" font="4">None</text>
<text top="262" left="709" width="23" height="11" font="4">None</text>
<text top="262" left="761" width="23" height="11" font="4">None</text>
<text top="340" left="64" width="35" height="11" font="4">Barbara</text>
<text top="355" left="64" width="27" height="11" font="4">Riegel</text>
<text top="340" left="121" width="55" height="11" font="4">University of</text>
<text top="355" left="121" width="104" height="11" font="4">Pennsylvania School of</text>
<text top="370" left="121" width="87" height="13" font="4">NursingdProfessor</text>
<text top="340" left="277" width="23" height="11" font="4">None</text>
<text top="340" left="374" width="23" height="11" font="4">None</text>
<text top="340" left="450" width="23" height="11" font="4">None</text>
<text top="340" left="530" width="23" height="11" font="4">None</text>
<text top="340" left="633" width="23" height="11" font="4">None</text>
<text top="340" left="709" width="23" height="11" font="4">None</text>
<text top="340" left="761" width="23" height="11" font="4">None</text>
<text top="388" left="64" width="46" height="11" font="4">Flora Sam</text>
<text top="388" left="121" width="77" height="11" font="4">Boston University</text>
<text top="402" left="121" width="89" height="11" font="4">School of Medicine,</text>
<text top="417" left="121" width="108" height="11" font="4">Whitaker Cardiovascular</text>
<text top="432" left="121" width="90" height="13" font="4">InstitutedAssociate</text>
<text top="447" left="121" width="101" height="11" font="4">Professor of Medicine,</text>
<text top="462" left="121" width="101" height="11" font="4">Division of Cardiology/</text>
<text top="477" left="121" width="113" height="11" font="4">Cardiomyopathy Program</text>
<text top="388" left="277" width="23" height="11" font="4">None</text>
<text top="388" left="374" width="23" height="11" font="4">None</text>
<text top="388" left="450" width="23" height="11" font="4">None</text>
<text top="388" left="530" width="23" height="11" font="4">None</text>
<text top="388" left="633" width="23" height="11" font="4">None</text>
<text top="388" left="709" width="23" height="11" font="4">None</text>
<text top="388" left="761" width="23" height="11" font="4">None</text>
<text top="495" left="64" width="42" height="11" font="4">Lynne W.</text>
<text top="510" left="64" width="46" height="11" font="4">Stevenson</text>
<text top="495" left="121" width="102" height="11" font="4">Brigham and Women’s</text>
<text top="510" left="121" width="105" height="11" font="4">Hospital Cardiovascular</text>
<text top="525" left="121" width="84" height="13" font="4">DivisiondDirector,</text>
<text top="540" left="121" width="92" height="11" font="4">Cardiomyopathy and</text>
<text top="555" left="121" width="99" height="11" font="4">Heart Failure Program</text>
<text top="495" left="277" width="23" height="11" font="4">None</text>
<text top="495" left="374" width="23" height="11" font="4">None</text>
<text top="495" left="450" width="23" height="11" font="4">None</text>
<text top="493" left="491" width="52" height="16" font="4"> Biosense</text>
<text top="510" left="515" width="36" height="11" font="4">Webster</text>
<text top="495" left="633" width="23" height="11" font="4">None</text>
<text top="495" left="709" width="23" height="11" font="4">None</text>
<text top="495" left="761" width="23" height="11" font="4">7.3.4</text>
<text top="573" left="64" width="54" height="11" font="4">W.H. Wilson</text>
<text top="588" left="64" width="22" height="11" font="4">Tang</text>
<text top="573" left="121" width="71" height="11" font="4">Cleveland Clinic</text>
<text top="588" left="121" width="103" height="13" font="4">FoundationdAssociate</text>
<text top="603" left="121" width="101" height="11" font="4">Professor of Medicine,</text>
<text top="618" left="121" width="96" height="11" font="4">Research Director for</text>
<text top="633" left="121" width="107" height="11" font="4">Heart Failure/Transplant</text>
<text top="570" left="241" width="57" height="16" font="4"> Medtronic</text>
<text top="585" left="241" width="88" height="16" font="4"> St. Jude Medical</text>
<text top="573" left="374" width="23" height="11" font="4">None</text>
<text top="573" left="450" width="23" height="11" font="4">None</text>
<text top="570" left="491" width="41" height="16" font="4"> Abbott</text>
<text top="570" left="532" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="585" left="491" width="42" height="16" font="4"> FoldRx</text>
<text top="600" left="491" width="60" height="16" font="4"> Johnson &amp;</text>
<text top="618" left="515" width="37" height="11" font="4">Johnson</text>
<text top="630" left="491" width="57" height="16" font="4"> Medtronic</text>
<text top="630" left="548" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="645" left="491" width="88" height="16" font="4"> St. Jude <a href="e147.full.html#88">Medical</a></text>
<text top="645" left="579" width="5" height="16" font="5"><a href="e147.full.html#88">y</a></text>
<text top="573" left="633" width="23" height="11" font="4">None</text>
<text top="573" left="709" width="23" height="11" font="4">None</text>
<text top="573" left="765" width="14" height="11" font="4">6.2</text>
<text top="588" left="765" width="14" height="11" font="4">6.3</text>
<text top="603" left="765" width="14" height="11" font="4">7.1</text>
<text top="618" left="765" width="14" height="11" font="4">7.2</text>
<text top="633" left="761" width="23" height="11" font="4">7.3.2</text>
<text top="648" left="761" width="23" height="11" font="4">7.3.3</text>
<text top="663" left="761" width="23" height="11" font="4">7.3.4</text>
<text top="678" left="765" width="14" height="11" font="4">8.6</text>
<text top="693" left="765" width="14" height="11" font="4">8.7</text>
<text top="708" left="767" width="11" height="11" font="4">10</text>
<text top="726" left="64" width="36" height="11" font="4">Emily J.</text>
<text top="741" left="64" width="18" height="11" font="4">Tsai</text>
<text top="726" left="121" width="113" height="11" font="4">Temple University School</text>
<text top="741" left="121" width="105" height="13" font="4">of MedicinedAssistant</text>
<text top="756" left="121" width="101" height="11" font="4">Professor of Medicine,</text>
<text top="771" left="121" width="47" height="11" font="4">Cardiology</text>
<text top="726" left="277" width="23" height="11" font="4">None</text>
<text top="726" left="374" width="23" height="11" font="4">None</text>
<text top="726" left="450" width="23" height="11" font="4">None</text>
<text top="726" left="530" width="23" height="11" font="4">None</text>
<text top="726" left="633" width="23" height="11" font="4">None</text>
<text top="726" left="709" width="23" height="11" font="4">None</text>
<text top="726" left="761" width="23" height="11" font="4">None</text>
<text top="789" left="64" width="38" height="11" font="4">Bruce L.</text>
<text top="803" left="64" width="30" height="11" font="4">Wilkoff</text>
<text top="789" left="121" width="83" height="13" font="4">Cleveland Clinicd</text>
<text top="803" left="121" width="109" height="11" font="4">Director, Cardiac Pacing</text>
<text top="818" left="121" width="94" height="11" font="4">and Tachyarrhythmia</text>
<text top="833" left="121" width="79" height="11" font="4">Devices; Director,</text>
<text top="848" left="121" width="92" height="11" font="4">Clinical EP Research</text>
<text top="789" left="277" width="23" height="11" font="4">None</text>
<text top="789" left="374" width="23" height="11" font="4">None</text>
<text top="789" left="450" width="23" height="11" font="4">None</text>
<text top="786" left="491" width="51" height="16" font="4"> Biotronic</text>
<text top="801" left="491" width="87" height="16" font="4"> Boston Scientific</text>
<text top="816" left="491" width="57" height="16" font="4"> Medtronic</text>
<text top="831" left="491" width="88" height="16" font="4"> St. Jude Medical</text>
<text top="789" left="633" width="23" height="11" font="4">None</text>
<text top="789" left="709" width="23" height="11" font="4">None</text>
<text top="789" left="765" width="14" height="11" font="4">7.2</text>
<text top="803" left="751" width="44" height="11" font="4">(Class IIa)</text>
<text top="818" left="761" width="23" height="11" font="4">7.3.4</text>
<text top="833" left="767" width="11" height="11" font="4">10</text>
<text top="876" left="76" width="723" height="11" font="4">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These</text>
<text top="891" left="64" width="735" height="11" font="4">relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process.</text>
<text top="906" left="64" width="735" height="11" font="4">The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest</text>
<text top="920" left="64" width="107" height="11" font="4">represents ownership of</text>
<text top="918" left="174" width="626" height="16" font="4">5% of the voting stock or share of the business entity, or ownership of $10, 000 of the fair market value of the business entity; or if funds</text>
<text top="935" left="64" width="735" height="11" font="4">received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are</text>
<text top="950" left="64" width="495" height="11" font="4">also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.</text>
<text top="965" left="76" width="723" height="11" font="4">According to the ACCF/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual</text>
<text top="980" left="64" width="735" height="11" font="4">property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device</text>
<text top="995" left="64" width="735" height="11" font="4">addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s household, has</text>
<text top="1010" left="64" width="635" height="11" font="4">a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.</text>
<text top="1025" left="76" width="723" height="11" font="4">*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may</text>
<text top="1040" left="64" width="295" height="11" font="4">apply. Section numbers pertain to those in the full-text guideline.</text>
<text top="1052" left="76" width="152" height="16" font="4"><a href="e147.full.html#88">yIndicates </a>significant relationship.</text>
<text top="1070" left="76" width="723" height="11" font="4">DSMB indicates Data Safety Monitoring Board; EP, electrophysiology; NYU, New York University; PARADIGM, a Multicenter, Randomized, Double-blind, Parallel</text>
<text top="1085" left="64" width="735" height="11" font="4">Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure</text>
<text top="1100" left="64" width="735" height="11" font="4">and Reduced Ejection Fraction; PI, Principal Investigator; SUNY, State University of New York; UCLA, University of California, Los Angeles; and VA, Veterans Affairs.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e234</text>
</page>
<page number="89" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="64" height="12" font="9">Appendix 2.</text>
<text top="103" left="141" width="641" height="14" font="9">Reviewer Relationships With Industry and Other Entities (Relevant)d2013 ACCF/AHA Guideline for the Management of</text>
<text top="119" left="64" width="69" height="12" font="9">Heart Failure</text>
<text top="196" left="64" width="41" height="11" font="4">Reviewer</text>
<text top="196" left="158" width="66" height="11" font="4">Representation</text>
<text top="196" left="266" width="55" height="11" font="4">Employment</text>
<text top="196" left="375" width="47" height="11" font="4">Consultant</text>
<text top="181" left="468" width="44" height="11" font="4">Speaker’s</text>
<text top="196" left="475" width="31" height="11" font="4">Bureau</text>
<text top="166" left="538" width="50" height="11" font="4">Ownership/</text>
<text top="181" left="536" width="54" height="11" font="4">Partnership/</text>
<text top="196" left="544" width="38" height="11" font="4">Principal</text>
<text top="181" left="612" width="38" height="11" font="4">Personal</text>
<text top="196" left="610" width="41" height="11" font="4">Research</text>
<text top="151" left="688" width="54" height="11" font="4">Institutional,</text>
<text top="166" left="676" width="79" height="11" font="4">Organizational, or</text>
<text top="181" left="681" width="67" height="11" font="4">Other Financial</text>
<text top="196" left="700" width="31" height="11" font="4">Benefit</text>
<text top="181" left="768" width="28" height="11" font="4">Expert</text>
<text top="196" left="765" width="35" height="11" font="4">Witness</text>
<text top="216" left="64" width="57" height="11" font="4">Nancy Albert</text>
<text top="216" left="148" width="31" height="11" font="4">Official</text>
<text top="231" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="245" left="148" width="46" height="11" font="4">ACCF/AHA</text>
<text top="260" left="148" width="50" height="11" font="4">Task Force</text>
<text top="275" left="148" width="50" height="11" font="4">on Practice</text>
<text top="290" left="148" width="46" height="11" font="4">Guidelines</text>
<text top="216" left="249" width="88" height="11" font="4">Kaufman Center for</text>
<text top="231" left="244" width="98" height="13" font="4">Heart FailuredSenior</text>
<text top="245" left="251" width="85" height="11" font="4">Director of Nursing</text>
<text top="260" left="273" width="41" height="11" font="4">Research</text>
<text top="213" left="352" width="69" height="16" font="4"> BG Medicine</text>
<text top="228" left="352" width="57" height="16" font="4"> Medtronic</text>
<text top="243" left="352" width="40" height="16" font="4"> <a href="e147.full.html#92">Merck</a></text>
<text top="243" left="392" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="216" left="479" width="23" height="11" font="4">None</text>
<text top="216" left="551" width="23" height="11" font="4">None</text>
<text top="216" left="619" width="23" height="11" font="4">None</text>
<text top="216" left="704" width="23" height="11" font="4">None</text>
<text top="216" left="771" width="23" height="11" font="4">None</text>
<text top="308" left="64" width="68" height="11" font="4">Kathleen Grady</text>
<text top="308" left="148" width="31" height="11" font="4">Official</text>
<text top="323" left="148" width="71" height="13" font="4">ReviewerdAHA</text>
<text top="308" left="245" width="97" height="11" font="4">Bluhm Cardiovascular</text>
<text top="323" left="270" width="47" height="13" font="4">Instituted</text>
<text top="338" left="241" width="105" height="11" font="4">Administrative Director,</text>
<text top="353" left="241" width="105" height="11" font="4">Center for Heart Failure</text>
<text top="308" left="387" width="23" height="11" font="4">None</text>
<text top="308" left="479" width="23" height="11" font="4">None</text>
<text top="308" left="551" width="23" height="11" font="4">None</text>
<text top="308" left="619" width="23" height="11" font="4">None</text>
<text top="308" left="704" width="23" height="11" font="4">None</text>
<text top="308" left="771" width="23" height="11" font="4">None</text>
<text top="371" left="64" width="68" height="11" font="4">Paul Hauptman</text>
<text top="371" left="148" width="31" height="11" font="4">Official</text>
<text top="386" left="148" width="71" height="13" font="4">ReviewerdAHA</text>
<text top="371" left="251" width="84" height="11" font="4">St Louis University</text>
<text top="386" left="272" width="42" height="11" font="4">School of</text>
<text top="401" left="246" width="94" height="13" font="4">MedicinedProfessor</text>
<text top="416" left="247" width="93" height="11" font="4">of Internal Medicine,</text>
<text top="431" left="245" width="97" height="11" font="4">Division of Cardiology</text>
<text top="368" left="352" width="69" height="16" font="4"> BG Medicine</text>
<text top="383" left="352" width="58" height="16" font="4"> BioControl</text>
<text top="401" left="376" width="35" height="11" font="4">Medical</text>
<text top="413" left="352" width="43" height="16" font="4"> <a href="e147.full.html#92">Otsuka</a></text>
<text top="416" left="395" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="371" left="479" width="23" height="11" font="4">None</text>
<text top="371" left="551" width="23" height="11" font="4">None</text>
<text top="371" left="619" width="23" height="11" font="4">None</text>
<text top="368" left="672" width="52" height="16" font="4"> EvaHeart</text>
<text top="368" left="724" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="371" left="771" width="23" height="11" font="4">None</text>
<text top="449" left="64" width="66" height="11" font="4">Hector Ventura</text>
<text top="449" left="148" width="31" height="11" font="4">Official</text>
<text top="464" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="479" left="148" width="66" height="11" font="4">ACCF Board of</text>
<text top="494" left="148" width="45" height="11" font="4">Governors</text>
<text top="449" left="261" width="64" height="11" font="4">Ochsner Clinic</text>
<text top="464" left="244" width="99" height="13" font="4">FoundationdDirector,</text>
<text top="479" left="271" width="45" height="11" font="4">Section of</text>
<text top="494" left="247" width="92" height="11" font="4">Cardiomyopathy and</text>
<text top="509" left="245" width="96" height="11" font="4">Heart Transplantation</text>
<text top="446" left="352" width="43" height="16" font="4"> Otsuka</text>
<text top="446" left="451" width="48" height="16" font="4"> Actelion</text>
<text top="449" left="551" width="23" height="11" font="4">None</text>
<text top="449" left="619" width="23" height="11" font="4">None</text>
<text top="449" left="704" width="23" height="11" font="4">None</text>
<text top="449" left="771" width="23" height="11" font="4">None</text>
<text top="527" left="64" width="55" height="11" font="4">Mary Norine</text>
<text top="542" left="64" width="27" height="11" font="4">Walsh</text>
<text top="527" left="148" width="31" height="11" font="4">Official</text>
<text top="542" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="557" left="148" width="66" height="11" font="4">ACCF Board of</text>
<text top="572" left="148" width="38" height="11" font="4">Trustees</text>
<text top="527" left="255" width="76" height="11" font="4">St. Vincent Heart</text>
<text top="542" left="273" width="41" height="11" font="4">Center of</text>
<text top="557" left="254" width="79" height="13" font="4">IndianadMedical</text>
<text top="572" left="276" width="35" height="11" font="4">Director</text>
<text top="524" left="352" width="40" height="16" font="4"> United</text>
<text top="542" left="376" width="47" height="11" font="4">Healthcare</text>
<text top="527" left="479" width="23" height="11" font="4">None</text>
<text top="527" left="551" width="23" height="11" font="4">None</text>
<text top="527" left="619" width="23" height="11" font="4">None</text>
<text top="527" left="704" width="23" height="11" font="4">None</text>
<text top="527" left="771" width="23" height="11" font="4">None</text>
<text top="590" left="64" width="50" height="11" font="4">Jun Chiong</text>
<text top="590" left="148" width="63" height="11" font="4">Organizational</text>
<text top="605" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="620" left="148" width="24" height="11" font="4">ACCP</text>
<text top="590" left="267" width="53" height="11" font="4">Loma Linda</text>
<text top="605" left="245" width="97" height="13" font="4">UniversitydAssociate</text>
<text top="620" left="248" width="90" height="11" font="4">Clinical Professor of</text>
<text top="634" left="273" width="40" height="11" font="4">Medicine</text>
<text top="590" left="387" width="23" height="11" font="4">None</text>
<text top="590" left="479" width="23" height="11" font="4">None</text>
<text top="590" left="551" width="23" height="11" font="4">None</text>
<text top="590" left="619" width="23" height="11" font="4">None</text>
<text top="587" left="672" width="43" height="16" font="4"> Otsuka</text>
<text top="605" left="696" width="33" height="11" font="4">(DSMB)</text>
<text top="590" left="771" width="23" height="11" font="4">None</text>
<text top="653" left="64" width="68" height="11" font="4">David DeLurgio</text>
<text top="653" left="148" width="63" height="11" font="4">Organizational</text>
<text top="668" left="148" width="71" height="13" font="4">ReviewerdHRS</text>
<text top="653" left="269" width="48" height="11" font="4">The Emory</text>
<text top="668" left="254" width="79" height="13" font="4">ClinicdAssociate</text>
<text top="682" left="245" width="96" height="11" font="4">Professor, Director of</text>
<text top="697" left="262" width="62" height="11" font="4">EP Laboratory</text>
<text top="653" left="387" width="23" height="11" font="4">None</text>
<text top="653" left="479" width="23" height="11" font="4">None</text>
<text top="653" left="551" width="23" height="11" font="4">None</text>
<text top="653" left="619" width="23" height="11" font="4">None</text>
<text top="653" left="704" width="23" height="11" font="4">None</text>
<text top="653" left="771" width="23" height="11" font="4">None</text>
<text top="715" left="64" width="147" height="11" font="4">Folashade Omole Organizational</text>
<text top="730" left="148" width="76" height="13" font="4">ReviewerdAAFP</text>
<text top="715" left="246" width="95" height="11" font="4">Morehouse School of</text>
<text top="730" left="246" width="94" height="13" font="4">MedicinedAssociate</text>
<text top="745" left="248" width="90" height="11" font="4">Professor of Clinical</text>
<text top="760" left="257" width="73" height="11" font="4">Family Medicine</text>
<text top="715" left="387" width="23" height="11" font="4">None</text>
<text top="715" left="479" width="23" height="11" font="4">None</text>
<text top="715" left="551" width="23" height="11" font="4">None</text>
<text top="715" left="619" width="23" height="11" font="4">None</text>
<text top="715" left="704" width="23" height="11" font="4">None</text>
<text top="715" left="771" width="23" height="11" font="4">None</text>
<text top="778" left="64" width="68" height="11" font="4">Robert Rich, Jr</text>
<text top="778" left="148" width="63" height="11" font="4">Organizational</text>
<text top="793" left="148" width="76" height="13" font="4">ReviewerdAAFP</text>
<text top="778" left="259" width="69" height="11" font="4">Bladen Medical</text>
<text top="793" left="249" width="88" height="13" font="4">AssociatesdFamily</text>
<text top="808" left="275" width="36" height="11" font="4">Practice</text>
<text top="778" left="387" width="23" height="11" font="4">None</text>
<text top="778" left="479" width="23" height="11" font="4">None</text>
<text top="778" left="551" width="23" height="11" font="4">None</text>
<text top="778" left="619" width="23" height="11" font="4">None</text>
<text top="778" left="704" width="23" height="11" font="4">None</text>
<text top="778" left="771" width="23" height="11" font="4">None</text>
<text top="826" left="64" width="56" height="11" font="4">David Taylor</text>
<text top="826" left="148" width="63" height="11" font="4">Organizational</text>
<text top="841" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="856" left="148" width="26" height="11" font="4">ISHLT</text>
<text top="826" left="256" width="74" height="11" font="4">Cleveland Clinic,</text>
<text top="841" left="261" width="64" height="11" font="4">Department of</text>
<text top="856" left="243" width="100" height="13" font="4">CardiologydProfessor</text>
<text top="871" left="267" width="53" height="11" font="4">of Medicine</text>
<text top="826" left="387" width="23" height="11" font="4">None</text>
<text top="826" left="479" width="23" height="11" font="4">None</text>
<text top="826" left="551" width="23" height="11" font="4">None</text>
<text top="826" left="619" width="23" height="11" font="4">None</text>
<text top="823" left="672" width="51" height="16" font="4"> <a href="e147.full.html#92">Biotronix</a></text>
<text top="823" left="723" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="838" left="672" width="59" height="16" font="4"> <a href="e147.full.html#92">Genentech</a></text>
<text top="838" left="731" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="853" left="672" width="59" height="16" font="4"> HeartWare</text>
<text top="853" left="731" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="868" left="672" width="38" height="16" font="4"> ISHLT</text>
<text top="883" left="672" width="48" height="16" font="4"> <a href="e147.full.html#92">Novartis</a></text>
<text top="883" left="720" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="898" left="672" width="57" height="16" font="4"> St. Jude’s</text>
<text top="916" left="696" width="35" height="11" font="4">Medical</text>
<text top="913" left="731" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="826" left="771" width="23" height="11" font="4">None</text>
<text top="934" left="64" width="39" height="11" font="4">Kimberly</text>
<text top="949" left="64" width="35" height="11" font="4">Birtcher</text>
<text top="934" left="148" width="34" height="11" font="4">Content</text>
<text top="949" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="964" left="148" width="24" height="11" font="4">ACCF</text>
<text top="979" left="148" width="65" height="11" font="4">Cardiovascular</text>
<text top="994" left="148" width="61" height="11" font="4">Team Council</text>
<text top="934" left="246" width="95" height="11" font="4">University of Houston</text>
<text top="949" left="271" width="45" height="11" font="4">College of</text>
<text top="964" left="249" width="88" height="13" font="4">PharmacydClinical</text>
<text top="979" left="272" width="42" height="11" font="4">Professor</text>
<text top="934" left="387" width="23" height="11" font="4">None</text>
<text top="934" left="479" width="23" height="11" font="4">None</text>
<text top="934" left="552" width="23" height="11" font="4">None</text>
<text top="934" left="619" width="23" height="11" font="4">None</text>
<text top="934" left="704" width="23" height="11" font="4">None</text>
<text top="934" left="771" width="23" height="11" font="4">None</text>
<text top="1012" left="64" width="43" height="11" font="4">Kay Blum</text>
<text top="1012" left="148" width="34" height="11" font="4">Content</text>
<text top="1027" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="1042" left="148" width="24" height="11" font="4">ACCF</text>
<text top="1057" left="148" width="65" height="11" font="4">Cardiovascular</text>
<text top="1072" left="148" width="61" height="11" font="4">Team Council</text>
<text top="1012" left="253" width="80" height="11" font="4">Medstar Southern</text>
<text top="1027" left="253" width="80" height="11" font="4">Maryland Hospital</text>
<text top="1042" left="260" width="67" height="13" font="4">CenterdNurse</text>
<text top="1057" left="268" width="50" height="11" font="4">Practitioner</text>
<text top="1012" left="387" width="23" height="11" font="4">None</text>
<text top="1012" left="479" width="23" height="11" font="4">None</text>
<text top="1012" left="552" width="23" height="11" font="4">None</text>
<text top="1012" left="619" width="23" height="11" font="4">None</text>
<text top="1012" left="704" width="23" height="11" font="4">None</text>
<text top="1012" left="771" width="23" height="11" font="4">None</text>
<text top="1096" left="669" width="131" height="11" font="4">(Continued on the next page)</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e235</text>
</page>
<page number="90" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="125" height="12" font="9">Appendix 2. Continued</text>
<text top="179" left="64" width="41" height="11" font="4">Reviewer</text>
<text top="179" left="158" width="66" height="11" font="4">Representation</text>
<text top="179" left="266" width="55" height="11" font="4">Employment</text>
<text top="179" left="375" width="47" height="11" font="4">Consultant</text>
<text top="164" left="468" width="44" height="11" font="4">Speaker’s</text>
<text top="179" left="475" width="31" height="11" font="4">Bureau</text>
<text top="149" left="538" width="50" height="11" font="4">Ownership/</text>
<text top="164" left="536" width="54" height="11" font="4">Partnership/</text>
<text top="179" left="544" width="38" height="11" font="4">Principal</text>
<text top="164" left="612" width="38" height="11" font="4">Personal</text>
<text top="179" left="610" width="41" height="11" font="4">Research</text>
<text top="134" left="688" width="54" height="11" font="4">Institutional,</text>
<text top="149" left="676" width="79" height="11" font="4">Organizational, or</text>
<text top="164" left="681" width="67" height="11" font="4">Other Financial</text>
<text top="179" left="700" width="31" height="11" font="4">Benefit</text>
<text top="164" left="768" width="28" height="11" font="4">Expert</text>
<text top="179" left="765" width="35" height="11" font="4">Witness</text>
<text top="199" left="64" width="61" height="11" font="4">Michael Chan</text>
<text top="199" left="148" width="34" height="11" font="4">Content</text>
<text top="214" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="229" left="148" width="24" height="11" font="4">ACCF</text>
<text top="244" left="148" width="65" height="11" font="4">Cardiovascular</text>
<text top="259" left="148" width="61" height="11" font="4">Team Council</text>
<text top="199" left="257" width="72" height="11" font="4">Royal Alexandra</text>
<text top="214" left="243" width="101" height="13" font="4">HospitaldCo-Director,</text>
<text top="229" left="260" width="66" height="11" font="4">Heart Function</text>
<text top="244" left="243" width="100" height="11" font="4">Program; University of</text>
<text top="259" left="251" width="85" height="13" font="4">AlbertadAssociate</text>
<text top="274" left="248" width="90" height="11" font="4">Clinical Professor of</text>
<text top="289" left="273" width="40" height="11" font="4">Medicine</text>
<text top="199" left="387" width="23" height="11" font="4">None</text>
<text top="199" left="479" width="23" height="11" font="4">None</text>
<text top="199" left="551" width="23" height="11" font="4">None</text>
<text top="199" left="619" width="23" height="11" font="4">None</text>
<text top="196" left="672" width="56" height="16" font="4"> Medtronic</text>
<text top="199" left="771" width="23" height="11" font="4">None</text>
<text top="307" left="64" width="48" height="11" font="4">Jane Chen</text>
<text top="307" left="148" width="34" height="11" font="4">Content</text>
<text top="322" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="337" left="148" width="39" height="11" font="4">ACCF EP</text>
<text top="351" left="148" width="48" height="11" font="4">Committee</text>
<text top="307" left="244" width="99" height="11" font="4">Washington University</text>
<text top="322" left="272" width="42" height="11" font="4">School of</text>
<text top="337" left="247" width="92" height="13" font="4">MedicinedAssistant</text>
<text top="351" left="244" width="98" height="11" font="4">Professor of Medicine</text>
<text top="304" left="352" width="57" height="16" font="4"> Medtronic</text>
<text top="319" left="352" width="50" height="16" font="4"> St. Jude</text>
<text top="337" left="376" width="35" height="11" font="4">Medical</text>
<text top="307" left="479" width="23" height="11" font="4">None</text>
<text top="307" left="551" width="23" height="11" font="4">None</text>
<text top="307" left="619" width="23" height="11" font="4">None</text>
<text top="307" left="704" width="23" height="11" font="4">None</text>
<text top="307" left="771" width="23" height="11" font="4">None</text>
<text top="370" left="64" width="61" height="11" font="4">Michael Clark</text>
<text top="370" left="148" width="34" height="11" font="4">Content</text>
<text top="385" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="400" left="148" width="24" height="11" font="4">ACCF</text>
<text top="414" left="148" width="65" height="11" font="4">Cardiovascular</text>
<text top="429" left="148" width="61" height="11" font="4">Team Council</text>
<text top="370" left="241" width="104" height="11" font="4">North Texas Cardiology</text>
<text top="385" left="250" width="86" height="13" font="4">and EPdAssociate</text>
<text top="400" left="272" width="42" height="11" font="4">Professor</text>
<text top="370" left="387" width="23" height="11" font="4">None</text>
<text top="367" left="451" width="79" height="16" font="4"> Abbott Pharma</text>
<text top="370" left="551" width="23" height="11" font="4">None</text>
<text top="370" left="619" width="23" height="11" font="4">None</text>
<text top="370" left="704" width="23" height="11" font="4">None</text>
<text top="370" left="771" width="23" height="11" font="4">None</text>
<text top="447" left="64" width="57" height="11" font="4">Marco Costa</text>
<text top="447" left="148" width="34" height="11" font="4">Content</text>
<text top="462" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="477" left="148" width="63" height="11" font="4">ACCF Imaging</text>
<text top="492" left="148" width="33" height="11" font="4">Council</text>
<text top="447" left="244" width="98" height="11" font="4">University Hospital for</text>
<text top="462" left="245" width="96" height="13" font="4">ClevelanddProfessor</text>
<text top="477" left="267" width="53" height="11" font="4">of Medicine</text>
<text top="445" left="352" width="82" height="16" font="4"> Abbott Vascular</text>
<text top="459" left="352" width="87" height="16" font="4"> Boston Scientific</text>
<text top="474" left="352" width="70" height="16" font="4"> Cardiokinetix</text>
<text top="477" left="422" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="489" left="352" width="57" height="16" font="4"> Medtronic</text>
<text top="504" left="352" width="50" height="16" font="4"> St. Jude</text>
<text top="522" left="376" width="35" height="11" font="4">Medical</text>
<text top="445" left="451" width="79" height="16" font="4"> Daiichi-Sankyo</text>
<text top="459" left="451" width="44" height="16" font="4"> Eli Lilly</text>
<text top="474" left="451" width="40" height="16" font="4"> Sanofi</text>
<text top="447" left="551" width="23" height="11" font="4">None</text>
<text top="447" left="619" width="23" height="11" font="4">None</text>
<text top="445" left="672" width="82" height="16" font="4"> Abbott <a href="e147.full.html#92">Vascular</a></text>
<text top="447" left="754" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="459" left="672" width="87" height="16" font="4"> Boston Scientific</text>
<text top="474" left="672" width="70" height="16" font="4"> Cardiokinetix</text>
<text top="474" left="742" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="489" left="672" width="56" height="16" font="4"> Medtronic</text>
<text top="492" left="728" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="504" left="672" width="50" height="16" font="4"> St. Jude</text>
<text top="522" left="696" width="35" height="11" font="4">Medical</text>
<text top="447" left="771" width="23" height="11" font="4">None</text>
<text top="540" left="64" width="59" height="11" font="4">Anita Deswal</text>
<text top="540" left="148" width="34" height="11" font="4">Content</text>
<text top="555" left="148" width="41" height="11" font="4">Reviewer</text>
<text top="540" left="255" width="77" height="11" font="4">Baylor College of</text>
<text top="555" left="246" width="94" height="13" font="4">MedicinedAssociate</text>
<text top="570" left="244" width="98" height="11" font="4">Professor of Medicine</text>
<text top="540" left="387" width="23" height="11" font="4">None</text>
<text top="540" left="479" width="23" height="11" font="4">None</text>
<text top="540" left="551" width="23" height="11" font="4">None</text>
<text top="537" left="596" width="43" height="16" font="4"> <a href="e147.full.html#92">Amgen</a></text>
<text top="537" left="639" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="552" left="596" width="48" height="16" font="4"> Novartis</text>
<text top="552" left="644" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="540" left="704" width="23" height="11" font="4">None</text>
<text top="540" left="771" width="23" height="11" font="4">None</text>
<text top="588" left="64" width="57" height="11" font="4">Steven Dunn</text>
<text top="588" left="148" width="34" height="11" font="4">Content</text>
<text top="603" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="618" left="148" width="74" height="11" font="4">ACCF Prevention</text>
<text top="633" left="148" width="48" height="11" font="4">Committee</text>
<text top="588" left="247" width="92" height="11" font="4">University of Virginia</text>
<text top="603" left="279" width="28" height="11" font="4">Health</text>
<text top="618" left="255" width="77" height="13" font="4">SystemdClinical</text>
<text top="633" left="248" width="90" height="11" font="4">Pharmacy Specialist</text>
<text top="588" left="387" width="23" height="11" font="4">None</text>
<text top="588" left="479" width="23" height="11" font="4">None</text>
<text top="588" left="551" width="23" height="11" font="4">None</text>
<text top="588" left="619" width="23" height="11" font="4">None</text>
<text top="588" left="704" width="23" height="11" font="4">None</text>
<text top="588" left="771" width="23" height="11" font="4">None</text>
<text top="651" left="64" width="70" height="11" font="4">Andrew Epstein</text>
<text top="651" left="148" width="34" height="11" font="4">Content</text>
<text top="666" left="148" width="41" height="11" font="4">Reviewer</text>
<text top="651" left="265" width="55" height="11" font="4">University of</text>
<text top="666" left="258" width="70" height="13" font="4">Pennsylvaniad</text>
<text top="681" left="266" width="54" height="11" font="4">Professor of</text>
<text top="696" left="273" width="40" height="11" font="4">Medicine</text>
<text top="648" left="352" width="51" height="16" font="4"> Biotronic</text>
<text top="663" left="352" width="60" height="16" font="4"> Boehringer</text>
<text top="681" left="376" width="43" height="11" font="4">Ingelheim</text>
<text top="693" left="352" width="57" height="16" font="4"> Medtronic</text>
<text top="708" left="352" width="28" height="16" font="4"> Zoll</text>
<text top="651" left="479" width="23" height="11" font="4">None</text>
<text top="651" left="551" width="23" height="11" font="4">None</text>
<text top="648" left="596" width="52" height="16" font="4"> Biosense</text>
<text top="666" left="620" width="36" height="11" font="4">Webster</text>
<text top="666" left="657" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="678" left="596" width="43" height="16" font="4"> Boston</text>
<text top="696" left="620" width="41" height="11" font="4">Scientific</text>
<text top="696" left="661" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="708" left="596" width="52" height="16" font="4"> Cameron</text>
<text top="726" left="620" width="28" height="11" font="4">Health</text>
<text top="726" left="649" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="648" left="672" width="43" height="16" font="4"> Boston</text>
<text top="666" left="684" width="41" height="11" font="4">Scientific</text>
<text top="666" left="725" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="678" left="672" width="50" height="16" font="4"> St. Jude</text>
<text top="696" left="684" width="35" height="11" font="4">Medical</text>
<text top="696" left="719" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="651" left="771" width="23" height="11" font="4">None</text>
<text top="744" left="64" width="118" height="11" font="4">Justin Ezekowitz Content</text>
<text top="759" left="148" width="71" height="13" font="4">ReviewerdAHA</text>
<text top="744" left="245" width="95" height="11" font="4">Mazankowski Alberta</text>
<text top="759" left="281" width="24" height="11" font="4">Heart</text>
<text top="774" left="251" width="85" height="13" font="4">InstitutedDirector,</text>
<text top="789" left="246" width="94" height="11" font="4">Heart Function Clinic</text>
<text top="741" left="352" width="66" height="16" font="4"> Abbott Labs</text>
<text top="756" left="352" width="67" height="16" font="4"> AstraZeneca</text>
<text top="771" left="352" width="43" height="16" font="4"> Pfizer</text>
<text top="744" left="479" width="23" height="11" font="4">None</text>
<text top="744" left="551" width="23" height="11" font="4">None</text>
<text top="741" left="596" width="43" height="16" font="4"> Amgen</text>
<text top="756" left="596" width="45" height="16" font="4"> Bristol-</text>
<text top="774" left="620" width="27" height="11" font="4">Myers</text>
<text top="789" left="620" width="30" height="11" font="4">Squibb</text>
<text top="744" left="704" width="23" height="11" font="4">None</text>
<text top="744" left="771" width="23" height="11" font="4">None</text>
<text top="807" left="64" width="47" height="11" font="4">Gerasimos</text>
<text top="822" left="64" width="42" height="11" font="4">Filippatos</text>
<text top="807" left="148" width="34" height="11" font="4">Content</text>
<text top="822" left="148" width="41" height="11" font="4">Reviewer</text>
<text top="807" left="265" width="55" height="11" font="4">University of</text>
<text top="822" left="246" width="94" height="13" font="4">AthensdDepartment</text>
<text top="837" left="264" width="59" height="11" font="4">of Cardiology</text>
<text top="807" left="387" width="23" height="11" font="4">None</text>
<text top="807" left="479" width="23" height="11" font="4">None</text>
<text top="807" left="551" width="23" height="11" font="4">None</text>
<text top="807" left="619" width="23" height="11" font="4">None</text>
<text top="804" left="672" width="50" height="16" font="4"> Corthera</text>
<text top="819" left="672" width="32" height="16" font="4"> Vifor</text>
<text top="807" left="771" width="23" height="11" font="4">None</text>
<text top="854" left="64" width="56" height="11" font="4">Linda Gillam</text>
<text top="854" left="148" width="34" height="11" font="4">Content</text>
<text top="869" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="884" left="148" width="63" height="11" font="4">ACCF Imaging</text>
<text top="899" left="148" width="33" height="11" font="4">Council</text>
<text top="854" left="249" width="88" height="11" font="4">Morristown Medical</text>
<text top="869" left="246" width="95" height="13" font="4">CenterdProfessor of</text>
<text top="884" left="270" width="47" height="11" font="4">Cardiology</text>
<text top="854" left="387" width="23" height="11" font="4">None</text>
<text top="854" left="479" width="23" height="11" font="4">None</text>
<text top="854" left="551" width="23" height="11" font="4">None</text>
<text top="854" left="619" width="23" height="11" font="4">None</text>
<text top="852" left="672" width="50" height="16" font="4"> Edwards</text>
<text top="869" left="696" width="55" height="11" font="4"><a href="e147.full.html#92">Lifesciences</a></text>
<text top="867" left="751" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="854" left="771" width="23" height="11" font="4">None</text>
<text top="917" left="64" width="19" height="11" font="4">Paul</text>
<text top="932" left="64" width="52" height="11" font="4">Heidenreich</text>
<text top="917" left="148" width="34" height="11" font="4">Content</text>
<text top="932" left="148" width="41" height="11" font="4">Reviewer</text>
<text top="917" left="245" width="96" height="11" font="4">Stanford VA Palo Alto</text>
<text top="932" left="276" width="35" height="11" font="4">Medical</text>
<text top="947" left="253" width="81" height="13" font="4">CenterdAssistant</text>
<text top="962" left="244" width="98" height="11" font="4">Professor of Medicine</text>
<text top="917" left="387" width="23" height="11" font="4">None</text>
<text top="917" left="479" width="23" height="11" font="4">None</text>
<text top="917" left="551" width="23" height="11" font="4">None</text>
<text top="915" left="596" width="57" height="16" font="4"> Medtronic</text>
<text top="915" left="653" width="5" height="16" font="5"><a href="e147.full.html#92">y</a></text>
<text top="917" left="704" width="23" height="11" font="4">None</text>
<text top="917" left="771" width="23" height="11" font="4">None</text>
<text top="980" left="64" width="44" height="11" font="4">Paul Hess</text>
<text top="980" left="148" width="34" height="11" font="4">Content</text>
<text top="995" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="1010" left="148" width="39" height="11" font="4">ACCF EP</text>
<text top="1025" left="148" width="48" height="11" font="4">Committee</text>
<text top="980" left="242" width="103" height="11" font="4">Duke University School</text>
<text top="995" left="247" width="93" height="13" font="4">of MedicinedFellow</text>
<text top="980" left="387" width="23" height="11" font="4">None</text>
<text top="980" left="479" width="23" height="11" font="4">None</text>
<text top="980" left="551" width="23" height="11" font="4">None</text>
<text top="980" left="619" width="23" height="11" font="4">None</text>
<text top="980" left="704" width="23" height="11" font="4">None</text>
<text top="980" left="771" width="23" height="11" font="4">None</text>
<text top="1050" left="669" width="131" height="11" font="4">(Continued on the next page)</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e236</text>
</page>
<page number="91" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="125" height="12" font="9">Appendix 2. Continued</text>
<text top="179" left="64" width="41" height="11" font="4">Reviewer</text>
<text top="179" left="158" width="66" height="11" font="4">Representation</text>
<text top="179" left="266" width="55" height="11" font="4">Employment</text>
<text top="179" left="375" width="47" height="11" font="4">Consultant</text>
<text top="164" left="468" width="44" height="11" font="4">Speaker’s</text>
<text top="179" left="475" width="31" height="11" font="4">Bureau</text>
<text top="149" left="538" width="50" height="11" font="4">Ownership/</text>
<text top="164" left="536" width="54" height="11" font="4">Partnership/</text>
<text top="179" left="544" width="38" height="11" font="4">Principal</text>
<text top="164" left="612" width="38" height="11" font="4">Personal</text>
<text top="179" left="610" width="41" height="11" font="4">Research</text>
<text top="134" left="688" width="54" height="11" font="4">Institutional,</text>
<text top="149" left="676" width="79" height="11" font="4">Organizational, or</text>
<text top="164" left="681" width="67" height="11" font="4">Other Financial</text>
<text top="179" left="700" width="31" height="11" font="4">Benefit</text>
<text top="164" left="768" width="28" height="11" font="4">Expert</text>
<text top="179" left="765" width="35" height="11" font="4">Witness</text>
<text top="199" left="64" width="52" height="11" font="4">Sharon Ann</text>
<text top="214" left="64" width="21" height="11" font="4">Hunt</text>
<text top="199" left="148" width="34" height="11" font="4">Content</text>
<text top="214" left="148" width="41" height="11" font="4">Reviewer</text>
<text top="199" left="251" width="84" height="11" font="4">Stanford University</text>
<text top="214" left="276" width="35" height="11" font="4">Medical</text>
<text top="229" left="251" width="85" height="13" font="4">CenterdProfessor,</text>
<text top="244" left="261" width="64" height="11" font="4">Department of</text>
<text top="259" left="261" width="65" height="11" font="4">Cardiovascular</text>
<text top="274" left="273" width="40" height="11" font="4">Medicine</text>
<text top="199" left="387" width="23" height="11" font="4">None</text>
<text top="199" left="479" width="23" height="11" font="4">None</text>
<text top="199" left="551" width="23" height="11" font="4">None</text>
<text top="199" left="619" width="23" height="11" font="4">None</text>
<text top="199" left="704" width="23" height="11" font="4">None</text>
<text top="199" left="771" width="23" height="11" font="4">None</text>
<text top="292" left="64" width="67" height="11" font="4">Charles McKay</text>
<text top="292" left="148" width="34" height="11" font="4">Content</text>
<text top="307" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="322" left="148" width="75" height="11" font="4">ACCF Council on</text>
<text top="337" left="148" width="65" height="11" font="4">Cardiovascular</text>
<text top="351" left="148" width="64" height="11" font="4">Care for Older</text>
<text top="366" left="148" width="27" height="11" font="4">Adults</text>
<text top="292" left="245" width="96" height="11" font="4">Harbor-UCLA Medical</text>
<text top="307" left="246" width="95" height="13" font="4">CenterdProfessor of</text>
<text top="322" left="273" width="40" height="11" font="4">Medicine</text>
<text top="292" left="387" width="23" height="11" font="4">None</text>
<text top="292" left="479" width="23" height="11" font="4">None</text>
<text top="292" left="551" width="23" height="11" font="4">None</text>
<text top="292" left="619" width="23" height="11" font="4">None</text>
<text top="292" left="704" width="23" height="11" font="4">None</text>
<text top="292" left="771" width="23" height="11" font="4">None</text>
<text top="385" left="64" width="29" height="11" font="4">James</text>
<text top="400" left="64" width="47" height="11" font="4">McClurken</text>
<text top="385" left="148" width="34" height="11" font="4">Content</text>
<text top="400" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="414" left="148" width="72" height="11" font="4">ACCF Surgeons’</text>
<text top="429" left="148" width="41" height="11" font="4">Scientific</text>
<text top="444" left="148" width="33" height="11" font="4">Council</text>
<text top="385" left="253" width="80" height="11" font="4">Temple University</text>
<text top="400" left="272" width="42" height="11" font="4">School of</text>
<text top="414" left="244" width="99" height="13" font="4">MedicinedDirector of</text>
<text top="429" left="261" width="64" height="11" font="4">Cardiothoracic</text>
<text top="444" left="244" width="99" height="11" font="4">Perioperative Services</text>
<text top="385" left="387" width="23" height="11" font="4">None</text>
<text top="385" left="479" width="23" height="11" font="4">None</text>
<text top="385" left="551" width="23" height="11" font="4">None</text>
<text top="385" left="619" width="23" height="11" font="4">None</text>
<text top="385" left="704" width="23" height="11" font="4">None</text>
<text top="385" left="771" width="23" height="11" font="4">None</text>
<text top="462" left="64" width="58" height="11" font="4">Wayne Miller</text>
<text top="462" left="148" width="34" height="11" font="4">Content</text>
<text top="477" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="492" left="148" width="51" height="11" font="4">ACCF Heart</text>
<text top="507" left="148" width="50" height="11" font="4">Failure and</text>
<text top="522" left="148" width="46" height="11" font="4">Transplant</text>
<text top="537" left="148" width="33" height="11" font="4">Council</text>
<text top="462" left="241" width="105" height="13" font="4">Mayo ClinicdProfessor</text>
<text top="477" left="267" width="53" height="11" font="4">of Medicine</text>
<text top="462" left="387" width="23" height="11" font="4">None</text>
<text top="462" left="479" width="23" height="11" font="4">None</text>
<text top="462" left="551" width="23" height="11" font="4">None</text>
<text top="462" left="619" width="23" height="11" font="4">None</text>
<text top="462" left="704" width="23" height="11" font="4">None</text>
<text top="462" left="771" width="23" height="11" font="4">None</text>
<text top="555" left="64" width="68" height="11" font="4">Rick Nishimura</text>
<text top="555" left="148" width="34" height="11" font="4">Content</text>
<text top="570" left="148" width="41" height="11" font="4">Reviewer</text>
<text top="555" left="241" width="105" height="13" font="4">Mayo ClinicdProfessor</text>
<text top="570" left="267" width="53" height="11" font="4">of Medicine</text>
<text top="555" left="387" width="23" height="11" font="4">None</text>
<text top="555" left="479" width="23" height="11" font="4">None</text>
<text top="555" left="552" width="23" height="11" font="4">None</text>
<text top="555" left="619" width="23" height="11" font="4">None</text>
<text top="555" left="704" width="23" height="11" font="4">None</text>
<text top="555" left="771" width="23" height="11" font="4">None</text>
<text top="588" left="64" width="28" height="11" font="4">Donna</text>
<text top="603" left="64" width="46" height="11" font="4">Petruccelli</text>
<text top="588" left="148" width="34" height="11" font="4">Content</text>
<text top="603" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="618" left="148" width="51" height="11" font="4">ACCF Heart</text>
<text top="633" left="148" width="50" height="11" font="4">Failure and</text>
<text top="648" left="148" width="46" height="11" font="4">Transplant</text>
<text top="663" left="148" width="33" height="11" font="4">Council</text>
<text top="588" left="247" width="92" height="11" font="4">Lehigh Valley Health</text>
<text top="603" left="257" width="72" height="13" font="4">NetworkdHeart</text>
<text top="618" left="263" width="60" height="11" font="4">Failure Nurse</text>
<text top="633" left="250" width="86" height="11" font="4">Practitioner/Clinical</text>
<text top="648" left="256" width="75" height="11" font="4">Nurse Specialist,</text>
<text top="663" left="247" width="92" height="11" font="4">Center for Advanced</text>
<text top="678" left="264" width="58" height="11" font="4">Heart Failure</text>
<text top="588" left="387" width="23" height="11" font="4">None</text>
<text top="588" left="479" width="23" height="11" font="4">None</text>
<text top="588" left="552" width="23" height="11" font="4">None</text>
<text top="588" left="619" width="23" height="11" font="4">None</text>
<text top="588" left="704" width="23" height="11" font="4">None</text>
<text top="588" left="771" width="23" height="11" font="4">None</text>
<text top="696" left="64" width="31" height="11" font="4">Geetha</text>
<text top="711" left="64" width="47" height="11" font="4">Raghuveer</text>
<text top="696" left="148" width="34" height="11" font="4">Content</text>
<text top="711" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="726" left="148" width="66" height="11" font="4">ACCF Board of</text>
<text top="741" left="148" width="45" height="11" font="4">Governors</text>
<text top="696" left="256" width="75" height="11" font="4">Children’s Mercy</text>
<text top="711" left="248" width="90" height="13" font="4">HospitaldAssociate</text>
<text top="726" left="243" width="101" height="11" font="4">Professor of Pediatrics</text>
<text top="696" left="387" width="23" height="11" font="4">None</text>
<text top="696" left="479" width="23" height="11" font="4">None</text>
<text top="696" left="551" width="23" height="11" font="4">None</text>
<text top="696" left="619" width="23" height="11" font="4">None</text>
<text top="696" left="704" width="23" height="11" font="4">None</text>
<text top="696" left="771" width="23" height="11" font="4">None</text>
<text top="759" left="64" width="29" height="11" font="4">Pasala</text>
<text top="774" left="64" width="60" height="11" font="4">Ravichandran</text>
<text top="759" left="148" width="34" height="11" font="4">Content</text>
<text top="774" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="789" left="148" width="72" height="11" font="4">ACCF Surgeons’</text>
<text top="803" left="148" width="41" height="11" font="4">Scientific</text>
<text top="818" left="148" width="33" height="11" font="4">Council</text>
<text top="759" left="256" width="74" height="11" font="4">Oregon Health &amp;</text>
<text top="774" left="276" width="35" height="11" font="4">Science</text>
<text top="789" left="245" width="97" height="13" font="4">UniversitydAssociate</text>
<text top="803" left="272" width="42" height="11" font="4">Professor</text>
<text top="759" left="387" width="23" height="11" font="4">None</text>
<text top="759" left="479" width="23" height="11" font="4">None</text>
<text top="759" left="551" width="23" height="11" font="4">None</text>
<text top="759" left="619" width="23" height="11" font="4">None</text>
<text top="759" left="704" width="23" height="11" font="4">None</text>
<text top="759" left="771" width="23" height="11" font="4">None</text>
<text top="837" left="64" width="35" height="11" font="4">Michael</text>
<text top="851" left="64" width="19" height="11" font="4">Rich</text>
<text top="837" left="148" width="34" height="11" font="4">Content</text>
<text top="851" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="866" left="148" width="75" height="11" font="4">ACCF Council on</text>
<text top="881" left="148" width="65" height="11" font="4">Cardiovascular</text>
<text top="896" left="148" width="64" height="11" font="4">Care for Older</text>
<text top="911" left="148" width="27" height="11" font="4">Adults</text>
<text top="837" left="244" width="99" height="11" font="4">Washington University</text>
<text top="852" left="272" width="42" height="11" font="4">School of</text>
<text top="866" left="246" width="94" height="13" font="4">MedicinedProfessor</text>
<text top="881" left="267" width="53" height="11" font="4">of Medicine</text>
<text top="837" left="387" width="23" height="11" font="4">None</text>
<text top="837" left="479" width="23" height="11" font="4">None</text>
<text top="837" left="551" width="23" height="11" font="4">None</text>
<text top="837" left="619" width="23" height="11" font="4">None</text>
<text top="837" left="704" width="23" height="11" font="4">None</text>
<text top="837" left="771" width="23" height="11" font="4">None</text>
<text top="929" left="64" width="26" height="11" font="4">Anitra</text>
<text top="944" left="64" width="29" height="11" font="4">Romfh</text>
<text top="929" left="148" width="34" height="11" font="4">Content</text>
<text top="944" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="959" left="148" width="50" height="11" font="4">ACCF Adult</text>
<text top="974" left="148" width="47" height="11" font="4">Congenital</text>
<text top="989" left="148" width="59" height="11" font="4">and Pediatric</text>
<text top="1004" left="148" width="47" height="11" font="4">Cardiology</text>
<text top="1019" left="148" width="33" height="11" font="4">Council</text>
<text top="929" left="251" width="84" height="11" font="4">Children’s Hospital</text>
<text top="944" left="256" width="74" height="13" font="4">BostondClinical</text>
<text top="959" left="249" width="88" height="11" font="4">Fellow in Pediatrics</text>
<text top="929" left="387" width="23" height="11" font="4">None</text>
<text top="929" left="479" width="23" height="11" font="4">None</text>
<text top="929" left="551" width="23" height="11" font="4">None</text>
<text top="929" left="619" width="23" height="11" font="4">None</text>
<text top="929" left="704" width="23" height="11" font="4">None</text>
<text top="929" left="771" width="23" height="11" font="4">None</text>
<text top="1043" left="669" width="131" height="11" font="4">(Continued on the next page)</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e237</text>
</page>
<page number="92" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="125" height="12" font="9">Appendix 2. Continued</text>
<text top="179" left="64" width="41" height="11" font="4">Reviewer</text>
<text top="179" left="158" width="66" height="11" font="4">Representation</text>
<text top="179" left="266" width="55" height="11" font="4">Employment</text>
<text top="179" left="375" width="47" height="11" font="4">Consultant</text>
<text top="164" left="468" width="44" height="11" font="4">Speaker’s</text>
<text top="179" left="475" width="31" height="11" font="4">Bureau</text>
<text top="149" left="538" width="50" height="11" font="4">Ownership/</text>
<text top="164" left="536" width="54" height="11" font="4">Partnership/</text>
<text top="179" left="544" width="38" height="11" font="4">Principal</text>
<text top="164" left="612" width="38" height="11" font="4">Personal</text>
<text top="179" left="610" width="41" height="11" font="4">Research</text>
<text top="134" left="688" width="54" height="11" font="4">Institutional,</text>
<text top="149" left="676" width="79" height="11" font="4">Organizational, or</text>
<text top="164" left="681" width="67" height="11" font="4">Other Financial</text>
<text top="179" left="700" width="31" height="11" font="4">Benefit</text>
<text top="164" left="768" width="28" height="11" font="4">Expert</text>
<text top="179" left="765" width="35" height="11" font="4">Witness</text>
<text top="199" left="64" width="62" height="11" font="4">Andrea Russo</text>
<text top="199" left="148" width="34" height="11" font="4">Content</text>
<text top="214" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="229" left="148" width="49" height="11" font="4">ACCF Task</text>
<text top="244" left="148" width="39" height="11" font="4">Force on</text>
<text top="259" left="148" width="51" height="11" font="4">Appropriate</text>
<text top="274" left="148" width="52" height="11" font="4">Use Criteria</text>
<text top="199" left="254" width="78" height="11" font="4">Cooper University</text>
<text top="214" left="243" width="101" height="13" font="4">HospitaldProfessor of</text>
<text top="229" left="273" width="40" height="11" font="4">Medicine</text>
<text top="196" left="352" width="52" height="16" font="4"> Biotronik</text>
<text top="211" left="352" width="87" height="16" font="4"> Boston Scientific</text>
<text top="226" left="352" width="84" height="16" font="4"> Cameron Health</text>
<text top="241" left="352" width="57" height="16" font="4"> Medtronic</text>
<text top="256" left="352" width="88" height="16" font="4"> St. Jude Medical</text>
<text top="199" left="479" width="23" height="11" font="4">None</text>
<text top="199" left="551" width="23" height="11" font="4">None</text>
<text top="196" left="596" width="52" height="16" font="4"> Cameron</text>
<text top="214" left="608" width="28" height="11" font="4">Health</text>
<text top="226" left="596" width="57" height="16" font="4"> Medtronic</text>
<text top="199" left="704" width="23" height="11" font="4">None</text>
<text top="199" left="771" width="23" height="11" font="4">None</text>
<text top="292" left="64" width="52" height="11" font="4">Dipan Shah</text>
<text top="292" left="148" width="34" height="11" font="4">Content</text>
<text top="307" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="322" left="148" width="63" height="11" font="4">ACCF Imaging</text>
<text top="337" left="148" width="33" height="11" font="4">Council</text>
<text top="292" left="250" width="87" height="11" font="4">Methodist DeBakey</text>
<text top="307" left="241" width="103" height="13" font="4">Heart CenterdDirector</text>
<text top="292" left="387" width="23" height="11" font="4">None</text>
<text top="289" left="451" width="67" height="16" font="4"> <a href="e147.full.html#92">AstraZeneca</a></text>
<text top="292" left="518" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="304" left="451" width="53" height="16" font="4"> Lantheus</text>
<text top="322" left="475" width="35" height="11" font="4">Medical</text>
<text top="337" left="475" width="35" height="11" font="4">Imaging</text>
<text top="292" left="551" width="23" height="11" font="4">None</text>
<text top="292" left="619" width="23" height="11" font="4">None</text>
<text top="289" left="672" width="85" height="16" font="4"> Astellas Pharma</text>
<text top="304" left="672" width="50" height="16" font="4"> Siemens</text>
<text top="322" left="684" width="35" height="11" font="4">Medical</text>
<text top="337" left="684" width="41" height="11" font="4">Solutions</text>
<text top="337" left="725" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="292" left="771" width="23" height="11" font="4">None</text>
<text top="355" left="64" width="65" height="11" font="4">Randy Starling</text>
<text top="355" left="148" width="34" height="11" font="4">Content</text>
<text top="370" left="148" width="41" height="11" font="4">Reviewer</text>
<text top="355" left="256" width="74" height="11" font="4">Cleveland Clinic,</text>
<text top="370" left="261" width="64" height="11" font="4">Department of</text>
<text top="385" left="261" width="65" height="11" font="4">Cardiovascular</text>
<text top="400" left="258" width="70" height="13" font="4">MedicinedVice</text>
<text top="414" left="272" width="42" height="11" font="4">Chairman</text>
<text top="352" left="352" width="48" height="16" font="4"> Novartis</text>
<text top="355" left="479" width="23" height="11" font="4">None</text>
<text top="355" left="551" width="23" height="11" font="4">None</text>
<text top="355" left="619" width="23" height="11" font="4">None</text>
<text top="352" left="672" width="52" height="16" font="4"> Biotronik</text>
<text top="367" left="672" width="56" height="16" font="4"> Medtronic</text>
<text top="355" left="771" width="23" height="11" font="4">None</text>
<text top="432" left="64" width="53" height="11" font="4">Karen Stout</text>
<text top="432" left="148" width="34" height="11" font="4">Content</text>
<text top="447" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="462" left="148" width="50" height="11" font="4">ACCF Adult</text>
<text top="477" left="148" width="47" height="11" font="4">Congenital</text>
<text top="492" left="148" width="59" height="11" font="4">and Pediatric</text>
<text top="507" left="148" width="83" height="11" font="4">Cardiology Council</text>
<text top="432" left="265" width="55" height="11" font="4">University of</text>
<text top="447" left="243" width="101" height="13" font="4">WashingtondDirector,</text>
<text top="462" left="243" width="101" height="11" font="4">Adult Congenital Heart</text>
<text top="477" left="255" width="76" height="11" font="4">Disease Program</text>
<text top="432" left="387" width="23" height="11" font="4">None</text>
<text top="432" left="479" width="23" height="11" font="4">None</text>
<text top="432" left="551" width="23" height="11" font="4">None</text>
<text top="432" left="619" width="23" height="11" font="4">None</text>
<text top="432" left="704" width="23" height="11" font="4">None</text>
<text top="432" left="771" width="23" height="11" font="4">None</text>
<text top="525" left="64" width="61" height="11" font="4">John Teerlink</text>
<text top="525" left="148" width="34" height="11" font="4">Content</text>
<text top="540" left="148" width="41" height="11" font="4">Reviewer</text>
<text top="525" left="254" width="79" height="11" font="4">San Francisco VA</text>
<text top="540" left="276" width="35" height="11" font="4">Medical</text>
<text top="555" left="246" width="95" height="13" font="4">CenterdProfessor of</text>
<text top="570" left="273" width="40" height="11" font="4">Medicine</text>
<text top="522" left="352" width="43" height="16" font="4"> <a href="e147.full.html#92">Amgen</a></text>
<text top="525" left="395" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="537" left="352" width="45" height="16" font="4"> Anexon</text>
<text top="552" left="352" width="69" height="16" font="4"> <a href="e147.full.html#92">CardioMEMS</a></text>
<text top="555" left="421" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="567" left="352" width="66" height="16" font="4"> Cytokinetics</text>
<text top="582" left="352" width="48" height="16" font="4"> <a href="e147.full.html#92">Novartis</a></text>
<text top="585" left="400" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="597" left="352" width="88" height="16" font="4"> St. Jude <a href="e147.full.html#92">Medical</a></text>
<text top="600" left="440" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="612" left="352" width="87" height="16" font="4"> Scios/Johnson &amp;</text>
<text top="630" left="364" width="37" height="11" font="4">Johnson</text>
<text top="642" left="352" width="48" height="16" font="4"> Trevena</text>
<text top="525" left="479" width="23" height="11" font="4">None</text>
<text top="525" left="551" width="23" height="11" font="4">None</text>
<text top="525" left="619" width="23" height="11" font="4">None</text>
<text top="522" left="672" width="43" height="16" font="4"> <a href="e147.full.html#92">Amgen</a></text>
<text top="525" left="715" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="537" left="672" width="40" height="16" font="4"> Merck</text>
<text top="552" left="672" width="48" height="16" font="4"> <a href="e147.full.html#92">Novartis</a></text>
<text top="555" left="720" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="525" left="771" width="23" height="11" font="4">None</text>
<text top="663" left="64" width="71" height="11" font="4">Robert Touchon</text>
<text top="663" left="148" width="34" height="11" font="4">Content</text>
<text top="678" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="693" left="148" width="74" height="11" font="4">ACCF Prevention</text>
<text top="708" left="148" width="48" height="11" font="4">Committee</text>
<text top="663" left="249" width="88" height="11" font="4">Marshall University,</text>
<text top="678" left="255" width="76" height="11" font="4">Joan C. Edwards</text>
<text top="693" left="244" width="98" height="13" font="4">School of Medicined</text>
<text top="708" left="244" width="98" height="11" font="4">Professor of Medicine</text>
<text top="663" left="387" width="23" height="11" font="4">None</text>
<text top="663" left="479" width="23" height="11" font="4">None</text>
<text top="663" left="551" width="23" height="11" font="4">None</text>
<text top="663" left="619" width="23" height="11" font="4">None</text>
<text top="663" left="704" width="23" height="11" font="4">None</text>
<text top="663" left="771" width="23" height="11" font="4">None</text>
<text top="726" left="64" width="72" height="11" font="4">Hiroyuki Tsutsui</text>
<text top="726" left="148" width="79" height="11" font="4">Content Reviewer</text>
<text top="726" left="273" width="41" height="11" font="4">Hokkaido</text>
<text top="741" left="245" width="96" height="13" font="4">UniversitydProfessor</text>
<text top="756" left="267" width="53" height="11" font="4">of Medicine</text>
<text top="723" left="352" width="79" height="16" font="4"> Daiichi-Sankyo</text>
<text top="726" left="431" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="738" left="352" width="48" height="16" font="4"> <a href="e147.full.html#92">Novartis</a></text>
<text top="741" left="400" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="753" left="352" width="37" height="16" font="4"> Pfizer</text>
<text top="768" left="352" width="45" height="16" font="4"> Takeda</text>
<text top="771" left="397" width="4" height="11" font="5"><a href="e147.full.html#92">*</a></text>
<text top="726" left="479" width="23" height="11" font="4">None</text>
<text top="726" left="551" width="23" height="11" font="4">None</text>
<text top="726" left="619" width="23" height="11" font="4">None</text>
<text top="726" left="704" width="23" height="11" font="4">None</text>
<text top="726" left="771" width="23" height="11" font="4">None</text>
<text top="789" left="64" width="65" height="11" font="4">Robert Vincent</text>
<text top="789" left="148" width="34" height="11" font="4">Content</text>
<text top="803" left="148" width="53" height="13" font="4">Reviewerd</text>
<text top="818" left="148" width="50" height="11" font="4">ACCF Adult</text>
<text top="833" left="148" width="67" height="11" font="4">Congenital and</text>
<text top="848" left="148" width="39" height="11" font="4">Pediatric</text>
<text top="863" left="148" width="83" height="11" font="4">Cardiology Council</text>
<text top="789" left="256" width="75" height="11" font="4">Emory University</text>
<text top="803" left="272" width="42" height="11" font="4">School of</text>
<text top="818" left="246" width="94" height="13" font="4">MedicinedProfessor</text>
<text top="833" left="265" width="56" height="11" font="4">of Pediatrics</text>
<text top="789" left="387" width="23" height="11" font="4">None</text>
<text top="789" left="479" width="23" height="11" font="4">None</text>
<text top="789" left="551" width="23" height="11" font="4">None</text>
<text top="789" left="619" width="23" height="11" font="4">None</text>
<text top="786" left="672" width="31" height="16" font="4"> AGA</text>
<text top="789" left="771" width="23" height="11" font="4">None</text>
<text top="891" left="76" width="723" height="11" font="4">This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant to</text>
<text top="906" left="64" width="735" height="11" font="4">this document. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the</text>
<text top="920" left="64" width="142" height="11" font="4">interest represents ownership of</text>
<text top="918" left="209" width="590" height="16" font="4">5% of the voting stock or share of the business entity, or ownership of $10,000 of the fair market value of the business entity; or if</text>
<text top="935" left="64" width="735" height="11" font="4">funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is</text>
<text top="950" left="64" width="735" height="11" font="4">less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in</text>
<text top="965" left="64" width="530" height="11" font="4">this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.</text>
<text top="980" left="76" width="723" height="11" font="4">According to the ACCF/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual</text>
<text top="995" left="64" width="735" height="11" font="4">property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device</text>
<text top="1010" left="64" width="735" height="11" font="4">addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s household has</text>
<text top="1025" left="64" width="638" height="11" font="4">a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.</text>
<text top="1040" left="76" width="109" height="11" font="4">*Significant relationship.</text>
<text top="1052" left="76" width="95" height="16" font="4"><a href="e147.full.html#92">yNo </a>financial benefit.</text>
<text top="1070" left="76" width="723" height="11" font="4">AAFP indicates American Academy of Family Physicians; ACCF, American College of Cardiology Foundation; ACCP, American College of Chest Physicians;</text>
<text top="1085" left="64" width="735" height="11" font="4">AHA, American Heart Association; DSMB, data safety monitoring board; EP, electrophysiology; HRS, Heart Rhythm Society; ISHLT, International Society for Heart and</text>
<text top="1100" left="64" width="213" height="11" font="4">Lung Transplantation; and VA, Veterans Affairs.</text>
<text top="51" left="118" width="28" height="10" font="4">Yancy</text>
<text top="48" left="149" width="23" height="16" font="4">et al.</text>
<text top="48" left="690" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="66" left="118" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="62" left="685" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="51" left="64" width="25" height="10" font="4">e238</text>
</page>
<page number="93" position="absolute" top="0" left="0" height="1160" width="864">
<text top="103" left="64" width="64" height="12" font="9">Appendix 3.</text>
<text top="103" left="141" width="73" height="12" font="9">Abbreviations</text>
<text top="134" left="64" width="18" height="11" font="4">ACE</text>
<text top="131" left="86" width="152" height="16" font="4">¼ angiotensin-converting enzyme</text>
<text top="152" left="64" width="18" height="11" font="4">ACS</text>
<text top="149" left="86" width="127" height="16" font="4">¼ acute coronary syndrome</text>
<text top="170" left="64" width="11" height="11" font="4">AF</text>
<text top="167" left="79" width="83" height="16" font="4">¼ atrial fibrillation</text>
<text top="188" left="64" width="18" height="11" font="4">ARB</text>
<text top="185" left="87" width="141" height="16" font="4">¼ angiotensin-receptor blocker</text>
<text top="206" left="64" width="17" height="11" font="4">BMI</text>
<text top="203" left="85" width="89" height="16" font="4">¼ body mass index</text>
<text top="224" left="64" width="19" height="11" font="4">BNP</text>
<text top="221" left="87" width="128" height="16" font="4">¼ B-type natriuretic peptide</text>
<text top="242" left="64" width="25" height="11" font="4">CABG</text>
<text top="239" left="93" width="140" height="16" font="4">¼ coronary artery bypass graft</text>
<text top="260" left="64" width="19" height="11" font="4">CAD</text>
<text top="257" left="87" width="119" height="16" font="4">¼ coronary artery disease</text>
<text top="278" left="64" width="18" height="11" font="4">CRT</text>
<text top="275" left="86" width="164" height="16" font="4">¼ cardiac resynchronization therapy</text>
<text top="296" left="64" width="21" height="11" font="4">DCM</text>
<text top="293" left="89" width="117" height="16" font="4">¼ dilated cardiomyopathy</text>
<text top="314" left="64" width="18" height="11" font="4">ECG</text>
<text top="312" left="86" width="93" height="16" font="4">¼ electrocardiogram</text>
<text top="332" left="64" width="11" height="11" font="4">EF</text>
<text top="329" left="79" width="85" height="16" font="4">¼ ejection fraction</text>
<text top="350" left="64" width="27" height="11" font="4">GDMT</text>
<text top="348" left="95" width="169" height="16" font="4">¼ guideline-directed medical therapy</text>
<text top="368" left="64" width="29" height="11" font="4">HbA1c</text>
<text top="366" left="97" width="85" height="16" font="4">¼ hemoglobin A1c</text>
<text top="387" left="64" width="12" height="11" font="4">HF</text>
<text top="384" left="80" width="68" height="16" font="4">¼ heart failure</text>
<text top="405" left="64" width="28" height="11" font="4">HFpEF</text>
<text top="402" left="96" width="214" height="16" font="4">¼ heart failure with preserved ejection fraction</text>
<text top="423" left="64" width="26" height="11" font="4">HFrEF</text>
<text top="420" left="94" width="206" height="16" font="4">¼ heart failure with reduced ejection fraction</text>
<text top="441" left="64" width="31" height="11" font="4">HRQOL</text>
<text top="438" left="99" width="138" height="16" font="4">¼ health-related quality of life</text>
<text top="459" left="64" width="15" height="11" font="4">ICD</text>
<text top="456" left="83" width="176" height="16" font="4">¼ implantable cardioverter-defibrillator</text>
<text top="477" left="64" width="24" height="11" font="4">LBBB</text>
<text top="474" left="92" width="123" height="16" font="4">¼ left bundle-branch block</text>
<text top="495" left="64" width="11" height="11" font="4">LV</text>
<text top="492" left="79" width="78" height="16" font="4">¼ left ventricular</text>
<text top="513" left="64" width="22" height="11" font="4">LVEF</text>
<text top="510" left="90" width="154" height="16" font="4">¼ left ventricular ejection fraction</text>
<text top="531" left="64" width="21" height="11" font="4">MCS</text>
<text top="528" left="89" width="151" height="16" font="4">¼ mechanical circulatory support</text>
<text top="549" left="64" width="11" height="11" font="4">MI</text>
<text top="546" left="79" width="107" height="16" font="4">¼ myocardial infarction</text>
<text top="567" left="64" width="32" height="11" font="4">NSAIDs</text>
<text top="564" left="100" width="178" height="16" font="4">¼ nonsteroidal anti-inflammatory drugs</text>
<text top="585" left="64" width="49" height="11" font="4">NT-proBNP</text>
<text top="582" left="117" width="197" height="16" font="4">¼ N-terminal pro-B-type natriuretic peptide</text>
<text top="603" left="64" width="25" height="11" font="4">NYHA</text>
<text top="600" left="93" width="138" height="16" font="4">¼ New York Heart Association</text>
<text top="621" left="64" width="23" height="11" font="4">PUFA</text>
<text top="618" left="91" width="134" height="16" font="4">¼ polyunsaturated fatty acids</text>
<text top="639" left="64" width="18" height="11" font="4">RCT</text>
<text top="636" left="86" width="133" height="16" font="4">¼ randomized controlled trial</text>
<text top="657" left="64" width="19" height="11" font="4">SCD</text>
<text top="654" left="87" width="110" height="16" font="4">¼ sudden cardiac death</text>
<text top="675" left="64" width="18" height="11" font="4">VAD</text>
<text top="672" left="86" width="122" height="16" font="4">¼ ventricular assist device</text>
<text top="47" left="64" width="110" height="17" font="11">JACC Vol. 62, No. 16, 2013</text>
<text top="51" left="691" width="27" height="10" font="4">Yancy</text>
<text top="48" left="722" width="23" height="16" font="4">et al.</text>
<text top="62" left="64" width="114" height="17" font="11">October 15, 2013:e147–239</text>
<text top="66" left="506" width="240" height="10" font="4">2013 ACCF/AHA Heart Failure Guideline: Full Text</text>
<text top="51" left="775" width="25" height="10" font="4">e239</text>
</page>
<outline>
<item page="1">2013 ACCF/AHA Guideline for the Management of Heart Failure</item>
<outline>
<item page="4">Preamble</item>
<item page="6">1 1 Introduction</item>
<outline>
<item page="6">1.1 1.1 Methodology and Evidence Review</item>
<item page="6">1.2 1.2 Organization of the Writing Committee</item>
<item page="6">1.3 1.3 Document Review and Approval</item>
<item page="7">1.4 1.4 Scope of This Guideline With Reference to Other Relevant Guidelines or Statements</item>
</outline>
<item page="7">2 2 Definition of HF</item>
<outline>
<item page="7">2.1 2.1 HF With Reduced EF (HFrEF)</item>
<item page="8">2.2 2.2 HF With Preserved EF (HFpEF)</item>
</outline>
<item page="9">3 3 HF Classifications</item>
<item page="10">4 4 Epidemiology</item>
<outline>
<item page="10">4.1 4.1 Mortality</item>
<item page="10">4.2 4.2 Hospitalizations</item>
<item page="10">4.3 4.3 Asymptomatic LV Dysfunction</item>
<item page="10">4.4 4.4 Health-Related Quality of Life and Functional Status</item>
<item page="11">4.5 4.5 Economic Burden of HF</item>
<item page="11">4.6 4.6 Important Risk Factors for HF (Hypertension, Diabetes Mellitus, Metabolic Syndrome, and Atherosclerotic Disease)</item>
<outline>
<item page="11">Hypertension</item>
<item page="11">Diabetes Mellitus</item>
<item page="11">Metabolic Syndrome</item>
<item page="11">Atherosclerotic Disease</item>
</outline>
</outline>
<item page="11">5 5 Cardiac Structural Abnormalities and Other Causes of HF</item>
<outline>
<item page="11">5.1 5.1 Dilated Cardiomyopathies</item>
<outline>
<item page="11">5.1.1 5.1.1 Definition and Classification of Dilated Cardiomyopathies</item>
<item page="11">5.1.2 5.1.2 Epidemiology and Natural History of DCM</item>
</outline>
<item page="12">5.2 5.2 Familial Cardiomyopathies</item>
<item page="12">5.3 5.3 Endocrine and Metabolic Causes of Cardiomyopathy</item>
<outline>
<item page="12">5.3.1 5.3.1 Obesity</item>
<item page="12">5.3.2 5.3.2 Diabetic Cardiomyopathy</item>
<item page="12">5.3.3 5.3.3 Thyroid Disease</item>
<item page="12">5.3.4 5.3.4 Acromegaly and Growth Hormone Deficiency</item>
</outline>
<item page="13">5.4 5.4 Toxic Cardiomyopathy</item>
<outline>
<item page="13">5.4.1 5.4.1 Alcoholic Cardiomyopathy</item>
<item page="13">5.4.2 5.4.2 Cocaine Cardiomyopathy</item>
<item page="13">5.4.3 5.4.3 Cardiotoxicity Related to Cancer Therapies</item>
<item page="13">5.4.4 5.4.4 Other Myocardial Toxins and Nutritional Causes of Cardiomyopathy</item>
</outline>
<item page="13">5.5 5.5 Tachycardia-Induced Cardiomyopathy</item>
<item page="13">5.6 5.6 Myocarditis and Cardiomyopathies Due to Inflammation</item>
<outline>
<item page="13">5.6.1 5.6.1 Myocarditis</item>
<item page="14">5.6.2 5.6.2 Acquired Immunodeficiency Syndrome</item>
<item page="14">5.6.3 5.6.3 Chagas Disease</item>
</outline>
<item page="14">5.7 5.7 Inflammation-Induced Cardiomyopathy: Noninfectious Causes</item>
<outline>
<item page="14">5.7.1 5.7.1 Hypersensitivity Myocarditis</item>
<item page="14">5.7.2 5.7.2 Rheumatological/Connective Tissue Disorders</item>
</outline>
<item page="14">5.8 5.8 Peripartum Cardiomyopathy</item>
<item page="14">5.9 5.9 Cardiomyopathy Caused by Iron Overload</item>
<item page="15">5.10 5.10 Amyloidosis</item>
<item page="15">5.11 5.11 Cardiac Sarcoidosis</item>
<item page="15">5.12 5.12 Stress (Takotsubo) Cardiomyopathy</item>
</outline>
<item page="15">6 6 Initial and Serial Evaluation of the HF Patient</item>
<outline>
<item page="15">6.1 6.1 Clinical Evaluation</item>
<outline>
<item page="15">6.1.1 6.1.1 History and Physical Examination: Recommendations</item>
<item page="15">6.1.2 6.1.2 Risk Scoring: Recommendation</item>
</outline>
<item page="17">6.2 6.2 Diagnostic Tests: Recommendations</item>
<item page="17">6.3 6.3 Biomarkers: Recommendations</item>
<outline>
<item page="17">A. Ambulatory/Outpatient</item>
<item page="17">B. Hospitalized/Acute</item>
<item page="18">6.3.1 6.3.1 Natriuretic Peptides: BNP or NT-proBNP</item>
<item page="18">6.3.2 6.3.2 Biomarkers of Myocardial Injury: Cardiac Troponin T or I</item>
<item page="19">6.3.3 6.3.3 Other Emerging Biomarkers</item>
</outline>
<item page="19">6.4 6.4 Noninvasive Cardiac Imaging: Recommendations</item>
<item page="21">6.5 6.5 Invasive Evaluation: Recommendations</item>
<outline>
<item page="21">6.5.1 6.5.1 Right-Heart Catheterization</item>
<item page="22">6.5.2 6.5.2 Left-Heart Catheterization</item>
<item page="22">6.5.3 6.5.3 Endomyocardial Biopsy</item>
</outline>
</outline>
<item page="22">7 7 Treatment of Stages A to D</item>
<outline>
<item page="22">7.1 7.1 Stage A: Recommendations</item>
<outline>
<item page="22">7.1.1 7.1.1 Recognition and Treatment of Elevated Blood Pressure</item>
<item page="22">7.1.2 7.1.2 Treatment of Dyslipidemia and Vascular Risk</item>
<item page="22">7.1.3 7.1.3 Obesity and Diabetes Mellitus</item>
<item page="23">7.1.4 7.1.4 Recognition and Control of Other Conditions That May Lead to HF</item>
</outline>
<item page="23">7.2 7.2 Stage B: Recommendations</item>
<outline>
<item page="24">7.2.1 7.2.1 Management Strategies for Stage B</item>
</outline>
<item page="25">7.3 7.3 Stage C</item>
<outline>
<item page="25">7.3.1 7.3.1 Nonpharmacological Interventions</item>
<item page="25">7.3.1.1 7.3.1.1 Education: Recommendation</item>
<item page="25">7.3.1.2 7.3.1.2 Social Support</item>
<item page="25">7.3.1.3 7.3.1.3 Sodium Restriction: Recommendation</item>
<item page="26">7.3.1.4 7.3.1.4 Treatment of Sleep Disorders: Recommendation</item>
<item page="26">7.3.1.5 7.3.1.5 Weight Loss</item>
<item page="26">7.3.1.6 7.3.1.6 Activity, Exercise Prescription, and Cardiac Rehabilitation: Recommendations</item>
<item page="26">7.3.2 7.3.2 Pharmacological Treatment for Stage C HFrEF: Recommendations</item>
<item page="27">7.3.2.1 7.3.2.1 Diuretics: Recommendation</item>
<item page="27">7.3.2.1.1 7.3.2.1.1 Diuretics: Selection of Patients</item>
<item page="27">7.3.2.1.2 7.3.2.1.2 Diuretics: Initiation and Maintenance</item>
<item page="28">7.3.2.1.3 7.3.2.1.3 Diuretics: Risks of Treatment</item>
<item page="28">7.3.2.2 7.3.2.2 ACE Inhibitors: Recommendation</item>
<item page="28">7.3.2.2.1 7.3.2.2.1 ACE Inhibitors: Selection of Patients</item>
<item page="28">7.3.2.2.2 7.3.2.2.2 ACE Inhibitors: Initiation and Maintenance</item>
<item page="28">7.3.2.2.3 7.3.2.2.3 ACE Inhibitors: Risks of Treatment</item>
<item page="29">7.3.2.3 7.3.2.3 ARBs: Recommendations</item>
<item page="30">7.3.2.3.1 7.3.2.3.1 ARBs: Selection of Patients</item>
<item page="30">7.3.2.3.2 7.3.2.3.2 ARBs: Initiation and Maintenance</item>
<item page="30">7.3.2.3.3 7.3.2.3.3 ARBs: Risks of Treatment</item>
<item page="30">7.3.2.4 7.3.2.4 Beta Blockers: Recommendation</item>
<item page="30">7.3.2.4.1 7.3.2.4.1 Beta Blockers: Selection of Patients</item>
<item page="31">7.3.2.4.2 7.3.2.4.2 Beta Blockers: Initiation and Maintenance</item>
<item page="31">7.3.2.4.3 7.3.2.4.3 Beta Blockers: Risks of Treatment</item>
<item page="31">7.3.2.5 7.3.2.5 Aldosterone Receptor Antagonists: Recommendations</item>
<item page="31">7.3.2.5.1 7.3.2.5.1 Aldosterone Receptor Antagonists: Selection of Patients</item>
<item page="32">7.3.2.5.2 7.3.2.5.2 Aldosterone Receptor Antagonists: Initiation and Maintenance</item>
<item page="32">7.3.2.5.3 7.3.2.5.3 Aldosterone Receptor Antagonists: Risks of Treatment</item>
<item page="33">7.3.2.6 7.3.2.6 Hydralazine and Isosorbide Dinitrate: Recommendations</item>
<item page="33">7.3.2.6.1 7.3.2.6.1 Hydralazine and Isosorbide Dinitrate: Selection of Patients</item>
<item page="33">7.3.2.6.2 7.3.2.6.2 Hydralazine and Isosorbide Dinitrate: Initiation and Maintenance</item>
<item page="33">7.3.2.6.3 7.3.2.6.3 Hydralazine and Isosorbide Dinitrate: Risks of Treatment</item>
<item page="33">7.3.2.7 7.3.2.7 Digoxin: Recommendation</item>
<item page="33">7.3.2.7.1 7.3.2.7.1 Digoxin: Selection of Patients</item>
<item page="34">7.3.2.7.2 7.3.2.7.2 Digoxin: Initiation and Maintenance</item>
<item page="34">7.3.2.7.3 7.3.2.7.3 Digoxin: Risks of Treatment</item>
<item page="34">7.3.2.8 7.3.2.8 Other Drug Treatment</item>
<item page="34">7.3.2.8.1 7.3.2.8.1 Anticoagulation: Recommendations</item>
<item page="35">7.3.2.8.2 7.3.2.8.2 Statins: Recommendation</item>
<item page="35">7.3.2.8.3 7.3.2.8.3 Omega-3 Fatty Acids: Recommendation</item>
<item page="36">7.3.2.9 7.3.2.9 Drugs of Unproven Value or That May Worsen HF: Recommendations</item>
<item page="36">7.3.2.9.1 7.3.2.9.1 Nutritional Supplements and Hormonal Therapies</item>
<item page="36">7.3.2.9.2 7.3.2.9.2 Antiarrhythmic Agents</item>
<item page="36">7.3.2.9.3 7.3.2.9.3 Calcium Channel Blockers: Recommendation</item>
<item page="36">7.3.2.9.4 7.3.2.9.4 Nonsteroidal Anti-Inflammatory Drugs</item>
<item page="36">7.3.2.9.5 7.3.2.9.5 Thiazolidinediones</item>
<item page="37">7.3.3 7.3.3 Pharmacological Treatment for Stage C HFpEF: Recommendations</item>
<item page="37">7.3.4 7.3.4 Device Therapy for Stage C HFrEF: Recommendations</item>
<item page="40">7.3.4.1 7.3.4.1 Implantable Cardioverter-Defibrillator</item>
<item page="42">7.3.4.2 7.3.4.2 Cardiac Resynchronization Therapy</item>
</outline>
<item page="43">7.4 7.4 Stage D</item>
<outline>
<item page="43">7.4.1 7.4.1 Definition of Advanced HF</item>
<item page="43">7.4.2 7.4.2 Important Considerations in Determining If the Patient Is Refractory</item>
<item page="44">7.4.3 7.4.3 Water Restriction: Recommendation</item>
<item page="44">7.4.4 7.4.4 Inotropic Support: Recommendations</item>
<item page="45">7.4.5 7.4.5 Mechanical Circulatory Support: Recommendations</item>
<item page="46">7.4.6 7.4.6 Cardiac Transplantation: Recommendation</item>
</outline>
</outline>
<item page="47">8 8 The Hospitalized Patient</item>
<outline>
<item page="47">8.1 8.1 Classification of Acute Decompensated HF</item>
<item page="48">8.2 8.2 Precipitating Causes of Decompensated HF: Recommendations</item>
<outline>
<item page="48">Common Factors That Precipitate Acute Decompensated HF</item>
</outline>
<item page="49">8.3 8.3 Maintenance of GDMT During Hospitalization: Recommendations</item>
<item page="49">8.4 8.4 Diuretics in Hospitalized Patients: Recommendations</item>
<item page="50">8.5 8.5 Renal Replacement Therapy—Ultrafiltration: Recommendations</item>
<item page="50">8.6 8.6 Parenteral Therapy in Hospitalized HF: Recommendation</item>
<item page="51">8.7 8.7 Venous Thromboembolism Prophylaxis in Hospitalized Patients: Recommendation</item>
<item page="52">8.8 8.8 Arginine Vasopressin Antagonists: Recommendation</item>
<item page="52">8.9 8.9 Inpatient and Transitions of Care: Recommendations</item>
</outline>
<item page="54">9 9 Important Comorbidities in HF</item>
<outline>
<item page="54">9.1 9.1 Atrial Fibrillation§§The “ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation” and  ...</item>
<item page="55">9.2 9.2 Anemia</item>
<item page="57">9.3 9.3 Depression</item>
<item page="57">9.4 9.4 Other Multiple Comorbidities</item>
</outline>
<item page="58">10 10 Surgical/Percutaneous/Transcatheter Interventional Treatments of HF: Recommendations</item>
<item page="59">11 11 Coordinating Care for Patients With Chronic HF</item>
<outline>
<item page="59">11.1 11.1 Coordinating Care for Patients With Chronic HF: Recommendations</item>
<item page="61">11.2 11.2 Systems of Care to Promote Care Coordination for Patients With Chronic HF</item>
<item page="61">11.3 11.3 Palliative Care for Patients With HF</item>
</outline>
<item page="61">12 12 Quality Metrics/Performance Measures: Recommendations</item>
<item page="62">13 13 Evidence Gaps and Future Research Directions</item>
<item page="63">Presidents and Staff</item>
<outline>
<item page="63">American College of Cardiology Foundation</item>
<item page="63">American College of Cardiology Foundation/American Heart Association</item>
<item page="64">American Heart Association</item>
</outline>
<item page="64">References</item>
<item page="86">Appendix 1 Appendix 1 Author Relationships With Industry and Other Entities (Relevant)—2013 ACCF/AHA Guideline for the Mana ...</item>
<item page="86">Appendix 2 Appendix 2 Reviewer Relationships With Industry and Other Entities (Relevant)—2013 ACCF/AHA Guideline for the Ma ...</item>
<item page="86">Appendix 3 Appendix 3 Abbreviations</item>
</outline>
</outline>
</pdf2xml>
